{
    "5bc844fc-e852-4270-bfaf-36ea9eface3d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT00684983",
        "Statement": "All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these.",
        "Label": "Contradiction",
        "explain": "The given statement contradicts the CTRs. In the primary trial, patients undergoing FLT PET scanning do receive oral capecitabine as part of the interventional description, even though cixutumumab is not mentioned. In the secondary trial, arm A and arm B both receive oral capecitabine and lapatinib ditosylate. Therefore, some primary trial participants receive the same interventions as secondary trial subjects, and the statement is not entailed by the information in the CTRs."
    },
    "86b7cb3d-6186-4a04-9aa6-b174ab764eed": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00662129",
        "Statement": "Patients with Platelet count over 100,000/mm\u00ac\u00a8\u201a\u00e2\u2022, ANC <  1,700/mm\u00ac\u00a8\u201a\u00e2\u2022 and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the CTR of the primary trial. \n\nJustification:\n\nThe contradiction arises from the discrepancy between the platelet count requirement in the statement and that in the CTR. According to the CTR, patients in the primary trial must have a platelet count of at least 100,000/mm\u00b3, which is higher than the minimum platelet count specified in the statement."
    },
    "dbed5471-c2fc-45b5-b26f-430c9fa37a37": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093145",
        "Secondary_id": "NCT00703326",
        "Statement": "Heart-related adverse events were recorded in both the primary trial and the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed. The primary trial's adverse events include Atrial fibrillation in one participant (0.13%), and the secondary trial's adverse events include Atrial fibrillation in two participants (0.26% and 0.26%). Therefore, heart-related adverse events were recorded in both trials."
    },
    "20c35c89-8d23-4be3-b603-ac0ee0f3b4de": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01097642",
        "Statement": "Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The given statement is entailed by the CTR's inclusion criteria for the primary trial, specifically the condition \"Patients with second primary breast cancers are eligible.\" This implies that patients with bilateral invasive breast carcinoma (T1 N1 M1) are included in the study. However, it's important to note that the CTR states that patients should have clinically measurable disease to be treated in the neoadjuvant setting. Therefore, the eligibility of patients with T1 N1 M1 disease in the primary trial depends on whether they have measurable disease or not. This is not explicitly stated in the provided CTR. If the patients have measurable disease, then the statement is entailed. If not, the statement is not contradicted but not entirely entailed.\n\nAdditionally, the statement does not contradict any of the exclusion criteria mentioned in the CTR."
    },
    "f17cb242-419d-4f5d-bfa4-41494ed5ac0e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02308020",
        "Statement": "Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided CTR information. In the primary trial, laser therapy is mentioned in the intervention sections for two different cohorts (INTERVENTION 1 and INTERVENTION 2). However, the secondary trial does not involve laser therapy in any cohort but rather includes Abemaciclib with hormone receptor positive breast cancer patients, with or without HER2 positivity, receiving endocrine therapy. Therefore, the statement's assertion that laser therapy is present in both trials with neoadjuvant chemotherapy is not supported by the provided data."
    },
    "fc5c4554-7ce9-4c16-b374-a3cd9d15b021": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT01027416",
        "Statement": "Patients must have already participated in a specific clinical study to participate in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. \n\nJustification:\n\nInclusion Criteria of the Primary Trial: \"Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participated in the preceding phase II clinical study.\"\n\nInclusion Criteria of the Secondary Trial: \"Patients in whom surgical excision of the tumor is part of standard of care management,\" which might include patients who have already undergone a clinical study as part of their treatment.\n\nTherefore, the statement is entailed, as per the inclusion criteria mentioned in both the primary and secondary trials of the CTRs."
    },
    "96b77cdd-aa9f-4770-8447-8a04d9ca5da7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00633750",
        "Statement": "Patients with Clinical stage II (T2 N1) invasive mammary carcinoma are not eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. According to the primary trial's inclusion criteria, patients with Clinical stage II (T2 N1) invasive mammary carcinoma are eligible, as long as they do not have locally advanced disease and are not planning to undergo preoperative neoadjuvant therapy. (Primary Trial: Inclusion Criteria)"
    },
    "c73faed2-371b-4238-bf7d-293fae380203": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00003404",
        "Secondary_id": "NCT00711529",
        "Statement": "the primary trial and the secondary trial have Hypnotherapy based interventions, the secondary trial also used pain medication in its intervention.",
        "Label": "Contradiction",
        "explain": "The statement can be contradicted. The primary trial does not mention the use of any pain medication in its intervention section, whereas the secondary trial specifically mentions the use of gabapentin (a pain medication) for patients in the intervention arm."
    },
    "8765009d-ffc4-4395-ab7a-11ecdfd43a40": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201773",
        "Statement": "Adele is an 85 year old woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she is eligible for the primary trial",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary trial's inclusion criteria as follows:\n1. Female\n2. Histologically confirmed breast cancer\n3.Stage II\n4. ER+\n5. ECOG Performance Status 0\n6. Postmenopausal (implied as no hormone replacement therapy is permitted and she is 85 years old)\n7. No prior treatment for current breast cancer\n8. No other active malignancy (adequately treated basal cell, squamous cell skin cancer, etc. is permitted)\n9. No significant renal or hepatic dysfunction (serum creatinine not specified, but bilirubin and liver functions are within normal limits)\n10. No use of other COX-2 inhibitors, but baby aspirin is permitted\n\nHowever, the statement contradicts the exclusion criteria:\n1. Age: The primary trial does not specify a maximum age limit, but the statement implies Adele is 85 years old, which is outside the age range for many clinical trials. However, this contradiction does not affect her eligibility in this specific trial.\n2. No history of thrombotic events: The statement does not mention Adele's history of thrombotic events, but it is an exclusion criterion in the primary trial. However, if Adele has no history of thrombotic events, this contradiction does not affect her eligibility."
    },
    "0ad7293d-df35-42e8-881d-f2afc3f7d3fd": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02606708",
        "Secondary_id": "NCT02504424",
        "Statement": "Only patients in the primary trial receive 40.5 Gy of brachytherapy, patients in the secondary trial receive no radiotherapy whatsoever.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided CTRs. In the primary trial, patients receive 40.5 Gy of radiation therapy through AIMRT, not brachytherapy (as stated in the CTR under INTERVENTION 1). In contrast, the secondary trial describes the use of an AeroForm Tissue Expander, which does not involve radiation therapy at all (as stated in the CTR under INTERVENTION 1 of the secondary trial)."
    },
    "2bc1e094-41a1-46d9-9b0c-b5a47f23323d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00895414",
        "Statement": "Certain drinks are banned for patients undertaking the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information given in the primary trial's inclusion criteria, specifically the exclusion of patients who agree to consume grapefruit juice while on the study."
    },
    "83b83400-1439-462d-bba3-42817b5b1fa1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777049",
        "Statement": "Most of the cases of CHF in the primary trial, were in cohort 1.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nThe CTR does not provide information regarding the distribution of Cardiac failure congestive cases among the cohorts in the primary trial."
    },
    "c3257f7b-f5b4-4a9c-8a8f-b037f27caa8f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00058058",
        "Statement": "Candidates for the primary trial must have a life expectancy over 6 months.",
        "Label": "Contradiction",
        "explain": "The statement \"Candidates for the primary trial must have a life expectancy over 6 months\" is entailed by the CTR under the section \"PRIOR CONCURRENT THERAPY: Life expectancy is not specified, but the requirement for candidates to have \"no severe claustrophobia\" and no other contraindications to MRI suggests that participants are expected to be in relatively good health and have a reasonable life expectancy. The statement made by the expert is more explicit about this requirement, making it a valid entailment."
    },
    "17a821f8-5e68-4bf7-ac01-3f96ddfc5187": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02964234",
        "Statement": "Patients eligible for the primary trial must live in the USA.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the primary trial's inclusion criterion specifying that patients must reside in Pilsen, Little Village, East Side or South Chicago, which are areas within the USA but not limited to it."
    },
    "d76d6c7f-ba39-483c-a89e-152af5ae2878": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02525718",
        "Secondary_id": "NCT02606708",
        "Statement": "Patients in group 1 of the secondary trial and the primary trial do not receive the same dosage of AIMRT.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nJustification: \n\nThe CTR for Primary Trial does not provide information about the intervention for the secondary trial, specifically Accelerated Intensity Modulated Radiation Therapy (AIMRT). Therefore, it's not possible for the statement to be entailed based on the information in the primary trial CTR. Additionally, the primary trial involves two interventions (placebo vs bupivacaine with epinephrine and dexamethasone) for intraoperative pain management, which is completely different from the intervention (AIMRT) in the secondary trial for radiation therapy. Thus, the statement contradicts neither the primary trial nor the expert's statement."
    },
    "65f3e755-3e23-4e84-a218-87922759094d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01669343",
        "Secondary_id": "NCT00146172",
        "Statement": "the primary trial administers letrozole for 28 days, whereas the secondary trial administers is intervention over 4 cycles of 21 days.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted. In the primary trial, letrozole is administered for 28 days as a routine care and in overweight/obese participants for an additional 28 days, totaling 56 days. In contrast, the secondary trial administers neratinib twice daily for 4 cycles, each cycle lasting 21 days, totaling 84 days. There is no direct comparison between the lengths of the interventions in the two trials."
    },
    "d3590771-806b-4754-a455-38113bfedfca": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00952692",
        "Statement": "Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial inclusion criteria state that the patient should not have received amiodarone for 6 months prior to screening, not just the last 28 days. (Primary Trial: Inclusion Criteria) Therefore, the expert statement is not entailed by the CTR information."
    },
    "941b960f-8d57-4830-9d4c-8e96765ba76c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00994279",
        "Secondary_id": "NCT00545077",
        "Statement": "both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the CTRs. In the primary trial, Arm 1 receives Yoga Intervention and Arm 2 receives Educational Wellness Group without any mention of Bevacizumab. In contrast, in the secondary trial, both Arms A and B receive Endocrine Therapy with or without Bevacizumab. However, the statement focuses on HER2+ patients and does not provide sufficient evidence that all patients in the trials are HER2+. Even if we assume that all patients in both trials are HER2+, the statement still contradicts the CTRs as only Arm A and B in the secondary trial receive Bevacizumab."
    },
    "f79a9011-0a68-4255-a40f-5d73af412bf0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01425268",
        "Secondary_id": "NCT01373671",
        "Statement": "CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTR sections. The primary trial includes two intervention groups, one using AeroForm Tissue Expansion (inflated with CO2) and the other using Saline Tissue Expansion. The statement correctly identifies that CO2 is used only in the AeroForm group. The secondary trial, on the other hand, does not involve tissue expansion at all, as it deals with Full Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) scans. Therefore, the absence of CO2 use in the secondary trial further supports the statement's validity."
    },
    "1b4f8828-cc7f-4831-a1c0-cc14e6ad23af": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777101",
        "Secondary_id": "NCT00559845",
        "Statement": "There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTRs as neither the Primary Trial (Adverse Events 1) nor the Secondary Trial (Adverse Events 1) report any completed suicides. However, the Secondary Trial (Adverse Events 1) does report one suicide attempt in cohort 1."
    },
    "57f3a264-9119-4931-9f9c-9cb20e945973": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00075270",
        "Secondary_id": "NCT01781299",
        "Statement": "the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing a physcotherapy course.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nJustification: \n\nIn the primary trial, both the intervention groups received a chemotherapy agent, paclitaxel. Therefore, both intervention groups are testing a chemotherapy treatment in the primary trial, not a physcotherapy course. The secondary trial, on the other hand, is testing different types of acellular dermal matrices (AlloDerm RTU and SurgiMend PRS) in the context of tissue expander placement, which is considered a surgical procedure. Therefore, it is not testing a physcotherapy course."
    },
    "589e2f5b-9286-465b-8162-bb1549cd5ece": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Statement": "At least 4 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR). ",
        "Label": "Entailment",
        "explain": "The statement can be entailed based on the information presented in the CTRs. \n\nJustification: \n\nThe primary trial reports that there were 45 participants in the Fulvestrant 250 mg arm and 11.1% of them had an objective response (OR), which means at least 5 patients had OR. In the secondary trial with 51 participants in the Fulvestrant 250 mg + Loading Dose arm, 17.6% had OR, which means at least 9 patients had OR. Since both trials report ORs for Fulvestrant 250 mg, and we know that at least 5 patients from the first trial and 9 patients from the second trial had ORs, the statement \"At least 4 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR)\" is entailed by the data."
    },
    "8275f846-59b6-404d-a6d8-e01335279f1a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03066947",
        "Statement": "Less than 1/4 patients in the primary trial experienced adverse events.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the data in the CTRs. In the primary trial, 8/24 (33.33%) of patients experienced adverse events, which is more than 1/4 (25%) of the patients."
    },
    "b3c1f5d1-6f7f-4bab-a4e8-5d1dab597cc7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01390064",
        "Statement": "The both Cohorts of the primary trial receive their treatment via Subcutaneous administration.",
        "Label": "Entailment",
        "explain": "The statement is entailed. Both the Initial and Escalation Cohorts in the Primary Trial receive their treatment (Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine) via subcutaneous administration (as stated in the INTERVENTION sections of the Primary Trial)."
    },
    "18d9991c-ca96-4bab-93af-77654857a07f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01142661",
        "Statement": "the primary trial does not accept patients with grade 1 alopecia.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the Primary Trial's Inclusion Criteria. In this trial, grade 2 neuropathy is an acceptable form of anti-cancer therapy-related toxicity. However, there is no mention of any exclusion based on grade 1 alopecia. Therefore, patients with grade 1 alopecia are still eligible for participation."
    },
    "6fb9056d-277c-4dc2-9b45-d7661bb41831": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01925170",
        "Secondary_id": "NCT00324259",
        "Statement": "Participant in cohort 1 of the primary trial undergo a Mammography, whereas patients in cohort 1 of the secondary trial receive 6 mg Estradiol as supplementation for the Mammography.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. \n\nJustification: \n\nIn the primary trial, patients in cohort 1 undergo Mammography only (CTR states: \"INTERVENTION 1: Mammography Only\"). In the secondary trial, patients in cohort 1 receive 6 mg Estradiol daily as supplementation (CTR states: \"INTERVENTION 1: Arm 1 (6 mg Estradiol)\"). However, the statement explicitly mentions that participants in the first cohort of the primary trial undergo \"Mammography,\" and participants in the first cohort of the secondary trial receive \"6 mg Estradiol as supplementation for the Mammography.\" This is exactly what the CTRs describe, and no contradictions are found."
    },
    "52b23601-2276-4634-96c7-8b6e55596085": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129376",
        "Statement": "A single patient in the primary trial experienced a clinically significant inflammation of the back of the throat.",
        "Label": "Entailment",
        "explain": "The statement \"A single patient in the primary trial experienced a clinically significant inflammation of the back of the throat\" is not explicitly entailed by the provided Adverse Events section in the primary CTR. The CTR mentions the occurrence of Acute Pharyngitis but no explicit detail about the clinical significance of this event for the individual patient is given. If such clinical significance is implied by the context or expert knowledge, it may be considered an entailed implication. However, the provided CTR data alone does not justify a definitive conclusion of entailment or contradiction."
    },
    "95e05332-4926-4381-90a4-87941269e7bf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00431067",
        "Statement": "More than 5% of the primary trial participants achieved partial response (PR).",
        "Label": "Contradiction",
        "explain": "The statement \"More than 5% of the primary trial participants achieved partial response (PR)\" is entailed by the CTRs provided. \n\nJustification: \n\nIn the primary trial, the Results 1 section states that \"Overall Number of Participants Analyzed: 41\" and \"Number of Participants with Partial Response (PR): 12\" (implicitly stated by the mention of \"12 participants had PR out of 29 evaluable patients\"). \n\nCalculating the percentage of participants with PR, we have (12/41)*100% = 29.27%. Since we're interested in the percentage exceeding 5%, the statement \"More than 5% of the primary trial participants achieved partial response (PR)\" is indeed entailed."
    },
    "20d51467-b059-4f39-b636-d32f2dc692da": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02162719",
        "Statement": "Both the primary trial and the secondary trial at least partly administer their interventions orally.",
        "Label": "Contradiction",
        "explain": "Justification for entailment: In the primary trial, paclitaxel is administered intravenously, but the expert statement only mentions the oral administration of interventions in a partial sense, which can still be considered true since the statement does not explicitly deny intravenous administration. In the secondary trial, both ipatasertib and placebo are orally administered. Therefore, the statement is entailed as it correctly describes an aspect of the administration methods in both trials."
    },
    "15c83d26-f9ba-44cc-a920-6941781cdd8b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01427933",
        "Statement": "Neutropenia affected the majority of patients in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nJustification:\n\nThe statement \"Neutropenia affected the majority of patients in cohort 1 of the primary trial\" is contradicted by the provided data in the CTRs. In the Primary Trial's Adverse Events 1 section, Neutropenia occurred in 4/69 (5.80%) of the patients. This number is not considered a majority for a cohort of 69 patients."
    },
    "e100212f-5bef-4f84-a3c1-d18a6b3e8355": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01648322",
        "Secondary_id": "NCT00436566",
        "Statement": "the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. Both the primary and secondary trials use the unit of measure \"days\" for the outcome measurement in the primary trial and \"participants\" for the outcome measurement in the secondary trial. However, the time frames are different, with the primary trial having a shorter duration."
    },
    "56d2a387-49dd-49b9-93bb-bcb092bf2714": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02286843",
        "Statement": "the primary trial is testing a novel radiotracer called 89Zr-trastuzumab to evaluate its use for visualization of HER2+ lesions.",
        "Label": "Entailment",
        "explain": "The expert's statement is entailed by the information provided in the Intervention 1 section of the primary CTR. The CTR states, \"89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions,\" directly supporting the expert's assertion about the primary trial testing 89Zr-trastuzumab for visualization of HER2+ lesions."
    },
    "2485a3e1-7520-47d2-b941-32ebf91e5b65": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00300781",
        "Statement": "Participants of the primary trial are assigned an intervention depending on their prior treatments.",
        "Label": "Entailment",
        "explain": "The statement \"Participants of the primary trial are assigned an intervention depending on their prior treatments\" is entailed by the CTRs. \n\nJustification: \nThe CTR clearly states that participants in the primary trial are allocated to two interventions based on their prior trastuzumab treatment history. Intervention 1 is for those participants with prior trastuzumab treatment, and Intervention 2 is for those with no prior trastuzumab treatment. This directly supports the expert's statement that participants in the trial receive an intervention based on their prior treatments."
    },
    "b97d9465-db14-43af-9451-4b824e67abb8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00899574",
        "Secondary_id": "NCT01007942",
        "Statement": "the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed, as the CTRs clearly state that the inclusion criteria for each cohort in the primary and secondary trials differ. Therefore, patients may meet the eligibility requirements for one trial but not the other. (CTRs provided)"
    },
    "798c0983-5265-47ea-bfcd-735738793482": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02010021",
        "Statement": "A patient has recently been receiving Tamoxifen to treat breast cancer, they are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "The statement should be contradicted based on the Primary Trial's Inclusion Criteria. Specifically, the exclusion criterion for patients having prior endocrine therapy for breast cancer (including Tamoxifen) within 5 years prior to the trial (line 2, \"Prior endocrine therapy for any histologically confirmed cancer is not allowed.\") conflicts with the patient having received Tamoxifen."
    },
    "127e9179-6781-4b9a-abe9-080d2ffad591": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02176083",
        "Secondary_id": "NCT03061175",
        "Statement": "Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTRs. Neither the primary trial nor the secondary trial specifies the use of chemotherapy or radiotherapy in their interventions. In the primary trial, Intervention 1 for the YBCS group does not involve chemotherapy or radiotherapy as stated in the text message management details. Similarly, Intervention 2 for the control group does not entail the use of chemotherapy or radiotherapy. Likewise, in the secondary trial, neither Arm I (web-based CPM-DA) nor Arm II (usual care) mentions the use of chemotherapy or radiotherapy. Therefore, the expert's statement is in accordance with the clinical trial information."
    },
    "a54e1dfa-3975-4dc6-8530-c0adc79b1b0d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00089479",
        "Secondary_id": "NCT02964234",
        "Statement": "Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial.",
        "Label": "Entailment",
        "explain": "Agatha's inclusion in the primary trial is justified as she meets the criteria of having a female gender, being between 18-70 years of age, having adenocarcinoma of the breast, and no evidence of metastatic disease, as stated in the Primary Trial: Inclusion Criteria. However, she does not meet all requirements for the secondary trial due to her age (being 50 instead of 52-75), ethnicity (not identified as Latina/Hispanic/Chicana), and residence (not specified). Therefore, her statement is entailed in the Primary Trial but excluded in the Secondary Trial."
    },
    "16dc5a77-5758-4d19-9801-6e9932d9fbc9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01401166",
        "Statement": "several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration.",
        "Label": "Contradiction",
        "explain": "The statement \"several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration\" is contradicted by the information in the CTRs. Neither Results 1 nor Results 2 mention the administration of Herceptin via oral tablets or participants preferring this method. Instead, the methods of administration mentioned are subcutaneous (SC) and intravenous (IV) injections."
    },
    "2ed770a0-fe98-4029-9511-ad04a94a1a69": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00190671",
        "Secondary_id": "NCT00455533",
        "Statement": "In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted. The primary trial data shows that cohort 1 had 1 case of leukopenia out of 42 patients (1.38%), while cohort 2 had 1 case out of 61 patients (1.64%). The secondary trial data shows that cohort 1 had 0 cases of leukopenia out of 145 patients (0.00%), while cohort 2 had 1 case out of 144 patients (0.69%). Therefore, the statement is not entailed by the data in the CTRs as the number of leukopenia cases does not follow the pattern described in the statement."
    },
    "b4c97206-66fd-468b-8388-fac076222c10": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00863655",
        "Statement": "There were 7 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort 2.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTR data as follows:\n\nPrimary Trial: Adverse Events 1 section (cohort 1) reports 7 more cases of Anaemia (1.66% vs. 0.84% in cohort 2) and 1 more case of Disseminated intravascular coagulation (0.21% vs. 0.00% in cohort 2) in the primary trial.\n\nAdditionally, both trials have similar frequencies of other adverse events, such as Febrile neutropenia (0.21% in both trials) and Lymphadenopathy, Neutropenia, and Thrombocytopenia (0.00% in both trials for Lymphadenopathy and Thrombocytopenia; 0.42% in both trials for Neutropenia). These similarities further support the entailment of the statement."
    },
    "6e22d118-af77-41bd-bd47-9385779f33aa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00450723",
        "Statement": "There are several types of surgical and therapeutic treatments which are banned for patients wanting to take part in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the CTRs. In the primary trial CTR, there are several treatments mentioned as being prohibited, including prior thoracic or cardiac surgery, ipsilateral chest tube placement, prior neoadjuvant chemotherapy, and prior radiotherapy to the mediastinum (PRIOR CONCURRENT THERAPY section). Similarly, in the secondary trial CTR, the statement refers to various types of treatments that are not allowed for patients participating in the trial."
    },
    "ccc5362a-33d0-4f1b-be46-d31729ba9194": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01945775",
        "Statement": "The shortest PFS in the Talazoparib group of the primary trial was over a month shorter than the Median PFS for that group.",
        "Label": "Entailment",
        "explain": "The statement \"The shortest PFS in the Talazoparib group of the primary trial was over a month shorter than the Median PFS for that group\" is entailed by the data provided in the CTRs. In Results 1, the Median (95% Confidence Interval) of PFS for the Talazoparib group is stated as 8.6 (7.2 to 9.3) months. The shortest PFS for a participant in the Talazoparib group is not explicitly stated in the provided CTR. However, it is mentioned that the maximum duration of treatment for participants in the Talazoparib arm is 70.2 months. Given that the shortest PFS cannot be longer than the maximum duration of treatment, the shortest PFS in the Talazoparib group is less than 8.6 months, which is over a month shorter than the median PFS for that group. In the secondary trial, the statement holds true as well, but the data is not available in the excerpt provided."
    },
    "fa530b28-9142-49f2-aa80-4d04fa532910": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03765996",
        "Statement": "Participants in group 2 of the primary trial receive taping to anastomosis regions., but no  Complex Decongestive Physiotherapy.",
        "Label": "Contradiction",
        "explain": "The provided statement contradicts the information in the CTR for the secondary trial. In the CTR, participants in group 2 did indeed receive Complex Decongestive Physiotherapy in addition to taping applied to anatomosis regions. The CTR description states, \"This group received Complex Decongestive Physiotherapy, and also applying taping to anastomosis regions.\" (secondary trial CTR - Intervention 2). Therefore, according to the CTR, participants in group 2 did not meet the conditions stated in the expert's claim, as they did receive Complex Decongestive Physiotherapy."
    },
    "7cbe445f-2df6-4a87-be6b-7ecc1e80b08b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00063570",
        "Statement": "None of the patients in cohort 1 of the primary trial had a platlet deficiency, and none of the patients in cohort 2 had Pyrexia.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs.\n\nJustification: \n\nThe CTR for the primary trial indicates that there were no cases of Thrombocytopenia (platelet deficiency) in cohort 1 (Total: 52, Thrombocytopenia: 0/52). The CTR for the secondary trial indicates that there were no cases of Pyrexia in cohort 2 (Total: 21, Pyrexia: 0/21). The statement made by the clinical trials expert is consistent with the information given in the CTRs, as both cohorts had no reported instances of the mentioned conditions."
    },
    "41cf791e-ed7a-48e5-af84-eefc9fa41ba7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00503906",
        "Secondary_id": "NCT01142661",
        "Statement": "The adverse events in the primary trial where all equally prevalent, whereas in the secondary trial, alcohol poisoning was reported as the most common event.",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nJustification:\nThe statement \"The adverse events in the primary trial were all equally prevalent, whereas in the secondary trial, alcohol poisoning was reported as the most common event\" is contradicted by the data provided in the CTRs. The adverse event frequencies in the primary trial were not all equally prevalent (3.45% for each event except for Neutropenic Fever with 2 occurrences, or 6.89%). In contrast, the secondary trial reported alcohol poisoning as a single event (11.11%) among other more frequently occurring adverse events (each occurring 11.11% of the time). Therefore, the statement contradicts the given information in the CTRs."
    },
    "d417aa7b-6d2c-46f8-812c-426ea60e0328": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00894504",
        "Statement": "There were only 3 adverse events in the primary trial which occurred more than twice.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nExplanation: \n\nThe statement asserts that only three adverse events in the primary trial occurred more than twice. However, the provided CTR lists ten distinct adverse events and each occurred only once. Therefore, the statement contradicts the given information in the CTR."
    },
    "2744cc0a-86e9-4764-ae1c-f10f635dc283": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171704",
        "Statement": "Most patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 24 months.",
        "Label": "Entailment",
        "explain": "The statement \"Most patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 24 months\" is entailed by the data in the CTRs.\n\nJustification:\nAccording to the Results 1 section of the primary CTR, the median percent change in BMD for the Letrozole group was -4.63 (-14.21 to 4.32) after 24 months. This value is negative, indicating a decrease in bone mineral density. The fact that most patients in the Letrozole group had a decreased BMD after 24 months is a logical conclusion based on the reported median change.\n\nThe expert's statement matches the clinical trial data and is not contradictory, as it accurately reflects the findings in the primary CTR."
    },
    "2e4717fd-b349-48a3-b751-88674dfaaa18": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02392611",
        "Statement": "In the primary trial cohort 1 patients must have failed or be intolerant to standard therapy, or have no standard therapy available, and cohort 2 patients must respond well to standard therapy.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided CTRs.\n\nExplanation:\n\nThe primary trial does not require patients in cohort 1 to have responded poorly to standard therapy, nor does it specify any requirements related to the response to standard therapy in cohort 2. Therefore, the statement goes beyond the information provided in the CTRs."
    },
    "b0c65cd7-8cad-404d-8704-ee074e480f57": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01237327",
        "Secondary_id": "NCT00030823",
        "Statement": "the primary trial and the secondary trial do not have any overlapping inclusion criteria, apart from the mimimum age limit of 18.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. The Primary Trial and Secondary Trial have no overlapping inclusion criteria regarding patient history of participation in study 971-ONC-0028-080, disease characteristics, or any other patient characteristics apart from minimum age limit of 18."
    },
    "28e20650-e100-4e30-a319-5eceb69a979d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00509769",
        "Statement": "1 patient in the primary trial had toxic hepatitis.",
        "Label": "Entailment",
        "explain": "The statement \"1 patient in the primary trial had toxic hepatitis\" is entailed by the CTR data in the Adverse Events section of the primary trial, specifically the entry \"Hepatotoxicity 1/112 (0.89%)\" which indicates one case of hepatotoxicity in the trial."
    },
    "8cf0c320-9486-4531-9212-bb3284b734f1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02336737",
        "Secondary_id": "NCT01432886",
        "Statement": "the secondary trial is testing for the DLT of its interventions, whereas the primary trial is evaluating the efficacy of lymph node detection through the use of SentiMag and SiennaXP. ",
        "Label": "Entailment",
        "explain": "The statement is entailed as the primary trial and secondary trial address different aspects of their interventions. The primary trial focuses on the detection of lymph nodes using SentiMag and SiennaXP, while the secondary trial investigates the dose-limiting toxicity (DLT) of E7389 in combination with different dosing regimens of Trastuzumab. There is no contradiction between the trials based on the provided CTR sections."
    },
    "34a75478-e7cc-495e-86c3-d0accdaf1ddd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00317603",
        "Statement": "Participants of the primary trial must be older than 18, have histologically confirmed stage 4 breast cancer, ECOG<2 and a life expectancy exceeding 6 months.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary trial's inclusion criteria as it specifies that participants must be 18 years or older, have histologically confirmed stage 4 breast cancer, ECOG performance status 0 or 1 (which is equivalent to <2), and have a life expectancy of greater than or equal to 6 months."
    },
    "47780450-1202-4934-8e50-b29416b124f5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00332709",
        "Secondary_id": "NCT00659373",
        "Statement": "All the primary trial participants receive the same dose of Letrozole, and all patients in the secondary trial are administered the same dose of Tamoxifen.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the given CTRs. \n\nJustification: \n\n1. In the primary trial, all participants in both intervention arms receive Letrozole, and the same dose of 2.5 mg/day is administered to all patients.\n2. In the secondary trial, all participants in the first intervention arm receive Tamoxifen, and the same dose of 20mg orally daily is given to all patients. \n\nTherefore, the statement that \"All the primary trial participants receive the same dose of Letrozole, and all patients in the secondary trial are administered the same dose of Tamoxifen\" is in agreement with the CTRs provided."
    },
    "27421e64-e9f0-42a9-8070-bdfb0ce4ce7c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00179309",
        "Statement": "There were 2 cases of severe back pain observed in the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nThe statement \"There were 2 cases of severe back pain observed in the primary trial\" is contradicted by the data presented in the CTRs, as there is no mention of severe back pain as an adverse event in either the primary or secondary trial."
    },
    "c5e6497a-2e2f-4663-97fd-e73ba8904b0c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01856543",
        "Secondary_id": "NCT00365599",
        "Statement": "Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Thrombosis.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nThe statement \"Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Thrombosis\" contradicts the provided data in the CTRs.\n\nIn the primary trial, there was one recorded case each of Myocarditis and Thrombosis/thrombus/embolism in the Adverse Events section. However, the secondary trial did not report any occurrence of Myocarditis, and it reported two cases of Thrombosis/thrombus/embolism. Thus, the total number of cases for both Myocarditis and Thrombosis across the two trials is more than a single case as stated in the expert's claim."
    },
    "c4dd814d-f525-465f-abe1-a7975771d57e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01105650",
        "Statement": "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 5 million units/m^2 less of IL-2, than participants over 45 kg, but all participants will be administered Methylprednisolone 3 times per week for 6 doses.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs as the information regarding IL-2 dosages for participants weighing less than 45 kg in the primary trial is specified in the given text, and it indeed states that they will receive 5 million units/m^2 less than the dosage for participants over 45 kg. The statement also correctly mentions that all participants, regardless of weight, will receive Methylprednisolone 3 times per week for 6 doses as per the given CTRs."
    },
    "cfd93077-87c5-458b-8712-e1896929309d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "One patient in the primary trial had abnormally low red blood cells, white blood cells, and platelets.",
        "Label": "Entailment",
        "explain": "The statement \"One patient in the primary trial had abnormally low red blood cells, white blood cells, and platelets\" is entailed by the information in the Adverse Events section of the CTR for the primary trial. Specifically, the statements \"Pancytopenia * 1/56 (1.79%)\" and \"Neutropenia * 1/56 (1.79%)\" in the Adverse Events section of the primary CTR indicate that one patient in the trial had both low red blood cell (anemia) and low white blood cell (neutropenia) counts, which together comprise pancytopenia. The statement does not contradict any information in the CTR."
    },
    "a3faaf85-62c6-430f-acf2-9c5992ee5221": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00503906",
        "Secondary_id": "NCT01142661",
        "Statement": "The adverse events in the primary trial where all equally prevalent, whereas in the secondary trial, progression of disease was reported as the most common event.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the information provided in the CTRs. In the primary trial, no single adverse event was equally prevalent as the statement asserts. Leukopenia, Thrombocytopenia, Abscess, Breast Abscess, Fever/Sepsis, Neutropenic Fever, Peripheral Neuropathy, Seizure/Syncope, Hematuria, UTI, and Shortness of breath all occurred in 1/29 (3.45%) of the patients. In contrast, in the secondary trial, progression of disease occurred in 4/9 (44.44%) of the patients."
    },
    "65e3afbb-70f6-4e1a-89e6-d819f8b95ab6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01931163",
        "Secondary_id": "NCT00274469",
        "Statement": "Less than 5% of cohort 1 of the primary trial had High blood sugar, 0% of the secondary trial patients were recorded as having High blood sugar.",
        "Label": "Entailment",
        "explain": "The statement can be contradicted. While the primary trial does have one instance of a patient experiencing hyperglycemia (high blood sugar), which is 4.55% of the total cohort size, the secondary trial has no record of any patient having high blood sugar. Therefore, the statement that \"0% of the secondary trial patients were recorded as having High blood sugar\" contradicts the information present in the primary trial."
    },
    "335936e4-9eaa-43b3-84fe-6f112c0d0226": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00574145",
        "Secondary_id": "NCT03167359",
        "Statement": "Radiotherapy and healing touch therapy is used in all cohorts of the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. In the Primary Trial, Intervention 1 includes healing touch therapy given to patients receiving radiotherapy. In the Secondary Trial, Intervention 1 does not specifically mention healing touch therapy; however, all participants receive radiotherapy. Therefore, the healing touch therapy can be considered an additional component to the radiotherapy in both trials, and the statement holds true."
    },
    "19921113-538e-4fd2-81a6-6053f2dd6459": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02622074",
        "Statement": "There was 38% more patients with DLT in cohort 2 of the primary trial than in cohort 1.",
        "Label": "Contradiction",
        "explain": "To determine if the statement \"There was 38% more patients with DLT in cohort 2 of the primary trial than in cohort 1\" is entailed or contradicted by the provided CTRs, let's calculate the number of participants with DLTs in each cohort based on the information given:\n\nIn the primary trial:\nCohort A (KNp/KAC): 2 participants had DLTs.\nCohort B (KNpCb): 4 participants had DLTs.\n\nSo, the difference in number of participants with DLTs between the two cohorts is: 4 - 2 = 2.\n\nThe ratio of the number of participants with DLTs in cohort 2 (KNpCb) to the number of participants with DLTs in cohort 1 (KNp/KAC) is:\n\n(4 / 10) / (2 / 10) = 0.4 or 40%\n\nThe provided statement claims that there is a 38% increase in the number of patients with DLTs in cohort 2 compared to cohort 1. However, the calculation based on the provided information indicates that there is a 40% increase instead. Therefore, the statement is not exactly contradicted but slightly off in numerical value. However, it's still worth noting that the provided CTRs do not directly entail the statement since they do not contain an overall count or percentage of participants with DLTs across both cohorts."
    },
    "6a013bb4-0688-4f02-96c5-062f3ca67ae1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448279",
        "Statement": "In total there were 5x more adverse events in cohort 1 of the primary trial, than in cohort 2.",
        "Label": "Contradiction",
        "explain": "Contradiction. The statement is not entailed based on the provided CTRs. The total number of adverse events in cohort 1 of the primary trial is 4/26 (15.38%), while in cohort 2 of the secondary trial, the total number of adverse events is 1/28 (3.57%). The difference is not equal to five times."
    },
    "c103a786-0b1d-4124-aa5d-4945ded2c384": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01106040",
        "Secondary_id": "NCT01441596",
        "Statement": "the primary trial and the secondary trial are not studying PFS, PBR or DLTs.",
        "Label": "Contradiction",
        "explain": "The statement can be contradicted. The primary trial does report on outcome measurement related to the Proportion of Lymph Nodes detected by blue dye and Lymphoseek, which can be considered a type of efficacy measure in a sense that it indicates the ability of the intervention to detect lymph nodes. However, Progression-Free Survival (PFS), Progression-Free Rate (PFR), or Disease-Free Survival (DFS) are commonly used measures of survival or disease progression in clinical trials. In contrast, the secondary trial reports on the Patient Benefit Rate, which is a measure of treatment efficacy as defined by the absence of CNS disease progression and no worsening of neurological signs and symptoms, no tumour-related increase in corticosteroid dosage, and no progression of extra CNS disease, according to RECIST 1.1 criteria. Therefore, both trials do report on measures related to treatment efficacy."
    },
    "2746a75c-7f01-4dc3-a05e-5c7499e75555": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274768",
        "Secondary_id": "NCT00654836",
        "Statement": "Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial\" is contradicted by the information in the CTRs. \n\nJustification:\n\nThe primary CTR specifies that only patients with stage IV disease are included, while the secondary CTR states that patients with locally recurrent or metastatic disease are eligible. Stage III is considered to be an advanced stage of breast cancer, and it is not explicitly stated in either CTR that patients with stage III disease are eligible. Therefore, the statement is contradicted by the information in the CTRs. \n\nAdditionally, the statement is contradicted by the specific inclusion criteria for each trial:\n\nPrimary Trial: \"DISEASE CHARACTERISTICS:...must have measurable disease...At least one measurable lesion as defined by the Response Evaluation Criteria in Solid Tumors (RECIST)...Treated brain metastases (surgery or radiation therapy) allowed if clinically stable.\"\n\nSecondary Trial: \"DISEASE CHARACTERISTICS:...Must have HER-2-negative breast cancer or, if HER-2-positive, must be unable to receive trastuzumab (Herceptin\u00ae) or have previously received trastuzumab in the past...Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm by conventional techniques or as > 10 mm by spiral CT scan.\"\n\nBoth trials require patients to have measurable disease, which is a characteristic of advanced-stage cancer, but they do not specify that patients with stage III disease are included. Therefore, the statement is not entailed by the information in the CTRs."
    },
    "df64a4c5-08f3-40c7-a4e7-2a6271bc9e53": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00416572",
        "Statement": "Patients with a prior malignancy of skin cancer are excluded from the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the Primary Trial's EXCLUSION CRITERIA (Patient Characteristics) which specifies that \"Other prior malignancies except skin cancer\" are excluded from the trial."
    },
    "682f5e80-75c4-4a36-9bc1-b389a98ad160": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193037",
        "Statement": "None of the patients in Cohort 1 of the primary trial suffered from Hypotension.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the information provided in the primary trial's Adverse Events 1 section. There is no record of any hypotension incidents in Cohort 1, as stated in the CTR, but the expert's statement asserts that none of the patients in the cohort experienced hypotension. This is in contrast to the actual data presented, making the statement contradictory to the CTR.\n\nSpecifically, in the provided CTR for the primary trial, the Adverse Events 1 section for Cohort 1 states that the total number of adverse events was 18, but none of them were hypotension (0/50 or 0.00%). However, the expert's statement claims that \"none of the patients in Cohort 1\" suffered from hypotension, suggesting there were no patients at all with hypotension, contradicting the CTR."
    },
    "7028841e-28e6-4fd3-a27c-2ae2e7dc7b52": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02673918",
        "Secondary_id": "NCT01042938",
        "Statement": "Only White and Asian patients are eligible for both the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nThe primary trial's inclusion criteria do not specify eligibility based on race or ethnicity, only the exclusion of patients with severe physical, cognitive, or psychiatric illness causing inability to follow the study protocol and planned hospitalization or surgery within the next twelve weeks.\n\nThe secondary trial's inclusion criteria do not mention race or ethnicity as a requirement for participation.\n\nTherefore, the statement \"Only White and Asian patients are eligible for both the primary trial and the secondary trial\" contradicts the information presented in the provided CTRs."
    },
    "348c9273-6aa1-43a8-840d-3cf080874669": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00934856",
        "Statement": "In total, across both cohorts of the primary trial, there were at least 2 patients with a fever.",
        "Label": "Entailment",
        "explain": "Justified - The statement is entailed by the information in the provided CTRs. Both cohorts of the primary trial had a total of 2 patients each with a fever (Febrile neutropenia) out of 6 patients in each cohort, resulting in a total of 4 patients with fever across both cohorts."
    },
    "dfe6228e-6bfb-49d3-b0b4-397aab177bea": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00068588",
        "Statement": "We cannot compare results between the two Arms of the primary trial as there were no patients in cohort 1.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nJustification:\nThe statement contradicts the information in the CTR of the primary trial regarding Results 1, which states that \"Overall Number of Participants Analyzed: 0\" in Arm 1. The expert's statement implies that there are no participants in Cohort 1 of the primary trial, but the CTR explicitly states that no patients were analyzed for DLTs in Arm 1, not that there are no participants at all."
    },
    "9f424ebb-63b8-4930-b2c1-cd46fff4d706": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01302379",
        "Statement": "Only one patient cohort of the primary trial had a positive median Insulin change from baseline.",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nThe statement \"Only one patient cohort of the primary trial had a positive median Insulin change from baseline\" contradicts the information given in the CTRs. According to Results 1 and Results 2, both the Metformin + Lifestyle Intervention and Placebo + Lifestyle Intervention arms had negative median Insulin changes from baseline, as indicated in the least squares mean (95% confidence interval) values (-21.8 to -13.0 for Metformin and -17.7 to -8.6 for Placebo). No positive Insulin change from baseline is reported for either cohort in the CTRs."
    },
    "c1f8c7fb-22de-4501-af86-d9eb59542ae3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00324259",
        "Statement": "Cohort 2 of the primary trial had one more patient with Stable disease than cohort 1.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTR data. In Arm 1 (CTR Results 1), the number of participants with Stable disease (SD) is 7. In Arm 2 (CTR Results 2), the number of participants with Stable disease is 8. Therefore, Arm 2 has one more participant with Stable disease than Arm 1, as claimed in the statement."
    },
    "6630047b-7ebc-4435-8203-cf6bbe6b6ee7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00331630",
        "Statement": "Left ventricular ejection fraction > 50% is required for participation in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR, as the eligibility criteria clearly state that LVEF should be 50% as measured by echocardiogram or MUGA scan for participation in the trial. Therefore, the statement is a correct representation of the information in the CTR."
    },
    "039c3fc2-f798-4d97-b904-9aa7d363eeef": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00903162",
        "Secondary_id": "NCT01674062",
        "Statement": "Patients with cancer in situ of the cervix are eligible for the primary trial and the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the provided CTRs. In the primary CTR, patients with cancer in situ of the cervix are listed as an exclusion criterion. In the secondary CTR, they are not mentioned in the inclusion or exclusion criteria, which is neutral but not entailing their eligibility."
    },
    "50a2a4a9-2b30-4901-b7bc-9c77b8ca870f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Statement": "the primary trial requires participants to have undergone PTR.",
        "Label": "Entailment",
        "explain": "The statement \"the primary trial requires participants to have undergone PTR\" is entailed in the CTR, as one of the inclusion criteria for the primary trial states \"Patients must have completed preoperative (neoadjuvant) chemotherapy with a standard chemotherapy regimen. No more chemotherapy should be planned.\" The term PTR (preoperative chemotherapy) is explicitly mentioned in this inclusion criterion. Therefore, the statement is a logical consequence of the information provided in the CTR."
    },
    "f8028143-35d1-4cc3-895a-acb577db4715": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00537771",
        "Secondary_id": "NCT00354640",
        "Statement": "participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole and 40 milligrams of simvastatin PO QD.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. \n\nJustification: \n\nIn the primary trial, participants in the Arimidex group take 1 mg of anastrozole PO QD. In the secondary trial, participants receive 1 mg of anastrozole PO QD during the pharmacological study. Therefore, the participants of cohort 1 in the primary trial take 1 mg of anastrozole as stated in the expert's claim.\n\nSimilarly, in the secondary trial, participants receive 40 mg of simvastatin PO QD for 14 days. Although there is no mention of the dosage being taken concurrently with anastrozole in the same sentence within the secondary trial, the fact that both drugs are being given during the same study implies that they are both being taken during the 14-day period. Therefore, the participants of the secondary trial also take 40 mg of simvastatin PO QD as stated in the expert's claim.\n\nThus, the statement is entailed by the CTRs as it correctly describes the anastrozole dosages for both trials and correctly describes the simvastatin dosage and timeframe for the secondary trial."
    },
    "907f7e56-b6ec-4a43-bf3a-14f93c644bc1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00193180",
        "Statement": "A female patient over the age of 18 suffering from chronic viral hepatitis would be eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial's Exclusion Criteria, as it mentions a female patient with a known diagnosis of chronic liver disease, which is an exclusion criterion for the trial."
    },
    "3fa58451-21ba-4ad9-8d13-6a9eefa17a5b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00853996",
        "Statement": "Women classified as high-risk of developing breast cancer within the next 5 years and within her lifetime by the Gail model are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the Primary Trial's Inclusion Criteria, specifically the condition \"Gail risk >= 1.7% and/or relative risk >= 3 times that for 5-year age group.\" This criterion identifies women at high risk for breast cancer according to the Gail model."
    },
    "a41bf7b0-9a09-4ce0-8832-f13758581f20": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01572727",
        "Statement": "Cohort 1 of the primary trial recorded more optical adversse events than cohort 2.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nThe provided statement asserts that cohort 1 of the primary trial recorded more optic neuroopathy events than cohort 2. However, the data presented in the CTRs contradicts this statement since there was only one reported optic neuroopathy event in each cohort. Therefore, the statement is not entailed by the information provided in the CTRs."
    },
    "5f2d2015-eaf9-45a8-9583-fddbc9807287": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00130533",
        "Statement": "Less than 0.25% of patients in cohort 1 of the primary trial suffered from Hyperbilirrubinemia.",
        "Label": "Entailment",
        "explain": "Contradicted. The CTR for the primary trial states that 1/436 (0.23%) of patients experienced Hyperbilirrubinemia, which is higher than the stated threshold of less than 0.25%."
    },
    "609ddd08-ebd5-4661-be43-874b65dbfe52": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03273426",
        "Secondary_id": "NCT01091168",
        "Statement": "Patients with dementia or schizophrenia may be eligible for the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradictory to the provided CTRs.\n\nJustification:\n\nThe primary trial's inclusion criteria explicitly exclude individuals with dementia and schizophrenia (exclusion criteria), while the secondary trial's inclusion criteria do not mention these conditions at all. Therefore, neither trial includes patients with dementia or schizophrenia as stated."
    },
    "b6ac985d-87ae-4e0f-83e1-38033c1db5cc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322348",
        "Secondary_id": "NCT00429572",
        "Statement": "the primary trial and the secondary trial use ECOG to evaluate potential candidates' performance status.",
        "Label": "Contradiction",
        "explain": "The statement is entailed.\n\nBoth primary and secondary trials mention the use of ECOG performance status as an inclusion criterion. In the primary trial, it is stated that potential candidates must have a WHO performance status of 0, 1, or 2. In the secondary trial, it is stated that candidates must have a Zubrod performance status less than 2. ECOG and WHO performance status scales are equivalent, and both are used to evaluate patients' overall health status. This entails that the primary and secondary trials are assessing performance status using the ECOG scale."
    },
    "43ff9425-5e6e-4a85-a8ca-0c0c67a96623": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00431067",
        "Statement": "More than 5% of the primary trial participants achieved Objective Response (OR).",
        "Label": "Entailment",
        "explain": "The statement \"More than 5% of the primary trial participants achieving Objective Response (OR)\" is entailed by the given CTR information. \n\nJustification: \nAccording to the CTR, the number of participants in the Afatinib 50 mg arm who achieved Objective Response (OR) is not specified. However, we do know that there were 41 participants in total in this arm. To determine if more than 5% of these participants achieved OR, we need to find the number of responders. Unfortunately, the CTR does not provide this information directly. However, since OR includes complete response (CR) and partial response (PR), and the CTR states that some participants experienced CR, it is a reasonable assumption that some participants achieved PR as well. Therefore, we can estimate the number of responders based on the percentage of patients with CR and PR. Let's assume that X% of the participants had CR and Y% had PR. Then, the total percentage of responders would be X+Y. If X+Y is greater than 5%, then the statement is entailed. Since the CTR does not provide sufficient information to determine the exact percentage of responders, we cannot make a definitive conclusion. However, if the percentage is publicly available or can be inferred from other sources (such as similar trials or expert knowledge), then the statement could be entailed or contradicted accordingly."
    },
    "b3ccde30-cdfc-4e18-aee0-8b3a921dde39": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470301",
        "Statement": "Every patient in the primary trial is given tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV, but only a subset of participants undergo axillary lymph node dissection.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs provided. While every patient in the primary trial receives tipifarnib PO and IV infusions of paclitaxel, doxorubicin hydrochloride, and cyclophosphamide, the mention of axillary lymph node dissection as a correlative study in the primary trial implies that only a subset of participants undergo this procedure. Therefore, the statement accurately reflects this detail in the CTR."
    },
    "8697a59e-0f1c-452a-b15a-6d24e2df387f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Secondary_id": "NCT01301729",
        "Statement": "None of the patients in the primary trial or the secondary trial committed suicide.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the secondary trial data, specifically the occurrence of \"Completed suicide\" in the Adverse Events section of the secondary trial (occurred once in 32 patients, or 3.13%)."
    },
    "4ab74186-5f4e-4139-af05-d4a9871a251d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02721147",
        "Statement": "Stephanie has been living with her husband for 31 years, she is eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the Primary Trial's Inclusion Criteria since Stephanie is female, has a partner or spouse who is > 21, has lived with her romantic partner for > 6 months, and has no hearing impairment in either herself or her partner. The age requirement is satisfied as Stephanie's length of marriage (31 years) indicates she is likely older than 21 years. The statement does not contradict any information in the CTR."
    },
    "082ee581-f420-4892-b098-ce82c6ad0210": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00432172",
        "Statement": "All of the adverse events recorded in the primary trial were cardiac related.",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nThe given statement is contradicted by the provided CTRs, as none of the listed adverse events in either Primary Trial 1 or 2 are related to the cardiovascular system. The CTRs mention several adverse events including neutropenia, diabetes decompensation, diarrhea, mucositis/stomatitis, vomiting, pancreatitis, and febrile neutropenia. No mention of any cardiac events is made in either trial."
    },
    "7bf084eb-873a-4011-9b98-3a899ee582ee": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00982319",
        "Statement": "Pre and Post menopausal women can enter the primary trial, as long as they do not have prior hormone replacement therapy.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs as both trials include the condition that pre and post menopausal women who have not used hormone replacement therapy within the specified time frame are eligible for participation. (Primary Trial: Inclusion Criteria - No use of hormone replacement therapy within 6 months prior to eligibility screening; Secondary Trial: No mention of hormone replacement therapy as an exclusion criterion)."
    },
    "ef0406b4-34ad-4cbd-83a4-dd0f118c4d5a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01575522",
        "Secondary_id": "NCT00181363",
        "Statement": "the primary trial and the secondary trial are testing completely different modalities of interventions, but utilising the same 21 day cycle.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. Both primary and secondary trials follow a 21-day cycle for intervention administration, but they involve testing distinct modalities: tivantinib administration PO BID in the primary trial versus prone and supine positions in the secondary trial. This difference in interventions is clear from their respective descriptions in the INTERVENTION sections and does not contradict the statement."
    },
    "06bc9cff-e9fc-42c7-a2a3-c01a036e04c6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00741260",
        "Statement": "Patients with ERBB2 positive tumors are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the given CTR. The eligibility criteria for the primary trial explicitly state that patients should have an erbB-2 gene amplified tumor (FISH or CISH) or erbB-2 overexpression (IHC 3+, or IHC2+ with FISH or CISH confirmation), which is equivalent to having ERBB2 positive tumors."
    },
    "f6c85ce8-e0fc-4186-a961-6207dd4cacd2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01268150",
        "Statement": "Most patients in the primary trial treated with Eribulin Mesylate did not achieve complete response (CR) or partial response (PR).",
        "Label": "Entailment",
        "explain": "The statement \"Most patients in the primary trial treated with Eribulin Mesylate did not achieve complete response (CR) or partial response (PR)\" can be contradicted based on the provided information in the Primary Trial's Results 1 section. According to the CTR, there is no clear statement about the percentage of participants in the Eribulin Mesylate arm that achieved CR or PR. However, it states that there were 28.6% of participants with an objective response (ORR), which comprises both CR and PR. Since the percentage of patients achieving CR or PR is not explicitly stated and the provided percentage of ORR is greater than 50%, the statement contradicts the information in the CTR."
    },
    "5bdd61d9-aadf-4944-afe3-a04242d9c2b2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02321527",
        "Statement": "Patients with invasive breast cancer with a diameter of less than 4 cm are included in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR as the inclusion criteria state \"Ipsilateral biopsy-proven invasive breast cancer <5 cm in maximal dimension by Ultrasound or Mammography.\" This criterion implies that patients with invasive breast cancer that measures less than 4 cm (<5 cm is the upper limit) are included in the trial."
    },
    "b8ce7d6a-d707-48e0-816c-de7ac3a63823": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01252277",
        "Statement": "Fiona's sister, who is 34 years old was diagnosed with a ductal carcinoma, therefore fiona may be eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Fiona's sister, who is 34 years old was diagnosed with a ductal carcinoma, therefore fiona may be eligible for the primary trial\" is entailed, based on the following justifications from the CTR:\n\n1. Fiona's age (34 years old) falls within the premenopausal range (25-54 years).\n2. Her sister's diagnosis of ductal carcinoma qualifies her as having a first degree relative with breast cancer under the age of 60, which makes Fiona eligible according to the CTR inclusion criteria.\n\nThe statement is entailed because it implies that Fiona may meet the eligibility criteria for the primary trial based on her family history. The CTR confirms this, as having a first degree relative with breast cancer is a criterion for inclusion in the study."
    },
    "53d88010-e7d7-41c7-b20d-6328c8e507d1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "For some adverse event types in the primary trial, there were no recorded cases.",
        "Label": "Contradiction",
        "explain": "Contradiction. \n\nThe statement \"For some adverse event types in the primary trial, there were no recorded cases\" contradicts the CTR data for the \"Adverse Events\" section of the primary trial. In this section, there are recorded cases of \"Thrombocytopenia\" (1/8), \"Hypertension\" (1/8), and \"Hepatotoxicity\" (3/8). No mention is made of any adverse event type having \"no recorded cases.\""
    },
    "8257bf5c-fae6-44c0-a86d-293746fdc468": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01416389",
        "Statement": "Cohort 1 of the primary trial had more cases of Hepatic encephalopathy and Pneumonia than cohort 2.",
        "Label": "Contradiction",
        "explain": "The statement \"Cohort 1 of the primary trial had more cases of Hepatic encephalopathy and Pneumonia than cohort 2\" is contradicted by the provided information in the CTRs. \n\nJustifications:\n- The statement asserts that cohort 1 had more cases of Hepatic encephalopathy and Pneumonia compared to cohort 2.\n- According to the CTR of the primary trial, cohort 1 had 2 cases of Hepatic encephalopathy out of 26 participants (7.69%), and 1 case of Pneumonia out of 26 participants (3.85%).\n- The CTR of the secondary trial does not provide any information about the number of cases of Hepatic encephalopathy and Pneumonia in cohort 2.\n- However, based on the provided information, cohort 1 had fewer cases of Hepatic encephalopathy (1 versus 2 in the primary trial) and the same number of cases of Pneumonia (1 in both cohorts).\n- Therefore, the statement is contradicted by the data presented in the CTRs."
    },
    "7ea00c54-b4a1-427b-8ef7-a8b3cb96e8c2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00372424",
        "Secondary_id": "NCT00041067",
        "Statement": "Patients with HER2 positive breast tumors are eligible for the primary trial, but excluded from the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the information provided in the CTRs. According to the Primary Trial's Inclusion Criteria, patients with breast cancer that over-express Her-2 are eligible. In contrast, the Secondary Trial's Disease Characteristics state that HER2-positive status is a requirement, but it's important to note that the method for determining HER2 positivity is specified differently between the two trials (FISH or IHC 3+ in the Primary Trial and not specified in the Secondary Trial). This potential difference in determining HER2 status could be a source of discrepancy between the trials, but the statement itself only refers to HER2 positivity in general and does not make any assumptions about the testing method. Therefore, the statement is entailed as it is based on the common requirement of HER2 positivity in both trials, even though the trials may use different methods to assess this characteristic."
    },
    "974225b7-9089-499c-9550-0a7207fd28b2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03346161",
        "Secondary_id": "NCT01000662",
        "Statement": "The intervention for the primary trial does not require patients to undergo any medical treatment during the study, whereas in the secondary trial, all patients receive Radiation Therapy.",
        "Label": "Entailment",
        "explain": "The statement should be contradicted based on the information provided in the CTRs. \n\nJustification:\n\nFor the primary trial, the intervention for both arms involved patients interacting with a decision tool or a surgical care booklet and answering a survey. No medical treatment was specifically mentioned or required during the study. \n\nFor the secondary trial, all patients underwent Radiation Therapy with a different dosing schedule. This medical treatment contradicts the statement that no medical treatment is required in the primary trial."
    },
    "6f533f52-c8e4-4983-8968-69af03a9e34a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01506609",
        "Statement": "Patients with cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the primary trial's inclusion criteria. According to the CTR, patients with locally recurrent breast cancer that are amenable to radiation with curative intent are excluded from the trial, while the expert's statement suggests that they are ineligible. This contradiction stems from the different descriptions of the patient population for the clinical trial and the expert's statement."
    },
    "690b8562-7d68-4642-bacb-601f227bb763": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00591864",
        "Statement": "the primary trial does not have an intervention section.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR's description of the INTERVENTION section, which states \"There are no arms or subgroups in this study.\" This implies that the trial does not involve any intervention, which aligns with the expert's statement that the trial does not have an intervention section."
    },
    "75f94edd-dbde-4a19-be18-e67c767f6d8f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03618017",
        "Statement": "the primary trial's intervention section does not describe the intervention dosage, frequency or duration for cohort 2, however cohort 1 recieves placebo twice daily for two months.",
        "Label": "Contradiction",
        "explain": "Contradiction. The primary trial's intervention section specifies no information about the dosage, frequency, or duration for cohort 2, whereas the secondary trial states that cohort 1 receives placebo twice daily for two months. This contradicts the primary trial's lack of information regarding the intervention details for cohort 2."
    },
    "e37ed9ee-b312-4ea3-a6eb-3785fa94ccc4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00687440",
        "Secondary_id": "NCT01307891",
        "Statement": "the primary trial had a higher percentage of patients with at least partial response than either cohort of the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement can be contradicted based on the provided CTRs. In the primary trial, the number of participants with a partial response is 13 out of 26 (50%), while in the first cohort of the secondary trial, the percentage of patients with at least a partial response is 14.9% (28/39), and in the second cohort, it is 38% (8 out of 21). Therefore, the percentage of patients with at least partial response in the secondary trials is lower, not higher, than in the primary trial."
    },
    "34ee4f66-e6f7-458c-964c-12fa730a9d56": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02556632",
        "Statement": "Both cohorts the primary trial apply the topical intervention for approximately every 4-6 hours every day for a week of the study.",
        "Label": "Entailment",
        "explain": "The statement is entailed. Both intervention arms in the primary trial instruct patients to apply the topical interventions approximately every 4-6 hours every day from the first day of radiation therapy until 1 week after completion. This description aligns with the statement made by the clinical trial expert, stating that both cohorts apply the topical intervention for approximately every 4-6 hours every day for a week of the study."
    },
    "9b0451fe-f760-46d3-b555-0a9b83546e73": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00087152",
        "Secondary_id": "NCT00203502",
        "Statement": "the primary trial recorded half as many patients vomiting as the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The expert's statement is not entailed by the data in the CTRs since the primary trial recorded one instance of nausea, not vomiting, and the secondary trial recorded four instances of nausea/vomiting. The number of patients with vomiting is not mentioned in the primary trial, making the comparison incorrect."
    },
    "b9304415-073d-476e-a056-cb2a747d56fa": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "Cohort 2 of the primary trial recieves Doxorubicin only during cycles 1-4, and then Doxorubicin, cyclophosphamide, Herceptin and docetaxel during Cycle 5 of the study.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary trial's CTR for Intervention 2 under the description of the administration of Herceptin and docetaxel in Cycle 5. The expert's statement is consistent with the CTR as it correctly specifies that Cohort 2 in the primary trial receives Doxorubicin only during cycles 1-4 and then receives Doxorubicin, Herceptin, and docetaxel during Cycle 5."
    },
    "6e365e33-16b8-43e1-99b5-49dfed6f7b13": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00316199",
        "Statement": "Only Chinese women with stage 4 or Unresectable, locally recurrent cancer breast cancer are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary trial's inclusion criteria which specifies that female patients of Chinese origin with unresectable, locally recurrent breast cancer or stage IV disease are eligible for participation."
    },
    "7c2dd3c3-8e72-451e-9fe7-c442f659bfc3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01306942",
        "Statement": "Participants of cohort 1 in the primary trial received more Dasatinib and Paclitaxel than those in cohort 2.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. In the primary trial, the dosage of Dasatinib for cohort 1 is 100mg, and for cohort 2 it is 140mg. The Paclitaxel dose is the same for both cohorts: 80mg/m2. Therefore, the participants in cohort 1 receive more Dasatinib in each cycle compared to those in cohort 2. This information aligns with the provided statement."
    },
    "27acc6d7-c12d-4a38-9133-a5c8429dd264": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656669",
        "Statement": "the primary trial recorded 23 adverse events.",
        "Label": "Contradiction",
        "explain": "Contradiction. The expert statement \"the primary trial recorded 23 adverse events\" is not entailed by the CTR data provided for the primary trial, which reports a total of 0 adverse events (0.00%) among the 23 participants."
    },
    "5919a080-2f0d-4c3b-9b03-10df80b2e680": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01007942",
        "Statement": "There were no adverse event in the primary trial which affected more than 10% of a particular patient cohort.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial data. The adverse events section of the primary trial reports that febrile neutropenia occurred in 10.71% (30/280) of patients."
    },
    "91f6e62a-97e7-49fa-8509-7ff8c1f0155e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00671918",
        "Secondary_id": "NCT00571987",
        "Statement": "Patients with pure ductal carcinoma in situ (DCIS) or Melanoma are eligible for both the secondary trial and the primary trial, and are able to participate in these trials alongside other drug trials, up to a maximum of 3.",
        "Label": "Contradiction",
        "explain": "Contradiction. The statement is not entailed by the provided CTR sections. According to the primary CTR, patients with pure ductal carcinoma in situ (DCIS) or non-invasive carcinoma are eligible for the trial if lymph node biopsy is part of the surgical plan. However, they are excluded from the secondary trial due to not having an invasive breast cancer. Additionally, melanoma patients are not mentioned as being eligible for the secondary trial. Therefore, the statement that patients with pure ductal carcinoma in situ (DCIS) or melanoma are eligible for both trials and able to participate in up to 3 trials at a time is incorrect based on the information provided in the CTR sections."
    },
    "b351a091-d5fb-49f9-a864-5c89c6316b1b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01688609",
        "Statement": " Patients must have histologically or cytologically confirmed PR+ invasive breast cancer, with Primary tumor > 2 cm in diameter TO PARTICIPATE in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary trial's inclusion criteria, as it shares the requirement that patients have histologically or cytologically confirmed primary invasive breast cancer with a tumor larger than 2 cm in diameter."
    },
    "d5ca2086-8404-42d1-bf45-5370f3d4e8e8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02139358",
        "Secondary_id": "NCT02574455",
        "Statement": "There was 16.67% more cases of hemorrhaging in the primary trial than in the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nThe statement asserts that there was a 16.67% difference in hemorrhaging cases between the primary and secondary trials. However, there is no mention of hemorrhaging cases in either Adverse Events section of the secondary trial. Therefore, the statement contradicts the provided clinical trial data, as the secondary trial does not report hemorrhaging cases at all."
    },
    "4c038972-20a9-4031-a1cd-ba00e9dd0908": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00410813",
        "Secondary_id": "NCT00617539",
        "Statement": "In the primary trial, Dasatinib, 70 mg, Twice Daily results in a better median PFS than Dasatinib, 100 mg, Daily. The opposite was true in the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"In the primary trial, Dasatinib, 70 mg, Twice Daily results in a better median PFS than Dasatinib, 100 mg, Daily. The opposite was true in the secondary trial.\" is contradicted by the provided CTRs. In the primary trial, the median PFS is 15.3 weeks for Dasatinib, 70 mg, Twice Daily and 10.3 weeks for Dasatinib, 100 mg, Daily, indicating that the former treatment had a longer median PFS than the latter. However, in the secondary trial, the percentage of participants with a CNS response (complete or partial) is 6.7% for those receiving Irinotecan and Temozolomide compared to 0% for Dasatinib, 100 mg, Daily and 12.5% for Dasatinib, 70 mg, Twice Daily. The primary and secondary trials assess different outcome measures, Progression-free Survival in the primary trial and Number of Patients With Objective Treatment Response (Complete or Partial) in the CNS in the secondary trial, and the statement compares the effects of Dasatinib in different dosages and frequencies across these distinct trials. Therefore, the statement contradicts the CTRs as the comparison made does not hold for the same treatment, dosage, and outcome measure."
    },
    "82d6275a-97e6-4d13-84eb-5f7c2585db8b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02132949",
        "Secondary_id": "NCT01111825",
        "Statement": "Between both of the patient cohorst of the primary trial and the secondary trial there was only a single patient who suffered heart failure.",
        "Label": "Contradiction",
        "explain": "The statement \"Between both of the patient cohorts of the primary trial and the secondary trial there was only a single patient who suffered heart failure\" is contradicted by the provided CTR data.\n\nExplanation:\n\nThe primary trial reports 3 cases of heart failure out of 199 patients, while the secondary trial reports 1 case of heart failure out of 8 patients. Therefore, there are a total of 4 patients suffering from heart failure across both trials. The statement suggests that there was only 1 patient, contradicting the actual data in the CTRs."
    },
    "286e74e5-74ed-4d42-b32d-f1398c514d37": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01125566",
        "Statement": "At least one participant in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR data. \n\nIn the Results 1 section for the Afatinib + Vinorelbine (AV) arm, there is a participant whose PFS was reported as 9.07 months (the upper end of the inter-quartile range). This value is greater than 9 months, which is the threshold specified in the expert's statement. Therefore, the statement is entailed by the data."
    },
    "634642da-db6d-49cc-a999-67f46e91dbca": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01237327",
        "Secondary_id": "NCT00030823",
        "Statement": "the primary trial and the secondary trial do not have any overlapping inclusion or exclusion criteria.",
        "Label": "Entailment",
        "explain": "The expert statement \"the primary trial and the secondary trial do not have any overlapping inclusion or exclusion criteria\" is contradicted by the information given in the CTRs. \n\nExplanation: \n\nThe primary trial has an inclusion criterion of \"Previous participation in study 971-ONC-0028-080\", and an exclusion criterion of \"Subjects who had not previously participated in study 971-ONC-0028-080\". \n\nThe secondary trial's Disease Characteristics section has several inclusion criteria that overlap with the primary trial's exclusion criteria. For instance, \"Stage I, II, or III previously treated with adjuvant chemotherapy and clinically free of identifiable disease\" and \"Stage IV that is stable on hormonal therapy\" could both be considered as having previously undergone treatment and being clinically free of disease, which aligns with the primary trial's inclusion criterion. However, the primary trial explicitly states that only participants from study 971-ONC-0028-080 are eligible, while the secondary trial does not have such a restriction. This difference in eligibility requirements results in non-overlapping criteria.\n\nFurthermore, there are also exclusion criteria shared between the two trial reports. For example, participants in either trial cannot have a prior seafood allergy and must not be pregnant or breastfeeding. These criteria are identical, indicating that there is an overlap in exclusion criteria. \n\nOverall, there are both inclusion and exclusion criteria that do not align between the two trials, and the statement made by the clinical trial expert is contradicted by the information provided in the CTRs."
    },
    "a529e364-2da7-4067-acb6-9fb2f0adf08b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01401062",
        "Statement": "A patient who underwent T-cell transfer therapy in the past 2 weeks would be excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR since T-cell transfer therapy is listed under \"Exclusion Criteria\" of the primary trial, specifically under \"Investigational agents within 4 weeks prior to study enrollment (6 weeks if treatment was long-acting agent).\" Therefore, any patient who underwent such therapy would not meet the eligibility requirements for the primary trial."
    },
    "317e00ae-9d17-4f85-8787-602cc2548fdb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00004092",
        "Statement": "Patients with Cancer that has spread from a breast tumor to their bone marrow are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary trial's ELIGIBILITY CRITERIA section, which states that there must be no histologically proven bone marrow metastasis for patient inclusion in the trial."
    },
    "de955acc-ce0e-4416-9884-644a06971603": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00195013",
        "Secondary_id": "NCT00620373",
        "Statement": "Cohort 2 of the primary trial and the secondary trial are test groups. ",
        "Label": "Contradiction",
        "explain": "The statement \"Cohort 2 of the primary trial and the secondary trial are test groups\" is entailed by the CTRs provided. There is no contradiction with the information presented in the CTRs as both trials involve testing of different interventions (glutamine vs placebo in the primary trial and mammography vs gamma imaging in the secondary trial) on distinct cohorts. However, the statement does not explicitly refer to the specific cohorts as \"test groups,\" but this inference can be made based on the context of clinical trials and the information provided in the CTRs."
    },
    "4956f0d0-4df4-4de3-9a46-6073927485c3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01017549",
        "Secondary_id": "NCT01390064",
        "Statement": "the secondary trial has more patients cohorts than the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed. \n\nJustification: \n\nThe primary trial has only one intervention arm (Electronic Brachytherapy), while the secondary trial has two intervention arms (Initial Cohort with 5 doses of 300 micrograms and Escalation Cohort with 5 doses of 500 micrograms). Therefore, the secondary trial indeed has more distinct patient cohorts than the primary trial."
    },
    "9ca0cc75-58b3-451d-abcc-378526744ca4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01985971",
        "Secondary_id": "NCT03273426",
        "Statement": "Patients will have to undergo an MRI scan for before entry for both the secondary trial and the primary trial, for the primary trial patients will also need to have a brain MR and PET imaging, after study entry.",
        "Label": "Entailment",
        "explain": "The statement is entailed in both CTRs since patients are required to undergo an MRI scan for study entry in both the primary and secondary trials. For the primary trial, an additional requirement is the need for a brain MR and PET imaging (mentioned in the Primary Trial: Inclusion Criteria under \"Interventional Procedures\" section)."
    },
    "6efb001b-5ed3-470b-a206-7768a1adf597": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01581619",
        "Statement": "histologically confirmed invasive ductal breast cancer would result in exclusion from the primary trial, but not from the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial's Eligibility Criteria, which explicitly states that histologically confirmed invasive ductal breast cancer is a requirement for inclusion in the trial. Therefore, the statement that invasive ductal breast cancer would result in exclusion from the primary trial but not from the secondary trial is incorrect."
    },
    "70dd1a42-6e40-4880-80a8-45dfd4941ce4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00089973",
        "Statement": "the primary trial uses a 3 week cycle for SB-715992 administration.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary trial specifies that the treatment cycle for SB-715992 administration lasts 21 days."
    },
    "85f43677-b680-4127-b1da-7e1cc966e4b2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01943916",
        "Secondary_id": "NCT01653964",
        "Statement": "Not all subjects in the primary trial and the secondary trial will be adminstered 4-8 mCi Tc-99m sestamibi.",
        "Label": "Entailment",
        "explain": "The statement is not contradicted by the provided CTR information. The primary CTR specifies that \"each subject served as her own control, with imaging of each mass by both the test and control modalities\" and \"Specificity difference is a single measure for the overall ITD population.\" It does not explicitly mention the dose of Tc-99m sestamibi for every subject. In the secondary CTR, it is stated that \"Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi.\" Therefore, it is possible that some subjects in the primary trial and the secondary trial received different doses or no dose of Tc-99m sestamibi at all. The statement acknowledges this fact and is in harmony with the CTRs."
    },
    "4cccea8a-22ae-4813-96df-b902850f4991": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03136367",
        "Statement": "Women of any age can participate in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Women of any age can participate in the primary trial or the secondary trial\" is contradicted by the provided CTRs. \n\nJustification: \n\nThe primary trial states that \"Key Inclusion Criteria: - Women with locally advanced, recurrent, or metastatic breast cancer along with confirmation of estrogen-receptor positive (ER+)\" and \"Exclusion Criteria: - Patients who have only non-measurable lesions other than lytic or mixed (lytic and blastic) bone metastasis\" does not provide any age restriction. However, the primary trial's eligibility criteria mention that women with locally advanced, recurrent, or metastatic breast cancer are the target population. This group of patients typically includes older women, but there is no explicit statement indicating that women of any age can participate.\n\nThe secondary trial has explicit age inclusion criteria, stating that \"Assigned female at birth; 18 years and older\" can participate. However, the primary trial does not have such a criterion and, moreover, its exclusion criteria state that it does not include patients with non-measurable lesions other than lytic or mixed bone metastases, making it less likely for younger women with such lesions to be included.\n\nTherefore, the statement \"Women of any age can participate in the primary trial or the secondary trial\" is contradicted by the provided CTRs."
    },
    "8574ecd7-4da7-49b0-a273-de495bc1fee7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00951665",
        "Statement": "Nausea and Death are two of the most common adverse events for patients in cohort 1 of the primary trial",
        "Label": "Entailment",
        "explain": "The statement \"Nausea and Death are two of the most common adverse events for patients in cohort 1 of the primary trial\" is contradicted by the data in the CTRs provided. According to the Adverse Events 1 section of the Primary Trial, there was only one instance (1/26) of nausea and one instance (1/26) of death in cohort 1. Therefore, neither nausea nor death can be considered the most common adverse events for patients in cohort 1 based on the provided clinical trial data."
    },
    "01b82c51-dd3d-430b-9523-0e93a9eb9c1a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00950300",
        "Secondary_id": "NCT00615901",
        "Statement": "the primary trial recorded a multitude of patients with chest pain, whereas the secondary trial observed only one patient with abdominal pain.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided CTR data. In the primary trial, there is no mention of any patient experiencing chest pain in the Adverse Events sections. The statement claims that the primary trial recorded \"a multitude of patients with chest pain,\" but the CTR does not substantiate this claim. Furthermore, the secondary trial only reports one patient with abdominal pain and no patients with chest pain."
    },
    "93149dfc-667b-48d3-a46d-ad48b15e701f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00451555",
        "Statement": "Cohort 1 and 2 of the primary trial recorded exactly the same number of each type of adverse events.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nJustification: \n\nThe statement \"Cohort 1 and 2 of the primary trial recorded exactly the same number of each type of adverse events\" is contradicted by the provided CTR data. While the number of certain adverse event types, such as anemia and nausea, is similar between the two cohorts, the total number of adverse events is different: 18.09% for Cohort 1 and 23.08% for Cohort 2. Therefore, the statement is not entailed by the information in the CTRs."
    },
    "d080eec7-412f-4a44-8c56-91e0ec459acc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01422408",
        "Statement": "the primary trial is a phase II trial in which all participants will recieve topical fluocinonide 0.05% cream to apply to their genitalia twice daily for two weeks.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the Primary Trial's INTERVENTION 1 description since it aligns with the following details:\n\n1. It is a phase II trial.\n2. All participants receive topical fluocinonide 0.05% cream.\n3. They apply the cream to their genitalia (vagina, according to the CTR).\n4. They apply it twice daily for two weeks.\n\nTherefore, the statement is an accurate reflection of the information presented in the CTR."
    },
    "fd18a599-f94a-478a-975f-854a4210ccad": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00659373",
        "Secondary_id": "NCT02202252",
        "Statement": "the primary trial has a 5 year long intervention, the duration of the secondary trial is only a single day after removal of the drains.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the CTRs. In the primary trial, the intervention lasts for 5 years (Tamoxifen with or without ovarian function suppression), while in the secondary trial, the intervention relates only to the removal and examination of drains, which takes place on a single day."
    },
    "ac9ca070-80b2-4913-97d8-06d1b90fcfce": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01797120",
        "Secondary_id": "NCT02005887",
        "Statement": "the secondary trial and the primary trial both have a placebo arm and a test arm.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. Both primary and secondary trials have a placebo arm and a test arm. In the primary trial, Intervention 2 includes a placebo for everolimus, and in the secondary trial, Arm B has a placebo for degarelix."
    },
    "19f5ff0d-3419-4f27-a7e5-6c7291c3cd21": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00082810",
        "Statement": "Throughout the duration of the primary trial, pariticpants receive increasing doses of Fulvestrant.",
        "Label": "Contradiction",
        "explain": "Contradicted. The CTR for the primary trial specifies a fixed dosage of fulvestrant at 250 mg intramuscularly, with no mention of dosage increases throughout the trial. The statement made by the clinical trial expert is not entailed by the data provided in the CTR."
    },
    "009d23bb-2179-4ce3-927d-4dedca6b32a8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00479674",
        "Statement": "Patients that have previously been trated with bevacizumab are not eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR as \"Prior treatment with bevacizumab\" is listed under the exclusion criteria for the primary trial."
    },
    "5152d810-7669-4fb2-a66b-a0a1d6026af5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00577122",
        "Secondary_id": "NCT01923168",
        "Statement": "the secondary trial and the primary trial both use Pathologic complete response (pCR) as their outcome measure, and use a 6 month time frame.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted. The primary trial uses Clinical Benefit Rate as its outcome measure, with a time frame of up to 3 years, while the secondary trial uses Pathologic Complete Response with a time frame of after 24 weeks of treatment. Therefore, the trials do not use the same outcome measure or the same time frame, making the statement incorrect."
    },
    "e8f4a600-0296-47d4-903b-2fa840ebcf28": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02005549",
        "Statement": "Patients with stage 3 Cervical carcinoma are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the Primary Trial's Inclusion Criteria, which does not include patients with cervical carcinoma, regardless of the stage."
    },
    "3fa8b747-b48d-4fb4-995d-38a23c64ccb3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02069093",
        "Statement": "2 of the patients in the primary trial were either symptomatic, but able to swallow a modified diet; symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences.",
        "Label": "Entailment",
        "explain": "The statement \"2 of the patients in the primary trial were either symptomatic, but able to swallow a modified diet; symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences\" is a contradiction of the information in the CTR. \n\nIn the CTR, it is stated that \"The incidence of grade  2 stomatitis was reported\" and \"Stomatitis grade >=2: Yes: 2\". However, the expert statement asserts that there were 2 patients with stomatitis grade >= 2, which is not consistent with the information reported in the \"Results 1\" section of the CTR. The CTR explicitly states that only 2 out of 86 participants had stomatitis grade 2. Therefore, the expert statement contradicts the information provided in the CTR."
    },
    "b9c294c3-93b7-4681-be02-285f9e5cd867": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03167359",
        "Secondary_id": "NCT01385137",
        "Statement": "Between all cohorts in the primary trial and the secondary trial Omega-3-fatty Acids are only used in one cohort.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the provided information. In the primary trial, radiation therapy is the only intervention mentioned for all cohorts, while in the secondary trial, Omega-3-fatty Acids are only used in Arm I. Therefore, there is no overlap in the interventions between the trials regarding the use of Omega-3-fatty Acids, and the statement accurately reflects the given data."
    },
    "9df90d78-d857-4e1d-a650-e47f7b6b68d6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00322374",
        "Statement": "Cohort 2 of the primary trial receive a higher dose of Ixabepilone, at a higher frequency, than cohort 1, ",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the information in the CTR. In the primary trial, the dosages of Ixabepilone for intervention 1 and intervention 2 are 25 mg/m^2 and 30 mg/m^2, respectively. This represents a higher dose for cohort 2. Additionally, the frequency of administration is the same for both cohorts, every 21 days. Therefore, the statement \"Cohort 2 of the primary trial receive a higher dose of Ixabepilone, at a higher frequency\" is justified based on the information given in the CTR."
    },
    "4923ff4f-b2a8-48ad-bf4b-1e193deb0dfe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03098550",
        "Statement": "There results section indicates there were no patients in the primary trial with 0 adverse events.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nThe primary trial Results 1 and Results 2 both report 100.0% of participants experienced adverse events. No data was provided regarding the number of participants with 0 adverse events."
    },
    "92ac6e0c-8427-454d-9218-36eda1c580a7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01653964",
        "Secondary_id": "NCT02660788",
        "Statement": "The interventions in the primary trial and the secondary trial are so different that it is not possible or useful to compare them.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the CTRs. The primary trial and the secondary trial involve distinct interventions for the participants. In the primary trial, molecular breast imaging is performed using Tc-99m sestamibi. In contrast, the secondary trial comprises two arms: the control arm, which only receives a standard reminder postcard via mail, and the intervention arm, which receives a family physician reminder letter along with a standard reminder postcard via mail. These interventions differ significantly in nature and cannot be directly compared in terms of their clinical impact or outcomes. The statement reflects this fact and is harmonious with the information provided in the CTRs."
    },
    "f0aff1fc-4a67-4b28-a974-a4a67a5c930f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00733408",
        "Statement": "There was over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"There was over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial\" can be entailed based on the provided CTRs. The primary CTR states that the lower bound for the median PFS of the Nab-Paclitaxel-bevacizumab induction therapy followed by bevacizumab-erlotinib hydrochloride maintenance therapy is greater than 8 months, while the median PFS is 9.1 months (95% CI: 7.2 to 11.1) months. This difference (9.1-7.2) exceeds the threshold of 14 weeks. Therefore, the statement is an accurate reflection of the data in the primary CTR."
    },
    "2e0c241f-0a3b-4b39-87fe-ee2e5c7768d6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121836",
        "Secondary_id": "NCT00256243",
        "Statement": "Patients that are not willing to sign and give written informed consent for participation of the primary trial or the secondary trial will not be made to take part.",
        "Label": "Entailment",
        "explain": "The statement is entailed by both CTRs since they both include a requirement for patients to give written informed consent for participation. (Primary Trial: Informed Consent in Eligibility Criteria section; Secondary Trial: Informed Consent under Participant Information and Study Staff and Investigator section)"
    },
    "96ab702d-cfe1-48fb-b348-a7c7b8db3f16": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00684983",
        "Statement": "The Median length of time that a patient in Arm A of the primary trial survived after receiving a TNBC diagnosis was 6 months.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTR information in Results 1 of the primary trial. Specifically, the median survival for Arm A is given as 6.0 months (4.3 to 8.6) in the CTr. Therefore, the expert's statement that \"The Median length of time that a patient in Arm A of the primary trial survived after receiving a TNBC diagnosis was 6 months\" is consistent with the data in the CTR."
    },
    "6224d2de-c62b-4b43-8517-475eaa565491": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00811135",
        "Statement": "The majority of patients in the primary trial experienced at least one adverse event.",
        "Label": "Contradiction",
        "explain": "The statement \"The majority of patients in the primary trial experienced at least one adverse event\" is entailed by the provided data in the Adverse Events section of the Primary Trial, as a total of 20 out of 88 patients (22.73%) experienced at least one adverse event."
    },
    "95154c62-9f79-4d80-90fd-2f61612285b0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01095003",
        "Secondary_id": "NCT01702571",
        "Statement": "In total more than 5 patients in the primary trial and the secondary trial experienced Earache.",
        "Label": "Contradiction",
        "explain": "The statement \"In total more than 5 patients in the primary trial and the secondary trial experienced Earache\" is contradicted by the given data. The Adverse Events sections of both trials report zero instances (0/383 and 0/181) of ear pain (which can be considered a type of earache) in each respective trial."
    },
    "2f6243a9-af40-426d-9a6a-a5c5708cf1b4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00721630",
        "Secondary_id": "NCT00364611",
        "Statement": "the primary trial and the secondary trial recorded the exact same number of cases of nausea.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary trial reported 1/23 (4.35%) cases of nausea in the Adverse Events section of the first cohort, while the secondary trial reported 0/52 (0.00%) cases of nausea in both Adverse Events sections combined. Therefore, the statement that they recorded the exact same number of cases of nausea is contradictory to the information provided in the CTRs."
    },
    "837f0588-22fc-4069-b2bc-297b3f6aabf7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00058058",
        "Statement": "Candidates for the primary trial do not need to meet a specific life expectancy criteria.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the following part of the Primary Trial's Eligibility Criteria: \"Life expectancy Not specified\". If life expectancy was not a requirement for the primary trial, it would have been stated explicitly as \"Life expectancy: no restriction\". Therefore, the statement that \"Candidates for the primary trial do not need to meet a specific life expectancy criteria\" is incorrect based on the information in the CTR."
    },
    "01ef1af2-bac4-4ff9-9f0e-bb39276a9d78": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00572728",
        "Secondary_id": "NCT02472964",
        "Statement": "Patients in the primary trial will not be made to take Herceptin\u00ac\u00a8\u00ac\u00a9 (trastuzumab) or paclitaxel intravenously like those in the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted. \n\nThe primary trial specifies that patients undergo 18F-FLT PET/CT scans, and there is no mention of administering Herceptin\u00a9 (trastuzumab) or paclitaxel intravenously in this trial. However, in the secondary trial, both Intervention 1 and Intervention 2 include the administration of Herceptin\u00a9 (trastuzumab) and paclitaxel intravenously as part of the treatment regimen. Therefore, the provided statement contradicts the information presented in the CTRs."
    },
    "e7b47e19-9cd0-4121-a79a-ee223e7f3ab7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03511378",
        "Statement": "Patients must have a life expectancy over half a year to participate in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary trial's inclusion criterion that patients have an estimated life expectancy of more than six months."
    },
    "21cf4dfe-2cd7-4e60-943d-2f7e1266a80d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02630693",
        "Statement": "A 30% of patients in the primary trial suffered a life-threatening reaction to an infection.",
        "Label": "Contradiction",
        "explain": "Contradicted\n\nExplanation: \n\nThe statement \"A 30% of patients in the primary trial suffered a life-threatening reaction to an infection\" is contradicted by the information in the primary trial's Adverse Events section. The total number of life-threatening adverse events, as indicated by \"Death NOS,\" is 3/90 (3.33%), which is less than 30%. Additionally, the statement does not specify which type of infection caused the life-threatening reactions, while the CTR provides specific numbers for different types of infections, including sepsis and lung infection."
    },
    "d72ecaae-c132-480c-af5e-87c58dd26082": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00679341",
        "Secondary_id": "NCT00201851",
        "Statement": "The only adverse event observed in Patients from both the secondary trial and the primary trial, was Endocervical cancer.",
        "Label": "Contradiction",
        "explain": "Contradicted. The CTRs provided do not mention any instance of Endocervical cancer as an adverse event in common between the primary and secondary trials. In the primary trial, there are no reported cases of Endocervical cancer in Adverse Events 1 or 2, and in the secondary trial, the same holds true. Therefore, the expert's statement contradicts the clinical trial data."
    },
    "80245791-4a95-4682-bd5f-856694c9f52f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00721409",
        "Secondary_id": "NCT02413320",
        "Statement": "Patients with HER2 negative tumours are eligible for the primary trial but not for the secondary trial",
        "Label": "Contradiction",
        "explain": "The statement \"Patients with HER2 negative tumours are eligible for the primary trial but not for the secondary trial\" is contradicted by the CTR information provided. \n\nJustification:\n\nIn the primary trial, the inclusion criteria specify that patients with HER2 negative breast cancer are eligible. In contrast, the secondary trial includes HER2 negativity as one of its inclusion criteria as well. Therefore, it is not accurate to state that patients with HER2 negative tumours are eligible for the primary trial but not for the secondary trial. Instead, patients meeting the HER2 negativity criterion are eligible for both trials as stated in the CTRs."
    },
    "be7a2ed3-49a3-45e0-ba0a-ee5ee95e6138": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01325428",
        "Secondary_id": "NCT00073073",
        "Statement": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity, to be able to speak a specific language or to be above a certain height threshold.",
        "Label": "Entailment",
        "explain": "The statement \"the secondary trial and the primary trial do not require participants to be of a particular ethnicity, to be able to speak a specific language or to be above a certain height threshold\" is entailed by both CTRs as neither specifies ethnicity, language, nor height as inclusion or exclusion criteria."
    },
    "f0da58e6-e937-41ac-b53a-d46ec8a28d11": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01923168",
        "Statement": "Intervention 1 of the primary trial require participants to take 300 mg alpelisib once daily.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR information in the PRIMARY TRIAL section under INTERVENTION 1, where it is explicitly stated that participants took \"alpelisib 300 mg once daily.\""
    },
    "5a74a63a-3912-44f0-9e83-4e6b678cbe90": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02685566",
        "Secondary_id": "NCT03076190",
        "Statement": "the primary trial and the secondary trial have the same number of study groups, and are both testing the effectiveness of Full-Field Digital Mammography.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. Both trials involve two study groups each, and one of the study groups in each trial uses Full-Field Digital Mammography (FFDM) as the intervention."
    },
    "43f03ba4-ef03-4f57-b059-3d9267f0dcf8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Statement": "Patients under the age of 18, wanting to participate in the primary trial, must discontinue any Antitumoral hormonal treatment prior to study entry, and have a life expectancy of more than 3 months.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary CTR since it requires females participating in the trial to have an estimated life expectancy of at least 3 months and to discontinue antitumoral hormonal treatment prior to enrollment. (ELIGIBILITY CRITERIA section) However, it does not directly contradict the CTR regarding age restrictions, as the primary CTR specifically mentions females only."
    },
    "6e106caf-2522-4022-898d-64b82093d77a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02413320",
        "Statement": "Females over the age of 20 with no prior chemotherapy with therapeutic intent for current cancer, are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary trial's inclusion criteria, specifically the condition \"Female subjects age 18 - 70 years\" with the additional requirement that \"no prior chemotherapy, endocrine therapy or radiation therapy with therapeutic intent for this cancer.\" However, the statement's upper age limit of 20 years is not explicitly stated in the given CTR, and thus, the statement does not contradict the primary trial's information but is not fully entailed."
    },
    "7f8a918c-fab8-4129-8178-0cda7d0441e1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "Cohort 2 of the primary trial recieves Doxorubicin, cyclophosphamide, Herceptin and docetaxel throughout the cycles of the study.",
        "Label": "Entailment",
        "explain": "Contradiction. \n\nIn the primary trial, Cohort 2 received AC (Doxorubicin+Cyclophosphamide) followed by TH (Docetaxel+Herceptin). However, the statement claims that this cohort received Doxorubicin, cyclophosphamide, Herceptin, and docetaxel throughout the cycles, which is not consistent with the specified intervention sequence in the CTR. Therefore, the statement contradicts the information provided in the CTR."
    },
    "84aa1194-c081-4acf-9ed6-8cf0d1a08f5d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01125566",
        "Statement": "At least 400 participants in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted. According to the Primary Trial CTR, only 339 participants received the Afatinib + Vinorelbine (AV) treatment and their median PFS was 5.49 months with an inter-quartile range of 3.55 to 9.07 months. Therefore, there are not at least 400 participants with a PFS over 9 months as stated in the expert's claim."
    },
    "2bd65df6-4f1d-461c-93f5-f2ddbfde57b6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02018458",
        "Secondary_id": "NCT00895414",
        "Statement": "Patients with unexplained fever below thirty eight degrees Celsius may be included in the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial explicitly states that a patient will be ineligible if they have an active infection or unexplained fever greater than 38.5\u00b0C during screening (Primary Trial, Exclusion Criteria). The secondary trial also includes this criterion for ineligibility (Secondary Trial, Exclusion Criteria), but the statement focuses on fevers below thirty eight degrees Celsius. Thus, the statement contradicts the information provided in the CTRs."
    },
    "0290bc2d-9cd3-44ab-9b04-385f19527c42": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02550210",
        "Statement": "Patients must have ductal carcinoma, that can be felt by touch to be eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is partially contradicted by the primary trial's inclusion criteria, which states that patients may have a histologic diagnosis of invasive breast cancer or ductal carcinina in situ. Not all ductal carcinoma in situ can be felt by touch, and the statement excludes those that cannot. The primary trial's inclusion criteria do not require the cancer to be palpable."
    },
    "505afbf8-b2b4-4b12-99c5-e0feef473248": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00577122",
        "Secondary_id": "NCT01923168",
        "Statement": "the secondary trial and the primary trial do not both use Clinical Benefit Rate as their outcome measure, and they do not use the same time frame.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary trial measures Clinical Benefit Rate within the time frame of baseline through end of study, up to 3 years, while the secondary trial evaluates Pathological Complete Response after 24 weeks of treatment. Therefore, they assess different outcome measures with distinct time frames."
    },
    "19e7469d-8a6f-4bbd-9c8c-ad6b127ce7a5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01816594",
        "Secondary_id": "NCT02222337",
        "Statement": "Patients with histologically confirmed, newly diagnosed stage 0  bilateral  breast cancer cannot take part in the primary trial, but may still be eligible for the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the information in the Primary Trial Inclusion Criteria, which specifies that patients with histologically confirmed, newly diagnosed breast cancer, including those with multifocal or multicentric disease, are eligible for the trial, but only if the cancer is unilateral and has a size of >2cm by clinical examination and/or >1.5 cm confirmed by ultrasound or MRI. There is no mention of the stage being limited to stage 0 or bilateral breast cancer being an exclusion criterion. Therefore, the statement is contradicted by the provided CTR information."
    },
    "2e540abd-06e3-483d-bd69-6eb5d2275e9e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT01224678",
        "Statement": "Patients in the primary trial and the secondary trial are administered daily oral medication.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the information in the CTRs. In the primary trial, Usual Care does not involve a change in medication, and in the secondary trial, both Intervention 1 (Placebo) and Intervention 2 (Vitamin D) involve the administration of oral medication daily for 12 months."
    },
    "d905f4cb-32aa-41b8-8f61-40578d8ea9ae": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00274469",
        "Statement": "No less than 2 patients from either cohorts of the primary trial felt nauseous.",
        "Label": "Contradiction",
        "explain": "The statement is entailed, since there is one participant in each trial reported to have experienced nausea. (NAUSEA: 1/101 in the primary CTR and 0/103 in the secondary CTR, but since there are 101 participants in the primary trial and 103 in the secondary trial, the statement covers both.)"
    },
    "45510043-7931-493b-8251-41b0be9aabbd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00232505",
        "Statement": "There were 2 instances of patients with Atrial tachycardia in the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nThe statement \"There were 2 instances of patients with Atrial tachycardia in the primary trial\" contradicts the information given in the CTR as no cases of Atrial tachycardia or Paroxysmal Atrial Tachycardia were reported in any of the Adverse Events sections in the Primary Trial. (Adverse Events 1 and Adverse Events 2)."
    },
    "e7037f34-bd2e-402e-a19c-48073781885a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193037",
        "Statement": "10 of the patients in Cohort 1 of the primary trial suffered from Hypotension.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided CTRs. In Cohort 1 of the primary trial, no patients (0.00%) suffered from Hypotension according to Adverse Events 1 section. Similarly, in Cohort 1 of the secondary trial, no such information about Hypotension is given, so it is impossible for 10 patients to have had Hypotension based on the data provided in the CTRs."
    },
    "5275a332-46c1-4941-8850-26a8033012e3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981305",
        "Statement": "Only people who have previously been diagnosed with cancer and have no signs of cancer after finishing treatment are eliglbe for the primary trial, as long as they are over the age of 20.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary trial's inclusion criteria. The criteria state that the participants must be breast cancer survivors who have completed treatment. This requirement aligns with the expert's statement that \"people who have previously been diagnosed with cancer and have no signs of cancer after finishing treatment\" are eligible. However, the expert's statement goes further and adds a minimal age requirement (over 20), which is also present in the primary trial's inclusion criteria. Therefore, the expert's statement is a valid entailment of the information provided in the primary trial's inclusion criteria."
    },
    "1ec6aca8-6e67-4535-aeb7-a250e1d7b6c0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "the secondary trial and the primary trial both used MRI and Letrozole for their interventions.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided information in the CTRs. Both trials involve the use of MRI, and while the primary trial uses MRI in conjunction with Letrozole for breast enhancement and safety in healthy postmenopausal women, and the secondary trial uses MRI for diagnostic evaluation in healthy volunteers and breast cancer patients, the underlying imaging technique remains the same. Additionally, Letrozole is mentioned as an intervention in the primary trial, further supporting the entailment."
    },
    "b02f43d7-44bb-4219-9a08-fd70e7cc9b87": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01004744",
        "Statement": "Patients must have a confirmed Postmenopausal status, defined as a lack of menses for over a year, if they are to take part in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the Primary Trial's Inclusion Criteria as it explicitly states that postmenopausal status is a requirement for the trial and is defined as \"cessation of menses for >1 year\" or \"FSH > 20 mIU/mL within the past month.\""
    },
    "1a6661e0-343f-4056-b568-611e7cc7750c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01827163",
        "Statement": "Any patients with breast cancer above stage, currently receiving radiation therapy or biotherapy are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "The statement should be entailed by the given CTR as patients with stage IV breast cancer, currently receiving chemotherapy, radiation therapy, immunotherapy, or biotherapy for their breast cancer are explicitly stated as exclusion criteria in the Primary Trial's Eligibility Criteria section."
    },
    "ec97c90e-f904-4cf2-9567-8525edf747cf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03196635",
        "Secondary_id": "NCT01943916",
        "Statement": "the primary trial and the secondary trial are both evaluating patient assisted imaging interventions.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided information in the CTRs. Both the primary and secondary trials involve patient-assisted imaging interventions (PA compression image sets in the primary trial and no explicit mention but implied in the \"each subject served as her own control\" in the secondary trial). Therefore, the statement accurately reflects the commonality between the trials in terms of the type of interventions being evaluated."
    },
    "7a129a1e-20d9-4f5a-a921-d30957460e27": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00820222",
        "Secondary_id": "NCT01819233",
        "Statement": "the secondary trial and the primary trial do not test the same modalities of cancer treatments.",
        "Label": "Entailment",
        "explain": "The statement should be entailed. The primary trial involves the use of lapatinib and capecitabine as cancer treatments, whereas the secondary trial involves a behavioral dietary intervention and therapeutic conventional surgery (lumpectomy) without any mention of lapatinib or capecitabine. Therefore, the treatments being tested in both trials are different."
    },
    "fa9bd6ab-bd69-43f9-a0c0-f8c80bad9da4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01566721",
        "Statement": "The difference in Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period in both cohorts of the primary trial is less than 1%.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the provided information in the CTRs. The percentage of participants with at least 1 adverse event in Cohort A is 88.6%, and in Cohort B, it is 89.0%. The difference between these percentages (0.4%) is less than 1%. This is consistent with the information reported in the CTRs."
    },
    "a1c99d5b-d53a-4195-ad5f-5e1b48c22078": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Secondary_id": "NCT01498458",
        "Statement": "Although there is a much higher percentage of patients with Thrombocytopenia in the secondary trial than in cohort 1 of the primary trial, no robust comparisons can be made due to the significant differences in cohort sizes.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTRs. \n\nJustifications: \nThe statement acknowledges the difference in Thrombocytopenia occurrences between the two trials while emphasizing the importance of considering cohort sizes before making robust comparisons. The given CTRs clearly indicate a higher percentage of Thrombocytopenia cases in the secondary trial (12.50%) compared to the first cohort of the primary trial (1.01%). However, the statement also correctly points out that the difference in cohort sizes (199 vs. 8) may affect any comparisons made. The CTRs do not contradict this statement, as they do not provide sufficient information to make direct comparisons of the severity or significance of Thrombocytopenia between the two trials."
    },
    "0203435e-03a0-4c41-afdf-6c497d8908c1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00331630",
        "Statement": "Men with Left ventricular ejection fraction > 50% are excluded from participating in the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nThe primary trial's inclusion criterion specifies an LVEF of at least 50% for participation. (Primary Trial: PRIOR CONCURRENT THERAPY: No section mentioned regarding gender or LVEF being an exclusion criterion.)"
    },
    "e6388dc2-b096-467d-8b70-fd5346dd581a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00083174",
        "Secondary_id": "NCT00190671",
        "Statement": "The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 2.",
        "Label": "Entailment",
        "explain": "Contradicted. The statement \"The highest number of occurrences for any adverse event in both the primary trial and the secondary trial was 2\" is contradicted by the CTR data. The primary trial reported 2 cases of Colitis and the secondary trial reported 1 case of Pericardial effusion, both having 2 occurrences. However, there is an adverse event in the secondary trial, Melaena, with 2 occurrences which the primary trial did not report at all. Therefore, the statement is contradicted by the CTR data."
    },
    "93511e52-1c12-4dee-858e-13b10793e2a6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429182",
        "Secondary_id": "NCT00429507",
        "Statement": "the secondary trial exclusively uses radiotherapy in its intervention, whereas the primary trial gives its patient cohorts Stem Cell Transplants on the first day of the study.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nJustification: \n\nThe statement \"the secondary trial exclusively uses radiotherapy in its intervention, whereas the primary trial gives its patient cohorts Stem Cell Transplants on the first day of the study\" is contradicted by the information provided in the CTRs. \n\nIn the primary trial, the intervention includes high-dose chemotherapy using Carboplatin, Cyclophosphamide, and Thiotepa administered prior to stem cell transplant on Day 0. \n\nIn the secondary trial, the intervention includes Samarium 153-EDTMP followed by a stem cell transplant about 14-21 days later. The administration of Samarium 153-EDTMP can be considered as a type of radiotherapy, but the trial also involves stem cell transplant which is different from radiotherapy only. Therefore, the statement is incorrect."
    },
    "cb932dbf-4c98-4488-b189-1286442968b6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02005549",
        "Statement": "Patients with Cervical carcinoma in situ are excluded from the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs provided. The primary trial's inclusion criteria state that patients with in situ cancer of the cervix are excluded. Therefore, the expert's statement that patients with cervical carcinoma in situ are excluded from the primary trial is consistent with the trial's conditions for patient eligibility, and the entailment relationship is established."
    },
    "0b9aa7e8-5912-44db-b9b0-6a84df769e19": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00545688",
        "Statement": "There were no patients with paranasal sinus reactions in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"There were no patients with paranasal sinus reactions in the primary trial\" is contradicted by the given CTRs since none of the Adverse Events sections in the primary or secondary trials mention paranasal sinus reactions, and no information in the CTRs justifies the assumption that there were no instances of this condition."
    },
    "570ab6bb-b23c-4955-b6b0-d756d1b69c0e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00756717",
        "Statement": "Patients with cytologically confirmed, metastatic, early stage invasive breast cancer with an Allred score of 3 are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial's inclusion criteria which states, \"Patients must have histologically or cytologically confirmed early stage, ER-positive (Allred score 3), INVASIVE breast cancer that is not metastatic.\" Therefore, the secondary trial's statement \"Patients with cytologically confirmed, metastatic, early stage invasive breast cancer with an Allred score of 3 are eligible for the primary trial\" is incorrect as per the information provided in the primary trial's CTR."
    },
    "daf105f8-58e8-47d7-b0a2-5949620b0a2b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00296036",
        "Statement": "the primary trial administers the placebo and Urea/Lactic Acid Cream in the same frequency and on the same areas of the skin.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR information provided. In the primary trial, both the intervention with Urea/Lactic Acid Cream and the placebo receive the same application frequency (twice daily) and on the same areas of the skin (palms and soles)."
    },
    "c4b671ae-4701-43a3-ada1-659c265d1f3a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01582971",
        "Statement": "In order to participate in the primary trial, participants must be aware of where they are, and what day it is.",
        "Label": "Entailment",
        "explain": "The statement \"In order to participate in the primary trial, participants must be cognitively oriented to time, place, and person\" from the CTR directly justifies the expert's statement. The inclusion criterion in the Primary Trial's Eligibility Criteria states that participants must be cognitively oriented to time, place, and person. This implies their awareness of where they are and what day it is. Therefore, the statement is entailed by the information in the CTR."
    },
    "0a17a404-ed1d-4c31-a192-509b68198ea8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00717405",
        "Statement": "There was a dental adverse event in the primary trial.",
        "Label": "Entailment",
        "explain": "Justified - The statement is entailed by the CTR of the primary trial, as there is a reported adverse event of tooth loss (1/52) in the Adverse Events section."
    },
    "9661db11-0c91-48c6-a8e8-6cb7cc2b06fd": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02699983",
        "Secondary_id": "NCT00994279",
        "Statement": "Neither the primary trial or the secondary trial require participants to practice yoga while Wearing a Fitbit activity monitoring device.",
        "Label": "Entailment",
        "explain": "Contradicted by the primary trial (Group I of Intervention 1 involves using both SparkPeople web-based program and Fitbit activity monitoring device) and is not mentioned in the secondary trial (no mention of yoga intervention while wearing a Fitbit activity monitoring device)."
    },
    "e8b86ef4-3ce8-4d81-a632-f30672c80ff5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT01823107",
        "Statement": "Patients in the primary trial receive an Infusion of Perflutren Lipid Microspheres, whereas in the secondary trial subjects are implanted with a Meso BioMatrix Acellular Peritoneum Matrix.",
        "Label": "Entailment",
        "explain": "The statement is not directly contradictory but entails a difference in intervention types between the two trials. In the primary trial, patients receive an infusion of Perflutren Lipid Microspheres (Definity), while in the secondary trial, subjects are implanted with a Meso BioMatrix Acellular Peritoneum Matrix. These interventions are distinct, with the former being an infusion and the latter being an implantation, and the statement correctly articulates this difference. No contradiction is present in the provided CTR descriptions."
    },
    "879f2f14-38a8-419a-bae0-e62ed81eb9dd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00146172",
        "Statement": "Cohort 1 of the primary trial recieves less than 60% of cohort 2's dose of LA-EP2006.",
        "Label": "Entailment",
        "explain": "The statement is entailed. In the primary trial, cohort 1 receives Neratinib 40 mg qd (40 mg/day), and cohort 2 receives Neratinib 80 mg qd (80 mg/day). Therefore, cohort 1 receives less than 60% (0.6 * 80 = 48 mg/day) of the dose administered to cohort 2."
    },
    "2ec46285-dd0c-4420-b9f6-e44a1ac74f20": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01752907",
        "Secondary_id": "NCT01940497",
        "Statement": "There were 0 observed cases of Tibia or Fibula fractures in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"There were 0 observed cases of Tibia or Fibula fractures in the primary trial or the secondary trial\" is entailed by the provided CTRs because:\n\n1. In Adverse Events 1 of the primary trial, there are no reports of Tibia or Fibula fractures (0/149).\n2. In Adverse Events 1 of the secondary trial, there is 1 report of Fibula fracture (1/95), but it does not contradict the statement since the number of reported Tibia fractures is 0 (0/151).\n3. In Adverse Events 2 of the primary trial, there are no reports of Tibia or Fibula fractures (0/151).\n4. In Adverse Events 2 of the secondary trial, there is 1 report of Tibia fracture (1/20), but it also does not contradict the statement since the total number of Tibia or Fibula fractures across both trials is 0.\n\nTherefore, the statement is entailed by the CTRs."
    },
    "f8afffdc-649b-4921-942a-66b804a3717f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "In order to be eligible for the primary trial, patients must not have prior radiation, anthracycline or systemic anticancer therapy , and must have T1-4, N1 and M1 bilateral breast cancer.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial's inclusion criteria state that patients cannot have prior radiation therapy for breast cancer, anthracycline therapy or systemic anticancer therapy. However, the patients must have T1-4, N1, and M1 bilateral breast cancer which is not eligible as per the primary trial's eligibility criteria as it includes advanced stage breast cancer (T4 and M1). The expert statement contradicts the primary trial's inclusion criteria."
    },
    "65f22210-47dd-4865-99e2-ddd414dddb08": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "In total Over 82% patient in the primary trial achieve Recurrence-free Survival after 5 years.",
        "Label": "Entailment",
        "explain": "The provided statement \"In total Over 82% patient in the primary trial achieve Recurrence-free Survival after 5 years\" can be entailed by the CTR information as follows:\n\n1. From the Primary Trial Outcome Measurement section, we know that the time frame for Recurrence-free Survival assessment is 5 years.\n2. From Results 1 and Results 2, we have the number of participants analyzed for each arm: 96 participants for the Ketorolac 30 mg arm (83.3% survival) and 107 participants for the NaCl 0.9% 3mL arm (89.7% survival).\n3. To find the total percentage of participants in the primary trial achieving Recurrence-free Survival after 5 years, we can sum the number of participants from both arms and divide the sum by the total number of analyzed participants: (96 + 107) / (96 + 107) * 100% = 90.9%. However, this is just a little below the 82% stated in the expert's claim. This slight difference may arise due to rounding errors or the fact that the expert's statement does not specify which trial the claim is referring to, potentially implying a combination of both trials.\n4. Nevertheless, the expert's claim is still within a reasonable range of the actual data in the CTR. Since the CTR data shows a high percentage of participants achieving Recurrence-free Survival after 5 years and the expert's claim does not contradict that, it is entailed.\n\nHowever, if there existed significant differences between the two groups in terms of their Recurrence-free Survival rates, such that the combined percentage was below 82%, then the expert's claim would be contradicted by the CTR data. In that case, the CTR sections relevant to the comparative analysis and the differences in outcomes between the two groups would need to be carefully examined to determine the reason for the discrepancy."
    },
    "ff8a1e0d-d2ee-4687-b429-5b3b6081edc6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00915603",
        "Secondary_id": "NCT02511730",
        "Statement": "INR of 1.35 is enough for participation in the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"INR of 1.35 is enough for participation in the primary trial and the secondary trial\" cannot be directly entailed or contradicted based on the provided CTR sections alone. The primary CTR includes the INR requirement for eligibility in the \"Adequate coagulation function\" section, which specifies an INR <=1.5 or PT/PTT within normal limits for patients not on anticoagulation therapy. The secondary CTR does not mention any INR requirement. Therefore, while an INR of 1.35 falls within the permissible range for the primary trial, there is no explicit statement in either CTR to confirm or deny that it is sufficient for both trials."
    },
    "b86f0f3c-7905-470d-ae5d-e1867eb8bd3b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00917735",
        "Statement": "One patient in cohort 2 of the primary trial crashed their motorbike.",
        "Label": "Entailment",
        "explain": "The statement \"One patient in cohort 2 of the primary trial crashed their motorbike\" is contradicted by the CTR data. According to the CTRs provided, there were no instances of motorcycle accidents reported in cohort 2 of the primary trial (0/538)."
    },
    "0aa3c085-b9c6-4918-a5d0-eabc55bdd177": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01560416",
        "Statement": "There was over 10 more cases of adverse events in cohort 2 than in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The statement \"There was over 10 more cases of adverse events in cohort 2 than in cohort 1 of the primary trial\" is contradicted by the data provided in the CTRs. \n\nExplanation: The number of adverse events in each cohort is as follows:\n\nPrimary Trial, Cohort 1: Total: 2/15 (13.33%)\nPrimary Trial, Cohort 2: Total: 11/35 (31.43%)\n\nThe difference between the number of adverse events in cohort 1 and cohort 2 is 9 (11-2 = 9), which is less than 10 cases. Therefore, the statement is contradicted by the data presented in the CTRs."
    },
    "333c2723-e2e8-4c68-9591-36b7f169ff26": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00828074",
        "Statement": "A higher percentage of cohort 1 of the primary trial showed signs of fever, compared to cohort 2.",
        "Label": "Entailment",
        "explain": "Contradicted. The CTRs provided do not show a higher percentage of cohort 1 participants exhibiting fever compared to cohort 2. In the primary trial, only 2/41 (4.88%) patients in cohort 1 reported fever, while none (0.00%) reported fever in cohort 2 of the secondary trial."
    },
    "1fa01b9a-1288-404c-ad58-8dcf3db3264c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00477464",
        "Statement": "59% of Arm A of the primary trial achieved a best overall response, classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR data. \n\nJustification: \n\nThe statement asserts that 59% of participants in Arm A of the primary trial achieved a best overall response (BOR) that met the CTR's definition of a clinical benefit response (CBR), which includes complete or partial (confirmed) tumor responses or stable disease for at least 6 months. \n\nThe CTR specifies that the outcome measure for this trial is the Clinical Benefit Response (CBR), as defined in the Outcome Measurement section. The CTR also reports that 28 out of 51 participants (54.9%) in Arm A achieved a CBR, meaning 54.9% is the percentage of participants who experienced a best overall response meeting the criteria. Since 54.9% is close to 59%, the discrepancy is not significant enough to contradict the expert statement. Therefore, the statement is entailed as it aligns with the information provided in the CTR."
    },
    "ed272c3f-37a1-4db7-8990-bf226f8c9822": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02049957",
        "Secondary_id": "NCT01506609",
        "Statement": "There is the same number of cases of Diplopia in the primary trial as anemia in the secondary trial.",
        "Label": "Entailment",
        "explain": "Contradicted\n\nExplanation:\n\nThere are no cases of Diplopia reported in either the primary or secondary trial Adverse Events 1 or 2. However, Anemia was not reported in the primary trial at all. Thus, the statement that there is the same number of cases of Diplopia in the primary trial as Anemia in the secondary trial is contradicted by the provided CTR data."
    },
    "b1497cf4-6b06-4227-b679-19e2ac5fb5c3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01421017",
        "Statement": "the primary trial studies the effects of CTX/IMQ/RT and Epothilone on Central Nervous System (CNS) Progression-free Survival(PFS), 9 weeks after the start of treatment.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed, as both the primary trials include the use of Imiquimod, Radiation, and the assessment of tumor response rates. However, the statement goes beyond the scope of the provided data in the CTRs by discussing CNS Progression-free Survival (PFS) and the inclusion of Epothilone, which is not mentioned in the CTRs. Therefore, while the entailment holds for the parts relating to the use of Imiquimod, Radiation, and tumor response rates, it does not hold for the entire statement due to the addition of CNS Progression-free Survival and Epothilone."
    },
    "186d5a67-1309-4abc-b31a-de026c5b8bda": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "Patients diagnosed with intradural tumors are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the Primary Trial's Inclusion Criteria which does not mention any specific exclusion based on intradural tumors."
    },
    "6b86f306-f989-4676-8f5e-c4c8a6aa4258": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470847",
        "Statement": "the primary trial participants will receive either Lapatinib, WBRT or Herceptin.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary trial's INTERVENTION 1 section, as it specifies that participants receive Lapatinib, Whole Brain Radiation Therapy (WBRT), and then Herceptin."
    },
    "0e8e4a92-b104-4192-ad36-33b683f94216": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02463032",
        "Statement": "There was less than a 5% difference in the results from the 9 mg and 18 mg group in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"There was less than a 5% difference in the results from the 9 mg and 18 mg group in the primary trial\" can be entailed by the information in the CTRs. This is because the text states that the number of participants with clinical benefit in both arms was similar: 16 out of 50 in the 9mg group and 15 out of 52 in the 18mg group. The difference between the two numbers is 1, which is less than 5% of the total number of participants analyzed (102) in the primary trial. Therefore, the statement is an accurate reflection of the data presented in the CTRs."
    },
    "47ea6e1a-c9dd-4fc6-82b6-7af46dec7a12": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00438659",
        "Secondary_id": "NCT01271725",
        "Statement": "the primary trial has a topical intervention, whereas the secondary trial has both oral and IV interventions.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTRs. In the primary trial, the intervention is a topical application of mometasone furoate cream, while in the secondary trial, one of the interventions is Afatinib monotherapy, which is administered orally. The secondary trial also includes an intravenous intervention of Paclitaxel or Vinorelbine. Therefore, the statement accurately reflects the difference between the interventions in the two trials."
    },
    "03a8a787-2bf3-43e5-9c9e-7bd9c3278751": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171704",
        "Statement": "All patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 3 years.",
        "Label": "Contradiction",
        "explain": "To determine if the statement is entailed or contradicted by the CTRs, we need to evaluate if the statement harmonizes with the provided clinical trial data and avoids contradiction.\n\nThe Letrozole group in the primary trial had a median percent change of -4.63 (-14.21 to 4.32) in Bone Mineral Density (BMD) of the Lumber Spine after 2 years. Although the statement refers to a 3-year time frame, the given data suggests that a decreased BMD can be observed within this period.\n\nHowever, the statement's scope is \"All patients in the Letrozole group,\" while the CTR provides median and range data for this group. The statement does not contradict the given data but does not fully entail it either, given the absence of specific information about individual patient data or the percentage of patients with decreased BMD after 3 years.\n\nTherefore, the statement \"All patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 3 years\" can be considered neither strictly entailed nor strictly contradicted by the provided clinical trial data."
    },
    "7d7a9a69-533a-4480-b2e7-aa59eb8a738b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02260531",
        "Statement": "the percentage of participants achieving complete response (CR) or partial response (PR) was 6x higher in the HER2-positive group in the primary trial, than in the ER+ and/or PR+ group.",
        "Label": "Contradiction",
        "explain": "The expert's statement contradicts the given CTR data. \n\nExplanation: \n\nThe statement asserts that the percentage of participants achieving CR or PR was 6x higher in the HER2-positive group compared to the ER+ and/or PR+ group based on the primary trial. However, neither CTR provides the actual percentage of participants achieving CR or PR for each group. The percentage mentioned in the CTRs (Results 1 and 2) only indicate the number of participants in each group. To make an entailment judgment, we require the actual percentage of participants who achieved CR or PR for each group. The provided data does not support the expert's statement as it is."
    },
    "c6fc8336-7c74-443e-9548-3bbafe21fc37": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00036270",
        "Statement": "In total Less than 10% of patients in the primary trial either had a disease relapse or died.",
        "Label": "Entailment",
        "explain": "The statement \"In total, less than 10% of patients in the primary trial either had a disease relapse or died\" cannot be directly entailed from the provided information in the CTRs. However, it can be calculated based on the given data. The total number of participants in both arms of the primary trial is 4898 (Exemestane: 2466, Tamoxifen followed by Exemestane: 2432). The number of events (disease relapse or death) in the Exemestane arm is 352 and in the Tamoxifen followed by Exemestane arm is 388. Therefore, the total number of events is 740. To find the percentage of patients with disease relapse or death, we divide the total number of events by the total number of participants and multiply by 100: (740/(4898*2))*100 \u2248 6.22%. Since this value is lower than 10%, the statement is not contradicted by the CTR data. However, it is important to note that this calculation is based on the information provided in the CTRs and does not necessarily reflect the actual percentage of patients in the trial who experienced disease relapse or death during the follow-up period."
    },
    "9035000f-d87b-439f-882a-e6e30694e391": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "Patients currently prescribed Diuretics are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The Exclusion Criteria in the Primary Trial explicitly states that medication(s) known to affect body fluid balance are among the exclusion criteria. Diuretics are a type of medication that influences body fluid balance, and hence patients taking diuretics are included within the list of exclusions."
    },
    "522ca0ec-aeb0-4083-a274-ab58c2cddb8a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03210220",
        "Secondary_id": "NCT00290745",
        "Statement": "Unlike the primary trial, the secondary trial does not test Gonadotrophin-releasing Hormone Analogues or medical devices.",
        "Label": "Contradiction",
        "explain": "The statement is entailed as neither of the primary or secondary trial's intervention sections mention the use of Gonadotrophin-releasing Hormone Analogs or medical devices."
    },
    "46d65581-7a0a-423b-907e-662c1f5843cc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "There were 4% more cases (1 more case) of Dyspnea than Dehydration in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the data in the primary trial's Adverse Events section. Specifically, there were 2 cases of Dyspnea and 1 case of Dehydration. The difference between the two is 1 case, which represents a 4% difference when expressed as a percentage of the total number of adverse events in the trial (48 cases in total)."
    },
    "f4ea6e98-75e1-43a0-8202-548bb7ceb66c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02725801",
        "Statement": "The intervention in the primary trial requires patients to receive multiple applications of treatment over a period of several weeks, whereas the interventions for the secondary trial are only apllied once.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTRs. \n\nJustification:\nIn the primary trial, patients in intervention 1 and intervention 2 receive treatment applications for multiple weeks: 1 g of gel (weeks 1-3, single daily application; weeks 4-12, twice weekly application). In contrast, the secondary trial describes interventions that are applied only once: one-port or two-port tissue expander placement during breast reconstruction. The statement accurately conveys this difference in treatment application schedules, making it entailed by the information within the CTRs."
    },
    "c3a618d6-2c2e-4ed6-bfe7-88d28ec18240": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00534417",
        "Statement": "The median TTP for patients in cohort one of the primary trial is NA.",
        "Label": "Contradiction",
        "explain": "Contradicted. The CTR for the primary trial states that the median TTP for the Capecitabine and Fulvestrant arm is 26.94 months (7.26 to NA)."
    },
    "932728c5-2e7f-401f-be64-e90597ff2ce2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129935",
        "Statement": "There were more cases of embolisms in cohort 2 of the primary trial than cohort 1.",
        "Label": "Entailment",
        "explain": "Contradiction. The statement contradicts the information in the CTRs as both cohorts 1 and 2 from the primary trial had an equal number of thrombosis/embolism cases (1 each), and cohort 2 from the secondary trial is not mentioned in the provided CTRs."
    },
    "54ad9406-852c-40fc-bd0e-8e7e81eacc71": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00291577",
        "Statement": "It is not possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 16, 17 or 20 hours",
        "Label": "Entailment",
        "explain": "Contradicted. The CTR states that the median Tmax for SU011248 and SU012662 at C1D2 and C2D3 is 6.0 hours (with ranges of 2.0 to 24.0 hours). The median Tmax for the total drug at C1D2 and C2D3 is also 6.0 hours (with ranges of 2.0 to 24.0 hours and 2.0 to 8.0 hours, respectively). None of the reported values fall within the range of 16, 17, or 20 hours."
    },
    "7021a4a9-b474-4568-a3b8-015a50c9d9cc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201760",
        "Secondary_id": "NCT00127933",
        "Statement": "Patients must have a triple negative infiltrating breast carcinoma to participate in the secondary trial or the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Patients must have a triple negative infiltrating breast carcinoma to participate in the secondary trial or the primary trial\" is not strictly entailed by either CTR as stated. The primary CTR includes eligibility criteria for Her 2/neu positive breast cancer, but it does not mention anything about the patients having to have triple negative breast cancer. The secondary CTR only includes criteria for HER2-neu negative or positive breast cancer, but it does not exclude patients with triple negative breast cancer. Therefore, the statement is not strictly entailed by the provided CTRs, as some trials within the study could allow for participation from patients with triple negative breast cancer, while others may not. \n\nHowever, the statement could be considered consistent with the primary CTR if we assume that the expert was only referring to the primary trial and that the statement is meant to add an additional eligibility criterion for that specific trial. In this case, the statement would be contradicted by patients who meet all the other eligibility criteria for the primary trial but do not have triple negative breast cancer. \n\nTherefore, the statement is not strictly entailed by the provided CTRs, and its validity would depend on the specific context and intentions of the clinical trial expert who crafted it."
    },
    "24eced44-40b2-4365-abd3-42eb13220cf0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290745",
        "Statement": "There is no radiotherapy or educational part of the intervention used in the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nThe primary CTR mentions \"conventional surgery\" as an intervention, which can include radiotherapy as part of the treatment modality. Therefore, the expert's statement is contradictory to the CTR information."
    },
    "3e2dda3a-815f-4681-a470-009d9f9b30d6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01448447",
        "Secondary_id": "NCT03252145",
        "Statement": "the primary trial is testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device ",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs. \n\nJustifications:\n1. In the primary trial, patients are treated with HDR brachytherapy using Mammosite ML as a sole method or as a boost technique for breast cancer or DCIS. HDR brachytherapy is a radiation therapy intervention.\n2. In the secondary trial, patients undergo Manual Lymph Drainage (MLD) or PhysioTouch (negative pressure massage) to manage lymphedema. These are not radiotherapy interventions but rather hand-held medical devices used for lymphatic drainage.\n\nThus, the statement accurately distinguishes the radiotherapy intervention in the primary trial from the hand-held medical devices in the secondary trial."
    },
    "1a293e7c-691f-4f93-bab8-6bf5d9b3f904": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01653964",
        "Secondary_id": "NCT02660788",
        "Statement": "The interventions in the primary trial and the secondary trial are similar, as they are testing the same medication, however they are not using the same doses.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs.\n\nJustification: \n\nThe primary trial and the secondary trial both involve the use of Tc-99m sestamibi for intervention, which is the same medication in both trials. However, the dosages used differ between the trials (4 mCi and 8 mCi for the primary trial, and no mention of dose in the secondary trial, which implies a standard dose). Despite this difference in dosage (which is a component of the intervention), the trials still test the same medication, making the statement true. The CTRs do not contradict the statement, and the statement is consistent with clinical trial data."
    },
    "a87e6e20-c7d0-4941-9933-204fab99b299": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00444535",
        "Statement": "Less than 1/3 participants in the primary trial treated with Lapatinib achieved Progression-free Survival Rate After 6 months of Study Treatment.",
        "Label": "Contradiction",
        "explain": "The statement \"Less than 1/3 participants in the primary trial treated with Lapatinib achieved Progression-free Survival Rate After 6 months of Study Treatment\" contradicts the given CTR information. The CTR reports the Progression-free Survival Rate After 12 Weeks of Study Treatment, which is not the same as 6 months. The provided information does not offer details regarding the progression-free survival rate beyond week 12."
    },
    "6c3427a8-27a1-459c-9fbc-175649210868": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01940497",
        "Statement": "There were more allergic reactions observed in cohort 1 of the primary trial than cohort 2.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nThe CTRs do not support the statement as they both report zero cases of anaphylactic shock in both cohorts of their respective trials."
    },
    "883bec6a-bce2-4e60-9304-49a056e66df7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00101400",
        "Statement": "A female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/\u00ac\u00a8\u00ac\u00b5l and total bilirubin < 1.2 x ULN are eligilbe for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the Primary Trial's Inclusion Criteria regarding Hemoglobin (>9.0 g/dl), Platelet count (100,000/\u00b5l), and normal liver function (total bilirubin =1.5 x ULN or <1.2 x ULN for this female). However, her absolute neutrophil count (ANC) of 1,733/mm3 falls below the stated requirement of >1,500/mm3. Therefore, the statement is not fully entailed but partially, as this criterion is not met.\n\nTo be clear, the female's eligibility for the clinical trial depends on all the stated inclusion and exclusion criteria, including the one related to the ANC. Thus, the female is not entirely eligible based on the statement alone, and further evaluation of her eligibility is necessary."
    },
    "8720143a-2611-4502-a5ee-da4e641df918": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02402764",
        "Secondary_id": "NCT00490646",
        "Statement": "There were no cases of extravasation in either the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"There were no cases of extravasation in either the primary trial or the secondary trial.\" is entailed by the provided CTR data, as both trials reported a total of 0/24 (0.00%) cases of extravasation in their respective Adverse Events sections."
    },
    "0fdda7a2-4119-40a7-84f3-6c5c6077df49": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02186015",
        "Statement": "Women in cohort A and B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the given CTRs.\n\nJustification: \n\nIn the primary trial, women with serum 25 (OH)D greater than or equal to 30 ng/ml were not given weekly supplementation of cholecalciferol according to INTERVENTION 2. Therefore, the statement about women in cohort A and B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml not receiving weekly supplementation of cholecalciferol is a logical conclusion from the provided information."
    },
    "e7eae332-6b6a-41e0-aa31-86a781fd373f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01273896",
        "Statement": "There was twice as many Cardiac adverse events as cases of Dyspnea in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nThe given statement claims that there were twice as many Cardiac adverse events as cases of Dyspnea in cohort 1 of the primary trial. However, the data in the CTR shows that there was only 1 case (4.55%) of Cardiac adverse events (General, other) and 2 cases (9.09%) of Dyspnea (shortness of breath). Thus, the statement contradicts the provided data, as the number of Cardiac adverse events does not equal twice the number of cases of Dyspnea."
    },
    "9a52d5d4-ff71-42ee-8672-ec4ac3cfd591": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01439945",
        "Statement": "In the primary trial Low Dose Magnesium Oxide is 400 mg/day less than high dose Magnesium Oxide.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the CTRs.\n\nJustification: \n\nThe statement \"In the primary trial, Low Dose Magnesium Oxide is 400 mg/day less than high dose Magnesium Oxide\" is entailed by the CTRs because the primary trial specifies that the low dose group receives 800 mg/Day of magnesium oxide (two 400 mg tablets daily), while the high dose group receives 1200 mg/Day of magnesium oxide (three 400 mg tablets daily). The difference between the low and high doses is indeed 400 mg/day."
    },
    "c09b9f7c-2d22-4c44-a79d-32929530dd9e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01735175",
        "Secondary_id": "NCT01216319",
        "Statement": "the secondary trial and the primary trial are both testing Biodesign interventions.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided CTRs.\n\nJustification:\n- The primary trial's Intervention 1 specifies the use of LA-EP2006 in the primary trial, but LA-EP2006 is a form of Biodesign product (as mentioned in the secondary trial).\n- The primary trial's Intervention 2 specifies the use of Neulasta\u00ae, which is a brand name for pegfilgrastim, and pegfilgrastim is also a Biodesign product.\n- The secondary trial's Intervention 1 specifies the use of Biodesign's Nipple Reconstruction Cylinder, which is not directly related to the interventions in the primary trial but the statement does not contradict the information in the CTRs because it only claims that both trials are testing Biodesign interventions, which is true according to the provided information."
    },
    "6f143256-52e4-40b7-950c-5c892f8632b9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00003199",
        "Statement": "The patient group with the highest percent of PFS at 5 months in the primary trial was Stage IIIB patients, and the worst was Stage IV Disease patients.",
        "Label": "Contradiction",
        "explain": "Contradiction. The primary trial's results do not support the expert's statement about PFS (Progression-Free Survival) at 5 months. The CTR mentions \"Event-free survival\" with a time frame of 11 years, but no information is provided about PFS within 5 months in the primary trial."
    },
    "d2718f05-1d35-4c84-a054-06a3fe4a0a9c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00217399",
        "Statement": "To be included in the primary trial, patients must have at least 1 unidimensionally measurable lesion, and must meet some specific size conditions.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR as per the inclusion criteria of the primary trial which states, \"Lesion >= 10 mm on CT scan (5 mm sections) or Lesion >= 20 mm on CT scan or MRI (10 mm sections) or Bone disease that is >= 10 mm on MRI or Lytic bone lesions that are >= 10 mm on CT scan (with 5 mm sections) OR >= 20 mm on plain film or CT scan (with 10 mm sections) or Lesion >= 10 mm on physical exam.\" These conditions specify that patients must have at least one measurable lesion that meets certain size requirements."
    },
    "7f49cafd-3a27-4fc8-872d-914b9176442e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01427933",
        "Statement": "Neutropenia was the most common adverse event for patients in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR data in Adverse Events 1 of the primary trial, as Neutropenia had the highest occurrence rate among all adverse events, with 4/69 (5.80%) reported cases."
    },
    "2e84c5ba-2de9-42a1-8e75-44f6d5e9ef25": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01998906",
        "Statement": "The same number of cases of Neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the CTRs. \n\nJustification: \n\nIn the primary trial, there is 1 case of Neutropenia (1/115) and no case of Pancytopenia (0/115). In the secondary trial, there is 1 case of Neutropenia (1/112) and no case of Pancytopenia (0/112). Therefore, the statement that the same number of cases of Neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial is incorrect."
    },
    "3bf314d0-2cd6-4331-ad4e-6aa7961d6cd8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00428922",
        "Secondary_id": "NCT00499083",
        "Statement": "Patients with prior radiotherapy for the treatment of stage 4 cancer over 5 years ago, are not eligible for either the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by both primary and secondary trial inclusion criteria, as neither trial accepts patients with prior radiation therapy within the last 4 weeks (primary trial) or at all (secondary trial). Therefore, the statement is consistent with the provided CTR information."
    },
    "4ab00376-83a4-467e-8a1e-6b8b1643a8f0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365599",
        "Secondary_id": "NCT01771666",
        "Statement": "Black men with and ECOG <=2, with ANC >1.5 x 10^9/L, PLT >100 x 10^9/L and no prior history of blood clots are eligible for the primary trial but excluded from the secondary trial",
        "Label": "Entailment",
        "explain": "The statement is entailed by the Primary CTR as it specifies the inclusion criteria for Black men in terms of ECOG (<=2), ANC (>1.5 x 10^9/L), PLT (>100 x 10^9/L), and absence of prior history of blood clots. However, the statement contradicts the Secondary CTR as Black men are excluded in the Secondary trial without any specific condition mentioned related to these laboratory parameters or blood clot history. Therefore, the statement should be entailed with the Primary CTR but contradicted with the Secondary CTR."
    },
    "e2d8e4b2-d5dc-404c-98a5-2a6799dd29c1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565499",
        "Secondary_id": "NCT01234402",
        "Statement": "None of the patients in the primary trial were recorded as having heart related adverse events, whereas many patients in the secondary trial experienced several different heart related issues.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary trial reported one case of cardiac failure in the adverse events section. Therefore, the statement that \"None of the patients in the primary trial were recorded as having heart related adverse events\" is contradicted by the data in the CTR."
    },
    "407369fa-92ba-4994-8a0f-d372995f3241": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02699983",
        "Secondary_id": "NCT00994279",
        "Statement": "Neither the primary trial or the secondary trial require participants to practice yoga.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nJustification:\n\nFor the primary trial, participants in Group I of INtervention 1 do receive a yoga intervention in Arm 1 of the secondary trial, which contradicts the statement that neither of the trials require yoga practice. For the secondary trial, Arm 1 of Intervention 1 does involve the yoga intervention, as stated in the text provided."
    },
    "05e50a3d-d5b2-4fe6-9709-c884c89c5f71": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01004172",
        "Secondary_id": "NCT00802945",
        "Statement": "the primary trial and the secondary trial both evaluate response rates, however the primary trial studies CNS response, whereas the secondary trial studies tumor response, additionally, they test different treatments.",
        "Label": "Entailment",
        "explain": "The statement is entailed. The primary trial evaluates CNS objective response rate, while the secondary trial evaluates objective response rate via RECIST v1.0 for tumor targets. Although the focus of the response evaluation is different between the trials, they both measure response rates. Additionally, they test distinct treatments (Carboplatin, Bevacizumab, Trastuzumab for the primary trial vs. NKTR-102 for the secondary trial). This difference in treatments does not contradict the statement, as the trials are separate and evaluate different aspects and treatments."
    },
    "59fd53e4-b38c-4018-bafc-6fd7f7becebe": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00546104",
        "Statement": "1 patient in the primary trial suffered from a blood clot blocking their blood vessels.",
        "Label": "Entailment",
        "explain": "The statement \"1 patient in the primary trial suffered from a blood clot\" is entailed, as thrombosis (a type of blood clot) is listed as an adverse event in the CTR with a frequency of 1/31 (3.23%)."
    },
    "c17eaeab-4e99-4cc4-8681-ae6ccddba572": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01926886",
        "Statement": "There were no cases of Cellulitis, Nausea or Anaemia in the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted, as the statement asserts that there were no cases of cellulitis, nausea, or anaemia in the primary trial, whereas the CTR reports 0 cases for cellulitis, 0 cases for nausea, but 1 case for anaemia (as part of an adverse event: Infected lymphocele leading to anemia). Therefore, the statement contradicts the information provided in the CTR."
    },
    "621d06ac-12dd-42c2-a012-15c1d94a4f0b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00952692",
        "Statement": "Candidates for the primary trial must have adequate renal and hepatic function, and must not be currently receiving amiodarone or have received amiodarone in the 6 months",
        "Label": "Entailment",
        "explain": "The statement is entailed by the Primary Trial's Inclusion Criteria since the CTR explicitly states that the patient must have adequate renal and hepatic function, and must not be currently receiving amiodarone or have received amiodarone in the 6 months prior to screening. (Section 4.1.3 and 4.3.3)."
    },
    "021e79d2-ce70-43cf-aac9-fa8d4c8d3770": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193063",
        "Statement": "In the primary trial patient cohort, 3 different types of infections are observed, these are pneumonia, urinary tract and Athlete's foot.",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nThe statement mentions \"Athlete's foot\" as one of the infection types in the primary trial, but the CTR does not list \"Athlete's foot\" under the Adverse Events section of the primary trial. Only \"pneumonia,\" \"urinary tract,\" and \"infection - port site\" are mentioned. Therefore, the statement contradicts the information provided in the CTR."
    },
    "06aa0fbc-fe49-4715-88cc-507646f6323f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00486525",
        "Statement": "The difference between the two cohorts of the primary trial is that cohort 1 participated in a Hatha yoga, whereas cohort 2 abstained from yoga.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the CTRs. Specifically, the ELIGIBILITY CRITERIA and INTERVENTION sections of the primary trial clearly outline that participants in Arm I (cohort 1) received Hatha yoga therapy, while those in Arm II (cohort 2) did not participate in any yoga practice during the study period."
    },
    "21947261-bbef-4d3a-adda-02bb4a91a3ca": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754325",
        "Secondary_id": "NCT00399529",
        "Statement": "the secondary trial and the primary trial both accept patients with progesterone receptors(PgR+) adenocarcinoma of the breast.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTR information. Both trials include patients with PgR+ breast cancer, which is specified in the inclusion criteria for the primary trial (\"Histologically confirmed hormone receptor positive (HR+) [(estrogen receptor (ER+) and/or progesterone receptors(PgR+)] breast cancer\") and in the inclusion criteria for the secondary trial (\"Patients with histologically confirmed HER-2/neu-overexpressing adenocarcinoma of the breast; this is defined as HER-2+ by immunohistochemistry (IHC) 3+ staining or Fluorescence In-Situ Hybridization (FISH), or HER-2/neu gene amplification by silver in situ hybridization (SISH). Hormone receptor status will be determined by IHC, and patients with hormone receptor positive disease are eligible for enrollment\")."
    },
    "71daae7c-3ee5-4451-91e2-273d8ff55aae": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00617942",
        "Secondary_id": "NCT00388726",
        "Statement": "the secondary trial had a lower total number of patients experiencing adverse events compared to the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed based on the data provided in the Adverse Events sections of both CTRs. In the primary trial, there were a total of 7/37 (18.92%) adverse events, while in the secondary trial there were 64/247 (25.91%) adverse events. The lower total number of adverse events in the secondary trial is evident from the numbers provided."
    },
    "4a14a8f4-c9c2-4aa2-85bc-caa1f9820e37": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00203502",
        "Statement": "Every single patient in the primary trial experienced at least 1 adverse event.",
        "Label": "Entailment",
        "explain": "The statement \"Every single patient in the primary trial experienced at least 1 adverse event\" is entailed by the provided data, as the total number of adverse events is equal to the total number of patients and each adverse event count is represented as a percentage of the total number of patients. (Adverse Events 1: Total = 39/39 * 100.00% = 100.00%). Therefore, it is guaranteed that every patient in the trial had at least one recorded adverse event.\n\nReference(s):\nAdverse Events 1 section of the Primary CTR."
    },
    "7d22937b-9823-45fa-a914-261f993e4d64": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01644890",
        "Statement": "Throughout the primary trial, one patient developed issues with their vision.",
        "Label": "Entailment",
        "explain": "The statement \"Throughout the primary trial, one patient developed issues with their vision\" is entailed by the CTR as one patient in the primary trial experienced macular fibrosis, which is a type of vision issue (CTR Adverse Events 1: Macular fibrosis 1/214). However, it is important to note that the statement is a broader claim, as it uses the term \"issues with their vision\" without specifying the exact type or severity of the vision problem. The CTR, on the other hand, lists macular fibrosis as an adverse event, indicating that it was observed during the trial, but it does not provide additional details about the impact on the patient's vision or the frequency or duration of the issue. Therefore, the statement is entailed, but it may not capture the full extent of the information provided in the CTR. Similarly, for the secondary trial, there is one case of cataract reported (Adverse Events 2: Cataract 1/213), which also fits the statement, but no further details are given. Therefore, the statement is also potentially entailed for the secondary trial with the limitation that it may not capture all the specifics of the cases reported."
    },
    "507a4189-4905-4752-8348-d715a5ce3962": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01940497",
        "Statement": "There were 3 more allergic reactions observed in cohort 1 of the primary trial than cohort 2.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nThe statement asserts that there were three more allergic reactions in cohort 1 of the primary trial than in cohort 2. However, there were no allergic reactions reported in either cohort in the given adverse event data. Specifically, the CTRs do not provide evidence for any occurrences of anaphylaxis, which is the type of allergic reaction typically referenced when making such a statement."
    },
    "24001e83-6a8c-4f67-9c24-55dc285c4cc2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00096356",
        "Statement": "the primary trial results indicate that CoQ10 reduces the level of fatigue experienced by patients compared to a placebo.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR information. In Results 1, the least squares mean for Arm 1 (CoQ10 & Vitamin E) is 6.96 with a standard error of 0.71. In Results 2, the least squares mean for Arm 2 (Placebo & Vitamin E) is 8.33 with a standard error of 0.79. The difference between the two least squares means is 1.37 (8.33 - 6.96); since lower values on the POMS-F scale indicate less fatigue, this difference suggests that participants in Arm 1 experienced less fatigue on average compared to those in Arm 2. Therefore, the statement that \"the primary trial results indicate that CoQ10 reduces the level of fatigue experienced by patients compared to a placebo\" is in agreement with the provided CTR data."
    },
    "d179396d-94fe-465f-a4f1-e7c3291a0a9a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00513695",
        "Statement": "filgrastim is the only drug in the primary trial given by subcutaneous injection.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR information. The primary trial specifies that filgrastim is given by subcutaneous injection in the section describing the interventions."
    },
    "4b893eeb-80a4-4a83-8df5-b5c668ce55b1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00796978",
        "Secondary_id": "NCT01276041",
        "Statement": "More patients in the secondary trial suffered from oedema in their limbs, compared to patients in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"More patients in the secondary trial suffered from edema in their limbs, compared to patients in the primary trial\" is entailed by the provided CTR data. The Adverse Events section of the primary trial reports 1 case (1.79%) of limb edema out of 56 participants, while the Adverse Events section of the secondary trial reports 2 cases (2.86%) out of 70 participants. Therefore, the secondary trial had a higher frequency of limb edema cases."
    },
    "44cd16f5-6638-4d82-9121-1941eb8ce4b5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448279",
        "Statement": "In total there were more adverse events in cohort 1 of the primary trial, than in cohort 2.",
        "Label": "Entailment",
        "explain": "Contradicted. The given CTRs state that there were an equal number of total adverse events in both cohorts of the primary trial (21/26 = 0.081, 20/28 = 0.071). Therefore, the statement that \"there were more adverse events in cohort 1\" is contradictory to the provided data."
    },
    "50ac2c53-3b63-4507-8712-41f8c257b4da": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01697345",
        "Secondary_id": "NCT00513292",
        "Statement": "Fluorouracil, epirubicin, and cyclophosphamide (FEC) are used in both cohorts of the secondary trial, but not in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the CTRs.\n\nJustification:\n\nIn the secondary trial, Intervention 1 specifies the use of FEC as part of the treatment regimen, while Intervention 2 also mentions the use of FEC after paclitaxel and trastuzumab. However, in the primary trial, there is no mention of the use of FEC in either intervention. This aligns with the statement, which asserts that FEC is used in the secondary trial but not in the primary trial."
    },
    "14607d45-9aef-458d-89cc-d47c62c23322": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02322814",
        "Secondary_id": "NCT00356148",
        "Statement": "A patient with Histologically confirmed triple-negative breast cancer, with no known Brain metastases and no prior history of either autoimmune disease or cardiac dysfunction, could be eligible for both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by both CTRs. The patient described in the statement meets the inclusion criteria for both trials. The primary trial includes patients with histologically confirmed ER-negative, PR-negative, and HER2-negative breast cancer, which fits the description of triple-negative breast cancer. The patient also meets the inclusion criteria for the secondary trial as a woman with early stage breast cancer (stage I-II) and an ASA score of I-II. Neither trial excludes patients based on a history of autoimmune disease or cardiac dysfunction, as specified in the statement."
    },
    "d2961e96-bd3b-4994-aa7e-2b310eb6204e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01300351",
        "Statement": "At least 1 participant in the primary trial showed signs of poor liver function.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR data, as one participant (ID: 109) in the primary trial experienced a Hepatic function abnormal adverse event."
    },
    "8a5d7285-f4be-4e50-9057-19f74bcc410b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03106077",
        "Statement": "Patients in the primary trial receive at most 200mg of IMGN853 by IV every 3 weeks.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial CTR. The CTR specifies that Cohort A in the primary trial receives 6 mg/kg of IMGN853 by IV every 3 weeks, which translates to approximately 212mg per 3-week cycle based on a body weight of 70kg (assuming a 1:1 conversion from mg to mg for simplicity). This is more than the 200mg limit stated in the expert's claim."
    },
    "512990dd-45d2-4b31-b571-66735ff02308": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394251",
        "Statement": "There were 4 different adverse events, for which 0 cases were recorded in cohort 1.",
        "Label": "Entailment",
        "explain": "Contradicted\n\nExplanation:\n\nThe statement \"There were 4 different adverse events, for which 0 cases were recorded in cohort 1\" is contradicted by the data presented in the CTRs. In Cohort 1 of the Primary Trial, zero cases were reported for Coagulopathy, Cardiac failure, Cardiac failure congestive, Pericardial effusion, Colitis, Ileus, and Abdominal pain upper. However, there was one case of Appendicitis perforated and one case of Gastrointestinal haemorrhage. Therefore, only two adverse events had zero cases in Cohort 1, not four."
    },
    "383db144-4bcd-4ebc-989c-b6ae7d282026": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00471276",
        "Secondary_id": "NCT00951665",
        "Statement": "Gastrointestinal haemorrhage was more common in patients from cohort 2 of the secondary trial. than cohort 1 of the primary trial .",
        "Label": "Contradiction",
        "explain": "Contradicted\n\nJustification:\n\nThe statement asserts that there is a higher occurrence of gastrointestinal haemorrhage in patients from cohort 2 of the secondary trial compared to cohort 1 of the primary trial. However, the data in the CTRs contradict the statement, as there are no reported cases of gastrointestinal haemorrhage in the secondary trial's cohort 2, whereas there is one case in cohort 1 of the primary trial."
    },
    "bfa07fb7-f8cb-4215-9bca-ddee8b3bea73": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00951665",
        "Statement": "Most patients in cohort 1 of the primary trial died of unknown causes.",
        "Label": "Contradiction",
        "explain": "Based on the provided CTRs, the statement \"Most patients in cohort 1 of the primary trial died of unknown causes\" is contradicted by the information in the Adverse Events section of the primary trial. In this section, it is mentioned that only one out of 26 patients (3.85%) in the primary trial died of unknown causes. Therefore, the statement made by the expert is not entailed by the data in the CTR."
    },
    "228e80ab-84d6-4b60-9960-dcdcbd78c03c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00328783",
        "Statement": "Patients with an FEV1 of 80% to 120% are ineligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial's eligibility criteria, as no mention of FEV1 (Forced Expiratory Volume in one second) is included in the eligibility or exclusion criteria. Instead, the primary trial specifies requirements related to radiation therapy, pulmonary function, presence of heart or liver tissue, and Karnofsky Performance Status."
    },
    "b7caad28-5fb2-4eb6-845e-8315cff97318": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00896649",
        "Statement": "prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in the primary trial, neither is Adequate organ function or a particular racial or ethnic background.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial's inclusion criteria which specify that \"PRIOR CONCURRENT THERAPY: None specified\" and the eligibility criteria stating that patients are selected based on their racial or ethnic backgrounds. Therefore, the statement \"prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in the primary trial\" is not entailed by the information in the primary CTR. Additionally, there is no mention of adequate organ function in either trial's eligibility criteria, so the statement \"nor is adequate organ function or a particular racial or ethnic background\" is also not entailed."
    },
    "73c37b9c-e7ba-4c90-b26e-23b7a65509c4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005957",
        "Statement": "T2 N1 M0 adenocarcinoma of the breast are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"T2 N1 M0 adenocarcinoma of the breast are eligible for the primary trial\" is entailed by the CTR. According to the Disease Characteristics of the primary trial, patients with node-positive or high-risk node negative breast cancer are eligible, which includes T2 N1 M0 cases."
    },
    "d5b81f6c-821a-4db5-8810-9cc47a952913": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02287675",
        "Statement": "Informed consent is obligatory for entry in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the Primary Trial's Inclusion Criteria section, where it states that \"The subject must provide written informed consent with Health Insurance Portability and Accountability Act (HIPAA) authorization before participating in the study.\""
    },
    "cdba382e-894b-4f79-a8e2-ff818746adc5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01202591",
        "Statement": "100% of patients in the primary trial suffered adverse events.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the information in the CTR. According to the provided data, each arm in the Primary Trial had 5 participants analyzed, and no mention was made that all patients (100%) in either arm experienced adverse events."
    },
    "0093175a-38cb-4f63-b391-709ac48158b8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971737",
        "Secondary_id": "NCT00392392",
        "Statement": "Patients with tumors overexpressing HER-2 are eligible for the secondary trial, but not for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial CTR, which includes the condition \"Does not overexpress HER-2/neu, defined as FISH negative or 0, 1+, or 2+ by IHC.\" Therefore, patients with tumors overexpressing HER-2 are not eligible for the primary trial."
    },
    "19106207-4fa2-4cc4-8e22-6e5330bf05ce": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00846027",
        "Statement": "None of the adverse events recorded for the primary trial occurred more than once.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nExplanation: \n\nIn the primary CTR, there are repeated occurrences of the following adverse events: Neutrophils count decreased (1.22%), Cardiac ischemia/infarction (1.22%), Hypertension (1.22%), Supraventricular and nodal arrhythmia (1.22%), Vomiting (1.22%), and Diarrhea (1.22%). Therefore, the statement that \"none of the adverse events recorded for the primary trial occurred more than once\" is incorrect."
    },
    "a015685e-f744-4bb2-a6d3-893f081d6dcc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02597452",
        "Secondary_id": "NCT01929395",
        "Statement": "the primary trial and the secondary trial both use 21 day cycles for their interventions up to a maximum of 10 and 4 cycles respectively.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nJustification: \n\nThe primary trial describes the use of an iBE and a clinical breast exam during scheduled breast screening appointments, with no requirement for a return visit. The secondary trial describes the use of supine MRI with intraoperative optical scanning and tracking. Neither trial mentions the length of their interventions in terms of 21-day cycles or the number of cycles they go through. Therefore, the statement is not entailed by the provided CTRs as it contradicts the information present, which does not support the claim of both trials using 21-day cycles for their interventions."
    },
    "b9578bae-6640-4ef1-ba2c-899b45c602ee": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01487954",
        "Statement": "All patients in the primary trial had to drink 4 cups of water, either Alkaline Water or Distilled, depending on which cohort they are in.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. According to the provided information, patients in both arms (I and II) are instructed to drink 8 ounces of either alkaline or distilled water, which is equivalent to approximately 24 ounces or 3 cups per day. Thus, patients in the trial had to consume at least 3 cups of water daily, meeting the expert's requirement of 4 cups, regardless of whether it was alkaline or distilled water."
    },
    "405369ef-d216-4d81-a04f-46f36f466a19": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01416389",
        "Statement": "Cohort 1 of the primary trial had more cases of urinary infections and lumbar fractures than cohort 2.",
        "Label": "Entailment",
        "explain": "Contradicted. There is no evidence in the CTRs to support the statement that cohort 1 of the primary trial had more cases of urinary infections and lumbar fractures than cohort 2. Urinary tract infection occurred in 1/26 participants in cohort 1 and 0/13 participants in cohort 2. Lumbar vertebral fracture occurred in 1/26 participants in cohort 1 and 0/13 participants in cohort 2. The statement is contradicted by the information provided in the CTRs."
    },
    "e424c65e-7c6f-43a4-95e4-6beb705d9903": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00559754",
        "Secondary_id": "NCT02924883",
        "Statement": "A higher percent of patients in cohort 1 of the secondary trial experienced stomatitis, than in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial reported 22/72 (2.78%) instances of mucositis/stomatitis in cohort 1, and none of the adverse events in the secondary trial were related to stomatitis."
    },
    "f2bd0a9c-74c4-443e-b666-0a0b3aa125e1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01466270",
        "Statement": "The the primary trial placebo group had a better mean retention than the donepezil hydrochloride PO QD group.",
        "Label": "Entailment",
        "explain": "Contradicted\n\nExplanation:\n\nThe primary trial's results show that the mean retention percentage for Arm I (donepezil hydrochloride PO QD) was 71.0 (8.3), while Arm II (placebo PO QD) had a mean retention percentage of 80.7 (7.2). This indicates that the patients in Arm I had a lower mean retention rate compared to the placebo group in Arm II, contradicting the statement made by the expert that the placebo group had a better retention rate."
    },
    "0bf293c5-f4fc-40f1-9bd2-8f1f781c7e4a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00072293",
        "Statement": "Patients with a nonpalpable breast lesion and 0 palpable axillary lymph nodes are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the Primary Trial's ELIGIBILITY CRITERIA since it specifies \"Nonpalpable breast lesion\" and \"No palpable axillary lymph node(s)\" as conditions for patient inclusion."
    },
    "6843daf8-8136-4973-9bf2-62a622d5a890": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "Participants in the primary trial are assigned an intervention depending on their HIV diagnosis, whereas in the secondary trial the interventions are randomly assigned.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nJustification:\nIn the provided primary trial CTR, the patient cohorts for Interventions 1 and 2 are specified as \"Healthy Volunteers\" and \"Breast Cancer Patients\" respectively, with no mention of an HIV diagnosis as a factor in intervention assignment. In contrast, the expert statement suggests that interventions in the secondary trial are assigned based on HIV diagnosis. Therefore, the statement contradicts the information presented in the CTRs."
    },
    "2687b547-c225-4838-bbcd-99212a74d815": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01828021",
        "Secondary_id": "NCT01326481",
        "Statement": "Patients in the primary trial and the secondary trial did not have any of the same adverse events.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nJustification:\n\nThe statement \"Patients in the primary trial and the secondary trial did not have any of the same adverse events\" is contradicted by the provided Clinical Trial Reports (CTRs). The primary trial reported one case of headache in patient number 1/25, whereas the secondary trial reported two cases of headache, one each in patients 1/19 and 2/19.\n\nTherefore, this statement cannot be entailed based on the data in the CTRs.\n\nCTRs:\nPrimary Trial: Adverse Events 1 (contains the information about adverse events in primary trial)\nSecondary Trial: Adverse Events 1 (contains the information about adverse events in secondary trial)"
    },
    "fadf7710-6e4d-49d6-82fc-4f3137b5e26b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00759785",
        "Statement": "Only one adverse event is observed in patients from cohort 1 of the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Only one adverse event is observed in patients from cohort 1 of the primary trial\" is contradicted by the CTR data provided. The Adverse Events section of the primary trial reports a total of 25 participants, one of whom (1/25 or 4.00%) experienced syncope, which is an adverse event. Therefore, the statement does not hold true based on the CTR data."
    },
    "8c4e6f36-37b4-4bde-b518-08a6dc55f7a5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00074152",
        "Statement": "All of the adverse event cases in the primary trial occurred in patients from cohort 2.",
        "Label": "Entailment",
        "explain": "Contradicted. The provided statement is contradicted by the given data, as there are adverse events reported in the primary trial for cohort 1 as well. For instance, \"Neutropenia\" occurred in 0/77 (0.00%) cases in cohort 1 of the primary trial, but it is not stated that all cases occurred in cohort 2."
    },
    "6c0896ac-db42-45b4-a6e2-620a27fd321a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01439945",
        "Statement": "In the primary trial Low Dose Magnesium Oxide is 5% less than high dose Magnesium Oxide.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nExplanation:\n\nThe statement \"In the primary trial, Low Dose Magnesium Oxide is 5% less than high dose Magnesium Oxide\" is contradicted by the given CTR information, as the dosages of Magnesium Oxide are not 5% less in the low dose intervention. The low dose intervention in the primary trial is 800 mg/Day, while the high dose intervention is 1200 mg/Day. These values cannot be calculated to be 5% less or more of each other based on the information provided in the CTRs."
    },
    "3a80ba8a-265f-4931-a9a8-b7e00e372599": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00432172",
        "Statement": "All of the adverse events recorded in the primary trial occurred in patients from cohort 1.",
        "Label": "Entailment",
        "explain": "Contradicted. In both the Primary and Secondary trial's Adverse Events sections, there are no reported occurrences (0/45 and 0/46, respectively) for diabetes decompensation, mucositis/stomatitis and vomiting, pancreatitis, or infection pulmonary/Upper airway NOS for either cohort. Therefore, the statement that \"All of the adverse events recorded in the primary trial occurred in patients from cohort 1\" is inconsistent with the information presented in the CTRs. Additionally, none of the adverse events were reported to have occurred in cohort 1 specifically within the provided sections of the Primary trial."
    },
    "df4b98f2-7ca9-4855-8d94-d62407ff8535": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01929395",
        "Secondary_id": "NCT01857882",
        "Statement": "the primary trial only has one test cohort whereas the secondary trial has both a test and control group.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary trial only involves a single intervention group (supine MRI with intraoperative optical scanning and tracking), and does not specify the presence of a control group. The secondary trial, on the other hand, involves both a test group (decision support workshop) and a control group (standard care). The statement's claim contradicts the information in the primary CTR."
    },
    "5d2542fa-5482-4aff-af29-80875a0a9dcc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01015131",
        "Secondary_id": "NCT00312208",
        "Statement": "the primary trial records instances of Rectal Hemorrhage within its patient cohort, whereas the secondary trial records Vaginal hemorrhages.",
        "Label": "Entailment",
        "explain": "Contradiction. The primary trial reports one instance of Rectal bleeding (a type of hemorrhage) in its adverse events, while the secondary trial reports no instances of Vaginal hemorrhages. These two trials present inconsistent findings."
    },
    "5deb8ebd-fbd2-4d84-8ad2-a1248426908b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00880464",
        "Secondary_id": "NCT00458237",
        "Statement": "HIV+ Patients are excluded from both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by both CTRs. \n\nJustification:\n\nThe primary CTR explicitly states \"Evidence of HIV infection\" as an exclusion criterion under the Exclusion Criteria section. Similarly, the secondary CTR also lists \"HIV positive patients\" as an exclusion criterion under the Exclusion Criteria section. Therefore, the statement \"HIV+ Patients are excluded from both the secondary trial and the primary trial\" is an accurate summary of the information provided in the CTRs and harmonizes with the clinical trial data."
    },
    "5f4880ac-1ce2-4b89-841b-a9918720b6ea": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365417",
        "Secondary_id": "NCT00853996",
        "Statement": " To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase  < 2 x ULN, aspartate aminotransferase  <= 1.5 x ULN and Hemoglobin > 10 g/dL.",
        "Label": "Entailment",
        "explain": "The statement \"To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase < 2 x ULN, aspartate aminotransferase <= 1.5 x ULN and Hemoglobin > 10 g/dL\" is entailed by the primary trial's inclusion criteria, specifically the conditions for evidence of adequate hepatic function and the blood counts criteria. The secondary trial also includes similar criteria for evidence of adequate hepatic function and blood counts, making this statement applicable to both trials."
    },
    "b3aabfaa-23cb-4a75-8416-761d8574f0a4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01441596",
        "Statement": "Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib monotherapy from 40mg PO to 50mg PO.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the primary trial's INTERVENTION 1 section, as it describes that if Afatinib monotherapy is well tolerated, the dose may be escalated from 40 mg to 50 mg."
    },
    "f697c2d8-e0dd-476e-8ff4-dffe053076f8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00524303",
        "Statement": "The Trastuzumab arm of the primary trial reported a pCR rate of 54%, significantly worse results than the Lapatinib arm which achieved a pCR rate of 45%.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed. In the primary trial, the percentage of participants with pCR after 26 weeks of therapy in the Trastuzumab arm was 54.0%, and in the Lapatinib arm it was 45.0%. These numbers directly support the statement."
    },
    "f2c0f753-1775-42af-94f0-b87b20156e65": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02835625",
        "Secondary_id": "NCT00486525",
        "Statement": "the primary trial and the secondary trial do not use chemotherapy, radiotherapy or mammography in their interventions ",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided CTRs as none of them mention the usage of chemotherapy, radiotherapy, or mammography in their interventions. Specifically, the Primary Trial employs Digital Breast Tomosynthesis and Synthetic Mammography for imaging procedures and Yoga Therapy as an intervention in the secondary trial. Neither of these methods involves chemotherapy or radiotherapy."
    },
    "17b31c1d-db62-4628-b390-02da22512079": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01028352",
        "Statement": "Patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or sensory neuropathy, are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR, specifically the inclusion criteria section, which states that patients with Grade 1 or higher musculoskeletal pain or sensory neuropathy that developed or worsened during AI therapy are eligible for the trial."
    },
    "2e6e1044-8b4a-41f7-8319-85fc5bba4482": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00574145",
        "Secondary_id": "NCT03167359",
        "Statement": "Radiotherapy is used in all cohorts of the primary trial and the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Radiotherapy is used in all cohorts of the primary trial and the secondary trial\" is entailed by the provided Clinical Trial Reports. In the primary trial, both the Intervention A and Control ARM involve radiotherapy. In Intervention 1 of the primary trial, patients receive radiotherapy, while in the Control ARM, they receive sham healing touch therapy in conjunction with radiotherapy. In the secondary trial, all participants undergo radiotherapy as per the given protocol. Therefore, the statement holds true based on the data presented in the CTRs."
    },
    "456c6011-52bb-4c8b-9e82-e5a85cbbe0e3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00493649",
        "Secondary_id": "NCT01201265",
        "Statement": "There was 1 MRSA infection in cohort 1 of the secondary trial and 4 in cohort 2 of the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"There was 1 MRSA infection in cohort 1 of the secondary trial and 4 in cohort 2 of the primary trial\" is not directly entailed by the provided information in the Adverse Events sections of the CTRs. The Adverse Events sections do not provide any mention of MRSA infections in the trials."
    },
    "0c0324d2-0672-45cb-b715-e51e48786afb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03618017",
        "Statement": "the primary trial's intervention section does not describe the intervention dosage, frequency or duration.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nExplanation: \n\nThe statement \"the primary trial's intervention section does not describe the intervention dosage, frequency or duration\" is contradicted by the given information in the primary trial's intervention section which mentions \"pre-randomization recruitment and enrollment\" but does not specify the dosage, frequency, or duration of the intervention. However, it is common for intervention sections to describe the recruitment process without specifying the dosage, frequency, or duration of the intervention itself. Therefore, the statement is not strictly entailed but rather contradicted in a technical sense. To entail the statement, the intervention section should have explicitly stated that the dosage, frequency, or duration were not mentioned."
    },
    "b3bd3522-8731-448a-bade-a5a350697a98": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01421472",
        "Statement": "Over 9 patients in the primary trial suffered from adverse events associated with a low number of white blood cells present in the bloodstream.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTR data in the \"Adverse Events 1\" section of the primary trial since 5/67 (7.46%) of the patients experienced Febrile Neutropenia, a condition characterized by a low number of white blood cells (neutrophils) in the bloodstream that increases the risk of infections. The statement does not need to be justified for the secondary trial as it does not provide any relevant information regarding adverse events or white blood cell counts."
    },
    "8607e8c1-6e99-49be-a63e-e707856c805a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572038",
        "Secondary_id": "NCT00826267",
        "Statement": "Each patient in the primary trial receives 3 different drugs, whereas in the secondary trial patients are given supportive-expressive group psychotherapy instead.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted based on the provided CTR sections. The primary trial specifies the administration of Pertuzumab, Trastuzumab, and either Docetaxel, Paclitaxel, or Nab-paclitaxel, while the secondary trial describes the use of Afatinib and Lapatinib only. No information about supportive-expressive group psychotherapy is mentioned in either trial."
    },
    "1c26e1a7-9d77-46ff-b1c6-179ece7c190f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03252431",
        "Statement": "On average patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time.",
        "Label": "Entailment",
        "explain": "The statement \"On average patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time\" is entailed by the provided Clinical Trial Reports (CTRs).\n\nJustification:\nThe CTRs indicate that the duration of Grade 4 Neutropenia in both arms (F-627 and Neulasta) was similar. More specifically, the mean (standard deviation) duration of Grade 4 Neutropenia for the F-627 arm was 0.2 (0.51) days and for the Neulasta arm was 0.2 (0.45) days. The difference between their standard deviations is relatively small, suggesting that the distribution of the data around their means is not vastly different. Thus, on average, patients from both arms experienced Grade 4 Neutropenia for approximately the same amount of time.\n\nReference(s):\nPrimary Trial: Results 1 and 2, specifically the Mean and Standard Deviation values for both arms."
    },
    "0a156ee2-eb90-40d2-9802-27b9b4a42ff3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Statement": "In cohort 2 and 3 of the primary trial there was only case 1 of jaundice.",
        "Label": "Contradiction",
        "explain": "The statement \"In cohort 2 and 3 of the primary trial there was only case 1 of jaundice\" is entailed by the CTR if we consider that the trial consists of a single cohort (as the term \"cohort\" is not explicitly defined in the provided information, and in the context of clinical trials, it can refer to different study groups). In this case, since there is only one reported case of jaundice in the entire study (as stated in the CTR), it is accurate that in cohorts 2 and 3, there were no additional cases of jaundice.\n\nHowever, if we interpret \"cohort\" to mean distinct study groups within the primary trial, as the information provided does not specify the number of participants or groups within cohorts 2 and 3, we cannot definitively say whether the statement is entailed or contradicted. We would need more information to make a conclusive assessment."
    },
    "82895f11-37bf-4d03-8de2-84818d93cce0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266110",
        "Secondary_id": "NCT00879086",
        "Statement": "the primary trial and the secondary trial have entirely different adverse event reports.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTRs. The primary and secondary trials report significantly different adverse event rates (37.25% in the secondary trial vs. 11.76% in the primary trial) and have different sets of reported adverse events. For example, the secondary trial reports \"Febrile neutropenia\" as an adverse event, whereas it does not appear in the primary trial's adverse event report. These differences indicate that the adverse event reports for the two trials are distinct, which is the claim made in the statement."
    },
    "f94643de-7122-4a58-972d-b0bb7e59d441": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00878709",
        "Secondary_id": "NCT02447003",
        "Statement": "the primary trial had a total of 3 patients experiencing Pancreatic Cancer, the secondary trial had 0.",
        "Label": "Contradiction",
        "explain": "Contradicted. The CTRs provided do not mention any information about patients having Pancreatic Cancer in either the primary or secondary trials."
    },
    "1485315b-3169-42a3-a672-6f7963d49a51": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01869764",
        "Secondary_id": "NCT02556632",
        "Statement": "Every participant in the secondary trial and the primary trial undergoes Laboratory Biomarker Analysis.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the provided information in both CTRs. In the Primary Trial, laboratory biomarker analysis is listed as a correlative study for both Arm I (Omega-3 Fatty Acid) and Arm II (Placebo). In the Secondary Trial, laboratory biomarker analysis is also mentioned as a correlative study for Arm I (Curcumin-based Gel) and Arm II (HPR Plus). This indicates that all participants in both trials undergo laboratory biomarker analysis as part of the trial procedures, and therefore, the expert's statement is consistent with the data in the CTRs."
    },
    "b4ef27ca-52b4-4af3-9b60-e9e0285e0e86": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03719677",
        "Statement": "Potential participants will be considered regardless of the hormone receptivity of their breast cancer.",
        "Label": "Contradiction",
        "explain": "The statement \"Potential participants will be considered regardless of the hormone receptivity of their breast cancer\" contradicts the Inclusion Criteria of the Primary Trial, which states \"one exception is that we will exclude HER2 positive BCS.\" Therefore, the statement is not entailed by the CTR."
    },
    "769bb3b2-9d2d-4dad-bd59-0042c55ac1ee": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03371732",
        "Statement": "patients with Karnofsky Index  = 72 are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs. The primary trial's inclusion criteria state that patients with a Karnofsky Index greater than 70 are eligible, and 72 falls within this range."
    },
    "426196d8-44ab-4c5c-8f81-5cb12345ad69": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00899574",
        "Secondary_id": "NCT01007942",
        "Statement": "the primary trial uses different inclusion criteria for its cohorts, the secondary trial only uses one set on inclusion criteria for all cohorts.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nThe primary trial indeed has different inclusion criteria for its two cohorts. Cohort 1 allows concurrent systemic cancer therapy if the skin metastases are non-responsive and distant metastases have been stable for more than 12 weeks. Cohort 2, on the other hand, does not have this requirement. However, the statement made by the expert is not entirely accurate because the secondary trial also has specific inclusion criteria for different patient subgroups, such as HER2+ status, resistance to trastuzumab, and prior taxane therapy. These requirements are not mentioned in the statement, which could lead to a misunderstanding of the information provided in the CTRs."
    },
    "bcf433b6-4029-4d00-9ccf-d8d94f1722d8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00365365",
        "Secondary_id": "NCT00005908",
        "Statement": "the primary trial and the secondary trial only recorded one type of acute adverse event.",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nThe primary and secondary trial Adverse Events sections list multiple types of acute adverse events for each trial. For example, in the primary trial, there are occurrences of febrile neutropenia, neutropenia, thrombocytopenia, acute coronary syndrome, cardiac failure congestive, myocardial infarction, cardiomyopathy, abdominal pain, diarrhea, and upper gastrointestinal hemorrhage in Adverse Events 1, and abdominal pain or cramping, colitis, dehydration, nausea, stomatitis/pharyngitis, and vomiting in Adverse Events 2 in the secondary trial."
    },
    "1268edfc-cce2-4f07-9fbb-392341b7f399": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01605396",
        "Statement": "The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 5 months.",
        "Label": "Entailment",
        "explain": "Contradiction. The median PFS for the Ridaforolimus + Dalotuzumab + Exemestane group was reported as 23.29 weeks (8.71 to 38.43). This value is less than 5 months."
    },
    "58ccfd13-aa6d-4604-bf3d-c69270fe50d2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01276041",
        "Statement": "1 patient in the primary trial died in an event not associated with a specifc CTCAE term.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR data. The event \"Death NOS\" (Death Not Otherwise Specified) is listed under the Adverse Events section of the Primary Trial with a frequency of 1/70 (1.43%). The expert's statement is consistent with the data provided, as both mention one death that was not attributed to a specific CTCAE term (Cardiac Toxicity Classification and Assessment of Events and Problems)."
    },
    "a6e4f4f3-72cc-4617-bf8b-7eac1c8b8249": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00509769",
        "Statement": "The majority of patients in the primary trial and the secondary trial experienced an adverse event.",
        "Label": "Contradiction",
        "explain": "The statement \"The majority of patients in the primary trial and the secondary trial experienced an adverse event\" is entailed based on the provided CTR data. The primary trial reported 24/32 (75.00%) adverse events and the secondary trial reported 30/112 (26.79%) adverse events. The total number of patients in both trials was 144 (32 from primary trial + 112 from secondary trial). The majority of patients in this total cohort of 144 experienced an adverse event, as the number of adverse events reported was greater than 50% of the total number of patients.\n\nJustifications:\n\n1. The statement is supported by the number of reported adverse events and the total number of patients in the CTRs.\n2. The statement does not contradict any information provided in the CTRs. Therefore, the statement is entailed."
    },
    "8c84c96f-1635-40dc-839b-fc937ed566a2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01105312",
        "Statement": "Patients with measurable diseases are only eligible for phase 2 of the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTR information as it clearly states, \"Measurable disease only for phase II study.\" Therefore, patients with measurable diseases are indeed the only ones eligible for phase 2 of the primary trial."
    },
    "7b48355e-3b9c-4cca-b7fa-1cbd612d1523": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320710",
        "Statement": "There was no adverse event in cohort 2 of the primary trial which occurred in more than 5% of patients.",
        "Label": "Entailment",
        "explain": "Contradiction. The statement \"There was no adverse event in cohort 2 of the primary trial which occurred in more than 5% of patients\" is contradicted by the data provided in the Adverse Events sections of the CTRs. In the Primary Trial Adverse Events 1, Neutropenia occurs in 1/198 (0.51%) of patients, which is more than 5% in cohort 2 (since the trial involves two cohorts but the provided data is for the entire cohort 1). In the Secondary Trial Adverse Events, Atrial fibrillation occurs in 1/202 (0.50%) of patients, which also contradicts the statement."
    },
    "3d188d93-13c6-48f3-b231-dcdeef81080e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "Presence of Extracranial metastases is part of the exclusion critera for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary CTR, as the document explicitly states that extracranial metastases are an exclusion criterion for the trial (Primary Trial: Disease Characteristics)."
    },
    "d7e81d80-5cbf-4969-be00-4fdf17aa4eb9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01209195",
        "Statement": "Lower doses of MM-121 and Paclitaxel are utilised in cohort1 of the primary trial than in cohort 2.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the given CTR information. In the primary trial, the dosage of MM-121 for cohort 1 is 20 mg/kg for the loading dose and 12 mg/kg for the weekly dose. In contrast, the dosage of MM-121 for cohort 2 is 40 mg/kg for the loading dose and 20 mg/kg for the weekly dose. Therefore, the dosage of MM-121 in cohort 1 is lower than that in cohort 2. Similarly, the dose of Paclitaxel remains constant at 80mg/m2 weekly for both cohorts."
    },
    "2206dc2a-93da-4c11-b110-81f9c39af807": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00101400",
        "Statement": "A female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/\u00ac\u00a8\u00ac\u00b5l and total bilirubin > 1.6 x ULN are eligilbe for the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The provided statement states that a female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/\u00b5l and total bilirubin > 1.6 x ULN are eligible for the primary trial. However, the CTR states that for Hemoglobin, the requirement is > 9.0 g/dl and for total bilirubin, it should be 1.5 x the upper limit of normal. Therefore, the statement contradicts the inclusion criteria in the CTR."
    },
    "6173faf3-f845-4cf1-94a9-756d1bff48bb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01419197",
        "Statement": "There was one patient in the primary trial who suffered from a significant decrease in the number of granulocytes in their blood.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the data in the primary trial's Adverse Events section, specifically the observation of one participant (1/403) having Granulocytopenia."
    },
    "512c72ab-f1b3-450d-8167-6e0d8d2bf5dd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02006979",
        "Statement": "Only one cohort of the primary trial needs to receive manual lymph drainage prior to each cycle of anthracyclines.",
        "Label": "Contradiction",
        "explain": "The statement is not entailed in the given CTRs. \n\nJustification: \n\nThe CTR does not provide any information regarding manual lymph drainage in the described trials, and the statement makes a claim about the application of this intervention to one cohort in the primary trial. Therefore, it cannot be directly derived from or harmonize with the information presented in the CTRs."
    },
    "ee54ca2d-ccd9-4ceb-b6e7-c1ee10de8104": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00849472",
        "Statement": "More than a dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes.",
        "Label": "Entailment",
        "explain": "The statement can be entailed by the given CTR, as the primary trial reported that \"16 out of 93 participants\" achieved pCR in the Breast and Nodes. Therefore, more than a dozen (12 or more) participants did experience this outcome."
    },
    "87987ebb-6799-4d1d-8529-d33c6b7799f8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00548184",
        "Statement": "64 of the study participants in the primary trial receiving lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week experienced at least Near Complete Pathologic Response, or better, after 12 weeks.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. In the Primary Trial's Results 1 section, there are 18 participants with Complete Pathologic Response and 16 participants with Near Complete Pathologic Response, making a total of 34 participants with a response of at least Near Complete Pathologic Response. The total number of participants analyzed in the primary trial is 64, and the statement asserts that \"64 of the study participants experienced at least Near Complete Pathologic Response.\" Therefore, the statement is a valid summary of the information presented in the CTR."
    },
    "bf94f208-a29b-4d8f-92a7-3cb8241ce344": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00097721",
        "Secondary_id": "NCT00896649",
        "Statement": "Black women cannot take part in the secondary trial or the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary CTR. The primary CTR includes patients irrespective of race. However, the secondary CTR specifically mentions inclusion for certain racial and ethnic backgrounds. Therefore, the statement that \"Black women cannot take part in the secondary trial or the primary trial\" is incorrect based on the provided CTRs."
    },
    "c68f6822-24fa-44b5-bf63-c272a8031fab": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02988986",
        "Statement": "Patients must have either AST or ALT < 1.5 ULN to participate in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Patients must have either AST or ALT < 1.5 ULN to participate in the primary trial\" is entailed by the CTR under the section \"Hepatic status: Serum total bilirubin 1 x ULN (in the case of known Gilbert's syndrome, a higher serum total bilirubin [< 1.5 x ULN] is allowed), aspartate aminotransferase and alanine aminotransferase 1.5 x ULN, and alkaline phosphatase 1.5 x ULN.\" This information is present in the eligibility criteria of the primary trial. However, it should be noted that the statement does not explicitly mention that AST and ALT refer to aspartate transaminase and alanine transaminase, respectively. Therefore, it is essential to consider the clinical context and assume that the expert intended those enzymes when making the statement.\n\nAdditionally, the statement may be contradicted by patients who have Gilbert's syndrome and meet the criteria for inclusion, as these patients are permitted to have a higher than normal (< 1.5 x ULN) serum total bilirubin level. Therefore, while the primary trial's inclusion criteria state that AST and ALT must be within the normal limits, the expert's statement only specifies that one or both liver enzymes must be below 1.5 x ULN, making it potentially more restrictive and contradictory to the provided CTR for certain individuals."
    },
    "54a459cf-f01a-4abc-a8cf-0efebc01c694": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02019277",
        "Secondary_id": "NCT00863655",
        "Statement": "the primary trial and the secondary trial recorded none of the same types of adverse events",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nThe statement is contradicted by the data presented in the CTRs. In the Primary Trial, adverse events including anaemia, febrile neutropenia, and diarrhoea, among others, were reported. In contrast, the Secondary Trial recorded adverse events such as anaemia, disseminated intravascular coagulation, and febrile neutropenia, which overlap with those reported in the Primary Trial. Therefore, the statement is incorrect.\n\nReferenced CTR Sections: \nPrimary Trial: Adverse Events 1 \nSecondary Trial: Adverse Events 1 and 2."
    },
    "dd4b5a08-c033-4429-81d0-1ad59596edbd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02683083",
        "Statement": "sufferers of hyperthyroidism and diabetes mellitus are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"sufferers of hyperthyroidism and diabetes mellitus are eligible for the primary trial\" is contradicted by the CTRs provided. \n\nExplanation: \n\nThe primary trial's exclusion criteria state that patients with thyroid disorders and abnormal kidney and liver function are ineligible. Diabetes mellitus can impact kidney function and hyperthyroidism is a thyroid disorder. Thus, according to the information given in the CTRs, patients with diabetes mellitus and hyperthyroidism are not eligible for the primary trial."
    },
    "d97ebc59-ab4b-462a-9057-12f4fc46df56": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01153672",
        "Secondary_id": "NCT01432145",
        "Statement": "Patients in the primary trial receive vorinostat at the same frequency and through the same route of administration as the secondary trial receive 6-Mercaptopurine.",
        "Label": "Entailment",
        "explain": "The statement \"Patients in the primary trial receive vorinostat at the same frequency and through the same route of administration as the secondary trial receive 6-Mercaptopurine\" is contradicted by the provided CTRs.\n\nExplanation:\n\nIn the primary trial, patients receive vorinostat PO QD (once a day) for 2 weeks followed by AI therapy PO QD (once a day) for 6 weeks. The courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. On the other hand, in the secondary trial, patients receive 6MP PO od (once a day) and Methotrexate PO QW (once a week), and both medications are administered continuously until disease progression.\n\nVorinostat and 6MP/Methotrexate are not given at the same frequency. Vorinostat is given in two distinct phases (vorinostat + AI therapy) with different durations (2 weeks vs. continuous), while 6MP/Methotrexate are given continuously. Therefore, the statement contradicts the information provided in the CTRs."
    },
    "2e4c7d0b-f1a2-4204-bac3-7445852fd916": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01727011",
        "Secondary_id": "NCT01420146",
        "Statement": "the primary trial and the secondary trial interventions involve a variety of scans, such as CT, PET, MRI and dosimetry ",
        "Label": "Contradiction",
        "explain": "The statement is entailed. In the Primary Trial, a dosimetry scanner is mentioned after irradiation, indicating the use of imaging techniques like CT for dose analysis. In the Secondary Trial, Zr89-trastuzumab PET/CT is stated, which includes PET and CT imaging modalities. Therefore, the statement about various scans being involved in both trials is in line with the provided CTR information."
    },
    "fafac1e0-1eaa-4a99-8f3f-72b3f71c4691": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT00684983",
        "Statement": "All the primary trial participants and cohort 1 participants in the secondary trial do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, however cohort 2 of the secondary trial receive all of these.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary trial involves FLT PET scan using [F18] fluorothymidine for patients undergoing standard endocrine treatment, while the secondary trial's intervention for cohort 1 includes oral capecitabine and oral lapatinib ditosylate, which contradicts the statement that no oral capecitabine or oral lapatinib ditosylate is administered in the primary trial. Furthermore, cohort 2 in the secondary trial receives all three treatments: oral capecitabine, oral lapatinib ditosylate, and cixutumumab IV, contradicting the statement that no cixutumumab IV is given in the secondary trial to the primary trial participants or cohort 1."
    },
    "4546c169-cc5c-4e03-bcce-31d491ed18e0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01989676",
        "Statement": "the primary trial only records cardiovasuclar adverse events.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the CTRs. In both Primary and Secondary trials, there are adverse events reported that are not cardiovascular in nature, such as anemia, leukopenia, neutropenia, thrombocytopenia, and atrial fibrillation."
    },
    "1bb3badf-41c6-4741-90f0-367473ce254d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00612560",
        "Statement": "children and illiterate adults are not able to take part in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the Primary Trial's Inclusion Criteria which states \"Willingness to comply with study guidelines and procedures\" and \"Willingness and ability to provide informed consent\" for all participants. The CTR does not mention any specific exclusion for children or illiterate adults based on these criteria."
    },
    "87953ba3-3e94-421c-b426-b716562b8b5d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02806544",
        "Secondary_id": "NCT00605267",
        "Statement": "A patient with stage 2B , pathologically confirmed PR positive breast cancer is elgible for both the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted. The patient described in the statement does not meet the inclusion criteria for the primary trial as it specifically mentions a requirement of ER Allred Score > 4, which is not stated in the secondary trial's inclusion criteria. Also, the primary trial excludes patients who have received prior hormonal therapy, while the secondary trial excludes patients unwilling to stop taking any drug known to affect sex hormone status, which could include hormonal therapies. Therefore, a patient who fits the description in the expert's statement would not be eligible for the primary trial according to the provided CTR."
    },
    "847b4dbe-428f-431c-8916-2a9c0c80cce4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT01129622",
        "Statement": "dosages are specified in the intervention section of the secondary trial and the primary trial",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided CTRs. \n\nJustification: \n\nThe statement \"dosages are specified in the intervention section of the secondary trial and the primary trial\" is in line with the information given in both trials. In the primary trial, the dosage for Lidocaine patch is stated as 5%, with the application of 1 patch to the affected site(s) for 12 hours each day. In the secondary trial, the dosage for Letrozole is given as 12.5 mg/day, with the administration of this dose for three successive days prior to the second MRI. This shows that the dosages for the interventions in both trials are indeed specified within the intervention sections, making the statement consistent with the information in the CTRs."
    },
    "9c00b318-0a3a-43c9-a6cd-2983c07be393": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00232505",
        "Statement": "There were no instances of patients with abnormal heart rates in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the primary trial Adverse Events section, where one instance of Cardiac General - Other (Specify, __) [1] is reported, and it is not specified as an abnormal heart rate, but the expert's statement assumes all general cardiac other events refer to abnormal heart rates. Therefore, the expert's statement contradicts the provided clinical trial data."
    },
    "cbfe14a5-5169-4de3-b69f-13b489be949a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02597452",
        "Secondary_id": "NCT01929395",
        "Statement": "the primary trial and the secondary trial do not use cyclical interventions.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the provided CTRs. There is no mention of cyclical interventions in either trial's intervention section. The primary trial's iBE intervention involves a single additional breast exam at the scheduled screening appointment, and the secondary trial's MRI intervention is performed as a pre-operative procedure with no indication of recurring treatments."
    },
    "bd6bf811-e9a8-4e1e-ace1-703aa8f5374b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00325598",
        "Statement": "There is a significant difference in the Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan between cohort 1 and 2 of the primary trial, the increase in Gy has a huge effect.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. \n\nJustifications: \n\nThe CTR provides data on the Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan for each cohort (Results 1 and Results 2). An increase in the dose of radiation (from 36 Gy to 40 Gy) could potentially lead to a difference in the number of participants who can receive a satisfactory treatment plan. The statement's assertion that \"there is a significant difference between cohort 1 and 2\" aligns with the provided data and does not contradict the CTR descriptions."
    },
    "3c4d9ab0-5e16-48b3-96d4-ae9d337b2822": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01332630",
        "Secondary_id": "NCT00121134",
        "Statement": "There were more patients with hypotension in cohort 1 of the primary trial, than in cohort 1 of the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The CTR for the primary trial reports 3 cases of hypotension in cohort 1 (14.29%). The CTR for the secondary trial reports no cases of hypotension. Therefore, the statement is contradicted by the provided CTR data."
    },
    "eae76b80-107c-4469-b06f-73d5f7a4c1d5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02073487",
        "Secondary_id": "NCT03371732",
        "Statement": "Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nJustification: \n\nThe statement that \"Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial\" is contradicted by the CTRs provided. In the primary trial inclusion criteria, smokers with \"more than one cigarette smoked per day\" are included, but those smoking \"more than 5 cigarettes smoked per day\" are excluded from the secondary trial. Therefore, the statement is inconsistent with the information in the CTRs."
    },
    "6cf7d10e-902e-4f78-85f6-e06d63e1cd0e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00347919",
        "Statement": "less than 50% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12.",
        "Label": "Contradiction",
        "explain": "Contradiction. The primary trial states that 38.9% of participants in Cohort 1 with Lapatinib 1500 mg had no progressive disease at Week 12 based on independently evaluated assessments, and 43.1% based on investigator assessments. These percentages are greater than less than 50%."
    },
    "91ad45ae-6714-4c27-ac1a-d8ff8e89684f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334542",
        "Statement": "A Female patients with a bilateral mastectomy would be excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"A Female patient with a bilateral mastectomy would be excluded from the primary trial\" is contradicted by the CTR. The CTR states, \"At least 1 healthy intact breast\" but does not specify that the breast to be enrolled in the trial must be the same breast. Therefore, a patient with a history of bilateral mastectomy, but meeting all other eligibility criteria, could have one intact breast and thus be eligible for the trial."
    },
    "91cf53f9-7233-49ee-a619-c027f6db67ac": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00605267",
        "Statement": "Only men can be eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the Primary Trial's Inclusion Criteria, where it is clear that only women are eligible for the trial."
    },
    "78894316-fc7d-4d61-a2d4-9ea369bfce20": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Statement": "Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than Bacterial diarrhoea.",
        "Label": "Entailment",
        "explain": "Contradicted. There were 2 cases of Erysipelas in the primary trial (CTR 1), while there were no cases reported for the secondary trial (CTR 2). However, there were 0 cases of Bacterial diarrhoea in both trials. This contradicts the expert statement that \"twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than Bacterial diarrhoea.\""
    },
    "889e6622-1614-4f6c-a47c-e7caad6e154f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00879086",
        "Statement": "Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia, but Cohort 1 had 1 more case of Leukopenia than cohort 2.",
        "Label": "Entailment",
        "explain": "The statement can be entailed based on the provided CTR data. In the Primary Trial, both cohorts had 1 case of anaemia and 1 case of Neutropenia each. However, there was 1 additional case of Leukopenia in Cohort 1 as compared to Cohort 2, which is consistent with the statement."
    },
    "4577d986-d7e5-4b5d-9852-b944a6f7f252": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01740323",
        "Secondary_id": "NCT00127205",
        "Statement": "the secondary trial and the primary trial accept patients in the same age range.",
        "Label": "Entailment",
        "explain": "The statement is entailed. Both trials specify that patients must be 18 years old and above. (Primary Trial: Inclusion Criteria; Secondary Trial: PATIENT CHARACTERS: Age, 18 and over)"
    },
    "e83b56ba-d129-4cde-976d-2865e67ef4a3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02472964",
        "Secondary_id": "NCT00089661",
        "Statement": "the primary trial studies tumours response, whereas the secondary trial investigates changes in Bone Mineral Density.",
        "Label": "Entailment",
        "explain": "The statement should be entailed, as there is no contradiction between the two trials in terms of their primary focus. The first trial investigates the effectiveness and safety of MYL-1401O Plus Taxane versus Herceptin\u00ae Plus Taxane in terms of Best Overall Response Rate (ORR), whereas the second trial explores the impact of Denosumab 60 mg Q6M versus Placebo on Lumbar Spine Bone Mineral Density Percent Change From Baseline. Both trials address different outcomes, making the statement true."
    },
    "eee75423-9a61-4a57-8baf-8f91b9562486": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01705691",
        "Statement": "The majority of patients in the primary trial suffered from Kidney stones.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the data in the provided CTRs. \n\nExplanation:\n\nThe statement asserts that the majority of patients in the primary trial suffered from Kidney stones, which is not supported by the data. Instead, the data for Adverse Events 1 in the primary trial indicates that there were no cases (0.00%) of nephrolithiasis (kidney stones) out of the total 19 patients. Similarly, for Adverse Events 2 in the secondary trial, there was only one case (3.33%) of nephrolithiasis out of the total 30 patients. Therefore, the statement contradicts the clinical trial data."
    },
    "9e046221-7d4b-4681-a374-96793350927d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00802945",
        "Secondary_id": "NCT01231659",
        "Statement": "Group 1 of the secondary trial has a higher ORR than both the Everolimus + Letrozole cohort of the primary trial and the trastuzumab cohort.",
        "Label": "Contradiction",
        "explain": "To evaluate the statement, we need to compare the ORR percentage in Group 1 of the secondary trial with the ORR percentages in Arm/Group 1 (NKTR-102 14 Day) and Arm/Group 2 (NKTR-102 21 Days) of the primary trial. However, without explicit ORR percentages given in the CTRs, it is impossible to determine entailment or contradiction. The statement may be justified if and only if specific ORR percentages are available that satisfy the stated condition."
    },
    "5448c6b8-244c-4a42-bbef-e1a1a2e254e2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01738438",
        "Secondary_id": "NCT00331552",
        "Statement": "Cyclophosphamide, Doxil and Trastuzumab were used in the secondary trial intervention, but not in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed as per the provided CTRs. The primary trial only mentions cabozantinib being used in the intervention, while the secondary trial describes a different intervention using cyclophosphamide, pegylated doxorubicin hydrochloride, and trastuzumab. This difference is explicitly stated in the CTRs and thus aligns with the expert statement."
    },
    "135a7d7b-b5d1-4fe6-9a41-4b303d6fb9b2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429572",
        "Secondary_id": "NCT02455453",
        "Statement": "pre-menopausal patients are excluded from the secondary trial, but eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The secondary trial explicitly states that pre-menopausal patients with ovarian suppression and falling into certain categories are eligible for the study. Therefore, the statement is not entailed by the information provided in the CTRs."
    },
    "8d450d42-4eb1-4edb-be76-b2885964aa90": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01506609",
        "Secondary_id": "NCT00656019",
        "Statement": "Patients with cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for the secondary trial, but are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the Primary CTR's Inclusion Criteria, which specifies that Locally recurrent disease must not be amenable to surgical resection or radiation with curative intent for patients to be eligible."
    },
    "2674e194-3113-4a11-b2cc-f089d960d194": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01104584",
        "Statement": "the primary trial does not use trastuzumab, Tamoxifen or Exemestane in its intervention.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the given CTR information since neither the primary nor the secondary trial specifies the use of trastuzumab, Tamoxifen, or Exemestane in their intervention sections."
    },
    "a7232387-b266-4bfb-8df8-ca9789188500": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00490646",
        "Statement": "Cohort 1 of the primary trial had 25% more patients experiencing adverse events than cohort 2.",
        "Label": "Entailment",
        "explain": "Contradiction. The statement \"Cohort 1 of the primary trial had 25% more patients experiencing adverse events than cohort 2\" contradicts the CTR data since the total number of adverse events for each cohort is different: 13/24 (54.17%) for cohort 1 in the primary trial and 6/24 (25.00%) for cohort 1 in the secondary trial. The percentage change between these numbers does not equate to 25%."
    },
    "2e317381-2704-4d06-a793-1d2b29139969": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01959490",
        "Statement": "In total only one participant of the primary trial did not achieve Pathological Complete Response.",
        "Label": "Entailment",
        "explain": "The statement \"In total only one participant of the primary trial did not achieve Pathological Complete Response\" can be entailed based on the provided data if we consider both cohorts (Cohort 1P and Cohort 1T) in the primary trial collectively. The total number of participants in both cohorts is 11 (5 from Cohort 1P and 6 from Cohort 1T), and according to Results 1 and Results 2, 10 out of 11 participants in both cohorts achieved pCR (80.0% and 100.0% respectively). Therefore, one participant did not achieve pCR, which matches the statement.\n\nHere is the specific reference to CTR data:\n- Results 1 and Results 2 report the number of patients with pCR for each cohort.\n- The total number of participants in both cohorts can be calculated based on the information provided in the descriptions.\n\nTherefore, the statement is entailed."
    },
    "030316a2-fb48-469d-9c55-04cdc9a37fb6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00559507",
        "Statement": "the primary trial participants are given saracatinib PO every single day of the study duration.",
        "Label": "Entailment",
        "explain": "The statement \"the primary trial participants are given saracatinib PO every single day of the study duration\" is contradicted by the CTR. According to the Intervention 1 section of the Primary Trial CTR, patients receive saracatinib PO on days 1-28 and the treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. This schedule does not entail that participants receive the drug every single day throughout the study duration."
    },
    "2c723e02-14d8-4a80-a95f-517e904bbbad": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00338286",
        "Statement": "No participants of the primary trial had a Progression Free Survival over 1 year, but several patients had a PFS of less than 1 month.",
        "Label": "Contradiction",
        "explain": "The statement \"No participants of the primary trial had a Progression Free Survival over 1 year, but several patients had a PFS of less than 1 month\" can be contradicted by the information provided in the CTRs. \n\nThe statement is contradicted because, according to Results 1 and Results 2, there were participants in both the Standard of Care and Epoetin Alfa arms who had a PFS longer than 1 year. Specifically, the median PFS for both arms was 7.4 months, which is longer than 1 year. Therefore, there were individuals who lived beyond the 1-year mark, and it is incorrect to claim that no participants had a PFS over 1 year.\n\nAdditionally, the statement does not contradict the information in the CTRs regarding participants who had a PFS of less than 1 month. The CTRs state that participants who had a missing interval immediately preceding the event were censored, so it is possible that some participants with very short PFS had their data censored due to missing information. This would not affect the validity of the median PFS estimate but could result in the existence of individual patients with a PFS shorter than reported.\n\nTherefore, the statement is contradicted due to the inaccurate claim that no participants had a PFS over 1 year."
    },
    "8befa03f-c3da-4950-8d27-491ea06b51ed": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00885755",
        "Secondary_id": "NCT01075100",
        "Statement": "Patients' appetites were not affected in the primary trial, but at least one was affected in the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement should be entailed, as there is no mention of appetite decreased as an adverse event in the primary trial (Appetite decreased: 0/33, 0.00%), but there is at least one instance (1/53, 1.89%) reported in the secondary trial."
    },
    "32424458-a3e2-440a-9693-6a2f8d4aaddb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01307891",
        "Statement": "Abraxane + Capecitabine group of the primary trial has 61 more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided information. While the statement asserts that the Abraxane + Capecitabine group of the primary trial has more patients with CR or PR than the Abraxane Alone group, the actual data in Results 1 and 2 indicate that the number of patients and response rates for the two groups are different, but there is no information directly comparing the number of patients with CR or PR between the two groups in the given time frame. Therefore, the statement is not entailed by the CTRs."
    },
    "a2b25229-c003-49c3-8b0b-94b68f756d3c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00468585",
        "Statement": "the primary trial did not record any skin infections in their patients.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTR data for both the Primary and Secondary Trials as neither reported any skin infections (0/4 for Primary Trial and 0/3 for Secondary Trial) among their participants."
    },
    "728721c4-6376-4ab8-9e4a-af8596bd1ab3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02308020",
        "Statement": "Laser Therapy is only used in cohort 1 of the primary trial,  neither cohort of the secondary trial make use of this.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the given CTRs. \n\nJustifications:\n\n1. In the primary trial, laser therapy is mentioned as one of the interventions given in the intervention section.\n2. In contrast, the statement claims that laser therapy is not used in either cohort of the secondary trial.\n3. Therefore, the statement contradicts the information given in the primary trial.\n\nHad the statement been entailed, it would have stated that laser therapy is only used in the primary trial, and not in the secondary trial, without implying that it is only used in cohort 1 of the primary trial. This would have been consistent with the information provided in the CTRs."
    },
    "c7151ad6-bcac-48e1-ba1e-e6f56a043804": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Secondary_id": "NCT00570921",
        "Statement": "the primary trial and the secondary trial both record cases of Cholecystitis.",
        "Label": "Contradiction",
        "explain": "The statement \"the primary trial and the secondary trial both record cases of Cholecystitis\" is entailed by the provided CTR data since both trials list \"Acute Cholecystitis\" as an adverse event in the secondary trial, and there are no conflicting adverse events related to Cholecystitis mentioned in the primary trial."
    },
    "4f71e33c-4f0f-4952-bb03-52402be5f9f4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02015676",
        "Statement": "There is 1 case (1.45%) of thrombocytopenia in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the information provided in the primary trial's Adverse Events section, where no case (0/69, 0%) of thrombocytopenia was reported."
    },
    "ef675459-a7d9-4ea1-8963-c95682c38d15": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03004534",
        "Statement": "Participants with T4 N1 M0 breast carcinoma are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted by the primary trial's inclusion criteria, as participants with T4 (T4 is a T-stage indicating a tumor of any size with directextension to the chest wall, and/or to the skin) are explicitly excluded from the trial. (Primary Trial: Inclusion Criteria)"
    },
    "f9df9e45-eb68-4257-801e-b086a89374b8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02658734",
        "Secondary_id": "NCT02073487",
        "Statement": "Female Patients with LVEF > 50%,  who have previously undergone treatment with any of the following drugs; trastuzumab emtansine, paclitaxel, abraxane or lapatinib are still eligible for the primary trial but are excluded from the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed in the primary trial but contradicted in the secondary trial.\n\nJustifications:\n\n1. Primary trial: The primary trial includes eligibility criteria that state \"No prior treatment with trastuzumab emtansine, lapatinib, or lapatinib with capecitabine or non-comparable biologic or biosimilar of trastuzumab\" (Exclusion Criteria). However, it does not exclude patients based on a history of treatment with paclitaxel or abraxane. Therefore, female patients with LVEF > 50% who have previously undergone treatment with any of these drugs are still eligible for the primary trial.\n\n2. Secondary trial: The secondary trial includes exclusion criteria that state \"No history of receiving any anti-cancer drug/biologic or investigational treatment within 21 days prior to enrollment except hormone therapy, which can be given up to 7 days prior to enrollment\" (Exclusion Criteria). It also excludes patients with a history of exposure to cumulative doses of anthracyclines or radiation therapy within 14 days of enrollment (Exclusion Criteria). However, it does not mention specific drugs like trastuzumab emtansine, paclitaxel, or abraxane. Instead, it excludes patients with a history of receiving any anticancer drug or biologic. Since the statement mentions these specific drugs, it contradicts the secondary trial's eligibility criteria."
    },
    "94fc10ff-65e1-4b0a-8ff3-1cc48db3433e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00319254",
        "Statement": "the primary trial did not use overall response rate, tumour response rate or progression-free survival rate as its outcome measurement.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nExplanation: \n\nThe primary trial's outcome measurement is indeed Progression-Free Survival (PFS) rate, which is explicitly stated in the Outcome Measurement section of the CTR."
    },
    "958721dc-e374-4fd1-abb9-071add70bde3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820170",
        "Statement": "According to the results of the primary trial the MTD of paclitaxel is approximately is 120 mg.",
        "Label": "Contradiction",
        "explain": "Contradicted. The statement that \"the MTD of paclitaxel is approximately is 120 mg\" is contradictory to the information in the primary trial CTR, where it is clearly stated that the MTD of paclitaxel in combination with dasatinib is not specified in the provided information, and the dosing of paclitaxel is given as a fixed dose of 80 mg/m2 given intravenously on day 1, 8, and 15 of a 28 day cycle. Therefore, the statement goes beyond what is mentioned in the CTR and contradicts the given information."
    },
    "19c0b2c7-e45c-4740-b25d-f6e738b59893": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01764022",
        "Statement": "Cohort 2 of the primary trial recorded 1 incident of thrombocytopenia.",
        "Label": "Entailment",
        "explain": "Contradicted. The statement mentions \"thrombocytopenia\" in Cohort 2 of the primary trial, while the CTR reports no incident of thrombocytopenia (0.00%) in Adverse Events 1 for Cohort 1 or Adverse Events 2 for Cohort 2."
    },
    "7bcfca9e-1b09-45d4-8165-cb6ac96b8815": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02896855",
        "Secondary_id": "NCT00171314",
        "Statement": "the secondary trial recorded more total occurences of gastrointestinal adverse events than the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted based on the provided CTRs, as neither Adverse Events section in the primary nor secondary trial mentions any gastrointestinal adverse events, such as esophagitis, ascites, or large intestine polyp."
    },
    "e3a8be03-20e4-460d-9ebc-f958a515ac45": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01095003",
        "Statement": "Less than 5 patients in the primary trial experienced Earache.",
        "Label": "Entailment",
        "explain": "The statement is not entailed by the provided data in the CTRs. \n\nExplanation: \n\nThe statement asserts that fewer than five patients in the primary trial experienced earache. However, neither CTR provides information on the occurrence of earache in the trial participants. Therefore, the statement contradicts the information given in the CTRs since there is no entailment relationship established."
    },
    "f1096271-3160-4483-9246-ba0d96735efb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01118624",
        "Statement": "Less than 5% of the primary trial participants achieved CR or PR.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nReasoning: \n\nThe Primary Trial CTR specifies that the proportion of patients achieving CR or PR is considered in the overall response, yet it does not provide the number of participants achieving CR or PR. The statement, however, claims that less than 5% of the participants achieved CR or PR. Therefore, the statement contradicts the information presented in the CTR, as it asserts a specific number that is not provided."
    },
    "329b6871-2edc-4142-a4af-e7f8cef118ee": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00004888",
        "Statement": "More the primary trial participants suffered Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events.",
        "Label": "Entailment",
        "explain": "The statement \"More participants in the primary trial suffered Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events\" is entailed by the data presented in the CTRs. In Results 1 of the primary trial, there were 4 participants with Grade 1 cardiotoxicity events after Cycle 8, compared to 0 participants with Grade 3 events after Cycle 8. Similarly, in Results 2 of the primary trial, there were 8 participants with Grade 1 cardiotoxicity events after Cycle 8, compared to 0 participants with Grade 3 events after Cycle 8. The total number of participants in each arm of the primary trial is 16 for Arm I and 37 for Arm II, so the overall number of participants suffering from each grade of cardiotoxicity after Cycle 8 in the primary trial can be calculated. The number of participants with Grade 1 cardiotoxicity after Cycle 8 is 4 (from Arm I) + 8 (from Arm II) = 12. There are no participants with Grade 3 cardiotoxicity after Cycle 8 in the primary trial. Therefore, the statement is entailed by the data presented in the CTRs."
    },
    "67522762-9423-4e3d-bf75-247f84ba7f05": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365417",
        "Secondary_id": "NCT00853996",
        "Statement": " To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase  < 2.5 x ULN, aspartate aminotransferase  <= 1.5 x ULN and Hemoglobin > 10 g/dL.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed for both trials as the alkaline phosphatase and aspartate aminotransferase (AST) requirements for both trials fall under the same conditions, and both trials require a hemoglobin level greater than 10 g/dL. (References: Primary Trial: Inclusion Criteria: Alkaline phosphatase section and Hemoglobin section; Secondary Trial: Inclusion Criteria: Alkaline phosphatase and Hemoglobin sections.)"
    },
    "efd37946-54f3-4813-b63d-6d7df6123677": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02630693",
        "Statement": "A total of 3 patients in the primary trial suffered a life-threatening reaction to an infection.",
        "Label": "Entailment",
        "explain": "The statement \"A total of 3 patients in the primary trial suffered a life-threatening reaction to an infection\" can be entailed based on the provided CTR data in both the primary and secondary trials, as there are a total of 3 cases of sepsis (a potentially life-threatening infection) in the primary trial, which is reported with a frequency of 2.22%, resulting in 2 cases out of the 90 patients. Although not explicitly stated as \"life-threatening reactions to an infection,\" the term \"sepsis\" itself indicates a severe and potentially life-threatening infection.\n\nHowever, the statement cannot be strictly entailed for the secondary trial, as no cases of life-threatening reactions to infection are mentioned in the provided data, only 1 case of sepsis is reported, which is a less severe form of the condition.\n\nAdditionally, the statement does not contradict the provided data from either trial."
    },
    "dcf62f43-04b7-4acb-b444-2d805238a8b1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02162667",
        "Statement": "The Herceptin group in the primary trial had a higher percentage of Patients Achieving partial Pathological Response than the CT-P6 and ZA group.",
        "Label": "Contradiction",
        "explain": "To determine if the expert statement is entailed or contradicted by the provided CTR data, let's compare the percentage of patients achieving partial pathological response between the Herceptin and CT-P6 groups. Unfortunately, the CTRs do not provide information about the percentage of patients with partial pathological response for each group. Therefore, based on the given data, it is impossible to establish entailment or contradiction of the expert statement.\n\nHowever, if we had access to the respective percentages for both groups in the primary trial, we could perform a statistical comparison to evaluate the statement's validity. In such a case, we would need to ensure that the trials' eligibility criteria, interventions, and patient populations were similar enough to make a fair comparison. The results section would be the primary source of evidence for this analysis.\n\nSo, the expert statement cannot be definitively judged as entailed or contradicted based on the provided CTR data alone. We need additional information about the percentage of patients achieving partial pathological response for both groups in the primary trial."
    },
    "83dc7b9a-b863-4f81-88fb-763afc3b79e8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03252145",
        "Secondary_id": "NCT00904033",
        "Statement": "None of the subjects in the primary trial are required to injest any pills, and half the subjects in the secondary trial must take a weekly tablet.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the information in the given CTRs. Specifically, the primary trial does not involve the administration of pills to any subjects in the Intervention 1 or Intervention 2 groups (Manual Lymph Drainage or Negative Pressure). In the secondary trial, one Intervention arm (Calcitriol Arm) does involve the weekly intake of a pill, while the other arm (Exercise Arm) does not. Therefore, the statement accurately reflects the information provided in the CTRs."
    },
    "d446920a-2b8e-4452-b9f2-17d2771dbb07": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00075764",
        "Statement": "The most common adverse event in cohort 1 of the primary trial is Neutropenia.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nThe CTRs do not indicate that neutropenia is the most common adverse event in cohort 1 of the primary trial. The primary trial's Adverse Events 1 section shows a total of 21 adverse events for 337 participants, with no occurrence of neutropenia (0/337). In contrast, the secondary trial's Adverse Events section has one occurrence of neutropenia for 348 participants (1/348), which is not the most frequent event in cohort 1 of the primary trial."
    },
    "aa710138-bf2a-4a7f-8014-4513fa1f448b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01269346",
        "Secondary_id": "NCT01597193",
        "Statement": "Cohort 1 of the primary trial and Cohort 1 of the secondary trial both have less than 30% occurrence of adverse events.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the provided CTRs data in the Adverse Events sections. The primary trial cohort has a total of 15 adverse events out of 52 participants, resulting in a percentage of 28.85%. Cohort 1 of the secondary trial has a total of 1 adverse event out of 8 participants, resulting in a percentage of 12.50%. Both percentages are below 30%."
    },
    "aa38a1cc-35d6-4194-9e9e-3bcc0298a95c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01340300",
        "Secondary_id": "NCT00671918",
        "Statement": "Patients must be doing less than 2 hours of physical exercise per week to participate in the primary trial, however, this is not a requirement for the secondary trial.",
        "Label": "Entailment",
        "explain": "Contradicted by the Primary CTR: The Primary CTR specifies a participation requirement of less than 120 minutes (2 hours) of exercise per week. Therefore, the statement that \"Patients must be doing less than 2 hours of physical exercise per week to participate in the primary trial\" is entailed by the CTR. However, the statement that \"however, this is not a requirement for the secondary trial\" contradicts the Primary CTR, as the Secondary CTR does not mention any exercise requirement."
    },
    "6a71c114-2e38-4d57-8f8b-8252d9c62cbe": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01491737",
        "Statement": "There were 4 cases of Febrile neutropenia in cohort 1 of the primary trial, and 0 cases of heart failure.",
        "Label": "Entailment",
        "explain": "The statement \"There were 4 cases of Febrile neutropenia in cohort 1 of the primary trial, and 0 cases of heart failure\" can be entails by the CTR data as follows:\n\n1. The statement \"There were 4 cases of Febrile neutropenia in cohort 1 of the primary trial\" is entailed by the data in Adverse Events 1, as there were indeed 4 cases reported.\n\n2. The statement \"and 0 cases of heart failure\" is not explicitly stated in the CTR but can be inferred from the given data, as there are no reported cases of heart failure in Adverse Events 1 or 2.\n\nTherefore, the expert's statement is entailed by the data in the CTRs."
    },
    "4333aaa3-dbe4-4275-a982-881fe25c96c0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00407888",
        "Statement": "Arm 2 of the primary trial receive dose-intensive chemotherapy on a21 day cycle up to 3 times in the absence of disease progression or unacceptable toxicity.",
        "Label": "Contradiction",
        "explain": "Contradicted\n\nExplanation:\n\nThe statement \"Arm 2 of the primary trial receive dose-intensive chemotherapy on a 21 day cycle up to 3 times in the absence of disease progression or unacceptable toxicity\" contradicts the information given in the CTR for the primary trial. In the CTR, the chemotherapy for Arm I is given on a 7-day cycle, and no information is provided about the cycle length for Arm 2. Therefore, the statement's assertion that Arm 2 receives dose-intensive chemotherapy on a 21-day cycle is not supported by the CTR. Additionally, the number of cycles mentioned in the statement (up to 3) also differs from the CTR, which states that courses repeat every 7 days for up to 12 weeks."
    },
    "d605b820-2915-4b19-b9cd-ca7850645f83": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00357110",
        "Statement": "Only 6 patients in cohort 1 of the primary trial had Varicose Veins.",
        "Label": "Contradiction",
        "explain": "The statement \"Only 6 patients in cohort 1 of the primary trial had Varicose Veins\" contradicts the Adverse Events section of the primary CTR, specifically the section that reports \"Varicose Vein 1/6 (16.67%)\". In this section, it is stated that one out of six patients in the primary trial had Varicose Veins. The statement made by the expert claims that only six patients had this condition, which is not consistent with the data reported in the Adverse Events section."
    },
    "d6de70df-d113-4bc8-9d3b-b71f31937ebe": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01525589",
        "Statement": "People who inherit harmful variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR's inclusion criteria for Cohorts A and A1, as they require patients to have a known deleterious germline mutation of BRCA1/2 for eligibility."
    },
    "9f897b29-7cfa-414c-8cf6-212a68ec2216": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03346161",
        "Secondary_id": "NCT01000662",
        "Statement": "Neither the secondary trial or the primary trial require patients to undergo any kind of medical treatment during their interventions, they are only testing effectiveness of consultations.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial's INTERVENTION 1 and INTERVENTION 2 descriptions, which specify that patients interacted with a decision tool (BREASTChoice) and a surgical care booklet, respectively, during their interventions. These interactions involve patient engagement with materials, indicating a form of medical intervention. Additionally, in the secondary trial, both arms receive radiation therapy, which is a medical treatment. Therefore, the statement does not entail the information provided in the CTRs."
    },
    "0d0deba5-c7bd-489b-a49d-c6af9a5cd92a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00676663",
        "Statement": "The the primary trial placebo group performed much better than the test group, as a lower PFS is ideal.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the data in the CTRs. In the primary trial, the Exemestane + Placebo group had a shorter median PFS compared to the Exemestane + Entinostat group (2.27 months vs 4.28 months). Therefore, the placebo group did not perform better than the test group in terms of PFS."
    },
    "4606f64f-64cc-4d73-a8be-75701c97008d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00024102",
        "Statement": "A patient in cohort 2 of the primary trial received a Plasma transfusion.",
        "Label": "Contradiction",
        "explain": "Contradiction. The statement that a patient in cohort 2 of the primary trial received a Plasma transfusion is contradicted by the information in the Adverse Events section of the CTR for the primary trial, specifically the line \"Transfusion: pRBCs 0/131 (0.00%)\", which indicates no patient in cohort 1 or 2 received plasma transfusions according to the trial data."
    },
    "40bef815-18ed-4db5-8108-9a1cdbdd0a13": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00478257",
        "Statement": "Adequate Hematologic, Hepatic and renal function is not necessary for participating in the primary trial. However, being pregnant is required.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial's inclusion criteria, which state that pregnancy is an exclusion criterion. (ELIGIBILITY CRITERIA section in the primary CTR)"
    },
    "5c676007-9ea4-4f80-82dd-89293237cb07": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00319254",
        "Statement": "the primary trial did not use overall response rate, tumour response rate or preference score as its outcome measurement.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTR information. The primary trial's outcome measurement was Progression-Free Survival (PFS), and it did not report the use of overall response rate, tumor response rate, or preference score."
    },
    "a6682883-ace7-4d83-a35c-956928fdc75a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01325428",
        "Secondary_id": "NCT00073073",
        "Statement": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity, sex, height or to be able to speak a specific language.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed based on the information provided in both CTRs. Neither trial specifies ethnicity, sex, height, or language as inclusion criteria, indicating that participants can come from any ethnicity, sex, height, or speak any language. Therefore, the statement harmonizes with the clinical trial data and avoids contradiction with the provided descriptions in both trials."
    },
    "1a271e29-477b-4819-a472-5c7c7df99e70": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00265759",
        "Secondary_id": "NCT00866905",
        "Statement": "2 cases of hematolysis were recorded in the primary trial, none in the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nJustification: \n\nThe statement \"2 cases of hematolysis were recorded in the primary trial, none in the secondary trial\" contradicts the provided CTR data as per the Adverse Events sections. In the primary trial, there was only 1 reported case of hematolysis (1/157), while in the secondary trial, there was no reported case of hematolysis (0/168). Therefore, the statement is not entailed by the given CTRs."
    },
    "060e833e-384f-48f0-8e56-ebd95f55f221": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01926886",
        "Statement": "There were no cases of Cellulitis, Vertigo or Anaemia in the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial reports one case of Vertigo in the Adverse Events section, as stated in the CTR."
    },
    "ac193d32-156e-48bf-bc6b-d613691f869c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01166763",
        "Statement": "the primary trial only recorded three types of adverse events.",
        "Label": "Entailment",
        "explain": "The statement \"the primary trial only recorded three types of adverse events\" is entailed by the provided information in the CTRs. \n\nJustification:\nThe CTR for the primary trial explicitly lists three distinct types of adverse events: cholecystitis, increase in diarrhea, and flank pain. Therefore, the statement made by the clinical trial expert is a correct observation based on the data presented in the CTR."
    },
    "d79173da-5e59-4150-99bd-f1c20118dddc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00503750",
        "Statement": "All participants of the primary trial must have recently undergone either an echocardiography.",
        "Label": "Contradiction",
        "explain": "The statement \"All participants of the primary trial must have recently undergone either an echocardiography\" is contradicted by the information in the Primary Trial's Inclusion Criteria, specifically the requirement for \"Normal (greater than 50%) left ventricular ejection fraction (LVEF) by MUGA scan or echocardiography.\" This means that all participants already have a normal LVEF determined by either MUGA scan or echocardiography, and thus there is no need for them to undergo a recent echocardiography as stated in the expert's claim."
    },
    "50559f15-636d-4265-8f8c-4aad016c6c50": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01176916",
        "Secondary_id": "NCT00186121",
        "Statement": "postmenopausal women are eligible for the primary trial, and Premenopausal women are eligible for the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the CTRs provided. \n\nExplanation: \n\nPostmenopausal women are eligible for the primary trial (as stated in the inclusion criteria), but premmenopausal women are explicitly excluded from the primary trial (as stated in the exclusion criteria, specifically \"The patient must be postmenopausal woman.\"). Premenopausal women, on the other hand, are eligible for the secondary trial, as stated in its inclusion criteria. Therefore, the statement that \"postmenopausal women are eligible for the primary trial, and premmenopausal women are eligible for the secondary trial.\" is contradicted by the information provided in the CTRs."
    },
    "a5af6d2b-4cea-40aa-acdc-59fab5362b3e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00635050",
        "Statement": "Patients with Breast cancers that have estrogen receptors are included in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Patients with Breast cancers that have estrogen receptors are included in the primary trial\" is entailed by the primary CTR's inclusion criteria, which state that patients must have known ER status and be ER-positive to be included."
    },
    "7e89b190-b8f7-4281-b0f1-0e65dcebf402": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00941330",
        "Statement": "Patients in cohort 1 of the primary trial receive Exemestane twice as often as cohort 2 patients receive Cytoxan.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided CTRs.\n\nExplanation:\n\nAccording to the primary trial, cohort A receives exemestane daily for a maximum of 12 months, which equals approximately 365 days (assuming 30 days per month). Cohort B receives docetaxel and cytoxan each once every 3 weeks, which equals approximately 24 infusions within 24 weeks or 8 infusions per 12 weeks. Therefore, cohort B receives approximately 48 doses of cytoxan per year (8 infusions x 6 cycles x 2 drugs per infusion). Since exemestane is given daily and cytoxan is given approximately every 3 weeks, cohort A receives more than twice as many doses of a treatment per year as cohort B receives of cytoxan. Consequently, the expert's statement is contradicted by the data in the CTRs."
    },
    "6036d341-9c6a-49fc-a2f4-19c0e2399f4c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565083",
        "Statement": "There were significantly more cases of ventricular tachycardia than Supraventricular tachycardia in cohort 2 of the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"There were significantly more cases of ventricular tachycardia than Supraventricular tachycardia in cohort 2 of the primary trial\" is contradicted by the data provided in the CTRs. The statement asserts that there are more cases of ventricular tachycardia than Supraventricular tachycardia in Cohort 2 of the primary trial, while the data shows that there was one case of Supraventricular tachycardia and none of ventricular tachycardia in Cohort 2 of the primary trial (Adverse Events 1 and 2)."
    },
    "a84afa25-2741-4a08-9e6c-4049f5feca48": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01790932",
        "Statement": "patients with Phosphoinositide 3-kinase inhibitor based treatments are eligible for the primary trial, if this treatment ended over 5 years prior.",
        "Label": "Contradiction",
        "explain": "Contradiction\n\nExplanation: \n\nThe primary trial's exclusion criteria clearly state that patients who \"Have received previous treatment with PI3K inhibitors\" are not eligible for the study (CTR, Inclusion/Exclusion Criteria section). The expert's statement implies that such patients are eligible if their prior PI3K inhibitor treatment ended over 5 years prior. This contradicts the information in the CTR, making the statement not entailed."
    },
    "09e4c746-642a-4a5d-a267-25258a3f2ec0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01669343",
        "Secondary_id": "NCT00146172",
        "Statement": "the primary trial and the secondary trial do not have the same duration of intervention administration.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the information provided in the CTRs. In the primary trial, the intervention period for Letrozole in Part A is 28 days and in Part B is also 28 days for overweight/obese participants. In contrast, in the secondary trial, the intervention periods for Neratinib 40 mg and 80 mg are both daily, but the lengths are not stated explicitly. However, the discrepancy in intervention durations is sufficient to justify the entailment of the statement."
    },
    "99855d11-e2e4-4a0e-b40e-2264ff128ac5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02502864",
        "Statement": "the primary trial recorded the same number of occurences for every type of adverse event.",
        "Label": "Entailment",
        "explain": "Contradicted. The CTR data indicates that each type of adverse event occurred with a frequency of 11.11% (or 1 out of 9 participants) in the primary trial. Therefore, the statement that every type of adverse event had the same number of occurrences contradicts the provided data."
    },
    "54fe69c7-5a67-49b1-8bc5-c975133e2bb7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00712985",
        "Secondary_id": "NCT02038010",
        "Statement": "Patients in the primary trial receive a lower dose of Zometa by IV than the secondary trial patients receive of ado-trastuzumab emtansine.",
        "Label": "Entailment",
        "explain": "The statement should be entailed. In the primary trial, Zoledronic Acid 5 mg IV is given in a single dose, while in the secondary trial, ado-trastuzumab emtansine is given IV with a dose of 3.6mg/kg. The dose of ado-trastuzumab emtansine given in the secondary trial is higher than the dose of Zoledronic Acid given in the primary trial."
    },
    "76362fd3-3a07-4aa3-a072-b9075d2ea791": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00436566",
        "Statement": "Not a single patient in the primary trial suffered from Congestive Heart Failure (during active treatment).",
        "Label": "Entailment",
        "explain": "The statement that \"Not a single patient in the primary trial suffered from Congestive Heart Failure (during active treatment)\" contradicts the information in the CTR. \n\nJustification:\n\nThe primary CTR includes the section \"ADVERSE EVENTS\" but it does not mention any occurrence of Congestive Heart Failure in patients while on active treatment within this trial. However, the absence of a specific adverse event does not logically entail that none of the participants suffered from it. The CTR may simply not have reported that information. Therefore, the expert's statement that \"not a single patient\" experienced Congestive Heart Failure contradicts the information in the CTR.\n\nIn contrast, the statement would be entailed if the CTR had explicitly stated that \"no participant suffered from Congestive Heart Failure (during active treatment)\" or if the CTR had been reviewed by the expert and the expert had determined that no cases went unreported based on a thorough analysis of the data."
    },
    "064b39e9-e9d8-4c51-a76a-ad150bb127f1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00878709",
        "Secondary_id": "NCT02447003",
        "Statement": "the primary trial had a total of 3 patients experiencing pancreas related adverse events, the secondary trial had 0.",
        "Label": "Entailment",
        "explain": "Contradicted\n\nJustification: \n\nThe statement is contradicted by the CTR data. In the primary trial, there were 2 reported cases of pancreatitis, which is considered a pancreas-related adverse event. The CTR of the primary trial reports 2/1408 (0.14%) cases. In contrast, there are no reported cases of pancreas-related adverse events in the CTR of the secondary trial (0/170, 0.00%)."
    },
    "67a628d7-d883-44b9-b351-901f20fd5d0a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429182",
        "Secondary_id": "NCT00429507",
        "Statement": "the secondary trial and the primary trial give their patient cohorts Stem Cell Transplants on the first day of the study.",
        "Label": "Entailment",
        "explain": "The statement is contradicted. In the primary trial, the Stem Cell Transplant is given on Day 0, which is prior to the last administration of chemotherapy. In contrast, the secondary trial specifies that the Stem Cell Transplant is given about 14-21 days after the administration of Samarium 153-EDTMP."
    },
    "78c60212-28f7-4306-9f63-549be04687b2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448591",
        "Statement": "Only two types of adverse events, Leukopenia and Anaemia, occurred in more than 1% of patient in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the data in the primary trial's Adverse Events section. Specifically, Leukopenia occurred in 8/2264 (0.35%) of patients, and Anaemia occurred in 8/2264 (0.35%) of patients. The total number of patients in cohort 1 is 2264, and the statement asserts that two types of adverse events occurred in more than 1% of the patients. Thus, both Leukopenia and Anaemia meet this condition."
    },
    "a72e1259-50be-48e5-bdf8-296040cbf7ce": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01593020",
        "Secondary_id": "NCT00834678",
        "Statement": "Patients with aspartate aminotransferase more than 2 times the upper limit of normal are excluded from both the secondary trial but eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted in the Primary Trial CTR as patients with AST > 2 times ULN are included, not excluded. [Reference: Primary Trial: Inclusion Criteria: ALT and AST > 2.5 times the upper limit of normal (ULN) are mentioned but AST specifically is more than 2 times ULN.]\n\nIn the Secondary Trial, patients with AST > 2 times ULN are excluded [Reference: Secondary Trial: ALT and AST > 2.5 times ULN (5 times ULN in the presence of liver metastases)]. The statement is incorrect for both trials as stated."
    },
    "19cfd511-8582-4116-8d51-7ec4a6221022": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03366428",
        "Statement": "0/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of <60ms.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed. According to the primary CTR, none of the 49 participants in the DS-8201a arm exhibited a maximum change from baseline in QTcF of >60 ms. Therefore, all participants in the study had a maximum change from baseline in QTcF of less than 60 ms."
    },
    "3f012bd3-bb89-414b-9dd9-35cef524a69a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820170",
        "Statement": "According to the results of the primary trial the MTD of dasatinib in combination with weekly paclitaxel is approximately is 120 mg.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR of the primary trial. According to the CTR, the phase I portion of the trial determined the MTD of dasatinib in combination with weekly paclitaxel through a dose escalation schedule. The statement provided by the clinical trial expert matches the determined MTD of dasatinib, which is 120 mg, as reported in the CTR."
    },
    "5eafb3a1-473a-4270-848d-173e5dca9466": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02600923",
        "Statement": "Patients with Leukemia, Hepatitis or Cataracts cannot be included in the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nThe statement \"Patients with Leukemia, Hepatitis or Cataracts cannot be included in the primary trial\" is contradicted by the inclusion and exclusion criteria provided in the CTR.\n\nThe inclusion criteria do not list Leukemia or Hepatitis as exclusionary conditions. However, Hepatitis is mentioned as a criterion for adequate liver function. Therefore, patients with Hepatitis may be included if they meet the other inclusion criteria and have adequate liver function.\n\nCataracts are neither mentioned in the inclusion nor exclusion criteria. Therefore, patients with cataracts are neither explicitly permitted nor excluded from participation in the trial. \n\nHence, the statement is contradicted by the information provided in the CTR."
    },
    "ed956644-5228-4915-b706-1cedb0462577": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00711529",
        "Secondary_id": "NCT02835625",
        "Statement": "the primary trial participants are treated with hypnosis, this is not used at all in the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement \"the primary trial participants are treated with hypnosis, this is not used at all in the secondary trial\" is contradicted by the provided CTR information. In the primary trial, patients in the hypnosis arm undergo three one-hour sessions with a certified hypnotherapist and are also instructed on self-hypnosis techniques. However, none of the interventions in the secondary trial involve hypnosis."
    },
    "02158762-9490-46a1-b494-0589885fd4ce": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00281697",
        "Statement": "the primary trial does not record any cardiac related adverse events.",
        "Label": "Contradiction",
        "explain": "Contradiction. The primary CTR records one instance of acute myocardial infarction (1/458) under Adverse Events 1."
    },
    "c0a8e1a0-cbe6-4240-b578-59afa4d6cf23": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00217672",
        "Secondary_id": "NCT00110084",
        "Statement": "the primary trial had a higher occurrence rate of fistula enterovesical than the secondary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nExplanation:\n\nThe primary trial reported one case (1.35%) of fistula enterovesical, while the secondary trial reported none. Therefore, the statement \"the primary trial had a higher occurrence rate of fistula enterovesical than the secondary trial\" is not entailed by the given clinical trial reports."
    },
    "7ec286e9-f519-41da-848d-a0bc5a50c0ee": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT01129622",
        "Statement": "dosages are specified in the intervention section of the secondary trial, whereas for the primary trial these are not made clear.",
        "Label": "Entailment",
        "explain": "Contradiction.\n\nJustification:\n\nThe statement \"dosages are specified in the intervention section of the secondary trial, whereas for the primary trial these are not made clear\" contradicts the information provided in the CTRs. In the primary trial, the intervention involves application of a lidocaine patch for 12 hours each day, but the dosage is clearly stated as \"Lidocaine patch 5%\" and no additional information regarding dosage is mentioned. In the secondary trial, the intervention involves administration of Letrozole at a dosage of 12.5 mg/day for three successive days. Therefore, the statement that \"dosages are specified\" in the secondary trial but not in the primary trial is in contradiction to the facts stated in the CTRs."
    },
    "d0af59a9-04ae-4922-97eb-dc29f5bc44e3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT03573804",
        "Statement": "the primary trial and the secondary trial use completely different drugs and techniques for their interventions, however they both require trained Radiologists on site for evaluation.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. \n\nJustification: \nIn the primary trial, there is no mention of a radiologist being present for the interventions with Fulvestrant + Anastrozole or Anastrozole alone. However, in the secondary trial, both Interventions involve MRI evaluations by separate radiologists, A and B. Although the drugs used in the primary trial are different from those in the secondary trial, the need for radiologists on site is a common requirement in both trials."
    },
    "5d4cbb15-ea50-4394-b1b9-ab4553b5b275": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00509587",
        "Statement": " Patients in the primary trial receive oral pazopanib once daily every day, continuing until disease progression or unacceptable toxicity.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs. Both trials specify that patients receive oral pazopanib daily, but the primary trial states that the treatment cycle repeats every 28 days, while the secondary trial states that patients continue to receive the treatment until disease progression or unacceptable toxicity. The essential similarity lies in the administration of oral pazopanib daily, and the differences in treatment duration reflect differences between the primary and secondary trials rather than contradictions within the same trial. Therefore, the expert statement is consistent with the CTR information."
    },
    "bd51e2f7-05a6-4d1a-b6eb-4f6426eec3d8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777049",
        "Statement": "All 4 of the CHF cases in the primary trial, were in cohort 1.",
        "Label": "Contradiction",
        "explain": "The statement \"All 4 of the CHF cases in the primary trial, were in cohort 1\" can be contradicted based on the information provided in the CTRs.\n\nJustification:\nThe adverse events information in the CTRs indicates that there is only 1 case of congestive cardiac failure reported in each trial, in the primary trial it was observed in cohort 1 and in the secondary trial it was not reported at all. Therefore, the statement \"All 4 of the CHF cases in the primary trial, were in cohort 1\" is incorrect, as only 1 case was reported in cohort 1 and not 4."
    },
    "78a5162d-140a-4631-b776-5c284446b5ec": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02366130",
        "Secondary_id": "NCT01262027",
        "Statement": "the primary trial and the secondary trial have entirely different adverse event profiles.",
        "Label": "Entailment",
        "explain": "The statement \"the primary trial and the secondary trial have entirely different adverse event profiles\" is contradicted by the provided Clinical Trial Reports. \n\nIn the primary trial, the total adverse events were 28/36 (77.78%), while in the secondary trial, the total adverse events were 1/22 (4.55%). Although the absolute numbers and percentages differ, not all individual adverse events are listed in both trials. However, some adverse events are common to both trials, such as nausea and diarrhea, albeit with higher frequency in the primary trial. Additionally, new adverse events appear in the secondary trial, such as blood bilirubin and alkaline phosphatase increase. \n\nHowever, the statement focuses on the overall adverse event profiles being entirely different, which is not supported by the information provided. If the CTRs included exhaustive lists of all adverse events for both trials, with no shared occurrences, then the statement would be entailed. But based on the given data, the statement is contradicted."
    },
    "633ef768-9e9b-4336-9142-8d4ce7ee2342": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01026142",
        "Secondary_id": "NCT00846027",
        "Statement": "There were 10x more patients with Left ventricular systolic dysfunction in the primary trial than in the secondary trial.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nThe statement claims that there were 10 times more patients with Left ventricular systolic dysfunction in the primary trial than in the secondary trial. However, the data provided in the CTRs indicate that there were 13 cases in the primary trial (1.83%) and only 1 case in the secondary trial (1.22%). Therefore, the statement contradicts the information in the CTRs."
    },
    "7c5b29bc-ac37-48bb-abb1-a102174f79ef": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00826267",
        "Statement": "Cohort 1 and 2 of the primary trial receive 50mg of different drugs, administered orally from Day 1 to Day 21 ",
        "Label": "Contradiction",
        "explain": "The statement \"Cohort 1 and 2 of the primary trial receive 50mg of different drugs, administered orally from Day 1 to Day 21\" is entailed by the CTR information provided, as Cohort 1 received Afatinib 50mg orally from Day 1 to Day 21, and Cohort 2 received Lapatinib 50mg orally from Day 1 to Day 21."
    },
    "b8881e2e-ca25-4c1b-bbd2-281ebdb7514a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708214",
        "Statement": "All Progression Free Participants (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group.",
        "Label": "Entailment",
        "explain": "The statement \"All Progression Free Participants (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group\" can be entailed by the given CTRs. \n\nJustification:\nThe outcome measurement in the primary trial describes the number and percentage of participants with progression-free status after 16 weeks of treatment. The definition of progression includes various criteria such as new bone lesions, new lesions according to RECIST, an increase in tumour marker CA 15.3, and clinical deterioration.\n\nIn Results 1 of the primary trial, the Afatinib 50 mg With Letrozole group consisted of 7 participants, with a percentage of progression-free participants being 28.57% (3.67-70.96). This indicates that 2 out of 7 participants in this group remained progression-free after 16 weeks of treatment.\n\nIn Results 2 of the primary trial, the Afatinib 40 mg With Letrozole group had zero progression-free participants out of 13 (0.00%).\n\nGiven that there are no progression-free participants in the Afatinib 40 mg With Letrozole group and the statement refers to all progression-free participants from the primary trial, it follows that the statement is entailed by the given CTRs since all progression-free participants indeed belong to the Afatinib 50 mg With Letrozole group."
    },
    "a70cc8e5-0ef5-4045-8fec-d9e7503b5e6e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00615901",
        "Secondary_id": "NCT00829166",
        "Statement": "the primary trial recorded many more seizures than the secondary trial, despite having less than one tenth the number of patients in its total cohort.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided CTR data. In the Primary Trial, there was only 1 seizure reported (1/38 = 2.63%), while in the Secondary Trial, there were no seizures reported (0/490 = 0.00%). Therefore, the statement that the Primary Trial recorded \"many more seizures\" than the Secondary Trial is not supported by the provided data."
    },
    "e852619c-312a-470f-8b77-149e79f69a3f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00390455",
        "Secondary_id": "NCT00558103",
        "Statement": "In both the secondary trial and the primary trial the test cohorts produced better results than the control groups.",
        "Label": "Entailment",
        "explain": "The statement \"In both the secondary trial and the primary trial, the test cohorts produced better results than the control groups\" can be justified based on the provided data in the following ways:\n\n1. For PFS:\n   - In the primary trial, Arm I (Lapatinib) had a median PFS of 4.7 months (3.7-5.7) compared to 3.8 months (3.8-5.6) in Arm II (Placebo), indicating a longer PFS in the Lapatinib arm.\n\n2. For OR in the secondary trial:\n   - In Cohort 1 of the secondary trial, there were 11 participants in Arm 1 (Lapatinib 1500 mg + Placebo) and 17 participants in Arm 2 (Lapatinib 1500 mg + Pazopanib 800 mg). Although the CTR does not provide explicit numbers for OR, the fact that more participants are in the Lapatinib-only group suggests that it may have had better results than the Pazopanib group in this cohort. However, it's important to note that more information is needed to definitively conclude this, as OR is not directly comparable between the primary and secondary trials.\n\nTherefore, the statement can be justified to a certain extent based on the PFS data in the primary trial but more evidence is needed to make a definitive statement about the secondary trial."
    },
    "27160f45-e4cb-48be-8cf2-c23ced4578c0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00003830",
        "Statement": "The most common adverse event in both cohorts of the primary trial was Anaphylaxis, which affected more than 10 patients in total.",
        "Label": "Contradiction",
        "explain": "Contradicted. The statement asserts that more than 10 patients experienced Anaphylaxis in both cohorts of the primary trial, while the data shows a total of 10 Anaphylaxis cases across both trials with 2788 and 2800 participants respectively."
    },
    "e4b65e9f-10f6-4424-95d2-837e29587a63": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754325",
        "Secondary_id": "NCT00399529",
        "Statement": "the secondary trial and the primary trial both accept patients with HER-2/neu-overexpressing adenocarcinoma of the breast.",
        "Label": "Entailment",
        "explain": "The statement is entailed. Both trials include patients with HER-2/neu-overexpressing adenocarcinoma of the breast as a common inclusion criterion. (Primary Trial: \"human epidermal growth factor receptor 2+ (HER2+) or HER2- breast cancer\", Secondary Trial: \"Patients with histologically confirmed HER-2/neu-overexpressing adenocarcinoma of the breast\")."
    },
    "68f6f3db-0bfb-4e03-8e2f-92ae5d0f55a1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01127373",
        "Statement": "Patients with T1N2M0, T2N1M0, T3N1M1 and TxN1M0 tumors are eliglbe for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTR's inclusion criteria for the primary trial. According to the CTR, eligibility is based on the tumor stage (T) and nodal involvement (N), as well as other conditions. The statement lists T1N2, T2N1, T3N1, and TxN1 tumors as eligible. The CTR allows patients with T stages from 1 to 3, but N stage must be 1. Therefore, T1N2 and T2N1 meet the criteria, and T3N1 is borderline (since T3 is allowed) but still eligible because N1 is specified. TxN1 refers to an unknown T stage, but the CTR permits that as well if N1 and M0 are present. Thus, all the mentioned tumor stages are eligible based on the provided CTR information."
    },
    "7796fe1b-1952-4339-90f3-47b051ebe927": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01432886",
        "Statement": "One of the patients in cohort 2 of the primary trial experienced neutropenia persisting for more than 7 days.",
        "Label": "Contradiction",
        "explain": "The statement \"One of the patients in cohort 2 of the primary trial experienced neutropenia persisting for more than 7 days\" is entailed by the CTR. This is because the CTR in the ELIGIBILITY CRITERIA section defines DLT as \"Neutropenia persisting for more than 7 days,\" and the RESULTS 1 section states that there was one participant in cohort 2 of the primary trial who experienced DLTs. Therefore, it follows that one participant in cohort 2 experienced neutropenia persisting for more than 7 days."
    },
    "c7df7b38-068b-48a8-b805-b8ebb3e854e6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Secondary_id": "NCT00570921",
        "Statement": "the primary trial and the secondary trial do not record any of the same adverse events.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nExplanation:\n\nIn the primary trial, the adverse events \"Hepatic failure\" and \"Alanine aminotransferase increased\" are reported in common between the two trials. Therefore, the statement is contradicted by the given data."
    },
    "39227bbb-0e26-4ba0-94a7-762376541889": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00945061",
        "Statement": "patients with Multi-focal breast cancer cannot be accepted for the primary trial.",
        "Label": "Entailment",
        "explain": "Contradiction. The primary trial's inclusion criteria state that patients with multicentric carcinoma (tumors in different quadrants of the breast or tumors separated by at least 4 cm) are excluded from the study. However, the expert's statement specifically mentions \"multi-focal breast cancer\" without specifying that the tumors are in different quadrants or separated by 4 cm or more. Therefore, the expert's statement contradicts the provided CTR as it may include patients with multifocal breast cancer that meet the size and margin requirements and would be eligible for the trial, but the CTR does not accept such patients."
    },
    "fdb7afc0-ef7e-44bf-bfe3-5252fa8b0106": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03283553",
        "Secondary_id": "NCT02679755",
        "Statement": "the primary trial and the secondary trial have a different number of cohorts.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the given information in the CTRs. The primary trial has two intervention arms, while the secondary trials each have only one intervention arm. Therefore, the statement correctly reflects the difference in the number of cohorts between the two trials."
    },
    "fd15ddaf-1abc-4551-a5b3-08217b975e36": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02321527",
        "Statement": "Patients with invasive breast cancer with a diameter of more than 70mm are included in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the Primary Trial's Inclusion Criteria, as it specifies that the maximal dimension of the invasive breast cancer should be less than 5 cm."
    },
    "067f4671-0720-4980-a0fa-8d01d31daa9a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00054132",
        "Secondary_id": "NCT01421017",
        "Statement": "As the primary trial and the secondary trial use very similar outcome metrics, we can easily compare and contrast across their results.",
        "Label": "Contradiction",
        "explain": "The statement \"As the primary trial and the secondary trial use very similar outcome metrics, we can easily compare and contrast across their results\" is entailed by the information provided in both CTRs. The primary trial uses EGFR as an outcome measurement, while the secondary trials use systemic tumor response rates. Both studies use a proportion as the unit of measure and provide the range of the result. Therefore, the similarity in the outcome metrics allows for comparison between the trials."
    },
    "026e7eb7-37fd-4aae-b74f-dacf905db262": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02366130",
        "Secondary_id": "NCT01262027",
        "Statement": "the primary trial reported more than 10 times the number of patients experiencing adverse events as the secondary trial .",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted based on the data provided in the CTRs. \n\nIn the Primary Trial, the total number of adverse events was 28/36 (77.78%), and in the Secondary Trial, the total number of adverse events was 1/22 (4.55%). Therefore, the Primary Trial reported approximately 6 times, not more than 10 times, the number of patients experiencing adverse events as the Secondary Trial."
    },
    "a79fc503-215f-40d4-9cc1-e101cec3a9c9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02878057",
        "Statement": "Patients that are fully active and able to carry on all pre-disease performance without restriction are excluded from the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Patients that are fully active and able to carry on all pre-disease performance without restriction are excluded from the primary trial\" cannot be directly entailed from the given CTR as there is no explicit statement in the primary CTR that patients who are fully active and able to carry on all pre-disease performance without restriction are excluded. However, the ECOG performance status of 0-1 implies that patients must be able to carry out all pre-disease activities without substantial impairment. This could be considered as a justification for the statement, but it is not a direct entailment since the CTR does not use the exact phrasing \"fully active and able to carry on all pre-disease performance without restriction.\" The CTR does exclude patients with an ECOG performance status of 2 or greater, which indicates that the patient is experiencing significant performance issues. The secondary trial statement may be a more stringent exclusion criterion, but it does not contradict the primary CTR as the primary CTR does not explicitly state that the more stringent criterion does not apply."
    },
    "ee5f95d0-3824-4ce4-bf58-1ecd3ce4e7ee": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00191269",
        "Statement": "the primary trial measured the Number of Participants With Disease Progression (PD) or Death, to evaluate the performance of its interventions.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. The primary trial's RESULTS sections (Results 1 and Results 2) report the number of participants with progressive disease for each arm, and the statement explicitly mentions the Number of Participants With Disease Progression (PD) or Death, which are included in the reported data."
    },
    "7a9fa9d8-8b71-4df3-918f-0f8e8ecb4b0a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00574587",
        "Secondary_id": "NCT00777049",
        "Statement": "There were no cases of cardiac tamponade in the primary trial or the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the provided CTRs. Both the primary and secondary trials report no cases of cardiac tamponade in their respective adverse events sections. (Primary Trial: Adverse Events 1 and 2, Secondary Trial: Adverse Events 1 and 2)"
    },
    "ccb703ea-df18-451b-8db8-ed0e510a4c0f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03592121",
        "Secondary_id": "NCT01439711",
        "Statement": "Unlike the secondary trial, the primary trial does not specify a specific dosage or frequency for its intervention.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs provided since both trials specify that AB-101 and placebo should be applied to the nipple/areola regions approximately 1 hour prior to sexual activity. However, the primary trial does not specify a dosage or frequency for the application of AB-101, as stated in the expert's comment. Nevertheless, this lack of specification does not contradict the information given in the CTR for the primary trial, as the application time is consistent between interventions. The secondary trial provides more detailed intervention information, including a specific therapy regimen for Letrozole, but it does not concern the application of AB-101 in the primary trial, making the statement entailed rather than contradicted."
    },
    "56cd4492-3884-4b2a-a000-7c859d86f6f5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00284180",
        "Statement": "Across both cohorts of the primary trial a total of two patients had low levels of oxygen in their body tissues.",
        "Label": "Entailment",
        "explain": "The statement \"Across both cohorts of the primary trial a total of two patients had low levels of oxygen in their body tissues\" is entailed by the CTR data. The condition \"Hypoxia\" was reported in two patients in each cohort of the primary trial (1/11 and 1/11 for Cohort 1 and 1/21 and 1/21 for Cohort 2). The term \"low levels of oxygen in their body tissues\" can be inferred from the definition of Hypoxia. Thus, the statement correctly summarizes the information provided in the CTRs."
    },
    "08b79e0d-5e97-45fb-ac83-0096b56f714b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01492101",
        "Statement": "less than 1% of either cohort of the primary trial was effect by either Pancytopenia or Coagulopathy.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nJustification: \n\nThe statement \"less than 1% of either cohort of the primary trial was effect by either Pancytopenia or Coagulopathy\" contradicts the information in the CTRs as follows:\n\nPrimary Trial (Adverse Events 1): \n- Total adverse events: 128/425 (30.12%)\n- Pancytopenia: 2/425 (0.47%)\n- Coagulopathy: 1/425 (0.24%)\n\nSecondary Trial (Adverse Events 2): \n- Total adverse events: 129/406 (31.77%)\n- Pancytopenia: 0/406 (0.00%)\n- Coagulopathy: 0/406 (0.00%)\n\nThe CTRs show that both Pancytopenia and Coagulopathy each occurred in greater than 0.1% of the respective trial cohorts."
    },
    "c524ecf2-1ca6-4a9a-bedf-f0709124fa1b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01466270",
        "Statement": "The the primary trial placebo group had a over 10% higher mean retention than the donepezil hydrochloride PO QD group.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial results show that the donepezil hydrochloride PO QD group had a mean retention of 71.0% (8.3%) and the placebo PO QD group had a mean retention of 80.7% (7.2%). The difference is not over 10%, but instead, the placebo group had a lower mean retention."
    },
    "6d549a9b-47bf-4369-962b-2759cfd7051e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00798135",
        "Secondary_id": "NCT01209195",
        "Statement": "the primary trial and the secondary trial both investigate Pharmacokinetics Itraconazole 500mg QD.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nJustification: \n\nThe primary trial investigates the pharmacokinetics of oral itraconazole at a dosage of 200mg a day, while the statement suggests a dosage of 500mg QD which is different from the one in the primary trial. Additionally, the primary trial measures the PK of itraconazole and its metabolite 6-OH itraconazole, while the statement does not specify which compound is being investigated. Therefore, the statement contradicts the information provided in the primary trial CTR."
    },
    "596f20cf-299d-40a3-881a-cdd49bcb21f6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00703326",
        "Secondary_id": "NCT00274768",
        "Statement": "Participants with HER2- primary breast tumors, confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Participants with HER2- primary breast tumors, confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial\" is entailed in both CTRs as both trials include participants with a histologically or cytologically confirmed diagnosis of adenocarcinoma of the breast and require HER2-negativity as an inclusion criteria by FISH or IHC methods. Specifically, the primary trial states \"Participant's primary and/or metastatic tumor is human epidermal growth factor receptor 2 (HER2)-negative,\" and the secondary trial does not specify the HER2 status, but the disease characteristic \"Histologically or cytologically confirmed diagnosis of adenocarcinoma of the breast\" already implies HER2- negativity, and the FISH method is mentioned in the eligibility criteria."
    },
    "78ae19aa-6e26-4f9a-b381-cd77d92e4ecb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03066947",
        "Statement": "At least one patient in the primary trial suffered from Gastroesophageal reflux disease.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the Primary Trial's Adverse Events section, as GERD (Gastroesophageal reflux disease) is listed as an adverse event with an occurrence rate of 4.17% (21 out of 24 patients)."
    },
    "1d4f9f95-6f97-4054-9dd8-fe78aa5fc685": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00293540",
        "Statement": "Sam has recently received a liver transplant, he is not eligible for the primary trial, but is eligible for the secondary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary trial's exclusion criteria include \"Patients with organ transplants,\" which directly contradicts the statement that Sam, who has recently received a liver transplant, is eligible for the secondary trial."
    },
    "d4b2d877-34af-4944-84f7-046e22c2854e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01781299",
        "Statement": "all subjects in the primary trial must undergo a minor surgery.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the primary trial intervention descriptions, as both arms involve tissue expander placement, which is a surgical procedure."
    },
    "d3ca3729-2795-4cd5-9968-666781d17fac": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00119262",
        "Statement": "cohorts 1 and 2 of the primary trial recorded a different number of patients that suffered from Congestive Heart Failure.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the information in the CTRs.\n\nReason:\n\nThe primary trial results provide the number of participants in each arm (Arm A and Arm B) who suffered from congestive heart failure. Arm A had 2.9% (0.6-8.3%) of participants experiencing congestive heart failure and Arm B had 2.5% (0.5-7.1%). The statement asserts that there was a difference in the number of patients who suffered from congestive heart failure between cohorts 1 and 2. The difference in percentage between the two arms supports this claim."
    },
    "fb85a3a5-b9a1-48f4-84f3-2e2307e2f104": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01752907",
        "Statement": "There were 0 observed cases of Tibia or Fibula fractures in the primary trial.",
        "Label": "Entailment",
        "explain": "The expert's statement is contradicted by the information in the given Adverse Events sections of the primary CTR. There is no mention of Tibia or Fibula fractures in either section, but there are several instances of other types of adverse events."
    },
    "b98c7a50-ed79-41ff-9733-fff143f630be": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01901146",
        "Secondary_id": "NCT00209092",
        "Statement": "Cohort 1 of the primary trial recorded the same number of instances of Neutropenic fever as Cohort 1 of the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradiction \n\nExplanation:\n\nThe statement claims that cohort 1 of the primary trial recorded the same number of instances of neutropenic fever as cohort 1 of the secondary trial. However, the given CTRs do not provide information on the occurrence of neutropenic fever in cohort 1 of the primary trial. While both trials have participants suffering from febrile neutropenia, they are not the same as neutropenic fever, as not all cases of febrile neutropenia result in neutropenia (low neutrophil count). The CTRs only mention the number of instances of febrile neutropenia for cohort 1 of the primary trial (3/364) and do not provide the number of cases with neutropenia. Therefore, the claim made by the expert is contradicted by the provided data."
    },
    "47aa5686-75af-4ed8-b4ff-715b458ce40a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02203565",
        "Secondary_id": "NCT00194779",
        "Statement": "laboratory biomarker analysis is used in the secondary trial and the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the information in the CTRs. \n\nJustification: Both the primary and secondary trials include laboratory biomarker analysis as optional correlative studies in their respective intervention sections. Therefore, the statement that \"laboratory biomarker analysis is used in the secondary trial and the primary trial\" is in agreement with the provided descriptions. \n\nSpecifically, in the primary CTR, laboratory biomarker analysis is mentioned as an optional correlative study under the RESULTS section. In the secondary CTR, laboratory biomarker analysis is listed as a correlative study under the INTERVENTION section for various drugs, such as methotrexate, vinorelbine tartrate, and capecitabine. \n\nTherefore, the statement is entailed as it correctly reflects the presence of laboratory biomarker analysis in both trials."
    },
    "e89fdc93-d624-4ba7-aa64-574a278e982b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00077376",
        "Secondary_id": "NCT01256008",
        "Statement": "the primary trial investigates a novel chemotherapy treatment, whereas the secondary trial is testing a type of psychological therapy.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the CTRs. \n\nJustification: \n\nThe primary CTR states that the intervention is a chemotherapy treatment consisting of Trastuzumab/Ixabepilone/Carboplatin. The secondary CTR states that the intervention for the experimental group is CBT, which is a type of psychological therapy. Therefore, the statement that the primary trial investigates a novel chemotherapy treatment and the secondary trial is testing a type of psychological therapy, is an accurate representation of the information provided in the CTRs."
    },
    "1739541a-2d3f-4a13-b956-769a1cbed4d7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00871858",
        "Statement": "1 patient in cohort 1 of the primary trial was diagnosed with a Clear cell renal cell carcinoma.",
        "Label": "Contradiction",
        "explain": "Contradicted\n\nJustification:\nThe statement \"1 patient in cohort 1 of the primary trial was diagnosed with a Clear cell renal cell carcinoma\" contradicts the CTR data since no such case was reported in either the primary or secondary trial under the \"Adverse Events\" sections. Specifically, in the primary trial, the number of Clear cell kidney cancer cases was zero in both Cohort 1 and Cohort 2, and in the secondary trial, there was no mention of any Clear cell renal cell carcinoma case in its \"Adverse Events\" section."
    },
    "c8f401a0-5e7d-4fd9-b31e-0866c9bee6a9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187744",
        "Statement": "One patient in the primary trial suffered from sepsis, due to the presence of an implanted device.",
        "Label": "Entailment",
        "explain": "The statement \"One patient in the primary trial suffered from sepsis, due to the presence of an implanted device\" is entailed by the CTR data in the Adverse Events section of the Primary Trial, as there is one instance of \"Device related sepsis\" reported."
    },
    "206fc00c-2c34-42bc-8fca-44be696e03c9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02312622",
        "Statement": "Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m\u00ac\u00a8\u201a\u00e2\u00a7 as monotherapy once every 21 days , the differences between the cohorts is the type of cancers that patients are diagnosed with, cohort 1 is NSCLC, whereas cohort 2 is mBC and the number of cycles for each cohort, 1 for cohort 1 and 4 for cohort 2.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. \n\nExplanation:\n\nThe statement correctly identifies that both cohorts receive identical interventions in terms of the dose, route, and frequency of pegylated irinotecan administration. It also acknowledges the difference in the number of cycles for each cohort. The CTRs explicitly state that patients in Cohort A receive pegylated irinotecan IV at 145 mg/m\u00b2 as monotherapy once every 21 days, and patients in Cohort C receive pegylated irinotecan IV at 145 mg/m\u00b2 as monotherapy once every 21 days for 4 cycles. Therefore, the statement accurately reflects the information provided in the CTRs."
    },
    "4a6d7f07-27b5-4281-b59c-f1c77dbd6e2d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00393939",
        "Statement": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a year higher for patients in the Trastuzumab + Sunitinib group of the primary trial than for the Docetaxel group.",
        "Label": "Contradiction",
        "explain": "The statement is entailed based on the information in the CTRs. Specifically, the median (95% Confidence Interval) PFS for the Docetaxel + Sunitinib group was 8.6 (8.2 to 10.3) months and for the Docetaxel group it was 6.9 (6.5 to 7.3) months, which is a difference of approximately 1.7 months."
    },
    "83cef795-d4a8-486c-8ac1-34a9acee9672": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00581256",
        "Statement": "Patients with left-sided breast cancer and an ECOG between 1-2 are excluded from the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted by the primary trial. The eligibility criteria for the primary trial explicitly states that patients with ECOG 1-2 are included, not excluded. Therefore, the expert's statement is in contradiction with the information in the primary trial."
    },
    "b3cee7a6-cec1-4676-974d-7cfb3ccd9919": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127933",
        "Secondary_id": "NCT00191789",
        "Statement": "the primary trial recorded one patient with a catheter-related complication, whereas in the secondary trial none where observed.",
        "Label": "Entailment",
        "explain": "The statement can be contradicted based on the provided CTRs. In the primary trial, there was one patient with catheter site cellulitis (a type of catheter-related complication), while in the secondary trial, no such cases were reported. Therefore, the statement does not follow the data in the CTRs."
    },
    "007de11b-4265-4695-b18e-e0d6909a347a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00944047",
        "Secondary_id": "NCT00228943",
        "Statement": "Patients with HER2 positive tumors are excluded from the primary trial, but may be included in the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. According to the primary CTR, patients with HER2 positive tumors are explicitly excluded from participation (EXCLUSION CRITERIA). The secondary CTR, however, includes patients with HER2 positive tumors (INCLUSION CRITERIA). This statement contradicts the information provided in the CTRs."
    },
    "ce621235-b584-439b-bb11-ab2fa04c3195": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01869764",
        "Secondary_id": "NCT02556632",
        "Statement": "Every participant in the secondary trial and the primary trial undergoes Laboratory Biomarker Analysis and completes a Questionnaire.",
        "Label": "Contradiction",
        "explain": "The statement is entailed, as both the primary and secondary trials include Laboratory Biomarker Analysis and Questionnaire Administration for all participants, as indicated in each CTR:\n\nPrimary Trial:\nINTERVENTION 1 & 2: \n\"...laboratory biomarker analysis: Correlative studies\"\n\"Questionnaire Administration: Ancillary studies\"\n\nSecondary Trial:\nINTERVENTION 1 & 2: \n\"...Laboratory Biomarker Analysis: Correlative studies\"\n\"Questionnaire Administration: Ancillary studies\""
    },
    "f358f023-2393-44eb-9535-3f0e1851318d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01646346",
        "Secondary_id": "NCT03283553",
        "Statement": "the secondary trial and the primary trial both use irradiation techniques in their studies.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. In the primary trial, Intervention 1 involves 4D Conformal Image-Guided Partial Breast RT, which is a type of irradiation therapy. In the secondary trial, though Intervention 1 is labeled as a multicomponent intervention, it also includes Intervention 2, where patients receive Usual Care from medical oncologists. Intervention 2 does not mention any specific treatment but falls under the broader category of medical care, which may include various treatments like chemotherapy or radiation therapy. Therefore, the use of irradiation techniques is present in both trials."
    },
    "0e963b25-0d2b-4fc6-89c6-1eb068bc092e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470301",
        "Statement": "Every patient in the primary trial is given tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV.",
        "Label": "Entailment",
        "explain": "The statement is entailed in the primary trial CTR as both tipifarnib and the listed chemotherapies (paclitaxel, doxorubicin hydrochloride, and cyclophosphamide) are stated as being given to patients in the trial. However, acyclophosphamide is listed under the \"INTERVENTION\" section of the primary trial as IV and not as part of the combination given to every patient with tipifarnib. Thus, there is a slight discrepancy, but the overall meaning of the expert's statement remains entailed given the context. If the expert's statement specifically required acyclophosphamide to be part of the combination given to every patient, then it would be a contradiction."
    },
    "390b08d3-e147-47f9-82d7-0643b8d5c8ae": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00733408",
        "Statement": "There was just under 8 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement can be entailed based on the information provided in the Primary Trial's Outcome Measurement section. According to the section, the time frame for measuring Progression-free Survival (PFS) is up to 8 years; however, the minimum PFS is not explicitly stated, while the maximum PFS (median PFS = 9.1 months, 95% CI: 7.2 to 11.1 months) is given. An 8-week difference is approximately 6 weeks or 1 month and a half, which falls within the range of the reported maximum PFS. Thus, the statement is justified based on the information in the CTRs."
    },
    "2570cb04-4edd-48c9-b634-9f2e086469de": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00994279",
        "Secondary_id": "NCT00545077",
        "Statement": "Between both the primary trial and the secondary trial Bevacizumab is only administered to patients in cohort 2 of the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed. According to the provided information in the primary trial, Bevacizumab is not mentioned in the Intervention section of Arm 1 or Arm 2. In the secondary trial, Arm A does not receive Bevacizumab, while Arm B, which has a different intervention than Arm 1 or Arm 2 in the primary trial, does receive Bevacizumab. Therefore, the statement accurately reflects the difference in administration of Bevacizumab between both trials."
    },
    "f6a7e279-b923-45e3-8ad5-e81e17c0a682": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00270894",
        "Statement": "60 patients in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTR information provided. In the Primary Trial's Results 1 section, it is stated that \"60 participants were able to complete > 85% of the planned dose on schedule\" (percentage is 60 and the statement in the expert's claim also mentions 60 patients). The time frame for measuring the completion of the planned dose in the trial is also consistent between the CTR and the expert's statement (from the start of treatment through the neoadjuvant treatment period, approximately 20 weeks)."
    },
    "3d82851c-f302-4988-bd78-232583e04e96": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02511730",
        "Secondary_id": "NCT00193206",
        "Statement": "Patients with prior chemotherapy are eligible for the primary trial, but excluded from the secondary trial.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nExplanation:\n\nThe statement \"Patients with prior chemotherapy are eligible for the primary trial, but excluded from the secondary trial\" is contradicted by the information presented in the given CTR sections. The primary trial's exclusion criteria explicitly state that \"Subjects with unknown clinical status not participating in FMSU004A protocol\" are not eligible, but there is no mention of prior chemotherapy in the primary trial criteria or exclusions. In the secondary trial, prior chemotherapy is mentioned in the exclusion criteria. Thus, the statement is contradicted since it implies that patients with prior chemotherapy can be included in the primary trial while being excluded from the secondary trial, but the CTRs do not support this assertion."
    },
    "5c9f5916-37d3-4f6f-977b-be70204cf57c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01819233",
        "Statement": "All the primary trial participants have the same number of calories in their diets throughout the duration of the study.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the information in the PRIMARY TRIAL Intervention section, specifically the part that mentions patients following a caloric-restricted diet for 10 weeks, which includes a reduction of 25% of their normal diet. This directly contradicts the assumption in the expert's statement that all participants have the same number of calories in their diets throughout the study."
    },
    "0c5f2498-4c10-4e51-8915-d86b37b08156": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "Participants in the primary trial are assigned an intervention depending on their cancer diagnosis, whereas in the secondary trial the interventions are randomly assigned.",
        "Label": "Entailment",
        "explain": "The statement should be entailed by the provided CTRs. In both the primary and secondary trials, interventions are assigned to participants based on specific conditions: cancer diagnosis in the primary trial and assignment to Group A or B in the secondary trial. Therefore, the statement accurately reflects the information in the CTRs."
    },
    "c54dc963-671a-4384-8b1f-d8058a832131": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00545688",
        "Statement": "There were no patients with paranasal sinus reactions, or Left ventricular dysfunction in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted, as there is no mention of paranasal sinus reactions in either the primary or secondary CTRs. However, the primary CTR reports one case of left ventricular dysfunction in the adverse events of the control group (0/107, 0.00%)."
    },
    "a4c62782-9f4c-4cf5-96b3-eb8e9098a3b4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02340221",
        "Statement": "A total of 32 patients in the primary trial had Diarrhoea.",
        "Label": "Entailment",
        "explain": "The statement \"A total of 32 patients in the primary trial had Diarrhea\" is entailed by the CTR Adverse Events 1 and Adverse Events 2 of the Primary Trial since the total number of patients who experienced Diarrhea in both sections adds up to 32 (0 + 32). Therefore, the statement is entailed. (Total number of Diarrhea cases in Adverse Events 1: 0 + Total number of Diarrhea cases in Adverse Events 2: 32 = 32)"
    },
    "91adb350-ab20-41a6-944d-c13b55cf33f2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00014222",
        "Statement": "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events, whereas cohort two recorded none.",
        "Label": "Entailment",
        "explain": "Based on the provided Clinical Trial Reports, the expert's statement is contradicted. In the primary trial, there was one case of keratitis (an eye-related adverse event) in 680 patients (section: Adverse Events 1), and in the secondary trial, there were no reported eye-related adverse events in 688 patients (section: Adverse Events 2)."
    },
    "78949f1f-6738-4220-a233-e7831902e6f3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038010",
        "Secondary_id": "NCT00764322",
        "Statement": "Neither the primary trial or the secondary trial are measuring Dose Limiting Toxicity of BYL719 in Combination With T-DM1.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nThe primary trial's outcome measurement explicitly states that dose limiting toxicity of BYL719 in combination with T-DM1 will be assessed according to National Cancer Institute's Common Toxicity Criteria for adverse events version 4.0. However, the provided expert statement claims that neither trial is measuring Dose Limiting Toxicity of BYL719 in combination with T-DM1.\n\nThis contradiction can be explained by the fact that while the trials do report adverse events, they do not specifically mention dose limiting toxicities for BYL719 in combination with T-DM1 in the given CTR sections. Therefore, the statement made by the expert is not entailed by the information provided in the CTRs."
    },
    "135311d8-c579-4568-913e-937be00dde7e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00390455",
        "Secondary_id": "NCT00558103",
        "Statement": "In both the secondary trial and the primary trial the test cohorts achieved better overall response than the control groups.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed based on the following information from the CTRs:\n\n1. In the primary trial, arm I (Lapatinib) had a median PFS of 4.7 (3.7-5.7) months compared to 3.8 (3.8-5.6) months in arm II (Placebo).\n2. In the secondary trial, cohort 1 with Lapatinib 1500 mg + Placebo had 11 participants with OR compared to 17 participants in cohort 1 with Lapatinib 1500 mg + Pazopanib 800 mg.\n\nBoth trials indicate that the test cohorts (Lapatinib in the primary trial and Lapatinib + Pazopanib in the secondary trial) had better overall response (as indicated by longer PFS or a greater number of participants achieving OR) compared to the control groups (Placebo in the primary trial and Placebo in secondary trial)."
    },
    "0984431d-4997-41dc-9ba4-07134568c3fa": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00258349",
        "Secondary_id": "NCT01328249",
        "Statement": "Cohort 1 of the primary trial does not receive any Eribulin Mesylate With Prophylactic Filgrastim, whereas both cohorts in the secondary trial receive some.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the CTRs. In the primary trial, Cohort 1 receives Eribulin Mesylate without Prophylactic Filgrastim, as stated in the Intervention section. In contrast, in the secondary trial, Cohort 1 receives Eribulin Mesylate but with Filgrastim as Needed, not as prophylactic. Cohort 2, on the other hand, receives Eribulin Mesylate with Prophylactic Filgrastim. Therefore, the statement accurately reflects the differences between the trials."
    },
    "d9dc4a6d-a913-46ac-b0aa-d50823ff2305": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00662129",
        "Statement": "Patients with Platelet count over 100,000/mm\u00ac\u00a8\u201a\u00e2\u2022, ANC <  1,700/mm\u00ac\u00a8\u201a\u00e2\u2022 and Hemoglobin between 11 to 18 grams per deciliter are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The given statement contradicts the platelet count requirement in the eligibility criteria of the primary trial, which specifies a minimum platelet count of 100,000/mm\u00b3 (CTR, Patient Characteristics section), while the expert statement allows for a platelet count over 100,000/mm\u00b3 but less than 150,000/mm\u00b3 (implied by the \"over\" qualifier and \"more than 50,000/mm\u00b3\" inference for ANC). Additionally, the statement incorrectly implies that hemoglobin falls within the specified range of 11 to 18 grams per deciliter when the CTR makes no such requirement for hemoglobin levels."
    },
    "9d9ab190-cdcf-4320-b69a-12f2dad9dba9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02435680",
        "Secondary_id": "NCT01743560",
        "Statement": "the secondary trial and the primary trial use non comparable evaluation metrics, and significantly different time frames.",
        "Label": "Entailment",
        "explain": "The statement should be entailed.\n\nJustification:\n\nThe primary trial measures Progression Free Survival (PFS) in months with a time frame of 4 years, while the secondary trial measures the Overall Response Rate (ORR) at 48 weeks. These metrics are not directly comparable as PFS refers to the time from treatment initiation to disease progression or death due to any cause, while ORR is the proportion of patients with a best overall response of complete response (CR) or partial response (PR) after 48 weeks of treatment. Therefore, the trials use different evaluation metrics. Additionally, the time frames are significantly different, with the primary trial assessing PFS over a much longer period of time than the secondary trial's assessment of ORR at 48 weeks."
    },
    "89fdf182-7474-4e70-baf7-03c8920c4ff3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01385137",
        "Secondary_id": "NCT00593346",
        "Statement": "Placebo treatment is used in cohort 2 of the secondary trial, but there is only a test group in the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nReasoning:\nThe primary trial only has two intervention groups: Arm I (Omega-3-fatty Acid) and Arm II (Placebo). However, the secondary trial has an intervention group (Accelerated Partial Breach Therapy) and a control group (Placebo). The statement suggests that there is only a placebo group in the secondary trial, which contradicts the given CTR."
    },
    "9f2fd0cc-af87-433d-9d2f-6235591d6cb1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00422903",
        "Statement": "Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.",
        "Label": "Contradiction",
        "explain": "The statement is entailed based on the provided CTR information. This is because the percentage of participants with cOR in cohort 2, which received Letrozole and Lapatinib, was higher (54%) compared to cohort 1 (48.3% for PR and 2% for CR) in the Primary Trial. Therefore, the statement is justified by the data presented in the CTRs."
    },
    "90364098-7e9a-47be-ab2e-f66958cfb09d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02725801",
        "Statement": "The interventions in the primary trial and the secondary trial are applied daily for a period of several months.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nJustification:\n\nIn the primary trial, the interventions (Estriol Vaginal Gel and Placebo Vaginal Gel) are administered weekly for certain weeks and not daily. Specifically, Weeks 1-3: single daily application and Weeks 4-12: twice weekly application. Therefore, the statement that \"The interventions in the primary trial and the secondary trial are applied daily for a period of several months\" contradicts the provided information in the CTRs."
    },
    "021c3f62-8067-49e3-9d4b-c7641feb2548": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00331552",
        "Secondary_id": "NCT01306942",
        "Statement": " The same dose of trastuzumab was used for the interventions in the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed based on the information provided in the CTRs. In both the primary and secondary trials, trastuzumab was given intravenously at a dose of 2 mg/kg for each cycle, except for the initial loading dose in the secondary trial which was 4 mg/kg in the first cycle for both cohorts. There is no contradiction to the statement in the CTRs."
    },
    "6893c9b4-d3a3-47a8-ada9-8aef67de2375": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01702571",
        "Statement": "Patients with incurable and unresectable Breast Cancer are eligible for the primary trial, unless it is metastatic.",
        "Label": "Contradiction",
        "explain": "The statement \"Patients with incurable and unresectable Breast Cancer are eligible for the primary trial, unless it is metastatic\" is entailed by the CTRs. \n\nJustification: \n\nThe primary trial inclusion criteria include \"Documented progression of incurable, unresectable, LABC, or mBC\" and \"Measurable and/or non-measurable disease,\" both of which indicate incurable and unresectable breast cancer. The exclusion criteria do not mention metastatic disease as an explicit exclusion criterion for the primary trial, implying that metastatic disease is not an absolute exclusion. Therefore, patients with metastatic disease can be included in the trial as long as they meet all other inclusion criteria. However, the expert's statement correctly identifies metastatic disease as a condition that makes patients ineligible for the trial. Therefore, the statement is entailed by the CTRs, but it provides a more precise definition of the patient population by excluding metastatic disease."
    },
    "b88cde11-ae29-48e8-832b-4b9cb2596c30": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00859651",
        "Statement": "Helen had stage III ovarian cancer 2 years prior, from which she is still recovering, she is excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The statement \"Helen had stage III ovarian cancer 2 years prior, from which she is still recovering, she is excluded from the primary trial\" contradicts the inclusion criterion of the primary trial, specifically, having \"no prior malignancy.\" Helen's history of stage III ovarian cancer disqualifies her from participation in the primary trial according to the stated inclusion criteria."
    },
    "ebe7078c-fd8b-439a-b1f5-7bd482071ead": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02472964",
        "Secondary_id": "NCT00089661",
        "Statement": "the primary trial studies changes in tumour diameter, whereas the secondary trial investigates changes in heart failure rate.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted. The primary trial and the secondary trial investigate different outcome measures, with the primary trial focusing on changes in tumor diameter using RECIST 1.1 criteria and the secondary trial examining changes in lumbar spine bone mineral density."
    },
    "d0b9c11c-50f2-4803-a96c-fff3ca90cf36": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02312622",
        "Statement": "Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m\u00ac\u00a8\u201a\u00e2\u00a7 as monotherapy once every 21 days (1 cycle), the difference between the cohorts is the type of cancers that patients are diagnosed with, cohort 1 is NSCLC, whereas cohort 2 is mBC.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the CTRs since both cohorts in the primary trial receive the same intervention, which is pegylated irinotecan administered intravenously at 145 mg/m\u00b2 as monotherapy once every 21 days. The difference mentioned in the statement, i.e., the type of cancer, is clearly stated in the CTR for each cohort (NSCLC for cohort 1 and mBC for cohort 2)."
    },
    "b620e1c5-69c4-4c30-9006-faa346200b60": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01256008",
        "Secondary_id": "NCT00300781",
        "Statement": "the primary trial is investigating Cognitive behavioural therapy, a type of psychotherapy, in contrast the secondary trial studies Trastuzumab, a type of chemotherapy.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided Clinical Trial Reports. \n\nJustification: \n\n1. In the primary trial, Intervention 1 describes Clinical Management, which is a type of psychological therapy. The expert's statement correctly identifies that this trial investigates Cognitive behavioural therapy as a contrast to another intervention. The statement does not contradict the CTR in any way.\n\n2. In the secondary trial, there is no description of a psychological therapy or intervention being tested. The trial only mentions the use of Neratinib with and without prior Trastuzumab. Therefore, the expert's statement accurately differentiates the types of interventions being investigated in each trial.\n\nHence, the semantic entailment between the statement and the provided CTRs is established based on the correct differentiation of interventions as psychotherapy (CBT) and chemotherapy (Trastuzumab) in their respective trials."
    },
    "0900325b-6ecd-46f1-b3f1-a2ce1605d151": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00325598",
        "Statement": "There is no difference in results or cohort size between cohort 1 and 2 of the primary trial, the increase in Gy has no notable effect.",
        "Label": "Entailment",
        "explain": "The statement can be contradicted. The CTRs provide information that there are two distinct cohorts with different doses (36 Gy and 40 Gy) and the size of each cohort is 50 participants. The expert's statement implies that the cohorts are identical, but the data in the CTRs demonstrates a distinction between them."
    },
    "6f10e1f3-1197-464e-b574-d697fb49331d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02419807",
        "Secondary_id": "NCT00777101",
        "Statement": "Patients with HER2 + breast cancer are eligible for both the primary trial and the secondary trial. However, only patients with stage 1-2 breast cancer are eligible for the primary trial, and patients with stage 3-4 are eligilbe for the secondary trial. ",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the provided CTRs.\n\nJustification:\n\nThe primary trial includes patients with clinical stage 1 or 2 breast cancer, while the secondary trial includes patients with stage IIIB, IIIC, or IV breast cancer. Therefore, patients with stage 3-4 breast cancer are not eligible for the primary trial, but they are eligible for the secondary trial. The statement incorrectly states that patients with HER2+ breast cancer are eligible for both trials regardless of their stage, but this is not the case based on the information provided in the CTRs."
    },
    "cbf91beb-829b-488f-8e80-3b08b891a181": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03592121",
        "Secondary_id": "NCT01439711",
        "Statement": "the secondary trial and the primary trial both require their patients to receive their respective interventions on a daily basis.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. \n\nJustification:\nThe primary trial specifies that AB-101 is to be applied approximately 1 hour prior to sexual activity, but it does not mention the frequency of application. However, since the expert's statement only refers to the requirement of daily application, it can be inferred that this instruction applies to both interventions (AB-101 and Placebo) in the primary trial. In the secondary trial, Letrozole is given orally at a dose of 2.5 mg/day, which can be considered a daily application. Therefore, the expert's statement is consistent with the information in both CTRs."
    },
    "985df98b-b397-4dbc-8fad-43ada30927d7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00254592",
        "Statement": "Patients needing active supportive care can participate in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the Primary Trial's Inclusion Criteria. The criteria explicitly state that patients with a clinical diagnosis of congestive heart failure or angina pectoris are not eligible for the trial. These conditions could be considered as needing active supportive care. Therefore, the statement \"Patients needing active supportive care can participate in the primary trial\" is incorrect based on the provided CTR information."
    },
    "0d4fdeef-89b2-463b-8252-66fa51d9ce8c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00356811",
        "Secondary_id": "NCT00296036",
        "Statement": "The the secondary trial intervention is applied to the palms and soles twice daily, the primary trial participants are not administered any medication on the skin of the hands or feet, but rather onto the breast or chest wall.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted. The primary trial intervention involves oral intake of lapatinib and intravenous infusion of paclitaxel, neither of which are administered topically to the hands or feet. The secondary trial involves topical application of urea/lactic acid cream and placebo cream to the palms and soles, which is distinct from the primary trial intervention."
    },
    "2c270b8f-d1a4-4686-a75c-bb3ac4b0c6fe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02595372",
        "Statement": "27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with Minocycline Hydrochloride did not have Pathological Complete Response.",
        "Label": "Contradiction",
        "explain": "Contradiction. The secondary trial does not provide information about the percentage of patients with FASN expression who did not have a pathological complete response when treated with Minocycline Hydrochloride. The primary CTR specifies the percentage of patients with FASN expression who had a pathological complete response when treated with Omeprazole, but it does not mention any data for Minocycline Hydrochloride. Therefore, the statement cannot be entailed based on the given CTRs."
    },
    "494c1f01-5a2d-409e-b614-5871f408fbe6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00450866",
        "Statement": "In the primary trial group A has a higher percentage of patients with >25% increase in tumor area at 3 months after treatment than group B. ",
        "Label": "Contradiction",
        "explain": "The statement \"In the primary trial, group A has a higher percentage of patients with >25% increase in tumor area at 3 months after treatment than group B\" is contradicted by the information in the CTRs.\n\nJustification:\n\nIn the primary CTR, there is no mention of the percentage of patients in either group A or B experiencing >25% increase in tumor area at 3 months after treatment. However, the CTRs do provide information on the number of patients with progression-free survival at 3 months after treatment. The statement makes a comparison between the percentage of patients with tumor progression (>25% increase in tumor area) at 3 months after treatment between the two groups, while the CTRs only report the number of patients with progression-free survival at this timepoint. Therefore, the statement contradicts the information provided in the CTRs."
    },
    "17881072-2517-483f-9c03-1edad21a58cf": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008150",
        "Secondary_id": "NCT00375427",
        "Statement": "In total the secondary trial recorded only 3 more cases of Pyrexia than the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed. \n\nJustification: The primary trial recorded 0/42 (0.00%) instances of Pyrexia, whereas the secondary trial recorded 0.48% (2/216) instances. The difference is 2 cases, which is fewer than the 3 cases mentioned in the statement. Therefore, the statement is correct as it indicates that the secondary trial recorded only \"3 more\" cases of Pyrexia than the primary trial."
    },
    "58ba5dfd-3d8d-42e4-8cff-3c179fcd43a7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00093795",
        "Statement": "Patients with cancer cells that have metastasised into less than 3 lymph nodes, with at least one larger than 2mm, cannot enter the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the eligibility criteria of the primary trial, specifically under the subsection \"Interpretation of Nodes\": \"By pathologic evaluation, ipsilateral nodes must be pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN3a, or pN3b (only if due to microscopic involvement of internal mammary node detected by sentinel lymph node dissection and with more than 3 positive axillary lymph nodes)\". In this trial, patients with fewer than three positive lymph nodes, at least one of which is larger than 2mm, are still eligible."
    },
    "da6ce3a9-b653-47b2-9271-f831e4de3f19": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00912340",
        "Statement": "Less patients in cohort 2 of the primary trial had an unusual amount of fluid around the lungs than in cohort 1.",
        "Label": "Contradiction",
        "explain": "The statement \"Less patients in cohort 2 of the primary trial had an unusual amount of fluid around the lungs than in cohort 1\" is contradicted by the CTR data. The number of participants with pleural effusion in cohort 2 was 2/30 (6.67%), whereas in cohort 1 there was no reported case (0.00%). Therefore, a greater number of patients in cohort 1 experienced pleural effusions than in cohort 2."
    },
    "66979ae5-a709-4adf-9067-287f0f92b9e2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00828074",
        "Statement": "A higher number of cohort 2 participants from the primary trial experienced fever, compared to cohort 1.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nThe CTRs provided do not support the statement that a higher number of cohort 2 participants from the primary trial experienced fever, compared to cohort 1. \n\nThe CTR for the primary trial shows that only 2 out of 41 participants (4.88%) experienced fever, and there is no mention of a higher occurrence in cohort 2 specifically. \n\nThe CTR for the secondary trial also reports no instances of fever among its 5 trial participants (0.00%)."
    },
    "0af6799b-655f-4b8b-a192-ce8dcbb2fcff": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02692755",
        "Statement": "Only Black women are eligible for the primary trial, as long as they do not have uncontrolled or symptomatic brain metastases.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the Primary Trial's Inclusion Criteria which specifies that \"Self-identified Black, African or African American women\" are eligible for the trial under consideration. However, it is necessary to note that the statement made by the clinical trials expert only pertains to the eligibility of Black women, while the CTR includes additional eligibility criteria such as having advanced adenocarcinoma of the breast, ER-positive and/or PgR-positive tumor, HER2-negative breast cancer, and suitability for letrozole or fulvestrant therapy. The statement does not contradict any information within the provided CTR.\n\nTherefore, the statement is entailed by the Primary Trial's Inclusion Criteria."
    },
    "3a3e2387-c4c7-48e6-b3ca-1257de7019c2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00072293",
        "Statement": "Patients with a palpable breast lesions and axillary lymph nodes are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary CTR specifies that there should be no palpable axillary lymph node(s). Therefore, patients with palpable breast lesions and axillary lymph nodes do not meet the eligibility criteria for the primary trial."
    },
    "46ac8a9f-77ab-40cf-9421-64aad4ae6976": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00537771",
        "Secondary_id": "NCT00354640",
        "Statement": "participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole PO QD.",
        "Label": "Entailment",
        "explain": "The statement is entailed in the CTRs. \n\nJustification: \n\n1. In the primary trial, the Arimidex Group receives an Intervention of 1 mg once daily oral dose of Anastrozole. Since Anastrozole is being administered, the statement about taking 1 mg of Anastrozole PO QD applies to the participants of the Arimidex Group in the primary trial.\n\n2. In the secondary trial, both Anastrozole and Simvastatin are part of the Intervention for Intervention 1. The participants receive Anastrozole at a dose of 1 mg once daily oral dose for 14 days. Hence, the statement about taking 1 mg of Anastrozol PO QD applies to the participants of the secondary trial as well.\n\n3. The statement does not contradict the provided descriptions since it accurately reflects the administration of Anastrozole as outlined in the CTRs."
    },
    "d2b7253b-0654-4bb1-a9a4-b203714d64f9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Secondary_id": "NCT00950742",
        "Statement": "the primary trial and the secondary trial measure the DLT of their respective interventions, using the same time frame.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the following:\n\nIn the primary trial, the outcome measurement is \"Dose Limiting Toxicity Incidence of Neratinib in Combination With Paclitaxel,\" and the time frame for measuring DLT is from first dose date through day 28. (CTR: Primary Trial, Outcome Measurement)\n\nIn the secondary trial, the outcome measurement is \"Number of Participants With Dose Limiting Toxicities (DLT),\" and the time frame for measuring DLT is 28 days. (CTR: Secondary Trial, Outcome Measurement)\n\nBoth primary and secondary trials have the same time frame (28 days) for measuring DLT. (Statement)\n\nTherefore, the statement is entailed as it correctly reflects the common time frame for measuring DLT in both trials."
    },
    "9a896e4a-ae6b-468c-a7c0-32c1514c0b48": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00107276",
        "Secondary_id": "NCT00232505",
        "Statement": "Less than 5% of patients undergoing the intervention in the primary trial had adverse events, in comparison almost 10% patients in cohort 1 of the secondary trial  experienced an adverse event, and more than 30% of those in cohort 2 of the secondary trial had adverse events.",
        "Label": "Entailment",
        "explain": "The statement is entailed. The primary trial's Adverse Events section reports 4.21% (2/95) instances, while for the secondary trial, cohort 1 has 9.68% (3/31) instances, and cohort 2 has 32.00% (8/25) instances. These figures correspond to the statement."
    },
    "41eb4b9a-3b8f-4895-9aa3-cb43dbe27dd4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00356811",
        "Secondary_id": "NCT00296036",
        "Statement": "The the secondary trial intervention is applied to the palms and soles twice daily, the primary trial participants are not administered any medication topically.",
        "Label": "Entailment",
        "explain": "Contradicted\n\nJustification:\nThe primary trial describes the administration of lapatinib orally and paclitaxel intravenously, which are systemic medications, and makes no mention of topical treatments. The secondary trial describes the use of topical urea/lactic acid cream and placebo cream for both interventions. The statement that the secondary trial participants are not administered any medication topically in the primary trial directly contradicts the absence of topical medications mentioned in the primary trial."
    },
    "0931065d-35e4-4f82-8ef6-ac6db900127a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT02748213",
        "Statement": "Patients whose breast cancer has spread into both the skin and the chest wall are eligible for the secondary trial, but not the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the primary CTR, as patients with \"known or suspected metastatic disease allowed provided mastectomy is planned\" are eligible for the primary trial. However, the statement is entailed by the secondary CTR, which specifically includes patients with \"histologically confirmed, HER2-positive advanced and/or metastatic breast cancer not amenable to curative therapy.\""
    },
    "70912726-ba1b-47ef-9005-9584c8caf559": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00853996",
        "Statement": "Women classified as low-risk of developing breast cancer within the next 5 years by the Gail model , and no Family history consistent with hereditary breast cancer, are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nThe inclusion criteria for the primary trial specify that eligibility is not limited to women classified as low-risk by the Gail model alone, but also includes those with a family history consistent with hereditary breast cancer or other specified risk factors. (Primary Trial: Inclusion Criteria) Therefore, the statement made by the expert is not entailed by the given CTR information."
    },
    "6743f85c-8318-49cc-acba-94aeb1f57130": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00493636",
        "Statement": "Cohort 1 of the primary trial had a longer PFS than cohort 2. However the patient with the longest PFS was in cohort 2.",
        "Label": "Contradiction",
        "explain": "The statement \"Cohort 1 of the primary trial had a longer median PFS than cohort 2\" is entailed by the data in the Results section. The median PFS for cohort A (Sorafenib + Gemcitabine or Capecitabine) is 103 (83 to 128) days, while for cohort B (Placebo + Gemcitabine or Capecitabine) it is 81 (48 to 95) days.\n\nHowever, the expert's additional statement \"however the patient with the longest PFS was in cohort 2\" contradicts the data in the CTR. The CTR does not provide information on the longest PFS for an individual patient in either cohort."
    },
    "ddffa26d-2581-477a-955c-ebf0c2ab0f97": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00784849",
        "Secondary_id": "NCT02104895",
        "Statement": "Accelerated partial Breast breast irradiation is used in some form for both cohorts of the secondary trial, but not at all in the primary trial.",
        "Label": "Contradiction",
        "explain": "The expert's statement is contradicted by the CTRs provided. In the primary trial, no partial breast irradiation (APBI) was used at all. In contrast, the secondary trial involved two arms: one with conventional whole breast irradiation (WBI) and the other with APBI. However, the statement incorrectly claims that APBI is used for both cohorts in the secondary trial, but not in the primary trial. Therefore, the statement is contradicted by the facts stated in the provided CTRs."
    },
    "f1a45b47-498d-45c8-b6d9-6c8f035da30b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01201265",
        "Statement": "1 patient in the primary trial was affected by Sepsis.",
        "Label": "Entailment",
        "explain": "The statement \"1 patient in the primary trial was affected by Sepsis\" is entailed by the CTR. The term \"Septic Shock\" mentioned in the CTR is a known complication of Sepsis, hence the presence of one reported case of Septic Shock (2.50%) in the primary trial implies that at least one patient experienced Sepsis."
    },
    "a5272c37-0e32-42db-a44a-d17df7bd70ff": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00179309",
        "Statement": "There were no pain related adverse events observed in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"There were no pain related adverse events observed in the primary trial\" is contradicted by the CTR data. In the primary trial, there were no specific entries related to pain under the Adverse Events section. However, there were reported cases of vomiting (1/25 or 4.00%) and injection site reaction (1/25 or 4.00%), which might be associated with pain. Additionally, in the secondary trial, an expert mentioned \"pain related,\" which is not an explicitly stated adverse event in either CTR, further complicating the comparison. Therefore, the statement is contradicted by the available data."
    },
    "4c67a7b4-36fa-4c20-a15a-122609550973": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201773",
        "Statement": "Adele is an 85 year old woman with Stage IV histologically confirmed ER+ breast cancer with an ECOG of 0, she has a life expectancy below 6 months and a history of thrombotic events. She is eligible for the primary trial",
        "Label": "Contradiction",
        "explain": "The statement that \"Adele is an 85 year old woman with Stage IV histologically confirmed ER+ breast cancer with an ECOG of 0, she has a life expectancy below 6 months and a history of thrombotic events. She is eligible for the primary trial\" is entailed by the primary CTR's inclusion criteria because it states that \"Must be female with histologically confirmed breast cancer, Stage II-IV disease, ER and/or PR positive, ECOG Performance Status 0-1, no prior treatment for current breast cancer\" and Adele fulfills all of these criteria. However, it contradicts with the exclusion criteria that \"History of myocardial infarction or other thrombotic events\" is not allowed in the primary trial. To make Adele eligible, a waiver from the sponsor or the Ethics Committee would be required."
    },
    "120c6aa7-fcaa-4eaa-b520-6382968a6724": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00620373",
        "Statement": "the primary trial tests two different dental imaging modalities, namely Mammography and gamma imaging.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. The primary trial does in fact test two different imaging modalities, as stated in the CTR: Mammography for Intervention 1 and gamma imaging for Intervention 2."
    },
    "e35ebcea-f1ca-4c26-aa3b-2dc5de1a8645": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00050011",
        "Statement": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for preventing any change in Lumbar Spine (L1-L4) Bone Mineral Density (BMD).",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted based on the provided CTR data. In the primary trial results, the mean percentage change of BMD for the Zoledronic Acid Upfront group was 1.955% (3.3658%), whereas for the Zoledronic Acid Delayed-start group it was -2.325% (3.9542%). A negative value indicates a decrease in BMD, suggesting that the Zoledronic Acid Delayed-start group experienced a greater average loss of BMD compared to the Upfront group. Hence, the statement is not entailed by the data presented in the CTRs."
    },
    "ac997ae1-7e48-48e2-af9e-f7e289622250": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00798135",
        "Secondary_id": "NCT01209195",
        "Statement": "the primary trial and the secondary trial investigate different outcome measures for different interventions.",
        "Label": "Entailment",
        "explain": "The statement should be entailed by the information provided in the CTRs. \n\nJustification: \nThe primary trial focuses on the investigation of the pharmacokinetics of oral itraconazole in patients with MBC, while the secondary trial evaluates the safety and tolerability of escalating doses of MM-121 in combination with paclitaxel. Both trials investigate distinct interventions and employ different outcome measures. The outcome measurement in the primary trial is related to the PK of oral itraconazole, whereas in the secondary trial, it concerns the safety and tolerability of escalating doses of the MM-121 and paclitaxel combination through reporting of DLTs. Therefore, the statement that \"the primary trial and the secondary trial investigate different outcome measures for different interventions\" is in line with the information in the provided CTRs."
    },
    "59328f44-6755-4dcb-b04c-4e0ce2ba3ac8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02915744",
        "Statement": "The difference in median Overall Survival (OS) of Patients between the two cohort of the primary trial was less than one month, the patient with the longest OS was in cohort 1.",
        "Label": "Contradiction",
        "explain": "The statement can be entailed based on the provided CTRs. \n\nExplanation: \n\nThe statement asserts that the difference in median OS between the two cohorts was less than one month and that the patient with the longest OS was in cohort 1. According to the given information, the median OS in cohort 1 (NKTR-102) was 7.8 months (6.1-10.2) and in cohort 2 (TPC) was 7.5 months (5.8-10.4). A difference of 0.3 months is less than one month, which supports the statement's claim. Furthermore, the longest OS in cohort 1 (7.8 months) is indeed higher than the longest OS in cohort 2 (10.4 months, upper bound of the 95% confidence interval), which does not contradict the statement."
    },
    "441c0760-ca4a-4f1d-864e-a77395fd1f18": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00399802",
        "Statement": "The Lapatinib group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the information in the CTRs. The percentage change from baseline in urinary N-telopeptide of Type I Collagen for the Lapatinib group (not provided in the given CTRs) cannot be directly compared to the results of the primary trial. However, we have the percentage change for the Odanacatib 5 mg group, which had a smaller percentage change (-77%) than the ZA 4 mg group (-73%). This difference supports the expert's statement that the Odanacatib 5 mg group had a smaller percentage change from baseline in urinary N-telopeptide of Type I Collagen than the Lapatinib group (implicitly assuming that the Lapatinib group had a larger percentage change)."
    },
    "fbe60029-8944-4e12-b4b2-3413037a10cc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00723125",
        "Statement": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery.",
        "Label": "Entailment",
        "explain": "The statement \"57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery\" is entailed by the CTR data in Results 1. This is because the CTR specifies that out of the 16 participants in Cohort 1, \"Pathological Complete Response Rates at Surgery\" were documented for 9 patients (16 x 0.57 = 9). The CTR does not explicitly state the percentage of patients with this outcome, but it does provide enough information for the expert's claim to be derived from the given data."
    },
    "fe1782aa-a871-4608-a7cb-8f83b7f76d8a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00278109",
        "Secondary_id": "NCT01881230",
        "Statement": "Gemcitabine is not used in the primary trial, and used only in cohort 2 of the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided information in the CTRs. The primary trial does not involve gemcitabine in its intervention, while the secondary trial includes gemcitabine only in intervention arm 2."
    },
    "a153ecbf-11ac-4c40-a3af-9dbb0e12c49b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02364388",
        "Secondary_id": "NCT01425268",
        "Statement": "There is no overlap in treatments used in the primary trial and the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed. \n\nJustification:\n\nThe primary trial involves the use of MAESTRO as the intervention, which is not mentioned in the secondary trial. The secondary trial lists two different interventions: AeroForm Tissue Expansion and Saline Tissue Expansion. Both interventions are distinct from MAESTRO. Therefore, the statement that there is no overlap in treatments used in the primary and secondary trials holds true, given the descriptions in the CTRs."
    },
    "bcd48c1e-bfeb-4f1e-993f-cbbe4fadbf6e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "Patients intracranial metastasis may be eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Patients intracranial metastasis may be eligible for the primary trial\" is contradicted by the primary trial's Eligibility Criteria which states \"No metastatic disease to the Central Nervous System.\""
    },
    "4dc22366-3ff3-41c8-aa4c-7342d7b7085d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00263588",
        "Statement": "The majority of the primary trial subjects either had Progressive disease or undetermined CNS objective response rate.",
        "Label": "Entailment",
        "explain": "The statement \"The majority of the primary trial subjects either had Progressive disease or undetermined CNS objective response rate\" is not entailed by the provided CTR information. \n\nIn Cohort A, there were 40 participants with Progressive disease and 8 participants with unknown CNS objective response rate. In total, there were 48 participants out of 94 whose response status was either Progressive disease or unknown. However, the CTR states that \"Overall Number of Participants Analyzed\" for Cohort A was 94, which means that all participants were included in the analysis. \n\nIn Cohort B, there were 70 participants with Progressive disease, 18 participants with unknown CNS objective response rate, and no participants with Complete response. In total, there were 88 participants out of 143 whose response status was Progressive disease or unknown. \n\nTherefore, the statement \"The majority of the primary trial subjects either had Progressive disease or undetermined CNS objective response rate\" is not entailed by the provided CTR information because not all participants were included in the calculation (all participants were analyzed in the primary trial). Additionally, the statement contradicts the information given in the CTR, which explicitly states the number of participants in each response category for both cohorts."
    },
    "196c2132-c735-4b79-bf03-3a830fcaf0fc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00645333",
        "Secondary_id": "NCT00006110",
        "Statement": "the primary trial records several central nervous system related adverse events in its patients, whereas the secondary trial does not.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nExplanation:\n\nThe statement \"the primary trial records several central nervous system related adverse events in its patients, whereas the secondary trial does not\" is contradicted by the provided data. In the primary trial, there is one reported instance of seizure under Adverse Events 1 of the RESULTS section, which can be considered a central nervous system related event. However, there are no central nervous system related adverse events reported in Adverse Events 1 or Adverse Events 2 of the secondary trial. Hence, the statement is contradicted by the data presented in the CTRs."
    },
    "72619b0a-57c2-465c-8428-72019b59f8ae": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02924883",
        "Statement": "In the primary trial, all cases of  Enteritis, Vertigo and Cardiac failure occurred in cohort 2.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nJustification:\n\nThe given statement contradicts the data provided in both Adverse Events sections of the CTRs for the primary and secondary trials. In the primary trial, there was one case of Enteritis (1/133, 0.75%), but it occurred in cohort 1, and there were no cases of Vertigo or Cardiac failure reported in either cohort. In the secondary trial, there was one case of Enteritis (1/67, 1.49%) and no cases of Vertigo or Cardiac failure reported. Therefore, the statement that \"all cases of Enteritis, Vertigo and Cardiac failure occurred in cohort 2\" contradicts the provided data in the CTRs."
    },
    "b8663fa7-585a-4cd9-afd2-89e8e1a58b82": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02732119",
        "Statement": "Mark complained he had a racing heart twice in the last month and he is therefore excluded from the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial's inclusion criteria, as Mark's complaint of a racing heart (potentially indicating cardiac disease) would make him ineligible for participation based on the exclusion criteria: \"Clinically significant, uncontrolled heart disease and/or recent cardiac events.\""
    },
    "7c92d075-ba9d-45b5-9834-83b09d2753bc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02536794",
        "Secondary_id": "NCT00712985",
        "Statement": "the primary trial and the secondary trial both administer treatments to their patients through IV.",
        "Label": "Entailment",
        "explain": "The statement is entailed. \n\nThe primary trial states that patients receive treatments \"IV over 1 hour\" for anti-B7H1 monoclonal antibody MEDI4736 and \"IV\" for tremelimumab. The secondary trial states that patients receive a treatment \"5 mg IV given over 15 minutes\". While the primary trial uses different treatments and infusion times, both trials administer the treatments intravenously."
    },
    "0e8d1b4f-d6f6-455a-a7e3-07f67a8fbcc8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00411788",
        "Statement": "If Hannah has been taking ketoconazole to treat athlete's foot for 6 weeks, until today, she will be eligible for the primary trial next Tuesday.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted based on the primary trial's exclusion criteria, as ketoconazole is listed as one of the medications that patients may not be taking within 4 weeks of enrollment. (Primary Trial: Exclusion Criteria, Line 11)"
    },
    "9a346aac-46c2-4a50-8f3a-309b3b7bc295": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00382785",
        "Secondary_id": "NCT00784849",
        "Statement": "Neither the primary trial or the secondary trial use Low Dose Magnesium Oxide, Biopsies or Mometasone in their intervention.",
        "Label": "Contradiction",
        "explain": "The statement is entailed based on the provided CTRs. Neither of the trials mentions the use of Low Dose Magnesium Oxide, Biopsies, nor Mometasone in their interventions. Specifically, the primary trial describes Intervention 1 as a moderated or professional healthcare provider-led 12-week online support group, and Intervention 2 as a non-facilitated, peer-led 12-week online support group. The secondary trial's Intervention 1 involves the use of 1 mCi of 125-I Methylene blue dye for sentinel lymph node biopsies. No mention of the stated substances is present in either CTR."
    },
    "949d79e0-95db-47a2-802a-6280c0255923": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02132949",
        "Secondary_id": "NCT01111825",
        "Statement": "Between both of the patient cohorts of the primary trial and the secondary trial there was only a single patient with a deficiency of granulocytes in the blood.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nExplanation: \n\nThe statement asserts that there was only one patient with a deficiency of granulocytes in the blood across both trials. However, the data in the CTRs contradicts this claim. In the primary trial, there were three instances of granulocytopenia (AGRANULOCYTOSIS, NEUTROPENIA, and PANCYTOPENIA) among the 199 participants, while no such cases were reported in the secondary trial with 8 participants. Therefore, the statement is incorrect and should not be considered an entailment based on the information provided in the given trial reports."
    },
    "6e080a1e-a03e-4547-a7c4-c9d5a80de977": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01325207",
        "Secondary_id": "NCT02429427",
        "Statement": "Patients participating in the primary trial and the secondary trial experienced serious eye disorders.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nThe CTR sections provided do not mention any information related to eye disorders in either the primary or secondary trials."
    },
    "63218fb2-3f5b-4738-bea8-11fbbc560949": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01730729",
        "Statement": "Patients with severe malabsorption disorders are ineligible for the primary trial, unless they are able to receive intravenous (IV) alimentation.",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nThe primary CTR explicitly lists malabsorption syndrome as an exclusion criterion for the study. Patients with this condition are ineligible regardless of their ability to receive IV alimentation."
    },
    "d7fa4f81-e108-491f-9b08-c147a33863e8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01953003",
        "Statement": "Patients receiving intervention 1 of the primary trial, will be administered medication orally and intraveinously.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nJustification: \n\nThe statement \"Patients receiving intervention 1 of the primary trial, will be administered medication orally and intraveinously\" is contradicted by the information given in the primary trial. The intervention 1 for Arm A in the primary trial specifies that Vinflunine is administered intraveinously, and Capecitabine is orally administered. There is no intraveinous administration of Capecitabine in intervention 1 of Arm A in the primary trial."
    },
    "f24afb09-ea65-457f-9f9b-0db3cc3101ac": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00849472",
        "Statement": "Two dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes.",
        "Label": "Contradiction",
        "explain": "To determine if the statement \"Two dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes\" is entailed or contradicted by the CTRs, let's examine the information provided in each trial:\n\nPrimary Trial:\n- The number of participants with pCR in the Breasts and Nodes is stated, but not an exact number is provided in the CTR.\n- pCR is defined as no histologic evidence of invasive tumor cells in the surgical breast specimen, axillary nodes, or sentinel node identified after neoadjuvant chemotherapy.\n- The time frame for the pCR measurement is from the start of the study until the time of surgery.\n\nSecondary Trial:\n- No information regarding the number of participants with pCR is given in the secondary CTR.\n\nComparing the two trials, there is no information that directly contradicts or entails the statement made by the clinical trials expert. The statement does not contradict the primary CTR as it does not provide a specific number that is known to be incorrect. However, the statement also does not entail the primary CTR, as it does not provide any new information that can be logically deduced from the data presented in the CTRs.\n\nTherefore, the statement is neither entailed nor contradicted by the information provided in the CTRs alone. Further context or information would be required to determine the validity of the statement."
    },
    "3cd79df2-e6dd-41dd-b819-4d993b5f7aed": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00403130",
        "Statement": "There were no cases of Leukopenia, Epitasis or Arrhythmia observed in patients participating in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the data in the Adverse Events section of the Primary Trial report. Specifically, there was one case each of Epitasis and Neutropenia (a type of leukopenia) observed. Therefore, the statement is not entailed by the given CTR data.\n\nExplanation:\n\nThe statement asserts that there were no cases of Leukopenia, Epitasis, or Arrhythmia observed in the primary trial. However, the data from the Adverse Events section of the CTR contradicts this claim, as there were indeed cases of Epitasis and Neutropenia (a type of leukopenia) reported. The absence of Arrhythmia in the primary trial is consistent with the statement, but the presence of Epitasis and Neutropenia makes the statement as a whole incorrect. Therefore, it is not entailed by the given CTR data."
    },
    "d2d6f646-5881-42a2-b965-0c6f79e89463": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00090857",
        "Statement": "Candidates for the primary trial must have a bone density scan 1 month prior to study entry, if the results from this are more than 2 standard deviations below normal, the study physician can still decide to let them participate.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary CTR states that bone density scan results more than 2 standard deviations below normal are allowed if approved by the study physician. However, the secondary statement requires the scan to be within 1 month prior to study entry and does not give discretion to the study physician. This contradicts the allowance for flexibility with bone density scan results as stated in the primary CTR. Specifically, the statement in the secondary CTR is more restrictive than the information provided in the primary CTR."
    },
    "428d5165-560b-4783-8c4b-5fd3a3289cab": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00022672",
        "Statement": "There were no patients in either cohort of the primary trial with a PFS exceeding one year.",
        "Label": "Entailment",
        "explain": "The statement \"There were no patients in either cohort of the primary trial with a PFS exceeding one year\" can be contradicted based on the provided CTR information. \n\nJustification:\n\nIn the Arm/Group titled \"Trastuzumab + Anastrozole\" of the primary trial, the Median PFS at 24 Months was 4.8 months (3.7 to 7) and at the End of Study was 5.8 months (4.6 to 8.3). These values indicate that there were patients whose PFS was above one year. Specifically, the 95% Confidence Interval for the End of Study PFS includes values above one year. \n\nSimilarly, in the Arm/Group titled \"Anastrozole\" of the primary trial, the Median PFS at 24 Months was 2.4 months (2 to 4.6) and at the End of Study was 2.9 months (2.1 to 4.5). Again, there were patients whose PFS was above one year, as evidenced by the values outside the one-year mark in the 95% Confidence Interval.\n\nTherefore, the statement \"There were no patients in either cohort of the primary trial with a PFS exceeding one year\" contradicts the information presented in the CTR."
    },
    "6e7df2e4-11b3-4183-aefc-760f85809515": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02536794",
        "Secondary_id": "NCT00712985",
        "Statement": "the primary trial and the secondary trial both administer Zometa to their patients through IV, although in different doses.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. In the primary trial, tremelimumab is given intravenously (IV) alongside MEDI4736 on day 1 and every 28 days thereafter, and MEDI4736 is given IV every 2 weeks starting 4 weeks after the last combination dose until disease progression or unacceptable toxicity, or for an additional 52 weeks if PD or clinical benefit is achieved. Although Zometa (zoledronic acid) is administered IV differently in the secondary trial, with a single dose of 5 mg given over 15 minutes, both trials involve IV administration of zoledronic acid to their patients."
    },
    "45e6b4b6-ca31-4318-936e-5b27cbca47a2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01439711",
        "Statement": "One patient in the primary trial had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume (FTV) over 3 months.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the Primary Trial's Results 1 section. The patient-level data in the CTR indicates that the decrease in FTV for one patient was -2.87 cm3 from baseline to 3 months. This is consistent with the expert's statement of a 2.87 cm3 decrease in FTV for one patient from the primary trial."
    },
    "22a6d10e-55c5-4a8c-8010-3e8252bcb279": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00458237",
        "Statement": "Patient who have recently undergone External beam radiation therapy are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the Primary Trial's Eligibility Criteria as there is no explicit exclusion of patients who have undergone external beam radiation therapy."
    },
    "7fd1ae1e-bfdb-4c37-aaea-ed97663758e3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00593346",
        "Secondary_id": "NCT00902330",
        "Statement": "the primary trial treament last for a shorter period of time than the secondary trial treatment, but is administered much more often.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. The primary trial intervention lasts for a shorter period of time (5-7 days) compared to the secondary trial interventions (18 weeks), but the primary trial intervention is administered more frequently (twice daily), resulting in a total dose delivery similar to or even greater than the secondary trial interventions."
    },
    "50d119f6-a657-4619-918e-7617ac57f052": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03078751",
        "Statement": "Cohort 1 of the primary trial reported one case of AML.",
        "Label": "Entailment",
        "explain": "The statement \"Cohort 1 of the primary trial reported one case of AML\" is entailed by the CTR data. The CTR for the primary trial under Adverse Events 1 section reports one case of Acute Myeloid Leukaemia (AML) out of 26 participants. Therefore, this statement correctly reflects the information in the CTR."
    },
    "e436827b-10db-4179-bf8f-07786ee6145b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01009918",
        "Statement": "There are no racial criteria for entry into the primary trial, however there are gender criteria.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nExplanation:\n\nThe CTR explicitly mentions that there are no racial criteria for patient inclusion in the primary trial, but it specifies gender criteria. The statement made by the expert contradicts the information in the CTR."
    },
    "fcc6708a-b0fc-4215-a45f-02b1e0e2d30a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00631852",
        "Statement": "Patients with hemophilia are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Patients with hemophilia are excluded from the primary trial\" is contradicted by the information in the CTR. Hemophilia is not listed as an exclusion criterion in the primary trial's inclusion/exclusion criteria."
    },
    "d63706f1-4fb8-488d-8f86-c1a19df341d4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00944047",
        "Secondary_id": "NCT00228943",
        "Statement": "Patients with tumors underexpressing HER2 are excluded from the primary trial, but may be included in the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the Primary Trial's Inclusion Criteria which state \"Female patient with HER-2/neu 0+ or 3+ by immunohistochemistry are excluded.\" However, the statement is entailed by the Secondary Trial's Inclusion Criteria which do not include any exclusion criteria based on HER2 status."
    },
    "ab357056-67a7-4227-966d-8c96eb1640fd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02694029",
        "Statement": "Candidates for the primary trial are expected to be capable of holding their breath for half a minute.",
        "Label": "Entailment",
        "explain": "The statement \"Candidates for the primary trial are expected to be capable of holding their breath for half a minute\" is entailed by the CTR, specifically under the inclusion criteria for the primary trial, where it states \"Patient must be able to maintain a 30 second breath hold.\""
    },
    "0359eef3-6339-485e-95bc-0cb6fa7bcd12": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00635050",
        "Statement": "Patients with Breast cancers that have estrogen receptors are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary trial includes patients with breast cancers that have ER or PR positivity (ELIGIBILITY CRITERIA), which is the opposite of the statement."
    },
    "57ef3c6c-b4e1-4302-b423-aa9faca21200": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT00606931",
        "Statement": "the primary trial and the secondary trial do not use the same route of administration for their interventions.",
        "Label": "Entailment",
        "explain": "Contradicted. In the primary trial, both HER2/neu peptide vaccine and ex vivo-expanded HER2-specific T cells are given intravenously (IV), whereas in the secondary trial, the intervention is PET Guided Biopsy, which is not a route of administration for a treatment or intervention."
    },
    "29d5779b-c228-4b82-9ca8-075beadae879": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Statement": "There were more cases of Febrile neutropenia than eukopenia observed in the primary trial, but less cases of Febrile neutropenia than Neutropenia.",
        "Label": "Entailment",
        "explain": "The statement is contradicted. The primary trial reports 10 cases of Febrile neutropenia and 14 cases of Neutropenia, which is the opposite of the claim that there were more cases of Neutropenia than Febrile neutropenia."
    },
    "4e124d90-68d7-40bd-a8b1-27cb49d64c64": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00591864",
        "Statement": "the primary trial patients receive Trametinib, Akt Inhibitor GSK2141795 PO QD on days 1-28, up to a maximum of 8 cycles.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nExplanation: The primary CTR states that the study does not have any arms or subgroups. The secondary statement asserts that participants in the primary trial receive a specific intervention, which contradicts the information in the CTR that no arms or subgroups exist in the study. Therefore, it is not entailed and is contradicted by the primary CTR."
    },
    "0a9a7f5b-eb32-4a11-86e3-5a9a6377eea3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00291694",
        "Statement": "the route of administration for both interventions in the primary trial is a topical skin cream.",
        "Label": "Contradiction",
        "explain": "The given statement is contradicted by the provided CTR information. The CTR states that Intervention 1 is celecoxib, which is an oral nonsteroidal anti-inflammatory drug (NSAID), and Intervention 2 is placebo. No mention is made of a topical skin cream as the route of administration for either intervention."
    },
    "f4c7dae5-012f-4f05-b5ba-da072fe1359c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01674062",
        "Statement": "One patient in the primary trial was observed suffering from Enteritis.",
        "Label": "Contradiction",
        "explain": "The statement is not entailed by the provided Primary Trial Adverse Events information as there is no mention of Enteritis in the listed adverse events."
    },
    "927bbb75-37da-4b75-9483-252d31a0fd98": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01067976",
        "Secondary_id": "NCT00941330",
        "Statement": "Unlike the secondary trial, the primary trial does not provide a duration of cycles or any dosages in the intervention section.",
        "Label": "Entailment",
        "explain": "Contradicted\n\nExplanation:\n\nThe statement asserts that the primary trial does not provide information on the duration of cycles or dosages for interventions. However, as per the provided description of the primary trial's intervention section, it does not contain any such information, which aligns with the statement. Therefore, the statement is not entailed but contradicted, as it incorrectly implies that the primary trial contains intervention information without specifying the duration or dosages, while the CTR actually does not include this information at all."
    },
    "80a5cdbc-0721-41b6-af1a-28e3f46557ce": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01610284",
        "Statement": "1 patient in the primary trial had a cardiac related adverse event.",
        "Label": "Contradiction",
        "explain": "The statement \"1 patient in the primary trial had a cardiac related adverse event\" is entailed by the given CTR data in the \"Adverse Events 1\" section of the primary trial, as there is a reported incidence of 1 case of cardiac arrest (a cardiac event) in that trial."
    },
    "af710d36-8062-4412-8d11-1c57a14b5e5a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00217672",
        "Secondary_id": "NCT00110084",
        "Statement": "the primary trial had three times the occurence rate of fistula enterovesical as the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial reported one occurrence (1.35%) of fistula enterovesical and the secondary trial reported none (0%). The statement asserts that the primary trial had three times the occurrence rate of fistula enterovesical in the secondary trial, but the secondary trial had no occurrences."
    },
    "c91c7dc1-17b7-4475-9aec-38999a18a306": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00717405",
        "Statement": "There were several patients who contracted Pneumonia in the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nThe CTR does not provide any evidence of pneumonia as an adverse event in either trial. The given statement asserts that \"several patients contracted pneumonia\" in the primary trial, but there is no mentions of pneumonia in the provided adverse events section of the primary or secondary trial."
    },
    "5357ce66-7f7b-4ffd-926c-f6116f5a2e20": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00243503",
        "Secondary_id": "NCT00448279",
        "Statement": "the primary trial and the secondary trial observed a different number of adverse events in their patients.",
        "Label": "Entailment",
        "explain": "The statement is entailed, given that the primary trial reported 25 adverse events in 60 patients (41.67%), while the secondary trial reported a different number of adverse events, which is 4 in 26 patients (15.38%). This difference in adverse event frequencies justifies the statement."
    },
    "3c7ecca8-5397-41f5-b72b-84217bf3acd2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00399529",
        "Statement": "Women with chronic obstructive pulmonary disease that do not require systemic corticosteroids, are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR for the Primary Trial as it states \"Chronic obstructive pulmonary disease that does not require daily systemic corticosteroids is acceptable\" under the exclusion criteria."
    },
    "2c53e14a-719c-4994-9090-73f9bddb60ba": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00615901",
        "Secondary_id": "NCT00829166",
        "Statement": "the primary trial recorded more seizures than the secondary trial, despite having less than one tenth the number of patients in its total cohort.",
        "Label": "Entailment",
        "explain": "Contradiction. The primary trial reported 1 seizure (2.63%) in 38 patients, whereas the secondary trial reported no seizures (0.00%) in 490 patients. The statement asserts that the primary trial recorded more seizures despite having fewer patients. This contradicts the data presented in the CTRs."
    },
    "7c1b03bc-d299-4ee8-b9ee-3d253f3fc33a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00089999",
        "Statement": "In total more participants in the primary trial had no tumor Response, than partial response, and only 3 patients had a complete response.",
        "Label": "Contradiction",
        "explain": "Contradiction. \n\nThe expert's statement claims that \"no tumor response\" is more common than \"partial response\" and that only three participants had a \"complete response.\" However, according to the provided CTRs (Results 1 and 2), for both the 1500 mg QD and 500 mg BID arms, there were participants with no response (treated as non-responders), but no clear data on \"no tumor response.\" Furthermore, while there were 15 PRs in the 1500 mg QD arm and 18 PRs in the 500 mg BID arm, there were no CRs reported. Therefore, based on the information provided in the CTRs, neither \"no tumor response\" nor \"partial response\" is more common overall, and the expert's statement contradicts the CTRs."
    },
    "bfb617c8-51ae-4ab2-be05-6346daad5437": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00820222",
        "Secondary_id": "NCT01819233",
        "Statement": "the secondary trial and the primary trial interventions both require subjects to follow caloric restricted diets or gluten free diets, while completing food diaries.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided CTR information. The primary trial mentions nothing about the subjects following gluten-free diets. The secondary trial specifies that the patients receive dietary modifications to reduce caloric intake but makes no mention of gluten-free diets. Therefore, the statement that both trials require subjects to follow caloric restricted diets or gluten free diets is incorrect."
    },
    "dcc5c3b0-848b-4ef4-afe6-e9c9933e33af": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00404066",
        "Statement": "Abnormal LVEF, Pregnancy or lactating automatically eliminates patients from participating in the primary trial, unless treated with herbal medicines.",
        "Label": "Contradiction",
        "explain": "Contradicted. The CTR explicitly states under EXCLUSION CRITERIA for the primary trial that Congestive heart failure, abnormal left ventricular ejection fraction (LVEF), or other significant heart disease are reasons for exclusion. It does not mention anything about allowing participation if patients are treated with herbal medicines. Additionally, pregnancy and lactating are also listed as exclusion criteria without mention of any exception."
    },
    "18fcd396-cb03-4e80-bb2d-ee03c12ba32a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00455533",
        "Secondary_id": "NCT00767520",
        "Statement": "Throughout both the secondary trial and the primary trial there was only one case of pregnancy, in cohort 1 of the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement does not contradict the provided CTRs as there is no mention of pregnancy-related adverse events in either of the trial sections. Therefore, the statement is entailed."
    },
    "694c5820-ebb6-4271-8685-a0b51c637f7f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00038103",
        "Statement": "There is no significant difference in the proportions of Subjects With Clinical Benefit in the Exemestane + Celecoxib cohort and in the Exemestane alone cohort of the primary trial.",
        "Label": "Entailment",
        "explain": "The expert's statement can be entailed by the CTR data if the proportions of subjects with clinical benefit in the Exemestane + Celecoxib and Exemestane alone cohorts are not significantly different. This information can be obtained from the RESULTS sections of both CTRs. Specifically, the number of participants with clinical benefit in each cohort and the time frame for assessment should be compared using appropriate statistical methods (such as chi-square test or Fisher's exact test for proportions). If these analyses do not reveal a significant difference, then the expert's statement is entailed by the data in the CTRs.\n\nCTR data for comparison:\nResults 1: Exemestane (Exemestane Alone) - Number of Participants with Clinical Benefit: 12, 24-week SD: 14, Total: 26\nResults 2: Exemestane + Celecoxib - Number of Participants with Clinical Benefit: 16, 24-week SD: 11, Total: 27\nIf the p-value from the statistical test is greater than the pre-specified significance level (e.g., 0.05), then there is no significant difference in the proportions of subjects with clinical benefit between the two cohorts."
    },
    "b87abb47-13b6-4dbe-9cfd-e63075b676aa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00662025",
        "Statement": "on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided data in the CTRs. In the primary trial, according to the outcome measurement section, the definition of CR includes \"disappearance of all target and non-target lesions,\" but the results section indicates \"Complete Response (CR): 0.\" Hence, none of the participants in the primary trial had a confirmed disappearance of all target and non-target lesions as stated in the expert's claim."
    },
    "eb025223-1b4a-4df7-a85e-2eeeb62a6bf5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754845",
        "Statement": "Patients who received over 5 years of anastrozole therapy, completed under a year ago, are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary trial's eligibility criteria. The statement specifies patients who received over 5 years of anastrozole therapy and completed it under a year ago, which is consistent with the primary trial's requirement of patients having received 4\u00bd - 6 years of aromatase inhibitor therapy, including anastrozole, completed 2 years ago."
    },
    "23df2cc2-6aae-4251-a8a7-e2f5a65f176a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02149524",
        "Statement": "None of the adverse events which occurred in the primary trial were not GI related.",
        "Label": "Contradiction",
        "explain": "Contradicted. The provided CTRs do not mention any adverse events related to the gastrointestinal system in either of the trials. Therefore, none of the adverse events occurred in the primary trial were not GI related. However, the statement claims that all adverse events occurred in the primary trial were GI related, which contradicts the data presented in the CTRs."
    },
    "1bd51c93-d7a8-4da4-825d-ada625033c34": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00293540",
        "Statement": "Samantha has recently received a liver transplant, and is taking the combined oral contraceptive pill, she is not eligible for the primary trial, but is eligible for the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted\n\nExplanation:\n\nSamantha's eligibility for the secondary trial is contradicted by the CTR for the primary trial since she has undergone a liver transplant, which is an exclusion criterion for that trial (Primary Trial: Exclusion criteria: Patients with organ transplants). Therefore, she cannot meet the eligibility requirements for the primary trial, regardless of her eligibility for the secondary trial."
    },
    "58c58b68-fc9a-438c-8a85-9233dde714c9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01827787",
        "Statement": "The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the HR+/HER2- cohort.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the CTRs. Specifically, the ORR values in Results 1 and Results 2 indicate that 35.6% of participants in the HR+/HER2- cohort had a PR or better response, while only 13.2% of participants in the TNBC cohort did. Therefore, the statement that the TNBC cohort had a much lower ORR than the HR+/HER2- cohort is in line with the data provided in the CTRs."
    },
    "843778c6-a320-49a1-93a0-5dc6239b822a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00965523",
        "Statement": "The most common adverse events in the primary trial where Infection and Stomatitis.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary trial's adverse events data since Infection and Stomatitis are among the most frequent adverse events reported, with frequencies of 2.47% and 2.47% respectively. (Adverse Events 1 in the Primary Trial)"
    },
    "a5486f80-69e5-4a5a-8435-f82f39cddf85": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00080301",
        "Statement": "There were 2 more cases of Gastrointestinal Haemorrhage in cohort 2 of the primary trial, than in cohort 1.",
        "Label": "Contradiction",
        "explain": "The given statement does not contradict the information in the provided CTRs. However, it does not entail any specific information from the CTRs either, as neither the primary nor the secondary CTRs mention \"Gastrointestinal Haemorrhage\" as an adverse event. To establish entailment, the statement should include data from the CTRs or be a logical implication of the given data."
    },
    "c2c60b25-f255-48ba-bcb7-2bcd2de4315d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00171314",
        "Statement": "There are four types of adverse events in the primary trial, for which no occurences are recorded.",
        "Label": "Entailment",
        "explain": "Contradicted. The CTRs list the specific types of adverse events, including some that did not occur in the primary trial such as Angina pectoris, Angina unstable, and Coronary artery disease. However, the statement incorrectly asserts that there are four types of adverse events with no occurrences, which is not the case according to the provided data in the CTRs."
    },
    "a8167a90-8ccf-4024-a4cc-8c1b047fd548": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00068601",
        "Secondary_id": "NCT01684215",
        "Statement": "the primary trial and the secondary trial do not employ the same route of administration for their interventions.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nExplanation:\n\nBoth the primary and secondary trials involve oral administration of PD-0332991 in their respective dose escalation cohorts. However, the primary trial does not have an intervention specified with a different route of administration than cyclophosphamide's intravenous or intramuscular route. Therefore, the statement \"the primary trial and the secondary trial do not employ the same route of administration for their interventions\" is contradicted by the information given in the CTRs."
    },
    "bdca0fa1-a3fa-4dcf-8f58-15d130dbfa75": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary trial participants are treated with 600 mg of Pemetrexed orally twice a month until complete response or disease progression.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial CTR as the intervention specified is intravenous administration of 600 mg/m2 Pemetrexed every 14 days, rather than oral administration twice a month mentioned in the statement."
    },
    "277f5d17-36cc-44c5-9b94-7e052f2bdb2c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01067976",
        "Secondary_id": "NCT00941330",
        "Statement": "Unlike the secondary trial, the primary trial only provides the duration of cycles and drug doses in the intervention section.",
        "Label": "Contradiction",
        "explain": "The statement can be entailed with the primary trial's CTR if the trial also specifies CMRM and UMRM as the interventions and the dosing and cycle duration information is not required for understanding the entailment since the comparison is only between the interventions (CMRM vs UMRM) and not the specific dosages or durations. However, with the information provided in the secondary trial, the statement can also be contradicted, as the secondary trial includes specific interventions with different types of treatments (exemestane and docetaxel/cytoxan) and durations (daily for months vs every 3 weeks for 6 cycles)."
    },
    "fcb195de-2143-44d8-8c46-136104554e2d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01492101",
        "Statement": "There less than 1% of either cohort of the primary trial was effect by Pancytopenia, but just over 5% of cohort 1 patients suffered from Coagulopathy.",
        "Label": "Contradiction",
        "explain": "Contradicted. The statement asserts that less than 1% of patients in the primary trial cohorts had Pancytopenia, but the CTR data indicates that 0.47% of patients in each cohort experienced this adverse event. Furthermore, the statement claims that cohort 1 had over 5% of patients with Coagulopathy, whereas the CTR data shows that only 0.24% of patients in cohort 1 had this condition."
    },
    "70337af9-3d4a-44bc-bbfa-0d97ea88553c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00317720",
        "Statement": "Patients must have at least 3 prior treatments with trastuzumab to be eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial's inclusion criteria which state that \"Patients who develop metastatic disease during or after adjuvant or neoadjuvant trastuzumab are eligible,\" and \"Patient may not have received more than 2 prior trastuzumab-based regimens and one lapatinib-based regimen.\" Therefore, it is not required for patients to have had 3 prior treatments with trastuzumab to be eligible for the primary trial."
    },
    "9cf89221-5801-4709-a098-de763b6e702e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334542",
        "Statement": "A Female patients with a mastectomy would be excluded from the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nExplanation:\n\nThe primary CTR states that \"At least 1 healthy intact breast\" is a requirement for patient inclusion, and there is no explicit exclusion for those with a history of mastectomy. Hence, the statement \"A Female patients with a mastectomy would be excluded from the primary trial\" contradicts the information in the CTR."
    },
    "f89883ea-dd60-4d5f-9354-13fbca2aeec8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01031446",
        "Statement": "Sarah has been experiencing epileptic seizures from a brain tumor. This will not prevent her from participating in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary CTR under the ELIGIBILITY CRITERIA section regarding patients with symptomatic brain metastases. Specifically, patients with symptomatic brain metastases are not eligible for the trial, whereas Sarah has been experiencing epileptic seizures from a brain tumor which is considered a symptom of brain metastases. Therefore, according to the CTR, Sarah would not be eligible for participation in the primary trial."
    },
    "a289f67c-ff56-44a9-b3da-152fb0d20271": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT02129556",
        "Statement": "Only 1 respiratory adverse event was recorded across the duration of both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Only 1 respiratory adverse event was recorded across the duration of both the secondary trial and the primary trial\" is entailed by the provided CTRs, as both trials reported one instance of upper respiratory tract infection (primary trial) and one instance of vomiting (secondary trial) that can be considered respiratory events."
    },
    "10ed1242-c6ab-4ad0-b93c-4738857f543a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02635737",
        "Statement": "Patients with ICDs may be eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Patients with ICDs may be eligible for the primary trial\" can be entailed based on the primary trial inclusion criteria, as the criterion \"Participant is willing and able to give informed consent for participation in the study\" is not specific to breast cancer patients or those undergoing specific surgeries, making it possible for patients with ICDs (Implantable CardioDefibrillators) to meet this requirement. However, there is no mention of ICDs in the primary trial's inclusion or exclusion criteria; therefore, the trial does not explicitly exclude patients with ICDs either. Thus, based on the given information, the statement is plausible but not directly entailed. To definitively determine entailment, further context or clarification from the domain expert or CTRs might be necessary."
    },
    "683b9885-4027-4108-b37e-61255611538a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02692755",
        "Statement": "Asian, white british and white irish women are eligible for the primary trial, as long as they do not have uncontrolled or symptomatic brain metastases.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the Primary Trial's Exclusion Criteria which clearly states \"Active uncontrolled or symptomatic brain metastases\" as an exclusion criterion for Black, African or African American women. This contradicts the expert's statement allowing Asian, white British, and white Irish women to be eligible for the trial regardless of the presence of uncontrolled or symptomatic brain metastases."
    },
    "a47e048a-56aa-49e0-9903-563f53797b6e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00600340",
        "Statement": "Cohorts 1 of the primary trial recieves Bevacizumab at a higher frequency and dose than cohort 2.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the given CTRs. Specifically, in the primary trial, cohort 1 receives Bevacizumab at a dose of 10 mg/kg on days 1 and 15, every 4 weeks, while cohort 2 in the secondary trial receives Bevacizumab at a dose of 15 mg/kg on day 1, every 3 weeks. Although the dosage per administration differs in the secondary trial, the total amount of Bevacizumab administered to cohort 2 over the course of a cycle (15 mg/kg) is less than that of cohort 1 in the primary trial (10 mg/kg * 2 = 20 mg/kg). However, the frequency of dosing is higher for cohort 2, with Bevacizumab given every 3 weeks versus every 4 weeks for cohort 1. Thus, while the dosing frequency and dosage differ, the overall exposure to Bevacizumab in terms of total amount administered per cycle is greater in cohort 1 of the primary trial."
    },
    "690de5e2-3d7f-407e-8eb9-783adf58841b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00356148",
        "Secondary_id": "NCT01856543",
        "Statement": "Women of any age can participate in the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by both CTRs. The primary trial includes a specific age criterion for women (at any age), while the secondary trial has an age restriction (18 years and over). Consequently, these trials do not entail the statement that \"Women of any age can participate in the primary trial and the secondary trial.\""
    },
    "f5477a02-dde7-44c8-80b5-2cdb9fa66f23": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01234337",
        "Secondary_id": "NCT00217672",
        "Statement": "More than 2 cases of Anaphylaxis occurred in either the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted\n\nJustification: \n\nThere is no mention of Anaphylaxis in the provided Adverse Events sections for either the primary or secondary trials."
    },
    "dc184dcb-a22d-4cac-bee1-6c182692e522": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03511378",
        "Statement": "Patients must have a life expectancy over a year to participate in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the Primary Trial Inclusion Criteria that requires a patient to have an estimated life expectancy of more than six months."
    },
    "4dfbdeba-cae0-48b2-a38d-07338512904e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03076190",
        "Secondary_id": "NCT03196635",
        "Statement": "Molecular Breast Imaging is not applied in either the primary trial or the secondary trial interventions.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the CTRs. In the primary trial, there is no mention of Molecular Breast Imaging being used in any intervention. However, in the secondary trial, there is no information provided regarding the type of imaging sets used in the interventions. Therefore, based on the given information, it cannot be entailed that Molecular Breast Imaging was not used in the secondary trial interventions."
    },
    "62489179-bb30-4b96-a904-ea907dd05e23": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01097460",
        "Secondary_id": "NCT01009918",
        "Statement": "Every patient in the primary trial and the secondary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years.",
        "Label": "Contradiction",
        "explain": "The given statement can be entailed by the provided CTRs, as follows:\n\nJustifications:\n- In the primary trial, the text states that \"Incidence of Treatment-emergent AE's\" is measured for a time frame of 2 years. While the number of participants experiencing these events isn't mentioned, it implies that every participant in the MM-111 + Herceptin arm had at least one treatment-emergent adverse event during the study.\n- In the secondary trials, both Arm I and Arm II report the number of patients who experienced cardiotoxicity. Although the statement doesn't mention this specific adverse event, the general claim about treatment-emergent adverse events during a 2-year timeframe is still applicable to these trials, as all participants had some form of adverse event.\n\nTherefore, the provided statement is entailed by the CTR data."
    },
    "45891239-bb78-4f83-8306-8edceb8247fe": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01011946",
        "Statement": "All patients in the primary trial must have a bilateral breast mammography prior to study entry.",
        "Label": "Contradiction",
        "explain": "Contradiction. The primary trial's inclusion criteria do not mandate a bilateral breast mammography prior to study entry. Instead, they only specify a standard of care bilateral breast MRI at UC as a requirement for patient exclusion."
    },
    "9ec1e3f0-64a2-4629-aee8-cdb516fd27f3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00258349",
        "Secondary_id": "NCT01328249",
        "Statement": "Cohort 1 of the primary trial does not receive any Eribulin Mesylate or Vorinostat, whereas both cohorts in the secondary trial receive some of both.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided CTRs. \n\nJustification: \nIn the primary trial, Cohort 1 receives Vorinostat + Trastuzumab, but not Eribulin Mesylate or Vorinostat as separate interventions. In contrast, both cohorts in the secondary trial (Cohort 1 and 2) receive Eribulin Mesylate, but only Cohort 2 receives Vorinostat (as a part of their intervention with filgrastim). Therefore, the statement accurately reflects the information presented in the CTRs."
    },
    "91f23b55-38b6-41c4-af30-baa15e989aa7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00371254",
        "Statement": "Patients must have eceptorsestrogen receptor (ER) -, progesterone receptor (PR) - and human epidermal growth factor receptor 2 (HER2) - non metastatic breast cancer, aswell as not having Dysphagia.",
        "Label": "Contradiction",
        "explain": "The given expert statement is not entailed by the primary trial's inclusion criteria, as the primary trial includes patients with metastatic breast cancer, which is a distinct condition from non-metastatic breast cancer. Furthermore, the primary trial does not specifically mention ER, PR, or HER2 status as inclusion criteria, although it does state that patients must have had prior chemotherapy with an anthracycline, a taxane, or both, which could potentially affect the expression of these receptors. The statement also mentions \"no Dysphagia,\" which is not mentioned or excluded in the primary trial. Therefore, the expert statement contradicts the primary trial's inclusion criteria."
    },
    "7eea6ac2-ef9a-4c3e-b14d-eb9671dab89d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00374322",
        "Statement": "the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were twice as likely to achieve DFS at 5 years than placebo patients.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTR data. \n\nJustification: \n\nIn the primary trial, the arm receiving lapatinib 1500 mg orally had 1318 participants censored due to follow-up ended, while the placebo arm had 1285 participants censored under the same category. The remaining numbers of participants with disease recurrence or death were 1 and 290 in the lapatinib and placebo arms, respectively. \n\nThe hazard ratio (HR) for disease-free survival (DFS) between the lapatinib and placebo arms can be calculated as:\n\nHR = (Number of Events in placebo arm / Number of participants at risk in placebo arm) / (Number of Events in lapatinib arm / Number of participants at risk in lapatinib arm)\n\nHR = (290 / 1285) / (1 / 1317)\nHR = 0.555 (approximately)\n\nSince the hazard ratio is less than 1, it implies that the lapatinib arm has a lower risk of disease recurrence or death than the placebo arm. \n\nThe 5-year DFS rate can be calculated as:\n\n5-Year DFS Rate in Lapatinib Arm = 100% - (1 - e^(-HR^(5)))\n5-Year DFS Rate in Placebo Arm = 100% - (1 - e^(-1))\n5-Year DFS Rate in Lapatinib Arm = 59.4% (approximately)\n5-Year DFS Rate in Placebo Arm = 37%\n\nThe difference in the 5-year DFS rates between the lapatinib and placebo arms is approximately 22.4 percentage points. Since the statement claims that participants receiving lapatinib were \"twice as likely\" to achieve DFS at 5 years, the difference of approximately 22.4 percentage points corresponds to a relative risk reduction of approximately 50% (or a risk ratio of approximately 0.5). \n\nThus, the statement is consistent with the CTR data, as the relative risk reduction is close to the 50% stated in the expert's claim."
    },
    "a2d489d5-3677-43ef-b03a-33d571c0c3b2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02650193",
        "Secondary_id": "NCT00656669",
        "Statement": "Patients with Class III obesity cannot be included in the primary trial, but can be entered into the secondary trial, as long as they do not have uncontrolled Hypertension.",
        "Label": "Entailment",
        "explain": "The statement should be contradicted based on the following reasons:\n\n1. The primary trial excludes patients with a BMI of over 40 kg/m^2 (Class III obesity) regardless of hypertension status (ELIGIBILITY CRITERIA section in the primary CTR).\n2. The secondary trial includes patients with a BMI of up to 40 kg/m^2 (Class III obesity), but only if they do not have uncontrolled hypertension (ELIGIBILITY CRITERIA section in the secondary CTR).\n\nTherefore, the statement is contradictory to the information provided in the CTRs."
    },
    "943ff737-4edd-4dbd-a3c9-213e3e0234d8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00423917",
        "Secondary_id": "NCT00082641",
        "Statement": "the primary trial and the secondary trial both report cases of confusion in their patient cohorts.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the information provided in both CTRs as both trials report cases of confusion in their respective patient cohorts. (Adverse Events 1 in the primary trial reports one case, and Adverse Events 1 and Adverse Events 2 in the secondary trial report one case each.)"
    },
    "be50c45f-ec51-40c8-904f-ffc200d39d9d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01042938",
        "Statement": "Only patients capable of understanding english are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement should be entailed. The inclusion criteria of the primary trial explicitly state that \"Participants must be able to understand English and able to complete assessment forms (all assessment forms are in English)\", making it a requirement for participants to be able to understand English to participate in the study."
    },
    "f53c8212-6da8-470f-a392-1bb037ed90e8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT04030104",
        "Secondary_id": "NCT02525718",
        "Statement": "Intervention 1 for the secondary trial and the primary trial either include no treatment at all, or a placebo.",
        "Label": "Contradiction",
        "explain": "The statement is entailed based on the information in the CTRs. \n\nExplanation: \n\nIn the primary trial, there are two interventions: IUS Alone and IUS+OA. IUS Alone can be considered as no treatment, as it is just the intrauterine system (IUS) being used without any additional treatment. In the secondary trial, Intervention 1 is a placebo, and it states that subjects will be randomly selected to receive an intraoperative injection of saline. Saline can be considered as no treatment since it does not provide any therapeutic effect. Therefore, both Intervention 1 in the primary and secondary trials can be seen as having no treatment or a placebo."
    },
    "7b7e6e8b-aa62-4fcd-af1e-c243995243d1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02622074",
        "Statement": "There were twice as many patients with DLT in cohort 2 of the primary trial than in cohort 1.",
        "Label": "Entailment",
        "explain": "To evaluate the statement, we need to calculate the number of participants with DLTs in each cohort from the given Primary Trial information and then compare them.\n\nFrom the provided Primary Trial Results 1 and 2:\n- Cohort A (KNp/KAC) had 2 participants with DLTs.\n- Cohort B (KNpCb) had 4 participants with DLTs.\n\nSo, there is indeed a difference of twice as many patients with DLTs in cohort 2 (KNpCb) compared to cohort 1 (KNp/KAC). Therefore, the expert's statement is entailed by the given data from the Clinical Trial Reports."
    },
    "74a53536-bb9d-4c64-9280-679d7b660cdd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02162719",
        "Statement": "the primary trial does not investigate the effects of its intervention on patient tpCR.",
        "Label": "Entailment",
        "explain": "Contradicted. The CTRs provided do not mention \"tpCR\" (tumor protein-specific complete response) as an outcome measure in either the primary or secondary trial. However, the statement specifically refers to the effects of the intervention on this particular outcome. Therefore, it is contradictory to the information presented in the CTRs."
    },
    "6b35c306-a699-44f2-8606-a58d58fc18f3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00728949",
        "Statement": "There were 6 adverse event categories for cohort 1 of the primary trial which recorded at least three cases.",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nJustification: The statement \"There were 6 adverse event categories for cohort 1 of the primary trial which recorded at least three cases\" contradicts the information in the CTR. In the CTR, only five adverse event categories, namely Abdominal pain, Diarrhea, Disease progression, Infusion related reaction, and Pain, have at least three cases in cohort 1 of the primary trial. The statement incorrectly includes Pancytopenia and Pericarditis, which have zero cases in cohort 1."
    },
    "62f50fe5-a83d-4f07-9dc7-8f495254d398": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00784849",
        "Secondary_id": "NCT02104895",
        "Statement": "Breast breast irradiation is used in some form for both cohorts of the secondary trial, but not at all in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs provided. The primary trial does not involve any form of breast irradiation in its intervention (Section: INTERVENTION 1). In contrast, the secondary trial employs two forms of breast irradiation: conventional whole breast irradiation (WBI) and accelerated partial breast irradiation (APBI). Therefore, although breast irradiation is used in the secondary trial, it is not used in the primary trial, as stated in the expert's claim."
    },
    "edcae553-8a0a-45d2-a0fa-4db68608ef03": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Statement": "the primary trial requires participants to have a primary tumor > 5cm in longest dimension. ",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the Primary Trial's Inclusion Criteria, as it specifies that participants must have histologically or cytologically confirmed invasive breast cancer but there is no requirement for the primary tumor to be larger than 5cm in longest dimension."
    },
    "a1b3667f-bfa5-426a-975a-20ed350c12c0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00748553",
        "Statement": "Patients in the primary trial receive 5 doses of Azacitidine (Vidaza) every month and 3 doses of Nab-paclitaxel (Abraxane) per month.",
        "Label": "Entailment",
        "explain": "The statement is entailed. \n\nExplanation:\n\nIn the primary CTR, Azacitidine is given at 50mg/m2, 75mg/m2, or 100mg/m2 daily for 5 days each 4-week cycle. Therefore, each 4-week cycle comprises 5 doses of Azacitidine, as stated in the expert's claim. Similarly, Nab-paclitaxel is given weekly for 3 weeks of each 4-week cycle, which equates to 3 doses per month. This also aligns with the expert's claim. Thus, the statement is entailed by the data presented in the CTR."
    },
    "903617fa-7c40-45ac-a03c-498f51879408": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02915744",
        "Statement": "The difference in median, maximum and minimum Overall Survival (OS) of Patients between the two cohort of the primary trial was less than one month.",
        "Label": "Entailment",
        "explain": "Based on the provided CTRs, the statement can be contradicted. Although the median OS differences between the two groups are relatively close, with NKTR-102 having a median OS of 7.8 months (6.1-10.2) and TPC having a median OS of 7.5 months (5.8-10.4), the minimum OS values in the NKTR-102 group (not provided in CTR) and the maximum OS value in the TPC group (not provided in CTR) might significantly impact the overall difference. The statement is not entailed by the information given in the CTRs."
    },
    "9436e18a-a055-41c3-980f-bf451b4da7ee": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00171314",
        "Statement": "There are four types of adverse events in the primary trial, for which one occurence is recorded.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed based on the given CTRs. In the Primary Trial section, under Adverse Events 1, there is a listing of six types of adverse events (Anaemia, Febrile neutropenia, Lymphadenopathy, Acute myocardial infarction, Angina pectoris, and Angina unstable) with at least one occurrence recorded for each type. In the Secondary Trial section, under Adverse Events 2, there are six types of adverse events mentioned (Anaemia, Febrile neutropenia, Lymphadenopathy, Acute myocardial infarction, Angina pectoris, and Cardiac failure) but only five types are explicitly listed with occurrences (Anaemia, Lymphadenopathy, Acute myocardial infarction, Angina pectoris, and Cardiac failure). However, Angina unstable, a mentioned type, is also present in the Primary Trial and has zero occurrences. The expert's statement does not specify that all adverse events in the Primary Trial have exactly one occurrence; it only says that four types have one occurrence each. Therefore, the expert's statement is entailed by the given CTR information."
    },
    "f57403d9-7278-481e-bcb9-066bf31b6158": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01201265",
        "Secondary_id": "NCT00932373",
        "Statement": "1 patient in the primary trial was affected by Sepsis, and several were affected in the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary CTR as one patient in the primary trial experienced Septic Shock, which is a type of Sepsis. However, the secondary CTR does not provide any information related to Sepsis, so it does not contradict the statement.\n\nExplanation:\n\nThe primary CTR mentions one patient with Septic Shock under Adverse Events, which is a type of Sepsis. The statement asserts \"one patient in the primary trial was affected by Sepsis, and several were affected in the secondary trial.\" Since one patient in the primary trial was indeed affected by Sepsis, the statement is entailed by the information present in the CTR for the primary trial. The statement does not contradict the secondary CTR as it does not make any claims about the secondary trial."
    },
    "ec601f6b-6ce3-4df7-b7b3-fbde1a241e93": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00129376",
        "Statement": "Patients in the primary trial and the secondary trial did not suffer from any of the same adverse events.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary trial reported cases of cholecystitis chronic (0.38%), post procedural bile leak (0.38%), spinal column stenosis (0.38%), depression (0.38%), mania (0.38%), and pulmonary embolism (0.38%) as adverse events. In comparison, the secondary trial reported cases of febrile neutropenia (6.35%), congestive heart failure (1.59%), cardiac-ischemia/infarction (1.59%), vomiting (1.59%), acute Pharyngitis (1.59%), infection (4.76%), neutrophil count decreased (1.59%), and pneumonitis/pulmonary infiltrates (1.59%). The primary trial reported cholecystitis and pulmonary embolism, which are not in the secondary trial but are adverse events. Therefore, patients in both trials suffered from some different adverse events."
    },
    "0f0e5a8e-3972-46c2-84dd-7436e82a9787": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00291135",
        "Secondary_id": "NCT00291694",
        "Statement": "The duration of treatment in the primary trial is half as long as in the secondary trial, but twice as frequent.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided CTRs. In the primary trial, letrozole is given at a dose of 2.5 mg daily for six months. In contrast, in the secondary trial, celecoxib is given randomly to one arm at an undefined daily dose for 12 months, and placebo is given to the other arm also at an undefined daily dose for 12 months. The duration of treatment in the primary trial (six months) is indeed half as long as in the secondary trial (12 months). However, the frequency of treatment in the primary trial is twice that of the secondary trial (letrozole given daily compared to celecoxib or placebo given daily in the secondary trial). The statement only focuses on the duration of treatment and not the frequency, hence the former comparison holds, making the statement entailed by the given CTRs."
    },
    "420e4977-ce75-4fab-99e0-3e7db837d521": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00191152",
        "Statement": "The longest Time to Disease Progression the primary trial was over 21 days  in the Docetaxel Plus Capecitabine group.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs provided since the median Time to Disease Progression in the Docetaxel Plus Capecitabine group was 8.88 months, which is more than 21 days. (CTR Results 2)"
    },
    "d07b4a30-e74f-468a-8420-7ade791d372d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00096356",
        "Statement": "the primary trial results indicate that CoQ10 reduces the PFS of breast cancer patients compared to a placebo by about 8%",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial results do not directly support the statement as no data regarding Progression-Free Survival (PFS) of breast cancer patients or CoQ10's impact on it is provided in the CTR. The provided information pertains only to fatigue measurements."
    },
    "412b2743-8f76-494a-af97-f7bf9541a890": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02536339",
        "Secondary_id": "NCT00371345",
        "Statement": "At least one type of respiratory illness was observed in patients from both the primary trial and the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement \"At least one type of respiratory illness was observed in patients from both the primary trial and the secondary trial\" is entailed based on the CTRs provided, as evidenced by the observation of pneumonia in one patient from the primary trial and sinusitis, lobar pneumonia in one patient each from the secondary trial. (Primary Trial: Adverse Events 1 - 1/39 (2.56%) with diagnosis \"Pneumonia\"; Secondary Trial: Adverse Events 1 - 1/70 (1.43%) with diagnoses \"Sinusitis\" and \"Lobar Pneumonia\")."
    },
    "fd43feb6-4a55-4de6-b21d-25ff723b0959": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00631852",
        "Secondary_id": "NCT00193037",
        "Statement": "Patients may be forced to take part in the secondary trial and the primary trial, even against their consent, as long as it is in their best interests.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nThe CTRs explicitly state the requirement for written consent from study participants for both primary and secondary trials. (Primary Trial: \"must be willing to sign written consent\" and \"if willing to forego surgery for minimum of 5 days\" implies voluntary participation, and Secondary Trial: \"Written informed consent\" also implies voluntary participation.) Therefore, the statement that patients may be \"forced to take part\" in the trials against their consent is in contradiction to the information provided in the CTRs."
    },
    "e1fa68ac-42b4-4223-a362-a89c43562e06": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT01926886",
        "Statement": "The most common adverse event in the primary trial was Febrile neutropenia (14.29%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%).",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTR information provided. In the primary trial, the most frequent adverse event was Febrile neutropenia occurring in 42.86% of participants, while in the secondary trial, a decrease in Ejection fraction occurred in 4.95% of participants, making it the most common adverse event for that trial. Both statements use the term \"most common,\" but they refer to different trials, and the frequencies given in each trial support the respective claims."
    },
    "6f5570c0-4114-47ee-9611-b2e4be91cf9a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03165955",
        "Secondary_id": "NCT00912340",
        "Statement": "2 patients in the primary trial suffer from DVT, 0 in the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted based on the provided CTR data. The primary trial reports one participant experiencing Deep Vein Thrombosis (DVT) out of 28 total participants, while the secondary trial reports no occurrences of DVT among the 30 participants. The contradiction arises due to the discrepancy in the presence and absence of DVT instances between the two trials."
    },
    "13b4a3c5-cf6e-4f65-9f94-be927c3ce5ef": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01224678",
        "Statement": "Intervention 2 of the primary trial resulted in a lower percentage change in tumor diameter than intervention 1.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the information provided in the CTRs. \n\nJustification:\n\nThe CTRs only report data on changes in mammographic density and do not provide data on tumor diameter. Therefore, it is not possible for the statement to be entailed or contradicted based on the provided CTR information alone."
    },
    "6495c223-f7d9-459f-8c57-66a2caac5ee4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02581839",
        "Statement": "All participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) >= 16 weeks.",
        "Label": "Contradiction",
        "explain": "The expert statement is contradicted by the primary trial results as the provided data indicates that one participant (11.1%) did not have a CNS PFS >= 16 weeks (the percentage is 88.9%). The CTR specifies that the percentage is between 51 and 99.7, and 11.1% falls outside of that range. The MRI data at week 12 and beyond will provide further information on the progression status of all participants, but the data presented does not support the expert statement."
    },
    "eb61fee2-30fc-42f9-80bd-4d73d6af592c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01216319",
        "Secondary_id": "NCT03346161",
        "Statement": "the secondary trial and the primary trial are evaluating interventions associated with breast reconstruction for patients that have had mastectomies.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the given CTRs as both primary and secondary trials focus on interventions related to breast reconstruction for patients who have had mastectomies."
    },
    "79c698bf-a756-4a73-8075-38c3c5eb7a04": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00091832",
        "Statement": "Both cohorts of the primary trial in a negative (mean) Percent Change From Baseline of Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr).",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the provided information in the Primary Trial Results 1 and 2. Both cohorts (Bisphosphonate IV Q4W and Denosumab 30 mg Q4W) exhibit negative Percent Change From Baseline in uNTx/Cr. Explicit values for the Bisphosphonate IV Q4W cohort are given as -10.19 (208.84), and for the Denosumab 30 mg Q4W cohort, the value is -52.87 (95.14). Since both values represent a decrease from Baseline, the expert's statement holds true."
    },
    "f7be0a6e-6c63-473e-af00-df009f3d7d46": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00571987",
        "Statement": "Breast implants and Diffuse microcalcifications will not disqualify a patient from entry to the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the Primary Trial Exclusion Criteria which explicitly states \"Breast implants\" and \"Diffuse microcalcifications\" as disqualification factors."
    },
    "6f686de9-f110-4be0-9cd8-1ceb0ce6f073": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01912612",
        "Statement": "Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects, of the two cohorts in the secondary trial only the cohort without pain recieves Duloxetine 30 mg daily.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided CTRs. In the primary trial, the intervention for cohort 2 involves a higher dose (6.5 mg) of vaginal DHEA gel application QD, compared to the 3.25 mg dose for cohort 1 in the same trial. In the secondary trial, cohort 1 receiving duloxetine undergoes treatment with 30 mg of the medication daily, while cohort 2 does not receive any medication. These facts align with the statement that cohort 2 in the primary trial receives more DHEA and cohort 1 in the secondary trial receives a daily dose of duloxetine, while cohort 2 in the secondary trial does not."
    },
    "2c602b4d-c8a5-4606-8e3a-a87ee7bbc480": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01004744",
        "Statement": "Patients must have a confirmed pregnancy by positive Hcg test, if they are to take part in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the Primary Trial's Inclusion Criteria, as it states that patients must not be pregnant to participate. The specific parts of the CTRs supporting this include:\n\nPrimary Trial: Inclusion Criteria:\n- No pregnant or lactating women\n\nTherefore, the expert's statement that patients must have a confirmed pregnancy to take part in the primary trial contradicts the provided inclusion criteria."
    },
    "ffa913b7-9875-458e-8a28-476f9e788bb0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02463032",
        "Statement": "There was less than a 5% difference in the Percentage of Participants With Objective Response in the GTx-024 9 mg and GTx-024 18 mg group in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"There was less than a 5% difference in the Percentage of Participants With Objective Response in the GTx-024 9 mg and GTx-024 18 mg group in the primary trial\" can be entailed by the CTRs provided based on the following reasoning.\n\n1. The primary trial's Outcome Measurement section defines the Clinical Benefit Rate (CBR) as the sum of complete responses (CR), partial responses (PR), and stable diseases (SD).\n2. The Results section for each of the GTx-024 arms provides the number of participants in each group and the measure type and unit.\n3. By calculating the percentage of participants with Objective Response for each group (CR+PR), one can compare the differences between the GTx-024 9 mg and GTx-024 18 mg groups.\n4. The difference in the percentage of participants with Objective Response between the two groups can be computed as: | (% Objective Response in GTx-024 9 mg - % Objective Response in GTx-024 18 mg) / (% Objective Response in GTx-024 9 mg + % Objective Response in GTx-024 18 mg) |\n5. According to the Results section, the number of participants with Objective Response for GTx-024 9 mg was 16 out of 50, and for GTx-024 18 mg was 15 out of 52. Calculating % Objective Response, we get: \n   - GTx-024 9 mg: % Objective Response = (16/50) * 100% = 32%\n   - GTx-024 18 mg: % Objective Response = (15/52) * 100% = 29%\n6. The difference between the percentages is: |(32% - 29%) / (32% + 29%) | \u2248 3.1% \n7. Since the expert statement mentions a difference of less than 5%, it is entailed that the difference between the two groups falls within the stated condition."
    },
    "5a4018ea-5d00-4d44-bfa3-a1dfb341b9e5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193206",
        "Statement": "the primary trial records a total of 7 different types of infections.",
        "Label": "Contradiction",
        "explain": "Contradicted\n\nExplanation:\n\nThe statement \"the primary trial records a total of 7 different types of infections\" is contradicted by the data presented. According to the Adverse Events section of the primary trial, there are a total of 5 types of infections reported: Skin infection [3], Gastrointestinal infection [1], Vein infection [2], Pneumonia [1], and Liver pain with infection [1] mentioned in the CTR. Therefore, there are only 5 types of infections reported in the primary trial, which is less than the 7 types stated in the expert's claim."
    },
    "d8e47fe7-be41-4f74-881b-a80cd3a1e95f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03456427",
        "Secondary_id": "NCT02685566",
        "Statement": "There are no details concerning the duration or frequency of administration in the intervention sections of the primary trial and the secondary trial",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nJustification:\n\nThe statement \"There are no details concerning the duration or frequency of administration in the intervention sections of the primary trial and the secondary trial\" is contradicted by the CTRs, as they do provide information about the frequency of the imaging procedures, which can be considered a type of administration. In the primary trial, the patient undergoes imaging of both breasts using both Patient-Assisted Compression and Technologist-controlled Compression for all standard views for each breast. No specific duration is mentioned, but the frequency is implicit in the statement that both breasts will be imaged using both techniques. In the secondary trial, breast images will be acquired using FFDM alone and FFDM Plus DBT, with no mention of different durations but an implicit frequency as all subjects in the study will undergo imaging for both endpoints."
    },
    "e77e15a3-d851-4174-80c3-7b5156e7f987": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00236899",
        "Secondary_id": "NCT01153672",
        "Statement": "the primary trial and the secondary trial do not use any of the same drugs in their interventions.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided Clinical Trial Reports. \n\nJustification:\nThe primary trial uses Docetaxel and Gemcitabine in arms C and D, and Paclitaxel and Gemcitabine in arms A and B. However, none of these drugs are used in the secondary trial's intervention. Instead, it employs vorinostat, anastrozole, letrozole, and exemestane. The statement correctly acknowledges this difference in drug usage."
    },
    "c003dd08-af3b-44cc-b31c-6fbdadfa1d83": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "In total Over 85% patient in the primary trial achieve Recurrence-free Survival after 3 years.",
        "Label": "Contradiction",
        "explain": "The given statement \"In total Over 85% patient in the primary trial achieve Recurrence-free Survival after 3 years\" cannot be directly entailed from the provided information in the CTRs since the CTRs do not report the exact number of participants who achieved Recurrence-free Survival after 3 years. However, the CTRs mention that the time frame for analyzing Recurrence-free Survival is 5 years, which includes 2 years of primary analysis and 3 additional years for secondary analysis. Therefore, the statement is not contradictory to the information in the CTRs, but it is an extrapolation that requires additional data to be verified."
    },
    "8ddf49c7-316e-4c7c-b2dd-423182a37612": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00455533",
        "Secondary_id": "NCT00767520",
        "Statement": "Throughout both the secondary trial and the primary trial there was only one case of sudden and unexpected death, in cohort 1 of the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTRs. In the primary trial, there was one case of sudden death in the first cohort (1/145), while in the secondary trial, there was one case of sudden death in the first cohort (1/79). The statement explicitly mentions both trials and both instances of sudden death, making it consistent with the information in the provided CTRs."
    },
    "d9e41be5-1e37-4dff-b51a-166576f351d0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "For all adverse event types in the primary trial, at least one case was recorded.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the data in the CTRs.\n\nExplanation:\n\nAccording to the primary trial Adverse Events section, there is at least one reported case for each of the mentioned adverse events: Thrombocytopenia (1/8), Hypertension (1/8), Hepatotoxicity (3/8), and Pancreatectomy (1/8). Therefore, the statement that \"for all adverse event types in the primary trial, at least one case was recorded\" is a correct summary of the CTR data and is an entailment of the provided information."
    },
    "ee2287bd-af76-4232-9575-d371fe3257dc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00544167",
        "Statement": "Every adverse event in the primary trial occurred once.",
        "Label": "Entailment",
        "explain": "The statement \"Every adverse event in the primary trial occurred once\" is entailed by the provided CTR data for Adverse Events section of the primary trial, as each adverse event is listed only once for each respective condition."
    },
    "e5495b51-5f42-4e97-80ec-c215652bd3ab": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00675259",
        "Secondary_id": "NCT01875367",
        "Statement": "Patients with an ImmunoHistoChemistry test result of 3+ are excluded from the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradiction (for both trials): \n\nThe statement \"Patients with an ImmunoHistoChemistry test result of 3+ are excluded from the primary trial and the secondary trial\" is contradictory to the inclusion criteria in both trials. In the primary trial, IHC 3+ is a criterion for HER-2 neu overexpression and eligibility (but the statement excludes these patients), while in the secondary trial, IHC 3+ with HER-2 amplification is one of the inclusion criteria for HER-2 positive breast cancer."
    },
    "9b6bd158-a66d-42b6-8fe6-843ff05e0c8d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00612560",
        "Statement": "children and illiterate adults are able to take part in the primary trial, unless they are can read and write in italian. ",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the Primary Trial inclusion criteria stating that \"Willingness to comply with study guidelines and procedures\" includes the ability to read and write in English."
    },
    "9ae51f9c-8544-4764-b731-e4efe9ae0ba6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00452673",
        "Statement": "1/7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities.",
        "Label": "Entailment",
        "explain": "The statement \"1/7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities\" is entailed by the CTR, as the number of participants with DLTs in cohort 1 is explicitly stated to be \"1 in 6 subjects\" or \"1/6\" in Results 1."
    },
    "5b1915da-1819-4504-81bd-3f44a83b5e95": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320541",
        "Statement": "Cohort 2 of the primary trial recorded three times as many cases of Leukopenia as cohort 1.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nJustification:\n\nThe statement asserts that cohort 2 of the primary trial recorded three times as many cases of Leukopenia as cohort 1. However, the information provided in the CTR contradicts this claim. In Cohort 1, there was 1 case of Leukopenia out of 94 participants, while in Cohort 2, there were 4 cases of Leukopenia out of 93 participants. Three times as many cases would equate to 3 * 1 = 3 cases in cohort 2 if we are following the information presented in the CTR. Therefore, the statement is contradicted by the data in the CTR."
    },
    "edb1e4c0-7669-4b8c-878b-ea8ca060c350": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00074152",
        "Statement": "Only 2 of the adverse event cases in the primary trial occurred in patients from cohort 1.",
        "Label": "Contradiction",
        "explain": "The statement \"Only 2 of the adverse event cases in the primary trial occurred in patients from cohort 1\" is not directly entailed by the provided data in the CTRs as no information about the distribution of adverse events across cohorts is given. The CTRs only report the total number of adverse events and their counts for the entire trial population, without specifying which cohort each case belongs to. Therefore, the statement is not substantiated by the provided CTRs and contradicts the available data if it is taken as strictly true."
    },
    "915939cf-7813-43e7-b503-e14a7eb4e568": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429299",
        "Statement": "Only one cohort in the primary trial is administered trastuzumab 600 mg/m^2.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted. The primary trial specifies that participants in intervention 1 received trastuzumab at a dose of 4 mg/kg on the first day and 2 mg/kg weekly thereafter, not 600 mg/m^2."
    },
    "126c1169-b375-4f89-95b2-52e971d19565": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00856492",
        "Statement": "Cohort 1 of the primary trial recorded no deaths and no cases of Enterocolitis infectious.",
        "Label": "Entailment",
        "explain": "The statement is entailed. In the Primary Trial Adverse Events 1 section, there are no instances of Death NOS (0/96) and Enterocolitis infectious (0/96) reported for Cohort 1."
    },
    "11235250-3627-427e-aae9-099507484456": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00284180",
        "Statement": "Across all three cohorts of the primary trial a total of two patients had low levels of oxygen in their body tissues.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. In the primary trial, one patient experienced Hypoxia (low levels of oxygen in body tissues) out of 11 total patients, and one patient experienced Hypoxia out of 21 total patients in the secondary trial. Therefore, in total, there are two patients across both trials who experienced Hypoxia."
    },
    "8a9f2247-7c51-44be-910b-5091d9abb2ea": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00236899",
        "Secondary_id": "NCT01153672",
        "Statement": "the primary trial and the secondary trial both administer Paclitaxel and Gemcitabine to their patients cohorts, but only the secondary trial utilises positron emission tomography.",
        "Label": "Contradiction",
        "explain": "The statement can be entailed by the provided CTRs. In both primary and secondary trials, Paclitaxel and Gemcitabine are used as treatment regimens for different arms. However, the secondary trial also includes positron emission tomography (PET) as a part of correlative studies in the secondary trial (INTERVENTION 1, under \"positron emission tomography: Correlative studies\"), while it is not mentioned in the primary trial. Therefore, the statement accurately reflects the information in the CTRs without contradicting any details."
    },
    "7e283897-4d9e-4353-8331-00f8db16cc7e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00038467",
        "Statement": "The patient groups in the primary trial each receive different oral medication, either Tamoxifen or Exemestane.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR information provided. \n\nJustification: \n\nThe CTR specifies that in the primary trial, the patient groups were given different oral medications: Tamoxifen for one group and Exemestane for the other, as stated in the INTERVENTION sections."
    },
    "54b15068-023b-4e60-bb82-2a22512fda62": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00847171",
        "Secondary_id": "NCT01764022",
        "Statement": "Male patients with Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Male patients with Systemic lupus erythematosis are excluded from the primary trial but may still be eligible for the secondary trial\" is contradicted by the provided CTRs.\n\nJustification for the Primary Trial:\nMale patients are explicitly listed as an exclusion criterion for the primary trial under the category \"No symptomatic intrinsic lung disease or extensive tumor involvement of the lungs resulting in dyspnea at rest\" and \"Other rheumatologic disease,\" which includes Systemic lupus erythematosus.\n\nJustification for the Secondary Trial:\nAlthough the secondary trial's inclusion criteria do not specify gender, the exclusion criteria state \"No symptomatic intrinsic lung disease or extensive tumor involvement of the lungs resulting in dyspnea at rest\" and \"No other rheumatologic disease, including Systemic lupus erythematosus.\"\n\nTherefore, based on the given CTRs, the contradictory statement is not entailed."
    },
    "78764961-52be-4235-a2b7-e581497d0099": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00900627",
        "Statement": "The two groups in the primary trial receive the same drug treatment, but different doses.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the CTRs. The statement correctly identifies that both groups in the primary trial are receiving the same drug (AZD8931) for treatment, but with different doses (160 mg bd for Intervention 1 and 120 mg bd for Intervention 2). The statement matches the data in the CTRs without contradiction."
    },
    "e09fe98c-ec5c-49cf-9f49-92ba8824e82e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03708393",
        "Secondary_id": "NCT03456427",
        "Statement": "The interventions in the primary trial and the secondary trial require active participation from the patient to apply the treatment.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by both the primary and secondary CTRs. In the primary trial, the use of Patient-Assisted Compression (PAC) in Intervention 1 for both IUS alone and IUS+OA requires active participation from the patients. Similarly, in the secondary trial, the use of Patient-Assisted Compression (PAC) in Intervention 1 for Patient-Assisted Compression (PAC) and Technologist-controlled (TC) Compression in Intervention 2 also necessitates patient involvement. The patient is instructed and guided by the technologist to apply the compression in the correct manner, ensuring active participation."
    },
    "a83d98c9-e3da-4449-878b-5fa2f3bee8cf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01277757",
        "Statement": "the primary trial is not testing a novel Physiotherapy or radiotherapy intervention.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the information provided in the CTRs. Both trials describe interventions using pharmaceutical agents (Akt Inhibitor MK-2206), neither mention Physiotherapy nor radiotherapy as interventions."
    },
    "41db854e-1565-4eda-8236-550556043b47": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01027416",
        "Statement": "To be eligible for the primary trial, patients must have an invasive carcinoma confirmed by core biopsy, and a -ive human chorionic gonadotropin urine test.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTR of the primary trial under the Eligibility Criteria section, specifically \"Negative serum or urine beta-hCG pregnancy test at screening for patients of child-bearing potential.\" However, the statement is missing the requirement about definitive invasive carcinoma diagnosis by core biopsy which is a necessary condition for eligibility in the primary trial. Therefore, the statement as it stands is not fully entailed by the CTR of the primary trial. However, if the statement is modified to explicitly include the requirement of invasive carcinoma confirmed by core biopsy, then it would be fully entailed by the CTR. \n\nIn the context of comparative analysis with the secondary trial, the statement is not directly related as the secondary trial does not mention anything about a pregnancy test or beta-hCG urine test in its eligibility criteria."
    },
    "f559cacb-30e7-47cf-9ac6-5929c1a508f7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00493649",
        "Secondary_id": "NCT01201265",
        "Statement": "There were no MRSA infections in either the secondary trial or the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by both CTRs as neither report mentions any MRSA infections in the Adverse Events sections."
    },
    "79362f6d-ef2c-4b93-8719-be361d0b5acc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03096847",
        "Secondary_id": "NCT01840163",
        "Statement": "Female Patients recently prescribed Rapamycin are not eligible for the primary trial, but may be eligible for the secondary trial unless they have a stage 1 to 2 Ductal carcinoma in situ and can speak english.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial's inclusion criteria as it states that \"Patient has not received any mTOR inhibitor\" (including Rapamycin) for the primary trial. Therefore, females currently prescribed Rapamycin are not eligible for the primary trial, but the statement incorrectly implies that they might be eligible for the secondary trial despite the secondary trial excluding females."
    },
    "54918996-1b4d-48bd-a0ca-13d8e259767b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02650193",
        "Secondary_id": "NCT00656669",
        "Statement": "Patients with Class III obesity cannot be included in the primary trial, but can be entered into the secondary trial, even if they have uncontrolled Hypertension.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted. The primary trial explicitly lists obesity as an inclusion criterion with a specified BMI range (19-40 kg/m^2), meaning that patients with Class III obesity fall within the acceptable range. However, the statement suggests that they cannot be included.\n\nAdditionally, regarding hypertension, in the primary trial inclusion criteria it is mentioned that patients must have an adequate bone marrow, hepatic, and renal function reserve, and the criteria specify normal values for serum creatinine and eGFR to determine renal function. Hypertension is not an exclusion criterion as long as it's adequately controlled. However, in the secondary trial, it is mentioned that hypertension that cannot be controlled by medications is an exclusion criterion.\n\nSo, the statement does not hold true as it contradicts the information provided in the CTRs."
    },
    "a5a1c7f1-92f4-4436-9dcb-ab222ff1c8a5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00679341",
        "Secondary_id": "NCT00201851",
        "Statement": "Patients in the secondary trial and those in the primary trial did not share any of the same adverse events.",
        "Label": "Entailment",
        "explain": "Based on the provided information in the CTRs, the statement \"Patients in the secondary trial and those in the primary trial did not share any of the same adverse events\" is entailed. None of the adverse events in the primary trial (except for Pyrexia with a frequency of 1.45%) were present in the secondary trial, and none of the adverse events in the secondary trial were present in the primary trial. Therefore, the statement is justified as per the data presented in the CTRs."
    },
    "52c8361f-75dc-45f1-a35c-79180a22b931": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02015676",
        "Statement": "There are no recorded cases of thrombocytopenia in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the Primary Trial Adverse Events section, where thrombophlebitis (a type of thrombotic event) is reported in 1/69 (1.45%) of participants. Therefore, the presence of thrombophlebitis contradicts the statement's claim of no recorded cases of thrombocytopenia (a different type of blood condition) in the primary trial. It is essential to note that the presence of thrombophlebitis, a thrombotic event, does not prove or disprove the absence of thrombocytopenia, but it is the statement's inaccuracy that contradicts the CTR."
    },
    "f2f05760-cc22-4fe8-a24f-f6d43f9c9a86": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01091168",
        "Statement": "Patients in the control group of the primary trial had a median Overall Survival of less than a year, however several patients in arm B survived longer than a year.",
        "Label": "Contradiction",
        "explain": "The statement \"Patients in the control group of the primary trial had a median Overall Survival of less than a year, however several patients in arm B survived longer than a year\" is a contradiction of the provided CTR data. In the primary CTR, the median Overall Survival for the control arm (arm B) was reported as 9.3 months (7.5 to 10.9 months). There is no evidence in the CTR to suggest that all patients in this arm had a median Overall Survival of less than a year."
    },
    "db8ffa86-bf52-47bb-89f7-42e7ae47b84d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01271725",
        "Statement": "In the primary trial The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 18% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group.",
        "Label": "Contradiction",
        "explain": "The statement \"In the primary trial, The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 18% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group\" is entailed by the given CTRs as follows:\n\n1. The percentage of participants with OR for the Afatinib Monotherapy is given as 18% (10-28%).\n2. The percentage of participants with OR for the Afatinib and Paclitaxel or Vinorelbine Combination Therapy is given as 31% (17-48%).\n3. A difference of 18 percentage points between the two groups implies a lower OR for Afatinib Monotherapy compared to the combination therapy.\n\nTherefore, the statement \"In the primary trial, The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 18% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group\" is entailed by the information in the CTRs."
    },
    "5a01d00f-8601-4c17-b814-be87e63b0d8a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02392611",
        "Statement": "the primary trial cohorts are not seperated based on patient characteristics.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the information provided in the CTRs. The primary trial involves two cohorts with distinct interventions, one receiving alobresib 0.6 mg and the other receiving alobresib 1.4 mg. This clear difference in treatment groups is in direct opposition to the statement that the primary trial cohorts are not separated based on patient characteristics."
    },
    "7577f05f-04e9-44de-9e00-b7411ff4010f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "Patients currently prescribed laxatives are not excluded from the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTR as laxatives are not mentioned in the exclusion criteria of the primary trial."
    },
    "3b0440e6-cf85-4236-8a1d-2e3572143946": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191451",
        "Statement": "Patients in the primary trial experienced a only one type of Oesophageal adverse events and several types of cardiac adverse events.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nExplanation:\n\nThe statement \"Patients in the primary trial experienced a only one type of Oesophageal adverse events and several types of cardiac adverse events\" is contradicted by the provided CTR data. According to the data, in the primary trial, there was one participant (1/50) who experienced oesophagitis in the \"Adverse Events 1\" section, and there were two participants (1/48 in Adverse Events 2) who experienced oesophageal spasm in the \"Adverse Events 2\" section. Thus, patients in the primary trial experienced more than one type of oesophageal adverse event. Furthermore, the statement suggests that cardiac adverse events were experienced by multiple patients in the primary trial, but the CTR does not specify any cardiac adverse events in either the \"Primary Trial: Adverse Events 1\" or \"Primary Trial: Adverse Events 2\" sections."
    },
    "6f342205-ef33-482a-b74a-74644537538b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00077857",
        "Statement": "Patients must be older than 18, female, have one or more target lesions and more than 2 regiments of chemotherapy to participate in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR's inclusion criteria, specifically the conditions: \"women >=18 years of age,\" \">=1 target lesion,\" and \">=2 regiments of chemotherapy for advanced/metastatic disease.\"\n\nJustification:\nThe statement's requirement of older females with at least one target lesion and more than 2 chemotherapy regimens aligns with the primary CTR's inclusion criteria. These conditions ensure that the patient meets the eligibility requirements for the clinical trial.\n\nThe exclusion criteria in both CTRs do not contradict the expert statement either, as they do not mention the requirement of \"one or more target lesions\" or the number of \"chemotherapy regimens.\"\n\nTherefore, the given statement is entailed by the information provided in the given primary CTR."
    },
    "5b63fffb-0a75-414f-8744-5fea78395f28": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00950742",
        "Statement": "100 participants in the Afatinib 20mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities.",
        "Label": "Contradiction",
        "explain": "Contradiction. \n\nThe statement asserts that 100 participants in the Afatinib 20mg + Herceptin group of the primary trial suffered DLTs. However, the CTR reports a total of 13 participants analyzed in this group and does not provide data regarding the exact number of participants who experienced DLTs. Thus, the statement contradicts the CTR data."
    },
    "9e655973-7d1d-4528-8394-a9cbcf0b978f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02279108",
        "Secondary_id": "NCT00943670",
        "Statement": "Adult Patients with Histologically proven HER2- infiltrating breast cancer that have had a Previous lumpectomy or same side mammary reduction are excluded from both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the primary CTR as it includes patients with a history of lumpectomy in the inclusion criteria. However, it is entailed by the secondary CTR as it lists lumpectomy among the exclusion criteria."
    },
    "ea62355f-aab9-4796-8658-746c0b669ca7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00073073",
        "Secondary_id": "NCT00054028",
        "Statement": "There is no placebo or control group in the primary trial, in the secondary trial, Suramin acts as placebo.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nJustification:\nThe primary trial does not mention any information about a placebo or control group. However, the statement claims that there is no placebo or control group in the primary trial and that Suramin acts as a placebo in the secondary trial. This contradicts the information in the primary CTR, which does not provide any information about the use of a placebo or control group. Therefore, the statement is contradicted."
    },
    "55eaae8d-611c-4dbb-b162-de664902e059": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454805",
        "Statement": "In the primary trial there were more cases of Intestinal Obstruction in cohort 1 than in cohort 2.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nJustification:\nThe CTRs provided do not support the statement that \"In the primary trial there were more cases of Intestinal Obstruction in cohort 1 than in cohort 2.\" In fact, both cohorts had only one case each (3.23%). Therefore, the statement contradicts the information in the CTRs."
    },
    "c3438bb2-4a49-4f14-ae50-a46fb48d0208": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00485953",
        "Secondary_id": "NCT00068601",
        "Statement": "the cyclophosphamide dose in the secondary trial and the Placebo dose in the primary trial are not specified.",
        "Label": "Entailment",
        "explain": "The statement should be contradicted. The primary trial specifies that the Intervention 1 Group receives risedronate 35 mg weekly, while the Placebo Group receives placebo medication once weekly. In contrast, the secondary trial specifies that patients in Intervention 1 receive cyclophosphamide as part of the chemotherapy regimen but does not mention the dose. Therefore, the statement's implication that the dose of cyclophosphamide in the secondary trial is not specified is incorrect, as it is stated that patients receive cyclophosphamide, but the dose is not explicitly provided. Similarly, the statement incorrectly claims that the placebo dose in the primary trial is not specified, when in fact, it is stated that placebo medication is given once weekly."
    },
    "8f505cec-6ad4-4142-a861-1771e3ae5cdd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00821964",
        "Statement": "the primary trial participants apply topical imiquimod to cutaneous lesions once daily on days for a total of 13 days every 28 day cycle.",
        "Label": "Entailment",
        "explain": "Contradiction \n\nExplanation:\n\nThe statement made by the clinical trial expert, \"the primary trial participants apply topical imiquimod to cutaneous lesions once daily on days for a total of 13 days every 28 day cycle,\" contradicts the information given in the CTR regarding the application schedule of imiquimod in the primary trial. According to the CTR, imiquimod is applied topically on days 1-4, 8-11, 15-18, and 22-25 within each 28-day cycle. This means a total of 16 days of application in every cycle instead of the claimed 13 days mentioned in the statement."
    },
    "8f4f9793-041d-448b-9da8-b0c787a875bb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00478257",
        "Statement": "Adequate Hematologic, Hepatic and renal function is not necessary for participating in the primary trial.",
        "Label": "Entailment",
        "explain": "Contradiction. \n\nJustification: \n\nThe primary trial inclusion criteria do not mention \"Adequate Hematologic, Hepatic and renal function\" as a condition for patient eligibility. Therefore, the statement that \"Adequate Hematologic, Hepatic and renal function is not necessary for participating in the primary trial\" contradicts the provided CTR information."
    },
    "d13e5689-2a9e-4295-b3f8-e4a18fe42bf1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01735175",
        "Secondary_id": "NCT01216319",
        "Statement": "the secondary trial is testing a surgical intervention, unlike the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed. The primary trial's Intervention sections describe the use of LA-EP2006 and Neulasta\u00ae, which are both forms of pegfilgrastim, used post-chemotherapy application. The secondary trial, on the other hand, involves a different intervention, the Biodesign\u00ae Nipple Reconstruction Cylinder, which is a surgical device. Thus, while the trials differ in their interventions, one involving a pharmaceutical treatment and the other a surgical one, the statement accurately reflects this distinction."
    },
    "61d56c2a-089f-4fa3-9e97-3a9007576077": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00376597",
        "Statement": "the primary trial do not receive any intervention by IV, orally or by surgery during the study.",
        "Label": "Entailment",
        "explain": "The statement is entailed by both CTRs as neither of them mention any intervention involving IV, oral or surgical methods. The primary trial's INTERVENTION sections describe lymphedema education and follow-ups, while the secondary trial's INTERVENTION section in Arm I is identical to the primary trial and Arm II does not include IV or surgical interventions."
    },
    "5b90b8de-97b9-4ed7-b5a4-e3724fd38c41": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00411788",
        "Statement": "If Hannah has been taking ketoconazole to treat athlete's foot for 6 weeks, until today, she will not be eligible for the primary trial for the next month.",
        "Label": "Entailment",
        "explain": "The statement \"If Hannah has been taking ketoconazole to treat athlete's foot for 6 weeks, until today, she will not be eligible for the primary trial for the next month\" is contradicted by the CTR, as per the exclusion criteria, ketoconazole is listed as one of the medications that would make a patient ineligible for the trial if used within 4 weeks before enrollment. (CTR: Exclusion Criteria: Use of any of these medications within 4 weeks: ketoconazole)."
    },
    "bad4d3e7-a05a-44fd-937a-c94a23655c03": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01712009",
        "Secondary_id": "NCT00343382",
        "Statement": "Cohort 2 patients in the primary trial receive naproxen at the same frequency and dosage as cohort 2 patients in the secondary trial receive Pilocarpine.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the CTRs. In the primary trial, cohort 2 patients received naproxen 500 mg orally BID for 5 days in each of the 4 cycles, whereas in the secondary trial, patients received pilocarpine 5mg orally 2 times per day for 6 weeks. The frequency and dosage of naproxen and pilocarpine are not the same."
    },
    "b88eaf78-957d-4b3d-bcb2-d029b7d7b7e2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00499122",
        "Secondary_id": "NCT00454805",
        "Statement": "There were several cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 2 of the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nExplanation:\n\nThe provided statement claims that there were cases of Multi-Organ Failure in both cohorts 1 and 2 of the secondary trial and the primary trial. However, the Adverse Events sections in the CTRs contradict this claim, as there were no reported cases of Multi-Organ Failure in either the primary or secondary trials."
    },
    "0c435231-a09c-4424-924a-13840c6b7068": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Statement": "In the primary trial there was 1 case of jaundice.",
        "Label": "Entailment",
        "explain": "The statement is entailed. The Primary Trial Adverse Events section reports one case of jaundice (1/65 or 1.54%), which matches the expert's statement of one case in the trial."
    },
    "0812dcc1-eab5-4d5f-9d51-934f9b1f05ca": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01217385",
        "Secondary_id": "NCT01202591",
        "Statement": "Prior exposure to exemestane is not allowed for patients in the secondary trial, however, the primary trial may accept patients despite this.",
        "Label": "Entailment",
        "explain": "Contradiction. \n\nThe statement \"Prior exposure to exemestane is not allowed for patients in the secondary trial, however, the primary trial may accept patients despite this\" contradicts the information presented in the Primary Trial CTR. The Primary Trial CTR does not have any exclusion criteria mentioning previous exposure to exemestane. Therefore, patients in the primary trial are allowed to have been exposed to exemestane in the past. Conversely, the Secondary Trial CTR explicitly states that patients should not have prior exposure to exemestane, making it incompatible with the statement."
    },
    "a29e6a86-65f3-4565-93e2-81f49fa837e4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Secondary_id": "NCT00479674",
        "Statement": "Unlike the secondary trial, the primary trial does not record any instances of Anemia, Dyspepsia, Nausea or depression.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary CTR reports no instances of Anemia, Dyspepsia, or Nausea. However, the expert's statement mentions the absence of these conditions specifically in the secondary trial but not in relation to the primary trial. The statement is contradictory as it implies that the primary trial did not have any occurrences of these conditions, which is not true according to the provided CTR."
    },
    "2470d8d1-27cd-41a5-9e5d-f62d4bbdd049": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418457",
        "Statement": "Scheduled flap reconstruction within 10 days prior to beginning is acceptable for patients entering the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradiction. The secondary trial explicitly states that \"Scheduled free flap reconstruction\" is an exclusion criteria in the primary trial. Therefore, a scheduled flap reconstruction within 10 days prior to beginning the trial is not acceptable for patients. The statement goes against the information provided in the primary trial's inclusion criteria."
    },
    "34bb7f09-3b2b-464f-96df-c8d80b1206fc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03190083",
        "Secondary_id": "NCT01805089",
        "Statement": "All cancer stages are accepted for the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted.\n\nJustification: \n\nThe primary trial only includes patients with a new diagnosis of breast cancer or a previous breast cancer patient with negative surgical margins (Section: Primary Trial, Inclusion Criteria). The secondary trial, on the other hand, specifically includes only patients with history of ductal carcinoma in situ, lobular carcinoma in situ, or stages 1-3 breast cancer (Section: Secondary Trial, Inclusion Criteria). Therefore, the statement that \"All cancer stages are accepted for the primary trial and the secondary trial\" contradicts the provided information in the CTRs."
    },
    "e9824c27-bb70-4707-9599-ff20281f873e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00357110",
        "Statement": "Less than 20% of patients in cohort 1 of the primary trial had Varicose Veins.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the information provided in the Primary Trial's Adverse Events 1 section. In this section, 1 out of 6 patients (16.67%) had Varicose Veins. This means that more than 20% (2 out of 7 if we assume the cohort size for the secondary trial) of the patients in Primary Trial's cohort 1 had Varicose Veins. Therefore, the statement is contradicted by the CTR data."
    },
    "43fcba9b-4edd-433d-86a7-370cbbf56853": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00320385",
        "Secondary_id": "NCT00075270",
        "Statement": "The median time from randomization until the first documented sign of disease progression or death due to any cause for all participants in the primary trial, was lower than the median time for patients in the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement can be contradicted. \n\nJustification: \n\nThe primary trial reports the median PFS, which is defined as the time from randomization until the first documented sign of disease progression or death due to any cause. The secondary trial reports time to progression (TTP), which is defined differently: it includes both radiological and clinical symptomatic progression as well as death due to breast cancer. The statement's assertion that \"the median time from randomization until the first documented sign of disease progression or death due to any cause for all participants in the primary trial, was lower than the median time for patients in the secondary trial,\" contradicts the information in the CTRs as they do not provide sufficient evidence to establish this claim.\n\nTo compare the PFS between the two trials, the expert should calculate or find a reported median PFS for each trial instead of comparing the medians of TTP and PFS. Without this information, it is not possible to make an entailed statement."
    },
    "196c7a35-58a0-4d2d-a0a6-e9e3de077fb1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02555657",
        "Statement": "The Median time from randomization to death due to any cause was higher in cohort 1 of the primary trial, compared to cohort 2.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the information provided in the CTRs. The median time from randomization to death due to any cause for cohort 1 (Pembrolizumab) was 12.7 (9.9 to 16.3) months, which is higher than cohort 2 (Chemo Therapy) with a median of 11.6 (8.3 to 13.7) months."
    },
    "27e0b995-b3d1-46a6-900a-d6e513504ff3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00398567",
        "Statement": "3/4 patients in the primary trial did not suffer any adverse events.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the data in the primary trial's Adverse Events section. According to the CTR, 1 out of 4 patients experienced an adverse event, which means 3 out of 4 patients did not. The listed adverse events for these 3 patients were none, thus the expert's statement is in agreement with the data."
    },
    "36a5357f-0c5f-4c64-a56a-a84aab165a16": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01727011",
        "Secondary_id": "NCT01420146",
        "Statement": "the primary trial and the secondary trial interventions involve a variety of scans, such as CT, PET and dosimetry ",
        "Label": "Entailment",
        "explain": "The statement is entailed. The primary CTR mentions the use of a \"post-implant dosimetry scanner to analyze the dose distribution within the target volume and organs at risk\" (CT scan for dosimetry purpose), and the secondary CTR mentions the use of a \"PET/CT single arm\" for Zr89-trastuzumab (a type of PET scan). Thus, both trials indeed involve various scans, including CT and PET, as stated in the expert's comment."
    },
    "c876167f-fe1e-4c3b-9183-dd3c1069ed0b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00024102",
        "Statement": "A patient in cohort 2 of the primary trial received a Packed red blood cell transfusion.",
        "Label": "Entailment",
        "explain": "The statement \"A patient in cohort 2 of the primary trial received a Packed red blood cell transfusion\" is contradicted by the information provided in the CTR, specifically in the Adverse Events section of the primary trial where it is stated that \"Transfusion: pRBCs 0/131 (0.00%)\" for cohort 1. Therefore, no patient in cohort 2 received a Packed red blood cell transfusion according to the data presented in the provided CTR."
    },
    "d6989b67-ae99-4c2a-a67d-c2285cc57058": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00191152",
        "Statement": "The longest Time to Disease Progression the primary trial was over 11 months  in the Docetaxel Plus Capecitabine group.",
        "Label": "Entailment",
        "explain": "Contradicted. The longest Time to Disease Progression in the Docetaxel Plus Capecitabine group was 11.05 months, but this value falls within the stated 95% Confidence Interval for the median Time to Disease Progression, which is (7.37 to 11.05) months. The statement goes beyond the provided data in the CTR by implying an outlier or exceptionally long TTDP that exceeds the upper limit of the 95% Confidence Interval. This contradicts the information given in the CTR."
    },
    "90dfb0bd-e0a0-47a9-945b-fd8ec8faaaa1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00320385",
        "Secondary_id": "NCT00075270",
        "Statement": "Both cohorts in the primary trial outperformed cohort 1 of the secondary trial in median PFS.",
        "Label": "Contradiction",
        "explain": "To evaluate the statement \"Both cohorts in the primary trial outperformed cohort 1 of the secondary trial in median PFS,\" we need to compare the median PFS of the Trastuzumab + Lapatinib arm of the primary trial with cohort 1 of the secondary trial. \n\nFrom the provided CTRs, we can find the following median PFS data:\n\nPrimary Trial (Trastuzumab + Lapatinib): 12.0 weeks (8.1 to 16.0)\nSecondary Trial (cohort 1 - Lapatinib): 8.1 weeks (7.6 to 9.0)\n\nGiven these median PFS values, the statement \"Both cohorts in the primary trial outperformed cohort 1 of the secondary trial in median PFS\" is entailed by the data.\n\nThe justification for this conclusion is that the median PFS value in the Trastuzumab + Lapatinib arm of the primary trial is greater than the median PFS value in cohort 1 of the secondary trial. The difference in the median PFS values indicates that the participants in the primary trial had longer survival periods, on average, than the participants in cohort 1 of the secondary trial."
    },
    "886d3280-bc44-4a58-a5ba-66b018210332": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00076024",
        "Statement": "The minimum period of time from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial, was just over a year.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the information in the CTRs. The median TTP for the Axitinib + Docetaxel arm was 247 days (95% CI: 208-265), and the median TTP for the Docetaxel + Placebo arm was 215 days (95% CI: 191-247). Since both medians are above 365 days (1 year), the minimum period of time from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial was indeed over a year."
    },
    "03dcb6d9-efae-40ec-87ee-68ef89424498": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00323479",
        "Secondary_id": "NCT03078751",
        "Statement": "There were more cases of deteriorating mental health in the primary trial than the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement \"There were more cases of deteriorating mental health in the primary trial than the secondary trial\" cannot be directly entailed or contradicted based on the provided CTR sections. The primary and secondary trials report different types of adverse events; the former mentions \"Depression worsened\" in 1/110 cases (0.91%), while the secondary trial does not include a similar event. However, the statement does not provide sufficient information to definitively conclude that there were more cases of deteriorating mental health in the primary trial. Other mental health-related adverse events, such as psychosis or anxiety, could also be considered. Moreover, the primary trial includes a larger sample size, which could influence the occurrence of certain adverse events, making a comparison of raw numbers potentially misleading. To accurately determine whether the statement is entailed or contradicted, a more comprehensive analysis of the CTRs, including their methodologies, outcome measures, and other relevant sections, would be required."
    },
    "b881b717-1c8a-41b8-9554-6ed9e8ee7c77": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193206",
        "Statement": "the primary trial records a total of 7 patients suffering from various infections.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR data. The secondary trial's description mentions patients suffering from various infections, and the primary CTR reports a total of 7 adverse events related to infections across all categories (skin, gastrointestinal, vein, and pneumonia), which amounts to 5.71% of the total adverse events (7/123). Although the expert's statement does not mention an exact number of infections, it does imply that there are several infections reported in the primary trial, which is consistent with the data."
    },
    "20530faf-addb-47bf-896d-b9666e149223": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01439282",
        "Statement": "In total cohort 1 of the primary trial recorded 20% more adverse events than cohort 2.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted. The adverse event total percentages in cohort 1 of the primary trial (20.90%) are higher than those in cohort 2 of the primary trial (10.00%), but the statement claims that cohort 1 recorded 20% more adverse events than cohort 2, which implies that cohort 1 should have a higher percentage. Therefore, the statement contradicts the information provided in the CTRs."
    },
    "52557c9f-f771-4f31-bb71-01f87f9f5821": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00041067",
        "Secondary_id": "NCT01273896",
        "Statement": "Patients with ER positive, PR positive or HER2 positive stage 4 tumors may be eligible for the secondary trial or the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Patients with ER positive, PR positive or HER2 positive stage 4 tumors may be eligible for the secondary trial or the primary trial\" is entailed by the primary and secondary CTRs as follows:\n\n1. For the primary trial:\n   - The primary CTR includes \"HER2-positive by fluorescence in situ hybridization (FISH) or immunohistochemistry 3+ staining confirmed in the adjuvant or metastatic setting.\" HER2 positivity is a subtype of breast cancer that meets the eligibility criteria for both trials.\n   - The primary CTR also mentions \"hormone receptor status: Not specified.\" This allows for the possibility of ER and/or PR positivity, which is stated in the expert's claim.\n\n2. For the secondary trial:\n   - The secondary CTR includes \"Patients with ER and/or PR+ disease must have received prior treatment with hormonal therapy,\" but it does not specify that ER and PR status must be negative for trial eligibility. Therefore, patients with these hormone receptor types can still be eligible for the secondary trial, as stated in the expert's claim.\n\nThe expert's statement is entailed by the provided CTRs."
    },
    "11472413-533f-45f9-9aac-c46bca318aab": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00373256",
        "Statement": "Cohort 1 of the primary trial included over 200 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death, and the median PFS for this group was just under 7 and a half months.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs as follows:\n\n1. The statement mentions that Cohort 1 of the primary trial included over 200 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death. This matches the number of participants analyzed (242) and the time frame mentioned in Results 1 of the primary trial.\n\n2. The statement also mentions the median PFS for this group being just under 7 and a half months. This is directly stated in Results 1 of the primary trial as having a median PFS of 7.4 months (6.9 to 8.5).\n\nTherefore, the statement is entailed by the information in the CTRs."
    },
    "3b8f5ef2-b0bb-42e8-a165-45a2d35780e0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00191854",
        "Statement": "Patients do not need to have a Her2neu positive tumours or a measurable indicator lesion to be included in the primary trial",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the primary trial's inclusion criteria, as stated in the following passage: \"Patients had to have previously received anthracycline based regimens as a adjuvant therapy or neo-adjuvant chemotherapy and then progressed and developed metastatic disease.\" There is no condition in this CTR that necessitates the patients to have Her2neu positive tumours or measurable indicator lesions for inclusion."
    },
    "6446f085-c6b0-43ce-82ed-16d6952b549e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00880022",
        "Secondary_id": "NCT00916578",
        "Statement": "Only patients in cohort 2 of the primary trial undergo Trunk compression. However all patients in the secondary trial are treated with Trunk compression.",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nThe statement contradicts the Primary Trial's INTERVENTION section as no information indicates that only a specific cohort in the primary trial undergoes Trunk compression. Conversely, the secondary trial's INTERVENTION section specifies that all patients receive Trunk compression."
    },
    "7348c2e8-9eb5-4ed6-9a5d-bcb02a5c3a0a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01104584",
        "Statement": "the primary trial participants receive either 50mg/m2 trastuzumab, Tamoxifen or Exemestane.",
        "Label": "Contradiction",
        "explain": "The statement contradicts the primary trial Intervention section as it mentions treatments (Tamoxifen and Exemestane) that are not explicitly stated in the description provided. The CTR only mentions a comparison between CMRM and UMRM. No specific information about the type or dosage of treatments for each arm is given."
    },
    "db90c9d8-b289-48e2-a7df-f41620b3feab": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00110084",
        "Secondary_id": "NCT01961544",
        "Statement": "the primary trial and the secondary trial both reported cases of sepsis in their patients.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTRs. The primary trial reported one case (1/50, 2.00%) of sepsis, and the secondary trial reported one case (1/101, 0.99%) of pseudomonal sepsis. Even though the labels of the specific types of sepsis may differ, the statement's general claim about sepsis occurring in both trials aligns with the data presented."
    },
    "f2533676-1e72-444e-8aef-1fa826ceb804": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01419197",
        "Statement": "There are no cases of agranulocytosis in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the primary trial data in the Adverse Events section where there is 1 case (0.25%) of granulocytopenia, which is a form of granulocyte deficiency, but the term \"agranulocytosis\" refers specifically to severe granulocytopenia with a complete absence of granulocytes in the blood. Therefore, the statement is incorrect."
    },
    "c15309b3-eb08-4d46-94ef-e4a504a111db": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03708393",
        "Secondary_id": "NCT03456427",
        "Statement": "The intervention in the primary trial is carried out by either a doctor, radiographer or a sonographer, whereas one of the interventions in the secondary trial requires active participation from the patient.",
        "Label": "Entailment",
        "explain": "The provided statement is not directly entailed by the provided CTRs. The statement asserts that in the primary trial, the intervention is carried out by a doctor, radiographer or a sonographer. However, the CTRs only specify that the procedures are carried out using IUS alone or with OA and PAC or TC Compression, but they do not mention who performs these procedures explicitly. In the secondary trial, it is stated that the patient assists in the compression process for the PAC intervention. This does not mean that the patient performs the entire procedure; rather, they participate only in the compression aspect of the intervention. Therefore, the statement does not contradict the information in the CTRs, but it is not explicitly stated either."
    },
    "4885cd77-628c-4b8f-8345-6bce2165938c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02964234",
        "Secondary_id": "NCT00246090",
        "Statement": "Patients eligible for the primary trial and the secondary trial must live in the USA.",
        "Label": "Contradiction",
        "explain": "Contradicted. The inclusion criteria for the primary trial specify that patients must reside in specific neighborhoods in Chicago and its surrounding areas, and there is no mention of the patients' nationality or country of residence. In contrast, there is no such restriction in the secondary trial inclusion criteria."
    },
    "8809cc5e-36d5-4f7e-b06d-b1915a421f71": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00759785",
        "Statement": "Only one adverse event, a Breast abscess, is observed in patients from cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The CTR for the primary trial reports no occurrence of breast abscesses in either cohort (Adverse Events 1 and 2), whereas the statement asserts the presence of one case in cohort 1."
    },
    "f0f7241c-0c2d-47cb-8b42-6e5d7494b2b1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00908791",
        "Secondary_id": "NCT00297596",
        "Statement": "Female patients over the age of 60, with Histologically confirmed breast cancer and advanced Alzheimer's disease are ineligible for both the secondary trial and the primary trial, unless they have an ECOG>2.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by both CTRs. In the primary trial, there is no mention of age or Alzheimer's disease as exclusion criteria. In the secondary trial, the inclusion criteria state that patients with dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol are excluded. However, there is no mention of Alzheimer's disease specifically, only dementia. Therefore, the statement is contradicted as stated because it extends the exclusion criterion beyond what is specified in the CTRs."
    },
    "ca27db58-14c4-4889-95b1-69be9c10a07a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623233",
        "Secondary_id": "NCT01525589",
        "Statement": "More patients with a Low Platelet Count where found in the primary trial than in the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"More patients with a Low Platelet Count were found in the primary trial than in the secondary trial\" cannot be directly entailed or contradicted from the provided CTR data. \n\nThe primary trial reports 1/52 (1.92%) incidence of Thrombocytopenia, a condition characterized by low platelet count. The secondary trial reports 6/54 (11.11%) incidence of Thrombocytopenia. At first glance, it appears that there are more patients with low platelet counts in the secondary trial. However, it is crucial to consider that the total number of participants in each trial differs. The primary trial involved 52 participants, whereas the secondary trial had 54 participants. Therefore, without information about the baseline characteristics of the patient populations or the statistical significance of these differences, it is impossible to determine whether the statement is entailed or contradicted based on the available CTR data alone.\n\nIf more context about patient populations, including their baseline platelet count distributions, were provided, it could potentially help determine the validity of the expert's statement."
    },
    "5147b171-b5dc-46d6-a153-1a6d9a062ef1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03190083",
        "Statement": "All cancer stages are accepted for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the Primary Trial's Inclusion Criteria, which specifies \"New diagnosis of breast cancer\" and \"New diagnosis if a previous breast cancer patient with negative surgical margins.\" The expert's statement \"All cancer stages are accepted\" goes beyond the scope of the stated inclusion criteria, which only accepts patients with new diagnoses of breast cancer or breast cancer patients with negative surgical margins."
    },
    "a5ed3500-1ea1-40b6-b1cb-3d5ae776f713": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656669",
        "Statement": "the primary trial did not record any adverse events.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the provided CTR data. Both primary and secondary trials indicate that there were no adverse events recorded in the primary trial, as evidenced by the \"Total\" rows reporting \"0/23 (0.00%)\" for each trial. The statement made by the clinical trial expert accurately reflects this information."
    },
    "3c482d5e-bfad-4a46-9e98-ba9967f2d900": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00903162",
        "Secondary_id": "NCT01674062",
        "Statement": "Patients with BCC are excluded from the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the Primary CTR as BCC (basal cell carcinoma) is not listed in the Exclusion Criteria for that trial."
    },
    "48ccd744-abf1-4e98-bc86-8ecd625e6279": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00654836",
        "Statement": "Patients with metastatic HER-2-negative adenocarcinoma of the breast may be eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR since it allows inclusion of patients with metastatic HER-2-negative breast cancer (disease characteristics section)."
    },
    "dce5d9c8-7da6-4732-b969-c492c876cdca": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Statement": "Women of any age can participate in the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted\n\nJustification:\nThe primary CTR's inclusion criteria clearly state that the trial includes women with locally advanced, recurrent, or metastatic breast cancer, which implies a certain age restriction due to the advanced nature of the disease. No age restriction is mentioned in the statement, making it contradictory to the provided information in the CTR."
    },
    "1882de62-2df2-4b73-a3d2-81811f85f661": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "2% of the primary trial patients were diagnosed with Fatty Liver Disease after 3 years of Treatment with Chemotherapy or Maintenance Therapy.",
        "Label": "Contradiction",
        "explain": "The statement is not directly entailed by the given CTR data, but it may be possible to derive it from the data with additional information. The provided CTR does not mention the incidence of Fatty Liver Disease among participants, and there is no information on how many patients in each arm received a diagnosis of Fatty Liver Disease. However, the statement is not contradictory to the CTR, as it falls within the 3-year time frame for follow-up and mentions the treatments administered in the trial.\n\nTo determine if the statement is entailed, further investigation is necessary, such as examining the CTRs' full text for mentions of Fatty Liver Disease or consulting other sources for incidence rates. Additionally, the percentage range (2%) in the statement does not match the percentage reported in the CTR (92.2-99.5 for participants analyzed), which may require clarification or correction before making an entailment judgment.\n\nTherefore, the statement is neither directly entailed nor contradicted by the given CTR data. It requires additional information or clarification to make a definitive determination."
    },
    "161c852e-a42c-47c2-ab6a-2b7bd6a4b934": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Statement": "Patients wanting to participate in the primary trial, must discontinue any Antitumoral hormonal treatment, and must have a life expectancy of more than 3 months.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the Primary Trial's Inclusion Criteria as it requires participants to have antitumoral hormonal treatment discontinued prior to enrollment and to have an estimated life expectancy of at least 3 months. (Primary Trial: Inclusion Criteria, Antitumoral hormonal treatment must be discontinued prior to enrollment, and Estimated life expectancy of at least 3 months.)"
    },
    "eb152d1b-a0d6-428c-8d1d-eb5d862a8147": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01120184",
        "Statement": "At least 1 patient in cohort 1 of the primary trial suffered from a Hemophilia, a rare coagulation disorder.",
        "Label": "Contradiction",
        "explain": "The statement should not be directly entailed by the provided CTRs, as there is no mention of any patient with Hemophilia in either the primary or secondary trials. To make such a determination, additional information beyond the given CTRs would be required."
    },
    "0701ac32-45b3-4199-aa20-a71080ce9bf6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00546156",
        "Secondary_id": "NCT00398567",
        "Statement": "There are no cases of Vertigo in the primary trial or the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs. \n\nJustification: \n\nThe statement \"There are no cases of Vertigo in the primary trial or the secondary trial\" is consistent with both the given CTRs as neither of them report any instance of Vertigo in their Adverse Events sections."
    },
    "866876f5-68de-44bd-b58a-e4b590aa4b39": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03573804",
        "Secondary_id": "NCT02781051",
        "Statement": "Participants of the primary trial must undergo at least one MRI during the intervention, in the secondary trial patients must use a fitbit.",
        "Label": "Entailment",
        "explain": "The statement is not directly entailed by the provided information in the CTRs. The primary trial mentions two groups undergoing MRI evaluations by different radiologists, but it does not specify whether this is done as part of the intervention or not. The secondary trial describes a physical activity intervention with the use of a Fitbit, but it does not mention any MRI scans. Therefore, there is no clear entailment relationship between the statements and the CTRs based on the given information."
    },
    "b4304362-1cb4-4606-9de4-03935ad509f1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00370552",
        "Statement": "There 55 more Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) in cohort 2 of the primary trial than in cohort 1.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the information in the CTRs. \n\nJustification: \n\nThe primary trial Results 1 and Results 2 provide the percentage of participants with best tumor response of partial response (PR) or complete response (CR) for two different arms/groups of the trial (Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg and Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg). The percentage of participants in Results 1 is 47.8 (32.9 to 63.1) and in Results 2 is 71.1 (55.7 to 83.6). The difference between the percentages does not equal 55 more for one cohort over the other."
    },
    "9cddd86a-4340-4918-b000-7e6e593a3f7f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03097653",
        "Secondary_id": "NCT00662129",
        "Statement": "Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial\" is contradicted by the CTRs provided. Neither CTR mentions any age restriction related to stable angina.\n\nPrimary Trial Inclusion Criteria: \n- Women aged 45-69\n- New invited women in mammography screening programme\n\nSecondary Trial Disease Characteristics: \n- No specific age restriction mentioned related to stable angina\n\nTherefore, based on the information provided in the CTRs, the statement contradicts the eligibility criteria for the trials."
    },
    "c3f01101-2259-4677-add1-1b1f48a0202b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00528567",
        "Secondary_id": "NCT01196052",
        "Statement": "The total number of patients affected by adverse events in cohort 2 the primary trial is more than 1000.",
        "Label": "Contradiction",
        "explain": "Contradicted\n\nJustification:\nThe total number of patients with adverse events in the primary trial's cohort 2 is 15, as per the provided CTR, which is far less than 1000."
    },
    "33b827a0-ada5-4204-abb8-d5239ea16f0b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00143390",
        "Statement": "In the primary trial There was less than 3 days difference between the maximum recorded TTP of the Exemestane group and the Anastrozole group.",
        "Label": "Entailment",
        "explain": "The statement should be contradicted. Based on the CTR information provided, the median TTP for the Exemestane group was 13.8 (10.8-16.5) months, and for the Anastrozole group was 11.1 (10.8-16.6) months. The difference between the two medians is approximately 2.7 months. This is more than 3 days, so the statement is incorrect."
    },
    "40f1d3ce-2ff8-4177-9b11-0bf10b7f6591": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00259090",
        "Statement": "the primary trial studies the impact of Fulvestrant, Anastrozole on Oestrogen Receptor H-score.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs as both trials explicitly investigate the effects of Fulvestrant and Anastrozole on the Oestrogen Receptor H-score. Therefore, the statement correctly reflects the contents of the CTRs."
    },
    "22bff413-a1bd-419b-b19b-2157dedc9948": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00802945",
        "Secondary_id": "NCT01231659",
        "Statement": "Group 1 of the secondary trial has a higher ORR than both the NKTR-102 14 Day cohort of the primary trial and the NKTR-102 21 Days cohort.",
        "Label": "Entailment",
        "explain": "The statement can be contradicted based on the provided CTRs. \n\nJustification:\n\nThe ORR in the secondary trial was defined differently than in the primary trial. In the secondary trial, ORR was defined as the proportion of patients with a complete or partial response according to RECIST 1.0 for target lesions and assessed by CT. In contrast, in the primary trial, ORR was based on MRI assessment and defined as the proportion of subjects with a complete response or partial response based on RECIST v1.0. Furthermore, in the primary trial, the time frame for assessing ORR was up to 2 years, while in the secondary trial it was from the date of randomization until the first documented disease progression or death, assessed for approximately 15 months. \n\nGiven these differences, a direct comparison of ORR between the primary trial and secondary trial may not be appropriate due to the differing definition and time frames. Moreover, the statement compares the ORR in the secondary trial with the ORR in each cohort of the primary trial, without providing the ORR data for each cohort in the primary trial. Thus, it is impossible to make a definitive comparison based on the available information.\n\nTherefore, the statement cannot be entailed based on the provided CTRs."
    },
    "b64d6e41-7ec7-4e62-beda-c28559a6cee7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00880022",
        "Statement": "Only patients in cohort 2 of the primary trial undergo Trunk compression.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the information in the CTR. In the primary trial, there is no mention of trunk compression being exclusive to cohort 2 for either intervention 1 or intervention 2. Therefore, the statement does not follow from the provided CTR data."
    },
    "2ea80a50-0db3-4ff2-8ca0-71eb048649f7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01875367",
        "Statement": "More than 3 patients in the primary trial had a common cold.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the data in both Adverse Events 1 and Adverse Events 2 of the provided CTRs, as no cases of a common cold are reported in either trial."
    },
    "20545360-b2a1-4be9-997a-97040866b239": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00880464",
        "Secondary_id": "NCT00458237",
        "Statement": "Patients with AIDS are eligible for both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by both CTRs. \n\nJustification:\n\nIn the primary CTR, HIV infection is listed as an exclusion criterion. (ELIGIBILITY CRITERIA section).\n\nIn the secondary CTR, HIV positive patients are explicitly mentioned as being excluded. (Exclusion Criteria)."
    },
    "3b1bdc19-62cd-4ff1-9e30-424e124342f3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02425891",
        "Secondary_id": "NCT00593827",
        "Statement": "the secondary trial and the primary trial both measure PFS of their patient cohorts and use the same time frame.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the information in the Clinical Trial Reports (CTRs). Both trials measure Progression Free Survival (PFS) in their respective patient cohorts. In the primary trial, PFS is measured using the time to disease progression or death from any cause, while in the secondary trial, PFS at 6 months is measured as the proportion of participants who did not progress or die within 6 months. Despite the different measures used, both trials use the same time frame from the date of randomization."
    },
    "a44cd0d1-92b3-4add-badf-b8dd5a324138": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Secondary_id": "NCT01446159",
        "Statement": "the primary trial recorded one patient with congestive heart failure, the secondary trial did not record any.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary trial recorded 1/30 (3.33%) cases of congestive heart failure while the secondary trial recorded 0/3 (0.00%) cases. The statement asserts a difference between the primary and secondary trials, whereas the CTRs provide contradictory information."
    },
    "291bb67e-f02f-49d4-b967-29cc9f5098c4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01738438",
        "Secondary_id": "NCT00331552",
        "Statement": "Cyclophosphamide, Cabozantinib and Trastuzumab were used in the secondary trial intervention, but not in the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. In the primary trial, only Cabozantinib was used, while in the secondary trial, Cyclophosphamide, Cabozantinib, and Trastuzumab were used. This discrepancy contradicts the expert's statement claiming that these medications were not used in the primary trial."
    },
    "55704a1f-eab2-44ea-a6de-8df508a28066": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274768",
        "Secondary_id": "NCT00654836",
        "Statement": "Patients with stage 4 cancer are eligible for the secondary trial and the primary trial.",
        "Label": "Entailment",
        "explain": "The statement should be contradicted. \n\nJustifications: \n\nPatients with stage 4 cancer are eligible for the secondary trial, according to its disease characteristics (histologically or cytologically confirmed primary adenocarcinoma of the breast with measurable disease and metastatic involvement), but they are ineligible for the primary trial due to the following exclusion criteria: (1) Evidence of metastatic involvement (stage IV disease) and (2) Prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to fluorouracil or known dihydropyrimidine dehydrogenase deficiency. Therefore, the statement contradicts the information provided in the two CTRs."
    },
    "6e1955b8-e6fa-42b2-a498-7ada9e733304": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01593020",
        "Secondary_id": "NCT00834678",
        "Statement": "Patients with aspartate aminotransferase more than 3 times the upper limit of normal are excluded from both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by both CTRs as both trials explicitly exclude patients with ALT (aspartate aminotransferase) more than 2.5 times the upper limit of normal (ULN) in their inclusion criteria (Primary Trial: ALT > 2.5 x ULN, Secondary Trial: ALT > 2.5 x ULN with 5 x ULN in presence of liver metastases). The statement extends this exclusion criterion to a more restrictive one by specifying ALT more than 3 times the ULN. Since the statement does not contradict any information in the CTRs and is a more restrictive version of the existing exclusion criteria, it is entailed by both reports."
    },
    "52337e14-7f51-40c1-b965-fb6aba8ae4e7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00821886",
        "Statement": "Patients prescribed with bisoprolol or labetalol to treat CHF are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Patients prescribed with bisoprolol or labetalol to treat CHF are eligible for the primary trial\" is contradicted by the CTR's exclusion criteria. Specifically, under Cardiac disease or cardiac risk factors, the CTR excludes participants with \"any documented myocardial infarction within the previous 6 months\" and \"clinically significant valvular heart disease.\" Bisoprolol and labetalol are commonly used to manage heart failure and hypertension, which may include a history of myocardial infarction or valvular heart disease, making them ineligible for the trial based on the provided exclusion criteria."
    },
    "8a6397e9-84cd-4a2e-ac6a-b56ee355d862": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00004092",
        "Statement": "Patients with Cancer that has spread from a breast tumor to their CNS are able to take part in the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The statement contradicts the eligibility criteria of the primary trial, which explicitly states \"No CNS metastasis.\""
    },
    "8b5f946c-71d9-42cd-aa9a-1d3a4845c460": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01401959",
        "Secondary_id": "NCT00852930",
        "Statement": "the primary trial designates specific interventions to its patients depending on their hormone status, Cohort A is TNBC patients and cohort B is ER/PR +HER2- BC Patients, in contrast the secondary trial assigns interventions randomly.",
        "Label": "Entailment",
        "explain": "The statement should be contradicted. \n\nExplanation: \n\nThe primary trial assigns interventions based on the hormone status of the patients, with distinct cohorts for triple-negative breast cancer (TNBC) and hormone receptor positive/human epidermal growth factor receptor 2 negative (ER/PR+, HER2-) breast cancer patients. In contrast, the secondary trial mentions that interventions are assigned randomly without regard to the hormone status of the patients. However, there is no information provided in the descriptions about the methods used to assign interventions in the secondary trial, and the statement only makes a comparison based on the given information. To establish entailment or contradiction, it would be necessary to have additional context or information from the CTRs that confirms the randomized assignment of interventions in the secondary trial, which is not provided in the statement."
    },
    "8f0aff7f-0d9e-498b-bcb6-05e6d309724c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01118624",
        "Statement": "the secondary trial administers placebo tablets at twice the rate of the primary trial, but less than half the dose.",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nIn the primary trial, Tomosynthesis Breast Scanning and breast CT Scanning are mentioned as interventions. In the secondary trial, Pralatrexate is mentioned as the study drug with a dosage of 190 mg/m^2 for 2 to 4 weeks. The statement provided by the clinical trial expert suggests that the secondary trial administers placebo tablets at a higher rate than the primary trial but with a lower dose. However, neither the primary nor the secondary trials mention any information regarding placebo administration or the dose being less than half of the dosage administered in the primary trial. Therefore, the statement contradicts the provided CTR descriptions."
    },
    "b7936bbc-f0c0-444c-a199-2db323c30396": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00313170",
        "Secondary_id": "NCT00305448",
        "Statement": "Patients in the primary trial treated with Fulvestrant 250 mg had a 33% higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided CTRs. \n\nJustification: \n\nThe statement asserts that patients in the primary trial treated with Fulvestrant 250 mg had a 33% higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose. However, according to the CTR data, the percentage of patients with Objective response (OR) in the Fulvestrant 250 mg arm was 8.5% (2.4 to 20.4%) and in the Fulvestrant 250 mg + Loading Dose arm was 5.9% (1.2 to 16.2%). This indicates that the ORR was actually lower in the Fulvestrant 250 mg arm compared to the Fulvestrant 250 mg + Loading Dose arm, not higher as asserted in the expert statement. Thus, the statement contradicts the information in the CTRs."
    },
    "6d6625ec-26b7-4157-a38c-87c770201323": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01373671",
        "Secondary_id": "NCT00686127",
        "Statement": "Lidoderm products are used in intervention arm 1 of the secondary trial, and a Siemens product is used in arm 1 of the primary trial",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs.\n\nJustification:\nIn the primary trial, Intervention 1 utilizes \"FFDM and DBT\" on a Siemens MAMMOMAT Inspiration system. \"FFDM\" stands for Full-Field Digital Mammography, which is a type of medical imaging technology. \"DBT\" refers to Digital Breast Tomosynthesis, another imaging modality. While the specific product used for DBT is not explicitly mentioned in the CTR, the Siemens MAMMOMAT Inspiration system is identified as the device used for both FFDM and DBT.\n\nIn the secondary trial, Intervention 1 involves the application of \"Lidocaine patch.\" Lidoderm is a commercially available lidocaine patch product manufactured by Endo Pharmaceuticals Inc. There is no mention of the device or system used in this trial, as it's likely that no imaging modality is involved since the intervention is described as topical application.\n\nThe statement asserts that Lidoderm products are used in intervention arm 1 of the secondary trial, and a Siemens product is used in arm 1 of the primary trial. While the specific Lidocaine product used in the secondary trial and the Siemens product used in the primary trial belong to different medical domains (imaging vs topical application), the statement correctly describes the use of Siemens in the primary trial and Lidoderm in the secondary trial in their respective intervention arms. Therefore, the statement is entailed by the provided CTRs."
    },
    "e8b8c2b7-612d-4bab-b8a6-3dbc756cc210": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01305941",
        "Statement": "Patients must present IHC 3+ or FISH amplified results to participate in the primary trial, meaning their cancer is Histologically-confirmed as being triple-positive.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed by the CTR. The inclusion criteria for the primary trial clearly state that patients must have Histologically-confirmed HER2-positive breast cancer, which can be confirmed through IHC 3+ or FISH amplification. Therefore, patients with triple-positive breast cancer (HER2-positive, estrogen receptor positive, and progesterone receptor positive) would meet this requirement. However, it's important to note that the CTR doesn't explicitly state that the cancer needs to be triple-positive, only that it must be HER2-positive. Therefore, patients with HER2-positive but not triple-positive tumors could still meet the inclusion criteria based on the information provided in the CTR."
    },
    "7e0259a3-073b-45f5-8e08-2cfaceecef0b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00606931",
        "Statement": "the primary trial tests MRI scanning as a technique for guiding biopsies.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the CTR description in thePrimary Trial Intervention section, where it is explicitly stated that PET guided biopsy was used instead of MRI scanning for guidance."
    },
    "c94ad26b-1f5e-4446-a4fe-bb949c5dc561": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Secondary_id": "NCT00662025",
        "Statement": "Patients must have BUN < 20 mg/dL,  Platelet count: <90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 to be eligible for either the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by both CTRs. \n\nPrimary Trial: The inclusion criteria state that Creatinine: within a normal upper value in the institution (imlying a BUN within normal range) and Platelet count: <100,000/mm3 or more and Neutrophils: >2,000/mm3 or more. Leukocyte count is included in the inclusion criteria, but it is specified with a broader range than what the statement suggests.\n\nSecondary Trial: The statement mentions BUN < 20 mg/dL and Platelet count: <90,000/mm3, while the CTR only provides a requirement for creatinine within a normal upper value in the institution, which implies BUN within normal range. Leukocyte count is not explicitly stated in the secondary CTR.\n\nHence, the statement is contradicted by both CTRs as the inclusion criteria differ significantly."
    },
    "4e31e4f8-a6da-49fc-8bfe-1309674ec2ee": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00244881",
        "Statement": "30% of the primary trial participants had an increased level of CECs after 42 days of treatment.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary CTR. The primary CTR reports that \"30%\" of the participants in the treatment arm had increased levels of circulating endothelial cells after \"42 days of treatment\". The expert's statement matches the data exactly. No contradiction is detected."
    },
    "5c00f992-5066-42f2-88d7-566b8b9104b5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00089661",
        "Statement": "On average cohort 1 participants in the primary trial had an increased Rate of Acute Toxicity , whereas those in cohort 2  did not experience any Acute Toxicities.",
        "Label": "Contradiction",
        "explain": "The statement \"On average cohort 1 participants in the primary trial had an increased Rate of Acute Toxicity, whereas those in cohort 2 did not experience any Acute Toxicities\" cannot be entailed based on the given CTRs.\n\nThe CTRs provided focus on Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 as the outcome measure and do not include information about acute toxicities or the number of participants experiencing them. The statement makes a claim about acute toxicities in the two cohorts which is not directly related to the outcome measures or results presented in the CTRs."
    },
    "4c0ffc50-5cb2-4574-b954-335d142edbe4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01527487",
        "Statement": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The stated claim is contradicted by the information in the primary trial's exclusion criteria. Specifically, patients with any of the following conditions are not eligible for the primary trial:\n\n- Hormonal agents such as raloxifene, tamoxifen or other selective estrogen receptor modulator (SERM) use, with the exception of GNRH agonists for the purpose of fertility preservation or suppression of heavy menses. (Section 4.5.3, Item 9). \n\nHowever, Citalopram is not mentioned in the list of excluded hormonal agents. Thus, the claim that patients prescribed Citalopram for depression are not eligible for the primary trial is incorrect."
    },
    "4e3379b9-f971-4ab6-8846-c395f1162bf2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00810797",
        "Secondary_id": "NCT00828074",
        "Statement": "Skin infections were more common in patients in cohort 1 of the secondary trial, than in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nJustification: \n\nThe statement \"Skin infections were more common in patients in cohort 1 of the secondary trial, than in cohort 1 of the primary trial\" is contradicted by the data presented in the Adverse Events sections of the provided CTRs. In the primary trial, there was 1 instance of Skin infection in cohort 1 out of 36 patients, resulting in a rate of 2.78%. In contrast, in the secondary trial, there were 2 instances of Skin infection in cohort 1 out of 41 patients, resulting in a rate of 4.88%. However, the rate in cohort 1 of the secondary trial is lower than that in the primary trial, contrary to the claim in the statement."
    },
    "9872394c-18b7-4f88-849e-0e2831e6ebf0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00579826",
        "Statement": "Participants of the primary trial cannot be currently receiving for treatment rheumatoid arthritis, experiencing poorly controlled migraines, receiving hormone replacement therapy or have any prior history of invasive breast cancer in the last 3 years.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. \n\nThe primary trial inclusion criteria state that participants cannot have a current history of rheumatoid arthritis or fibromyalgia. The secondary trial statement also includes this requirement. \n\nThe primary trial exclusion criteria state that participants cannot have a current history of poorly controlled migraines or perimenopausal symptoms. The secondary trial statement also includes the requirement that participants cannot be experiencing poorly controlled migraines. \n\nRegarding hormone replacement therapy and invasive breast cancer, the primary trial inclusion criteria state that participants must be on a stable dose of hormone replacement therapy and have cytomorphologic evidence of hyperplasia +/- atypia and Ki-67 expression >1.5% in benign breast epithelial cells acquired by RPFNA, but they cannot have a prior history of invasive breast cancer or other invasive cancer within five years from the date of study entry. The secondary trial statement also includes the requirement that participants cannot have any prior history of invasive breast cancer in the last 3 years, which is more restrictive than the primary trial's 5-year limit. However, since the primary trial's inclusion criteria already exclude participants with a history of invasive breast cancer, the secondary trial statement does not contradict the primary trial's information and is still entailed.\n\nTherefore, the secondary statement is entailed by both CTRs."
    },
    "adf3bb50-ec36-467a-987a-f33c10380c60": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01771666",
        "Secondary_id": "NCT01256567",
        "Statement": "Japanese participants with an ECOG of 2 are eligible for the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Japanese participants with an ECOG of 2 are eligible for the secondary trial and the primary trial\" is contradicted by the information presented in the CTRs. According to the primary CTR, the inclusion criteria specify that participants should have an ECOG or Karnofsky Performance Status of 0,1, or 2. In the secondary CTR, the inclusion criteria also require an ECOG performance status of 0 or 1. However, the statement goes further by suggesting that Japanese participants with an ECOG of 2 are eligible for both trials, which is not the case according to the CTRs."
    },
    "2ef37a06-a1ed-47eb-b8f4-2f97f46293d1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01875367",
        "Statement": "One patient in the primary trial suffered a cerebral infarction.",
        "Label": "Entailment",
        "explain": "The given statement does not contradict the provided CTRs, as there is no cerebral infarction mentioned in the Adverse Events sections of either trial. However, the statement does not entail any information from the CTRs either, as it refers to only one patient experience, while the CTRs provide aggregated data for all patients in the trials."
    },
    "03cb39e4-1d21-47e5-9b09-ebe508eb2a17": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00477464",
        "Statement": "59 patients from Arm A of the primary trial achieved a best overall response, classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the information in the CTR for the following reasons:\n\n1. The statement mentions that 59 patients from Arm A achieved a best overall response, which is consistent with the definition of Clinical Benefit Response (CBR) in the CTR (percentage of participants who achieved a best overall response classified as a complete or partial response or stable disease for at least 6 months).\n2. The CTR states that the overall number of participants analyzed in Arm A (Lapatinib 1250 mg and Capecitabine 2000 mg/m^2) was 51. The fact that 59 patients achieved a best overall response means that at least 51% of the participants in this arm experienced this outcome (given that there is at least one patient with a best overall response), which is in agreement with the measurement unit mentioned in the CTR (percentage of participants).\n3. The time frame for assessing CBR in the primary trial (every 6 weeks until Week 24 and then every 12 weeks until disease progression) is long enough for participants to potentially achieve a response lasting for at least 6 months.\n\nTherefore, based on the information provided, the statement is entailed by the CTR."
    },
    "dca6ba74-441e-482f-b667-6c45800ed8c1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00425672",
        "Statement": "Patients receiving intervention 1 of the primary trial must undergo a 21 day treatment cycle, for a total of 6 courses, unless death occurs .",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTR of the primary trial, specifically the information provided under INTERVENTION 1, which states that patients receive ONTAK IV over 1 hour on days 1-5 and treatment repeats every 21 days for up to 6 courses. The statement by the clinical trial expert is consistent with this information. The condition of the statement (\"unless death occurs\") does not contradict the CTR as it does not alter the number of treatment courses."
    },
    "aeecc244-13a9-4944-858e-27ef49585e90": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01702571",
        "Statement": "Patients with incurable and  unresectable Locally Advanced Breast Cancer are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR as the inclusion criteria for the primary trial explicitly state that patients must have incurable and unresectable Locally Advanced Breast Cancer."
    },
    "741ca5eb-4737-4a35-a9fd-4235d6552b4f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01256008",
        "Secondary_id": "NCT00300781",
        "Statement": "the primary trial is investigating Cognitive behavioural therapy, a type of psychotherapy, in contrast the secondary trial studies Neratinib, a type of chemotherapy.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the CTRs. In the primary trial, Intervention 1 specifies that the group will receive \"clinical management,\" which is described as a \"clear contrast method of psychological therapy\" that includes elements such as introducing knowledge about cancer and depression and encouraging adherence to treatment. In contrast, Intervention 2 in the secondary trial refers to the use of \"Neratinib,\" which is a type of chemotherapy and not a psychological therapy. Therefore, the statement accurately reflects the differences in the interventions between the two trials."
    },
    "b8e0458c-b834-42b5-b5fd-8791f89b0853": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01881230",
        "Statement": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group",
        "Label": "Entailment",
        "explain": "The statement \"The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group\" is entailed based on the information provided in the CTRs. \n\nJustification: \nFrom the primary trial's results, we can find the median PFS for Arm A (Gemcitabine group) is 5.5 months (4.1 to 7.0), and for Arm B (Carboplatin group), it is 8.3 months (5.7 to 10.6). The difference between the two is more than 2 months, as stated in the expert's claim.\n\nAdditionally, no information contradicting the statement is present in the CTRs."
    },
    "1a112ed3-8318-493b-8973-10de01794892": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00382018",
        "Secondary_id": "NCT03012477",
        "Statement": "Between the patients in the primary trial and the secondary trial, only a single one suffered from sepsis.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the CTRs. The secondary trial had one patient (1/34) suffering from sepsis, whereas the primary trial had no patients (0/161) experiencing sepsis. This difference supports the statement that only a single patient in both trials suffered from sepsis."
    },
    "6044590d-0f89-4a6e-8be7-54ca0c0327d9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00003404",
        "Secondary_id": "NCT00711529",
        "Statement": "the primary trial does not have a Hypnotherapy based intervention, and the secondary trial does not have a Radiotherapy intervention.",
        "Label": "Entailment",
        "explain": "Contradicted\n\nExplanation:\n\nThe statement asserts that neither the primary nor the secondary trial includes interventions based on hypnotherapy or radiotherapy as stated in the given CTR sections. However, the primary trial explicitly mentions the use of \"Adjuvant Radiotherapy\" as intervention 1, whereas the secondary trial mentions \"Hypnotherapy\" as intervention 1 and \"Gabapentin\" as intervention 2. The statement's content contradicts the provided clinical trial information."
    },
    "8d3378f7-caaf-4654-b12a-382a0e911eb1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02429427",
        "Statement": "Patients with a platelet count of 50 x 109/l are not eligible for the primary trial",
        "Label": "Entailment",
        "explain": "Contradiction. \n\nThe primary trial's inclusion criteria state that platelets must be greater than or equal to 100 x 109/l."
    },
    "f701473d-e034-4a06-9829-d20cc483162c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01516736",
        "Secondary_id": "NCT00733408",
        "Statement": "the primary trial and the secondary trial have non comparable results as the different in cohort size is too significant.",
        "Label": "Contradiction",
        "explain": "The statement can be contradicted. The non-comparability of results between the two trials stated in the expert's comment is not entailed by the provided information. The primary and secondary trials assess different outcome measures, with the first focusing on the mean duration of severe neutropenia, and the second assessing progression-free survival. The statement only addresses the difference in sample sizes and does not provide sufficient information about how this difference might influence the comparability of the results. The CTRs do not provide enough context for determining whether the differences in sample sizes could potentially impact the results."
    },
    "3889cecd-aa2d-4f58-857e-11d7209f9cf4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00450866",
        "Statement": "In the primary trial a cohort 1 has a higher percentage of patients with progression free survival at 3 months after treatment, than cohort 2. ",
        "Label": "Entailment",
        "explain": "Based on the provided information in the given CTRs, it is not entailed that cohort 1 has a higher percentage of patients with progression free survival at 3 months after treatment, than cohort 2. In fact, the CTRs do not include any data on the percentage of patients with progression free survival for either cohort. The primary trial only reports the number of participants who have progression free survival at 3 months after treatment in each group. Therefore, it is not possible to make a definitive statement about the percentage of patients in each group based on the provided data."
    },
    "19d0c9de-02ad-4a8e-937b-e9d0f0cc8051": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00338286",
        "Statement": "No participants of the primary trial had a Progression Free Survival over 1 year.",
        "Label": "Entailment",
        "explain": "Contradicted. The median Progression Free Survival for both the Standard of Care and Epoetin Alfa arms were over 1 year, with values of 7.4 months (95% CI: 7.1 to 7.6) and 7.4 months (95% CI: 6.9 to 7.6), respectively. These values indicate that a significant number of participants in both arms had a Progression Free Survival longer than 1 year."
    },
    "cb023dbc-3e99-4c32-a857-7f8d49ef5a96": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00789581",
        "Secondary_id": "NCT02445586",
        "Statement": "the secondary trial reported more cases of Haematemesis, but the primary trial had more total cases of DIASTOLIC DYSFUNCTION across both its cohorts.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the provided CTRs. In the primary trial, there was only 1 reported case of Haematemesis (in Adverse Events 1) while the secondary trial had 1 reported case (in Adverse Events 1). However, the primary trial reported a total of 3 cases of Diastolic Dysfunction across both cohorts (in Adverse Events 1), while the secondary trial had 0 reports. Therefore, the statement is incorrect.\n\nCTR references:\nPrimary Trial: Adverse Events 1\nSecondary Trial: Adverse Events 1"
    },
    "1d0ce237-70eb-45b4-9c77-f0b70d410387": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00193180",
        "Statement": "A female patient over the age of 18 suffering from Cirrhosis cannot take part in the primary trial.",
        "Label": "Entailment",
        "explain": "The given statement is contradicted by the Primary Trial's Eligibility Criteria section, as it states that \"there are no exclusion criteria for known diagnosis of HIV infection or liver disease ( Cirrhosis) mentioned explicitly. However, patients with severe or uncontrolled medical disease are excluded, but the term 'severe' is not defined in the provided information. Therefore, the statement about a female patient with cirrhosis being unable to take part in the primary trial is contradicted based on the information in the CTR."
    },
    "93290529-38b1-444b-9ac8-fa32b98821c5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00256243",
        "Secondary_id": "NCT00721630",
        "Statement": "Patients wanting to take part in the secondary trial must be at a specific location, this is not necessary for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Patients wanting to take part in the secondary trial must be at a specific location, this is not necessary for the primary trial\" is contradicted by the information in the given CTRs. In the primary trial's Eligibility Criteria section, there is no requirement mentioned for patients to be at a specific location. However, for the secondary trial, there is no such mention regarding the location of the patients. Therefore, the statement is not entailed by the information in the CTRs. Additionally, there is no location requirement mentioned for the secondary trial in the provided text."
    },
    "dad5ecc6-afcf-496c-8193-778a100c0318": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00436917",
        "Statement": "Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine, or with a prior surgery at the lumbosacral spine are excluded from the primary trial, as these constitute contraindications to spine dual energy x-ray absorptiometry (DXA).",
        "Label": "Entailment",
        "explain": "The statement should be contradicted based on the primary trial's eligibility criteria. The primary trial excludes patients with a Cobb angle > 15 degrees at the lumbar spine as a condition that would preclude the proper acquisition of a lumbar spine DXA. However, the expert's statement suggests a higher threshold of 20 degrees. Additionally, the primary trial excludes patients with a history of surgery at the lumbosacral spine, but the expert's statement mentions surgery specifically. The CTR's eligibility criteria do not match the expert's statement in these aspects."
    },
    "d0efe29c-1d76-4129-9cf5-2955564d1370": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00976989",
        "Statement": "Patients with LVEF greater than or equal to 60% are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the CTRs' Eligibility Criteria sections, where the primary trial specifies an LVEF requirement of >/=55%, while the secondary trial proposes eligibility for LVEF >/=60%."
    },
    "63ec91be-7e12-431e-84b0-ca401bfb157b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Secondary_id": "NCT02502864",
        "Statement": "the primary trial recorded 2.38% more total adverse events than the secondary trial",
        "Label": "Entailment",
        "explain": "Contradiction. \n\nThe primary trial reported a total of 5/14 (35.71%) adverse events, while the secondary trial reported a total of 3/9 (33.33%). The difference in the total adverse event rates is 2.48% (35.71% - 33.23%), which is greater than the stated 2.38%. Therefore, the statement is contradicted by the data provided in the primary and secondary CTRs."
    },
    "fd5af11f-7270-49d5-924a-755ff399c463": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00373256",
        "Statement": "Cohort 1 of the primary trial included 250 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death, and the mean PFS for this group was just under 7 and a half months.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed by the CTRs. In the Primary Trial Results 1, it is mentioned that the time frame for measuring PFS is from date of randomization through Day 1 and every 8 weeks thereafter up to 18 months or death. The statement specifies a duration of 18 months or until death for Cohort 1 being treated with Sunitinib and Paclitaxel. Furthermore, the median PFS for this cohort in the Results 1 is 7.4 months. The statement reports a mean PFS, which is a descriptive statistic that is similar to the median and lies close to it. Therefore, the mean being just under 7 and a half months aligns with the given median, and the statement's value falls within the 95% Confidence Interval of the median reported in the CTR."
    },
    "f07e932e-1d79-4e1f-9ac2-ed9e2db1c276": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02186015",
        "Statement": "Women in cohort B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the CTR.\n\nJustification: \n\nIn the primary trial, Intervention 2 specifies that women with a serum 25 (OH)D concentration greater than or equal to 30 ng/ml received no intervention, which aligns with the statement made by the expert that women in cohort B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol."
    },
    "6a5ee728-7db9-4ec0-b98c-0500e9a6187e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "One patient in the primary trial had abnormally low levels of AST, ALT and ANC.",
        "Label": "Contradiction",
        "explain": "There is no clear entailment or contradiction with the provided CTR information.\n\nThe expert statement mentions \"abnormally low levels of AST, ALT and ANC,\" but the CTR does not specify which adverse events correspond to these lab findings. Therefore, we cannot directly confirm or deny the statement based on the available data.\n\nHowever, if we consider the potential connection with the mentioned lab tests in the adverse events section:\n\n1. ANC (An absolute neutrophil count, a type of white blood cell, is mentioned as having one patient below the normal limit in the primary trial.)\n2. AST (Aspartate transaminase) and ALT (Alanine aminotransferase) are markers for liver damage or injury. There is no mention of any liver-related adverse events in the CTR, but the frequency and severity of such events might not be reported due to the small sample size in this trial.\n\nIn conclusion, the expert statement is not clearly entailed or contradicted by the CTR information given. Further analysis, such as accessing additional data or speaking with the trial researchers, might be necessary for a definitive answer."
    },
    "a495df61-260d-479c-8d5f-d586f295c672": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02297412",
        "Secondary_id": "NCT02667626",
        "Statement": "Cohort 2 of the secondary trial and the primary trial are control groups, receiving a placebo tablet PO BID.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the information in the CTRs. \n\nJustification: \n\nIn the primary trial, Arm II patients receive a placebo PO BID, and in the secondary trial, participants in the control arm receive access to web-based resources and study adherence reminders, but they do not receive the SCPR intervention. The statement asserts that both Cohort 2 of the secondary trial and the primary trial are control groups, receiving a placebo. The primary trial's placebo group matches the description of the control in the secondary trial, as both receive a placebo or a non-intervention, making the statement entailed."
    },
    "917afeec-5152-4424-89e3-7f3ffad6378f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01105650",
        "Statement": "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than participants over 45 kg, but all participants will be administered IL-2 3 times per week for 6 doses.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs. The IL-2 dosage for participants weighing less than 45 kg is specified as 5 million units/m^2 3 times a week for 6 doses, which is 4 million units/m^2 less than the 9 million units given to participants weighing more than 45 kg. Both groups are given IL-2 3 times a week for 6 doses according to the CTRs."
    },
    "19f84eca-6bb1-4d32-a9b0-b2dd7c3f22e6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01617668",
        "Statement": "Patients must have healthy kidneys, liver and bone marrow to participate in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Patients must have healthy kidneys, liver and bone marrow to participate in the primary trial\" is entailed by the CTR, specifically the inclusion criteria which state \"Adequate renal function\", \"Adequate liver function and serum transaminases\", and \"Adequate bone marrow function\"."
    },
    "f5aa1aa3-7be3-4518-8cc5-df2394e70e96": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT01901146",
        "Statement": "Patients with undetermined estrogen receptor status can be accepted by both the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted. \n\nJustification: \n\nThe primary trial explicitly includes patients with known ER and PR hormone receptor status at study entry (CTR: Inclusion Criteria: The patient provides a written informed consent for study participation. The estimated risk of breast cancer recurrence is high (25% or higher within the first 5 years from the date of the diagnosis, over >35% within the first 10 years from the diagnosis).), while the secondary trial also requires this information for eligibility (CTR: Known estrogen receptor (ER) and progesterone receptor (PR) hormone receptor status at study entry). Therefore, patients with undetermined ER status do not meet the inclusion criteria for both trials."
    },
    "45338f7c-5aaa-40fb-8503-7c943e1f3a29": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03584009",
        "Statement": "Participants in the primary trial administered with Fulvestrant 500mg via intramuscular injection had a higher % of clinical benefit than participants who were administered an additional 800mg of Venetoclax orally.",
        "Label": "Entailment",
        "explain": "To determine if the statement is entailed or contradicted, we need to compare the clinical benefit percentage data from the two trials. However, the provided CTRs do not contain sufficient information to assess clinical benefit directly. The primary trial only defines clinical benefit according to RECIST v1.1 and does not report the specific number of participants achieving CR, PR, or SD lasting \u226524 weeks. Therefore, it is impossible to make an accurate comparison based on the provided information alone.\n\nThe statement should be neither entailed nor contradicted due to insufficient data from the CTRs."
    },
    "0964be32-f9e7-49ec-ad22-b030d483702a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429507",
        "Secondary_id": "NCT00038467",
        "Statement": "Unlike the secondary trial, the primary trial does not administer any medication orally.",
        "Label": "Entailment",
        "explain": "The statement should be entailed by the information in the CTRs. The primary trial specifies the use of Samarium 153-EDTMP through intravenous infusion and bone therapy, while the secondary trial outlines the administration of oral medications (exemestane and tamoxifen). Therefore, the statement correctly identifies a difference in medication administration routes between the two trials."
    },
    "73cfc4ea-afc0-465b-a403-c1bd771ded33": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01527487",
        "Statement": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial, as Psychological illnesses are not permitted.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial eligibility criteria do not explicitly exclude patients with psychological illnesses, such as depression. However, patients prescribed Citalopram as an ongoing treatment for depression would not meet the \"Willingness and ability to comply with trial and follow-up procedures\" requirement, as stated in the primary trial's inclusion criteria (Section 5.4.8)."
    },
    "75b67d63-9727-418d-afd5-c0fb867417b5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "Patients suffering from Ulcerative colitis are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nJustification: \n\nThe secondary trial's statement \"Patients suffering from Ulcerative colitis are excluded from the primary trial\" contradicts the Primary Trial's Inclusion Criteria which does not list Ulcerative colitis as an exclusion criterion."
    },
    "94cd9451-35a4-4035-a7de-2d385f771607": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01671319",
        "Statement": "1/42 patients in cohort 2 of the primary trial fainted.",
        "Label": "Contradiction",
        "explain": "The statement \"1/42 patients in cohort 2 of the primary trial fainted\" is entailed by the CTR information if there is a separate cohort 2 mentioned in the secondary trial with a total of 42 participants and one instance of syncope (fainting). Therefore, the entailment holds true if the statement refers to the same cohort as the syncope event described in the primary trial's adverse events section.\n\nCTR for Primary Trial, Adverse Events section: \"Syncope 1/42 (2.38%)\"\n\nThis entailment holds if cohort 2 from the secondary trial is identical to the entire cohort from the primary trial, or if it is a distinct subgroup of the primary trial cohort with the same eligibility criteria.\n\nHowever, if cohort 2 in the secondary trial has different eligibility criteria or intervention specifications compared to the primary trial, the entailment might not hold, and further investigation would be needed to determine if there is a contradiction instead.\n\nCTR for Secondary Trial: Cohort 2 specifications are not provided in the given information."
    },
    "18310f83-54ca-4530-92f1-7c41419ab69e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00068341",
        "Statement": "More patients in cohort 1 of the primary trial experienced febrile neutropenia than in cohort 2.",
        "Label": "Entailment",
        "explain": "The statement is entailed. The primary trial reports 3 instances of febrile neutropenia in cohort 1 with a total of 15 patients, whereas the secondary trial reports 2 instances of febrile neutropenia in cohort 2 with a total of 14 patients. Therefore, a higher percentage of patients in cohort 1 of the primary trial experienced febrile neutropenia."
    },
    "4fa6b99e-0e70-465d-8b24-b728979b3689": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00567190",
        "Statement": "There was the same number of anemic patinets in both cohorts of the primary trial.",
        "Label": "Entailment",
        "explain": "Contradict\n\nExplanation:\n\nThe primary CTR reports 3/396 (0.76%) anemic patients in cohort 1, while the secondary CTR reports no anemic patients in cohort of the secondary trial. Therefore, the expert's statement contradicts the provided clinical trial data."
    },
    "e0fac0a4-a5ab-4089-8986-f601586506af": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00627978",
        "Statement": "Women with leptomeningeal metastases are unfortunately excluded from the primary trial, as it would prevent them from giving informed consent to study entry.",
        "Label": "Contradiction",
        "explain": "The given statement is contradicted by the Primary Trial's Eligibility Criteria, which explicitly excludes patients with known and active brain and/or leptomeningeal metastases from participating in the study. Therefore, women with leptomeningeal metastases cannot give informed consent to study entry due to this exclusion criterion."
    },
    "85210693-996a-4ab9-92f4-62060571da21": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01847001",
        "Statement": "Spanish women with a heart rate of at most 50 beats per minute are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The inclusion criteria for the primary trial specify a heart rate greater than 60 bpm for eligibility. The statement provided indicates a maximum heart rate of 50 beats per minute for Spanish women eligible for the trial, which contradicts the information in the CTR."
    },
    "f0fbdbf4-af12-4cde-a5f1-a56cc60658f4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00148668",
        "Statement": "Cohort 1 and 2 of the primary trial recorded the same number of patients with Neutropenia.",
        "Label": "Entailment",
        "explain": "The statement \"Cohort 1 and 2 of the primary trial recorded the same number of patients with Neutropenia\" is contradicted by the provided CTR data. The number of patients with Neutropenia in Cohort 1 is 4/41 (9.76%) and in Cohort 2 it is 4/40 (10.00%). Since the number of patients with Neutropenia is not equal in both cohorts, the statement should be contradicted."
    },
    "6a37e999-4b7e-4654-b9ac-7776a0720040": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01310231",
        "Secondary_id": "NCT00093808",
        "Statement": "1 patient in the secondary trial developed an eating disorder, there were no cases of this happening in the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The secondary trial report lists one case of anorexia (an eating disorder), while there were no such cases reported in the primary trial. However, the statement does not hold because the CTRs provide different participant counts in each trial, which could lead to differing adverse event frequencies even if the actual number of cases for a specific adverse event is the same between trials. To establish entailment, the statement should compare adverse event frequencies or rates between the two trials while accounting for the different participant numbers."
    },
    "a625ff4b-9c91-4ab8-a78b-df833d15759a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00423917",
        "Secondary_id": "NCT00082641",
        "Statement": "the primary trial and the secondary trial both report cases of confusion in all their patient cohorts.",
        "Label": "Contradiction",
        "explain": "The statement \"the primary trial and the secondary trial both report cases of confusion in all their patient cohorts\" is contradicted by the provided CTRs.\n\nJustification:\nIn the primary trial, there is one case of confusion reported out of 33 participants (3.03%). In the secondary trial, there are two cases of confusion reported in total, but these cases are not distributed evenly across the two reported cohorts. One cohort has zero cases of confusion (out of 12 participants), and the other cohort has two cases (8.33%). Thus, not all cohorts in the secondary trial reported cases of confusion. Therefore, the statement is contradicted."
    },
    "b25e7c40-a1db-4ae7-9613-0f65ddb4c040": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00082641",
        "Statement": "At least one patient in the primary trial suffered from a life threatening bone fracture.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial data as no patient suffered from a life-threatening hip fracture (0/11, 0.00%)."
    },
    "25f1f3b8-15ed-4339-bf56-1cf1e0c2909f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00856492",
        "Statement": "Cohort 1 of the primary trial recorded no deaths and no cases of Anemia.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the data in Adverse Events 1 section of the Primary Trial, where 1 case of Anemia (1.04%) and 0 deaths were reported among 96 participants."
    },
    "c0ddffa9-4a88-4ee1-8525-a77e887c3d85": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01268150",
        "Statement": "The Eribulin Mesylate group in the primary trial had a higher proportion of patients with complete response (CR) or partial response (PR) than the control group.",
        "Label": "Contradiction",
        "explain": "The statement can be entailed based on the information provided in the CTRs. \n\nIn the primary trial, the ORR for the Eribulin Mesylate group was 28.6% (16/56), while the specific information about the ORR for the control group is not given. However, since ORR is defined as the sum of CR and PR, a higher ORR for the Eribulin Mesylate group implies a higher proportion of participants with CR or PR compared to the control group. Additionally, the time frame for outcome measurement is the same for both groups. Therefore, the expert's statement is in agreement with the provided clinical trial data."
    },
    "64ea58e5-e28f-42bc-818e-31bbf347080c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00129389",
        "Secondary_id": "NCT00304096",
        "Statement": "Patients with permanent sensory loss, interfering with daily activities are excluded from the primary trial, but may still be eligible for the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is not directly contradicted by the information provided in the CTRs. However, the primary trial's inclusion criteria do not mention any exclusion based on permanent sensory loss. The secondary trial does not have specific information regarding sensory loss. Therefore, the statement can be seen as making an additional allowance for patients with sensory loss in the secondary trial. It does not contradict the information in the CTRs."
    },
    "7a0f4365-9775-4f1d-a1c7-4630b41b43ea": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01905592",
        "Statement": "the primary trial only defines intervention dosage for cohort 2.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nIn the primary trial, both Intervention 1 and Intervention 2 specify that the treatments continue until progression or unacceptable toxicity occur. However, neither Intervention 1 (the physician's choice of chemotherapies) nor the CTR itself defines a specific dosage for each individual patient within the chemotherapy cohort (Intervention 1). Therefore, the statement is not entailed by the provided CTR data and is, in fact, contradicted. Only Intervention 2 in the secondary trial explicitly states a specific dosage of niraparib, which is not applicable to Intervention 1."
    },
    "64dcb690-ef14-4cf2-85e5-670eb0645d7f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01073865",
        "Statement": "Females over the age of 18, whose last period was 2 weeks prior are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nExplanation: \n\nThe statement \"Females over the age of 18, whose last period was 2 weeks prior are eligible for the primary trial\" directly contradicts the eligibility criteria specified in the CTR. According to the CTR, females must be pre-menopausal, defined as \"last menses within 1 year of randomisation,\" and have hormone sensitivity (ER positive) of primary or secondary tumour tissue. Therefore, a woman whose last period was only 2 weeks prior may still have regular menstruation and not meet the definition of pre-menopausal, and thus would not be eligible for the trial."
    },
    "cacd1b1b-510e-421b-9adb-c5715f281794": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01566721",
        "Statement": "More patients in cohort 2 of the primary trial had At Least 1 Adverse Event (AE) During the Treatment Period than in cohort 1.",
        "Label": "Contradiction",
        "explain": "To determine if the statement \"More patients in cohort 2 of the primary trial had At Least 1 Adverse Event (AE) During the Treatment Period than in cohort 1,\" is entailed or contradicted, we need to compare the percentage of participants with at least one AE between the two cohorts.\n\nThe percentage of participants with at least 1 AE in cohort 1 (SC Herceptin by needle/syringe) is 88.6, and the percentage of participants with at least 1 AE in cohort 2 (SC Herceptin by SID) is 89.0.\n\nSince the percentage of participants with at least 1 AE in cohort 2 (89.0) is higher than that in cohort 1 (88.6), the expert's statement is entailed by the data presented in the CTRs."
    },
    "c3e5a015-e8b5-4281-828c-deb1f7fc7e3a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02502864",
        "Statement": "The maximum number of occurences for an adverse event in the primary trial was 3.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided CTR data from the Primary Trial Adverse Events section. The statement specifies that the maximum number of occurrences for an adverse event was 3, which aligns with the reported 33.33% total adverse events in the trial."
    },
    "7926bfa3-cf49-4589-8143-0a0826336b67": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01401166",
        "Statement": "All patients in cohort 1 of the primary trial had a Preferred Method of Drug Administration.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nReasoning: \n\nThe statement \"All patients in cohort 1 of the primary trial had a Preferred Method of Drug Administration\" cannot be entailed from the provided CTR data, as there are participants in Cohort 1 who did not express a preference (0.0 for SC Herceptin in Cohort 1 of Results 1 and 3.4 for SC Herceptin in Cohort 1 of Results 2)."
    },
    "1e0da2b7-b91e-4b83-bcb6-7bfafff7e39b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00975676",
        "Secondary_id": "NCT00632489",
        "Statement": "the primary trial does not explicitly state the dosage of Triptorelin for either of its patient cohorts. On the other hand, the secondary trial gives details of doses used for LBH589, Capecitabine and Lapatinib.",
        "Label": "Entailment",
        "explain": "The statement is not contradicted by the provided CTR sections, but it does not entail any information about the semantic relationships between the trials as they pertain to triptorelin dosages. In the primary trial, the dosage of triptorelin is not mentioned, whereas in the secondary trial, no mention is made of triptorelin doses specifically. The statement only highlights the difference in the level of detail regarding the dosage information between the two trials. Therefore, neither entailment nor contradiction is established based on the given statement and CTR sections."
    },
    "a81e4dbe-e9cf-4f2b-b2f7-b1bf6d630c42": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00887575",
        "Secondary_id": "NCT01610284",
        "Statement": "Cohort 1 of the secondary trial had more than 50x the number of patients as cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "explain": "The given statement \"Cohort 1 of the secondary trial had more than 50x the number of patients as cohort 1 of the primary trial\" cannot be directly entailed or contradicted based on the provided CTRs data, specifically the adverse events sections, as the information does not contain details about the size of each cohort in either trial. The cohort sizes need to be examined in the main text or other sections of the CTRs to make a definitive assessment."
    },
    "36957dd8-fe28-4b70-b651-8f6ea7d1d0e9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01269346",
        "Secondary_id": "NCT01597193",
        "Statement": "Cohort 1 of the primary trial and Cohort 1 of the secondary trial  have the same total number of adverse events.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided Clinical Trial Reports (CTRs). In the primary trial, the total number of adverse events is 15/52 (28.85%), while in the secondary trial, the total number of adverse events is 1/8 (12.5%). These numbers differ, so the statement is contradicted."
    },
    "1aee22c7-96f2-4ea6-909a-48741f87ba07": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01111825",
        "Statement": "There were no observed cases of Constipation, Diarrhoea, Nausea or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the data provided in the CTRs. The statement asserts that there were no observed cases of Constipation, Diarrhoea, Nausea, or Febrile neutropenia in patient cohorts 1 and 2 of the primary trial. This aligns with the data presented in the CTRs, as neither Constipation, Diarrhoea, Nausea, nor Febrile neutropenia are reported as adverse events in either cohort 1 or cohort 2 of the primary trial. The absence of these adverse events in the CTRs supports the claim made in the expert statement."
    },
    "d677707e-9ca9-4801-8fcd-7960a9f4f30a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00513695",
        "Statement": "paclitaxel is the only drug in the primary trial given by IV.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the information provided in the CTRs. \n\nJustification: \n\nIn the primary trial, paclitaxel is given intravenously (IV), as stated by the trial description. There is no mention of any other drug being administered via the intravenous route in the given intervention details. Thus, the statement that \"paclitaxel is the only drug in the primary trial given by IV\" is consistent with the provided data."
    },
    "5335a9c9-bae1-42e9-9428-eb0eded62d7f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03252145",
        "Secondary_id": "NCT00904033",
        "Statement": "None of the subjects in the primary trial are required to injest any pills, whereas both cohorts of the secondary trial must take a weekly tablet.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the CTRs.\n\nJustification: \nIn the primary trial, the Intervention 1 and Intervention 2 both involve treatments that do not include taking pills. In the Manual Lymph Drainage (MLD) intervention, patients undergo manual massage therapy three times a week for 4 weeks, and in the Negative Pressure intervention, the PhysioTouch device is used for the same frequency and duration. Neither treatment involves the intake of pills.\n\nHowever, in the secondary trial, both Intervention 1 and Intervention 2 have cohorts that take a weekly pill. The Calcitriol Arm in Intervention 1 takes only the Calcitriol pill, while the Calcitriol+ Exercise Arm in Intervention 2 takes the Calcitriol pill plus exercises.\n\nTherefore, the expert's statement that \"None of the subjects in the primary trial are required to ingest any pills, whereas both cohorts of the secondary trial must take a weekly tablet\" is contradicted by the given CTRs."
    },
    "e6c0f7af-b549-4aad-8f3c-15f367a04a50": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01307891",
        "Statement": "Abraxane + Tigatuzumab group of the primary trial has 10% more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the given CTR data. In the Abraxane + Tigatuzumab group, 28 out of 39 patients had a CR or PR response, which is 14.9-45.0% (based on the given range). In contrast, in the Abraxane Alone group, 8 out of 21 patients had a CR or PR response, which is 18-61.1% (based on the given range). A difference of 10 percentage points exists between the two groups (45.0% - 18% = 27%, and 27% is more than 10%). This difference supports the expert's statement.\n\nCTR references used:\nPrimary Trial: Results 1 (Section \"Arm/Group Title\" and \"Overall Number of Participants Analyzed\") and Results 2 (Section \"Overall Number of Participants Analyzed\")\nSecondary Trial: N/A (no CTR data provided)"
    },
    "1fc3aeac-3bc0-4a47-8222-ea267a822804": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00929240",
        "Statement": "There are no cases of Febrile bone marrow aplasia in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"There are no cases of Febrile bone marrow aplasia in the primary trial\" is contradicted by the given CTR data in the Adverse Events 1 section of the primary trial. Although the term \"Febrile bone marrow aplasia\" is not explicitly mentioned, the condition can be inferred to be a type of Febrile neutropenia, which is listed with an occurrence of 28/284 (9.86%). This contradicts the expert's statement that there are no cases of Febrile bone marrow aplasia in the trial."
    },
    "9e664bcb-38cc-4ca6-9738-28d96248b7f2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00320411",
        "Statement": "the primary trial participants must take 6 tablets of Lapatinib Monotherapy (1500g) PO once daily.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs provided since both the expert's statement and the CTR specify that participants in the primary trial take six 250 mg tablets of Lapatinib Monotherapy once daily, which sums up to a total dose of 1500mg.\n\nReferences:\n1. Primary Trial: INTERVENTION 1 - Lapatinib Monotherapy: 1500mg orally once daily, consisting of six 250mg tablets.\n2. Expert statement: participants must take 6 tablets of Lapatinib Monotherapy (1500g) PO once daily."
    },
    "1b8403ac-7eb3-41cb-8b7e-a89af3492805": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02924883",
        "Statement": "In the primary trial, all cases of  Enteritis, Vertigo and Anaemia occurred in cohort 2.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nExplanation:\n\nThe statement asserts that all cases of Enteritis, Vertigo, and Anaemia occurred in cohort 2 in the primary trial. However, the provided CTR data shows that:\n- There was one case of Enteritis in cohort 1 of the primary trial.\n- No cases of Vertigo were reported in either cohort of the primary trial.\n- One case of Anaemia occurred in cohort 1 of the primary trial.\n\nTherefore, this statement contradicts the data provided within the CTR."
    },
    "ad853675-40ed-4a65-a401-d09ac3153570": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03004534",
        "Statement": "Participants with T2 N1 M0 breast carcinoma are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR. The inclusion criteria of the primary trial specify that participants with T1 to T3 breast carcinoma, either clinically positive or negative axillary nodes (N0 or N1), and M0 are eligible. T2 is within the range of T1 to T3, and N1 is an allowable axillary node status. Therefore, participants with T2 N1 M0 breast carcinoma meet the inclusion criteria and are eligible for the trial."
    },
    "b43bee02-cc3f-4dc8-b13f-8a93de5dc422": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00493636",
        "Statement": "Cohort 1 of the primary trial had a longer median, maximum and minimum pfs than cohort 2.",
        "Label": "Entailment",
        "explain": "Justifications for entailment: \n1. The CTRs provide the median (95% Confidence Interval) values for Progression Free Survival (PFS) for both cohorts A and B. \n2. Cohort 1 had a median PFS of 103 (83 to 128) days, while cohort 2 had a median PFS of 81 (48 to 95) days. This implies that cohort 1 had a longer median PFS than cohort 2.\n3. The CTRs do not contradict the statement as there are no mentions of a maximum and minimum PFS for cohort 1 that contradict the given values or any mention of these values for cohort 2.\n\nThe statement \"Cohort 1 of the primary trial had a longer median, maximum and minimum pfs than cohort 2\" is entailed by the data presented in the CTRs."
    },
    "62258901-8207-413d-913f-a04682635add": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00050011",
        "Statement": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for increasing Lumbar Spine (L1-L4) Bone Mineral Density (BMD).",
        "Label": "Entailment",
        "explain": "The statement can be justified based on the results of the primary trial. The percentage change in L1-L4 BMD in the Zoledronic Acid Upfront arm was 1.955% (3.3658%) compared to -2.325% (3.9542%) in the Zoledronic Acid Delayed-start arm. The positive value in the Upfront arm indicates an increase in BMD, whereas the negative value in the Delayed-start arm indicates a decrease in BMD. The larger absolute difference in percentage change between the two arms supports the conclusion that Zoledronic Acid Upfront is a better treatment for increasing Lumbar Spine BMD based on the primary trial data.\n\nReferences:\n1. Primary Trial: Results 1 (Zoledronic Acid Upfront arm) and Results 2 (Zoledronic Acid Delayed-start arm)\n2. Primary Trial: Outcome Measurement section describing the methodology for measuring BMD using dual energy x-ray absorptiometry (DXA) and the time frame for data collection."
    },
    "d23aee47-e80f-42fe-b095-9cd81f9e0ed3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02657889",
        "Statement": "Both the primary trial cohorts reported identical results.",
        "Label": "Entailment",
        "explain": "The statement \"Both the primary trial cohorts reported identical results\" is contradicted by the provided data in the CTRs. \n\nJustification:\nThe results section of both the primary trials reports the number and percentage of participants in each cohort (Arm/Group). The two cohorts are titled \"Phase 1: Niraparib 200mg + Pembrolizumab\" and \"Phase 1: Niraparapib 300mg + Pembrolizumab\". The number of participants analyzed in each cohort is given as 6. The percentage of participants in each cohort is reported as 16.7%. These values are identical between the two cohorts. However, the statement \"Both the primary trial cohorts reported identical results\" is not supported by the data in the CTRs, as the CTRs do not provide information about the identicality of the results in terms of DLTs or any other clinical outcome measures. Therefore, the statement contradicts the provided data by implying more information than what is actually stated in the CTRs."
    },
    "d23eb56e-c232-4754-94aa-903bc174cb35": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00524303",
        "Statement": "The Trastuzumab arm of the primary trial had 9% better results than the Lapatinib arm.",
        "Label": "Entailment",
        "explain": "To determine if the statement \"The Trastuzumab arm of the primary trial had 9% better results than the Lapatinib arm\" is entailed or contradicted by the CTRs, we need to calculate the difference in percentage of participants with overall pCR between the two arms. \n\nThe percentage of participants with overall pCR in the Trastuzumab arm was 54.0%, and in the Lapatinib arm it was 45.0%. The difference is 9.0 percentage points. \n\nTherefore, the statement is entailed by the CTRs."
    },
    "1c0dcd29-4a04-4b78-abbf-b047d4c29597": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00562718",
        "Statement": "Patients with breast implants are always excluded from the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nThe primary CTR states that patients having tissue expanders or implants placed prior to radiation may be enrolled at the physician's discretion. This implies that patients with breast implants are not universally excluded from the trial."
    },
    "b1a17048-dfe8-4173-ae80-6ec273244848": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01298193",
        "Statement": "More than 20% of  patients in cohort 1 of the primary trial experienced adverse events.",
        "Label": "Contradiction",
        "explain": "Contradiction. The statement \"More than 20% of patients in cohort 1 of the primary trial experienced adverse events\" contradicts the CTR data which states that the total adverse events for cohort 1 was 16.76% or 31/185."
    },
    "33652443-0bb4-493e-adfe-f5032b96b13d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "the primary trial Patients receiving Neratinib Plus Capecitabine had a PFS  much longer than the study time frame of 38 months.",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nThe statement contradicts the information in the CTR. According to the CTR, the restricted mean survival time for PFS in the Neratinib Plus Capecitabine arm was reported up to 38 months, not longer than it."
    },
    "74dba58a-8f5d-478b-a886-0e9758847fe3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00228943",
        "Statement": "Clinically anxious patients are not able to participate in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Clinically anxious patients are not able to participate in the primary trial\" is contradicted by the information in the CTR. The primary trial's inclusion criteria do not specify anxiety as an exclusion criterion, allowing women with anxiety to be potential participants."
    },
    "5344044c-127d-4a39-80dc-277538b5ad33": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02131064",
        "Statement": "less than 60 participants in the TCH + P group of the primary trial achieved Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples.",
        "Label": "Contradiction",
        "explain": "The statement \"less than 60 participants in the TCH + P group of the primary trial achieved Total Pathological Complete Response (tpCR)\" cannot be entailed based on the provided CTR information. The primary trial CTR reports the percentage of participants with tpCR in the TCH + P arm as 56.1% (49.29% to 62.76%) with a total of 221 participants analyzed. Therefore, it is possible that more than 60 participants achieved tpCR based on this data."
    },
    "ed43519d-9954-4e0f-9d42-39a3ed81e4a5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Statement": "Hyperglycemia was the most common adverse event in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The statement is incorrect based on the provided CTR. According to the primary trial's Adverse Events 1 section, the most common adverse event was actually diarrhea (7/30 or 23.33%). The section does not mention hyperglycemia as the most common adverse event for cohort 1 of the primary trial."
    },
    "8d2fde27-a5e8-40ee-a35d-3d4697198a4e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00929240",
        "Statement": "There are no cases of Febrile neutropenia in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"There are no cases of Febrile neutropenia in the primary trial\" is contradicted by the data in the Adverse Events section of the Primary Trial, where there are 28 reported cases of Febrile neutropenia out of 284 participants (9.86%)."
    },
    "fc0da76b-e5b5-44e3-abaf-6231fff493c3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00676663",
        "Statement": "The the primary trial placebo group performed worse than the test group.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nThe primary trial results (Results 1 and 2) report the median PFS for each of the two study arms - Exemestane 25 mg + Placebo and Exemestane 25 mg + Entinostat 5 mg. The median PFS in the placebo group was 1.81 to 3.68 months, while in the test group it was 3.26 to 5.36 months. The longer median PFS in the test group does not directly imply that the placebo group performed worse. Instead, it indicates that the experimental treatment (Exemestane + Entinostat) had a more positive effect on the progression-free survival compared to the placebo."
    },
    "1a32e1c1-31b1-40e5-bbb6-84041ef796fe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00119262",
        "Statement": "cohorts 1 and 2 of the primary trial both had 3 patients that suffered from Congestive Heart Failure.",
        "Label": "Entailment",
        "explain": "Contradiction \n\nJustification:\n\nThe statement that \"cohorts 1 and 2 of the primary trial both had 3 patients that suffered from Congestive Heart Failure\" is contradictory to the CTR information. The primary CTR provides the percentage of participants with Congestive Heart Failure in each arm/group. Arm A had a percentage of 2.9 (0.6 to 8.3) and Arm B had a percentage of 2.5 (0.5 to 7.1). The sum of the number of participants in both arms/groups is 223 (103 in Arm A and 120 in Arm B). Based on this information, it is impossible for both cohorts to have exactly 3 participants with Congestive Heart Failure."
    },
    "9a31db67-e28a-4114-a308-e899f9c22813": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02291913",
        "Statement": "One patient in the primary trial suffered from an inflammation of the esophagus.",
        "Label": "Entailment",
        "explain": "The statement \"One patient in the primary trial suffered from an inflammation of the esophagus\" is entailed by the CTR, as there is one occurrence of esophagitis reported in the Adverse Events section of the Primary Trial."
    },
    "f948a2d1-2e22-47c8-9345-0eb68569bd3f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00996632",
        "Secondary_id": "NCT01644890",
        "Statement": "Emily has an Inoperable breast cancer, she is eligible for both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nThe statement that \"Emily has an Inoperable breast cancer, she is eligible for both the secondary trial and the primary trial\" is contradicted by the provided CTR information. Emily's inoperable breast cancer makes her ineligible for the primary trial as per the exclusion criteria stated: \"Inoperable breast cancer.\" However, she is eligible for the secondary trial based on its inclusion criteria: \"Histologically confirmed metastatic or recurrent adenocarcinoma of the breast,\" which her condition meets, regardless of the operable or inoperable status. Yet, these two trials do not overlap for Emily."
    },
    "e3265040-8316-4f62-969c-27af396ba18c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00479674",
        "Statement": "Patients that have previously been trated with bevacizumab are not eligible for the primary trial, unless they have also received carboplatin 2 weeks prior to study entry.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted according to the Primary Trial's Eligibility Criteria, where patients with prior treatment with bevacizumab are explicitly excluded from the study without any mention of carboplatin as a prerequisite. (Primary Trial: Inclusion Criteria)"
    },
    "6c25e195-47cd-48af-bb51-5b5c44772baa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00656019",
        "Statement": "Candidates with hyperparathyroidism are automatically excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary CTR's EXCLUSION CRITERIA do not explicitly mention hyperparathyroidism as an exclusion criterion. However, it does exclude individuals with a history of parathyroid disease or kidney stones. It's essential to remember that not all individuals with parathyroid disease have hyperparathyroidism, and not all individuals with kidney stones have hyperparathyroidism. Therefore, the statement is not entailed by the information in the CTR and contradicts it."
    },
    "382747d3-69df-41be-a771-4218407ce5d3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171340",
        "Statement": "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density, whereas Zoledronic Acid 4 mg Delayed causes a loss in Bone Mineral Density (within a certain patient demographic).",
        "Label": "Entailment",
        "explain": "The statement is entailed. The primary trial results show that the percentage change in BMD for the Zoledronic Acid 4 mg Upfront arm was 2.208% (positive value) and the secondary trial results show that the percentage change in BMD for the Zoledronic Acid 4 mg Delayed arm was -3.617% (negative value). Therefore, the statement that Zoledronic Acid 4 mg Upfront causes a positive change in Bone Mineral Density and Zoledronic Acid 4 mg Delayed causes a loss in Bone Mineral Density (in a certain patient demographic) is in line with the data provided in the CTRs."
    },
    "d05ec90a-f267-44be-aaa6-3be960a0d50c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00376688",
        "Statement": "Most the primary trial subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the Primary Trial CTR information under \"Outcome Measurement\" and \"Results 1\" sections, as it aligns with the definition of clinical benefit rate (CR, PR, or SD for at least 24 weeks) and the reported percentage (9.7) of participants in the Temsirolimus arm who experienced this benefit."
    },
    "37301690-9b68-48de-b280-6307e632043e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02301988",
        "Secondary_id": "NCT00728949",
        "Statement": "The only types of adverse events recorded by both the secondary trial and the primary trial is Diarrhoea and various pains .",
        "Label": "Entailment",
        "explain": "The statement is entailed. In the primary trial, Diarrhoea is listed as an adverse event with a frequency of 1.32% (1/76). In the secondary trial, Diarrhoea is also listed as an adverse event with a frequency of 1.79% (1/56) and 2.70% (1/37) in Adverse Events 1 and 2, respectively. Additionally, various pains are mentioned in the secondary trial as \"Oesophageal pain\" (1/37), \"Vomiting\" (2/37), and \"Pain\" (1/37), while in the primary trial there are no specific types of pain listed. However, pain is mentioned in both trials as a category of adverse events, with a frequency of 1.32% (1/76) in the primary trial and 2.70% (1/37) in the secondary trial for Adverse Events 1. Therefore, the statement is entailed as Diarrhoea is mentioned explicitly in both trials, and pain is mentioned as a category with some frequency in both trials."
    },
    "b61e798c-d38f-4c72-91bb-4d3e28b6184c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00356148",
        "Secondary_id": "NCT01856543",
        "Statement": "Women of any age can participate in the primary trial, but only adults can be eligible for the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the information in the CTRs. The primary trial's inclusion criteria state \"Women at any age,\" while the secondary trial's inclusion criteria specify \"Age 18 years\" as a requirement. This discrepancy indicates that the statement is contradictory to the information presented in the CTRs.\n\nAdditional information: \n\nPrimary Trial CTR: Inclusion Criteria: includes \"Women at any age\"\nSecondary Trial CTR: Inclusion Criteria: specifies \"Age 18 years\"\n\nTherefore, the women mentioned in the primary trial may include individuals of any age, while those in the secondary trial must be adults. Since the statement asserts that only adults are eligible for the primary trial, it is contradictory to the information presented in the CTRs."
    },
    "3ca27248-0728-4b10-b940-6e2603acef30": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201760",
        "Secondary_id": "NCT00127933",
        "Statement": "Patients must have an infiltrating breast carcinoma to participate in the secondary trial or the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Patients must have an infiltrating breast carcinoma to participate in the secondary trial or the primary trial\" is entailed by both CTRs. \n\nJustifications:\n- Primary CTR: The first eligibility criterion for both arms of the primary trial is \"Must have invasive breast cancer,\" which explicitly states that participants must have an infiltrating breast carcinoma.\n- Secondary CTR: The first inclusion criterion for the secondary trial is \"infiltrating (invasive) HER2-neu-negative or HER2-neu-positive breast cancer,\" implying that patients must have an infiltrating (invasive) breast carcinoma."
    },
    "c2da6504-96a1-4669-b609-16731a5330d3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00248170",
        "Secondary_id": "NCT01299038",
        "Statement": "Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer, she is ineligible for both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the CTRs. \n\nJustification: Ae-Cha is a Korean woman who is ineligible for both trials based on their exclusion criteria. In the primary trial, Korean descent is not listed as an exclusion criterion. However, in the secondary trial, Korean descent is an exclusion criterion. Therefore, the statement that \"Ae-Cha is ineligible for both the secondary trial and the primary trial\" is contradicted by the fact that she meets the inclusion criteria for the primary trial but not the secondary trial due to a criterion that does not apply to the primary trial."
    },
    "646959e4-25d0-4eb1-b7b0-2d7b1e02e132": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01262027",
        "Statement": "Less than 5% of patients in the primary trial suffered an adverse event.",
        "Label": "Entailment",
        "explain": "The statement \"Less than 5% of patients in the primary trial suffered an adverse event\" is entailed by the CTR as stated in the Adverse Events section of the Primary Trial where it is indicated that \"Total: 1/22 (4.55%)\"."
    },
    "0e6eebe9-46c2-4fa5-b9ed-e0997044960b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01293032",
        "Secondary_id": "NCT00849472",
        "Statement": "None of the patients in the primary trial or the secondary trial are required to undergo radiotherapy or surgery.",
        "Label": "Contradiction",
        "explain": "The statement \"None of the patients in the primary trial or the secondary trial are required to undergo radiotherapy or surgery\" is contradicted by the information in both CTRs.\n\nIn the primary trial, patients with an intermediate RS (11-25) were randomized to treatment Arm 1 or 2, neither of which specifies radiation therapy or surgery as a mandatory intervention. However, the absence of such information does not entail that neither treatment involves radiotherapy or surgery, it only signifies that the CTR does not mention it as a requirement. Therefore, the statement contradicts the CTRs since there is evidence that some clinical trials in the provided text do involve surgery (implicitly stated in the term \"neoadjuvant therapy\").\n\nIn the secondary trial, the intervention involves a neoadjuvant setting as well, where the goal is to shrink the tumor prior to surgery. This is evident from the statement \"This was followed by surgery.\" Although the CTR does not specify if all patients underwent surgery, it clearly indicates that it is a subsequent intervention for some participants.\n\nTherefore, the statement contradicts the information given in the CTRs."
    },
    "a781374c-99e1-47ee-a266-bff9267c2ed1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00950742",
        "Statement": "100% of participants in the Afatinib 30mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities.",
        "Label": "Entailment",
        "explain": "Contradiction.\n\nExplanation:\nThe CTR for the primary trial states that there were only 2 participants in the Afatinib 30mg + Herceptin group. Hence, it is not possible for 100% of them to have suffered from Dose Limiting Toxicities according to the provided data."
    },
    "9aea5a84-bced-4441-b8b8-154c307f5a03": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01151046",
        "Statement": "The placebo group in the primary trial had a much lower Median PFS than the MM-121 cohort.",
        "Label": "Contradiction",
        "explain": "The statement \"The placebo group in the primary trial had a much lower Median PFS than the MM-121 cohort\" is entailed by the provided CTRs. \n\nJustification: \n\nThe CTRs indicate that the Median PFS for the MM-121 + exemestane cohort was 15.9 (9.3 to 30.3) weeks, and for the placebo + exemestane cohort was 10.7 (8.1 to 16.1) weeks. A lower Median PFS in the placebo group is explicitly stated in the given trial data."
    },
    "deb77d34-76a5-4e6e-bc9d-176cc30eca07": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00917735",
        "Statement": "One patient in cohort 2 of the primary trial died in a motorcycle crash.",
        "Label": "Contradiction",
        "explain": "The statement \"One patient in cohort 2 of the primary trial died in a motorcycle crash\" is contradicted by the information in the CTR. According to the CTR, there were no cases of motorcycle accidents reported in cohort 2 of the primary trial (0/538)."
    },
    "bfe97430-fcec-4c4a-9621-51f6ec05d8d3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00068341",
        "Statement": "More patients in cohort 1 of the primary trial experienced death progressive disease  than in cohort 2.",
        "Label": "Contradiction",
        "explain": "Contradicted. The statement is contradicted by the Adverse Events sections of both the primary and secondary trials, as no cases of death progressive disease were reported in either cohort of the primary trial (0/15 in each cohort), while only one case was reported in cohort 2 of the secondary trial (1/14)."
    },
    "568beebd-b350-4ba1-b8fc-c43f4d6ed517": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01421017",
        "Statement": "the primary trial studies the effects of CTX/IMQ/RT and IMQ+RT on Systemic Tumor Response Rates 9 weeks after the start of treatment.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTRs, as both trials report on Systemic Tumor Response Rates 9 weeks after the start of treatment for CTX/IMQ/RT and IMQ+RT arms. Specifically, Results 1 and 2 of each CTR provide the number of responsive tumors (proportion of tumors) in each group, which can be used to calculate Systemic Tumor Response Rates. Therefore, the statement correctly summarizes the focus of the primary trial."
    },
    "6bcc18b7-b063-49a1-8ab7-773636c02f1d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00076024",
        "Statement": "The minimum number of days from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial, was 191.",
        "Label": "Entailment",
        "explain": "Contradiction. The statement is contradicted by the data in the CTRs. The median TTP for the Docetaxel + Placebo arm was 191 days, but this number does not represent the minimum number of days for any patient in that arm or in the Axitinib + Docetaxel arm. There are participants in both arms who experienced tumor progression or death earlier than 191 days. Additionally, there is no information given in the CTRs about the minimum TTP for any patient in the Axitinib + Docetaxel arm."
    },
    "dfa2ecee-96cf-4551-875e-aedd8aac5df9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01519700",
        "Statement": "There was less than 24hrs difference in Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTR data. \n\nJustification: \n\nThe statement claims that there is less than 24 hours difference in Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy between the two arms of the primary trial. \n\nResults 1 and 2 of the CTR provide the mean durations of severe neutropenia (defined as ANC less than 0.5*10^9 cells/L) for the two arms during the time frame of 21 days (Cycle 1 of chemotherapy treatment). The mean duration of severe neutropenia for Arm/Group Title: EP2006 + EP2006 & Neupogen is 1.17 (1.11) days, and for Arm/Group Title: Neupogen + Neupogen & EP2006 is 1.2 (1.02) days. \n\nA difference of 1.2 days (Neupogen + Neupogen & EP2006) - 1.17 days (EP2006 + EP2006 & Neupogen) = 0.03 days, which is well below the stated difference of less than 24 hours. Therefore, the statement is entailed by the data provided."
    },
    "81c85a29-d449-4f79-a3b3-682ba5f288ca": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00190671",
        "Secondary_id": "NCT00455533",
        "Statement": "In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 2 of the primary trial had the highest proportion of patients with leukopenia.",
        "Label": "Entailment",
        "explain": "The statement contradicts the information in both Adverse Events sections of the CTRs. In the primary trial, cohort 1 had 0 cases of Leukopenia, whereas cohort 2 had 1 case. In the secondary trial, cohort 1 had 1 case and cohort 2 had 1 case as well. Therefore, neither cohort had a higher proportion of patients with Leukopenia in their respective trials."
    },
    "9c48c5d6-83fd-42cc-aacc-2e888099bcdb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00338728",
        "Statement": "Participants of the primary trial more Imatinib mesylate than Letrozole on a daily basis.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the primary CTR section as follows: \n\n- In the primary trial, patients received Imatinib mesylate 400 mg twice a day (which sums up to 800 mg daily) and Letrozole 2.5 mg once a day, thus, patients received more Imatinib mesylate (800 mg) than Letrozole (2.5 mg) daily."
    },
    "79a3bb0d-315f-4c39-8786-2aa98e2e3f6f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00293540",
        "Statement": "Males are not eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the primary trial CTR's inclusion criteria which state, \"ESTROGEN RECEPTOR OR PROGESTERONE RECEPTOR POSITIVE BREAST CANCER,\" implying female participants. Therefore, males are not eligible and the statement is contradicted by this information in the CTR."
    },
    "cea17554-6736-4b52-b76c-b3c5dc9ecb77": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00503750",
        "Statement": "All participants of the primary trial must have recently undergone either an echocardiography or a MUGA scan.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR as both echocardiography and MUGA scan are mentioned in the inclusion criteria of the primary trial for measuring normal left ventricular ejection fraction (LVEF)."
    },
    "b250a17c-9d4d-405d-ba64-40f7eda16707": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00368875",
        "Statement": "the primary trial results indicate that the Recommended Phase II Dose for paclitaxel, as Assessed by NCI Common Terminology Criteria for Adverse Events, is 90 mg/m2 .",
        "Label": "Contradiction",
        "explain": "The statement should be entailed by the CTR data as the primary trial results explicitly state that paclitaxel was administered at a dose of 90 mg/m2 for every 28-day cycle, and this dose was not escalated or de-escalated based on toxicity during the trial. The statement also aligns with the description of the outcome measurement in the primary trial that defined DLTs for paclitaxel as any toxicity leading to a dose reduction or inability to complete protocol-specified doses. Since no such occurrences were reported in the trial for paclitaxel, the statement is consistent with the CTR information."
    },
    "698849c5-78fa-4c15-a1dc-f44eb9c970c2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00082641",
        "Statement": "At least one patient in the primary trial suffered from impaired mobility.",
        "Label": "Entailment",
        "explain": "The statement can be contradicted by the information in both the primary and secondary trials' Adverse Events sections. There is no mention of impaired mobility in the given data for either trial. Specifically, there is no record of hip fracture (a common cause of impaired mobility) in the primary trial and only one case in the secondary trial."
    },
    "4b4e6ac7-107c-46f4-adbb-c77c01f51935": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00075764",
        "Statement": "The most common adverse event in cohort 1 of the primary trial is low Hemoglobin levels.",
        "Label": "Entailment",
        "explain": "The statement \"The most common adverse event in cohort 1 of the primary trial is low Hemoglobin levels\" is contradicted by the provided data in the CTRs. In the primary trial, the total percentage of participants with low Hemoglobin levels in both cohorts is 0.59% (2/337). This percentage is shared between the two cohorts, thus it cannot be considered the most common adverse event for cohort 1 alone."
    },
    "6b73dee4-0291-455e-90c2-786f0c2371d4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00579826",
        "Statement": "Participants of the primary trial cannot be currently receiving treatment for rheumatoid arthritis, experiencing poorly controlled migraines or have any prior history of invasive breast cancer in the last 3 years.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs. In the primary CTR, \"Current history of rheumatoid arthritis\" is listed as an exclusion criterion, while \"Prior history of invasive breast cancer or other invasive cancer within five years from date of study entry\" is mentioned in the secondary trial as \"in the last 3 years\", which is less restrictive but still consistent with the primary trial's condition. However, the primary trial's exclusion criteria for breast cancer history applies to \"prior history of invasive breast cancer or other invasive cancer within five years from date of study entry\" which is more restrictive than the statement's condition \"in the last 3 years\". So, the primary CTR's condition covers the statement's requirement. Therefore, the statement is entailed by the CTRs."
    },
    "2a1d9064-fde9-4645-95ab-7ddaea4ad322": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00324259",
        "Statement": "Cohort 2 of the primary trial 3 had more patients with Complete response than cohort 1.",
        "Label": "Contradiction",
        "explain": "Contradiction. \n\nThe CTRs provided do not support the statement that cohort 2 of the primary trial had more participants with a complete response than cohort 1. Both cohorts reported zero complete responses."
    },
    "847de3fe-b584-4d43-b82d-93263ce88830": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00509587",
        "Statement": " Patients in the primary trial receive 300 mg pazopanib once daily intravenously every day, continuing until disease progression or unacceptable toxicity.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial's INTERVENTION 1 description, which clearly states \"pazopanib hydrochloride: Given orally.\" Therefore, the patients in the primary trial do not receive pazopanib 300 mg once daily intravenously every day."
    },
    "3c798991-6366-43e2-94ca-0523629930c2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00149214",
        "Secondary_id": "NCT01004744",
        "Statement": "Prior use of Anthracycline drugs in the last 6 months for anticancer therapy is prohibted for patients in the primary trial, but not for patients in the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted. The primary trial explicitly states that patients with a history of anthracycline use \"as part of prior anticancer therapy\" are excluded (Primary Trial: Exclusion Criteria). In contrast, the secondary trial allows patients who have not received anthracyclines \"within 6 months of study entry\" (Secondary Trial: Exclusion Criteria)."
    },
    "64fe54a2-8897-4324-af88-f627c1c208ed": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01764022",
        "Statement": "Cohort 2 of the primary trial recorded multiple incidents of thrombocytopenia.",
        "Label": "Contradiction",
        "explain": "The statement \"Cohort 2 of the primary trial recorded multiple incidents of thrombocytopenia\" is entailed by the CTR data, as shown in the ELIGIBILITY CRITERIA and ADVERSE EVENTS sections of both primary and secondary trials. In the ELIGIBILITY CRITERIA sections, there is no mention of thrombocytopenia as an exclusion criterion. In the ADVERSE EVENTS sections, thrombocytopenia is mentioned as occurring in both primary trial cohorts, with a total of 2/223 (0.90%) incidents across both cohorts. In the secondary trial's ADVERSE EVENTS section, there is no mention of thrombocytopenia occurrence, but this does not contradict the primary trial's findings, as the two trials involve different cohorts of patients.\n\nTherefore, the statement is entailed based on the provided CTR data."
    },
    "4eac6a2d-64cd-4289-a545-211eb835f0e9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01328249",
        "Statement": "The Percentage of Participants With Feasibility was 70% higher in cohort 1 of the primary trial than in cohort 2.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted. According to the given CTRs, the percentage of participants with feasibility in Cohort 1 (Eribulin Mesylate With Filgrastim as Needed) was 70.4% (58.5 to 80.4%) and in Cohort 2 (Eribulin Mesylate With Prophylactic Filgrastim) it was 60.0% (41.7 to 76.4%). The difference between the percentage of participants with feasibility in both cohorts is actually 6.4%, not a 70% difference as stated in the expert's claim."
    },
    "3ee1c60e-46ce-4f25-af52-31d5c6d8eba1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02435680",
        "Secondary_id": "NCT01743560",
        "Statement": "the secondary trial and the primary trial use best Overall Response (OR) as their evaluation metrics, however they use significantly different time frames.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed. The primary and secondary trials both use the Best Overall Response (OR) as their evaluation metric. However, the primary trial measures PFS at 4 years while the secondary trial measures ORR at 48 weeks. This does not contradict the statement, as the use of the same metric in both trials does not necessitate identical time frames. The statement correctly points out the difference in time frames for measuring OR in each trial."
    },
    "da1e1019-adb5-47bf-8093-e03352ca9e51": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01340300",
        "Secondary_id": "NCT00671918",
        "Statement": "Patients cannot do more than half an hour of physical exercise in a day, if they are to participate in the primary trial, however, this is not a requirement for the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted by the primary trial inclusion criteria stating, \"Participants will be allowed to receive concomitant adjuvant endocrine therapy for breast cancer; however, all endocrine agents must be initiated at least 1 month prior to enrollment in the study and continued throughout the duration of study participation.\" Some patients may engage in more than half an hour of physical exercise daily while undergoing endocrine therapy, which would make them ineligible for the primary trial but eligible for the secondary trial. Therefore, the statement is not an entailed relationship between the trials."
    },
    "e7fb6490-1ec7-48ff-95b1-715d79faec92": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01042938",
        "Statement": "Patients must be english to participate in the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial inclusion criteria state that participants must be able to understand English and able to complete assessment forms (all assessment forms are in English). However, the statement focuses solely on the language aspect without mentioning the requirement of understanding and completing assessment forms, which is a more comprehensive aspect of the inclusion criteria. Therefore, the statement's focus on just the English language is narrower than what's required in the CTR and could potentially lead to incorrect assumptions or misunderstandings. Additionally, the secondary trial doesn't have any specific English language requirement mentioned, which further distinguishes the two trial sections and reinforces the contradiction between the statement and the CTR."
    },
    "d5ea3443-103f-4d29-9be3-522210b84152": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00618826",
        "Secondary_id": "NCT02040857",
        "Statement": "the primary trial and the secondary trial only record 2 of the same adverse events.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial recorded a total of 10 adverse events in 14 participants, while two adverse events were identified in the secondary trial out of 162 participants. Among the two identical adverse events in both trials, \"Fatigue\" was present in 2/14 (14.29%) participants of the primary trial and 6/162 (3.70%) participants in the secondary trial. However, there was an additional adverse event \"Mucositis oral\" in the secondary trial, which was not reported in the primary trial. Therefore, the statement is contradicted by the provided data."
    },
    "d54cae08-3ac9-4460-bf6d-7338b45d8cd7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00193050",
        "Statement": "Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary trial's inclusion criteria state that patients must have a life expectancy of over 6 months, whereas the provided statement is the negation of this condition, stating that patients must have a life expectancy over 6 months to participate. The statement contradicts the information in the CTR."
    },
    "608c5521-c9a6-47de-9ebf-791ce317a02d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00086957",
        "Statement": "All of the patients in cohort 1 of the primary trial experienced an adverse event.",
        "Label": "Entailment",
        "explain": "The statement \"All of the patients in cohort 1 of the primary trial experienced an adverse event\" is contradicted by the Adverse Events section of the Primary Trial report, where it is stated that \"Total: 2/2 (100.00%)\". However, this refers to the total number of adverse events experienced by the two patients in the cohort, not the number of patients experiencing an adverse event. Therefore, the statement should be contradicted. \n\nTo clarify, the primary trial had only two patients in cohort 1, and both experienced an adverse event. However, not all adverse events were experienced by the same patient, hence the contradiction with the statement that \"All of the patients in cohort 1 experienced an adverse event\"."
    },
    "14a8e9e9-0a46-4537-bc07-53c786bcbe97": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00593827",
        "Secondary_id": "NCT00478257",
        "Statement": "Patients with HER2 negative MBC are eligible for both the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. \n\nJustification: \n\nThe primary CTR includes the criterion \"Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer,\" while the secondary CTR specifies \"stage I-III breast cancer with HER2 negative disease.\" Both trials allow for inclusion of patients with HER2 negative breast cancer."
    },
    "2d97bfa0-336f-4976-95e5-1262327a730b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Secondary_id": "NCT02502864",
        "Statement": "the primary trial recorded 2 more total adverse events than the secondary trial",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the data in the CTRs. In the primary trial, there were 5 adverse events out of 14 subjects (35.71%), while in the secondary trial, there were 3 adverse events out of 9 subjects (33.33%). The difference between the two trials is 2 adverse events. Therefore, the statement is an accurate reflection of the data presented in the CTRs."
    },
    "e68dddc8-ea04-49b2-ae91-ff7b4fcb1240": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00003199",
        "Statement": "The patient group with the highest percent of Event-free Survival in the primary trial was Stage IIIB patients, and the worst was Stage IV Disease patients.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the data in the Primary Trial's Results 1 section, as it aligns with the provided percentages of Event-free Survival for Stage IIIB and Stage IV Disease patients:\n\n1. Stage IIIB patients had an event-free survival of 61.1% (11 out of 18).\n2. Stage IV Disease patients had an event-free survival of 28.1% (9 out of 32).\n\nThese numbers show that a higher percentage of Stage IIIB patients had event-free survival compared to Stage IV Disease patients, thus justifying the expert's statement. Additionally, the statement does not contradict any information in the provided CTRs."
    },
    "8c83330f-f2f3-48e1-9905-dc2ba1970c54": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03765996",
        "Statement": "Participants in group 2 of the primary trial receive the same Complex Decongestive Physiotherapy as those in group 1, with the addition of applying taping to anastomosis regions.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the CTRs. \n\nJustification:\nBoth groups in the primary trial (groups 1 and 2) received Complex Decongestive Physiotherapy as specified in the INTERVENTION sections of the CTRs. Group 2, in addition to the CDP protocol, also received taping applied to the anastomosis regions. This detail is explicitly stated in the description of INTERVENTION 2 in the primary trial CTR. The expert's statement reflects and summarizes this information accurately, making it an entailed statement."
    },
    "4613834d-c178-475c-b9fd-c9c66d5681eb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT02780713",
        "Statement": "Cohort 2 of the primary trial receives higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants.",
        "Label": "Entailment",
        "explain": "The statement is entailed. In the primary trial, the dosage of Intervention 1 is 100 mg Q-122 and in Intervention 2, it is 200 mg Q-122, which is double the dosage of Intervention 1 in the secondary trial, where the dosage in both cohorts is 100 mg AZD9496 - Variant A and AZD9496 - Reference, respectively. However, it's essential to note that Q-122 and AZD9496 are not directly comparable due to their differences in composition."
    },
    "b4555685-6e25-4797-8616-bcab5b06a135": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00259090",
        "Statement": "the primary trial studies the impact of Fulvestrant, Docetaxel on Oestrogen Receptor H-score.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nJustification: \n\nThe statement asserts that the primary trial studies the impact of Fulvestrant and Docetaxel on Oestrogen Receptor H-score. However, according to the provided CTR, the primary trial compares the antitumour effects of Fulvestrant, Anastrozole, and a combination of both on ER H-score. Docetaxel is not mentioned in the CTR. Therefore, the statement contradicts the information in the CTR."
    },
    "c1b90c18-45f4-4e28-b50a-a00b0eadc523": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT02748213",
        "Statement": "Patients whose breast tumour is 0.1 cm across or less are eligible for the secondary trial, but not the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nThe primary trial specifies eligibility criteria for breast carcinoma with a size range of T1-3, but it does not have a minimum size restriction (CTR, Disease Characteristics). In comparison, the secondary trial only includes patients with at least one measurable lesion according to RECIST, which does not necessitate a specific size (CTR, Inclusion Criteria). Therefore, there is no basis in the provided CTRs for the statement that patients with a breast tumor 0.1 cm across or less are eligible for the secondary trial but not the primary trial. Instead, the contradiction arises due to the missing size limitation in the primary trial and the presence of other eligibility criteria not mentioned in the statement."
    },
    "33ef3abf-97c0-4d15-909d-258fb47ac54a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232479",
        "Statement": "Only patients with HER2 positive breast carcinoma are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Only patients with HER2 positive breast carcinoma are eligible for the primary trial\" is entailed by the CTR as the primary trial's inclusion criteria explicitly states \"HER-2 overexpressing breast cancer.\""
    },
    "a381e340-18b1-4baa-91ce-0c420bcb411c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01323530",
        "Secondary_id": "NCT01106040",
        "Statement": "the secondary trial and the primary trial results indicate that the PFS of participants is partially linked to age, cancer grade and ethnicity.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted. The CTRs do not provide sufficient information to support a claim that the PFS (Progression-Free Survival) is partially linked to age, cancer grade, and ethnicity based on the provided information. The primary trial results only report the occurrence of dose-limiting toxicities in two different dosage groups, while the secondary trial results only report the concordance of blue dye and Lymphoseek. There is no information regarding PFS or any relationship to age, cancer grade, and ethnicity in either of the trials."
    },
    "15e6b2b9-ba8f-4ca5-99d7-a1bbf9497b4b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00383500",
        "Statement": "the primary trial is not testing a drug based intervention, it is testing a Medical device called Manual Lymphatic Drainage.",
        "Label": "Contradiction",
        "explain": "Contradiction. \n\nThe primary trial clearly specifies Intervention 1 as the Flexitouch Device, which is identified as a medical device and not a drug intervention. The statement, however, erroneously claims that the primary trial is testing Manual Lymphatic Drainage as an intervention, which is actually stated to be part of Intervention 2 in the secondary trial and not the primary trial."
    },
    "8e246d8f-e063-4f2e-a382-5d201a946b87": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00436566",
        "Statement": "Not a single patient in the primary trial suffered from Congestive Heart Failure during active treatment with Trastuzumab and RAD001.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary CTR reports that the number of patients with CHF while on active treatment is not specified for the AC/PTL arm. However, the absence of CHF in the secondary trial, involving trastuzumab and RAD001, is in contrast to the primary trial where the specific intervention regimen for CHF during treatment is not mentioned."
    },
    "8154bd8c-90a2-4b2f-8090-fcc89aeae30c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00097721",
        "Statement": "Patients of any ethnicity can participate in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the Primary Trial's Inclusion Criteria as they do not specify any ethnicity limitations."
    },
    "537781f9-3693-479e-af22-824cdd827b9c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02657889",
        "Statement": "the primary trial indicates that varying Pembrolizumab dosage has no effect on the Number of Subjects Reporting Dose-Limiting Toxicities (DLTs).",
        "Label": "Contradiction",
        "explain": "The statement can be entailed based on the CTR information provided in the Primary Trial section under the ELIGIBILITY CRITERIA and OUTCOME MEASUREMENT. Both arms of the trial, Niraparib 200mg + Pembrolizumab and Niraparib 300mg + Pembrolizumab, have the same dose of Pembrolizab in common (200 mg intravenously on Day 1 of each 21-day cycle), and the DLTs are defined as treatment-related Grade 3 or 4 non-hematologic lab abnormalities or hematologic toxicities, regardless of the Pembrolizumab dosage. The CTR results show the number of participants experiencing DLTs in each arm is equal (1 out of 6, or 16.7%). Therefore, the statement is supported by the data in the CTRs."
    },
    "5feefe8b-ddca-4eb8-af68-d1e211963d1f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02748213",
        "Statement": "2 patients, in cohort 1 of the primary trial was recorded as having an overactive pituitary gland.",
        "Label": "Contradiction",
        "explain": "The expert's statement is not directly entailed nor contradicted by the provided CTRs. The CTRs do not mention any information regarding patients having an overactive pituitary gland. Therefore, neither entailment nor contradiction can be established based on the given data."
    },
    "2a5d8ca7-1608-4607-b996-490fc447b593": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00956813",
        "Statement": "All the primary trial subjects are required to take the intervention tablet PO daily.",
        "Label": "Contradiction",
        "explain": "The statement \"All the primary trial subjects are required to take the intervention tablet PO daily\" is contradicted by the information in the Primary Trial's INTERVENTION section. In the Primary Trial, patients do not take tablets; instead, they receive either a Nutrigrad\u2122 flaxseed bar (for Intervention 1) or an identical looking placebo bar (for Intervention 2). There is no mention of tablets in this study."
    },
    "178c50cc-49ee-4083-bc8e-b5832037498a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Statement": "4 patients in the primary trial experienced a grade 3 or above adverse event.",
        "Label": "Contradiction",
        "explain": "The statement \"4 patients in the primary trial experienced a grade 3 or above adverse event\" is entailed by the information in the primary trial's Adverse Events section. Specifically, there are a total of 6 patients who had a grade 3 or above adverse event (3/48 for febrile neutropenia, 1/48 for neutropenia, 1/48 for holocraneal cephalea, 2/48 for hypersensibility reaction, 1/48 for palmoplantar erythrodysesthesia and stomatitis, and 1/48 for neutropenia, fever, and oral mucositis). Therefore, 4 is indeed a valid number of patients who experienced a grade 3 or above adverse event."
    },
    "92ace4fa-4426-4f34-af52-ee62913e60aa": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01026142",
        "Secondary_id": "NCT00846027",
        "Statement": "There were 10% more patients with Left ventricular systolic dysfunction in cohort 1 of the primary trial than in the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nJustification:\n\nThe statement asserts that there were 10% more patients with Left ventricular systolic dysfunction in cohort 1 of the primary trial than in the secondary trial. However, the CTR for the primary trial reports 4 cases (1.83%) out of 218 patients, and the CTR for the secondary trial reports 1 case (1.22%) out of 82 patients. Thus, the primary trial had fewer cases of Left ventricular systolic dysfunction than the secondary trial, which contradicts the statement."
    },
    "7dbde84d-f1c9-4197-9d44-500fd337bebd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01823107",
        "Statement": "At most 12 Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events.",
        "Label": "Entailment",
        "explain": "The expert's statement is entailed by the provided data in the CTR for the primary trial. The number of reconstructed breasts affected by breast-related adverse events in the Meso BioMatrix Acellular Peritoneum Matrix arm is reported to be 12. This number is consistent with the upper limit stated in the expert's claim (at most 12 patients)."
    },
    "824da29f-b2ff-440e-8b78-7a8291cbd6d2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02340221",
        "Statement": "A total of 89 patients in the primary trial had Supraventricular tachycardia.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by both CTRs. \n\nJustification: \n\nIn the Primary CTR Adverse Events section, there are no reported cases of Supraventricular tachycardia among the 213 patients (0.00%). \n\nSimilarly, in the Secondary CTR Adverse Events section, only one patient out of 416 (0.24%) experienced Supraventricular tachycardia. \n\nTherefore, the statement claiming that \"a total of 89 patients in the primary trial had Supraventricular tachycardia\" is contradicted by the data present in the CTRs."
    },
    "6cbac938-baf2-4f0b-b67b-9caeb7ea4fe1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02748213",
        "Statement": "1 patient, in cohort 1 of the primary trial was recorded as having an overactive thyroid gland.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR as there is one instance of hyperthyroidism recorded in the primary trial's Adverse Events 1 section. (Hyperthyroidism: 1/112 = 0.89%). The expert's description matches the reported data, and the data does not contradict the statement."
    },
    "052ee533-7daa-4cbf-a64c-bc9a50444173": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00244933",
        "Statement": "the primary trial does not monitor the occurrence of Hemoglobin C Disease in its adverse events.",
        "Label": "Entailment",
        "explain": "The statement is not contradicted by the given CTRs as neither of them mentions Hemoglobin C Disease as an adverse event in their respective cohorts."
    },
    "1d7dbb44-049d-4887-8bd6-6aefc77aa1e9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00444587",
        "Statement": "A total of 7 patients in the primary trial were observed with either Leukopenia, Cardiopulmonary failure or Diarrhoea.",
        "Label": "Entailment",
        "explain": "The statement is entailed. In the primary trial section, there are a total of 93 patients, and 2.15% had Cardiopulmonary failure, 2.15% had Leukopenia, and 3.23% had Diarrhoea. Therefore, a total of 7 patients had either Leukopenia, Cardiopulmonary failure, or Diarrhoea (2.15% + 2.15% + 3.23% = 7.53%, which rounds down to 7 patients)."
    },
    "9b622b9b-3ad3-4cff-acb3-4127d0304de0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00571987",
        "Statement": "occupational exposure to ionizing irradiation will not disqualify a patient from entry to the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the Primary Trial's Inclusion Criteria, which explicitly mentions \"Previous prior radiation to the breast\" as an exclusion criterion under the Eligibility Criteria section. This indicates that patients who have undergone radiation therapy to the breast are not allowed to participate in the trial. Thus, occupational exposure to ionizing irradiation would also be considered a disqualifying factor, as both involve exposure to ionizing radiation."
    },
    "825ba6fd-8c08-49d2-941b-3338ef01e7fd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02673918",
        "Secondary_id": "NCT01042938",
        "Statement": "African American patients are eligible for both the primary trial and the secondary trial.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nJustification:\n\nThe primary trial excludes participants based on race, limiting inclusion to Danish-speaking patients (ELIGIBILITY CRITERIA section in the Primary Trial description). African American patients do not meet this criterion, making them ineligible for the primary trial. The secondary trial, on the other hand, does not include any such exclusion based on race (ELIGIBILITY CRITERIA section in the Secondary Trial description). However, African American patients may still be ineligible for the secondary trial due to other exclusion criteria."
    },
    "0421750d-66c6-47be-bde7-0c41ee43a28b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01730729",
        "Statement": "Patients with severe malabsorption disorders are ineligible for the primary trial, even if they are able to receive intravenous (IV) alimentation.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary trial exclusion criteria list malabsorption syndrome as a reason for ineligibility, but it does not specify that patients with severe malabsorption who can receive IV alimentation are still excluded. Therefore, the expert's statement goes beyond the information provided in the CTR."
    },
    "95345dbe-446f-4999-8f3e-a429b77ea554": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02872103",
        "Secondary_id": "NCT02995980",
        "Statement": "Adequate renal, hepatic and blood work is required for entry to the primary trial, this includes the following criteria; hemoglobin  11.5 g/dL, aswell as ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and Serum creatinine should be less than 1.7x ULN. These conditions are not explicitly required for the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement should be entailed for the primary trial as the CTR explicitly states that adequate renal, hepatic function should be met, with the specific conditions listed in the statement (hemoglobin 11.5 g/dL, ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and Serum creatinine less than 1.7x ULN) being requirements for inclusion in the trial. However, for the secondary trial, these conditions are not explicit inclusion criteria, so the statement should not be strictly entailed but can still be considered an expected condition for clinical trials in general."
    },
    "b05fde86-4004-427f-8baf-2ea4a0a535c7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00376597",
        "Statement": "the primary trial all undergo surgery twice, first at 2 weeks and then again a month later.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided CTR information. In both the primary and secondary trials, it is stated that patients undergo surgery only once. Specifically, no mention is made of a second surgery at 2 weeks or a month later for any of the patients."
    },
    "21e24c6c-d282-48fb-8d68-3e723458794e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00825734",
        "Statement": "Patients with any of the following conditions will be excluded from the primary trial; grade 3 infection, unstable angina or a grade 4 hemorrhage within the last month.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR as it lists \"serious non-healing wound, ulcer, or bone fracture,\" \"evidence or history of bleeding diathesis or coagulopathy,\" \"uncontrolled hypertension,\" \"thrombolic or embolic events,\" and \"pulmonary hemorrhage or bleeding event  grade 2 within 4 weeks of the first dose of study treatment, or any other hemorrhage or bleeding event  grade 3 within 4 weeks of the first dose of study treatment\" as exclusion criteria for the primary trial under \"Cardiac Disease\" and \"Bleeding events.\" Additionally, \"unstable angina (anginal symptoms at rest) or new onset angina (i.e., began within the last 3 months)\" is mentioned as a cardiac disease exclusion criterion. While \"grade 3 infection\" is not explicitly stated in the inclusion or exclusion criteria, it can be inferred as an exclusion based on the general term \"serious non-healing wound\" which can include infections. Therefore, all conditions listed in the expert's statement are covered under the CTR's exclusion criteria and are thus entailed."
    },
    "d1e579e2-b057-43da-8a2f-64dad964b789": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00821964",
        "Statement": "the primary trial participants apply topical imiquimod to cutaneous lesions once daily every other day for a total of 14 days every 28 day cycle.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial CTR as per the intervention section, where it specifies that imiquimod is to be applied topically QD on days 1-4, 8-11, 15-18, and 22-25 of every 28 day cycle, not once daily every other day as mentioned in the statement."
    },
    "5ac83a45-db7d-44d1-bf37-9cbf3c8fabb6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093145",
        "Secondary_id": "NCT00703326",
        "Statement": "Heart-related adverse events were recorded in the secondary trial, but not  the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted. \n\nJustification: \n\nHeart-related adverse events were reported in the secondary trial with an occurrence of 1/752 (0.13%), specifically Atrial fibrillation in one participant. However, there were no heart-related adverse events reported in the primary trial as stated in both Adverse Events sections (1 and 2)."
    },
    "d130c981-f602-4f17-b1cb-11a7ad632b92": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01234402",
        "Statement": "the primary trial more than 6 different types of cardiac related adverse events.",
        "Label": "Entailment",
        "explain": "Contradicted. Based on the provided data, the primary trial only reported 7 cardiac-related adverse events: cardiac failure (1 case), cardiogenic shock (1 case), palpitations (0 cases), pericardial effusion (0 cases), right ventricular failure (1 case), and an unspecified \"cardiac event\" (1 case). Therefore, the statement that the primary trial reported more than 6 different types of cardiac-related adverse events is incorrect."
    },
    "c1f9982f-c4c9-48dc-887a-7ae05f508c21": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03329937",
        "Statement": "the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle, for 2 cycles",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR's description of the Niraparib intervention. In the primary CTR, it is stated that participants received niraparib 200 mg orally (PO) once daily for a 28-day treatment cycle. This description matches the statement exactly for the first two treatment cycles."
    },
    "e966302f-9378-4681-b2c6-9d8b5b5f709f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Statement": "The majority of patients in the primary trial experienced an adverse event.",
        "Label": "Entailment",
        "explain": "The statement should be entailed based on the data in the primary trial CTR, as 75.00% of patients experienced an adverse event."
    },
    "75130da8-77be-45d1-bc32-dfc97c1a1dae": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00325598",
        "Statement": "the secondary trial has a much longer duration than the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the information provided in the CTRs. \n\nThe primary trial in the given CTRs has a total treatment duration of 16 weeks, while the secondary trial in the CTRs also has a total treatment duration of 16 weeks. Hence, neither trial is longer than the other in terms of treatment duration.\n\nHowever, it is important to note that the outcome measurements and treatments differ between the two trials, so the overall length of each trial in terms of the time spent in the study, including follow-up visits and other assessments, could potentially vary. But based on the given information, the statement is incorrect."
    },
    "c71cbcd6-3786-4b90-8991-b3c6e159ae77": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00975676",
        "Secondary_id": "NCT00632489",
        "Statement": "the primary trial uses the same dosage of Triptorelin as the secondary trial uses for Capecitabine and Lapatinib.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided CTRs. The primary trial specifies the use of triptorelin, while the secondary trial discusses the use of Capecitabine and Lapatinib with triptorelin. The dosage of triptorelin is not the same for both trials; in the primary trial, it is used in combination with tamoxifen or exemestane, while in the secondary trial, it is administered with Capecitabine or Lapatinib."
    },
    "ed48936e-4933-437b-a7ba-e65b4c1fd276": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03167359",
        "Secondary_id": "NCT01385137",
        "Statement": "Hypofractionated Simultaneous Integrated Boost Radiotherapy is used in  the secondary trial. but not the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. According to the primary CTR, Hypofractionated Simultaneous Integrated Boost Radiotherapy is used in the primary trial."
    },
    "b01e966e-6624-4740-b477-a8bbbd8eec50": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02102490",
        "Secondary_id": "NCT00768222",
        "Statement": "In contrast to the secondary trial, the primary trial did not record any cases of Skin lymphangitis, Bone marrow suppression or Allergic shock.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTR data. In the primary trial, there were no recorded cases of Skin lymphangitis, Bone marrow suppression, or Allergic shock in the given Adverse Events sections, while the secondary trial reported at least one case for each of these adverse events. Therefore, the statement accurately contrasts the occurrence of these adverse events between the two trials based on the information available in the CTRs."
    },
    "92acd36d-ea44-4b98-acbc-e51382233089": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Statement": "Diarrhea was the most common adverse event in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Diarrhea was the most common adverse event in cohort 1 of the primary trial\" is entailed by the given CTR data in the Adverse Events section of the primary trial since 7 out of 30 participants (or 23.33%) experienced diarrhea, which is indeed the highest frequency of any adverse event listed in the CTR."
    },
    "01280892-ca31-4e46-831b-a076426f65e5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01401062",
        "Statement": "A patient who underwent T-cell transfer therapy in the past 6 months prior, and has fully recovered from the associated toxicities, would be excluded from the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary CTR's exclusion criteria as it specifies that patients who have undergone immunotherapy within 6 months prior to study enrollment are excluded, which includes T-cell transfer therapy. (Primary CTR: Exclusion Criteria - Immunotherapy)"
    },
    "959bd67a-1b2a-48da-ae44-211cbab4b665": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00393939",
        "Statement": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a month higher for patients in the Docetaxel + Sunitinib group of the primary trial than for the Docetaxel group.",
        "Label": "Entailment",
        "explain": "The statement is entailed as per the given CTR data. The median PFS values for the Docetaxel + Sunitinib group and Docetaxel group were 8.6 (8.2-10.3) months and 6.9 (6.5-7.3) months, respectively. The difference between these values is over a month (1.7 months). This difference is larger than the 95% confidence intervals for both groups, indicating that the observed difference is statistically significant. Therefore, the statement is entailed."
    },
    "92923765-76d4-4a27-a240-101690d9fea4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01432145",
        "Statement": "the primary trial patients are administered cyclophosphamide more often and in higher dosages than Methotrexate and 6-Mercaptopurine.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nJustification:\nThe statement that \"the primary trial patients are administered cyclophosphamide more often and in higher dosages than Methotrexate and 6-Mercaptopurine\" is contradicted by the information in the CTRs. In the primary trial, Methotrexate and 6-Mercaptopurine are administered weekly and daily, respectively, with dosages of 20mg/m2 and 75mg/m2 (initially) and 55mg/m2 (later), while Cyclophosphamide is not mentioned in the provided CTR. Therefore, it cannot be inferred that patients in the primary trial received Cyclophosphamide more often or in higher dosages than Methotrexate and 6-Mercaptopurine."
    },
    "437cb2c2-63e8-4d9b-a501-4b6a35db8d2b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429507",
        "Secondary_id": "NCT00038467",
        "Statement": "Unlike the secondary trial, the primary trial does not administer any medication orally or intravenously.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the information in the primary CTR since it describes an intervention involving Samarium 153-EDTMP, which is administered intravenously, not orally. The secondary CTR, on the other hand, only describes interventions involving oral medications (exemestane and tamoxifen)."
    },
    "5a5695e8-9b84-42ad-9f34-6dd043153943": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02872103",
        "Secondary_id": "NCT02995980",
        "Statement": "Adequate renal, hepatic and blood work is required for entry to the primary trial and the secondary trial, this includes the following criteria; hemoglobin  11.5 g/dL, aswell as ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and Serum creatinine should be less than 1.7x ULN.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by both primary and secondary CTRs. The primary CTR specifically mentions that liver function tests (ALT, AST, alkaline phosphatase and total bilirubin) and serum creatinine should be less than 2.5x ULN and 1.7x ULN, respectively. The secondary CTR also requires hemoglobin, ALT, AST, alkaline phosphatase, and total bilirubin to be within normal limits. However, the secondary CTR does not explicitly state the ULN values, but they are generally accepted as 2.5x ULN for ALT and AST and 1.7x ULN for creatinine in clinical practice. Therefore, the statement is consistent with the given CTRs."
    },
    "33634c51-0fb9-4de1-966d-14784bca93f8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01847001",
        "Statement": "Spanish women with a heart rate of at least 60 beats per minute are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the Primary Trial's Inclusion Criteria which states \"English or Spanish speaking women age 18 with Heart Rate > 60 bpm\" and \"Spanish women\" are eligible for the trial."
    },
    "8e46dc77-fa36-4231-a124-0ff6392891a1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02297412",
        "Secondary_id": "NCT02667626",
        "Statement": "Cohort 2 of the secondary trial and the primary trial are control groups.",
        "Label": "Entailment",
        "explain": "The statement \"Cohort 2 of the secondary trial and the primary trial are control groups\" is entailed by the provided CTRs information. \n\nJustification:\n\nIn the primary trial, Arm II is the placebo group and is referred to as the control arm. In the secondary trial, Cohort 2 (Control) receives web-based resources and study adherence reminders but does not receive the intervention (SCPR) immediately. They only gain access to the SCPR at the end of the 24 weeks of follow up. Therefore, both Arm II of the primary trial and Cohort 2 (Control) of the secondary trial can be considered as control groups according to the provided trial descriptions."
    },
    "d11b0673-42a9-46c0-887f-d5a9b038264f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00407888",
        "Statement": "Arm 1 of the primary trial receive dose-intensive chemotherapy on a week long cycle up to 12 times in the absence of disease progression or unacceptable toxicity.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the primary trial's INTERVENTION section. The statement accurately describes the number of cycles of dose-intensive chemotherapy that Arm 1 patients receive, which is up to 12 times, as stated in the CTR."
    },
    "e08c196a-e3f0-420b-a252-7e2818949038": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03197389",
        "Statement": "All women (regardless of Reproductive status) must use adequate methods of contraception to be eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"All women (regardless of Reproductive status) must use adequate methods of contraception to be eligible for the primary trial\" is entailed by the CTR as follows:\n\n- For female subjects of childbearing potential: they must use an adequate method of contraception as outlined in Section 5.7.2 - Contraception, for the course of the study through 120 days after receiving the study medication. [Primary Trial, Inclusion Criteria, Section 5.7.2]\n- Male subjects of childbearing potential must also agree to use an adequate method of contraception as outlined in Section 5.7.1- Contraception, until 120 after receiving the study therapy. [Primary Trial, Inclusion Criteria, Section 5.7.1]"
    },
    "83511f04-e07c-438d-bf1e-f680fa49b384": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01901146",
        "Secondary_id": "NCT00209092",
        "Statement": "Cohort 1 of the primary trial recorded more instances of Neutropenic fever than Cohort 1 of the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Cohort 1 of the primary trial recorded more instances of Neutropenic fever than Cohort 1 of the secondary trial\" is not entailed by the provided data in the CTRs. The primary trial reported one case of Febrile neutropenia in Adverse Events 1 of Cohort 1, while the secondary trial reported no cases in Adverse Events 1 of Cohort 1. However, there are differences in the overall rates of adverse events between the two trials, but the statement only compares the incidence of Neutropenic fever specifically in Cohort 1. The statement contradicts the data provided in the CTRs."
    },
    "c06a6571-6bc9-4bc1-b4f5-3e7aa71c8c94": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00290758",
        "Statement": "There was one genitourinary adverse events recorded in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the Primary Trial Adverse Events section since it reports one genitourinary adverse event (Obstruction, GU: Uterus) out of 62 participants."
    },
    "72bb3c6e-66b0-4380-9da2-5a5867d715fd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00475670",
        "Statement": "compared to cohort 1 of the primary trial, there are more cases of every observed adverse event in cohort 2. ",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the provided CTR information. In the Primary Trial, the total number of adverse events was 0 for cohort 1 and 6 for cohort 2, meaning that cohort 1 experienced fewer adverse events than cohort 2 in the Primary Trial. However, the statement suggests that cohort 2 of the secondary trial, which is not provided in the CTR, has more cases of every observed adverse event than cohort 1 of the primary trial."
    },
    "1b433096-f36a-4205-b16e-f9a370be3d05": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01365845",
        "Statement": "More than 18 participants in the primary trial had radiation dermatitis.",
        "Label": "Contradiction",
        "explain": "Contradiction. The primary trial report indicates a total of 18 participants and 4 (22.22%) of them had radiation dermatitis, which is less than 19 (more than 18) participants."
    },
    "076ead15-ce03-4c33-9050-1f6eb13764a1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01490892",
        "Secondary_id": "NCT02364388",
        "Statement": "The intervention in the primary trial requires an injection and two different imaging modalities, whereas the secondary trial provides almost no details in the intervention section.",
        "Label": "Entailment",
        "explain": "Contradiction. The statement in the clinical trial expert's observation directly contradicts the information provided in the primary CTR's INTERVENTION section, which clearly outlines the injection followed by two distinct imaging modalities, while the secondary CTR does not provide any details about the imaging modalities used."
    },
    "0d76e3b7-c6ed-48b2-a3c2-4857a9c02f76": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00323479",
        "Secondary_id": "NCT03078751",
        "Statement": "There were more cases of Pulmonary embolisms in the primary trial than the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial reports one case of Pulmonary embolism out of 110 participants (0.91%), while the secondary trial reports no cases of Pulmonary embolism out of 26 or 24 participants."
    },
    "3e1037fd-cc1e-4229-892f-95d0987d9a68": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042535",
        "Statement": "The Maximum Tolerated Dose (MTD) of of 1-methyl-d-tryptophan (indoximod) observed in the primary trial was 800 mg.",
        "Label": "Entailment",
        "explain": "The statement \"The Maximum Tolerated Dose (MTD) of 1-methyl-d-tryptophan (indoximod) observed in the primary trial was 800 mg\" is entailed by the CTRs. \n\nJustification: \n\nThe MTD of 1-methyl-d-tryptophan in the primary trial was defined as the highest dose level at which 0 or 1 out of 6 patients experienced a dose limiting toxicity. The text states that the MTD was 0 or 1 out of 6 patients experiencing DLTs at the 800 mg dose level. Therefore, the statement made by the expert is an accurate representation of the information contained in the CTR."
    },
    "f25adbc7-c0a0-44ed-af93-02f4bced7208": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00343382",
        "Secondary_id": "NCT00798135",
        "Statement": "Cohort 2 of the primary trial recieves the same dose of Pilocarpine as cohort 2 of the secondary trial recieves of oral itraconazole.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the information in the CTRs. In the primary trial, cohort 2 receives 1 capsule of placebo 4 times per day, which is not the same dose of Pilocarpine, 5mg given 2 times per day, that cohort 2 in the secondary trial receives of oral itraconazole. Therefore, the statement is not entailed."
    },
    "99951bae-37c8-4299-8ec1-4577a97d0b81": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394082",
        "Secondary_id": "NCT01033032",
        "Statement": "the primary trial recorded cases of pleural effusion and Spinal compression fracture, neither of these were observed in the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the information in the CTRs. In the primary trial, there was one case of pleural effusion (1/50 or 2.00%), but in the secondary trial, there were no cases reported (0/3 or 0.00%). Similarly, in the primary trial, there was one case of spinal compression fracture (1/50 or 2.00%), but in the secondary trial, no such cases were reported (0/3 or 0.00%). Therefore, the statement that \"neither of these were observed in the secondary trial\" is not in agreement with the CTR data, as both pleural effusion and spinal compression fractures were present in the primary trial but absent in the secondary trial."
    },
    "b66b62c4-902d-4e19-929e-2086b349bd93": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00149214",
        "Statement": "Prior use of Anthracycline drugs for anticancer therapy is prohibted for patients in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Prior use of Anthracycline drugs for anticancer therapy is prohibited for patients in the primary trial\" is entailed by the primary CTR's exclusion criteria, specifically the line \"Prior anthracyclines as part of prior anticancer therapy.\""
    },
    "c789e79c-a254-4bb1-9d15-73d1726da8a6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334802",
        "Secondary_id": "NCT00167414",
        "Statement": "There is no age limit for either the secondary trial or the primary trial. Patients simply need to be diagnosed with interstitial pneumonia or pulmonary fibrosis to be eligible.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the CTRs provided, as the eligibility criteria for both primary and secondary trials explicitly state that patients cannot have interstitial pneumonia or pulmonary fibrosis to participate in the trials (Primary Trial: Exclusion Criteria; Secondary Trial: Exclusion Criteria). Therefore, the statement that there is no age limit but patients need to have interstitial pneumonia or pulmonary fibrosis for eligibility is contradictory to the given CTR data."
    },
    "2b182323-9357-486a-87aa-09ddc6230bf1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02481050",
        "Statement": "There is only 1 adverse event in the primary trial that occurred more than once.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nExplanation: \n\nIn the primary CTR, there are two cases of Sepsis reported, which contradicts the statement that only one adverse event occurred more than once."
    },
    "9681ec15-7545-455e-ac8c-1052fc199b11": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02162667",
        "Statement": "The Herceptin group in the primary trial had a higher number of Patients Achieving Pathological Complete Response than the CT-P6 group.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the data presented in the CTRs. The percentage of patients achieving pathological complete response in the Herceptin group (50.39%) is higher than that of the CT-P6 group (46.77%). This difference is statistically significant as indicated by the confidence intervals (44.10-56.68% for Herceptin vs 40.43-53.19% for CT-P6), suggesting that the Herceptin group had a higher proportion of responders.\n\nJustifications:\n1. The CTRs describe that both trials used the same inclusion criteria and treatment regimens (neoadjuvant chemotherapy with docetaxel, FEC, and either Herceptin or CT-P6) except for the addition of Herceptin in the Herceptin group.\n\n2. The outcome measurement (Pathological complete response) and time frame (after Neo-adjuvant therapy and Surgery) are the same for both trials, ensuring consistency in the data being compared.\n\n3. The number of participants in each arm and their respective response percentages are provided, making it possible to directly compare the groups.\n\n4. The confidence intervals indicate the precision of the response estimates and suggest that the observed difference between the two groups is not due to chance."
    },
    "8ca512c3-72d8-4179-a63e-51d83d76445f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00256243",
        "Secondary_id": "NCT00721630",
        "Statement": "the secondary trial and the primary trial are both taking place at the Memorial Sloan Kettering Cancer Center.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. Both trials are taking place at Memorial Sloan Kettering Cancer Center. There is no contradiction with the provided descriptions as there are no statements in the CTRs that suggest the trials are not being conducted at Memorial Sloan Kettering Cancer Center."
    },
    "171d0a20-8943-4994-a48a-7dff124e62ee": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00046891",
        "Statement": "cohort 1 of the primary trial recieves 60 mg of Ginkgo Biloba twice daily.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary trial CTR as cohort 1 of the primary trial indeed receives 60 mg of Ginkgo Biloba twice daily, as stated in the intervention section (60 mg BID)."
    },
    "25cc9a6e-656d-44ee-a301-93f5879407a0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01923168",
        "Statement": "Intervention 1 of the primary trial require participants to take a total of 150 mg alpelisib every two days.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the CTR as the dosage of alpelisib in Intervention 1 is stated to be 300 mg once daily, not 150 mg every two days."
    },
    "d9b4d4aa-0094-405e-83a3-cf2978cfda38": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00347919",
        "Statement": "56.9% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12.",
        "Label": "Entailment",
        "explain": "The statement \"56.9% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12\" is entailed by the CTRs, as the percentage of participants without progressive disease for Cohort 1: Lapatinib 1500 mg (Independently Evaluated) is 51.1% (100% - 38.9%), which is quite close to 56.9%. The statement is derived from the information provided, and there is no contradiction in the CTRs that would invalidate the claim."
    },
    "caa55802-329d-4a1f-a9a7-b99afc44fd67": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00038467",
        "Statement": "The patient groups in the primary trial each receive the same doses of different oral medication, either Tamoxifen or Exemestane.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. \n\nJustifications: \nThe statement correctly describes that both patient groups in the primary trial receive the same doses (20 mg or 30 mg) of different oral medications, either Tamoxifen or Exemestane. This matches the information provided in the INTERVENTION sections of the primary CTR."
    },
    "6df9ec3b-43ba-442a-a4f5-4ce3cdb7a2a0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02525718",
        "Secondary_id": "NCT02606708",
        "Statement": "Patients in group 1 of the secondary trial and the primary trial receive the same dosage of oral placebo.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nThe primary trial involves the administration of placebo injections during surgery and not as an oral medication. Therefore, the statement does not hold true for both trials."
    },
    "0880bb0b-9e8d-4fce-8795-2ec6526d9bfb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT01106898",
        "Statement": "In the secondary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy  compared to other patients. Whereas all the primary trial participants receive the same treatment.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs. The primary trial involves all participants receiving the same treatment with vorinostat, while in the secondary trial, Her-2 neu positive patients receive additional maintenance therapy with trastuzumab, making it an extra treatment compared to other patients."
    },
    "baea8eb9-a6e7-4473-9b4b-28a4fdb531ad": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02780713",
        "Statement": "Both cohorts of the primary trial are administered the same drugs in different doses .",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided CTR information. \n\nJustification: \nBoth the Intervention 1 and Intervention 2 descriptions in the Primary Trial state that participants received AZD9496, and the doses are different (100 mg for each), which fulfills the requirement stated in the clinical trials expert's sentence that \"both cohorts of the primary trial are administered the same drugs in different doses.\""
    },
    "01f89936-1621-4dd5-93b7-8b0c64b397fd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00054275",
        "Statement": "A patient with severe anginal syndrome but angiographically normal coronary arteries would be unable to participate in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement should be contradicted. \n\nJustification: \nThe primary CTR does not include any exclusion criteria related to anginal syndrome or cardiac arrhythmia. Therefore, a patient with severe anginal syndrome but angiographically normal coronary arteries would be permitted to participate in the trial."
    },
    "ee7fe82e-de91-45c7-bd12-bff5d6c887a3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00320411",
        "Statement": "the primary trial participants must take 6 tablets of Lapatinib Monotherapy (250mg) PO once daily.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR of the primary trial since it specifies that \"Lapatinib: 1500 mg orally once daily\" can be achieved by taking \"six 250 mg tablets.\" Therefore, the statement that \"the primary trial participants must take 6 tablets of Lapatinib Monotherapy (250mg) PO once daily\" is consistent with the provided information."
    },
    "888a8d39-3ad6-401e-acf2-cf5e01a73bf2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266110",
        "Secondary_id": "NCT00879086",
        "Statement": "the primary trial had a much higher rate of adverse events than the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial reported an adverse event rate of 11.76%, while the secondary trial reported a lower rate of 34.00%. However, the specific types and frequencies of adverse events differed significantly between the two trials, with the primary trial reporting more cases of nausea, pain, and constipation, and the secondary trial reporting more cases of anemia, leukopenia, neutropenia, thrombocytopenia, atrial flutter, visual impairment, cardiac failure congestive, and dysphagia. Therefore, a direct comparison of the total adverse event rates alone does not provide enough information to establish semantic entailment or contradiction, and it is necessary to consider the specific types and frequencies of adverse events as well.\n\nJustification:\n\nThe statement made by the expert in clinical trials asserts that the primary trial had a much higher rate of adverse events than the secondary trial based on the total adverse event rates alone. However, the CTRs provide more detailed information about the specific types and frequencies of adverse events, revealing significant differences between the two trials that cannot be ignored. The primary trial reported more cases of certain adverse events, such as nausea, pain, and constipation, while the secondary trial reported more cases of other adverse events, such as anemia, leukopenia, neutropenia, thrombocytopenia, atrial flutter, visual impairment, cardiac failure congestive, and dysphagia. Therefore, a direct comparison of the total adverse event rates alone does not accurately reflect the relationship between the primary and secondary trials, and the statement is contradicted."
    },
    "13466cbb-9f78-46ff-a983-09e2e9ad5a2c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00679211",
        "Statement": "1 patient in the primary trial presented a fever, in addition to either a cough or a sore throat.",
        "Label": "Entailment",
        "explain": "The statement \"1 patient in the primary trial presented a fever, in addition to either a cough or a sore throat\" is not directly entailed by the provided CTR data. However, the statement does not contradict the CTR either since there are no mentions of cough or sore throat in the primary trial's adverse events section. The statement pertains to the secondary trial, which is not provided."
    },
    "0beaef44-a39a-462c-a084-d3f824857673": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00374322",
        "Statement": "the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were more likely to achieve DFS at 5 years than placebo patients, however, there was less than a 30% difference in DFS rate between the two cohorts.",
        "Label": "Entailment",
        "explain": "The statement should be entailed based on the information provided in the CTRs. \n\nJustifications: \n1. The primary trial results state that Participants receiving lapatinib 1500 mg had a lower number of recurrences or deaths than the placebo group (252 vs 290).\n2. The time frame for assessing DFS in the primary trial is from randomization until disease recurrence, development of a second primary cancer, or death from any cause (assessed up to 6 years).\n3. The lapatinib treatment was continued for a longer duration compared to the placebo group due to the maximum treatment period being 12 months or until a recurrence or development of a second primary cancer.\n4. The statement specifies a 5-year DFS rate, which is consistent with the median follow-up time of 5.3 years for the primary analysis.\n\nTherefore, the statement that Participants receiving lapatinib 1500 mg were more likely to achieve DFS at 5 years than placebo patients, but the difference was less than 30%, is entailed based on the data presented in the primary CTR."
    },
    "8e45da73-f016-4ca0-b106-a3fabc960b36": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01432145",
        "Statement": "the primary trial patients are administered 6-Mercaptopurine more often and in higher dosages than Methotrexate.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nThe CTR indicates that both treatments are given continuously until disease progression, and the frequency of administration is once a day for 6MP and once a week for Methotrexate. Additionally, the dosages before the Urgent Safety Measure were 75mg/m2 of 6MP and 20mg/m2 of Methotrexate daily, while the reduced dosages were 55mg/m2 of 6MP and 15mg/m2 of Methotrexate weekly. Based on this information, patients in the primary trial receive Methotrexate less frequently and in lower dosages than 6-Mercaptopurine."
    },
    "37dc56a4-4756-4ab0-8055-7637bf579740": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01420146",
        "Secondary_id": "NCT00077376",
        "Statement": "the primary trial and the secondary trial are both single arm clinical trials.",
        "Label": "Entailment",
        "explain": "The statement should be entailed, as both the primary and secondary trials involve a single arm of patients receiving distinct interventions."
    },
    "65e370b7-7726-477e-8730-8cea734d1609": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT01823107",
        "Statement": "Patients in the primary trial receive an Infusion of 3 ml Perflutren Lipid Microspheres at a rate of approximately 3ml/min, whereas in the secondary trial subjects are implanted with a permanent Meso BioMatrix Acellular Peritoneum Matrix.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial describes the administration of an infusion of Definity (Perflutren Lipid Microspheres) using a specific dosage and infusion rate, while the secondary trial mentions the implantation of a Meso BioMatrix Acellular Peritoneum Matrix, which is not a comparable intervention to the infusion described in the primary trial."
    },
    "affdd551-15e2-4a47-8c20-209cc01570ec": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03012477",
        "Statement": "One patient in the primary trial experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Diarrhea.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the Primary Trial Adverse Events section, specifically the entry for the Thromboembolic event (1/34 or 2.94%) and Diarrhea (7/34 or 20.59%). The statement correctly identifies that one patient experienced a thromboembolic event and that diarrhea was the most common adverse event."
    },
    "2152f503-4fa4-4f32-b766-a05a4c69742f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02176083",
        "Secondary_id": "NCT03061175",
        "Statement": "Neither the primary trial or NCT0306117 use chemotherapy, adverse event management courses or radiotherapy in their intervention.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided CTRs. The Intervention sections of both primary and secondary trials indicate that text message management and web-based CPM-DA are being used, neither of which involve chemotherapy, adverse event management courses, or radiotherapy."
    },
    "a7903e59-9620-457a-8d83-eb6eb5dd8a2b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01300351",
        "Statement": "At least 1 participant in each cohort of the primary trial showed signs of poor liver function.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the CTR data. \n\nExplanation: \n\nAccording to the CTR data for the primary trial, only one participant in cohort 1 showed signs of poor liver function (Hepatic function abnormal). Similarly, none of the participants in cohort 2 reported signs of poor liver function (Hepatic function abnormal was not listed in the Adverse Events section for the secondary trial). Therefore, the statement that \"at least 1 participant in each cohort of the primary trial showed signs of poor liver function\" is incorrect as per the provided CTR data."
    },
    "dc7e7fbe-eed9-4307-b584-30ecaeb77c95": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00186121",
        "Statement": "Patients with E2 outside the premenopausal range are ineligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Patients with E2 outside the premenopausal range are ineligible for the primary trial\" is entailed by the CTR. \n\nJustification: \n\nThe CTR states that for a patient to be eligible for the primary trial, their estrogen (E2) levels must be in the premenopausal range. This is stated in the following conditions: last menstrual period within 3 months, follicle-stimulating hormone (FSH) in the premenopausal range, or plasma estradiol in the premenopausal range for those who have received tamoxifen within the past 3 months. Therefore, patients with E2 levels outside the premenopausal range would not meet the eligibility criteria and are indeed ineligible for the trial."
    },
    "a34c6194-b6d9-49c3-8ddb-72de10c8a18c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02006979",
        "Statement": "Neither cohort of the primary trial need to perform low intensity exercise prior to each cycle of anthracyclines.",
        "Label": "Entailment",
        "explain": "Contradiction.\n\nIn the primary trial, Intervention 1 specifies that an acute bout of exercise is performed 24 hours prior to each cycle of anthracyclines. This directly contradicts the statement that neither cohort of the primary trial need to perform low intensity exercise prior to each cycle of anthracyclines."
    },
    "da00532d-57a8-4fe2-a2de-acc525161fd9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01120184",
        "Statement": "At least 1 patient in cohort 1 of the primary trial suffered from a coagulation disorder.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nExplanation:\n\nThe statement asserts that at least one patient in cohort 1 of the primary trial suffered from a coagulation disorder. However, neither the primary nor the secondary CTRs provide any mention of coagulation disorders among the listed adverse events. Therefore, the statement contradicts the information in the provided CTRs."
    },
    "f90364e9-caee-4075-b444-2db1bf846d3a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02511730",
        "Secondary_id": "NCT00193206",
        "Statement": "Patients with prior chemotherapy are excluded from the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the given CTRs.\n\nExplanation:\n\nIn the primary CTR, the exclusion criteria state that \"Subjects with unknown clinical status not participating in FMSU004A protocol\" are excluded. Although it does not explicitly mention \"prior chemotherapy\" in this particular exclusion, the fact that the CTR is related to a clinical trial implies that patients with a history of chemotherapy treatment would also be excluded since they are not participating in the trial.\n\nIn the secondary CTR, the exclusion criteria clearly state that \"Prior chemotherapy for breast cancer\" is a reason for exclusion. This directly aligns with the statement made by the expert in clinical trials.\n\nTherefore, both primary and secondary CTRs provide sufficient information to support the entailment of the statement."
    },
    "deb78676-8f04-44c4-a5f6-389740d8a268": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01908101",
        "Statement": "Prior exposure to doxatel is obligatory for patients in the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradiction. The CTR for the primary trial specifies prior exposure to taxane, not doxatel, as a requirement for patient inclusion. (Primary Trial, Inclusion Criteria)."
    },
    "a06d1ca5-c890-4157-b1d2-0b70fd0092bd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00591851",
        "Statement": "There were 4 different cardiac adverse events recorded in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"There were 4 different cardiac adverse events recorded in cohort 1 of the primary trial\" is contradicted by the information in the CTR. The listed cardiac adverse events are Sinus bradycardia and Pericarditis, which only amount to 2 distinct types. The other mentioned events (Febrile Neutropenia, Abdominal Pain, Diarrhea, Lower gastrointestinal hemorrhage, Nausea, Non Cardiac-Chest pain, Fever, Skin infection, Neutrophil count decreased) are not cardiac adverse events."
    },
    "5bc0d21d-a040-4d30-b0c7-8793cba6aba8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01091168",
        "Statement": "Patients in the control group of the primary trial had a median Overall Survival of less than a year.",
        "Label": "Entailment",
        "explain": "Contradicted. The median overall survival of the control group in the primary trial was 9.3 (7.5 to 10.9) months, which is more than one year. Therefore, the statement made by the clinical trial expert is contradicted by the provided information in the CTRs."
    },
    "9bcbadcc-ae56-4254-ac8b-ab5d35e80eba": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00952731",
        "Secondary_id": "NCT00956813",
        "Statement": "Cohort 2 in the primary trial and the secondary trial but receive daily placebo doses.",
        "Label": "Entailment",
        "explain": "Contradiction.\n\nExplanation:\n\nIn the primary trial, Cohort 1 received daily placebo doses (Placebo Gel + Oral Placebo), but Cohort 2 received active treatment with afimoxifene (4-hydroxytamoxifen gel 2mg/breast). In contrast, the statement claims that Cohort 2 in both the primary and secondary trials receives daily placebo doses. This statement contradicts the descriptions in the CTRs. In the primary trial, Cohort 2 does not receive a daily placebo dose; instead, they receive afimoxifene treatment. In the secondary trial, Cohort 2 receives a placebo."
    },
    "5a1358af-f51b-49f8-b1c0-99a0b108b0a2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Statement": "There were more cases of Febrile neutropenia than leukopenia observed in the primary trial, but less cases of neutropenia than leukopenia.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the data in the given CTRs. In the primary trial, there were 10 cases of Febrile neutropenia and 1 case of leukopenia. In the secondary trial, there were 10 cases of Febrile neutropenia and 4 cases of leukopenia. However, according to the statement, there should have been more cases of Febrile neutropenia than leukopenia in the primary trial but less cases of neutropenia than leukopenia overall between the trials. This is not supported by the data in the CTRs."
    },
    "ed0e1b04-aea7-4da0-922f-2be69c768c09": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02635737",
        "Statement": "Patients with implantable cardioverter defibrillators are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs. \n\nJustification: The primary CTR explicitly lists patients with a Pacemaker or implanted device as an exclusion criterion (Section: Inclusion/Exclusion Criteria). The secondary trial expert's statement aligns with this information by mentioning patients with implantable cardioverter defibrillators as being excluded from the primary trial."
    },
    "73d323e7-1a38-49d4-97f4-a15f1664fb3e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01439711",
        "Statement": "One patient in the primary trial had a 0.98 cm3 increase in Total MRI Functional Tumor Volume (FTV) over 3 months, almost 1cm3 less than average.",
        "Label": "Contradiction",
        "explain": "Contradiction. The expert statement mentions a specific patient in the primary trial with a 0.98 cm3 increase in FTV over 3 months, which is almost 1 cm3 less than the average mean change of -1.93 cm3 mentioned in the CTR for the Letrozole + MRI arm. This contradicts the statement in the CTR that the mean change in FTV was -1.93 cm3 (-2.87 to -0.98) over 3 months."
    },
    "02dea6a3-d94f-4650-bf4f-be8fdb0a382f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02010021",
        "Statement": "A patient has recently had an oophorectomy,they are excluded from the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the inclusion criteria of the primary trial, specifically the condition: \"Women must be either post-menopausal, or pre-menopausal having undergone oophorectomy.\" Therefore, a patient who has had an oophorectomy should not be excluded from the primary trial based on the provided information in the CTR."
    },
    "4c8a124b-f015-42e2-8ad3-6168f21fe705": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00943670",
        "Statement": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle, before T-DM1 intravenous (IV) infusion.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the information in the CTRs. The Change From Baseline in Mean Duration of the QTcF Interval for patients in the T-DM1 arm is indeed reported to be highest on Day 1 of the third cycle, before the T-DM1 IV infusion, as stated in the CTR under \"Results 1\" for Cycle 3, Day 1, 15 minutes pre-dose."
    },
    "fb43432d-6c1b-4ff7-aea8-72bc2519a12d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00130533",
        "Statement": "Nobody in cohort 1 of the primary trial suffered from Hyperbilirrubinemia.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the information provided in the CTRs. In the primary trial, one participant in cohort 1 experienced Hyperbilirrubinemia as an adverse event (see Adverse Events 1 section)."
    },
    "d6df95f5-472f-4b14-9cd4-5d5ef238175a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005879",
        "Statement": "There are criteria for PRIOR CONCURRENT THERAPY, PATIENT CHARACTERISTICS and DISEASE CHARACTERISTICS for entry to the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs provided, as both trials list \"PRIOR CONCURRENT THERAPY,\" \"PATIENT CHARACTERISTICS,\" and \"DISEASE CHARACTERISTICS\" as sections with specified criteria for trial entry."
    },
    "bd8c39c6-96a3-40f8-80e6-6cbb6bdaecb5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553410",
        "Statement": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial due to her age.",
        "Label": "Contradiction",
        "explain": "Contradicted \n\nJustification: \n\nThe patient's age (55 years old) falls within the acceptable range for postmenopausal status in the primary trial, as long as she has biochemical evidence of definite postmenopausal status (defined as estradiol, LH, and FSH in the postmenopausal range). The statement incorrectly assumes that the patient would be excluded from the trial based on her age alone, disregarding the requirement for definitive postmenopausal status as outlined in the CTR."
    },
    "52ae415a-d8ab-48f5-abcb-9e8c5bb4fc83": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00982319",
        "Statement": "Only Post menopausal women can enter the primary trial, as long as they do not have prior hormone replacement therapy.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the Primary Trial's Inclusion Criteria since only postmenopausal women are included in the trial if they have not used hormone replacement therapy within the prior 6 months."
    },
    "3bb3f3d5-e2e8-4cde-9d4f-dfc4b25c0b70": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01425268",
        "Secondary_id": "NCT01373671",
        "Statement": "CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and saline is used in both of the study groups in the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided CTRs. In the primary trial, Intervention 1 (AeroForm Tissue Expansion) involves the use of carbon dioxide for inflation. In the secondary trial, Intervention 1 (FFDM and DBT) does not involve the use of carbon dioxide but Intervention 2 (FFDM Only) does not specify the type of imaging modality used, so it can be assumed that it doesn't involve carbon dioxide either. The statement explicitly mentions that CO2 is used in one study group of the primary trial and saline is used in both study groups of the secondary trial, making it an accurate reflection of the information provided in the CTRs."
    },
    "f820384b-0bf5-4f2e-96fd-2c8b13a4646c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01289353",
        "Secondary_id": "NCT00429182",
        "Statement": "the primary trial and the secondary trial share at least one drug in their chemotherapy regiment.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the CTRs. \n\nJustifications: \n\nBoth the primary and secondary trials utilize Carboplatin in their chemotherapy regimens. In the primary trial, Carboplatin is given intravenously at a weekly dose of 2.0 AUC for 6 weeks. In the secondary trial, Carboplatin is given intravenously at a target AUC of 20, which is then divided into 4 doses given on days -6, -5, -4, and -3 prior to stem cell infusion."
    },
    "f7410166-82a7-4d15-8a04-47287ef6884c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448591",
        "Statement": "Only two types of adverse events occurred in more than 1% of patient in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "explain": "The statement should be contradicted. According to the given CTR for the primary trial, febrile neutropenia (5.17%) and neutropenia (4.33%) occurred in more than 1% of the patients in cohort 1."
    },
    "80726ab0-e8e4-4c42-860b-fdedad407517": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121836",
        "Statement": "Patients that are not willing to sign and give written informed consent for participation of the primary trial will still be included.",
        "Label": "Contradiction",
        "explain": "The statement is not contradicted by the provided CTR information as there is no mention of informed consent as an inclusion criterion in either the primary or secondary trial's eligibility criteria. Therefore, the statement does not necessarily entail that patients without written informed consent are included, but it does not contradict this possibility according to the provided CTR information."
    },
    "f2e1c4f6-2f62-4a5e-b033-d798ba781d1d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02725801",
        "Secondary_id": "NCT04030104",
        "Statement": "Neither the primary trial or the secondary trial have placebo groups.",
        "Label": "Entailment",
        "explain": "The given statement is entailed by the provided CTRs as neither of them mention a placebo group in any of their interventions."
    },
    "d42054cd-deb6-4436-941c-9e3a06c713cc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00036270",
        "Statement": "In total Less than 10% of patients in the primary trial either had a disease relapse or died.",
        "Label": "Contradiction",
        "explain": "Contradiction. The CTRs provide the number of events (disease relapse or death) for both the Exemestane and Tamoxifen Followed by Exemestane arms. The sum of those events for both arms in the primary trial is 740 (352 + 388), which is greater than 10% of the overall number of participants analyzed in the primary trial (4898). Therefore, the statement contradicts the information provided in the CTRs."
    },
    "0507fbf8-3557-4ace-b015-5e106b96f6a9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00068588",
        "Statement": "the primary trial and the secondary trial use Maximum Tolerated Dose Determined by Dose-limiting Toxicities as their outcome measurements.",
        "Label": "Entailment",
        "explain": "The statement should be entailed. \n\nExplanation: Both primary and secondary trials use \"Maximum Tolerated Dose Determined by Dose-limiting Toxicities\" as their outcome measurements. The primary trial determines the MTD using the number of DLTs observed in cohorts during dose escalation, whereas the secondary trial uses the same concept but with different cohort sizes and a definition of DLT that aligns with the revised NCI CTC v 2.0. The trials may differ in their dosing regimens and drugs used, but they share the common objective of identifying the maximum tolerated dose based on the occurrence of dose-limiting toxicities."
    },
    "49ecc5a6-89be-48b6-85c5-c809c83f5baf": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00825734",
        "Statement": "Patients with any of the following conditions will be excluded from the primary trial; grade 1 infection, unstable angina or a grade 4 hemorrhage within the last month.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed by the CTR. The exclusion criteria in the CTR include uncontrolled intercurrent illness including, but not limited to, ongoing or active infection >grade 2 and previous pulmonary hemorrhage or bleeding event  grade 2 within 4 weeks of the first dose of study treatment. While the expert's statement mentions only grade 1 infection and grade 4 hemorrhage, these conditions fall under the broader category of uncontrolled intercurrent illness mentioned in the CTR. Therefore, patients with these conditions would also be excluded according to the CTR."
    },
    "68792f63-d7b5-4570-bf8e-95e4cb8094e9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00343382",
        "Secondary_id": "NCT00798135",
        "Statement": "Cohort 2 of the primary trial recieves a lower dose of Pilocarpine than cohort 2 of the secondary trial recieves of oral itraconazole.",
        "Label": "Entailment",
        "explain": "The statement is entailed. In the primary trial, cohort 2 receives 1 capsule of placebo 4 times per day, which is less frequent than 5mg of Pilocarpine 2 times per day administered to cohort 2 in the secondary trial. Additionally, the dose of Pilocarpine is lower than the dose of oral itraconazole given in the secondary trial. Therefore, the statement that cohort 2 of the primary trial receives a lower dose of Pilocarpine than cohort 2 of the secondary trial receives of oral itraconazole is justified."
    },
    "2ddd64c7-98ef-4b06-9f01-e59d3731e8ca": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00483223",
        "Secondary_id": "NCT00811135",
        "Statement": "There are more cases of Intestinal perforation, Chest pain, death, Erysipelas and Pneumonia in the secondary trial than in the primary trial",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the given CTRs. In the primary trial, there is 1 case (1.16%) of intestinal perforation, 1 case (1.16%) of chest pain, and no cases of death, Erysipelas, or Pneumonia reported. In contrast, the secondary trial reports 1 case (1.14%) of intestinal perforation, 1 case (1.14%) of chest pain, 1 case (1.14%) of death, 1 case (1.14%) of Erysipelas, and 1 case (1.14%) of Pneumonia. The discrepancy in the number of adverse events for each type between the two trials contradicts the statement."
    },
    "a1a5767f-07e7-4a33-a26f-586cf71a208d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01118624",
        "Statement": "We cannot compare the doses and frequencies provided in the intervention sections of the secondary trial and the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR information. \n\nExplanation:\n\nThe primary trial does not specify the dose or frequency of Tomosynthesis Breast Scanning and breast CT Scanning, while the secondary trial only mentions the dose (study drug 190 mg/m^2) and frequency (for 2 to 4 weeks) of Pralatrexate administration. Therefore, the statement that \"We cannot compare the doses and frequencies provided in the intervention sections of the secondary trial and the primary trial\" is correct, as the primary trial lacks specific dose or frequency information for the intervention."
    },
    "9c80fb61-66dc-4b3d-82b9-4fb62db89422": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01326481",
        "Statement": "Patients with Myocardial Infarction or Deep vein thrombosis within the last 3 months are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the primary trial's exclusion criteria which include patients with angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, DVT, PTCA or CABG within the past 6 months. However, the statement is more specific as it mentions Myocardial Infarction or Deep vein thrombosis within the last 3 months, which is not covered by the primary trial's exclusion criteria. Therefore, the statement is contradicted as it stands, but a more specific version of the statement, such as \"Patients with Myocardial Infarction or Deep vein thrombosis within the last 3 months are excluded from the primary trial, except for those with MI or DVT more than 2 months ago,\" may be entailed if the CTR includes such a provision."
    },
    "6755a378-08bf-4e9b-a6de-166733d0307b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00181363",
        "Statement": "The only difference between the interventions used in the primary trial is the patients location.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the information provided in the CTRs. In both trials, the only difference stated regarding the interventions is the position of the patients (prone in the primary trial and supine in the secondary trial), which supports the expert's statement that the difference is in patient location."
    },
    "b7f3e657-638b-4463-9639-4fb0da2be042": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT01106898",
        "Statement": "In the secondary trial and the primary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy  compared to other patients.",
        "Label": "Contradiction",
        "explain": "The statement \"In the secondary trial and the primary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy compared to other patients\" is entailed by the provided CTR information. The statement is harmonious with the descriptions of the interventional sections in both CTRs. \n\nIn the primary trial, there is no mention of maintenance therapy, but in the secondary trial, Her-2 neu positive patients receive maintenance therapy with trastuzumab after the six initial courses. This additional therapy is not given to other patients in this trial. In the primary trial, patients were treated with vorinostat, which is not maintenance therapy. The statement correctly identifies a difference in treatments for a subgroup within the trials, making it entailed."
    },
    "5498a85b-a086-4d5d-b677-9ae44646a382": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00546156",
        "Secondary_id": "NCT00398567",
        "Statement": "There are no cases of Vertigo, Abdominal distension or Neutropenia in the primary trial or the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the information in the CTRs provided. \n\nJustification:\n\nThe statement asserts that there are no cases of Vertigo, Abdominal distension, or Neutropenia in the primary trial or the secondary trial. This claim is in agreement with the data presented in the CTRs, as there are no instances of Vertigo reported in either the primary or secondary trials, and no cases of Abdominal distension were noted in either trial. Furthermore, the primary trial reported one case (1/104) of Neutropenia in the primary trial, but the statement correctly asserts that there were no cases in the primary or secondary trials. The absence of Neutropenia in the secondary trial is also confirmed by the CTR, as no instances were reported. Therefore, the statement is entailed by the information in the CTRs."
    },
    "f3d2337e-6cd9-4e8c-b327-cbc48557b8dd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418457",
        "Statement": "antibiotics within 10 days prior to beginning is acceptable for patients entering the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR as it does not explicitly mention any restriction on the use of antibiotics within 10 days prior to surgery. However, it's worth noting that specific interventions, such as the type of anesthesia, are mentioned in the eligibility criteria but no mention is made about any restrictions related to antibiotic usage. Therefore, antibiotic usage prior to the trial does not affect the inclusion or exclusion of patients in the trial based on the provided information."
    },
    "f25d63c8-9033-4db6-9c15-2151d82e2a6d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00068588",
        "Statement": "between the two Arms of the primary trial, cohort 1 vastly outperformed cohort 2 in terms of the number of patients with complete tumor response.",
        "Label": "Contradiction",
        "explain": "Contradicted\n\nJustifications: \n\n1. The primary trial CTR does not provide information about the number of patients with complete tumor response in either Arm 1 or Arm 2. It focuses solely on the occurrence of DLTs.\n2. The secondary statement makes a comparison between the two arms based on a different outcome measure - complete tumor response - which is not mentioned or evaluated in the primary trial."
    },
    "5ab5f2e8-d1cf-4789-86b4-e2f6dbf443ea": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Secondary_id": "NCT00631852",
        "Statement": "A patient with a Histologically confirmed breast cancer would be accepted for the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by both CTRs.\n\nJustification: \n\nA patient with a histologically confirmed breast cancer would not be accepted for the secondary trial due to multiple exclusion criteria, such as history of prior chemotherapy or radiation therapy, usage of herbal supplements or alternative medications, history of chronic inflammatory process, and active bleeding or high risk of bleeding. Therefore, the statement is contradicted as it asserts that a patient with histologically confirmed breast cancer would be accepted for both the primary and secondary trials, but the information provided in the CTRs indicates that this is not the case."
    },
    "4fd10abc-81d1-44f4-825a-26e2eaeae979": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02308020",
        "Statement": "There were 23 participants in cohort 1 of the primary trial with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the information provided in the CTR. In Results 1, it states that there is no mention of the number or percentage of participants in the Abemaciclib: HR+, HER2+ Breast Cancer group achieving CR or PR based on RANO-BM response criteria."
    },
    "a12a46de-9d3e-4c6a-becb-d43653040bf0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00089973",
        "Statement": "the primary trial uses a 3 week cycle for SB-715992 administration, and the study lasts for 21 cycles.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary CTR. The primary trial specifies that one treatment cycle lasts for 3 weeks (21 days), and the study lasted for a total of 21 cycles. Therefore, the statement accurately reflects the administration schedule and duration of the trial as described in the CTR."
    },
    "66ee10ac-1bfe-44d6-9b91-8a2bb1983606": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01017549",
        "Secondary_id": "NCT01390064",
        "Statement": "the secondary trial has 5 more patients cohorts than the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is neither entailed nor contradicted based on the provided CTR information. There is no mention of the number of patient cohorts in either the primary or secondary trials in the given text."
    },
    "714c540c-1fa1-47c7-ac13-1e8f056d1e31": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115984",
        "Statement": "A total of 3 patients in cohort 1 of the primary trial experience a Herpes related adverse event.",
        "Label": "Contradiction",
        "explain": "The statement contradicts the information in the CTRs. In the primary trial, no patient in cohort 1 experienced a Herpetic eruption adverse event (0/33). In the secondary trial, all patients experienced the trial (23/23), but the information about Herpetic eruptions is missing in the provided Adverse Events 2 section. Therefore, we cannot infer that 3 patients in cohort 1 of the primary trial experienced a Herpes related adverse event based on the given CTR data."
    },
    "3948b30d-934d-485c-b324-b3571e2957a3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00688740",
        "Secondary_id": "NCT00191815",
        "Statement": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts.",
        "Label": "Entailment",
        "explain": "Contradiction.\n\nThe statement \"The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts\" is contradictory to the information provided in the CTRs, as Neutropenia occurs in a total of 4 cases in the primary trial (0.27% of 1492 participants) and not in the secondary trial, according to the data presented. The CTR for the primary trial lists 2 cases of Neutropenia in Adverse Events 1 (out of 744 participants), while the CTR for the secondary trial indicates no cases of Neutropenia in Adverse Events 1 (out of 67 participants). Therefore, the statement's assertion contradicts the information in the CTRs."
    },
    "45cf29ce-25f5-4719-8468-69d94893c9e7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01166763",
        "Statement": "the primary trial recorded 4 life-threatening adverse events.",
        "Label": "Contradiction",
        "explain": "Contradicted. The statement that \"the primary trial recorded 4 life-threatening adverse events\" contradicts the information in the Adverse Events 1 section of the CTR for the primary trial, which reports a total of 3 adverse events (none of which are specified as life-threatening) among 30 participants (10.00%)."
    },
    "7502090d-1bcb-4be9-9358-81afb9440a17": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "Patients with metallic vascular clips placed to prevent bleeding from conditions such as intracranial aneurysms, are elligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradiction. The primary trial's exclusion criteria explicitly list \"evidence of bleeding diathesis or coagulopathy\" as a reason for exclusion (CTR: Exclusion Criteria). Patients with metallic vascular clips for conditions like intracranial aneurysms are known to have coagulopathies, thus they would not meet the eligibility criteria for the primary trial (CTR: Eligibility Criteria)."
    },
    "89f84928-82a9-413e-ab25-400657002c55": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01840163",
        "Secondary_id": "NCT02005549",
        "Statement": "the primary trial and the secondary trial do not exclude patients with concurrent systemic antitumor therapy.",
        "Label": "Contradiction",
        "explain": "Contradiction. According to the provided CTR sections, the primary trial explicitly excludes participants with \"prior or concurrent systemic antitumor therapy\" (Primary Trial: Exclusion Criteria), while the secondary trial includes this criterion in its exclusion list as well (Secondary Trial: Exclusion Criteria). Therefore, the expert's statement contradicts the CTR data."
    },
    "79dbf7bf-e08d-4eae-a804-0daeb83d6f01": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00930930",
        "Statement": "The most frequent adverse event in cohort 1 of the primary trial was lymphopenia.",
        "Label": "Contradiction",
        "explain": "Contradiction. The most frequent adverse event in cohort 1 of the primary trial according to the given CTR was actually dehydration, with a frequency of 5/96 (5.21%). Lymphopenia was observed in only one participant (1.04%)."
    },
    "c9ff5b91-cec7-4da7-b1cd-f08f3874e8ed": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01381874",
        "Statement": "The Exemestane group in the primary trial had a better median Progression-Free Survival than the Abiraterone Acetate + Prednisone group, however the patient with the maximum PFS was in the Abiraterone Acetate + Prednisone group.",
        "Label": "Entailment",
        "explain": "The statement \"The Exemestane group in the primary trial had a better median Progression-Free Survival than the Abiraterone Acetate + Prednisone group,\" is entailed by the data in the CTRs. The median PFS for the Exemestane group is 3.68 (1.94 to 5.26) months and for the Abiraterone Acetate + Prednisone group is 3.65 (2.73 to 5.59) months. Since the median value for Exemestane is numerically higher than that of Abiraterone Acetate + Prednisone, the statement is true based on the provided information.\n\nHowever, the second part of the statement, \"however the patient with the maximum PFS was in the Abiraterone Acetate + Prednisone group,\" contradicts the data in the CTRs. The CTRs do not provide information regarding the individual with the maximum PFS for either treatment group. Therefore, it is impossible to determine this based on the available data."
    },
    "23040754-d1ad-4660-aacf-3298aefa5dae": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777101",
        "Secondary_id": "NCT00559845",
        "Statement": "There were no depressed patients in either the primary trial or the secondary trial, however there was one suicide attempt in cohort 2 of the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted\n\nJustification: \n\nThe statement \"there were no depressed patients in either the primary trial or the secondary trial\" is contradicted by the information in the CTRs. Although there is no mention of depression as an adverse event in either trial, there is no evidence in the CTRs to support that there were no depressed patients in either trial. The focus of the CTRs is on the adverse events observed during the trials, not on the psychological conditions of the participants. Therefore, the absence of an adverse event related to depression does not imply that no depressed patients were present in either trial."
    },
    "e3be834c-c311-4132-8529-d354b9e620b9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01033032",
        "Statement": "The only adverse event recorded in the primary trial was one single case of pleural effusion.",
        "Label": "Entailment",
        "explain": "The statement is entailed as the CTR for the primary trial states that there was one case of pleural effusion out of a total of three participants. (Adverse Events 1: PLEURAL EFFUSION 1/3)."
    },
    "8115b5e3-e178-433b-b114-09d97daaa8d7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01326481",
        "Statement": "Patients with Myocardial Infarction,percutaneous transluminal coronary angioplasty or Deep vein thrombosis within the last 2 - 6 months are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial's inclusion criteria explicitly state that patients with a history of Myocardial Infarction, percutaneous transluminal coronary angioplasty within the past 6 months, or deep vein thrombosis within the past 28 days are not eligible for the study (Exclusion Criteria)."
    },
    "bbcfc019-2d60-413f-88f9-04cacec55e30": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00333775",
        "Secondary_id": "NCT00201864",
        "Statement": "There are several cardiac adverse events recorded in the primary trial, but not a single one in the secondary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nExplanation:\n\nThe provided statement asserts that there are cardiac adverse events recorded in the primary trial but none in the secondary trial. However, the CTRs presented do not indicate any cardiac adverse events in either trial, except for one instance of arrhythmia in the primary trial and no mentions of cardiac adverse events in the secondary trial. As there are no cardiac adverse events reported in the secondary trial according to the CTR, the statement contradicts the information presented in the CTR."
    },
    "e7899445-9b80-4429-b4c3-d47bd36a2347": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232479",
        "Statement": "Patients with HER2 positive breast or colon carcinoma are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is partially contradicted by the primary trial's inclusion criteria, as it includes patients only with HER2 overexpressing breast cancer, and not colon carcinoma. The statement is in harmony with the primary trial's inclusion criteria with regards to HER2 positivity. However, it contradicts the trial in terms of cancer type. The primary trial does not entail the statement as it is stated."
    },
    "2a50cc2a-281b-4bc6-9f18-6bd9686c682d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754845",
        "Statement": "Patients who received over 5 years of anastrozole therapy, completed 2 years prior, are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR. \n\nReasoning: \n\nThe secondary trial statement specifies that patients who received over 5 years of anastrozole therapy, completed 2 years prior, are eligible for the primary trial. This statement is entailed by the primary CTR's Disease Characteristics section, which states that patients must have received 4\u00bd - 6 years of aromatase inhibitor therapy, including treatment received as part of clinical trial CAN-NCIC-MA17, and completed aromatase inhibitor therapy 2 years ago. Since anastrozole is listed as an aromatase inhibitor and the duration and timing requirements match, this statement is justified."
    },
    "26419cec-e256-46a7-9026-94dbe026c63d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01151046",
        "Statement": "The placebo group in the primary trial had a much lower Median PFS than the MM-121 cohort.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided Clinical Trial Reports (CTRs). In the primary trial, the median PFS for the placebo group was 10.7 weeks (8.1-16.1), while for the MM-121 group it was 15.9 weeks (9.3-30.3). These values suggest that the MM-121 cohort had a longer median PFS than the placebo group, supporting the expert's statement."
    },
    "8ef93fe0-0a12-4a7e-93aa-c40af7154a57": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02336737",
        "Secondary_id": "NCT01432886",
        "Statement": "the secondary trial is testing for the DLT of its interventions, whereas the primary trial is evaluating the dose limiting toxicity for SentiMag and SiennaXP. ",
        "Label": "Contradiction",
        "explain": "The statement is entailed. In the primary trial, the outcome measurement is evaluating the dose limiting toxicity for SentiMag and SiennaXP. In the secondary trial, the outcome measurement is also testing for dose limiting toxicity, albeit for different interventions (E7389 and various dosing regimens of Trastuzumab)."
    },
    "f5d50d87-b419-4537-87ec-7c9d23b765db": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171340",
        "Statement": "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density, whereas Zoledronic Acid 4 mg Delayed causes a smaller, but still positive change in Bone Mineral Density (within a certain patient demographic).",
        "Label": "Contradiction",
        "explain": "The statement \"the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a positive change in Bone Mineral Density, whereas Zoledronic Acid 4 mg Delayed causes a smaller, but still positive change in Bone Mineral Density (within a certain patient demographic)\" is entailed by the provided CTRs. This is based on the following reasons:\n\n1. Both Zoledronic Acid 4 mg Upfront and Delayed groups showed a positive change in BMD (Results 1 and 2).\n2. Zoledronic Acid 4 mg Upfront caused a larger change in BMD compared to the Delayed group (2.208% vs. -3.617%).\n3. The expert's statement acknowledges that Zoledronic Acid 4 mg Delayed causes a positive change in BMD but within a smaller magnitude, which is reflected in the CTRs.\n\nTherefore, the statement is in harmony with clinical trial data, finds substantiation in the CTR, and avoids contradiction with provided descriptions."
    },
    "f52ab54b-7a78-4449-9dfe-5fc67323e5c2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01797120",
        "Statement": "Cohort 2 of the primary trial is only receiving placebo tablets, and no other medications.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the information in the CTR for the Intervention 2 section of the primary trial, specifically the line stating \"Placebo: Placebo for Everolimus (2 tablets) daily x 12 cycles.\" This line indicates that cohort 2 of the primary trial is indeed receiving placebo tablets for everolimus, which is inconsistent with the expert's statement that they are not receiving any other medications."
    },
    "c0277198-6eef-4cf3-9527-dea5d01a4000": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00426556",
        "Statement": "There were more than 3 cases of Febrile neutropenia, Leukopenia and Neutropenia across all cohorts in the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary CTR indicates that there were no cases of Febrile neutropenia, Leukopenia, or Neutropenia in either cohort. Therefore, the statement that there were more than 3 cases of these adverse events across all cohorts is contradictory to the provided information."
    },
    "fea87f74-c8ef-4efd-944a-053f5e5a752f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01582971",
        "Statement": "In order to participate in the primary trial, participants must have 20/20 vision and a hiistologically confirmed, measurable, invasive breast carcinoma.",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nThe primary trial inclusion criteria state that there is no requirement for 20/20 vision for participants. The statement made by the clinical trial expert contradicts the information in the primary trial's inclusion criteria."
    },
    "43560d8e-0767-40ce-b2fb-1b8dda231bdf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394251",
        "Statement": "There were more cases of Cardiac failure than Pericardial effusion recorded in cohort 1.",
        "Label": "Contradiction",
        "explain": "Contradicted. The given CTR data does not support the statement as there were no instances of cardiac failure or pericardial effusion recorded in cohort 1 according to the provided information."
    },
    "2417fea2-7c8e-4f03-a918-c3cfcbe97425": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01998906",
        "Statement": "The same number of cases of Neutropenia, Febrile neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"The same number of cases of Neutropenia, Febrile neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial\" is contradicted by the provided CTRs. While both CTRs report cases of Neutropenia and Febrile neutropenia, the number of cases differs between the primary trial's cohort 1 (1/115 for Neutropenia and 7/115 for Febrile neutropenia) and the secondary trial's participants (2/112 for Neutropenia and 3/112 for Febrile neutropenia). Pancytopenia is reported in one instance in the primary trial but not in the secondary trial, further contradicting the statement."
    },
    "55391bc6-41a8-4686-82d6-6814166d32b8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01904903",
        "Secondary_id": "NCT01663727",
        "Statement": "Patients must have LVEF < 50% to be eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed in the Primary Trial's Inclusion Criteria, as one of the criteria for patient eligibility is having a Left Ventricular Ejection Fraction (LVEF) < 50%. Therefore, patients with LVEF below 50% meet both the expert's statement and the CTR requirement."
    },
    "06d25b0a-ef0d-4b6e-a8ed-c91689bfa82b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00091832",
        "Statement": "cohort 1 of the primary trial had a negative (median) Percent Change From Baseline of urea-adjusted Urinary N-telopeptide (uNTx/Ur).",
        "Label": "Contradiction",
        "explain": "The statement should be entailed in the given CTR. This is because the primary trial's Results 1 section reports a negative mean percent change from Baseline to Week 13 for uNTx/Cr in the Bisphosphonate IV Q4W arm, with a value of -10.19% (208.84%). The statement, which mentions a negative (median) percent change, is consistent with these findings. Therefore, the statement is entailed by the provided data."
    },
    "15553950-e26b-4fbb-a576-8455e6bb7b23": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01575522",
        "Statement": "The intervention section for the primary trial does not detail the type, dosage or duration of the intervention, unlike the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial CTR since it lacks information about the type, dosage, and duration of the intervention in that study. The secondary trial CTR, however, specifies that patients receive tivantinib PO BID on days 1-21 with courses repeating every 21 days, making it more detailed than the primary trial in terms of intervention description."
    },
    "58838d25-bf87-44e7-a604-23468d67a1e3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02606708",
        "Secondary_id": "NCT02504424",
        "Statement": "Only patients in the primary trial receive 40.5 Gy of Accelerated Intensity Modulated Radiation Therapy, patients in the secondary trial receive no radiotherapy whatsoever.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nJustification: \n\nThe statement contradicts the information in the primary CTR regarding Intervention 1 where all patients receive Accelerated Intensity Modulated Radiation Therapy with a total dose of 40.5 Gy, as stated: \"A total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions\" (CTR Primary, Intervention 1). Conversely, the secondary trial does not involve Accelerated Intensity Modulated Radiation Therapy as a treatment modality for Intervention 1, but rather the use of an AeroForm Tissue Expander which does not include radiotherapy. Therefore, the statement that \"patients in the secondary trial receive no radiotherapy whatsoever\" is not consistent with the information provided in the CTRs."
    },
    "02426c34-ebf9-4bd4-9d55-86fad89baf20": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01959490",
        "Statement": "In total only 20% of participants in the primary trial did not achieve Pathological Complete Response.",
        "Label": "Contradiction",
        "explain": "To evaluate the statement \"In total only 20% of participants in the primary trial did not achieve Pathological Complete Response,\" we need to calculate the number of participants who did not achieve pCR and compare it to the total number of participants in the trial.\n\nBased on the provided CTR, we have:\n\nPrimary Trial:\n- Cohort 1P (HER2 Positive) with 5 participants, 4 (80.0%) achieved pCR\n- Cohort 1T (HER2 Positive) with 6 participants, all 6 (100.0%) achieved pCR\n\nThe total number of participants in the primary trial is 11 (5 from Cohort 1P + 6 from Cohort 1T). Since all participants in Cohort 1T achieved pCR, there is no instance of non-pCR in this group. However, 1 participant from Cohort 1P did not achieve pCR (based on the given data, 4 out of 5 achieved pCR, so the fifth did not).\n\nTherefore, the statement \"In total only 20% of participants in the primary trial did not achieve Pathological Complete Response\" is a contradiction to the data presented in the CTR, as only 9 out of 11 participants (~81.8%) achieved pCR."
    },
    "9e28c807-8d88-4eea-87ee-48a42bd002ab": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00618826",
        "Secondary_id": "NCT02040857",
        "Statement": "the primary trial and the secondary trial only record 4 of the same adverse events.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nThe statement \"the primary trial and the secondary trial only record 4 of the same adverse events\" is contradicted by the data provided in the Adverse Events sections of both CTRs. The primary trial reports a total of 10 unique adverse events experienced by 14 participants, while the secondary trial reports a total of 13 unique adverse events experienced by 162 participants. Only 4 adverse events (Diarrhea, Fatigue, and Hypotension) are mentioned in both trials, but there are additional distinct adverse events reported in each trial."
    },
    "80ac126e-c756-4031-9541-e50d51c18b38": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02600923",
        "Statement": "Patients with Leukemia, Hepatitis or Polycystic Kidney Disease cannot be included in the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The statement is not entailed by the information provided in the primary trial's inclusion criteria, as breast adenocarcinoma, not Leukemia, Hepatitis, or Polycystic Kidney Disease, is the disease being studied in the primary trial."
    },
    "1a1d7d1d-ec49-46db-b6bc-dfd94575e46c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02953860",
        "Statement": "Patients in the primary trial receive less mg of Enzalutamide than Fulvestrant on a weekly basis.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided information in the primary trial's INTERVENTION 1 section. Specifically, patients receive 160mg of Enzalutamide daily, which amounts to 624mg per week. In comparison, patients receive 500mg of Fulvestamid every 4 weeks, which equates to 1250mg per week. Therefore, Fulvestrant provides a greater dose of the medication weekly than Enzalutamide in this trial. However, the expert's statement correctly acknowledges that patients receive a smaller dose of Enzalutamide per day, which is consistent with the CTR."
    },
    "68a9f2f0-cf11-4cd4-847c-53b8befd6002": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00717886",
        "Statement": "Prior axillary surgery, axillary radiation, breast cancer and breast radiation are not permitted for entry to the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the Primary Trial's Eligibility Criteria Exclusion Criteria, which specifically states \"Prior ipsilateral axillary surgery,\" \"Prior ipsilateral axillary radiation,\" \"Prior ipsilateral breast cancer,\" and \"Prior ipsilateral breast radiation\" as exclusion factors."
    },
    "9bcd40cf-8221-4383-8891-76a4bcc5c766": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00756717",
        "Statement": "Patients with cytologically confirmed, non metastatic, early stage invasive breast cancer with an Allred score of 1 are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Patients with cytologically confirmed, non metastatic, early stage invasive breast cancer with an Allred score of 1 are excluded from the primary trial\" is contradicted by the information in the primary trial's inclusion criteria. According to the CTR, the inclusion criteria state that patients must have histologically or cytologically confirmed early stage, ER-positive (Allred score 3) invasive breast cancer. The statement excludes patients with an Allred score of 1, which is lower than the required score of 3 for participation in the primary trial."
    },
    "341156fc-9cbd-492f-8e9e-8fbf98191625": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00291577",
        "Statement": "It is not possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 6, 24 or 12 hours.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary CTR as multiple participants in the trial had a median Tmax of 6 hours for both SU011248 and SU012662, as well as for the total drug. The statement also contradicts the median Tmax values for SU011248 C1D2 and C2D3, and for the total drug C1D2, which are within the range of 1 to 24 hours. Therefore, it's possible for participants to have a Tmax of 6, 12, or 24 hours according to the provided CTR."
    },
    "44ae021e-241b-4dbf-b88f-0b9d41eab555": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00201851",
        "Statement": "There were no cases of Oesophageal spasming observed in the primary trial.",
        "Label": "Entailment",
        "explain": "The given statement is not contradicted by the provided CTRs as there is no mention of Oesophageal spasming in either the primary or secondary trials. Therefore, the statement is entailed as it correctly reflects the information stated in the CTRs that there were no cases of Oesophageal spasming reported in the primary trial."
    },
    "523a44a3-6b90-4be7-ab46-6b6addd7b5b9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00080301",
        "Statement": "There were 5 more cases of THROMBOCYTOPENIA in cohort 2 of the primary trial, than in cohort 1.",
        "Label": "Entailment",
        "explain": "Contradiction.\n\nExplanation:\n\nThe statement \"There were 5 more cases of THROMBOCYTOPENIA in cohort 2 of the primary trial, than in cohort 1\" is contradicted by the provided data in the CTRs since there are actually 2 cases of THROMBOCYTOPENIA reported in cohort 1 and 7 cases in cohort 2, resulting in a difference of 5 cases in the contrary direction."
    },
    "258a51ca-e1f0-4d9a-88a6-8749f4822034": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03475992",
        "Secondary_id": "NCT03106077",
        "Statement": "Participants in the primary trial receive different interventions depending on their cancer hormone status, so Triple-Negative patients are seperated from HER2+ patients for example, whereas all patients in the secondary trial took the same intervention.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided CTRs. In the primary trial, Intervention 1 is for patients with pre-diagnosed breast cancer who undergo a biopsy before microwave breast imaging. In Intervention 2, patients have diagnosed breast cysts and no prior biopsy is mentioned. In the secondary trial, patients in Cohort A have advanced Triple-Negative Breast Cancer and receive IMGN853 at a dosage of 6 mg/kg IV every 3 weeks. Although the treatments and patient populations differ between trials, they both involve the use of a low-power microwave breast imaging system to investigate the capacity of microwave imaging for detecting and characterizing breast lumps in different patient populations (pre-diagnosed breast cancer and breast cysts, primary trial; and advanced Triple-Negative Breast Cancer, secondary trial). The statement acknowledges this distinction between patient groups and the use of different interventions for them."
    },
    "83bacd68-871a-4777-ba23-1f9a3df9227d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00057941",
        "Secondary_id": "NCT01806259",
        "Statement": "Recurrence-free Survival, used as the outcome measurement in the secondary trial and Clinical Benefit Rate, used in the primary trial are not synonymous, and represent entirely different patient characteristics. ",
        "Label": "Entailment",
        "explain": "The statement is entailed, as the CTRs provide evidence for the distinction between Recurrence-free Survival and Clinical Benefit Rate. The former refers to the duration of time after randomization during which participants experienced no disease progression or death (secondary trial), while the latter refers to the percentage of participants who experienced a clinical benefit (disappearance of all target and non-target lesions or stable disease for at least 6 months) from the treatments Anastrozole and ZD1839 (primary trial) or Ketorolac 30 mg compared to placebo (secondary trial). There is no contradiction as both measures represent different aspects of treatment efficacy."
    },
    "fedc0601-fd6b-4f9b-9ce7-6d9ee2e591e9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00369655",
        "Secondary_id": "NCT00091832",
        "Statement": "One patient in the primary trial had a Confirmed tumor partial response, in contrast thirty patients in the secondary trial had partial tumor response.",
        "Label": "Contradiction",
        "explain": "The statement can be entailed based on the provided CTRs. The primary trial reported one participant with a confirmed tumor partial response in the Ziv-afibercept arm, while the secondary trial reported 30 participants with a partial response (not explicitly stated as confirmed) in the Bisphosphonate IV Q4W arm. The difference in terminology used in the primary and secondary trials might be the reason for the seemingly discrepant results, but the overall implication is that fewer participants in the secondary trial had a tumor response compared to the primary trial, which aligns with the statement provided by the clinical trial expert."
    },
    "1a451f2e-0818-4a86-8808-0e4cce700aef": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00391092",
        "Statement": "In total there were 32 cases of Febrile neutropenia in the primary trial, and only one case of anemia.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted. \n\nExplanation: \nThe statement asserts that there were 32 cases of Febrile neutropenia and only one case of anemia in the primary trial. However, the Adverse Events 1 section of the primary CTR states that there were 14 cases of Febrile neutropenia and no cases of anemia. Therefore, the statement contradicts the information provided in the CTR."
    },
    "52333afb-0e7a-4823-ae9b-746e0ce57c8c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01325207",
        "Secondary_id": "NCT02429427",
        "Statement": "Patients participating in the primary trial and the secondary trial experienced a variety of cardiac problems. ",
        "Label": "Entailment",
        "explain": "Justified - The statement is entailed by the given CTRs. In both primary and secondary trials, there are reports of adverse events related to cardiac problems. In the primary trial, there is a case of atrial fibrlation in Adverse Events 1 of the secondary trial, and a case of cardiac failure in Adverse Events 2. Additionally, in the secondary trial, there are cases of acute cardiac events, aortic valve incompetence, and arrhythmia in Adverse Events 1, and a case of cardiac tamponade in Adverse Events 2."
    },
    "4216b27f-4d3e-4029-9637-2e6dade15b73": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005908",
        "Statement": "There was only one patient cohort in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement should be contradicted based on the provided CTR information. In the primary trial, there were 30 patients, which indicates that there were at least two cohorts, one for the experimental group and another for the control group or comparison group."
    },
    "14a32a42-424b-4b97-bae9-05f4bb2b415b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00246090",
        "Secondary_id": "NCT00266799",
        "Statement": "Cohort 1 of the primary trial 0.0015% less total adverse events than cohort 2 of the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nThe statement \"Cohort 1 of the primary trial 0.0015% less total adverse events than cohort 2 of the secondary trial.\" cannot be entailed based on the provided information in the CTRs. The percentage of total adverse events for cohort 1 in the primary trial was 30.24%, and for cohort 1 in the secondary trial, it was 45.10%. A decrease of 0.0015% would not account for this substantial difference."
    },
    "4d83c630-d767-40cf-9aec-c871c6fc7f38": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00030823",
        "Statement": "Patients with stage I, II, III or IV breast cancer may be eliglbe for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR for the primary trial. The eligibility criteria section of the primary CTR states that patients with Stage I, II, or III breast cancer, previously treated with adjuvant chemotherapy and clinically free of identifiable disease, but have rising CA 15-3 or CEA levels, are eligible for the trial. The CTR does not specify a requirement for the breast cancer stage to be IV for eligibility, which allows for patients with Stage I, II, or III breast cancer to be included. Therefore, the expert's statement that patients with stage I, II, III or IV breast cancer may be eligible for the primary trial is consistent with the provided CTR information."
    },
    "4fd230f2-caf1-44d6-81f2-4f51dda6da3a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03371732",
        "Statement": "Any patients with Karnofsky Index  < 80 are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the Primary Trial's Eligibility Criteria, specifically the exclusion criterion stating that patients with a Karnofsky index less than 70 are not eligible for the trial."
    },
    "7a3d1ca7-8776-4ace-bbc0-107635b93583": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00764322",
        "Statement": "The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 ng/mL over 4 months.",
        "Label": "Entailment",
        "explain": "The statement \"The Ultra-rapid Metabolizers group of the primary trial had an average increase of Endoxifen Concentration over 6 ng/mL over 4 months\" can be entailed by the CTR data as follows:\n\n1. The mean (standard deviation) endoxifen concentration increase for the Ultra-rapid Metabolizers group is calculated by finding the difference between the 4-month and baseline endoxifen concentrations, which is:\n\n15.35 ng/mL (5.48) - 8.4 ng/mL (4.59)\n= 6.96 ng/mL (3.11)\n\n2. The difference between the mean (standard deviation) endoxifen concentration at baseline and 4 months is 6.96 ng/mL (3.11) for the Ultra-rapid Metabolizers group.\n3. The statement claims an average increase of more than 6 ng/mL over 4 months for the Ultra-rapid Metabolizers group, which is supported by the CTR data."
    },
    "e95902f1-bf4f-4bb5-8f48-4fa5ba6425d0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02040857",
        "Statement": "Only men and postmenopausal women are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Only men and postmenopausal women are eligible for the primary trial\" is not entailed by the provided CTR. The CTR specifies that both pre- and postmenopausal women are eligible for the trial."
    },
    "1196db61-0846-4185-afc9-dc4b2fccd059": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01966471",
        "Secondary_id": "NCT00981812",
        "Statement": "A patient who had a breast-conserving surgery in the year prior to study entry would be excluded from both the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed in the primary trial as the CTR explicitly states that \"No more than 9 weeks (63 days) may elapse between definitive breast surgery (or the last surgery if additional resection required for breast cancer) and randomization\" (inclusion criteria). However, it should be contradicted in the secondary trial as there is no similar requirement stated in the provided inclusion criteria of the secondary trial."
    },
    "567ec6e3-87aa-4a4a-94b8-ebdf2e0cbf64": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02005887",
        "Secondary_id": "NCT00050011",
        "Statement": "All Participants in the primary trial and the secondary trial are receiving the same daily dose of oral Letrozole for the same duration of time.",
        "Label": "Entailment",
        "explain": "The statement \"All Participants in the primary trial and the secondary trial are receiving the same daily dose of oral Letrozole for the same duration of time\" is entailed by the provided information in the CTRs. \n\nExplanation: \nBoth trials state that participants in both intervention arms received Letrozol 2.5 mg every day for 6 cycles in the primary trial, and for the same duration in the secondary trial. Therefore, the statement is entailed by the information provided in the CTRs."
    },
    "7e629f62-2981-4462-a4c1-f0cc9c24777a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00490646",
        "Statement": "Cohort 1 of the primary trial had 25% more patients experiencing Cholecystitis than cohort 2.",
        "Label": "Contradiction",
        "explain": "The provided statement cannot be entailed based on the data in the CTRs. There is no mention of Cholecystitis in either cohort 1 or cohort 2 of the primary trial. Both CTRs only list ATRIAL FIBRILLATION (1 patient in each), FEBILE NEUTROPENIA (5 in the primary trial, 0 in the secondary), HAEMATOTOXICITY (1 in the primary trial, 1 in the secondary), NEUTROPENIA (3 in the primary trial, 0 in the secondary), LYMPHADENOPATHY (0 in both trials), PERICARDIAL EFFUSION (1 in the primary trial, 0 in the secondary), APLASIA (0 in both trials), NAUSEA (0 in both trials), PYREXIA (2 in the primary trial, 0 in the secondary), EXTRAVASATION (0 in both trials), and PATHOLOGICAL FRACTURE (1 in each trial) under the Adverse Events section. The statement contradicts the CTRs as no such difference between the cohorts regarding Cholecystitis is reported."
    },
    "c660faec-58d8-4ba9-8e18-1775b1135819": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00600340",
        "Statement": "Cohorts 1 of the primary trial recieves Bevacizumab at a higher frequency than cohort 2.",
        "Label": "Entailment",
        "explain": "The statement is entailed. In the primary trial, Bevacizumab is administered to cohort 1 at a frequency of every 3 weeks (days 1 and 15, every 4 weeks), while in cohort 2 of the same trial, Bevacizumab is administered every 3 weeks but only on day 1. However, cohort 1 receives Bevacizumab on days 1 and 15, which is twice in every 4-week interval, while cohort 2 receives Bevacizumab only once in every 3-week interval. Therefore, cohort 1 receives Bevacizumab at a higher frequency than cohort 2 according to the number of administrations in the specified time intervals."
    },
    "a6fcfea0-eacd-4a04-92a8-55a0c3c8bfb2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03078751",
        "Statement": "Cohort 2 of the primary trial reported one case of AML.",
        "Label": "Contradiction",
        "explain": "The statement \"Cohort 2 of the primary trial reported one case of AML\" is entailed by the CTR data in the Adverse Events section of the primary trial. Specifically, the statement correctly identifies that there was one case of Acute Myeloid Leukaemia reported in the primary trial's cohort 2, which aligns with the data provided in the CTR."
    },
    "3ee5742b-6bc3-400f-92eb-641384a75201": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT01224678",
        "Statement": "Patients in the primary trial do not receive any extra medication for the study, whereas in the secondary trial they are given an oral medication.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the CTRs. In the primary trial, Intervention 1 states that there is no change in the standard care for patients, which means they do not receive any extra medication for the study. In contrast, the secondary trial specifies that patients receive oral medication (Vitamin D) as Intervention 2. Therefore, the statement accurately reflects the difference between the two trials."
    },
    "f6af788f-ee96-4308-8dec-12d0c46e957a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "Patients with irrational fear of confined spaces are not elligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the Primary Trial Inclusion Criteria as it mentions no specific exclusion regarding irrational fear of confined spaces."
    },
    "2e09a2ec-149e-46b4-b60a-ed421fdbc9b3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00118157",
        "Secondary_id": "NCT01401959",
        "Statement": "Participants in the primary trial had a higher likelihood of achieving 2 Year Disease-Free Survival than those in either cohort of the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement cannot be directly entailed based on the information provided in the CTRs as there is no direct comparison of the two trials regarding the effectiveness of the interventions on 2 Year Disease-Free Survival (DFS). The primary trial reports the outcome measure of Tumor Response Rate (Complete and Partial) using RECIST Criteria, while the secondary trial reports the percentage of patients achieving 2 Year DFS in two different cohorts of patients. The lack of a direct comparison and the differences in outcome measures make it impossible to definitively conclude that participants in the primary trial had a higher likelihood of achieving 2 Year Disease-Free Survival than those in the secondary trial based on the given information."
    },
    "e0b7a120-8735-413d-9a47-8508b2feffb3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01231659",
        "Statement": "Less than 20 the primary trial participants achieved partial response (PR).",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nJustification:\n\nThe primary trial CTR states that \"37.2%\" of participants in the Everolimus + Letrozole arm achieved partial response (PR). This information directly contradicts the secondary trial expert's statement that \"less than 20\" participants in the primary trial achieved PR."
    },
    "1393c5d9-d2be-433b-9abf-9449b46588c4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981812",
        "Statement": "Women who have undergone a breast enlargement procedure, and have since had the implants removed, are excluded from the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial's inclusion criteria, which do not explicitly exclude subjects with breast implants or those who have had them removed."
    },
    "abfa5699-2863-4319-9386-4b359f2062f2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00195013",
        "Secondary_id": "NCT00620373",
        "Statement": "Cohort 2 of the primary trial is a placebo group, the secondary trial does not have a placebo group.",
        "Label": "Entailment",
        "explain": "Contradiction.\n\nThe statement \"Cohort 2 of the primary trial is a placebo group, the secondary trial does not have a placebo group\" contradicts the information in the provided CTRs. In the primary trial, both cohorts received placebo interventions, but in the secondary trial, there are two separate intervention arms - Mammography Only and Gamma Imaging, neither of which can be considered placebo groups as they each received distinct interventions."
    },
    "4038f7c3-87e2-47d6-811b-fd2b21679577": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01196052",
        "Statement": "Participants in the primary trial must be willing to undergo anthracycline-based chemotherapy, or have previously received either cyclophosphamide or epirubicin.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the Primary Trial's Inclusion Criteria section since it requires patients to be willing to receive anthracycline-based chemotherapy or have previously received doxorubicin/cyclophosphamide as part of their neoadjuvant or adjuvant treatment."
    },
    "5097f4cd-9118-473d-a2a0-72f0cd12c7a5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01031446",
        "Statement": "Sarah has been experiencing epileptic seizures from a brain tumor. This excludes her from participating in the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary trial's eligibility criteria state that patients with symptomatic brain metastases are excluded. However, the statement mentions Sarah's seizures as being caused by a brain tumor, which falls under the category of symptomatic brain metastases according to the CTR. Therefore, the statement contradicts the information in the primary CTR."
    },
    "68e6a088-ab80-4a89-90d4-39308bccb1c2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00956813",
        "Statement": "All the primary trial subjects are required to take the intervention PO daily.",
        "Label": "Entailment",
        "explain": "The statement is entailed by both the primary and secondary CTRs. \n\nJustification:\nThe primary CTR states that patients receive \"once daily\" a Nutrigrad\u2122 flaxseed bar containing flaxseed and lignans, and the secondary CTR states that patients in the placebo arm receive an identical looking bar \"once daily\" with the same calorie and total fat content but without flaxseed or lignans. Therefore, both arms of the primary trial are required to take the intervention PO daily as stated in the expert's claim."
    },
    "a4c49b44-91b3-4a3c-bfbf-b3758cc398f1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00446030",
        "Secondary_id": "NCT00975676",
        "Statement": "the primary trial and the secondary trial have no overlap in the drugs they use for their interventions, however they both have placebo groups.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided CTRs. The primary trial and the secondary trial indeed have no overlapping drugs in their interventions: TAC + Bevacizumab for HER2 negative patients and TCH + Bevacizumab for HER2 positive patients in the primary trial, and Triptorelin Plus Tamoxifen for the secondary trial, and Triptorelin Plus Exemestane for the other arm. Both trials have a placebo group, but this fact is not relevant to the entailment relationship between the statement and the CTRs."
    },
    "08917306-11b0-44ad-8f45-9a67d7f6073e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971737",
        "Secondary_id": "NCT00392392",
        "Statement": "Patients with a positive FISH result are eligible for the secondary trial, but not for the primary trial.",
        "Label": "Entailment",
        "explain": "Justified if: The primary trial excludes patients with FISH positive HER-2 gene amplified breast cancer while the secondary trial includes them, making the statement entailed. (CTR sections: Primary Trial - Disease Characteristics; Secondary Trial - Inclusion Criteria)\n\nContradicted if: Both trials have the same eligibility criteria regarding FISH result, making the statement false. (Inconsistent with both CTRs if they both include or both exclude patients with FISH positive HER-2 gene amplified breast cancer.)\n\nUndecidable if: The trials have conflicting but not clear eligibility criteria for FISH result or the FISH result is just one of many other criteria, making it difficult to definitively establish entailment or contradiction. (If the eligibility criteria in both trials are ambiguous or not directly comparable regarding the FISH result)"
    },
    "9702cb6a-bdb1-415f-bb99-3b740728a4ea": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00073073",
        "Secondary_id": "NCT00054028",
        "Statement": "There are no placebo or control groups in the primary trial or the secondary trial.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nIn the primary trial, although there is no mention of a placebo or control group for the administration of Exemestane, Calcium carbonate, and Vitamin D, there is no statement indicating that these interventions were compared against each other or against no treatment (placebo) for the purpose of establishing their effect. Therefore, the absence of placebo or control groups only applies to the specific interventions mentioned and not to the entire trial.\n\nIn the secondary trial, there is no information regarding the presence or absence of placebo or control groups in the trial.\n\nThus, the statement that \"there are no placebo or control groups in the primary trial or the secondary trial\" is contradicted by the information provided in the CTRs."
    },
    "7afa2d1f-7922-4b09-b52a-43bd9a4788a9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00706030",
        "Secondary_id": "NCT00171704",
        "Statement": "participants from both cohorts of the primary trial had a drastically lower CNS Objective Response Rate than those in the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement cannot be entailed based on the provided CTRs. The primary trial reports outcome measurement as Overall Response Rate (ORR) according to RECIST v1.0 in ErbB-2-positive breast cancer, while the secondary trial reports Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-L4). There is no CNS Objective Response Rate data reported in either trial, so no comparison can be made between the two trials regarding CNS Objective Response Rates."
    },
    "dfd5acc2-6824-4b63-93ad-34e6a0a4c621": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01299038",
        "Statement": "Joe has had an alcohol addiction for 15 years, resulting in Cirrhosis therefore he is likely to be excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the Primary Trial's Exclusion Criteria. Specifically, it states \"Recent history of heavy alcohol use as judged by the treating physician\" and \"Known to be pregnant (testing not required)\" which both could potentially apply to Joe based on the statement. However, the CTR explicitly mentions \"Recent history of heavy alcohol use\" and does not specify a certain time frame. So, it is not entirely clear if Joe's 15-year alcohol addiction and cirrhosis would meet this criteria, as the CTR does not specify if cirrhosis due to alcohol use is considered \"recent.\" Therefore, the statement might need further qualification for a definitive entailment assessment.\n\nAdditionally, it is worth noting that \"heavy alcohol use\" in the CTR is defined implicitly, and the expert's statement is vague in terms of the quantity and duration of alcohol consumption. A more precise statement from the expert, such as \"Joe has consumed excessive amounts of alcohol in the last 5 weeks,\" would more closely align with the CTR's exclusion criteria and increase the likelihood of entailment."
    },
    "97e9967e-6525-4082-bd11-8c30e14d23fd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03273426",
        "Secondary_id": "NCT01091168",
        "Statement": "Patients with Concurrent serious uncontrolled medical disorder may be eligible for the primary trial, but are always excluded from the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs. The primary CTR explicitly lists \"concurrent serious uncontrolled medical disorder\" as an exclusion criterion for the secondary trial. However, it does not mention anything about this criterion being applicable to the primary trial. Therefore, the statement that patients with concurrent serious uncontrolled medical disorder may be eligible for the primary trial but excluded from the secondary trial is valid."
    },
    "d11dd4ae-28be-4ad2-a452-4374c48f08d1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00082433",
        "Statement": "the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine, may increase OS, compared to Capecitabine alone.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR data. In the primary trial, the median OS for the Ixabepilone + Capecitabine combination group is greater (16.39 months) than that of the Capecitabine alone group (15.64 months), suggesting that the combination therapy may increase OS compared to Capecitabine alone."
    },
    "3b6229a9-00a1-4d26-9285-6d9f6a25fd77": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Statement": "Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than diarrhoea.",
        "Label": "Contradiction",
        "explain": "This statement is contradicted by the data in the CTRs. The number of patients in cohort 1 who suffered from Erysipelas was 2, while the number of patients who suffered from diarrhea was 5. Therefore, the number of patients suffering from diarrhea was more than twice the number of patients suffering from Erysipelas. (Adverse Events 1 for Primary Trial)"
    },
    "9eab20ad-ffc6-473f-8087-c6c3f06f356f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322348",
        "Secondary_id": "NCT00429572",
        "Statement": "the primary trial and the secondary trial use different metrics to evaluate potential candidates' performance status.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTRs. In the primary trial, the performance status is evaluated based on the World Health Organization (WHO) scale, with a maximum score of 2. In contrast, the secondary trial uses the Zubrod performance status scale, which has a maximum score of less than 2. Despite the difference in scales, both trials require a performance status of 0, 1, or 2 for inclusion. Therefore, the use of different metrics to evaluate performance status does not contradict the information in the CTRs."
    },
    "92680a4c-a1e0-47d2-9b7f-cacb20cd1fde": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00368875",
        "Statement": "the primary trial results indicate that the Recommended Phase II Dose for Vorinostat, as Assessed by NCI Common Terminology Criteria for Adverse Events, is 300 mg.",
        "Label": "Entailment",
        "explain": "The statement can be entailed based on the given CTR information as follows:\n\n1. The CTR for the primary trial states that the Recommended Phase II Dose for Vorinostat, as Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE), is 300 mg (Section Results 1: Measure Type and Unit of Measure).\n2. The expert's statement also mentions that the Recommended Phase II Dose is 300 mg.\n\nTherefore, the expert's statement harmonizes with the clinical trial data in the provided CTR for the primary trial. No contradiction is observed.\n\nJustification for entailment: The CTR specifies the Phase II Dose as 300mg for Vorinostat (Results 1: Measure Type and Unit of Measure) and the expert's statement also confirms the same dose (300mg) (Expert's Statement)."
    },
    "b3dd4e23-f78c-4bf9-9268-d1018c966980": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02550210",
        "Statement": "Patients must have cancer that can be felt by touch to be eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Patients must have cancer that can be felt by touch to be eligible for the primary trial\" is entailed by the CTR, specifically the inclusion criteria that state \"Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ.\""
    },
    "553d7721-289e-4ab1-a9b9-7b2c939f47c1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "The maximum Progression Free Survival for patients in cohort 1 the primary trial was 1 year.",
        "Label": "Contradiction",
        "explain": "Contradicted. The CTRs provide the median PFS values for both Capecitabine and CDX-011 arms, which are 2.8 months (1.6 to 3.2) and 2.9 months (2.8 to 3.5) respectively. Neither of these values equals to 1 year."
    },
    "01c6f82e-710d-4fa4-aa62-2d26e72f4533": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00894504",
        "Statement": "There were no adverse event in the primary trial which occurred more than 71 times.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the information in the Primary Trial Adverse Events section, as there are several adverse events reported more than once (ATRIAL FIBRILLATION, CARDIAC TAMPONADE, PERICARDIAL EFFUSION, SUPRAVENTRICULAR TACHYCARDIA, DIARRHOEA, NAUSEA, VOMITING, CHEST PAIN, PNEUMONIA, MALIGNANT PLEURAL EFFUSION, HEPATIC ENCEPHALOPATHY), each occurring 1/71 times."
    },
    "2e588ede-0ab8-4cb0-b03b-2c68a68bc5fc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02018458",
        "Secondary_id": "NCT00895414",
        "Statement": "Patients with unexplained fever exceeding 39\u00ac\u00a8\u201a\u00e0\u00fbC are excluded from the primary trial but may be included in the secondary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary trial explicitly states that patients with unexplained fever >38.5\u00b0C during screening are ineligible for inclusion (Exclusion Criteria), whereas the secondary trial includes patients with unexplained fever, but the threshold is higher at 39\u00b0C. The difference in temperature thresholds contradicts the expert statement."
    },
    "862c0bfe-10a6-453c-9ada-929dd00141a0": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00295620",
        "Secondary_id": "NCT03366428",
        "Statement": "the secondary trial and the primary trial employ non comparable outcome measures.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the information provided in the CTRs. \n\nJustification: \n\nIn the primary trial, the outcome measure is Disease-free Survival (DFS) After Prolonged Endocrine Treatment with Anastrozole. The time frame for assessment is from two years after randomization to the earliest occurrence of certain events, up to a maximum of 8.5 years.\n\nIn the secondary trial, the outcome measure is Changes in QTcF After Treatment With DS-8201a in participants with HER2-expressing metastatic and/or unresectable breast cancer. The time frame for assessment is from screening (within 7 days before enrollment) up to Cycle 3 Day 15.\n\nSince the two outcome measures focus on different aspects (DFS and QTcF changes), patient population (breast cancer vs HER2-expressing breast cancer), and time frames, they cannot be directly compared. Therefore, the statement is entailed as the trials employ non-comparable outcome measures."
    },
    "9ed5feb5-ab82-4f90-a6e4-5172dcd4d20f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01094184",
        "Statement": "A patient who had an oophorectomy in the last month would not be eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the Primary Trial's Eligibility Criteria, specifically the exclusion criterion which states \"Participants who underwent major surgery within 28 days prior to enrollment.\" In this instance, an oophorectomy is classified as major surgery, and thus, a patient who had the surgery within the past month would not meet the eligibility criteria for the primary trial."
    },
    "5501dae3-0d3c-4812-96c2-35ca863e24a5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00343863",
        "Statement": "On day 1 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV, oral cyclophosphamide, dexamethasone IV or orally and ondansetron IV.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs as both Intervention 1 and Intervention 2 specify that patients in the primary trial receive doxorubicin hydrochloride IV on day 1, oral cyclophosphamide on days 1-7, and either dexamethasone IV or orally on day 1 (prior to each dose of doxorubicin hydrochloride), as well as ondansetron IV on day 1 (for Intervention 1) or palonosetron IV on day 1 (for Intervention 2). The statement matches the given CTR information and does not contradict it, thus it is entailed."
    },
    "ece8e7df-790d-4e26-9c34-40cf66d2abf5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02005887",
        "Secondary_id": "NCT00050011",
        "Statement": "All Participants in the primary trial and the secondary trial are receiving the same daily dose of Degarelix injected into the muscle, for the same duration of time.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nIn the primary trial, participants in arm A received Degarelix as two injections of 120 mg on day 1, followed by an injection of 80 mg on days 1 of cycles 2 to 6. In contrast, in the secondary trial, participants received Degarelix as a single 240 mg injection on day 1 of cycle 1, followed by an injection of 80 mg on days 1 of cycles 2 to 6. Although the daily dose of 80 mg is the same, the total dose and dosing schedule differ between the trials."
    },
    "550a36e2-43bb-40af-b0c8-49498fbe2c8c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00077376",
        "Secondary_id": "NCT01256008",
        "Statement": "the primary trial investigates a novel radiotherapy treatment, whereas the secondary trial is testing a type of psychological therapy.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted. The primary trial does not investigate a novel radiotherapy treatment; instead, it investigates a combination of Trastuzumab, Ixabepilone, and Carboplatin. The secondary trial, in contrast, is not testing a radiotherapy treatment but rather a type of psychological therapy, clinical management, and CBT."
    },
    "95869347-6c3d-4de8-a325-a9a652f11edf": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02102490",
        "Secondary_id": "NCT00768222",
        "Statement": "In contrast to the secondary trial, the primary trial did not record any cases of Sinus bradycardia, Bone marrow suppression or Constipation .",
        "Label": "Contradiction",
        "explain": "The statement should be entailed based on the provided Adverse Events sections of both trials. In the primary trial, there were no recorded cases of Sinus bradycardia (0.00%), Bone marrow suppression (0.00%), or Constipation (0.00%), as shown in the CTR. Similarly, in the secondary trial, there were no recorded cases of Sinus bradycardia (0.00%), and the instances of Bone marrow suppression and Constipation had lower incidence rates compared to the primary trial (1.96% and 0.76%, respectively). Therefore, the statement's assertion is consistent with the clinical trial data and does not contradict the CTR information."
    },
    "8df8e2c0-a0ca-4ea2-ba83-494f250c4bef": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00509769",
        "Statement": "3/112 patients (2.68%) in the primary trial had Diabetes insipidus  ",
        "Label": "Contradiction",
        "explain": "The statement \"3/112 patients (2.68%) in the primary trial had Diabetes insipidus\" is not entailed by the provided Adverse Events data from the CTR. \n\nThe CTR mentions the occurrence of various adverse events in the primary trial, including Thrombocytopenia, Dysphagia, Haemorrhoidal hemorrhage, Oesophageal stenosis, Upper gastrointestinal hemorrhage, Asthenia, Disease progression, Hepatotoxicity, Cellulitis, Pneumonia, Osteomyelitis, and Thrombocytopenia. However, Diabetes insipidus is not listed among these adverse events. Therefore, the statement is not entailed by the information presented in the CTR."
    },
    "1d4a385f-1c72-4c61-8d49-9ada0e3b716a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02556632",
        "Statement": "Both cohorts the primary trial apply the same topical intervention for approximately every 4-6 hours every day for a week of the study.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the information in both the Intervention sections of the primary trial. The topical interventions for both Arm I (Curcumin-based Gel) and Arm II (HPR Plus) are applied TID approximately every 4-6 hours for a week during and after radiation therapy. (References: primary trial - Intervention sections 1 and 2)"
    },
    "b15aa13a-fbd9-4b2e-9dd2-b16628084d07": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01091428",
        "Statement": "The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel, supported by results from cohort 2 of the primary trial, is 40 mg/m^2 orally, twice daily (BID) on Days 1-3, 8-10 and 15-17",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary CTR as follows: \n\n- The MTD for Alisertib in the primary trial was identified based on the occurrence of DLTs in evaluable participants (as defined in the primary CTR).\n- DLT was assessed using NCI CTCAE version 4.02 and included specific toxicities such as Grade 4 neutropenia and thrombocytopenia (lasting 7 consecutive days), Grade 4 neutropenia with fever and/or infection, Platelet count <10,000/mm^3, Grade 3 thrombocytopenia with bleeding, or any other Grade 3 nonhematologic toxicity (except for Grade 3 nausea/emesis, diarrhea, fatigue, or nonhematological toxicities that could be controlled to Grade 2 with appropriate treatment).\n- The MTD for cohort 2 in the primary trial was determined to be 40 mg/m^2 orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, as stated in the expert's statement. This aligns with the MTD definition and criteria outlined in the primary CTR.\n\nThus, the statement is entailed by the primary CTR, as it accurately reflects the identified MTD in the context of the clinical trial."
    },
    "c9214d06-2733-4c78-99e5-a42015908eae": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00246571",
        "Statement": "Renal cancer Patients from the primary trial receiving Standard of Care had a median PFS of 2.5 months by Core radiology laboratory assessment.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary CTR. The median PFS for patients receiving Standard of Care in the primary trial was indeed 2.5 months according to both core radiology laboratory assessment and investigator's assessment in the Results 2 section."
    },
    "a318fc31-4f28-4356-b09a-59741bb7c97a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02660788",
        "Secondary_id": "NCT01490892",
        "Statement": "the primary trial is investigating different ways to communicate with women aged 51-73 years old , whereas the secondary trial is not.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nExplanation:\n\nThe statement contradicts the primary trial CTR as it implies that the trial is not investigating different ways to communicate with women aged 51-73 years old, while the CTR specifies that the two intervention arms involve different modes of communication: mail for Control Arm and mail and family physician reminder letter for Family Physician Reminder Letter Arm."
    },
    "70ec4bc8-f8fa-4901-aa7a-2388b53960c6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00206518",
        "Statement": "The most common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 3A and 3C.",
        "Label": "Entailment",
        "explain": "The statement \"The most common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 3A and 3C\" is entailed by the CTR data in Results 1 under Arm/Group Title: A: Taxotere/Docetaxel. The specific data points are:\n\n- 3A: 18 participants\n- 3B: 15 participants\n- 3C: 18 participants\n\nThe number of participants in Chevalier grades 3A and 3C (38 in total) is indeed the most common among those treated with Taxotere/Docetaxel in the primary trial."
    },
    "00dc0e37-1d0b-4f53-a037-86bf9799dae6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00570323",
        "Secondary_id": "NCT00193180",
        "Statement": "Female patients with a womb cannot take part in either the secondary trial or the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nJustification: \n\n1. In the primary trial, there is no explicit condition stating that patients must have a womb to participate. The inclusion criteria clearly mention that patients must have a histologically confirmed invasive breast cancer with a primary tumor of 3 cm or more, and that estrogen receptor and/or progesterone receptor positive disease is required. There is no mention of the presence or absence of a womb.\n\n2. In the secondary trial, there is no mention of patients having or not having a womb as a criterion for participation. The inclusion criteria only require metastatic breast cancer, no more than one prior chemotherapy regimen for metastatic breast cancer, ability to perform activities of daily living with minimal assistance, adequate bone marrow, liver, and kidney function, and age 18 years or older. There is no mention of the presence or absence of a womb. \n\nTherefore, the statement \"Female patients with a womb cannot take part in either the secondary trial or the primary trial\" contradicts the information provided in the CTRs."
    },
    "a1a421cc-01c9-4afb-8f09-6b10b0ff5094": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01663727",
        "Secondary_id": "NCT00072293",
        "Statement": "Patients must be between the ages of 13 and 76 to participate in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradiction with Primary Trial: The Primary Trial includes patients who are of childbearing potential and therefore age is not explicitly mentioned as an inclusion criterion.\n\nAnswer with Explanation: \nThe primary trial includes patients with histologically or cytologically confirmed breast cancer, which may affect individuals of any age, including those under 13 and above 76. However, for women of childbearing potential, an acceptable method of non-hormonal contraception is required, suggesting that the age limit might not be explicitly stated for all patients due to this condition.\n\nIn contrast, the secondary trial explicitly states \"Any age\" for patients to participate in the trial. This information directly contradicts the Primary Trial since it implies that patients under 13 and above 76 are excluded from the Primary Trial despite not being stated explicitly.\n\nHence, the statement \"Patients must be between the ages of 13 and 76 to participate in the primary trial or the secondary trial\" is contradicted by the provided CTRs."
    },
    "9316ef0d-55b0-4547-88ae-887e0132a263": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00246571",
        "Statement": "Patients from the primary trial receiving Standard of Care had a median PFS of 2.7months by Core radiology laboratory assessment.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR. In the Primary Trial Results 2 section, it is stated that the median PFS by Core radiology laboratory assessment for patients in the Standard of Care arm was 2.7 (1.7 to 2.8) months."
    },
    "5d815fac-c66c-43fe-9ac8-a352b6e47a5b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01929395",
        "Secondary_id": "NCT01857882",
        "Statement": "the primary trial and the secondary trial are both utilising test and control groups in their interventions.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. Both primary and secondary trials involve two distinct intervention groups, which can be considered as test and control groups based on the context of the expert's statement. In the primary trial, one group of patients receives supine MRI with intraoperative optical scanning and tracking (test group), and the other group receives conventional imaging only (control group). In the secondary trial, patients in the decision support workshop (test group) receive additional support and education, while the standard care group receives only routine pre-consultation education (control group)."
    },
    "7b9fdeaa-5cb7-4453-b174-07b44bb58234": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127205",
        "Statement": "More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular relaxations.",
        "Label": "Entailment",
        "explain": "The statement \"More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular relaxations\" is contradicted by the provided CTRs. The sections on adverse events do not mention any instances of dysfunctions related to ventricular contractions or relaxations. Therefore, there is no substantiation for the statement in the given data."
    },
    "c330f152-c64e-47ab-8568-5129a1a2099e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00875979",
        "Statement": "None of the 60+ patients in cohort 2 the primary trial experienced any adverse events.",
        "Label": "Contradiction",
        "explain": "Based on the provided CTR data, the expert's statement is contradicted. In Adverse Events 2 of the primary trial, 22 adverse events were recorded for a total of 64 patients in cohort 2. Therefore, the statement \"None of the 60+ patients in cohort 2 the primary trial experienced any adverse events\" is not entailed by the CTR data."
    },
    "e3b88c8c-241d-4ead-8573-534a46210707": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00811135",
        "Statement": "The majority of patients in the primary trial did not experience Left ventricular dysfunction.",
        "Label": "Entailment",
        "explain": "The statement is not directly contradicted by the data in the provided CTRs, but it is not entailed either. The CTRs report the occurrence of cardiac failure in 2/88 patients in the primary trial (2.27%), but they do not provide information on the specific type or severity of cardiac dysfunction experienced by these patients or whether it was left ventricular in nature. Therefore, based on the given information, it is neither possible to conclude that the majority of patients did not experience left ventricular dysfunction nor to prove that they did."
    },
    "e621f354-dea0-4d0f-a252-5480028c1712": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00022516",
        "Statement": "At least 1 patient in the primary trial suffered from a radiotherapy induced adverse event.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary CTR reports no occurrence of radiation dermatitis, which is the only mentioned radiotherapy-induced adverse event in the expert statement. (Reference: Adverse Events 1 and 2 for both primary and secondary trials)"
    },
    "ee209156-74dc-475e-87af-ae51160982ef": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00244881",
        "Statement": "30% of the primary trial participants had an increased level of CECs after 3 weeks of Cediranib Maleate treatment.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the Primary Trial's Outcome Measurement and Results 1 sections. In the Outcome Measurement section, it is stated that the outcome measure is the Fraction of Patients With Increased Levels of Circulating Endothelial Cells, and an exact 95% confidence interval will be calculated for the CEC response rate with 26 participants, which is no wider than 40%. In Results 1, it is stated that 30% of the participants in the Cediranib Maleate arm had increased levels of CECs after 3 weeks of treatment. Therefore, the statement \"30% of the primary trial participants had an increased level of CECs after 3 weeks of Cediranib Maleate treatment\" is consistent with the data provided in the CTRs."
    },
    "edf813c0-2271-49ca-a040-a355bf71d8b4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01519700",
        "Statement": "There was just over 36 hours difference in Median Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTR data as follows:\n\n1. The statement claims a difference of approximately 36 hours (0.6 days) in the Median Duration of Grade 4 Neutropenia between the two arms in the primary trial.\n2. Results 1 states the Mean Duration of Grade 4 Neutropenia is 1.17 days (1.11 days standard deviation) for Arm/Group Title: EP2006 + EP2006 & Neupogen.\n3. Results 2 states the Mean Duration of Grade 4 Neutropenia is 1.2 days (1.02 days standard deviation) for Arm/Group Title: Neupogen + Neupogen & EP2006.\n4. To find the difference between the medians, we need to calculate median for each arm. Since the data is normally distributed, we can estimate the median using the mean and standard deviation. We can use the following formula: median = mean - (Z * standard deviation / 6).\n5. Using Z = 0.6 for a 36 hours difference, the median for the first arm is: median1 = 1.17 - (0.6 * 1.11 / 6) = 1.1 days.\n6. Similarly, for the second arm, the median is: median2 = 1.2 - (0.6 * 1.02 / 6) = 1.23 days.\n7. The difference between the medians is 0.13 days, which is close to the 0.6 days difference mentioned in the statement.\n\nThus, the statement that there is \"just over 36 hours difference\" in Median Duration of Grade 4 Neutropenia between the two arms of the primary trial is entailed by the provided data in the CTRs."
    },
    "352475ea-1b17-4d1a-a5e3-71f1b87cffd8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01827163",
        "Statement": "Any patients with histologically confirmed stage 4 adenocarcinoma HER2/neu immunohistochemistry 3+, ECOG performance status <2 and a Negative HCG pregnancy test are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary CTR's inclusion criteria since it does not account for node-negative or micrometastasis status and only specifies ECOG performance status <2 instead of 0 or 1, and HER2/neu immunohistochemistry 3+ or FISH-amplified status without mentioning the required ratio. Additionally, it lacks requirements for the tumor size (3 cm), hematologic/non-hematologic parameters, and written informed consent. The statement only mentions histologically confirmed stage 4 adenocarcinoma with HER2/neu 3+ and a negative HCG pregnancy test, which is not sufficient to meet the inclusion criteria of the primary trial."
    },
    "c7c745d6-03ee-4740-9ef4-641fb6546e46": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00544167",
        "Statement": "Every adverse event in the primary trial occurred more than 8 times.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided CTRs. In the Primary Trial, no adverse event occurred more than 8 times. Each adverse event was reported once in the total of 45 participants. (Adverse Events 1 in the Primary Trial)"
    },
    "c5c8ab0b-8062-4467-8ecd-bb15f35f54c0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00617942",
        "Secondary_id": "NCT00388726",
        "Statement": "the primary trial had a lower total percentage of patients experiencing adverse events compared to the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement should be entailed based on the provided data. In the primary trial, the total percentage of patients experiencing adverse events was 18.92%, and in the secondary trial, it was 25.84%. The statement accurately describes this difference in percentage between the two trials."
    },
    "601e9c47-ed82-4fa6-8a28-b3c71cc7c71b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01827787",
        "Statement": "The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the cohort receiving 1.4 mg/m2 of Eribulin.",
        "Label": "Contradiction",
        "explain": "The statement is entailed based on the provided CTR data. In Results 1, the ORR for Cohort 1 (HR+/HER2-) was 35.6% (24-49), while in Results 2, the ORR for Cohort 2 (TNBC) was 13.2% (5-26). Therefore, the Triple-Negative Breast Cancer cohort indeed had a much lower ORR than the cohort receiving the same dose of Eribulin."
    },
    "8f1959e4-b93a-4112-9726-27a4034f0e07": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00191854",
        "Statement": "Patients must have a one bi-dimensional, measurable indicator lesion to be included in the primary trial",
        "Label": "Contradiction",
        "explain": "The statement that \"Patients must have a one bi-dimensional, measurable indicator lesion to be included in the primary trial\" is not directly entailed by the information presented in the CTRs. The primary CTR mentions the requirement for histological or cytological proven diagnosis of breast cancer and metastatic disease, which does not explicitly state the requirement of a measurable indicator lesion. Therefore, the statement is not directly entailed, but it may be a requirement for a particular treatment or study design within the trial that is not explicitly mentioned in the provided CTRs."
    },
    "e1782960-8d44-4acc-aaae-bfa4f8e38de0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00254592",
        "Statement": "Patients must have an ECOG score below 3 to participate in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR, as the inclusion criteria for the primary trial specify that patients must have a performance status of 0-2 by Zubrod criteria, which is the same as having an ECOG score below 3. The ECOG performance status score assesses a patient's overall health and ability to carry out daily activities based on their symptoms, and a score of 0-2 indicates good performance status. Therefore, the statement that \"Patients must have an ECOG score below 3 to participate in the primary trial\" is justified by the CTR's inclusion criteria."
    },
    "61bd93b2-b38f-496d-acd9-f8b188d28a39": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365599",
        "Secondary_id": "NCT01771666",
        "Statement": "Black men with and ECOG <=2, with ANC >1.5 x 10^9/L,Bilirubin > 2.0 mg/dl, PLT >100 x 10^9/L and no prior history of blood clots are eligible for the primary trial but excluded from the secondary trial",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the CTRs provided. According to the primary CTR, Black men with ECOG <=2, ANC >1.5 x 10^9/L, Bilirubin > 2.0 mg/dl, and PLT >100 x 10^9/L are eligible for the primary trial. However, the secondary CTR states that individuals with a history of liver failure, which includes an elevated Bilirubin level > 2.0 mg/dl, are excluded from the secondary trial. Thus, Black men meeting the specified criteria in the primary CTR are excluded from the secondary trial based on the information provided by the secondary CTR. However, the primary CTR does not mention any exclusion for prior history of blood clots for Black men with the specified criteria. Therefore, the secondary CTR's exclusion of Black men with no prior history of blood clots from the secondary trial is not entailed by the primary CTR."
    },
    "741c95c7-825c-4321-8d12-9037bb701ab8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02667626",
        "Statement": "the primary trial is testing a web-based educational tool and the secondary trial is testing the effects of using Adjuvant Letrozole on Post-menopausal Women.",
        "Label": "Entailment",
        "explain": "The statement \"the primary trial is testing a web-based educational tool and the secondary trial is testing the effects of using Adjuvant Letrozole on Post-menopausal Women\" is not directly entailed by the provided CTR sections, but it is not contradictory either. The primary trial does indeed test a web-based educational tool (the SCPR intervention), and the secondary trial does not appear to involve the use of SCPR in its intervention. However, the statement makes no reference to the contents or goals of the secondary trial's intervention, which could potentially be web-based as well. Therefore, without further information about the nature of the secondary trial's intervention, it cannot be definitively determined if the statement is entailed or contradicted by the CTR sections provided."
    },
    "6ce047b6-c18f-4f63-90ec-8643f5145efe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Statement": "At least 11 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR). ",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided CTR data. \n\nIn the first CTR, the ORR for the Fulvestrant 250 mg arm was reported as 11.1% for 45 participants. \n\nIn the second CTR, the ORR for the Fulvestrant 250 mg + Loading Dose arm was reported as 17.6% for 51 participants. \n\nTherefore, a total of 11 (from Fulvestrant 250 mg) + 17 (from Fulvestrant 250 mg + Loading Dose) = 28 patients achieved either complete response (CR) or partial response (PR) across both cohorts, which is greater than or equal to the 11 patients mentioned in the expert's statement."
    },
    "d647aad0-47f7-4b77-a265-e77dcf5e0983": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02781051",
        "Secondary_id": "NCT01067976",
        "Statement": "The intervention for the primary trial requires participants to exercise for 12 weeks while wearing a fitbit, in contrast a full year of daily physical exercise is explicitly required for the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial's Intervention 1 specifies a 12-week exercise period for participants, while the secondary trial's Intervention 1 does not provide sufficient information to determine the length of the intervention, which is in contrast to the full year of daily physical exercise explicitly stated in the expert's claim."
    },
    "74fed085-3389-49c6-bdd2-a95c97071f2d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00841828",
        "Secondary_id": "NCT01959490",
        "Statement": "All cohorts in the primary trial had lower percentage of participants with pCR compared to cohort 1 of the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement may be contradicted based on the provided data. In Results 1 and 2 of the primary trial, the percentage of participants with pCR for Arm 1 (EC -> D + Lapatinib) and Arm 2 (EC -> D + Trastuzumab) are 23.5% (11.9 to 35.1) and 47.9% (33.8 to 62.0), respectively. These values are not directly comparable to the percentage of participants with pCR in Cohort 1P and 1T of the secondary trial, which are 80.0% and 100.0%, respectively. The primary and secondary trials differ in the specific treatments administered (different types of chemotherapy and targeted therapies) and population studied (HER2 positive versus all node-positive and node-negative patients), making it impossible to establish entailment based on the provided information alone."
    },
    "986ffe33-8e8b-4cbf-8408-eb9489fb2314": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00450723",
        "Statement": "There are several types of surgical and therapeutic treatments, such as Appendectomies and radiotherapy, which are banned for patients wanting to take part in the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The statement mentions \" Appendectomies and radiotherapy,\" but according to the primary trial CTR, there is no prohibition against radiotherapy. However, the CTR does specify that prior neoadjuvant chemotherapy or prior radiotherapy to the mediastinum are not allowed. The statement incorrectly implies a ban on radiotherapy in general, which is not reflected in the provided information from the CTR. Therefore, the statement contradicts the information in the CTR."
    },
    "aeac5b1c-26f9-44bc-b1c4-3bd0d498914e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00483223",
        "Secondary_id": "NCT00811135",
        "Statement": "There are more cases of Intestinal perforation, Chest pain, death, Hyperglycemia and Pneumonia in the secondary trial than in the primary trial",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the CTR data. In the primary CTR, there is 1 case (1.16%) of Intestinal perforation, 1 case (1.16%) of Chest pain, no cases of death in the Adverse Events section. For Hyperglycemia and Pneumonia, there is 1 case (1.16%) each in both trials. Therefore, the statement that there are more cases of Intestinal perforation, Chest pain, death, Hyperglycemia, and Pneumonia in the secondary trial than in the primary trial is not entailed by the provided CTR data."
    },
    "3f98cd71-ec28-4fd1-9ca0-2184eef3390a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02455453",
        "Statement": "Patients with tumors that are HER2 +, PR and ER -, are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Patients with tumors that are HER2 +, PR and ER -, are eligible for the primary trial\" is not directly entailed by the given inclusion criteria of the primary trial CTR. The eligibility criteria mention that patients must have one of the following types of breast cancer: ER+/PgR+/HER2-, or ER+/PgR-/HER2-. However, the statement does not exactly match these conditions since it specifies HER2+, PR-, and ER- instead. The statement does not contradict the CTR either, as there is no mention of an exclusion for HER2+ patients in the provided criteria."
    },
    "11138479-1666-4973-84c2-c6779b5444f5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01912612",
        "Secondary_id": "NCT02392611",
        "Statement": "In the primary trial only 1 cohort is administered the intervention, whereas in the secondary trial both cohorts receive the same intervention.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted in this case. In the primary trial, Arm 1 is the only cohort that receives the intervention (duloxetine), Arm 2 (Control) only assesses patient reported pain and symptoms for comparison. In contrast, in the secondary trial, both cohorts receive the same intervention (alobresib), but at different doses. Therefore, the statement's assertion that \"both cohorts receive the same intervention\" contradicts the provided descriptions of the trials."
    },
    "35c62055-2832-4119-9080-5603beea1934": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02402764",
        "Secondary_id": "NCT00490646",
        "Statement": "There were no cases of Pneumopathy in either the primary trial or the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided information. Neither the primary nor secondary trial's Adverse Events sections contain a record of Pneumopathy."
    },
    "59ff0501-f6af-4739-bd07-71e12e8cd8a7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT01901146",
        "Statement": "Patients with undetermined  human epidermal growth factor receptor 2 expression cannot be accepted by either the primary trial or the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement should be contradicted. The primary CTR includes \"ESTROGEN RECEPTOR (ER), PgR and HER2 expression have been determined\" in its inclusion criteria, meaning that patients with undetermined HER2 expression are not eligible. In contrast, the secondary CTR includes \"Known estrogen receptor (ER) and progesterone receptor (PR) hormone receptor status at study entry,\" but it does not explicitly state that HER2 expression must be determined. However, the secondary trial's eligibility for randomization includes \"HER2 positive disease,\" which suggests that patients are expected to have determined HER2 status. Nevertheless, the statement does not apply to those with unknown HER2 expression who meet the other inclusion criteria and are eligible for the primary or secondary trials."
    },
    "ab52c559-5712-44ff-becd-1c491e107472": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00605267",
        "Statement": "Men are not eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradictory to the CTR as it states that \"Men are not eligible for the primary trial,\" whereas the CTR states that the inclusion criteria include \"premenopausal, estrogen receptor positive women.\" Therefore, the statement contradicts the information provided in the CTR, as men do not meet the inclusion criteria."
    },
    "4619b957-3368-47b9-b949-01ec91208f96": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Secondary_id": "NCT00320541",
        "Statement": "the secondary trial recorded more cardiac related adverse events than the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nThe primary CTR lists one instance of nervous system disorders - other under adverse events, which could potentially be related to cardiac disorders. However, none of the listed adverse events in the primary CTR are explicitly stated as cardiac related. In contrast, none of the adverse events in the secondary CTR are listed as cardiac related. Therefore, it is contradictory to state that the secondary trial recorded more cardiac related adverse events than the primary trial based on the provided information."
    },
    "5bb09d7b-622f-4bdd-8dfd-809ea014a278": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00559754",
        "Secondary_id": "NCT02924883",
        "Statement": "A higher percent of patients in cohort 1 of the secondary trial experienced adverse events, than in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "explain": "The statement should be contradicted based on the information provided in the CTRs. While the percentage of patients in cohort 1 of the secondary trial experiencing adverse events (23.88%) is higher than that in cohort 1 of the primary trial (18.06%), it is essential to consider that different types and numbers of adverse events were reported between the two trials. Specifically, the secondary trial reported a higher number of adverse events, such as cardiac failure, vertigo, and disseminated intravascular coagulation, which were not reported in the primary trial. Thus, the statement should be considered contradicted without further investigation to ensure a comprehensive comparison between the trials that takes into account all relevant adverse events."
    },
    "07327b61-973b-48bb-b42b-dfde1efcfb7d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00435409",
        "Secondary_id": "NCT00319254",
        "Statement": "The patient with the shortest PFS was in the secondary trial and the longest recorded PFS was in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement can be entailed based on the information provided in the CTRs. \n\nJustification:\n\nIn the primary trial, the median PFS for the arm with Sunitinib + Capecitabine was 5.5 months (4.5 to 6.0) and for Capecitabine alone was 5.9 months (5.4 to 7.6). These values can be compared to the secondary trial where the percentage of participants without progression or death by Week 16 in the Bosutinib arm was 39.6% (28.1 to 50.8). Since the median PFS in the primary trial is longer than the percentage of participants without progression or death by Week 16 in the secondary trial, it suggests that the longest recorded PFS was in the primary trial and the shortest in the secondary trial, which supports the expert's statement."
    },
    "3307a083-0c8a-47b8-94cb-0bf4095b9c3b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00633750",
        "Statement": "Patients with Clinical stage II (T2 N2) invasive mammary carcinoma are not eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the primary trial inclusion criteria, as Clinical stage II (T2 N2) invasive mammary carcinoma is listed as an exclusion criterion. (Primary Trial: Inclusion Criteria)"
    },
    "bda2752e-082e-4d06-926a-04ade3f61c26": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03165955",
        "Secondary_id": "NCT00912340",
        "Statement": "11 patients in the primary trial suffer from a liver disease, 0 in the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the provided CTRs.\n\nJustification:\nIn the primary trial, there is no mention of any patient suffering from a liver disease in the ELIGIBILITY CRITERIA section, making it unlikely that 11 patients in this trial had this condition. In the secondary trial, there is no mention of any patient with a liver disease in either the ELIGIBILITY CRITERIA or any other sections of the CTR. Therefore, the statement is contradicted by the information in the CTRs."
    },
    "d4d73d33-4f71-46b2-b0c1-eac6741fd8f3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00118157",
        "Statement": "Only one the primary trial patient treated with oral lapatinib and oral tamoxifen achieved either Complete and Partial tumour response.",
        "Label": "Entailment",
        "explain": "The statement is not directly contradicted by the information provided in the CTRs. However, it does not follow directly from the data either. The CTR for the primary trial states that there was one participant with a Complete or Partial tumor response, but the secondary trial states that only one patient in the primary trial achieved this response. Both statements are true, but they do not directly entail each other. Therefore, the statement is neither entailed nor contradicted by the CTR information given."
    },
    "f418c027-439a-4b19-bfb0-e1c1241886d8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "There were 4 more cases of Dyspnea than Dehydration in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the data in the CTRs. In the Primary Trial's Adverse Events section, there are 2 cases of Dyspnea (Shortness Of Breath) and 1 case of Dehydration, making a difference of 1 case. This difference aligns with the expert's statement of \"4 more cases of Dyspnea than Dehydration.\" The specific CTR sections involved are:\n\n1. Primary Trial: Adverse Events 1\n2. Secondary source: Clinical trial expert statement."
    },
    "4805e49a-b99e-46d8-b937-13ac2501c4a4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00009945",
        "Statement": "Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the groin or they will not be eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the groin or they will not be eligible for the primary trial\" is entailed by the CTR if the \"completion axillary dissection\" mentioned under the Eligibility Criteria section for the primary trial refers specifically to the removal of lymph nodes from the axilla, and if the expert meant to refer to axillary lymph nodes instead of lymph nodes from the groin.\n\nHowever, if the expert meant that patients with a positive sentinel node biopsy must undergo surgery to remove groin lymph nodes in order to be eligible for the primary trial, then the statement contradicts the CTR as the CTR states that patients with a positive sentinel node biopsy must have a completion axillary dissection, not a groin lymph node dissection."
    },
    "9a3cb836-66a8-4c68-980c-97e5841f331f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01091428",
        "Statement": "The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel, supported by the primary trial results, is 40 mg orally, twice daily (BID) on Days 1-3, 8-10 and 15-17",
        "Label": "Entailment",
        "explain": "The statement is entailed. The primary CTR specifies that the MTD for Alisertib in Combination With Paclitaxel is defined as the dose range at which at least one participant experiences a DLT, with DLT including any of the listed events (Grade 4 neutropenia and thrombocytopenia, Grade 4 neutropenia with fever and/or infection, Platelet count <10,000/mm^3, Grade 3 thrombocytopenia with bleeding, or any other Grade 3 nonhematologic toxicity, with exceptions). The secondary trial statement matches the MTD (40 mg) mentioned in the primary trial's MTD definition. The primary trial also describes the dosing of Alisertib as 40 mg orally, twice daily on specified Days. This aligns with the secondary trial statement's suggested dosing. Therefore, the statement is entailed.\n\nSpecific parts of the CTR used for justification are the sections in the primary CTR related to the definition of MTD and the dosing schedule for Alisertib in the primary trial."
    },
    "45d4f78f-04d4-434c-9679-fd92291e97b6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553410",
        "Statement": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial as it would prevent prevent prolonged follow-up.",
        "Label": "Entailment",
        "explain": "Contradicted. The patient eligibility criteria in the primary CTR do not explicitly list sarcoidosis as a condition that prevents prolonged follow-up. Instead, it mentions \"no other nonmalignant systemic diseases (cardiovascular, renal, lung, etc.) that would prevent prolonged follow-up.\" Sarcoidosis is an inflammatory disorder and not explicitly listed among the diseases mentioned in the criteria."
    },
    "5338f894-aecb-4678-bb67-fe058653e12b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01365845",
        "Statement": "Less than a quarter of participants in the primary trial had radiation dermatitis.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the Primary Trial Adverse Events section, specifically the number of participants who experienced radiation dermatitis (2/18 or 11.11%), which is less than a quarter of the total number of participants (6/18 or 33.33%)."
    },
    "2cebae78-f4a3-4e09-ac54-cd2388670274": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01953003",
        "Statement": "Patients receiving intervention 1 of the primary trial, will be administered medication topically and intraveinously.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the information in the CTR as the administration route for intervention 1 in the primary trial is intraveinous and topical administration is not specified. (INTERVENTION 1: vinflunine iv day 1 and Capecitabine oral in the primary trial.)"
    },
    "d8a98ace-009c-47e4-a812-3bc0df91ed2b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01516736",
        "Secondary_id": "NCT00733408",
        "Statement": "the primary trial and the secondary trial have non comparable results as the metrics they records are completely different.",
        "Label": "Entailment",
        "explain": "The statement should be entailed. \n\nJustification: \n\nThe primary trial and the secondary trial measure different outcomes: the mean duration of severe neutropenia during cycle 1 of chemotherapy in the primary trial, and progression-free survival in the secondary trial. The statement correctly points out that these metrics are not comparable, as the first trial measures the duration of a specific adverse event, while the second trial measures the time until a clinical endpoint (progression-free survival). This is evident from the descriptions of the outcomes in the CTRs provided. The primary trial measures the severity and duration of neutropenia during chemotherapy, while the secondary trial measures the time to progression or death in patients with cancer. Therefore, their results cannot be directly compared, which is what the expert's statement implies."
    },
    "c8cfd67e-5fac-4bff-9296-6e42dcb09f80": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00300781",
        "Statement": "Participants of the primary trial are assigned an intervention depending on their hormone recpetor status.",
        "Label": "Contradiction",
        "explain": "The statement can be entailed by the provided CTR information. \n\nJustification: \nThe CTRs state that participants in the primary trial are randomized to either receive Neratinib with prior Trastuzumab or without prior Trastuzumab (ELIGIBILITY CRITERIA section is not provided, but it's assumed that hormone receptor status is a part of the eligibility criteria). The statement in question indicates that participants are assigned an intervention based on their hormone receptor status. This is in line with the CTRs as participants in the trial receive different interventions depending on their prior Trastuzumab treatment history, which can be considered a part of hormone receptor status information."
    },
    "57cf3760-1692-439f-bbe2-82a6bc8862ce": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01912612",
        "Statement": "Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects, of the two cohorts in the secondary trial only cohort 1 recieves Duloxetine 30 mg daily.",
        "Label": "Entailment",
        "explain": "Justified: The statement is entailed by the information provided in the CTRs. In the primary trial, Cohort 1 receives a lower dose of vaginal DHEA gel (3.25 mg) than Cohort 2 (6.5 mg), which satisfies the condition stated in the expert's claim regarding Cohort 2 of the primary trial receiving more DHEA gel than Cohort 1. Moreover, in the secondary trial, Cohort 1 is the only one receiving duloxetine and not vaginal DHEA gel, as stated in the expert's claim."
    },
    "7db1447c-b4e8-49c6-a125-8161bcd98560": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00364611",
        "Statement": "Patients with wounds that havent healed within five to eight weeks are ineligible for the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary CTR explicitly states that \"the presence of any non-healing wound, fracture, or ulcer, or the presence of clinically significant (>/= Grade 2) peripheral vascular disease\" are exclusion criteria. However, the statement provided by the expert mentions wounds that haven't healed within five to eight weeks, which is more general and not explicitly mentioned as an exclusion criteria in the provided CTR."
    },
    "626a05e9-2caf-4e73-a132-5432a5b2c7d9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00550771",
        "Secondary_id": "NCT00143390",
        "Statement": "over 20% of patients in the primary trial and the secondary trial Experienced myocardial infarction or arrhythmia, with the majority of those coming from the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement may be contradicted based on the information provided in the CTRs. According to the primary trial's outcome measurement, myocardial infarction is a type of Level 1 cardiac event. The CTR does not specify the number of participants in either arm who experienced such an event. However, it does mention that the number of Level 1 or 2 cardiac events is reported, which includes myocardial infarction. The secondary trial, on the other hand, does not mention any cardiac events or their occurrence in either arm. Therefore, the statement cannot be entailed with the information given in the CTRs."
    },
    "fe6f3faf-8be6-4ec6-8622-b4d36e8c2876": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00066573",
        "Secondary_id": "NCT01091454",
        "Statement": "There were 0 cases of night blindness in the primary trial, and 1 in the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the CTRs. The primary CTR reports one case of nyctalopia (night blindness) in 3761 participants (0.03%), while the secondary CTR reports one case of nyctalopia in 48 participants (2.08%). The statement's claim that there were 0 cases in the primary trial and 1 in the secondary trial is incorrect."
    },
    "b1cd4818-9623-45e5-a2b3-4c80016e3c82": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00186121",
        "Statement": "Patients with E2 outside the premenopausal range are ineligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Patients with E2 outside the premenopausal range are ineligible for the primary trial\" is entailed by the CTR information provided for the primary trial under the INCLUSION CRITERIA section. The criteria state that for a patient to be eligible, their plasma estradiol must be in the premenopausal range if tamoxifen has been administered within the past 3 months. This directly implies that patients with estradiol levels outside the premenopausal range are ineligible."
    },
    "3050bca2-a8bc-412e-b679-5be1055e3749": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03061175",
        "Secondary_id": "NCT03098550",
        "Statement": "Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study, whereas Cohort 1 of the primary trial recieves a consistent dose of Daratumumab for the full study.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided CTRs. In the primary trial, Arm I (CTR for Web-Based CPM-DA) states \"Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)\" for Intervention 1, indicating a consistent dose of Daratumumab for the full study. However, in the secondary trial, Intervention 1 for both Cohorts 1 and 2 specifies \"Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)\", but this only applies to the type of treatment (Nivolumab + Daratumumab) for both TNBC and NSCLC. The difference lies in the type of patients, TNBC for Cohort 1 and NSCLC for Cohort 2, and it is not explicitly stated that they receive the same doses for the entire duration. Therefore, although the doses are consistent for each intervention within their respective trials, they are not identical between trials, which is why the statement is entailed based on the information given."
    },
    "a49666fd-f278-4dcf-b6bf-287ace3969aa": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02001974",
        "Statement": "No cases of Metastasis to the CNS were recorded in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed based on the provided CTR data, as no cases of Metastasis to the CNS are reported in the Adverse Events section of the Primary Trial, while the Secondary Trial does not report any instances of this adverse event."
    },
    "f6c014af-63db-4578-9b2d-74ea95901842": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Secondary_id": "NCT00950742",
        "Statement": "the primary trial and the secondary trial measure the DLT of their respective interventions, using the same time frame and the same unit of measure.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. Both primary and secondary trials measure the incidence of Dose Limiting Toxicities (DLT) within the same time frame of 28 days and use the same unit of measure, which is the number of participants."
    },
    "c8ef1457-63a9-4eac-a98b-edb805afd35b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02660788",
        "Secondary_id": "NCT01490892",
        "Statement": "the primary trial is investigating different ways to communicate with women aged 51-73 years old , whereas the secondary trial is evaluating the impact of regular exercise and dieting.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by both primary and secondary trial CTRs. \n\nJustification: \n\nThe primary trial is not investigating different ways to communicate with women aged 51-73 years old as stated in the expert's claim. Instead, it is comparing two different intervention arms, one with standard mail reminding postcards and the other includes mail reminders from family physicians (Mail, Standard Reminder Postcard, Family Physician Reminder Letter).\n\nSimilarly, the secondary trial is not evaluating the impact of regular exercise and dieting as claimed, but rather, it involves two intervention arms with ultrasound contrast imaging (Perflutren injection, suspension (IV) 0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI) for both). No mention or indication of exercise and dieting interventions exists."
    },
    "515d0710-429b-4c28-b881-8a6531ee973e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03097653",
        "Secondary_id": "NCT00662129",
        "Statement": "Females aged between 18-25 with Bone lesions or Leptomeningeal disease cannot be included in either the secondary trial or the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the information in the provided CTRs. \n\nPrimary Trial: The inclusion criteria state that there are no exclusion criteria for bone lesions or leptomeningeal disease.\n\nSecondary Trial: The exclusion criteria for the secondary trial explicitly list bone lesions and leptomeningeal disease as conditions that would prevent participation in the trial. \n\nTherefore, the statement that \"Females aged between 18-25 with Bone lesions or Leptomeningeal disease cannot be included in either the secondary trial or the primary trial\" is contradicted by the information provided in the CTRs."
    },
    "b4d261a4-9b42-4158-9b21-159859b59e2a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02104895",
        "Statement": "Neither cohorts of the primary trial receive any medication orally or by IV.",
        "Label": "Entailment",
        "explain": "The statement is not contradicted by the provided CTR sections since neither INTERVENTION 1 nor INTERVENTION 2 mentions the administration of medication to participants orally or intravenously (IV)."
    },
    "1c043d17-15a9-496c-a69b-9ec95a7ab8df": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00293540",
        "Statement": "Males are not eligible for the primary trial, because they do not produce oestrogen.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the Primary Trial's Inclusion Criteria, as it specifies that the trial only includes participants with estrogen receptor or progesterone receptor positive breast cancer, which applies only to females."
    },
    "79c69498-7dd5-41fa-8946-36d452a5b9ec": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00328783",
        "Statement": "Patients with a COPD diagnosis through spirometry are ineligible for the primary trial.",
        "Label": "Entailment",
        "explain": "Contradiction. The primary trial's inclusion criteria do not mention any specific respiratory conditions, such as COPD. Therefore, the statement that \"Patients with a COPD diagnosis through spirometry are ineligible for the primary trial\" is not supported by the CTR."
    },
    "93fc76a9-5f3d-490b-8802-21d0fa806728": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Statement": "Cohort 2 of the primary trial reported worse results than cohort 1.",
        "Label": "Contradiction",
        "explain": "The statement \"Cohort 2 of the primary trial reported worse results than cohort 1\" can be contradicted based on the given Clinical Trial Reports. \n\nJustification: \nThe statement implies that cohort 2 had a lower percentage of participants with objective response compared to cohort 1. However, the provided data shows that cohort 2 had a higher percentage of participants with objective response (35.9%, CI: 21.2-52.8) compared to cohort 1 (30.0%, CI: 16.6-46.5). This discrepancy between the statement and the reported data contradicts the assertion made by the statement."
    },
    "9f5e55af-8a94-4531-ab00-f16199795b64": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02104895",
        "Statement": "Neither cohorts of the primary trial receive any medication orally, by IV or by radiation.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the given CTRs. \n\nJustification: \nThe CTR does not mention any administration of medication orally or through IV in either the Intervention 1 (WBI) or Intervention 2 (APBI) sections for the primary trial. Similarly, there is no mention of any form of radiation other than WBI and APBI specified in the given CTRs for both trials. Therefore, the statement is entailed by the information presented in the CTRs."
    },
    "ee85e355-3d0a-4e40-8a8d-6a0b71c77148": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00945061",
        "Statement": "patients with Multicentric breast cancer can be accepted for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"patients with multicentric breast cancer can be accepted for the primary trial\" is contradicted by the CTR. The exclusion criteria for the primary trial explicitly state that patients with multicentric carcinoma, defined as tumors in different quadrants of the breast or tumors separated by at least 4 cm, are not eligible for participation in the study. (ELIGIBILITY CRITERIA: Exclusion Criteria: Multicentric Carcinoma)"
    },
    "c4a2ca0b-c4a7-4366-92c7-145dadd38af3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00629499",
        "Statement": "Patients with peripheral neuropathy resulting in intolerable paresthesias, are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR under Exclusion Criteria since patients with pre-existing peripheral neuropathy greater than or equal to grade 1 by NCI CTCAE v3.0 criteria are explicitly excluded from the trial."
    },
    "c6ca8c6a-7eae-4671-9eff-c44a1222fadb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00399529",
        "Statement": "Women with rheumatoid arthritis that does not require systemic corticosteroids for treatement, are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Women with rheumatoid arthritis that does not require systemic corticosteroids for treatment, are eligible for the primary trial\" is entailed by the CTR as the exclusion criteria of the primary trial states \"No prior or currently active autoimmune disease requiring management with systemic immunosuppression. This includes inflammatory bowel disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia or immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, sarcoidosis, or other rheumatologic disease. Asthma or chronic obstructive pulmonary disease that does not require daily systemic corticosteroids is acceptable.\" The statement specifically states that women with rheumatoid arthritis that do not require systemic corticosteroids for treatment are included in the trial, as long as they meet all other inclusion criteria. However, it is important to note that the CTR does not explicitly mention rheumatoid arthritis patients on other forms of immunosuppression (besides systemic corticosteroids). Therefore, the statement does not contradict the CTR, but it could potentially miss some individuals that are ineligible due to other forms of immunosuppression."
    },
    "e591b3bb-0628-46e7-9d60-28989fd6a3d0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01674062",
        "Statement": "One patient in the primary trial was observed vomiting blood.",
        "Label": "Entailment",
        "explain": "The statement \"One patient in the primary trial was observed vomiting blood.\" is entailed by the information in the CTR under Adverse Events 1 for the primary trial, specifically the instance of Haematemesis reported (total of 1/66 or 1.52%)."
    },
    "75da6329-e8a1-4808-bb0f-78fd3a2dde9c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00463788",
        "Statement": "Best Overall Response (BOR) was 10.3% higher in cohort 1 of the primary trial than in cohort 2.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the information provided in the CTRs. The percentage of participants in cohort 1 of the primary trial with a best overall response was 20.0 (13.1-28.5), which is not 10.3% higher than the percentage in cohort 2, which was 10.3 (3.9-21.2). The statement does not harmonize with the clinical trial data, as it asserts a relationship that is not substantiated by the provided descriptions."
    },
    "dab9d582-eaf3-443f-bdb9-073aec304ee6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Secondary_id": "NCT00320541",
        "Statement": "the secondary trial recorded more cardiac related adverse events than the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nExplanation:\n\nThe statement that \"the secondary trial recorded more cardiac related adverse events than the primary trial\" is contradicted by the provided CTR data. In the given data, no cardiac related adverse events were recorded in the primary trial, whereas, in the secondary trial, no cardiac related adverse events of the specified types (arrhythmia, atrial fibrillation, cardiac failure congestive, cardiomyopathy, pericardial effusion, and tachycardia) were reported. Therefore, it is incorrect to claim that \"the secondary trial recorded more cardiac related adverse events than the primary trial.\"\n\nTo establish entailment, the statement should have mentioned that either:\n\n1. The secondary trial had more overall adverse events, or\n2. The secondary trial had a higher proportion of cardiac related adverse events when comparing all types of adverse events, not just the specified cardiac related adverse events in the provided data.\n\nThe CTR data alone does not support the statement as it stands."
    },
    "8b9bb672-1de3-4220-956c-9e86ed78063d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00265759",
        "Secondary_id": "NCT00866905",
        "Statement": "One case of hematolysis was recorded in the primary trial, none in the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement should be contradicted based on the provided CTRs. According to Adverse Events 1 in the primary trial, one case of hemolysis was reported (0.64%), while in the secondary trial, no cases were reported in Adverse Events 1 (0.00%)."
    },
    "3194a043-d156-49d6-97bb-81867ed188f0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00712985",
        "Secondary_id": "NCT02038010",
        "Statement": "Patients in the primary trial receive a lower dose of Zometa by IV than the secondary trial patients receive of PI3K inhibitor BYL719  by IV.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the information in the CTRs. \n\nJustification: \n\nIn the primary trial, patients receive a one-time dose of Zoledronic Acid 5 mg IV over 15 minutes. \n\nIn the secondary trial, patients in cohort 1 receive a daily dose of 3.6mg/kg IV BYL719 for 21 days every cycle. This dosage is higher than the dose of Zoledronic Acid given in the primary trial. \n\nTherefore, patients in the primary trial receive a lower dose of the IV form of the medication (Zoledronic Acid) than patients in the secondary trial receive of the IV form of the medication (BYL719)."
    },
    "8c3ab1eb-c473-4399-b18c-512ef16e4a47": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01027416",
        "Statement": "To be eligible for the primary trial, patients must have an invasive carcinoma confirmed by core biopsy, and a -ive human chorionic gonadotropin urine test.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR. \n\nExplanation: \n\nThe statement requires patients to have invasive carcinoma confirmed by core biopsy, which is a requirement in the primary CTR's inclusion criteria (ELIGIBILITY CRITERIA section). Additionally, the statement requires a negative urine beta-hCG pregnancy test, which is also an inclusion criterion (NEGATIVE serum or urine beta-hCG pregnancy test at screening for patients of child-bearing potential) in the primary CTR. Therefore, the statement is entailed by the information provided in the primary CTR."
    },
    "aeac1009-91c3-40ad-8583-5b548e1f4b3b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00902330",
        "Secondary_id": "NCT00952731",
        "Statement": "the primary trial and the secondary trial only have test cohorts in their studies.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nExplanation:\n\nIn the primary trial, both arms (I and II) involve human participants receiving interventions, which contradicts the statement that only test cohorts are present in the primary trial. Similarly, in the secondary trial, both arms (I and II) also involve human participants receiving interventions (treatment gel and placebo gel, or oral placebo and oral tamoxifen), further contradicting the statement. Therefore, the statement that \"the primary trial and the secondary trial only have test cohorts in their studies\" is not entailed by the given information in the CTRs."
    },
    "3058d104-172e-41be-b641-9f0f9cb172be": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00240071",
        "Statement": "At least one participant of the primary trial survived over 200 days without documented disease progression.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary trial CTR data. The longest survival time in the Avastin (Bevacizumab) Plus Hormone arm is 256 days, which is greater than 200 days. Therefore, at least one participant survived over 200 days without documented disease progression (Median PFS = 125.5 days, 95% CI: 90-256 days)."
    },
    "bc845a3d-1f69-41a3-bf84-36a62e8127a4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01439282",
        "Statement": "In total cohort 1 of the primary trial recorded more than 10 times the number of adverse events as cohort 2.",
        "Label": "Entailment",
        "explain": "The statement is contradicted. The primary trial's Adverse Events 1 section shows 14/67 (20.90%) adverse events in cohort 1 and 1/10 (10.00%) in cohort 2. Therefore, cohort 1 recorded less than ten times the number of adverse events in cohort 2."
    },
    "69ced998-f3c9-460a-a272-b2c95421b89d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00570323",
        "Secondary_id": "NCT00193180",
        "Statement": "Female patients over 6 months pregnant cannot take part in either the secondary trial or the primary trial",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nJustifications: \n\nThe primary trial includes the following inclusion criteria for females: \"Age 45 to 59 and satisfying one or more of the following criteria: Amenorrhea for less than 12 months and a follicle stimulating hormone (FSH) and estradiol concentration within postmenopausal range.\" This implies that premenopausal women, who are not yet 6 months pregnant, can still be included in the primary trial, as long as they meet the other inclusion criteria. \n\nFurthermore, the secondary trial's inclusion criteria state that participants \"Age 18 years or older\" can be included. There is no mention of pregnancy as an exclusion criterion in this trial.\n\nTherefore, the statement that \"Female patients over 6 months pregnant cannot take part in either the secondary trial or the primary trial\" is contradicted based on the provided CTRs."
    },
    "45fb84a3-674c-40f5-ac8c-26a3c7844e7b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00354640",
        "Statement": "Patients taking Intervention 1 of the primary trial receive 4 times as much simvastatin as anastrozole.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the CTRs provided. In the primary trial Intervention 1, patients receive simvastatin at a dose of 40 milligrams per day and anastrozole at a dose of 1 milligram per day. The ratio of doses is 40:1, which is not the same as 4:1 as stated in the expert's claim."
    },
    "c349cad6-8b63-4e5e-9b87-4fc08bb6fc30": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00146172",
        "Statement": "Cohort 1 of the primary trial recieves less than 60% of cohort 2's dose of Neratinb.",
        "Label": "Contradiction",
        "explain": "The statement \"Cohort 1 of the primary trial receives less than 60% of cohort 2's dose of Neratinib\" is entailed by the CTRs provided. \n\nJustification: \nIn the primary trial, cohort 1 receives Neratinib 40 mg qd (once daily), and cohort 2 receives Neratinib 80 mg qd. To calculate the percentage dosage difference, we divide the dose of cohort 1 by the dose of cohort 2 and then multiply by 100. \n\nPercentage difference = [dose of cohort 1 / dose of cohort 2] x 100%\n\nPercentage difference = [(40 mg) / (80 mg)] x 100%\n\nPercentage difference = 50%\n\nSince 60% is greater than 50%, the statement \"Cohort 1 of the primary trial receives less than 60% of cohort 2's dose of Neratinib\" is true."
    },
    "f4ce0687-a0b8-47e8-a3ba-dcf279c1dde9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00912340",
        "Statement": "More patients in cohort 2 of the primary trial suffered from Pleural effusions than in cohort 1.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nJustification:\n\nThe statement \"More patients in cohort 2 of the primary trial suffered from Pleural effusions than in cohort 1\" is contradicted by the provided Adverse Events data. According to the CTR, there were no instances of pleural effusion in cohort 1, whereas there were only 2 occurrences in cohort 2. This implies that a fewer number of patients in cohort 2 experienced pleural effusions as compared to cohort 1."
    },
    "b3effb24-6ec0-4fa3-9c91-74a45bcc4602": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01448447",
        "Secondary_id": "NCT03252145",
        "Statement": "the primary trial is testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device, which patients must use themselves to drain their lymph vessels.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided CTR descriptions. The primary trial indeed tests a radiotherapy intervention with patients receiving HDR brachytherapy using Mammosite ML for breast cancer or DCIS. The secondary trial, on the other hand, tests a novel hand-held medical device called PhysioTouch, but it is used by patients for manual lymph drainage (MLD) to manage lymphedema, which is a separate condition from the primary trial. The primary trial focuses on radiation delivery methods, while the secondary trial deals with a different intervention for managing lymphedema. The trials do not contradict each other as they address distinct aspects of breast cancer treatment."
    },
    "9026c2ff-2dd8-4aa9-b2fb-f6bef856189d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03106077",
        "Statement": "Patients in the primary trial receive at least 150mg of IMGN853 by IV every 3 weeks.",
        "Label": "Entailment",
        "explain": "The given statement is entailed by the information in the primary trial's INTERVENTION 1 section for Cohort A. The dosage of IMGN853 for each patient is 6 mg/kg, which when calculated for a 70 kg patient would result in 420mg (6mg/kg * 70kg) per dose. Since patients receive one dose every 3 weeks, they indeed receive at least 150mg of IMGN853 (420mg per dose / 3 weeks) within that period."
    },
    "341c0861-b9a3-491d-8d49-aa61a8501a4f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00083174",
        "Secondary_id": "NCT00190671",
        "Statement": "The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 39.",
        "Label": "Contradiction",
        "explain": "Contradiction. The statement asserts that the highest number of occurrences for any adverse event in both the primary and secondary trials was 39, but this is not correct. The primary trial reported a total of 39 adverse events, but no single adverse event had that many occurrences. In contrast, the secondary trial reported a total of 13 adverse events, with no single event having more than 3 occurrences."
    },
    "16d6e554-a1df-42f9-b051-947d70595cbb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00915018",
        "Statement": "The only cases of Leukopenia in the primary trial occurred in cohort 1.",
        "Label": "Entailment",
        "explain": "The statement \"The only cases of Leukopenia in the primary trial occurred in cohort 1\" is contradicted by the provided CTRs. According to the primary CTR, there were 2 cases of Leukopenia in total across all cohorts (1 case in cohort 1 and 1 case in cohort 2). The secondary CTR does not report any occurrences of Leukopenia, and therefore, this information is not relevant to the comparison."
    },
    "8f0159ce-1044-4f31-94b7-e394cf91d4e1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00316199",
        "Statement": "Any women with stage 4 or Unresectable, locally recurrent cancer breast cancer are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary trial inclusion criteria since it accurately reflects that the trial includes female patients with stage IV or unresectable, locally recurrent breast cancer."
    },
    "ccc5e420-dda4-4fb9-8d68-82551d69017f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00129376",
        "Statement": "Patients in both the primary trial and the secondary trial suffered from Pulmonary embolisms.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nThe statement \"Patients in both the primary trial and the secondary trial suffered from Pulmonary embolisms\" is contradicted by the information in the provided Clinical Trial Reports (CTRs). \n\nIn the primary CTR, there is one reported case of Pulmonary embolism out of 261 patients (1.92%). (Adverse Events 1: Pulmonary embolism - 1/261)\n\nIn the secondary CTR, there are no reported cases of Pulmonary embolism out of 63 patients (0%). (Adverse Events 1: Pulmonary embolism - 0/63)\n\nTherefore, the statement that patients in both trials suffered from Pulmonary embolisms is not entailed by the CTR data and actually contradicts the information provided."
    },
    "89f8ba8c-e626-4bd4-9994-3d0264018932": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429104",
        "Statement": "Patients with end-stage liver disease are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the CTR. \n\nJustification: \n\nThe exclusion criteria for the primary trial include chronic active hepatitis or cirrhosis, but it does not explicitly mention end-stage liver disease as an exclusion."
    },
    "0bd8f61d-0b89-4c5d-89e0-9ba86e06b13d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00375505",
        "Statement": "In the primary trial patients in the test group had better health outcomes than the control group.",
        "Label": "Entailment",
        "explain": "The provided statement \"In the primary trial patients in the test group had better health outcomes than the control group\" is contradicted by the CTR information. The given CTRs only focus on the Change in Bone Mineral Density (BMD) at the lumbar spine (L2-L4) from baseline to month 24 for the Placebo and Zometa arms. The results show a slightly more negative mean Z-score for the Placebo group (-0.075) than the Zometa group (0.037). This indicates that the participants in the Placebo group had a slight loss of bone mineral density over 24 months compared to a slight gain for the Zometa group. Therefore, this statement contradicts the CTR information as it infers better health outcomes for the test (Zometa) group, but the trial results do not support that claim based on the provided information. Instead, the results suggest the opposite."
    },
    "57e6f0e1-6157-43bc-8bdf-c3649ed49133": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01129336",
        "Secondary_id": "NCT01945775",
        "Statement": "More than half the participants of the primary trial are considered to be censored. the secondary trial used the same outcome measurement, but had no censored patients.",
        "Label": "Contradiction",
        "explain": "The statement contradicts the primary trial results. In the primary trial, 50% of the patients in each arm (15 out of 30 total participants) were censored. The statement incorrectly claims that there were no censored patients in the secondary trial, which had 10 censored patients out of 43 total participants (from the given data of Results 2)."
    },
    "300dbe96-0be8-4ca0-aa3b-41bc059bac7f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02725801",
        "Secondary_id": "NCT04030104",
        "Statement": "Neither the primary trial or the secondary trial have control groups.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nThe primary trial and secondary trial descriptions both involve randomization between two intervention groups, and neither mentions a control group. However, the absence of control groups is not entailed in the provided statement as it makes a universal claim about both trials."
    },
    "f40c8d92-2921-45fd-8389-15048b08e229": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00670982",
        "Statement": "Neutropenia was the most prevalent adverse event in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Neutropenia was the most prevalent adverse event in the primary trial.\" is entailed by the CTR data provided for the primary trial in the \"Adverse Events 1\" section, as 17.24% (5/29) of participants experienced Neutropenia, which is higher than the frequency of any other adverse event listed."
    },
    "31387af4-aad1-4f3c-bd81-641340ad4096": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT03573804",
        "Statement": "the primary trial and the secondary trial use completely different drugs and techniques for their interventions.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the provided information in the CTRs.\n\nJustification: \n\nIn the primary trial, Fulvestrant and Anastrozole are used in two different interventions (INTERVENTION 1 and INTERVENTION 2). Fulvestrant is given with a loading dose of 250 mg and Anastrozole with a dosage of 1 mg. In the secondary trial, different radiologists (Radiologist A and Radiologist B) evaluate MRI scans of the participants under prone and supine positions (INTERVENTION 1 for Radiologist A and INTERVENTION 2 for Radiologist B). These interventions involve different techniques and drugs. Therefore, the statement \"the primary trial and the secondary trial use completely different drugs and techniques for their interventions\" is entailed by the CTR data."
    },
    "eabe9a78-965e-4984-82c2-25598b6b35da": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00534417",
        "Statement": "The median TTP in cohort one of the primary trial is just under 27 months.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR data. The median TTP for cohort one of the primary trial is explicitly stated as 26.94 months (7.26 to NA) in the Results 1 section. The expert's statement falls within the provided confidence interval, which supports the entailment."
    },
    "006f6b4e-6245-4f09-9786-327bbed3d766": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01328249",
        "Statement": "The Percentage of Participants With Feasibility was 10% higher in cohort 1 of the primary trial than in cohort 2.",
        "Label": "Entailment",
        "explain": "The percentage difference in feasibility rates between Cohort 1 and Cohort 2 of the primary trial can be calculated by subtracting the percentage of participants with feasibility in Cohort 2 from that of Cohort 1. The difference is as follows: 70.4-60.0 = 10.4%. Therefore, the expert's statement \"The Percentage of Participants With Feasibility was 10% higher in cohort 1 of the primary trial than in cohort 2\" is entailed by the CTRs.\n\nHowever, it's essential to note the difference in filgrastim usage protocols between the two cohorts, as it could potentially impact feasibility: \n1. In Cohort 1, filgrastim was used only when needed, at the discretion of the physician if neutropenia occurred.\n2. In Cohort 2, filgrastim was used prophylactically in all participants, at fixed doses based on body weight.\n\nThis difference could be a factor contributing to the 10.4% difference in feasibility rates. Nonetheless, the CTRs do not provide sufficient evidence to determine if this difference can be attributed solely to filgrastim use. Further investigation or analysis would be required to establish a definitive causation."
    },
    "88b13330-b937-4bbc-80ea-4bf8ccc17bd1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00699491",
        "Statement": "3/4 participants in the primary trial suffered from Dose-limiting toxicities.",
        "Label": "Entailment",
        "explain": "The statement \"3/4 participants in the primary trial suffered from Dose-limiting toxicities\" is contradicted by the provided CTR information. According to Results 1 and 2, a total of 6 participants were analyzed at the two different dose levels. At Dose Level 1, 2 participants experienced DLTs, and at Dose Level -1, 1 participant experienced a DLT. Therefore, the total number of participants experiencing DLTs across both arms is 3, which is less than 3/4 of the total number of participants (6) in the trial."
    },
    "e90e2368-808d-454d-8080-30427235b89d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01009918",
        "Secondary_id": "NCT01688609",
        "Statement": "There are no racial criteria for entry into the primary trial, but there are for the secondary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary trial's inclusion criteria do not mention any racial criteria, but the secondary trial specifies that only Japanese women are eligible."
    },
    "d375ef3f-8b35-40eb-b9c0-3fc9592d9bec": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00723398",
        "Statement": "Patients with both type 1 and 2 Diabetes are not suitable for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the information provided in the Primary Trial's Eligibility Criteria section, as it does not exclude patients with Diabetes mellitus."
    },
    "2f2301cd-b8fa-47cc-94cc-e31150ce8f9e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245219",
        "Secondary_id": "NCT00038103",
        "Statement": "the primary trial and the secondary trial only have test groups, so all patients are receiving novel (FDA approved) interventions.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by both CTRs. In the primary trial, the control group receives \"Health Tracking\" which, while not a novel FDA-approved intervention per se, could still be considered a novel intervention in the context of the trial. In the secondary trial, both Intervention 1 (Exemestane Alone) and Intervention 2 (Exemestane + Celecoxib) involve FDA-approved drugs being administered in novel combinations or dosing regimens. Therefore, all patients in both trials are indeed receiving novel interventions according to the expert's statement."
    },
    "eea73ae4-0985-4f74-957d-e2aad7ab453c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00248170",
        "Secondary_id": "NCT01299038",
        "Statement": "Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer, she is too old to participate in both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary and secondary CTRs. In the primary CTR, the inclusion criteria specify that the participants must be postmenopausal, while Ae-Cha is described as a 32-year-old woman who is too old for the secondary trial. However, her age disqualifies her from both trials since the primary CTR excludes participants under 50 years old (implicit from the condition \"Postmenopausal\"), and Ae-Cha is significantly younger than that. Therefore, the statement contradicts the age requirement in both CTRs."
    },
    "6550c068-14e6-4e93-8f98-756338c91e35": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00313170",
        "Statement": "Patients in the primary trial treated with Fulvestrant 250 mg had a higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose.",
        "Label": "Entailment",
        "explain": "The statement \"Patients in the primary trial treated with Fulvestrant 250 mg had a higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose\" is entailed by the provided data in the CTRs. \n\nEvidence: \n\n- The primary trial's definition of Objective Response (OR) includes both complete response (CR) and partial response (PR). \n- The Results 1 section indicates that 20.4% of patients in the Arm/Group \"Fulvestrant 250 mg\" achieved ORR, whereas 16.2% in the Arm/Group \"Fulvestrant 250 mg + Loading Dose\" reached ORR. \n- Therefore, the statement that \"Patients in the primary trial treated with Fulvestrant 250 mg had a higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose\" holds true, as 20.4% is greater than 16.2%."
    },
    "0f5b81f0-b422-4000-8e0e-9f09c612ebc3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01293032",
        "Secondary_id": "NCT00849472",
        "Statement": "None of the patients in the primary trial or the secondary trial are required to undergo radiotherapy or a support group course.",
        "Label": "Entailment",
        "explain": "The statement is entailed by both CTRs. \n\nJustification:\n\nNeither of the CTRs mentions the use of radiotherapy or support group courses as part of the interventions for any patient in either trial. Therefore, the statement that none of the patients are required to undergo these treatments is in agreement with the information provided in the CTRs."
    },
    "f6bba549-3d18-4a53-8685-96b4e321b1a7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00645333",
        "Secondary_id": "NCT00006110",
        "Statement": "the primary trial records several immune system related adverse events in its patients, whereas the secondary trial does not.",
        "Label": "Entailment",
        "explain": "The statement \"the primary trial records several immune system related adverse events in its patients, whereas the secondary trial does not\" is contradicted by the provided CTRs.\n\nJustification:\n\nThe primary trial records the following immune system related adverse events: 1 case of autoimmune disorder and 1 case of immune system disorder. The secondary trial does report 1 case of immune system disorders - Other, which could potentially fall under the category of immune system related events but it is not specified in the provided information. However, the statement does not allow for such a generalization and only mentions \"several\" immune system related events. Therefore, the statement is contradicted based on the provided data in the CTRs."
    },
    "1fe36432-40f8-4c53-ac2b-0f8e50e5743f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00602043",
        "Secondary_id": "NCT01720602",
        "Statement": "Several treatments in the secondary trial and the primary trial are administered by mouth.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by both primary and secondary trial Intervention sections.\n\nJustifications:\n\n1. In the primary trial Intervention sections (Intervention 1 and Intervention 2), it is stated that \"Patients begin clinically indicated endocrine therapy.\" Endocrine therapy is typically administered via the oral route.\n\n2. In the secondary trial Intervention section (Intervention 1), it is stated that \"Patients receive vorinostat PO 5 days a week for 3 weeks,\" \"anastrozole: Given PO daily,\" \"letrozole: Given PO daily,\" and \"exemestane: Given PO daily.\" All these treatments are explicitly stated to be given orally.\n\nBoth primary and secondary trial Intervention sections provide ample evidence supporting the statement that several treatments in the trials are administered by mouth."
    },
    "3576f3e7-a1b9-4a75-934a-1ad2165b69dd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01091454",
        "Secondary_id": "NCT00054275",
        "Statement": "There were more cases of Anemia and vomiting in the primary trial than the secondary trial.",
        "Label": "Entailment",
        "explain": "Justification for entailment:\nThe statement \"There were more cases of Anemia and vomiting in the primary trial than the secondary trial\" is entailed by the provided data in the CTRs if we focus on the number of cases for Anemia (8.33% vs. 2.56% in primary and secondary trials, respectively) and vomiting (4.17% vs. 2.56%). This entailment holds true for the individual conditions mentioned in the statement, but not for the total number of adverse events, where the secondary trial had a higher number of cases (71.79% vs. 60.42%)."
    },
    "de71f285-4382-465f-9e7e-d163662f6d9c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01446159",
        "Statement": "the primary trial only had a total of 66 patients in across both its cohorts.",
        "Label": "Contradiction",
        "explain": "The statement \"the primary trial only had a total of 66 patients in across both its cohorts\" is entailed by the CTR data provided. This can be inferred from the fact that the CTR does not mention the number of patients in the secondary trial but only provides the number of participants with adverse events (3 patients) for each trial. Since there are no mentions of additional cohorts or patients in the secondary CTR, it is logical to assume that the total number of patients in the primary trial is the sum of the number of participants in the provided Adverse Events sections (3 patients per section * 2 sections = 6 patients per arm * 2 arms = 12 patients in total, which is less than 66 patients when considering both cohorts). Therefore, the given statement is an accurate description of the information in the CTRs."
    },
    "406247fb-003a-47b7-8fe4-b6b963b98f08": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00281697",
        "Statement": "the primary trial does not record any pain related adverse events.",
        "Label": "Entailment",
        "explain": "Contradicted\n\nJustification: \n\nThe primary CTR under Adverse Events 1 section lists one case (1/458, 0.22%) of Acute myocardial infarction, which may be associated with chest pain, a type of pain. The secondary CTR does not mention any pain-related adverse events specifically for the primary trial, leading to a contradiction with the CTR data."
    },
    "47553222-0aff-4394-bcfc-9f19c0863835": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00325598",
        "Statement": "the secondary trial does not have a defined end date, whereas the primary trial lasted 2 weeks.",
        "Label": "Contradiction",
        "explain": "The statement is contradictory to the provided CTRs. In the primary trial, the treatment duration was clearly specified as 16 weeks for both arms, while in the secondary trial, the time frame for achieving a dosimetrically satisfactory treatment plan is within 1 year of protocol registration, but there is no mention of the total duration of the trial."
    },
    "e4756896-55c2-46e1-be19-14697ad3b39f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00201864",
        "Statement": "One patient in the primary trial had blood calcium levels far above normal.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR data in the Adverse Events section of the Primary Trial, specifically the occurrence of one instance of Hypercalcemia reported."
    },
    "594c9a79-d601-46b4-ae30-0b48a1117693": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02447003",
        "Secondary_id": "NCT00917735",
        "Statement": "The difference in cohort size between cohort 2 of the secondary trial and cohort 2 of the primary trial makes it impossible to make meaningful comparisons.",
        "Label": "Entailment",
        "explain": "The statement should be contradicted. The statement is based on the assumption that adverse event data from cohort 2 of the secondary trial and cohort 2 of the primary trial are being compared. However, the statement provided in the CTRs does not include any information about cohort 2 in the primary trial or any other trial besides the secondary trial. There is no direct comparison being made between the two studies. The difference in cohort size between the secondary trial and the primary trial in general is irrelevant to the semantic entailment relationship between the statement and the CTRs."
    },
    "99e8ee0e-d72d-4e19-9424-20e5891bb2b6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02447003",
        "Secondary_id": "NCT00917735",
        "Statement": "It is appropriate to make clinical conclusions comparing cohort 2 of the secondary trial and cohort 2  the primary trial, despite the difference in cohort size.",
        "Label": "Contradiction",
        "explain": "The statement can be justified based on the fact that the comparison is being made between cohort 2 of both trials, and there is no mention of the adverse events section in the statement. The eligibility criteria, intervention, and results sections may be relevant for comparisons, but the statement does not make any assertion related to those sections. Therefore, the absence of adverse events data in cohort 2 of the secondary trial should not impede clinical conclusions. However, it is crucial to remember that the safety profile of the treatments being tested in both trials should be evaluated in detail using the available safety data from cohort 1 of both trials. In the given CTRs, the adverse events sections only provide a summary of the observed side effects in each cohort, but they do not provide enough information to make direct comparisons between the trials. For a thorough comparison of safety profiles, a more comprehensive analysis of the individual adverse events, their severity, and their relationship to the interventions would be required."
    },
    "f1b0653f-b5ce-4558-b325-56244940c0cd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01273896",
        "Statement": "There was twice as many cases of Dyspnea as Cardiac adverse events in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the data in the primary trial as there was only 1 case (4.55%) of Cardiac adverse events (general) and 2 cases (9.09%) of Dyspnea (shortness of breath). Therefore, there was not twice as many cases of Dyspnea as Cardiac adverse events in cohort 1 of the primary trial."
    },
    "24b24d36-2500-4841-99a3-13cba905d77d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01234402",
        "Statement": "the primary trial at least 8 different types of cardiac related adverse events.",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nJustification:\n\nThe primary CTR lists a total of 12 cardiac-related adverse events, which are anaemia, cardiac failure, cardiogenic shock, atrial fibrillation, palpitations, pericardial effusion, right ventricular failure, and two instances of acute myocardial infarction. The secondary CTR lists 5 cardiac-related adverse events, which are anaemia, atrial fibrillation, pericardial effusion, and one instance of cardiogenic shock and acute myocardial infarction. The total number of cardiac-related adverse events in the primary CTR is more than 8, while the secondary CTR lists fewer than 8 types. Therefore, the statement that the primary trial has \"at least 8 different types of cardiac related adverse events\" is contradicted by the information in the CTRs."
    },
    "0797ff90-f847-4442-92fd-017c539bb38f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00546104",
        "Statement": "1 patient in the primary trial suffered from a blood clot blocking their trachea.",
        "Label": "Contradiction",
        "explain": "The given statement \"1 patient in the primary trial suffered from a blood clot blocking their trachea\" cannot be directly entailed or contradicted from the provided adverse event data in the CTRs. The CTR for the primary trial mentions one instance of thrombosis, but it does not specify the location of the thrombosis. Therefore, we cannot determine if the patient who experienced thrombosis suffered from a blood clot blocking their trachea based on the available information in the CTR."
    },
    "6b595151-7e51-4062-b587-3207ea251677": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00606931",
        "Statement": "the primary trial tests positron emission tomography as a technique for guiding a medical procedure.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR's INTERVENTION 1 description, which states that the primary trial involves the use of PET Guided Biopsy as the intervention for all enrolled participants. The expert's statement accurately identifies that the primary trial tests PET as a technique for guiding a medical procedure."
    },
    "e802b1f6-62fb-4759-b261-c69dbdc1d7ef": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT02780713",
        "Statement": "Both cohorts of the primary trial receive higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants.",
        "Label": "Contradiction",
        "explain": "The statement is entailed.\n\nJustification:\n\nThe primary trial's Intervention 1 and Intervention 2 both involve the administration of Q-122 at a dosage of 100 mg Q-122 per day, while the secondary trial's Intervention 1 and Intervention 2 both involve the administration of AZD9496-Variant A and AZD9496-Reference, respectively, at a dosage of 100 mg. However, as stated in the primary trial, Q-122 is administered as two 50 mg capsules once daily for a total daily dose of 100 mg, whereas the secondary trial does not provide details about the dosage form of AZD9496. Regardless, the total daily dose for each participant in the primary trial is 100 mg, which is more than the total daily dose for either cohort in the secondary trial. Therefore, the statement \"Both cohorts of the primary trial receive higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants\" is entailed."
    },
    "0a24a07e-2cb4-4591-aea4-a370f462cc49": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00593346",
        "Secondary_id": "NCT00902330",
        "Statement": "the primary trial treament last for a shorter period of time than the secondary trial treatment.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nJustification:\n\nThe statement that \"the primary trial treatment lasts for a shorter period of time than the secondary trial treatment\" is contradicted by the information in the provided CTRs. In the primary trial, patients receive accelerated partial breast brachytherapy with a total dose of 3400 cGy delivered in 10 fractions over 5-7 days (with a minimum of 6 hours separation between fractions). In the secondary trial, patients in both arms (I and II) receive their CES units once daily for 18 weeks. Therefore, the primary trial treatment lasts longer than the secondary trial treatments."
    },
    "97d0bbf0-c2c5-409b-820b-6e14a6326b06": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02322814",
        "Secondary_id": "NCT00356148",
        "Statement": "A patient with Histologically confirmed estrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor 2 positive breast cancer, with no known Brain metastases and no prior history of cardiac dysfunction, could be eligible for both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary CTR's inclusion criteria as the patient described would be ineligible for the primary trial due to having HER2-positive breast cancer (incompatible with ER-negative and PR-negative). Additionally, the primary CTR includes cardiac dysfunction as an exclusion criteria. Therefore, the statement's assertion of a patient meeting both trial inclusion criteria without these disqualifications cannot be entailed from the provided CTRs."
    },
    "bbb5ebc0-83c8-46cb-89b4-e1c67e042350": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00859651",
        "Statement": "Helen had stage III ovarian cancer 7 years prior, but has been disease-free for 5 years., she is excluded from the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The participant, Helen, is excluded from the primary trial due to a prior history of cancer (other than breast or in situ cervical cancer) for which she has not been disease-free for 5 years (Exclusion Criteria)."
    },
    "620106e8-2a7f-4078-80b6-d5f1840c66e1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00699491",
        "Statement": "the primary trial results show that the Recommended Dose Level for Phase II Testing (RPTD) (Phase I) is 3 mg/ks cixutumumab.",
        "Label": "Contradiction",
        "explain": "Justification for entailment: The statement \"the primary trial results show that the Recommended Dose Level for Phase II Testing (RPTD) (Phase I) is 3 mg/ks cixutumumab\" is entailed by the CTR as follows: The RPTD is defined as the dose level at which no more than one patient (out of six) experiences a dose-limiting toxicity (DLT), and the next highest dose level has 2 or more DLTs. In Results 1, there are 2 DLTs reported in the 3 mg/ks cixutumumab arm, indicating that the RPTD is 3 mg/ks cixutumumumab. Therefore, the expert's statement is entailed by the CTR.\n\nAdditional context: In the given CTR, temsirolimus and cixutumumab are combined and administered concurrently, and their individual dose levels are provided. The expert's statement only mentions cixutumumab. However, the information about RPTD applies to the combination therapy and can be determined from the given data. The statement does not contradict any information in the CTR."
    },
    "94a7b007-0332-4d01-979e-9677e5da4316": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Statement": "In the primary trial the FEC-75 Then Paclitaxel/Trastuzumab group had more Invasive Tumor Remaining in the Breast than the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group.",
        "Label": "Contradiction",
        "explain": "The statement contradicts the information in the CTRs, specifically the pCR rates in Results 1 and 2. According to the CTRs, the pCR rate was 56.5% (47.8-64.9) in the FEC-75 Then Paclitaxel/Trastuzumab group and 54.2% (45.7-62.6) in the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group. The statement suggests the opposite, that the FEC-75 Then Paclitaxel/Trastuzumab group had more invasive tumor remaining in the breast."
    },
    "2849d0ce-fed2-4c49-bec1-777c440caaeb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127205",
        "Statement": "More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular systole.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nJustification:\nThe CTRs provided do not support the statement. The Adverse Events sections in both trials list instances of left ventricular diastolic dysfunction and left ventricular systolic dysfunction, but the numbers are equal for each type of dysfunction in both trials (Primary Trial: 3/2125 for diastolic dysfunction and 1/2125 for systolic dysfunction; Secondary Trial: 3/2186 for diastolic dysfunction and 1/2186 for systolic dysfunction). Therefore, the statement that \"More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular systole\" cannot be entailed based on the given information in the CTRs."
    },
    "aa6a20f8-ee49-42b7-9b9b-64caa8b22e35": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992225",
        "Statement": "Only 2 of the 12 adverse event types recorded in the primary trial, occurred more than once.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the data in the Adverse Events section of the primary CTR. Specifically, only two types of adverse events, Sepsis and Dehydration, occurred more than once. Therefore, the expert's claim that \"only 2 of the 12 adverse event types recorded in the primary trial, occurred more than once\" harmonizes with the clinical trial data."
    },
    "01a57096-0278-4c70-be43-acd57010cd6f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01332630",
        "Secondary_id": "NCT00121134",
        "Statement": "There were more patients with significantly elevated blood pressure in cohort 1 of the primary trial, than in cohort 1 of the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the provided CTR data. The primary trial reports a higher rate of hypertension in cohort 1, with 3/21 (14.29%) cases compared to the secondary trial, which has 1/41 (2.44%) cases in cohort 1. Contradictory to the expert statement, there were fewer instances of hypertension in cohort 1 of the secondary trial."
    },
    "49213077-0a5b-4368-a48a-282d2ca9d77a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02953860",
        "Statement": "Patients in the primary trial receive more mg of Enzalutamide than Fulvestrant over the course of the study.",
        "Label": "Entailment",
        "explain": "The statement \"Patients in the primary trial receive more mg of Enzalutamide than Fulvestrant over the course of the study\" is entailed by the provided CTR information. \n\nJustification: \n\nFrom the primary trial CTR, we know that patients receive 160mg of Enzalutamide PO daily, whereas they are given 500mg of Fulvestamidre IM every 4 weeks. To calculate the total amount of each drug given over the study period, we can determine the number of doses and frequency of each medication:\n\n- Fulvestrant: 500mg IM every 4 weeks, given for an undisclosed number of cycles\n- Enzalutamide: 160mg PO daily\n\nLet N represent the total number of 4-week cycles for Fulvestrant. Then, the total mg of Fulvestrant administered to each patient is: 500mg * N.\n\nThe total mg of Enzalutamide administered to each patient is calculated as: 160mg/day * 30days/month * N months. \n\nSince N is the same for both Fulvestrant and Enzalutamide, and the Enzalutamide dosage is greater per day and per month, the statement \"Patients in the primary trial receive more mg of Enzalutamide than Fulvestrant over the course of the study\" follows from the CTR data."
    },
    "426d3ecd-73e3-4226-83c6-cfcb9212ed62": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00263588",
        "Statement": "All the primary trial subjects either had Progressive disease, Complete CNS objective response rate or partial response rate.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nJustification: \n\nThe statement \"All the primary trial subjects either had Progressive disease, Complete CNS objective response rate or partial response rate\" is contradicted by the given CTR data. Based on Results 1 and 2, we have:\n\n1. The number of participants in Cohort A and Cohort B with Complete response (CR) was 0 for each arm, meaning none of these participants had a complete response.\n2. For Cohort A, there were 6 participants with a partial response (PR).\n3. The remaining participants in both cohorts (Stable disease, SD, Progressive disease, PD, and Unknown) did not have a Complete CNS objective response.\n\nSince none of the primary trial participants had a Complete response according to the data presented, the expert's statement cannot be entailed."
    },
    "7c12676c-7973-4e9d-b1fc-3b14d241d0c8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00696072",
        "Statement": "20 patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the information provided in the CTRs. In both the Dasatinib + Letrozole and Letrozole arms of the primary trial, the number of patients with DFI > 2 Years is reported to be 20. Therefore, the statement that 20 patients treated with Dasatinib and Letrozole had a DFI greater than 2 years is consistent with the data presented in the CTRs."
    },
    "3419e901-5880-488d-912c-023e8d1b51c7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Secondary_id": "NCT01446159",
        "Statement": "the primary trial recorded one patient with congestive Cardiac failure, the secondary trial recorded more.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nJustification: \n\nThe primary trial reported one case of pleural effusion, which can be a symptom of cardiac failure, but it did not explicitly state that there was a patient with cardiac failure. Therefore, the statement that the primary trial recorded one patient with congestive cardiac failure, while the secondary trial recorded more, contradicts the information provided in the CTRs."
    },
    "cd645637-0a31-4f54-bc75-4a52349cf100": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00748553",
        "Statement": "Patients in the primary trial receive 50mg/m2, 75mg/m2 and 80mg/m2 daily every 5 days for each 4-week cycle",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nExplanation: \n\nThe statement that patients in the primary trial receive 50mg/m2, 75mg/m2 and 80mg/m2 daily every 5 days for each 4-week cycle contradicts the given CTR as it specifies incorrect dosages for Azacitidine and Nab-paclitaxel. In the CTR, Azacitidine is given in doses of 50mg/m2, 75mg/m2, or 100mg/m2 daily for 5 days per cycle, while Nab-paclitaxel is given weekly for 3 weeks of each 4-week cycle at a dose of 100mg/m2."
    },
    "adfc79ba-2996-47ce-9986-7d287931df89": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115984",
        "Statement": "A total of 3 patients in the primary trial experience a Herpes related adverse event.",
        "Label": "Entailment",
        "explain": "The statement contradicts the data in CTR Adverse Events 1 and 2. The combined total of Herpetic eruption cases in both trials is 3/86 (3.51%), not 3/57 or 3/23 as stated."
    },
    "414ae027-b420-4f01-afd5-164cd8146a30": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01129336",
        "Secondary_id": "NCT01945775",
        "Statement": "16 participants of the primary trial are considered to be censored. the secondary trial used the same outcome measurement, but had no censored patients.",
        "Label": "Entailment",
        "explain": "The statement \"the secondary trial had no censored patients while the primary trial had 16 participants considered to be censored\" is contradicted by the information provided in the CTRs. The primary trial and secondary trial use the same outcome measurement, which is Progression-Free Survival (PFS). However, the primary trial and secondary trial differ in their definitions of censored patients. In the primary trial, censored patients are those with missing data for the time to event, whereas in the secondary trial, there is no mention of censored patients. Specifically, the statement mentions that \"the secondary trial had no censored patients,\" but the CTR does not provide any information about the number or status of censored patients in the secondary trial. Therefore, the statement contradicts the CTR as written because it makes an assumption about the absence of censored patients in the secondary trial based on insufficient information."
    },
    "45b2b9ec-ba58-4323-810a-4baed9c84a0e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470847",
        "Statement": "the primary trial participants will not receive any Lapatinib post WBRT.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the information in the primary trial's INTERVENTION 1 section, where it is explicitly stated that Lapatinib is administered both before and during Whole Brain Radiation Therapy (WBRT), and then Herceptin is given weekly IV at a dose of 4mg/kg. This indicates that Lapatinib is indeed given post-WBRT, so the expert's statement is not entailed by the data in the CTR."
    },
    "72ffdfbf-aa72-4d44-814a-1d6ab8883898": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Statement": "Patients must have already participated in a specific clinical study to participate in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs provided. \n\nJustification:\n\nIn the primary CTR, it is stated that \"subjects who had participated in the preceding phase II clinical study\" are eligible for inclusion in the primary trial. Therefore, the statement \"Patients must have already participated in a specific clinical study to participate in the primary trial\" is entailed by the information given in the CTR."
    },
    "db613a72-e300-41a7-987f-788c306d94a4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00403130",
        "Statement": "There were no cases of Leukopenia or Arrhythmia observed in patients participating in the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The statement is contradicted by the data presented in the primary trial's Adverse Events section. Leukopenia is not mentioned, but Neutropenia is, which is a type of leukopenia characterized by a low absolute neutrophil count. Arrhythmia is not mentioned in either trial. However, the statement incorrectly asserts that there were no cases of leukopenia in the primary trial. The statement's assertion contradicts the data in the CTR."
    },
    "2667d301-2efb-4d92-bc12-ccfc869e4835": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02202252",
        "Statement": "The difference between cohort 1 and 2 of the primary trial is the insertion of an additional negative pressure drain for patients in cohort 2.",
        "Label": "Entailment",
        "explain": "The statement should be entailed based on the provided information in the CTRs. In the Primary Trial, the description of INTERVENTION 1 specifies the insertion of one negative pressure drain for the single drain group, while INTERVENTION 2 specifies the insertion of two negative pressure drains for the double drain group. The statement made by the expert highlights the presence of an additional drain in cohort 2, which is consistent with the description of INTERVENTION 2. Additionally, both interventions follow the same procedure for drain removal and ultrasonography, ensuring that the ultrasound examination is applicable to both cohorts."
    },
    "60bff573-0251-4f05-b2b7-dec74c7363cc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00934856",
        "Statement": "In total, across both cohorts of the primary trial, there was at least 2 fatigued patients.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nExplanation:\n\nThere is no information in the CTRs indicating that there were at least 2 fatigued patients across both cohorts of the primary trial. The statements in the CTRs regarding adverse events do not mention fatigue for either cohort, as shown in the provided data with a total of 0/12 (0.00%) for both trials."
    },
    "f6f8a0d3-6288-44cf-9b34-27444110dd10": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT01008150",
        "Statement": "histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from the primary trial, but not from the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement \"histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from the primary trial, but not from the secondary trial\" could be entailed if there is no exclusion criterion related to histologically confirmed extensive intraductal component of primary breast carcinoma in the secondary trial's inclusion/exclusion criteria.\n\nJustifications for entailment:\n1. In the primary trial's exclusion criteria, there is no mention of \"histologically confirmed extensive intraductal component of primary breast carcinoma.\"\n2. The secondary trial's inclusion criteria do not mention this condition as an exclusion criterion.\n3. The statement is consistent with clinical trial data since it only specifies a difference in exclusion criteria between the two trials.\n4. The statement does not contradict the provided descriptions as it only discusses exclusion from one trial versus the other.\n\nHowever, if the secondary trial does have an exclusion criterion for histologically confirmed extensive intraductal component of primary breast carcinoma, then the statement would be contradicted in this case."
    },
    "8b0482c1-74d4-48ae-96bc-d80f8f1a0f50": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00572728",
        "Secondary_id": "NCT02472964",
        "Statement": "Patients in the primary trial and the secondary trial will take Herceptin\u00ac\u00a8\u00ac\u00a9 (trastuzumab) or paclitaxel intravenously.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by both primary and secondary trials as they both specify the use of Herceptin\u00a9 (trastuzumab) intravenously as one of the interventions. The secondary trial also mentions the use of paclitaxel intravenously, which is in line with the statement as well."
    },
    "878dcfeb-c3db-4077-9a3e-8098efa80a99": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00836186",
        "Statement": "Patients cannot be excluded from the primary trial on the basis of race or ethnicity.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR as it states, \"Women of all races and ethnic groups are eligible for this trial.\" (INCLUSION CRITERIA section)."
    },
    "fc5dbfec-ba79-4c5d-9e38-3c97d0397570": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04396665",
        "Secondary_id": "NCT00493636",
        "Statement": "Any patient can enter into the primary trial or the secondary trial; as long as they are willing to provide Informed consent and are capable of using the internet.",
        "Label": "Contradiction",
        "explain": "The statement is not entailed by the provided CTRs.\n\nJustification:\n\nThe primary trial includes specific eligibility criteria, such as the absence of a breast cancer diagnosis during the intervention. This excludes patients with active breast cancer, which is not stated in the expert's statement. The secondary trial has far more rigorous eligibility requirements, which includes breast cancer patients with histologically or cytologically confirmed adenocarcinoma of the breast. The expert's statement does not mention any specific type or stage of cancer, which contradicts the eligibility criteria for both trials. Additionally, the secondary trial requires patients to have discontinued chemotherapy at least 3 weeks prior to randomization, while the primary trial does not have such a requirement. These differences in eligibility criteria indicate that the expert's statement is not entailed by the CTRs."
    },
    "a8514489-cb31-4c8a-abca-e1f7b3a8d4ce": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01234337",
        "Secondary_id": "NCT00217672",
        "Statement": "No cases of Anaphylaxis occurred in either the primary trial or the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the provided CTRs. Neither the primary nor the secondary trial reports mention any cases of \"anaphylaxis\" as an adverse event. Therefore, the statement \"No cases of Anaphylaxis occurred in either the primary trial or the secondary trial\" is in agreement with the data presented in the CTRs."
    },
    "64411610-090b-42d2-a176-d2b13ffef591": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03210220",
        "Secondary_id": "NCT00290745",
        "Statement": "Unlike the primary trial, the secondary trial has no control group.",
        "Label": "Entailment",
        "explain": "The statement \"Unlike the primary trial, the secondary trial has no control group\" is a contradiction of the CTRs provided. The primary CTR specifies interventions for two groups: a Pecs group (with pectoral nerve blocks) and a control group (without blocks). Conversely, the secondary CTR describes only interventions for a single group (tamoxifen or letrozole therapy). No control group is mentioned."
    },
    "82bd50ac-9407-413b-9eb8-653cef49706c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02364388",
        "Secondary_id": "NCT01425268",
        "Statement": "warm saline solution is used in both the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the given CTRs. In the primary trial, MAESTRO intervention is not mentioned to use warm saline solution explicitly. However, the secondary trial states that saline tissue expansion involves filling and inflating the expander with saline, implying that the saline solution used is warm since it is the standard temperature for administering saline. Therefore, the use of warm saline solution is an entailed consequence of the information provided in the CTRs."
    },
    "470611af-16b2-4094-ae2a-c9c6155e2672": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01575522",
        "Statement": "The intervention section for the primary trial does not detail the type or duration of the intervention, unlike the secondary trial.",
        "Label": "Entailment",
        "explain": "Contradiction. The primary trial's intervention section does not mention the type (tivantinib) or the duration (PO BID on days 1-21, with courses repeating every 21 days) of the intervention specified in the secondary trial."
    },
    "f3a03aec-194d-4538-9be3-cea8281d995c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00693719",
        "Statement": "the primary trial recorded less than 3 different Adverse Events .",
        "Label": "Contradiction",
        "explain": "Contradiction. The primary trial recorded five different adverse events, namely bleeding, pain, dehydration, dyspnea, and total adverse events. (Primary Trial: Adverse Events 1)"
    },
    "14a5e557-b223-4649-9867-0ff0e9001f5e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Secondary_id": "NCT02352779",
        "Statement": "the primary trial and the secondary trial do not explain their interventions in the intervention section.",
        "Label": "Contradiction",
        "explain": "Contradicted\n\nExplanation: \n\nThe statement \"the primary trial and the secondary trial do not explain their interventions in the intervention section\" is contradicted by the provided Clinical Trial Reports (CTRs). The intervention sections for both the primary and secondary trials are clearly stated, with detailed information about the type of intervention (Omega-3 Fatty Acid), dosage (Low-dose or High-dose), frequency (BID), and duration (6 weeks), as specified in both trials' intervention sections."
    },
    "c8df3461-4063-4fb0-ae48-f57062eb0a68": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03329937",
        "Statement": "the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle, for 3 cycles, after which all participants undergo neoadjuvant chemotherapy.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTR for the primary trial, as it accurately captures the dosage (niraparib 200 mg PO once daily), cycle length (28 days), and number of cycles (up to 3) that participants received before undergoing neoadjuvant chemotherapy."
    },
    "1cd7cf90-bf66-480b-9227-2f7d2eccd647": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01539317",
        "Secondary_id": "NCT01323530",
        "Statement": "the primary trial uses a topical intervention and the secondary trial exclusively uses intravenous treatments.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the information in the CTRs. In the primary trial, both topical interventions (topical saline and topical liquid lidocaine) are described, and no intravenous treatments are mentioned. In contrast, the secondary trial exclusively outlines intravenous interventions using eribulin mesilate. Thus, the statement's assertion that the primary trial uses only topical interventions while the secondary trial uses only intravenous treatments is not an entailment of the data provided in the given CTRs."
    },
    "15f9d033-ebf7-44b3-94e2-3b8ee90b862b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00370552",
        "Statement": "There over 20% difference in the Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) between the 2 cohorts of the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the data provided in Results 1 and Results 2. The difference in percentage of participants with PR or CR between the two cohorts is indeed over 20%. Specifically, the percentage of participants in the Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg arm was 47.8% (32.9 to 63.1), while in the Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg arm it was 71.1% (55.7 to 83.6)."
    },
    "ab6a9d30-eb92-4503-a69c-bdf3f3e6c38d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266799",
        "Statement": "None of the patients in cohort 1 of the primary trial had Acute coronary syndrome.",
        "Label": "Entailment",
        "explain": "The statement is not contradicted by the provided Adverse Events data. Neither CTR reports any instance of Acute coronary syndrome among their cohorts. Thus, no justification for contradiction is present based on the given information."
    },
    "51cf1333-78b1-410a-82fe-aabfaa00a840": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02995980",
        "Statement": "A patient presenting Glomerular filtration rate of 63, a severe iodinated contrast allergy and with BI-RADS category c breast tissue would be eligilbe for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the Primary Trial's Inclusion Criteria as the patient's Glomerular filtration rate is within the acceptable range (>60). However, they have a severe iodinated contrast allergy which is listed under Exclusion Criteria in the Primary Trial. Therefore, the statement is not entailed by the information in the CTRs."
    },
    "d2e957c3-1e20-4ccd-9cf7-4cc2da63f74d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00662025",
        "Statement": "on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions.",
        "Label": "Entailment",
        "explain": "Contradiction \n\nJustification: \n\nThe primary trial results section clearly states that there were no participants (Complete Response or CR) in the Sunitinib+Capecitabine arm who achieved a confirmed disappearance of all target and non-target lesions. Hence, the expert's statement that \"on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions\" contradicts the provided data."
    },
    "aef2367d-78a5-4dc7-a6f7-d96415082362": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00570921",
        "Secondary_id": "NCT00274456",
        "Statement": "There is one case of Cardiopulmonary failure in cohort 2 of the secondary trial, but none in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the provided Adverse Events sections in the CTRs. In the primary trial, there is no report of Cardiopulmonary failure in either cohort. However, in the secondary trial, there is one case reported in cohort 2 but none in cohort 1. This contradicts the expert's statement."
    },
    "29ae75a2-d8d2-4427-bba3-ab2c411d5718": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00201851",
        "Statement": "There were no cases of Oesophageal spasming, Diastolic dysfunction or thrombosis observed in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed based on the provided Adverse Events sections in the CTRs for both the primary and secondary trials. Neither trial reported any cases of Oesophageal spasming, Diastolic dysfunction, or thrombosis in their respective cohorts. The statement accurately reflects the information in the CTRs."
    },
    "985c4cb3-2684-4a67-a479-998602044a0d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00475670",
        "Statement": "compared to cohort 1 of the primary trial, other than sudden death, there are more cases of every observed adverse event in cohort 2. ",
        "Label": "Contradiction",
        "explain": "The statement \"compared to cohort 1 of the primary trial, other than sudden death, there are more cases of every observed adverse event in cohort 2\" can be entailed by the provided CTRs. \n\nExplanation: \n\nIn the primary trial, the incidence of all adverse events in cohort 1 is 0.00%, and in cohort 2, the incidence of these same adverse events, except for sudden death, is 14.63%. Therefore, the statement that \"there are more cases\" in cohort 2 than in cohort 1 for every adverse event, except for sudden death, is consistent with the data presented in the CTRs. \n\nTherefore, the statement is entailed by the data in the Clinical Trial Reports."
    },
    "39e8a353-4eb0-4cf6-b0c2-f36c4bf589f3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00107276",
        "Secondary_id": "NCT00232505",
        "Statement": "Less than 5% of patients undergoing the intervention in the primary trial had adverse events, in comparison almost 10% patients in cohort 1 of the secondary trial  experienced an adverse event, and less than a 1/3 of those in cohort 2 of the secondary trial had adverse events.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the data in the CTRs. In the primary trial, the total number of adverse events is 4/95 (4.21%). In the secondary trial, the total number of adverse events in cohort 1 is 3/31 (9.68%) and in cohort 2 is 0/25 (0.00%). The statement correctly compares the percentage of patients experiencing adverse events between the primary trial and cohort 1 of the secondary trial, and also mentions the significantly lower percentage in cohort 2."
    },
    "d695120e-db68-481d-9023-881e48654e29": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "Patients with Extracranial metastases are still permited to enter in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Patients with Extracranial metastases are still permitted to enter in the primary trial\" is entailed by the CTR information in the \"DISEASE CHARACTERISTICS\" section, as it explicitly states \"Extracranial metastases allowed\" in the eligibility criteria for the primary trial."
    },
    "5319ac1a-07ae-4531-bf93-5fce83016c87": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00941330",
        "Statement": "Patients in cohort 1 of the primary trial receive Exemestane more often than cohort 2 patients receive Cytoxan.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the given CTR information. In the primary trial, patients in arm A receive exemestane daily for 6 to 12 months, which is more frequent than the cytoxan treatment in arm B, which is given once every 3 weeks for 6 cycles within about 24 weeks."
    },
    "087aba29-40c6-4453-a44b-e63c3867e5b4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00388726",
        "Statement": "A 75 year old female patient, with an ECOG of 3 and an estimated life expectancy of more than a year would be eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"A 75 year old female patient, with an ECOG of 3 and an estimated life expectancy of more than a year would be eligible for the primary trial\" is contradicted by the CTR. The eligibility criteria state that \"Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2\" is required for patient enrollment in the primary trial. The stated patient's ECOG Performance Status is 3, making her ineligible according to the provided CTR."
    },
    "c66f3e9e-f232-4035-b705-2785946d1542": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03624972",
        "Secondary_id": "NCT01216176",
        "Statement": "A 72 year old patient suffering from dementia would be excluded from both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs as both the primary and secondary trials explicitly exclude patients with \"severe mental illness,\" which includes dementia, from participating in the trials (Primary Trial: Exclusion Criteria, point 3; Secondary Trial: Inclusion Criteria - Phase 1 and 2, point 3)."
    },
    "c679f426-b235-4ae9-ad6c-4f1a46a494d2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01390064",
        "Secondary_id": "NCT00485953",
        "Statement": "All Cohorts of the primary trial and the secondary trial receive their treatment via Subcutaneous administration.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided CTR information. \n\nIn the primary trial, both intervention groups receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous administration as stated (INTERVENTION 1 and INTERVENTION 2, both mention \"Subcutaneous administration\" for both doses and schedules). \n\nIn the secondary trial, both intervention groups receive their treatments via weekly subcutaneous injections, although the treatments themselves (risedronate and placebo) differ; however, this fact does not alter the fact that the administration routes are identical to those in the primary trial. Therefore, the expert's statement that \"All Cohorts of the primary trial and the secondary trial receive their treatment via Subcutaneous administration\" is an entailed statement based on the given CTR data."
    },
    "122b1aef-4506-464d-9852-47caa508b047": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00879086",
        "Statement": "Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia, but Cohort 1 had 8 more cases of Leukopenia than cohort 2.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nJustification:\nThe statement \"Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia\" aligns with the provided information in both the CTRs, as the number of participants experiencing anaemia and Neutropenia is identical in both cohorts (1 case each). However, the statement \"but Cohort 1 had 8 more cases of Leukopenia than cohort 2\" contradicts the CTRs, as Cohort 1 had 2 cases of Leukopenia more than Cohort 2 (total of 3 cases vs 1 case)."
    },
    "4a4f3e9e-6a29-4715-8000-2eec90e9bb5d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00841828",
        "Secondary_id": "NCT01959490",
        "Statement": "All cohorts in the primary trial had lower number of participants with pCR compared to cohort 1 of the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"All cohorts in the primary trial had lower number of participants with pCR compared to cohort 1 of the secondary trial\" can be contradicted based on the information provided in the CTRs. \n\nJustification:\n1. The statement is incomparable as the primary trial includes two arms (EC -> D + Lapatinib and EC -> D + Trastuzumab), whereas the secondary trial includes two cohorts (Cohort 1P and Cohort 1T) within the same group (HER2 Positive). \n\n2. The outcome measurement and time frame are different for the two trials. In the primary trial, the outcome measured is the pCR rate, whereas in the secondary trial, the outcome is the number of patients with pCR who received targeted therapy. Additionally, the time frame for the secondary trial is 30 days after the last cycle of treatment.\n\n3. Without further information, it is unknown if any of the participants from the primary trial fall under the HER2 positive or HER2 negative genomically-derived molecular subtypes specified in the secondary trial. Hence, it is not possible to directly compare the two trials based on their provided details."
    },
    "9f7dc38b-1945-4035-a0ff-e08ead55145b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00297596",
        "Secondary_id": "NCT00580333",
        "Statement": "Patients who completed a trastuzumab regiment, to treat the current breast cancer  > 2 weeks before study entry are eligible for the primary trial but excluded from the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR as it allows patients who have received a trastuzumab regimen for the current breast cancer more than 2 weeks before study entry (ELIGIBILITY CRITERIA, Prior trastuzumab therapy). However, the secondary CTR excludes patients who have received trastuzumab for the current breast cancer (Exclusion Criteria, Prior treatment with investigational therapy: HER2-targeted therapy). This discrepancy leads to the contradiction between the two trials. Therefore, the statement is not fully entailed by the available information in both CTRs.\n\nAdditionally, the primary CTR has specific requirements regarding prior trastuzumab therapy. For instance, patients can have received one prior trastuzumab/chemotherapy containing regimen or single-agent trastuzumab (ELIGIBILITY CRITERIA, Prior trastuzumab therapy). This information might be important when interpreting the expert's statement as it specifies that only patients who have completed a trastuzumab regiment are eligible for the primary trial."
    },
    "b259774e-410a-49aa-b5d4-31b8d9505fc3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01525589",
        "Statement": "People who inherit undamaged variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary trial inclusion criteria as it states that \"Patients in Cohorts A and A1\" have a known deleterious germline mutation of BRCA1/2."
    },
    "e09a11e4-afc8-4351-a5bc-d847424c79ce": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565499",
        "Secondary_id": "NCT01234402",
        "Statement": "Some of the patients in the primary trial were recorded as having heart related adverse events, whereas many patients in the secondary trial experienced several different breathing related issues.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. The primary trial's Adverse Events section reports instances of \"Cardiogenic shock\" (1/81 or 1.23%), \"Cardiac failure\" (1/81 or 1.23%), and \"Palpitations\" (0/81 or 0.00%, but mentioned in the expert statement). The secondary trial's Adverse Events sections report instances of \"Cardiac failure\" (1/52 or 1.92%), \"Cardiogenic shock\" (1/52 or 1.92%), and \"Palpitations\" (1/49 or 2.04%). The expert statement is a generalization of these data, and it is in line with the CTRs.\n\nHowever, the expert statement mentions that \"many patients in the secondary trial experienced several different breathing related issues.\" The CTRs do not provide data related to breathing issues for either the primary or secondary trials, and the statement does not contradict the provided CTR information. It is essential to note that the expert statement is not a contradiction because it is not based on information found in the CTRs. Instead, it is a separate observation made by the expert."
    },
    "d22f01f0-b2be-45b9-8996-11727750b91e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01720602",
        "Secondary_id": "NCT00082810",
        "Statement": "the primary trial participants receive more anastrozole, Fulvestrant and exemestane than patients in the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nExplanation:\n\nIn the primary trial, patients receive either anastrozole, letrozole, or exemestane as part of AI therapy, and the dosage is given PO daily. In the secondary trial, fulvestrant is given intramuscularly on day 1 and tipifarnib is given orally twice daily on days 1-21. Therefore, the type and dosing frequency of the hormonal agents are different between the trials. The statement asserts that participants in the primary trial receive more anastrozole, Fulvestrant, and exemestane than patients in the secondary trial, but it is contradicted since the trials involve different medications and administration methods."
    },
    "893d5684-03f8-4acd-86e4-6d38eea3ce16": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129935",
        "Statement": "There were 80% more cases of embolisms in cohort 2 of the primary trial than cohort 1.",
        "Label": "Contradiction",
        "explain": "Contradicted\n\nExplanation: \n\nThe statement asserts that there were 80% more cases of embolisms in cohort 2 (CTR 1) than in cohort 1 (CTR 1). However, the CTRs provided do not allow for such a conclusion. The total number of cases in each cohort and the number of cases of embolisms for each cohort are presented. There's no information about the number of participants or the size of the cohorts, which would be necessary to determine whether there was an 80% difference in the number of embolisms between the cohorts. Additionally, the information in CTR 2 for embolisms contradicts the statement, as the number of cases in CTR 2 is less than the number in CTR 1 (2 vs. 3)."
    },
    "4b46164d-a4c2-4738-be36-588ab231ceb1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01596751",
        "Secondary_id": "NCT00193050",
        "Statement": "There were 0 patients with Dysphagia or Fever in the primary trial and the secondary trial cohorts.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the CTR information. In the primary trial, there were 0/5 (0.00%) occurrences of Dysphagia and 0/5 (0.00%) occurrences of Fever. In contrast, in the secondary trial, there was 1/110 (0.91%) occurrence of Dysphagia and 1/110 (0.91%) occurrence of Fever."
    },
    "d9236874-7f3d-4402-9699-2889db9f5c61": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320541",
        "Statement": "Cohort 2 of the primary trial recorded 10% more cases of Leukopenia than cohort 1.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted based on the provided CTR data. According to the Primary Trial's Adverse Events section, cohort 1 had 3/94 (3.17%) cases of Leukopenia, while cohort 2 of the Secondary Trial had 4/93 (4.30%) cases of Leukopenia. Therefore, cohort 2 had fewer cases (1 less) of Leukopenia than cohort 1, which contradicts the expert statement suggesting a 10% increase in cases in cohort 2."
    },
    "e33825f1-45df-41f5-ba07-e9059636a146": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00057941",
        "Secondary_id": "NCT01806259",
        "Statement": "DLT occurence, used as the outcome measurement in the secondary trial and Clinical Benefit Rate, used in the primary trial are not synonymous, and represent entirely different patient characteristics. ",
        "Label": "Contradiction",
        "explain": "The statement is entailed as the Clinical Trial Reports (CTRs) for the primary and secondary trials provide distinct outcome measurements for different patient characteristics. The primary trial measures Clinical Benefit Rate, which is a measure of response to treatment, while the secondary trial measures Recurrence-free Survival, which is a measure of time until disease progression or death. The statement correctly highlights that these two outcomes are not synonymous and represent different aspects of patient treatment and outcomes. The CTRs provide sufficient evidence to support this entailment."
    },
    "5b0295e1-a322-40af-9acf-9cc1d55d3e64": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00295620",
        "Secondary_id": "NCT03366428",
        "Statement": "the secondary trial and the primary trial use similar outcome measures, evaluating how long patients survive after treatment.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial and the secondary trial do not use similar outcome measures. The primary trial measures disease-free survival, while the secondary trial measures changes in QTcF after treatment with DS-8201a. Therefore, the statement is not entailed by the provided CTR information."
    },
    "3658f2f7-a497-4abb-badb-c877036456f2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00077857",
        "Statement": "Patients must be older than 18, female, have three or more target lesions and more than 1 regiment of chemotherapy to participate in the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial's inclusion criteria state that patients must have \">=1 target lesion,\" not \"three or more target lesions.\" Furthermore, the requirement for \">=2 regimens of chemotherapy for advanced/metastatic disease\" is met but not the simpler \">=1 regime.\""
    },
    "37bc71d5-d9c0-4174-8da5-725d2d53a91b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00303108",
        "Statement": "The Cohort of the primary trial which received D+C and Taxane Na\u201a\u00e0\u00f6\u221a\u00f2ve, produced marginally better results than the other cohort.",
        "Label": "Contradiction",
        "explain": "The statement \"The Cohort of the primary trial which received D+C and Taxane Naive produced marginally better results than the other cohort\" is entailed by the CTRs, given that the percentage of participants with Objective Response (ORR) in the D+C and Taxane Naive cohort (30.8%, 17.0-47.6%) is slightly higher than that of the D+C and Taxane Pretreated cohort (31.0%, 17.6-47.1%). The difference may not be substantial, but it does represent a statistical tendency toward better response rates in the former cohort.\n\nCTR References: \n- Primary trial: Outcome Measurement and Results Sections.\n- Secondary trial: No applicable information provided."
    },
    "51ac9fe0-2bfa-42f5-aaec-69e0c5cdff7c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02781051",
        "Secondary_id": "NCT01067976",
        "Statement": "The intervention for the primary trial requires participants to exercise for 12 weeks while wearing a fitbit, no physical activity is explicitly required for the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is not entailed in the provided CTR information. The primary trial's intervention includes wearing a Fitbit during exercise for 12 weeks, not a requirement of exercise itself. The secondary trial does not mention the use of Fitbit or any requirement for participants to wear one. The statement focuses only on the aspect of exercise being present or absent in both trials, without taking into account the specifics of the interventions."
    },
    "8bcc9fa3-0317-471a-a5b5-b115b5b72dea": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01302379",
        "Statement": "Both patient cohorts of the primary trial had a median Insulin change from baseline lower than -15%.",
        "Label": "Entailment",
        "explain": "The statement is entailed, as both the Metformin + Lifestyle Intervention and the Placebo + Lifestyle Intervention cohorts of the primary trial had a Least Squares Mean (95% Confidence Interval) of the Insulin change from baseline below -15% ( Metformin + Lifestyle Intervention: -21.8% (-29.7% to -13.0%; Placebo + Lifestyle Intervention: -17.7% (-25.9% to -8.6%) )."
    },
    "52610141-321d-4e3d-8660-ebc14b9f1696": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00082433",
        "Statement": "the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine, triples patient OS, compared to Capecitabine alone.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided CTRs data. The primary trial results do not suggest that the combination of Ixabepilone (40 mg/m2 IV infusion on Day 1 of each cycle) + Capecitabine triples patient OS compared to Capecitabine alone. The primary trial reported a median OS of 16.39 months (14.95-17.91) for the combination group and 15.64 months (13.86-17.02) for the Capecitabine alone group, indicating that the Capecitabine alone group had a slightly longer median OS."
    },
    "90203158-6477-4486-b8d9-09dcaca63617": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00570921",
        "Secondary_id": "NCT00274456",
        "Statement": "There is one case of Cardiopulmonary failure in cohort 1 of the secondary trial, but none in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted based on the provided Adverse Events data from the CTRs. In the primary trial, there is no case of Cardiopulmonary failure reported in cohort 1. In the secondary trial, there is one case reported in the entire trial population but not in cohort 1 specifically. Therefore, the statement is contradicted by the data in the CTRs."
    },
    "03334f23-49ab-47e5-b420-a6753ce6e832": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00574587",
        "Secondary_id": "NCT00777049",
        "Statement": "There were no cases of Myocardial ischaemia in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the data in the CTRs, as there are no reported cases of Myocardial ischaemia in both the primary and secondary trials, according to the Adverse Events sections provided.\n\nExplanation: \n\nThe expert's statement \"There were no cases of Myocardial ischaemia in the primary trial or the secondary trial\" is in agreement with the clinical trial data presented in the Adverse Events sections. In both trials, Myocardial ischaemia is listed with zero occurrences in each trial, indicating the absence of this condition. Therefore, the expert's statement is entailed by the provided clinical trial data."
    },
    "a847cfc1-9556-4a55-9698-69c22696148f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "There were 2 cases of Angina in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the information in the Primary Trial's Adverse Events section as there is no mention of Angina reported (0/61) in that trial."
    },
    "fcbb7e0f-d106-44bd-a252-9b57adc6f071": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01075100",
        "Statement": "No mental health issues were observed in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"No mental health issues were observed in the primary trial\" cannot be entailed based on the provided CTR data as there is no information regarding mental health issues reported in the ELIGIBILITY CRITERIA, INTERVENTION, RESULTS, or ADVERSE EVENTS sections for either the primary or secondary trial."
    },
    "f82d94fe-c633-4bae-b28d-074196a08577": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03584009",
        "Statement": "Participants in the primary trial administered with Fulvestrant 500mg via intramuscular injection had a higher % of clinical benefit than participants who were administered an additional 160 mg of Neratinib.",
        "Label": "Contradiction",
        "explain": "The statement may be contradicted based on the provided information. In the primary trial, the percentage of participants achieving clinical benefit in the Fulvestrant-only arm was 13.7% (5.70-26.26), while the percentage of participants in the Venetoclax + Fulvestrant arm was 11.8% (4.44-23.87). The secondary trial data is missing from the description. Even if we assume that the secondary trial involved a comparison between Fulvestrant and Fulvestrant + Neratinib, the statement is not entailed as the data from the primary trial does not support a higher percentage of clinical benefit in the Fulvestrant-only arm compared to the Venetoclax + Fulvestrant arm."
    },
    "e5379a89-f880-44c1-bee0-a0d8ad2abfce": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00659373",
        "Secondary_id": "NCT02202252",
        "Statement": "the primary trial has a 5 year long intervention, the duration of the secondary trial is not specified in the intervention section.",
        "Label": "Entailment",
        "explain": "Contradicted\n\nExplanation: \n\nThe given statement asserts that the primary trial has a 5-year-long intervention, while the secondary trial's duration is not specified. The primary trial's intervention duration is mentioned in the Intervention section, but the statement does not directly refer to the Intervention section of the secondary trial. However, the secondary trial's intervention duration is not mentioned anywhere in the provided description. The absence of duration mention in the secondary trial intervention section contradicts the expert's statement."
    },
    "d811aaec-b3bd-4376-a9d6-d14eacae875a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00717886",
        "Statement": "Prior axillary surgery, axillary radiation, breast cancer and breast radiation are not permitted for entry to the primary trial, patients with prior High-dose chemotherapy can still enter if they satisfy all other inclusion criteria.",
        "Label": "Contradiction",
        "explain": "Contradiction. The primary trial's exclusion criteria include a history of ipsilateral axillary surgery, axillary radiation, breast cancer, and breast radiation (CTR, Inclusion Criteria and Exclusion Criteria sections). The statement allows patients with these conditions to enter the trial if they have undergone high-dose chemotherapy and meet all other inclusion criteria."
    },
    "99312d82-614c-4422-b6e6-104fe5a7fa54": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00050167",
        "Statement": "Only Patients with metastasis in less than 9 infraclavicular lymph nodes are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradiction. According to the Primary Trial's Eligibility Criteria, patients with pN2a, which refers to metastasis in 4 to 9 axillary lymph nodes, are eligible. However, the statement excludes patients with metastasis in less than 9 infraclavicular lymph nodes, which is not consistent with the CTR."
    },
    "b02c99f3-70bd-4404-8d80-c57c6dfef7b7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02049957",
        "Secondary_id": "NCT01506609",
        "Statement": "There is are the same total number of patients in the primary trial as in the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"There is the same total number of patients in the primary trial as in the secondary trial\" is entailed by the provided Clinical Trial Reports (CTRs), as the total number of patients in each trial can be determined by adding up the number of participants in their respective Adverse Events sections. The primary trial has 6 patients and the secondary trial has 2 patients, but if we add up the total number of patients in each Adverse Events section for both trials, we get:\n\nPrimary Trial: 1+2=3 for Adverse Events 1 and 0+1=1 for Adverse Events 2, totaling 4 patients.\nSecondary Trial: 0+0=0 for Adverse Events 1 and 0+0=0 for Adverse Events 2, totaling 0 patients.\n\nHowever, when we look at the total number of patients in the CTRs, we find that there are 6 patients in the primary trial and only 2 in the secondary trial. Therefore, the statement is not literally true according to the given data in the CTRs. However, since the statement is not contradictory to the CTRs (as it does not claim that the trials have the same number of subjects in each Adverse Events section), it can still be considered to be entailed if we understand the statement in a more nuanced way, such as it being intended to only relate to the total number of subjects across all sections in the CTRs and not just in the Adverse Events sections. In this interpretation, the statement is entailed by the CTRs.\n\nThus, depending on the intended meaning and context of the statement, it could be considered either entailed or contradicted by the provided Clinical Trial Reports. It's important to note that understanding the meaning and intent behind a clinical expert's statement is crucial for determining entailment relationships."
    },
    "3cbf2726-ddb0-460c-9dd2-082b8dda495d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Statement": "Less than half of patients in cohorts 1 in the primary trial experienced adverse events, but more than 45% of patients cohort 2 did experience adverse events.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the data in the CTRs. In the primary trial, 5/11 (45.45%) of patients experienced adverse events. However, the statement does not specify which cohort (1 or 2) the expert is referring to when saying \"patients in cohorts 1\" had less than half of the patients experience adverse events. But, the statement does indicate that \"more than 45%\" of patients in cohort 2 experienced adverse events, which is in line with the data in the primary trial for cohort 2, which had 21/11 (9.09%) + 21/11 (9.09%) + ... + 22/11 (18.18%) = 114/11 > 5/11 = 45.45% experiencing adverse events. Therefore, the statement is entailed by the data in the CTRs.\n\nHowever, it is worth noting that the CTR for the secondary trial was not provided, which could potentially influence the justification of the statement's entailment or contradiction. But, given that the statement only refers to the primary trial and makes no mention of the secondary trial, its entailment or contradiction should be assessed based on the information provided in the primary trial CTR alone."
    },
    "e7741151-2b2c-4e78-a4df-fe998c580714": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01912612",
        "Secondary_id": "NCT02392611",
        "Statement": "In the primary trial only 1 cohort is administered the intervention, whereas in the secondary trial both cohorts receive the intervention, but cohort 2 recieves more than double the dose of cohort 1.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTRs as follows:\n\n1. In the primary trial, there is only one arm (intervention 1) that receives the treatment (duloxetine).\n2. In the secondary trial, there are two arms (intervention 1 and intervention 2), and both arms receive the same intervention (alobresib), but the dose in intervention 2 is more than double that of intervention 1 (1.4 mg versus 0.6 mg).\n\nThese facts are consistent with each other. However, it is important to note that the primary and secondary trials involve different interventions (duloxetine vs alobresib). Therefore, the statement only applies to the relationship between these two specific trials, and not to a general statement about all clinical trials.\n\nThere is no contradiction with the provided descriptions in the CTRs."
    },
    "8cff36b0-a022-4469-8d14-7120be891cb1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00376688",
        "Statement": "Less than 1/10 the primary trial subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks.",
        "Label": "Entailment",
        "explain": "The statement \"Less than 1/10 the primary trial subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks\" is contradicted by the information in the CTRs. \n\nIn the primary trial, the Clinical Benefit Rate (defined as the proportion of subjects who experienced a CR, PR, or SD for at least 24 weeks) is given as 9.7%. This directly contradicts the statement that \"less than 1/10\" of the subjects in the primary trial experienced a CR, PR, or SD for at least 24 weeks, as 9.7% is greater than 10%. \n\nFurthermore, the CTR specifies the evaluation criteria for CR, PR, and SD and the time frame of up to 24 months, supporting the accuracy of the reported Clinical Benefit Rate."
    },
    "4ce24508-3d12-499f-ab7f-4b437ea51366": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00304096",
        "Secondary_id": "NCT00876395",
        "Statement": "A minimum bodyweight of 50kg is required to participate in either the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradiction. The primary CTR specifies a body weight > 110 lbs (without clothes) as a requirement, which is higher than 50 kg. The secondary CTR also has no mention of a minimum body weight requirement."
    },
    "2514da19-b30a-44bb-8853-4545e97295da": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Statement": "The Ixabepilone 40 mg/m^2 group in the primary trial reported worse results than the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 group.",
        "Label": "Entailment",
        "explain": "The statement can be entailed based on the given CTR data. The percentage of participants with Objective Response in the Ixabepilone 40 mg/m^2 group is lower (30.0%, 16.6-46.5) compared to the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 group (35.9%, 21.2-52.8)."
    },
    "cb9f8a52-b88e-4b04-bb28-a0eabead1439": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00728949",
        "Statement": "There were 6 adverse event categories for cohort 1 of the primary trial which recorded at least one case.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTR data. In the Adverse Events section of the Primary Trial, there are 6 categories with at least one reported case: Abdominal pain, Anal fissure, Constipation, Diarrhoea, Disease progression, and Infusion related reaction. Therefore, the statement is a correct summary of the data presented in the CTR."
    },
    "c921d3a1-bd6e-41c9-b0e9-23babf7ead7c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02806544",
        "Secondary_id": "NCT00605267",
        "Statement": "A patient with stage 2B , pathologically confirmed  estrogen receptor-positive breast cancer is elgible for both the primary trial and the secondary trial.",
        "Label": "Entailment",
        "explain": "The patient with stage 2B, pathologically confirmed ER-positive breast cancer can be included in the primary trial based on the following inclusion criteria: \n\n1. Patient has clinical locally advance breast cancer (Stage IIB)\n2. Patient has a pathologically confirmed diagnosis of ER-positive breast cancer with ER Allred Score > 4.\n\nHowever, there are also some exclusion criteria that need to be considered in the primary trial for this patient:\n\n1. The patient has not received any prior chemotherapy, radiation therapy, or biologic therapy for invasive breast cancer within the past five years. Since the patient's breast cancer was diagnosed and is now being treated, it is likely that they have undergone some form of prior treatment which would exclude them from the primary trial.\n2. The patient must be able to swallow and retain oral medication. It is not explicitly stated in the provided information whether the patient is able to swallow and retain oral medication.\n\nThe patient is also eligible for the secondary trial based on the following inclusion criteria:\n\n1. Patient is premenopausal, estrogen receptor positive, and aged 20 years and over.\n2. Patient has operable and measurable breast cancer.\n3. Patient has provided written informed consent.\n\nHowever, the patient's eligibility for the secondary trial is questionable due to the following exclusion criteria:\n\n1. The patient has a medical history of chemotherapy or endocrine therapy for breast cancer, or with a treatment history of radiotherapy. Since the patient has been diagnosed and is undergoing treatment for breast cancer, they are likely to have received prior treatment, which would exclude them from the secondary trial.\n\nTherefore, based on the information provided, the statement that \"A patient with stage 2B, pathologically confirmed ER-positive breast cancer is eligible for both the primary trial and the secondary trial\" is contradicted by the provided CTR information."
    },
    "358a1d3c-9ccc-48fc-badc-1644e326c8cb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02301988",
        "Secondary_id": "NCT00728949",
        "Statement": "The only type of adverse event recorded by both the secondary trial and the primary trial is Diarrhoea and Abdominal pain.",
        "Label": "Contradiction",
        "explain": "The statement is entailed based on the provided data in the Adverse Events sections of both primary and secondary trials. In the primary trial, Diarrhoea is reported as an adverse event with a frequency of 1.32% (1/76), and Abdominal pain is reported as an adverse event with a frequency of 1.79% (1/56) in the secondary trial. Both trials report these adverse events in their respective sections. Thus, the statement is entailed as it correctly identifies Diarrhoea and Abdominal pain as the only types of adverse events present in both trials."
    },
    "60a86c87-7387-4eae-b5dd-6245f8bf541e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00045032",
        "Secondary_id": "NCT00416572",
        "Statement": "WOCBP that refuse to use contraception are excluded from the primary trial, but may be eligible for the secondary trial if they are a UK resident.",
        "Label": "Contradiction",
        "explain": "Contradiction\n\nJustification:\n\nThe primary trial excludes women of childbearing potential or less than 1 year post-menopause who are unwilling to use adequate contraceptive measures (CTR, Primary Trial: Inclusion Criteria). Conversely, the secondary trial includes female patients only, but it does not specify any contraceptive requirement (CTR, Secondary Trial: Inclusions Criteria, Patient Characteristics). Therefore, the statement that WOCBP who refuse to use contraception are eligible for the secondary trial contradicts the primary trial's inclusion criteria."
    },
    "bd3055c6-09aa-47f0-89ed-67ad3798a580": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00090857",
        "Statement": "Candidates for the primary trial must have a bone density scan 1 month prior to study entry, if the results from this are more than 2 standard deviations below normal, they must be excluded.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed by the CTR for the Primary Trial, as it aligns with the requirement for a bone density scan within 30 days before randomization (2 standard deviations from normal allowed if approved by the study physician) and exclusion of candidates with a bone density scan more than 2 standard deviations below normal. (Primary Trial: Disease Characteristics)"
    },
    "21d7d726-8557-459f-a307-fae3e08f45d8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00656019",
        "Secondary_id": "NCT00328783",
        "Statement": "Candidates with hyperparathyroidism are automatically excluded from the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary and secondary CTRs since hyperparathyroidism is explicitly listed as an exclusion criterion in both trials. (Primary CTR under EXCLUSION CRITERIA: History of parathyroid disease, secondary CTR under EXCLUSION CRITERIA: No specific mention but similar exclusion criteria are present in both trials.)"
    },
    "9a8157a9-82fc-4d7e-9254-295123459430": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00054132",
        "Statement": "The majority of patients in the primary trial had an EGFR Expression level of 0, and 0 patients had an EGFR of 3 or above.",
        "Label": "Entailment",
        "explain": "The expert's statement is entailed in the provided CTR data for the primary trial as indicated below:\n\n1. The statement \"The majority of patients in the primary trial had an EGFR Expression level of 0\" is justified because the CTR reports that 24 out of 38 participants had an EGFR expression level of 0.\n2. The statement \"and 0 patients had an EGFR of 3 or above\" is also justified since the CTR reports that no participant had an EGFR expression level of 3+ (as mentioned in both the outcome measurement and results sections)."
    },
    "ff37494d-2c61-4c06-86c1-d6bcfbe9e360": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01856543",
        "Secondary_id": "NCT00365599",
        "Statement": "Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Pericarditis.",
        "Label": "Entailment",
        "explain": "The statement should be contradicted. \n\nJustification:\nThe primary trial reported one case (1.37%) of Myocarditis and one case (1.37%) of Pericarditis in the Adverse Events section. However, the secondary trial reported no cases in its corresponding section for either condition. Therefore, the statement that there was only one recorded case of Myocarditis and Pericarditis across all cohorts of the secondary trial and primary trial is incorrect based on the provided data in the CTRs."
    },
    "eb00b609-f17b-4595-87bd-d0843ec9e39a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01857882",
        "Secondary_id": "NCT01439945",
        "Statement": "the secondary trial administers 150 mg/Day more of Magnesium Oxide to its patients than the primary trial does.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided clinical trial reports. In the primary trial, patients receive a total of 1200 mg of Magnesium Oxide per week (two tablets of 400 mg daily from Week 2 to Week 9). In the secondary trial, patients receive a total of 1320 mg of Magnesium Oxide per week (three tablets of 400 mg daily from Week 2 to Week 9). The difference is 120 mg/Day (3 tablets x 400 mg - 2 tablets x 400 mg), and since this amount is equivalent to 150 mg/Week (120 mg/Day x 7/4), the expert's statement is correct."
    },
    "8bc9ea31-b731-4799-a1cc-a5ba63da00c1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Secondary_id": "NCT03592121",
        "Statement": "Patients are not required to be sexually active to receive the primary trial intervention, this is however a requirement for the secondary trial where the intervention must be applied during sexual activity.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. In the primary trial, patients are not required to be sexually active to receive the intervention (Multivitamin Arm and Calcitriol Arm). In contrast, in the secondary trial, patients are required to apply the intervention (AB-101) during sexual activity. Therefore, the statement accurately reflects the differences in intervention administration between the two trials."
    },
    "0864493d-9f64-49d1-a585-21be71704c59": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01684215",
        "Statement": "In the primary trial there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991, meaning 0% of patients in the primary trial suffered grade 4 or above thrombocytopenia.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. The CTRs state that there were no participants in either the 100 mg or 125 mg dose escalation cohorts that experienced grade 4 or above thrombocytopenia. Therefore, the statement's assertion that \"0% of patients in the primary trial suffered grade 4 or above thrombocytopenia\" harmonizes with the clinical trial data and is substantiated by the provided descriptions."
    },
    "c49428a7-cc55-474e-a773-88ff2019de1b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02780713",
        "Statement": "Both cohorts of the primary trial are administered the same doses of their respective drugs .",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided information in the CTRs. Both primary trial cohorts were administered AZD9496, one with Variant A (100 mg) during Treatment Period 1, and the other with the Reference form during Treatment Period 2. The doses administered to both cohorts are indeed the same (100 mg)."
    },
    "78136809-c8de-4c40-9a7e-1d61d879ba27": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00611624",
        "Secondary_id": "NCT00600340",
        "Statement": "the primary trial and the secondary trial administer their interventions at different frequencies.",
        "Label": "Entailment",
        "explain": "The statement is entailed. In the primary trial, Mammosite Therapy is given for 5 days, which is not specified to have a particular frequency. In contrast, the secondary trial administers interventions at different frequencies - Bevacizumab is given every 4 weeks for the combination with Paclitaxel and every 3 weeks for the combination with Capecitabine, while Paclitaxel and Capecitabine have specific treatment schedules of their own."
    },
    "b430ea52-fa55-4280-9e23-8a7392afca58": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00009945",
        "Statement": "Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the armpit (underarm or axilla) or they will not be eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR for the primary trial in the Eligibility Criteria section, as patients with histologically positive or suspicious sentinel nodes by H&E and confirmed positive by IHC must undergo completion axillary dissection (which includes surgery to remove lymph nodes from the armpit). Therefore, having a positive sentinel node biopsy makes a patient ineligible for the trial unless they undergo the required surgery."
    },
    "adfeff22-7bdd-4868-ab6e-90dd43d9621d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00038103",
        "Statement": "There is no difference in the proportions of Subjects With Clinical Benefit in the Exemestane + Celecoxib cohort and in the Exemestane alone cohort of the primary trial.",
        "Label": "Contradiction",
        "explain": "To evaluate the statement, we need to calculate the proportion of subjects with clinical benefit in each cohort based on the information provided in the CTRs. \n\nPrimary Trial: Exemestane Alone cohort: \nNumber of subjects with clinical benefit = (Number of CR + Number of PR + Number of SD for 24 weeks or longer)\nFrom the given CTR, 11 subjects had complete response (CR), 13 subjects had partial response (PR), and 25 subjects had long term disease stabilization (SD) for at least 24 weeks out of 49 participants analyzed. So, the number of subjects with clinical benefit is 29.\n\nPrimary Trial: Exemestane + Celecoxib cohort:\nNumber of subjects with clinical benefit = (Number of CR + Number of PR + Number of SD for 24 weeks or longer)\nFrom the given CTR, 7 subjects had complete response (CR), 14 subjects had partial response (PR), and 30 subjects had long term disease stabilization (SD) for at least 24 weeks out of 51 participants analyzed. So, the number of subjects with clinical benefit is 41.\n\nThe proportion of subjects with clinical benefit in the Exemestane Alone cohort = 29/49 = 0.592\nThe proportion of subjects with clinical benefit in the Exemestane + Celecoxib cohort = 41/51 = 0.804\n\nSince both proportions are different, the statement contradicts the information in the CTRs."
    },
    "51b8964b-86b8-4e93-9fb1-cb4b6f7f3451": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00371345",
        "Secondary_id": "NCT00475670",
        "Statement": "There only overlap between adverse events obeserved in the primary trial and the secondary trial is the several case of Sepsis which occurred in both trials.",
        "Label": "Contradiction",
        "explain": "The statement is entailed based on the CTR information provided. In both trials, there is mention of an occurrence of Sepsis in their respective Adverse Events sections. In the primary trial, there are 1/70 cases (1.43%) of Sepsis, and in the secondary trial, there is 1/41 cases (2.44%). The statement accurately reflects the overlap of this particular adverse event between the two trials."
    },
    "276f5523-f45b-45b0-ad30-b737f2c1b1d0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00468585",
        "Statement": "the primary trial recorded several skin infections in their patients.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted based on the provided CTRs as neither trial recorded any instance of skin infection (0/4 for primary trial and 0/3 for secondary trial)."
    },
    "884ba067-d3fe-4837-ad2a-a802b671b53c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00295867",
        "Statement": "Patients with an ECOG score between 3-5 are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Patients with an ECOG score between 3-5 are eligible for the primary trial\" is not entailed in the provided information of the Primary Trial's Inclusion Criteria. There is no mention of ECOG score (Eastern Cooperative Oncology Group performance status) in the Primary Trial's Inclusion Criteria. Therefore, the statement contradicts the provided CTR information."
    },
    "6619c75a-4073-47e9-8586-5070be1b3d39": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02222337",
        "Statement": "Participants for the primary trial must be in pairs, a breast cancer survivor and a caregiver, both must either be fluent in english or spanish.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR's Inclusion Criteria section for both the survivor and caregiver requirements: \"has a Caregiver who is willing to participate\" and \"a primary caregiver for a Latina breast cancer survivor\". This implies that both survivor and caregiver need to meet the language requirement, which aligns with the expert's statement.\n\nHowever, the expert's statement doesn't address the exclusion criteria. Therefore, it doesn't contradict the CTR either.\n\nFor the secondary trial, the statement holds true since it's an extension of the inclusion criteria from the primary trial."
    },
    "d81fafa4-1196-407b-a8c2-27d7b5da2f4f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01816594",
        "Secondary_id": "NCT02222337",
        "Statement": "Patients with histologically confirmed, newly diagnosed stage 0 breast cancer cannot take part in the primary trial, or the secondary trial, unless they present LVEF below 50% ",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary CTR includes the following exclusion criteria for LVEF: \"LVEF below 50% as determined by MUGA scan or ECHO.\" (Primary Trial: Exclusion Criteria) Therefore, patients with LVEF below 50% are not allowed in the primary trial. However, the secondary CTR does not mention any exclusion criteria related to LVEF. Hence, the statement is contradicted by the information in the provided CTRs."
    },
    "6d8b4720-e600-47d7-b6c5-3b8627f2358f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320710",
        "Statement": "There was no adverse event in cohort 2 of the primary trial which occurred in more than 0.5% of patients.",
        "Label": "Contradiction",
        "explain": "The given statement is entailed by the CTRs provided. In the primary trial, none of the adverse events listed in cohort 2 occurred in more than 0.5% of the patients, as indicated by the numbers in the Adverse Events 2 section. Specifically, no event such as anaemia, Febrile neutropenia, Leukocytosis, Leukopenia, Neutropenia, Pancytopenia, Atrial fibrillation, Cardiac failure congestive, Palpitations, Pericardial effusion, or Supraventricular tachycardia occurred in more than 0.5% of this cohort."
    },
    "1b84007d-0002-4ab6-8e05-609e7de58684": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01646346",
        "Secondary_id": "NCT03283553",
        "Statement": "the secondary trial and the primary trial do not use topical medications in their studies.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the provided CTRs. \n\nJustification: \nNeither of the primary nor secondary trials mention the use of topical medications in their interventions. In the primary trial, the intervention is specified as 4D Conformal Image-Guided Partial Breast RT, which is a type of radiation therapy. In the secondary trial, the interventions include a paper-pencil agenda setting checklist, facilitated registration for the patient portal, and education on access to doctor's electronic visit notes; none of these interventions involve topical medications."
    },
    "dc4f9c4a-ca42-4f4d-b93a-0e8dd627b009": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00213980",
        "Secondary_id": "NCT02536339",
        "Statement": "Adequate hematologic, renal, and hepatic function are required to participate in the secondary trial and the primary trial, however, patients with severe loss in cognitive function are still eligible.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted. The primary trial inclusion criteria do not mention cognitive function as a requirement for patient eligibility, while the secondary trial includes Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 as a requirement, which may indicate cognitive function but is not a specific cognitive function requirement. Additionally, the secondary trial has specific exclusion criteria for cognitive impairment (progressive neurologic dysfunction, symptomatic central nervous system disease) that contradict the statement's assumption of \"severe loss in cognitive function\" being acceptable."
    },
    "dc7c4409-32e5-4211-83fe-0a97b6176ca0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01007942",
        "Statement": "Febrile neutropenia was in excess of 5 times more common in cohort 1 of the primary trial, than in cohort 2.",
        "Label": "Entailment",
        "explain": "Contradicted. The frequency of febrile neutropenia in cohort 1 was 10.71% (30/280), and in cohort 2, it was 1.42% (4/282). A difference of this magnitude is not 5 times greater than, but rather approximately 7.5 times smaller."
    },
    "73e7447b-a940-4126-a1d9-fffd7c56c900": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00337103",
        "Statement": "Several patients in the Eribulin Mesylate group in the primary trial survived less than a year.",
        "Label": "Contradiction",
        "explain": "The statement \"Several patients in the Eribulin Mesylate group in the primary trial survived less than a year\" is entailed by the information in the CTR. While the median OS for the Eribulin Mesylate group is 484 days (95% CI: 462 to 536), this value represents the midpoint of the distribution of survival times for this group. It means that half of the patients in the Eribulin Mesylate group lived longer than 484 days, and the other half lived shorter than that. Therefore, it is expected that some patients in the Eribulin Mesylate group survived less than a year, and the CTR does not provide any information suggesting that this was an unusual occurrence or contradicting this statement."
    },
    "c160ae6e-4dfe-47a4-ac9a-7497babbc2a2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00629499",
        "Statement": "Patients with peripheral neuropathy, but no symptoms of neuropathy, are excluded from the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted\n\nExplanation:\n\nThe primary trial inclusion criteria state that \"pre-existing peripheral neuropathy must be less than or equal to grade 1 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 criteria.\" However, the expert's statement excludes patients with peripheral neuropathy, regardless of the symptoms. This contradicts the inclusion criteria."
    },
    "9f1afdf1-1ecf-4c8b-9b40-cc96cac0e063": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00129389",
        "Secondary_id": "NCT00304096",
        "Statement": "Patients with permanent sensory loss, interfering with daily activities are excluded from the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Patients with permanent sensory loss, interfering with daily activities are excluded from the primary trial and the secondary trial\" is entailed by the CTRs.\n\nIn the primary trial's exclusion criteria, under \"Other medical problems,\" there is a statement that excludes patients with \"any other serious medical pathology, such as congestive heart failure, unstable angina, history of myocardial infarction during the previous year, uncontrolled hypertension or high risk arrhythmias\" and \"any neurological or psychiatric disorders, which could preclude the patients to free informed consent.\" Although the statement from the expert does not specifically mention neurological disorders causing sensory loss, it falls under the broader category of neurological disorders mentioned in the CTR. Therefore, the statement is entailed by the CTR.\n\nSimilarly, in the secondary trial's exclusion criteria, under \"Medical History,\" there is an exclusion criterion for \"Any medical conditions, including neurological or psychiatric disorders, which could interfere with the patient's ability to comply with the study requirements.\" The statement from the expert falls under this category, making it entailed by the CTR."
    },
    "a7106a35-36da-423a-a6b3-3da62fc0eea8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01908101",
        "Statement": "Prior exposure to taxane is obligatory for patients in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Prior exposure to taxane is obligatory for patients in the primary trial\" is entailed by the CTR's inclusion criteria, specifically the condition \"Prior exposure to taxane in the adjuvant, neoadjuvant or metastatic setting.\""
    },
    "f4f50a05-9d63-4006-9680-b7ef68dbb5fe": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00952731",
        "Secondary_id": "NCT00956813",
        "Statement": "Cohort 2 in the primary trial and the secondary trial but receive daily placebo doses PO.",
        "Label": "Contradiction",
        "explain": "Contradiction. In the primary trial, Cohort 1 received oral placebo daily, while Cohort 2 received 4-hydroxytamoxifen gel 2mg/breast applied daily. However, in the secondary trial, Cohort 2 received a placebo identical looking bar with no flaxseed or lignans, which does not equate to receiving daily placebo doses PO as stated in the expert's claim."
    },
    "f34760f4-965e-4bbb-b88f-8b63a7045808": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00741260",
        "Statement": "Patients with HER2 positive tumors are ineligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial's inclusion criteria state that patients should have erbB-2 gene amplified tumors or erbB-2 overexpression. This means that patients with HER2 positive tumors are eligible for the trial. Therefore, the expert's statement is contradictory to the CTR information."
    },
    "f4a33395-7e6b-46b9-b222-af3bbfff1591": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00866905",
        "Statement": "Less than 2% of patients in the primary trial experienced an adverse event.",
        "Label": "Contradiction",
        "explain": "The expert's statement is entailed by the data in the CTR of the primary trial (Adverse Events section) as 3.57% (which is less than 2%) is the total percentage of patients who experienced an adverse event."
    },
    "e7d00591-381f-45e2-abdb-2ae1e568b193": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01421472",
        "Statement": "More than 3 patients in the primary trial suffered from adverse events associated with a low number of white blood cells.",
        "Label": "Entailment",
        "explain": "Justified: The statement is contradicted by the data in the CTRs since neither the primary nor the secondary trial reported an adverse event related to a low number of white blood cells for more than 3 patients. Specifically, neither trial reported any adverse events related to neutropenia or leukopenia for more than 3 patients in their respective cohorts."
    },
    "59da1fb5-2636-4ca8-8970-6cb45dedbed3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00885755",
        "Secondary_id": "NCT01075100",
        "Statement": "Patients' appetites were not affected in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is not entailed by the provided CTRs as stated, since the trials reported instances of appetite decreased in both trials: \n\nPrimary Trial: 0/33 (0.00%) - This information is not explicitly mentioned in the provided data, but the absence of \"Appetite Decreased\" event in the list does not guarantee that there were no instances of it, and it is mentioned in the secondary trial.\n\nSecondary Trial: 1/48 (2.08%) - There is a clear occurrence of appetite decreased in this trial.\n\nTherefore, the statement \"Patients' appetites were not affected in the primary trial or the secondary trial\" is contradicted by the available data."
    },
    "f144c34b-9428-4836-bf01-5f7030eb579c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT04030104",
        "Secondary_id": "NCT02525718",
        "Statement": "Intervention 1 for the secondary trial and the primary trial are for the control groups.",
        "Label": "Entailment",
        "explain": "The statement is entailed. In both the primary and secondary trials, Intervention 1 refers to control groups where subjects receive placebo or saline injections. The CTRs describe that subjects in these arms will not receive the active treatment (IUS or local anesthetic solution with bupivacaine, epinephrine, and dexamethasone) but rather a placebo or saline instead. Therefore, the statement that Intervention 1 in the secondary trial and the primary trial are for the control groups is entailed based on the information provided in the CTRs."
    },
    "e7e87023-2227-4594-931a-0a3d89ec686e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02073487",
        "Secondary_id": "NCT03371732",
        "Statement": "Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opiod addiction are eligible for the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary CTR explicitly states that individuals with \"more than one cigarette smoked per day\" are included in the secondary trial, but it excludes individuals undergoing methadone or buprenorphine maintenance therapy for opioid addiction. The CTRs do not allow individuals who consume more than 5 cigarettes per day in the primary trial. Therefore, the statement goes against the information provided in both trials and should be contradicted."
    },
    "ca4a190a-9007-4f8f-a199-b8fe4064e55b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02149524",
        "Statement": "Several adverse events which occurred in the primary trial were not heart related.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the provided CTR data. Both trials report similar types of adverse events excluding cardiac failure congestive, myocardial infarction, and supraventricular tachycardia. These heart-related events are absent in both trials. Therefore, the statement that several adverse events in the primary trial were not heart related is correct."
    },
    "4f790768-7fa4-4729-bcd6-cf7bcb44fa3c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00711529",
        "Secondary_id": "NCT02835625",
        "Statement": "the primary trial participants are treated with Cognitive behavioural therapy, this is not used at all in the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted. \n\nExplanation: \n\nThe primary trial participants are treated with hypnotherapy and self-hypnosis techniques, as specified in the Intervention 1 section of the primary CTR. The secondary trial participants are treated with Digital Breast Tomosynthesis and Synthetic Mammography in Intervention 1 and Digital Mammography in Intervention 2. There is no mention or indication of cognitive behavioural therapy being administered to the participants in either the primary or secondary trials."
    },
    "cb133915-dc40-4f93-a6a7-076e4d7f07a1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02685566",
        "Secondary_id": "NCT03076190",
        "Statement": "the primary trial and the secondary trial have the same number of study groups, but are testing different interventions.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the given CTRs. The primary trial and the secondary trial both have two study groups each, and the interventions being tested are different for each trial."
    },
    "1f0825b6-8e32-44ff-96b7-ab082e24b493": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00045032",
        "Secondary_id": "NCT00416572",
        "Statement": "WOCBP that refuse to use contraception are excluded from the primary trial, but may be eligible for the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR but contradicts the secondary CTR. In the primary CTR, women of childbearing potential or less than 1 year post-menopause unwilling to use adequate contraceptive measures are explicitly listed as exclusion criteria. In contrast, the secondary CTR does not mention anything about contraceptive use, but it only states that women must be able to communicate and does not include the restriction for women of childbearing potential or less than 1 year post-menopause. Therefore, while WOCBP who refuse to use contraception may be excluded from the primary trial, they may still be eligible for the secondary trial based on the available information from the secondary CTR. However, the primary CTR provides a more definitive answer, and any potential participants should follow its guidelines since it provides more comprehensive inclusion and exclusion criteria."
    },
    "db96c4d6-ffcd-401a-8af3-807f665f16f7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Secondary_id": "NCT00579826",
        "Statement": "Patients diagnosed with osteonecrosis are eligible for the primary trial but excluded from the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the given CTRs as per the following justifications:\n\nThe primary trial excludes patients with a history of osteonecrosis (ONJ) in the jaw or exposed bone in the mouth as stated under \"Exclusion criteria\" in the section. Therefore, patients diagnosed with ONJ can't participate in the primary trial.\n\nSimultaneously, the secondary trial includes female patients with histologically confirmed Stage IV breast cancer as part of inclusion criteria in the primary trial. However, the secondary trial explicitly excludes patients with a history of osteonecrosis as stated under \"Exclusion criteria.\" Thus, patients diagnosed with ONJ cannot participate in the secondary trial.\n\nSince the patients diagnosed with ONJ are ineligible for the secondary trial but allowed in the primary trial, the statement \"Patients diagnosed with osteonecrosis are eligible for the primary trial but excluded from the secondary trial\" is entailed by the provided CTRs."
    },
    "b74dc1bc-76c3-4ce6-9735-634e7a507ff5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00976989",
        "Statement": "Patients with LVEF equal to 53.5% are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial's inclusion criteria which specify that LVEF must be greater than or equal to 55%."
    },
    "f078c722-b879-40f2-ac72-c733001b93dd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01740323",
        "Secondary_id": "NCT00127205",
        "Statement": "the secondary trial and the primary trial only accept 18 year olds.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. Both the primary and secondary trials include the inclusion criterion that patients must be 18 years old or older. Therefore, the statement that \"the secondary trial and the primary trial only accept 18 year olds\" is in accordance with the provided CTRs."
    },
    "c33d78e5-13be-4cde-b36e-7cc097f180a2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00068588",
        "Statement": "the primary trial and the secondary trial use the same outcome measurements, same drugs and the same cohort sizes.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nJustification:\n\nIn the primary trial, the maximum tolerated dose (MTD) is determined through the occurrence of dose-limiting toxicities (DLTs) in cohorts with escalating doses of ruxolitinib, and the time frame for MTD evaluation is 8 weeks (the first 2 cycles of treatment). Conversely, in the secondary trial, the MTD is determined based on DLTs observed during the first course of treatment with specific doses of capecitabine and GTI-2040, and the time frame for DLT evaluation is 21 days. Furthermore, different drugs are involved in each trial (ruxolitinib vs. capecitabine and GTI-2040), and there is no mention of similar cohort sizes between the trials. Therefore, the statement that the primary and secondary trials use the same outcome measurements, same drugs, and the same cohort sizes is contradicted by the provided CTR information."
    },
    "58dbc33b-d32c-4e91-a940-ca1148bbdae4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00075270",
        "Secondary_id": "NCT01781299",
        "Statement": "the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing an implant.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the CTRs. The primary trial describes the administration of lapatinib and paclitaxel, which are chemotherapy drugs. The secondary trial mentions the use of AlloDerm RTU and SurgiMend PRS, which are implants. Hence, the statement correctly identifies that the primary trial is investigating a chemotherapy treatment and the secondary trial is investigating an implant."
    },
    "fbbad9dc-58a9-4527-86c5-49cb0a3e7d0e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00602043",
        "Secondary_id": "NCT01720602",
        "Statement": "Several treatments in the secondary trial are administered by mouth, none of the treatments in the primary trial are given via this route.",
        "Label": "Entailment",
        "explain": "Contradicted. In the primary trial, patients receive clinically indicated endocrine therapy, which includes hormonal treatments given by mouth (anastrozole, letrozole, or exemestane). (Primary Trial: INTERVENTION 1 for both groups)"
    },
    "2c462296-35f5-482a-9ece-3b4ed4c2f53a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Statement": "Urosepsis was the only recorded adverse event in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the CTR data in the primary trial. In the primary trial, there were 2 cases of Urosepsis out of 12 participants (16.67%), whereas the statement implies that Urosepsis was the sole adverse event."
    },
    "16358be6-3895-48f7-8006-4effeb3f74b3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01196052",
        "Statement": "Participants in the primary trial must be willing to undergo cyclophosphamide-based chemotherapy.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary CTR as patients are required to have received doxorubicin/cyclophosphamide (AC) or 5-fluorouracil (FU)/epirubicin/cyclophosphamide (FEC) in a similar dose and schedule as described in the protocol as part of neoadjuvant or adjuvant treatment. Cyclophosphamide is a component of both AC and FEC regimens."
    },
    "6d4ecb16-6586-4ea8-a1dc-f825e951e060": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00703326",
        "Secondary_id": "NCT00274768",
        "Statement": "Participants with HER2- primary liver tumors, confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by both CTRs. \n\nJustification:\nIn the primary CTR, the inclusion criteria specify that participants must have histologically or cytologically confirmed adenocarcinoma of the breast that is HER2-negative. In contrast, the secondary CTR makes no mention of HER2 status in its inclusion criteria, only specifying that participants must have a histologically or cytologically confirmed diagnosis of adenocarcinoma of the breast. The statement proposes that participants with HER2-positive primary liver tumors are eligible for both trials, which contradicts the primary CTR. Therefore, the statement is not entailed by either CTR."
    },
    "5bb009f0-bc19-4a85-85b8-bd7bf0675f3f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Secondary_id": "NCT00479674",
        "Statement": "Unlike the secondary trial, the primary trial does not record any instances of Anemia, Dyspepsia, Nausea or vomiting.",
        "Label": "Entailment",
        "explain": "Contradicted. The expert's statement contradicts the information provided in the Primary Trial's Adverse Events section, where no instances of Anemia, Dyspepsia, Nausea, or vomiting are reported."
    },
    "2731552d-195a-4f43-b6b5-02a3fbda81d9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01323530",
        "Secondary_id": "NCT01106040",
        "Statement": "the secondary trial and the primary trial do not have comparable Outcome Measurements.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nJustification: \n\nThe primary trial and the secondary trial have different outcome measurements. The primary trial focuses on the incidence of Dose-limiting Toxicities (DLTs) using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) in Phase 1b clinical trials of Eribulin Mesilate and Capecitabine. The secondary trial, on the other hand, measures the concordance of blue dye and Lymphoseek during lymphatic mapping and surgical resection of lymph nodes. Both trials have different objectives and use different measures to evaluate the safety and efficacy of treatments, respectively. Therefore, the statement is contradicted based on the provided CTR data."
    },
    "8fee5ce4-3e46-4731-842e-a5b1df451c7d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01231659",
        "Statement": "Less than 40% of the primary trial participants achieved either complete response (CR) or partial response (PR).",
        "Label": "Entailment",
        "explain": "The statement can be contradicted with the information provided in the primary trial Results 1 section. The ORR for the Everolimus + Letrozole arm was 37.2%, which is more than 40%. Therefore, less than 40% of the participants did not achieve either CR or PR."
    },
    "def4199f-a22d-4939-b15d-66fd073fb280": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02518191",
        "Statement": "Cohort 2 of the primary trial is the control group.",
        "Label": "Entailment",
        "explain": "The statement \"Cohort 2 of the primary trial is the control group\" is entailed by the provided information in the CTRs. This is because Cohort 2 in the primary trial refers to the group of patients who were not treated with GnRHa (Gonadotrophin-releasing Hormone Analogues) while receiving chemotherapy. According to the information in the CTR, this group serves as the control arm in the trial. Therefore, the statement made by the clinical trial expert is an accurate reflection of the information in the CTRs."
    },
    "c16dcd52-f2f0-40b7-9b2b-af3fd7f438b2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00871858",
        "Statement": "1 patient in the primary trial was diagnosed with a Clear cell renal cell carcinoma.",
        "Label": "Entailment",
        "explain": "Contradicted\n\nJustification:\nThe statement \"1 patient in the primary trial was diagnosed with a Clear cell renal cell carcinoma\" contradicts the CTR as no cases were reported in either Adverse Events section of the primary trial. The provided CTRs do not mention any instance of Clear cell renal cell carcinoma among the participants in either trial."
    },
    "d97c3981-50f9-4221-aec6-60661b831c8e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03624972",
        "Secondary_id": "NCT01216176",
        "Statement": "A 56 year old patient presenting occasional memory loss would be excluded from both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"A 56 year old patient presenting occasional memory loss would be excluded from both the secondary trial and the primary trial\" is contradicted by the CTRs. \n\nJustification: \n\nThe primary and secondary trials both have exclusion criteria related to cognitive dysfunction or psychiatric disturbance, however, the statement specifically mentions a patient with occasional memory loss, which is not the same as cognitive dysfunction or psychiatric disturbance as defined in the CTRs. The CTRs define cognitive dysfunction as severe mental illness such as dementia, suicidal behavior, or psychosis, while occasional memory loss does not meet these criteria. Therefore, the statement contradicts the information provided in the CTRs."
    },
    "86c1430c-553b-4388-a034-b82f78afdc0d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01028352",
        "Statement": "Patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or grade 0 sensory neuropathy, are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the Primary Trial's Inclusion Criteria, specifically the condition that patients must have AI-associated musculoskeletal symptoms (Grade 1 or higher musculoskeletal pain or Grade 1 or higher sensory neuropathy) to be eligible for the study."
    },
    "b7cef0e1-7bd8-4c0e-a044-b11708cf927c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01905592",
        "Statement": "both the primary trial cohorts receive Physician selection from 4 standard of care metastatic breast cancer chemotherapies.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. The primary trial's Intervention 1 specifies \"Physician's Choice\" from 4 standard of care metastatic breast cancer chemotherapies. Similarly, the secondary trial does not mention a specific intervention but indicates that the participants will receive \"Physician selection from 4 standard of care metastatic breast cancer chemotherapies.\" Therefore, both trials involve physician selection from the same 4 standard of care chemotherapies."
    },
    "0b55d5b7-5e71-497f-96ad-9dc2f872c4aa": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00444587",
        "Statement": "A total of 2/93 patients in the primary trial were observed with either Leukopenia, Cardiopulmonary failure or Diarrhoea.",
        "Label": "Contradiction",
        "explain": "The statement \"A total of 2/93 patients in the primary trial were observed with either Leukopenia, Cardiopulmonary failure or Diarrhoea\" is entailed in the provided CTR data.\n\nJustification:\n\nThe statement asserts that 2 patients experienced one of the mentioned adverse events (Leukopenia, Cardiopulmonary failure, or Diarrhoea). This information is directly derived from the CTR data in the Primary Trial section under Adverse Events where it is stated that a total of 2/93 patients suffered from Leukopenia, and 2/93 patients experienced Cardiopulmonary failure or Diarrhoea individually.\n\nAdditionally, it should be noted that no patient in the primary trial suffered from all three conditions simultaneously, so the statement does not contradict any part of the CTR."
    },
    "225f95a5-7c22-4cb7-a463-1c57d5b69d7a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01217385",
        "Secondary_id": "NCT01202591",
        "Statement": "Prior exposure to exemestane is not explicitly banned for patients in the secondary trial or the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement can be contradicted by the primary CTR since it explicitly states \"Previous treatment (chemotherapy, radiation, or surgery) to involved breast, including hormone therapy,\" under exclusion criteria. Exemestane is a type of hormone therapy, thus, patients in the primary trial who have been previously treated with exemestane are excluded from the study. However, the secondary CTR does not have such a restriction for exemestane, but it does have a specific requirement for a safety run-in phase where patients must not have been exposed to exemestane during that phase. Therefore, the statement's assertion is not entirely entailed by either CTR."
    },
    "5464e8a7-159c-4e00-8710-45a44ceaeda3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03061175",
        "Secondary_id": "NCT03098550",
        "Statement": "Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study, whereas Cohort 1 of the primary trial has the same intervention for the full study.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the CTRs. In the primary trial, Arm I of Intervention 1 specifies that patients receive Daratumumab IV 16 mg/kg Q1W for the first 8 weeks and Q2W for the remaining weeks, indicating they receive different doses for distinct durations of the study. Consequently, Cohort 1 in the primary trial is in line with the description in the expert's statement.\n\nIn contrast, the secondary trial's Cohort 1 (TNBC) and Cohort 1 (NSCLC) receive different drugs, and though both undergo the same Daratumumab dosage regimen, it is for distinct diseases, TNBC and NSCLC. However, the expert's statement focuses solely on the doses administered to Cohort 1 within the same trial. Thus, the comparison between the two trials is not directly relevant to the statement.\n\nTherefore, the statement is entailed by the data from the primary trial."
    },
    "98965d07-e2db-41bf-ac3e-a5c130513275": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00382018",
        "Secondary_id": "NCT03012477",
        "Statement": "Between the patients in the primary trial and the secondary trial, only 1.56% suffered from sepsis.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the given CTR data. In the primary CTR, no patient suffered from sepsis (0/161 or 0.00%), and in the secondary CTR, one patient suffered from sepsis (1/34 or 2.94%). Therefore, the percentage of patients suffering from sepsis in the primary trial is lower than that in the secondary trial, which is in line with the expert's statement."
    },
    "784cc905-937f-43fd-96a6-34ea8dce9e8d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429104",
        "Secondary_id": "NCT00878709",
        "Statement": "Patients with end-stage liver disease are excluded from the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted\n\nExplanation:\n\nThe statement \"Patients with end-stage liver disease are excluded from the primary trial and the secondary trial\" is contradicted by the information provided in the CTRs.\n\nIn the primary CTR, the exclusion criteria include \"Chronic active hepatitis or cirrhosis,\" but it does not mention \"end-stage liver disease\" specifically.\n\nIn the secondary CTR, there is no mention of liver disease exclusion criteria.\n\nTherefore, the statement is contradicted as it goes beyond the information provided in the CTRs."
    },
    "2e3f2fde-569e-46ef-958d-710599fec9a1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00706030",
        "Secondary_id": "NCT00171704",
        "Statement": "the primary trial studies the interventions impact on target lesions and the secondary trial measures changes in Bone Mineral Density, the results from these two studies are therefore not directly comparable.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided information. The primary trial measures the impact of treatments on target lesions using RECIST v1.0 criteria, while the secondary trial measures changes in bone mineral density using DXA scans. The trials investigate different outcomes and patient populations, and the results cannot be directly compared based on the given information."
    },
    "d1080199-2591-44bd-bdad-0dea3830e657": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary trial participants are treated with 600 mg/m2 of Pemetrexed intravenously every 2 weeks until complete response or disease progression.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the Intervention 1 section of the primary CTR, as both the dose (600 mg/m2) and frequency (every 2 weeks) of Pemetrexed administration specified in the statement match the details provided in the CTR."
    },
    "c37c21f5-19a0-4fcc-af92-89690fb64091": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02352779",
        "Secondary_id": "NCT00263588",
        "Statement": "The differences between cohorts in the primary trial is once cohort recieves a 750mg Low-dose Omega-3 Fatty Acid and the other 500mg, in contrast the difference in the secondary trial is patient characteristics.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. In the primary trial, both cohorts receive omega-3 fatty acid, but with different dosages (low-dose: 500mg PO BID and high-dose: 750mg PO BID). Therefore, the difference between the cohorts in the primary trial indeed relates to the dosage of omega-3 fatty acid administration. In the secondary trial, the difference between the cohorts (ECOG performance status and number of prior trastuzumab-containing regimens) is not related to the type or dosage of omega-3 fatty acid administration, but to the patient characteristics.\n\nTherefore, the expert's statement correctly describes the differences between the two trials."
    },
    "bea7f10e-09d6-42c3-9e89-dfd1112a33d5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01276041",
        "Secondary_id": "NCT00688909",
        "Statement": "0 patients in the primary trial or the secondary trial died.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nJustification: \n\nIn the primary trial, 1/70 (1.43%) patients experienced death NOS, which stands for \"death of unknown cause.\" Therefore, at least one patient in the primary trial died. Similarly, in the secondary trial, there is no mention of any deaths, but the absence of information on deaths does not imply that no patients died. The statement that \"0 patients in the primary trial or the secondary trial died\" contradicts the available data in the CTRs."
    },
    "3d41d86b-f53f-4bf9-a4dd-eae2412c485e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00545077",
        "Statement": "Only cohort 2 of the primary trial receive letrozole, but both cohorts undergo Endocrine Therapy .",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nReasoning:\n\nThe statement \"Only cohort 2 of the primary trial receive letrozole, but both cohorts undergo Endocrine Therapy\" contradicts the CTR as both cohorts in the primary trial undergo Endocrine Therapy and receive either letrozole or fulvestrant as part of the treatment regimen. The statement incorrectly infers that only cohort 2 receives letrozole, while cohort 1 does not."
    },
    "0159bfb3-231e-4711-b3ee-2798c66f5f6a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01015131",
        "Secondary_id": "NCT00312208",
        "Statement": "Both the primary trial and the secondary trial record instances of Rectal Hemorrhage within their patient cohorts.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs, as both trials report instances of rectal bleeding within their respective patient cohorts. However, it is important to note that there are no records of rectal hemorrhage in the given CTRs. Instead, there are individual reports of rectal bleeding in the Adverse Events sections for the primary trial (1 instance out of 44) and the secondary trial (0 instances out of 1634 for Adverse Events 1 and 2 instances out of 1635 for Adverse Events 2)."
    },
    "9e7628cd-931e-4b1f-b4c1-f03f0449ac27": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00392392",
        "Secondary_id": "NCT00503906",
        "Statement": "the primary trial records two different types of pain in its adverse events, in the cranial and foot area, the secondary trial does not record any types of pain in its participants. ",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nJustification:\n\nThe statement asserts that the secondary trial does not record any types of pain in its participants. However, the secondary trial's CTR does record the presence of \"Pain - Chest\" (3.45%) in its adverse events section, which is a form of pain. Therefore, the information in the CTR contradicts the statement."
    },
    "f1108cbc-db27-431d-9154-1a267278bda4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00312208",
        "Statement": "Cases of Cardiomyopathy and  Leukopenia were only observed in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted. \n\nExplanation:\n\nThe CTRs provided indicate that there was one case of Cardiomyopathy in the primary trial's Adverse Events section for both cohorts (1 and 2), and one case of Leukopenia occurred in each cohort (Primary Trial: Adverse Events 1: 18/1634 (1.10%); Adverse Events 2: 56/1635 (3.43%)). Hence, both conditions were observed in both cohorts, which contradicts the expert statement that they were only observed in cohort 1."
    },
    "8eb69e3e-ac08-4e85-98be-211aecd4525d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04396665",
        "Statement": "Any patient can enter into the primary trial as long as they are willing to provide Informed consent and are capable of using the internet.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided Primary Trial's Inclusion Criteria section, as it explicitly states that the requirement for participation is the willingness to provide informed consent and being capable of using the internet. There is no contradiction with the Exclusion Criteria section, as it only mentions that having a breast cancer diagnosis during the intervention is a reason for exclusion."
    },
    "baf7e338-91fd-47d0-b766-a4e039efc5d7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01432886",
        "Statement": "None of the patients in either cohort of the primary trial experienced DLT.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary trial definition of DLT includes grade 4 neutropenia persisting for more than 7 days, grade 3 or above febrile neutropenia, grade 4 thrombocytopenia or grade 3 thrombocytopenia requiring blood transfusion, and non-hematologic toxicity greater than or equal to grade 3 (exceptions apply). However, neither CTR provides any information about the occurrence or absence of DLTs in either cohort, making the statement unjustified and contradictory to the CTR information."
    },
    "9401b12d-3888-4a41-93a1-b2075930098b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00458237",
        "Statement": "Patient who have undergone External beam radiation therapy and major surgery in the last two weeks are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The given statement is contradicted by the primary trial CTR as it excludes patients who have undergone major surgery within 2 weeks before study entry. (Primary Trial: Exclusion Criteria)."
    },
    "c7aa030a-6b76-4bd7-a934-f02a4638a1ac": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00908791",
        "Secondary_id": "NCT00297596",
        "Statement": "Female patients over the age of 60, with Histologically confirmed breast cancer and advanced Alzheimer's disease are ineligible for both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nJustification: \n\nThe statement is contradicted by the inclusion criteria of both the primary and secondary trials. \n\nIn the primary trial, there is no age limit specified for breast cancer patients, and Alzheimer's disease is not mentioned as an exclusion criterion. \n\nIn the secondary trial, there is no mention of Alzheimer's disease as an exclusion criterion for females over the age of 60. However, it should be noted that the secondary trial specifically mentions that patients with dementia or significantly altered mental status that would interfere with proper consenting are excluded. Alzheimer's disease is a form of dementia, but not all patients with Alzheimer's disease would meet the criteria for significantly altered mental status that would interfere with proper consenting. Therefore, the exclusion criteria for the secondary trial do not necessarily mean that female patients over the age of 60 with Alzheimer's disease are ineligible.\n\nHowever, the statement is contradicted overall because it claims that female patients over the age of 60 with histologically confirmed breast cancer and advanced Alzheimer's disease are ineligible for both the primary and secondary trials, while the CTRs do not support this claim for either trial."
    },
    "94f9a957-33bb-4409-8878-ba734d6b0d5c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01823107",
        "Statement": "several Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events in both reconstructed breasts.",
        "Label": "Contradiction",
        "explain": "The statement \"several Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events in both reconstructed breasts\" is contradicted by the given CTRs. \n\nJustification: \n\nIn the Primary Trial, the Results section specifies that a total of 25 participants had the Meso BioMatrix Acellular Peritoneum Matrix implanted, and 12 out of these participants experienced a breast related adverse event. However, no information is provided about whether these adverse events occurred in one or both reconstructed breasts. \n\nIn the Secondary Trial, no information is given about the occurrence of breast related adverse events in relation to the Meso BioMatrix Acellular Peritoneum Matrix.\n\nTherefore, the statement that \"several Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events in both reconstructed breasts\" contradicts the provided CTRs as no information in the CTRs supports the claim that the adverse events occurred in both breasts for the same patients."
    },
    "04fd88c2-cf92-468d-bbc4-567cae19948d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00087152",
        "Secondary_id": "NCT00203502",
        "Statement": "the primary trial recorded less patients with nausea than the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement that \"the primary trial recorded less patients with nausea than the secondary trial\" can be contradicted based on the provided CTR data. According to the given information, there was one instance of nausea reported in the primary trial among 20 patients, whereas in the secondary trial, there were four cases of nausea or vomiting among 39 patients. Therefore, the secondary trial recorded more cases of nausea or vomiting than the primary trial."
    },
    "8a0d98d1-3a04-4fe4-8dc9-a41fdad5acdd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00499122",
        "Secondary_id": "NCT00454805",
        "Statement": "There were no cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 1 of the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the provided CTRs. In the primary trial, there was one case of Multi-Organ Failure in cohort 1 (1/41). In the secondary trial, there was one case in cohort 1 (1/31) and one case in cohort 2 (1/31)."
    },
    "8074c35f-b74c-4250-94f1-9ad22fa315d7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Secondary_id": "NCT00579826",
        "Statement": "Patients diagnosed with osteoporosis are eligible for the primary trial but excluded from the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the provided CTRs. \n\nJustification: \n\nPatients diagnosed with osteoporosis are mentioned as a part of the exclusion criteria for the secondary trial (CTR 2), but they are not explicitly specified as inclusion or exclusion criteria in the primary trial (CTR 1). However, osteoporosis is a condition that can be diagnosed based on radiological confirmation of bone metastasis, which is included in the primary trial's inclusion criteria (female patients with histologically confirmed Stage IV breast cancer and at least one bone metastasis radiologically confirmed). Therefore, patients with osteoporosis would fall under the eligibility category for the primary trial, but their inclusion could be contingent on the presence of other criteria mentioned in the primary trial. Conversely, in the secondary trial, osteoporosis is listed as an exclusion criterion, meaning that patients with osteoporosis would not be eligible for this study."
    },
    "afc4a45b-6592-4ca8-b174-033fb6a0624a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00580333",
        "Secondary_id": "NCT00934856",
        "Statement": "Candidates must have a life expectancy less than 12 weeks to particpate in the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary CTR explicitly lists \"Life expectancy of less than 12 weeks\" as an exclusion criterion. The statement asserts that candidates must have a life expectancy less than 12 weeks to participate. Since the statement contradicts the information provided in the CTR, it should not be entailed."
    },
    "2e1d4811-ae58-4b81-b53a-dbcb8c980a08": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00033514",
        "Statement": "Elizabeth has HER2 positive breast cancer, she is eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed. The primary CTR includes \"Women aged > 18 years with histologically documented metastatic breast cancer who are HER2 positive using FISH\" as inclusion criteria. Elizabeth having HER2 positive breast cancer meets these criteria. Additionally, the statement does not contradict any information presented in the CTR."
    },
    "d4f738c5-c99a-4d8d-b335-5821ce97fbd5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00568022",
        "Secondary_id": "NCT01120184",
        "Statement": "Completely disabled patients, totally confined to bed or chair and unable to carry on any selfcare are eligible for the primary trial but excluded from the secondary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nExplanation:\n\nThe statement \"Completely disabled patients, totally confined to bed or chair and unable to carry on any selfcare are eligible for the primary trial but excluded from the secondary trial\" contradicts the information provided in the given CTRs. \n\nIn the primary trial, there is no mention of any disability or mobility requirement as an inclusion or exclusion criterion. Therefore, there is no basis for the claim that completely disabled patients are eligible for this trial. \n\nIn contrast, the secondary trial explicitly states that participants with Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 are included. While ECOG performance status does not directly correlate to complete disability or inability to carry on self-care, it generally indicates a level of functional ability. Additionally, no mention of exclusion for complete disability is made in this CTR. Therefore, according to the provided information, completely disabled patients are not eligible for the secondary trial, but there is no basis for the claim that they are eligible for the primary trial."
    },
    "f27b25bd-c28e-4aac-8ad6-951fd7381ce4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01262027",
        "Statement": "More than 1 patient in the primary trial suffered an adverse event.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the data in the CTR for the primary trial, specifically the Adverse Events section where it is stated that \"Total: 1/22 (4.55%)\". This number indicates that more than one patient experienced an adverse event, making the expert's statement true according to the CTR information."
    },
    "5311216c-94e0-4d04-acd2-b95b932ddc02": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127933",
        "Secondary_id": "NCT00191789",
        "Statement": "the primary trial recorded at least one patient with an infection, whereas in the secondary trial none where observed.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided CTRs. While the primary trial recorded one case (1/34) of infection in Adverse Events 2, no cases were reported in Adverse Events 1 of the secondary trial. Therefore, the statement that \"in the primary trial, at least one patient had an infection, whereas in the secondary trial none were observed\" is not entailed by the data presented."
    },
    "01dfa37b-ce65-4e90-addc-395241c92f5f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191451",
        "Statement": "Patients in the primary trial experienced a variety of Oesophageal and cardiac adverse events.",
        "Label": "Entailment",
        "explain": "Justification for entailment: Both CTRs mention adverse events for the trials, and one of these adverse events is oesophageal spasm in the primary trial (0/50, 0.00% in Adverse Events 1 and 1/48, 2.08% in Adverse Events 2). Additionally, the statement refers to cardiac adverse events, but none are explicitly mentioned in the provided CTRs. However, diastolic dysfunction is reported in both trials (0/50, 0.00%, and 1/48, 2.08%, respectively), and it could be considered a cardiac adverse event. \n\nTherefore, the statement \"Patients in the primary trial experienced a variety of oesophageal and cardiac adverse events\" is entailed by the provided CTRs."
    },
    "43588c50-7dc4-4d46-a53d-e94576e8ab55": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03197389",
        "Statement": "Both men and women of child bearing potential must use adequate methods of contraception to be eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR as it is explicitly stated in the inclusion criteria for both male and female subjects in Section 5.7 that they must use an adequate method of contraception throughout the study."
    },
    "f419f810-ca53-4168-86fd-d1d9a9154d3a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02683083",
        "Statement": "sufferers of hyperthyroidism are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nJustification: \n\nThe primary trial exclusion criteria do not include hyperthyroidism as an exclusion criterion. Therefore, the statement that \"sufferers of hyperthyroidism are excluded from the primary trial\" contradicts the provided CTR information."
    },
    "630a8241-b776-4799-a7ca-b1fddf17686c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00206518",
        "Statement": "The least common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 1, 3D and 3C.",
        "Label": "Contradiction",
        "explain": "The statement \"The least common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 1, 3D and 3C\" is entailed, as evidenced by Results 1 in the CTR. Specifically, the number of participants in Chevalier grades 1, 3D, and 3C for the Taxotere/Docetaxel arm is 3, 10, and 18, respectively. Therefore, these grades represent the least frequent occurrences among the participant population in that arm."
    },
    "8f3fddf2-97ab-4456-bff7-8f83b27e3849": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00675259",
        "Secondary_id": "NCT01875367",
        "Statement": "Patients with an ImmunoHistoChemistry test result of 3+ are excluded from the primary trial but included in the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed in both CTRs since the primary CTR excludes patients with IHC 3+ for HER-2 neu, whereas the secondary CTR includes patients with this test result. However, there is an additional requirement for HER-2 amplification in the secondary trial, which is not specified in the primary trial but does not contradict the statement."
    },
    "11617367-193f-4f6b-bc3e-e58ea76d1052": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00485953",
        "Secondary_id": "NCT00068601",
        "Statement": "the cyclophosphamide dose in the secondary trial is 150mg once every 4 weeks and the Placebo dose in the primary trial is 12mg QD.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted. In the primary trial, risedronate is given at a dose of 35 mg weekly in the active medicine group and placebo is given once weekly. There is no mention of cyclophosphamide or its dose in the primary trial. In the secondary trial, cyclophosphamide is given as part of the planned chemotherapy regimen, but there is no specific dose mentioned in the given statement. Therefore, the statement that the cyclophosphamide dose in the secondary trial is 150mg once every 4 weeks contradicts the lack of mention of any cyclophosphamide dose in the primary trial. Additionally, the statement provides incorrect information about the placebo dose in the primary trial, stating it is 12mg QD whereas in reality, placebo was given once weekly in the primary trial, with no specific dose mentioned."
    },
    "882f22f6-36d9-4c2f-8f49-52469d570977": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01840163",
        "Secondary_id": "NCT02005549",
        "Statement": "the primary trial and the secondary trial do not exclude patients with non-melanoma skin cancer.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nJustification: \n\nThe primary trial explicitly lists \"no male\" under exclusion criteria, but this is not related to the statement. The statement concerns the exclusion of non-melanoma skin cancer in the primary and secondary trials. \n\nThe primary trial includes \"DCIS (Ductal Carcinoma In Situ)\" in the inclusion criteria and does not mention any specific exclusion for non-melanoma skin cancer.\n\nThe secondary trial has explicit exclusion criteria for \"no prior or current neoplasm except for non-melanoma skin cancer, or in situ cancer of the cervix.\" This means that patients with non-melanoma skin cancer are included in the trial. \n\nTherefore, the statement \"the primary trial and the secondary trial do not exclude patients with non-melanoma skin cancer\" is contradicted by the information provided in the CTRs."
    },
    "8f5423c9-17b5-4f66-aa9f-1fc9763958b2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01250379",
        "Statement": "None of the patients in the primary trial had Thrombocytopenia, heart failure, Pancytopenia, Acute coronary syndrome or Atrial fibrillation.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the data in both the Adverse Events sections of the primary and secondary trials. In the primary trial, there is a reported case of Thrombocytopenia (0/238, 0.00% reported, but 1 case occurred), and cases of heart failure (0/238, 0.00% reported, but 1 case occurred), Acute coronary syndrome (0/238, 0.00% reported, but 0 cases occurred, but not reported as \"acute\"), and Atrial fibrillation (0/238, 0.00% reported) in the secondary trial. Therefore, the statement is contradicted by the data in the CTRs."
    },
    "0c45a782-1a3d-4e9b-a258-136ab080dbb6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00846027",
        "Statement": "None of the adverse events recorded for the primary trial occurred less than twice.",
        "Label": "Contradiction",
        "explain": "Contradiction. The statement \"None of the adverse events recorded for the primary trial occurred less than twice\" is in contradiction with the CTR data provided. From the CTR data for the primary trial, it is clear that several adverse events occurred only once, such as Neutrophils count decreased, Cardiac ischemia/infarction, Left ventricular systolic dysfunction, Hypertension, Supraventricular and nodal arrhythmia, Anorexia, Gastrointestinal perforation, Vomiting, Dehydration, and Diarrhoea, each occurring in only one of the 82 participants."
    },
    "4e42302d-2cd9-4a91-9338-8e3b0ffb9292": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00654836",
        "Statement": "Patients with metastatic HER-2 positive adenocarcinoma of the breast can never be eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted\n\nJustification:\nThe primary trial includes the condition that patients with HER-2 positive breast cancer can participate if they are unable to receive trastuzumab or have previously received trastuzumab in the past. This means that patients with HER-2 positive breast cancer are indeed eligible for the primary trial under certain circumstances, which contradicts the statement that they can never be eligible."
    },
    "a5d5e6da-f3cd-49c7-92a7-f789468c4c4c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00270894",
        "Statement": "60% of Subjects in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information provided in the CTRs. In the Primary Trial's Outcome Measurement section, it is stated that feasibility will be determined by evaluating the percentage of subjects able to complete the neoadjuvant portion of the study on time with > 85% of the protocol-specified dose. In the Results 1 section, it is reported that 60% of the participants in the Neoadjuvant Therapy arm completed at least 85% of the planned dose on schedule. This aligns with the statement made by the clinical trial expert."
    },
    "da2ea2e9-3109-433e-9033-9ae322c30c4b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981812",
        "Statement": "Women who have undergone a breast enlargement procedure in the last 2 years are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the Primary Trial's Inclusion Criteria, as it does not explicitly mention the exclusion of women who have undergone breast enlargement procedures within the last 2 years. The CTR only lists exclusion criteria related to breast implants and recent breast surgeries or radiation therapies."
    },
    "c77c8e02-7abb-4b63-8917-01babe5cd372": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00863655",
        "Statement": "There were 5 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort 2.",
        "Label": "Entailment",
        "explain": "The statement is entailed. The primary trial's Adverse Events section for cohort 1 reports 35 cases of Anaemia (1.58% of total) compared to 30 cases (1.28%) in cohort 2 in the secondary trial. The difference is 5 cases. The primary trial also reported 2 cases of Disseminated intravascular coagulation (0.41% of total) in cohort 1, compared to none in cohort 2 of the secondary trial. The difference is 1 case. Therefore, the given expert statement matches these findings."
    },
    "f2b14720-6ff2-4ff7-a5bc-3841b93f647e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "the primary trial does not explain its intervention in the intervention section.",
        "Label": "Entailment",
        "explain": "Contradiction. \n\nThe primary CTR explicitly states \"INTERVENTION 1: MM-111 All participants\" in the INTERVENTION section. The statement made by the expert implying the absence of intervention description in the primary trial's INTERVENTION section contradicts the provided information."
    },
    "03e9368b-18a7-4643-a38b-a7b002403bf1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00568022",
        "Secondary_id": "NCT01120184",
        "Statement": "Completely disabled patients below the age of 20, totally confined to bed or chair and unable to carry on any selfcare are eligible for the primary trial but excluded from the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nJustification:\n\nThe statement asserts that completely disabled patients below the age of 20, who are eligible for the primary trial, are excluded from the secondary trial. However, neither CTR provides information regarding patient disability status. The primary CTR states that only women aged 20 years with histologically or cytologically confirmed breast adenocarcinoma are eligible, while the secondary trial specifies adult participants (>=18 years old) with HER2-positive breast cancer and certain other inclusion and exclusion criteria. No information regarding patient disability is given, making it an invalid comparison. Thus, the statement contradicts the provided data in the CTRs."
    },
    "c5dbd52d-01d4-4919-bfe9-2b7885490d6a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00422903",
        "Statement": "Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided information in the CTRs. The percentage of participants with cOR in cohort 2 (Letrozole + Lapatinib) is indeed higher than in cohort 1 (Letrozole + Placebo). Specifically, the percentage of participants in cohort 2 with cOR was 12, while in cohort 1 it was 2 for CR and 58 for PR. Although not explicitly stated in the provided information, it can be inferred that the higher percentage of participants in cohort 2 having a Clinical Objective Response contributes to the statement being entailed. \n\nReference to CTR sections:\n- Primary Trial: Results 1 and 2 for both cohorts\n- Secondary Trial: None, as the statement is not directly related to the secondary trial. However, the statement can be justified based on the information from the primary trial."
    },
    "83115abd-1c07-4ee7-8ba5-b4575be2d50f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00630032",
        "Secondary_id": "NCT00428922",
        "Statement": "Patients with radiologically confirmed bone metatases are excluded from both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed in both CTRs as both trials explicitly exclude patients with \"any clinically or radiologically suspect and non-explored damage to the contralateral breast\" and \"metastatic impairment, including homolateral subclavicular node involvement, regardless of its type.\" This covers cases of radiologically confirmed bone metastases. (Primary Trial: ELIGIBILITY CRITERIA - Exclusion criteria; Secondary Trial: EXCLUSION CRITERIA)"
    },
    "784872db-8ccf-4ddc-a432-6ee00fd0b0cc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01857882",
        "Secondary_id": "NCT01439945",
        "Statement": "the secondary trial administers Magnesium Oxide to its patients whereas the primary trial tests an education intervention.",
        "Label": "Entailment",
        "explain": "The statement should be entailed based on the following justifications drawn from the provided CTRs:\n\n1. In the primary trial, no specific medication or treatment intervention is stated within the intervention section. The decision support workshop is an educational intervention, which does not involve the administration of Magnesium Oxide to patients.\n2. In the secondary trial, patients are administered Magnesium Oxide, specifically with different doses throughout the trial.\n\nTherefore, the statement's assertion that the secondary trial \"administrates Magnesium Oxide to its patients whereas the primary trial tests an education intervention\" aligns with the provided information in the CTRs."
    },
    "adae7d81-bc8e-48e4-b966-27c2633eb72d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02131064",
        "Statement": "over 100 participants in the TCH + P group of the primary trial achieved Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples.",
        "Label": "Entailment",
        "explain": "Contradiction. According to the provided CTR for the primary trial, the percentage of participants in the TCH + P group who achieved tpCR was 56.1 (49.29 to 62.76). This percentage is far from exceeding 100 participants, making the statement a contradiction of the trial's findings."
    },
    "4ee4061e-a532-459e-8d03-3055bd92419c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00082810",
        "Statement": "Throughout the duration of the primary trial, pariticpants receive tipifarnib more often than Fulvestrant.",
        "Label": "Entailment",
        "explain": "Contradicted. According to the primary CTR, patients receive fulvestrant intramuscularly once on day 1, while tipifarnib is given orally twice daily on days 1-21. Therefore, patients receive fulvestrant less often than tipifarnib throughout the trial duration."
    },
    "4cbb7f8f-ea60-453d-b4ab-e967944426d3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992225",
        "Statement": "Only 2 of the 16 adverse event types recorded in the primary trial, occurred more than once.",
        "Label": "Contradiction",
        "explain": "Contradicted. The statement \"Only 2 of the 16 adverse event types recorded in the primary trial, occurred more than once\" contradicts the information provided in the CTRs. In the primary trial, a total of 11 distinct adverse events were recorded, which is more than 2 out of 16 if we assume that each adverse event type is represented by a distinct number in the sequence. Therefore, the statement is not entailed by the data in the CTRs."
    },
    "47f11df7-6c82-4c50-9249-5085313a5064": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Secondary_id": "NCT00631852",
        "Statement": "A patient with a cytologically confirmed breast cancer with a 5 millimeter greatest diameter on imaging would be accepted for the primary trial, but not for the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by both CTRs. The patient meeting the primary trial inclusion criteria with a 5mm largest diameter on imaging is acceptable, as per the primary CTR. However, the same patient does not meet the secondary trial inclusion criteria due to having a smaller tumor size (1.0 cm is the minimum size requirement in the secondary CTR)."
    },
    "3114ff0f-184c-48ba-b33d-631505cffeef": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01961544",
        "Statement": "the primary trial reported a combined total of 3 cases of Ascites, Asthenia and Gastritis in cohort 1.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR under the ADVERSE EVENTS section, where a total of 1/101 (0.99%) cases for Ascites, 1/101 (0.99%) for Asthenia, and 1/101 (0.99%) for Gastritis are reported."
    },
    "edf31a43-a774-4f2a-8a02-89b84de941bb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02595372",
        "Statement": "27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with High Dose Omeprazole did not have Pathological Complete Response.",
        "Label": "Entailment",
        "explain": "The statement \"27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with High Dose Omeprazole did not have Pathological Complete Response\" can be contradicted by the given CTR data. \n\nIn the primary trial, the percentage of patients with FASN expression who had pCR was calculated to be (100% - 72.4%) = 27.6%, but the statement asserts that 27.6% of the patients did not have pCR. This contradicts the CTR data.\n\nAdditional justification: The CTR provides the exact percentage of patients with FASN expression and pCR, and the statement asserts a different percentage of patients not having pCR."
    },
    "ffdc4c5b-a091-4fa6-b2c1-49a131d7d109": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01596751",
        "Secondary_id": "NCT00193050",
        "Statement": "There were at least 15 patients with Dysphagia or Fever between the primary trial and the secondary trial patient cohorts.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial reported no cases (0.00%) of Dysphagia, whereas the statement asserts that there were at least 15 patients with Dysphagia in the primary and secondary trial cohorts combined. Similarly, the primary trial reported no cases (0.00%) of Fever, while the statement implies that there were at least 15 patients with Fever between the two trials. The statement contradicts the data provided in the Adverse Events section of the CTRs."
    },
    "df3e8e6b-fcfd-4909-bbb5-0d69df23f2c5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00632489",
        "Statement": "the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib, whereas the dose of Capecitabine changes with patients body weight.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial description. In the primary trial, Capecitabine dosage varies based on body weight (ranging from 825 mg/m2 to 1250 mg/m2), while Lapatinib is fixed at a dose of 1000 mg PO daily."
    },
    "5a076708-c8d4-4341-9c1d-3ee762f57be5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03456427",
        "Secondary_id": "NCT02685566",
        "Statement": "There are no details concerning the types of imaging that are being used in the intervention sections of the primary trial and the secondary trial",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nExplanation: \n\nThe CTRs provided specify the types of imaging used in each intervention, i.e., Patient-Assisted Compression with standard of care imaging on a FujiFilm Aspire Cristalle System and Technologist-controlled compression with standard of care imaging on a FujiFilm Aspire Cristalle System for the primary trial. For the secondary trial, the imaging type is Full-Field Digital Mammography with a FujiFilm Aspire Cristalle System. The expert's statement contradicts this information, as it asserts that there is a lack of details regarding the imaging used in the trials."
    },
    "98a946b0-2be1-474c-b373-043f329ba261": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038010",
        "Secondary_id": "NCT00764322",
        "Statement": "Neither the primary trial or the secondary trial are measuring Percentage of Participants With Overall Response Rate (ORR) Following Administration of Ispinesib.",
        "Label": "Entailment",
        "explain": "Contradicted. The CTRs provided do not mention the measurement of Percentage of Participants With Overall Response Rate (ORR) following administration of Ispinesib. The primary trial focuses on Dose Limiting Toxicity (DLT) of BYL719 in combination with T-DM1, while the secondary trial measures endoxifen concentrations in participants receiving Tamoxifen Citrate doses of 20 mg or 40 mg stratified by the metabolizing CYP2D6 genotypes. No mention of Ispinesib or its response rate is present in either trial."
    },
    "b82e6861-3908-43e9-8e54-cf60c7d96a4e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00721409",
        "Secondary_id": "NCT02413320",
        "Statement": "Patients with ER-positive tumours are eligible for the primary trial but not for the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs. In the primary trial, patients must have estrogen receptor positive breast cancer to be eligible. In contrast, patients in the secondary trial must have hormone receptor-poor invasive tumors, which excludes estrogen receptor positive tumors."
    },
    "b8e5baf7-ddc5-407f-84d3-4c93224477cd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02445586",
        "Secondary_id": "NCT02115984",
        "Statement": "More than half of patients in the primary trial experienced adverse events, and there was not a single patient in either cohort of the secondary trial that did not experience an adverse event.",
        "Label": "Entailment",
        "explain": "The statement is entailed. In the primary trial, 59.62% (31/52) of patients experienced adverse events. In the secondary trial, every patient (100.00% or 57/57) in both cohorts experienced an adverse event. Therefore, more than half of the patients in the primary trial and every patient in the secondary trials experienced adverse events, as claimed by the statement."
    },
    "79c34b71-a90f-4ddb-9aee-5f61f71f0846": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01277757",
        "Statement": "the primary trial is not testing a novel Physiotherapy or chemotherapy intervention.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary CTR as it clearly states that the intervention is an Akt Inhibitor (MK-2206), which is not a form of physiotherapy or chemotherapy."
    },
    "e1f6d1b3-92eb-4ad8-8c00-e44b58650e62": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02995980",
        "Statement": "A patient presenting Glomerular filtration rate of 63 and with BI-RADS category c breast tissue would be eligilbe for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR information. The patient's Glomerular filtration rate of 63 falls above the inclusion criteria's minimum requirement of a GFR > 60. Additionally, the patient's BI-RADS category c breast tissue matches the inclusion criteria for this category."
    },
    "02d5fe7a-60e2-422f-98c0-92461b8fa13f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00438659",
        "Secondary_id": "NCT01271725",
        "Statement": "the primary trial and the secondary trial have a topical intervention, to be applied to the breast or face.",
        "Label": "Contradiction",
        "explain": "The statement is entailed in both the primary and secondary trials. \n\nExplanation: \n\nIn the primary trial, the topical intervention is mometasone cream applied to the breast or chest wall. In the secondary trial, the topical intervention is afatinib or vinorelbine/paclitaxel combinations given after initial afatinib monotherapy, but the application site is not explicitly stated. However, there is no mention of systemic administration for either afatinib or these combination therapies in the secondary trial, implying a topical application for afatinib is possible since it is given as monotherapy before combination therapy. Thus, both trials involve a topical intervention applied to the breast or face (chest wall in the primary trial) based on the available information."
    },
    "869e413e-01c5-4a9e-8a4a-b6079f7ae300": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00996632",
        "Secondary_id": "NCT01644890",
        "Statement": "Emily has an Inoperable non-metastatic breast cancer, she is eligible for both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted. Emily's inoperable breast cancer makes her ineligible for the primary trial due to the exclusion criterion mentioned in the primary CTR: \"Inoperable breast cancer.\" Therefore, she cannot be eligible for both trials as claimed in the statement."
    },
    "c0b528ef-ae9f-4c01-8915-b47856f07c95": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01142661",
        "Statement": "the primary trial accepts patients with grade  3 neuropathy.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial excludes subjects with Grade 3 neuropathy as a toxicity from participation in the treatment protocol. (Primary Trial: Inclusion/Exclusion Criteria: \"Existing anti-cancer therapy-related toxicities of Grade >/= 2, except that alopecia and Grade 2 neuropathy are acceptable.\")"
    },
    "b6e484ff-d0c7-48bc-ab98-f0bd570d4b4e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01743560",
        "Statement": "By week 48 of the primary trial the majority of patients had Stable Disease, none of them had complete or partial response.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nThe statement that \"by week 48 of the primary trial the majority of patients had Stable Disease, none of them had complete or partial response\" contradicts the information in the CTR. According to the CTR, the number of patients with stable disease at week 48 was 18, which is less than the total number of patients (49). Furthermore, the CTR reports that 7 patients had a best partial response at week 48. Therefore, it is not true that none of the patients had a complete or partial response at week 48."
    },
    "da15fae6-7fa1-4fe0-b61c-e043df3e9e74": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01011946",
        "Statement": "All patients in the primary trial must have a bilateral breast MRI prior to study entry.",
        "Label": "Entailment",
        "explain": "Contradiction. The primary trial's inclusion criteria state that patients who have NOT undergone a standard of care bilateral breast MRI at UC are eligible for the study. This explicitly indicates that such an imaging procedure is not mandatory before study entry for this trial."
    },
    "8ce665b5-20fb-44a3-b3c9-25493e8dd7ff": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02455453",
        "Statement": "Patients with tumors that are HER2 negative, PR and ER positive are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR. The eligibility criteria of the primary trial specify that patients must have \"any one of the following types of breast cancer (primary or metastatic): ER+/PgR+/HER2- or ER+/PgR-/HER2-.\" Therefore, patients with tumors that are HER2 negative but PR and ER positive meet the eligibility requirements."
    },
    "01236718-14da-450c-8051-0207d31743a5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02555657",
        "Statement": "The Median time from randomization to death due to any cause, was a month longer for patients in cohort 1 of the primary trial, compared to those in cohort 2.",
        "Label": "Contradiction",
        "explain": "Based on the provided information in the CTRs, the statement is contradicted. In the primary trial, the median time from randomization to death in cohort 1 (Pembrolizumab) was 12.7 months (9.9-16.3) and in cohort 2 (Treatment of Physician's Choice, TPC) was 11.6 months (8.3-13.7). However, the statement suggests that there was a difference of one month between the two cohorts, which is not supported by the data provided."
    },
    "3419af1a-7923-419d-a673-2de96d41eabb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03719677",
        "Statement": "Potential participants will be considered regardless of the hormone receptivity of their breast cancer, except if they are overexpressing ERBB2.",
        "Label": "Entailment",
        "explain": "Contradiction. The primary CTR explicitly states that they will exclude participants who have HER2 positive BCS (breast cancer subtype), which is a type of hormone receptor overexpression."
    },
    "2048912d-9e9f-4cbc-89cc-19020f20a976": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01966471",
        "Secondary_id": "NCT00981812",
        "Statement": "A patient who had a total bilateral mastectomy in the year prior to study entry would be excluded from both the primary trial and the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by both primary and secondary trial CTRs. Inclusion in the primary trial requires adequate surgical excision, which includes breast-conserving surgery or mastectomy/skin-sparing mastectomy. However, the patient mentioned had a total bilateral mastectomy, which exceeds the allowed surgical intervention as per the primary trial's 9 weeks time frame between definitive breast surgery and randomization. Similarly, the secondary trial excludes participants who have undergone breast surgery within the 24 hours prior to the PEM study (Photoemission Mammography) and those who had breast surgery within the past year. The statement aligns with these exclusion criteria."
    },
    "f5907902-d4d1-4d73-a196-7fbe0dcb44ad": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245219",
        "Secondary_id": "NCT00038103",
        "Statement": "the primary trial and the secondary trial both have control groups. ",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTRs. \n\nJustification: \n\nBoth the primary and secondary trials mention a control group in their Intervention sections. In the primary trial, participants in Intervention 1 received usual care with no additional treatments or meetings (health tracking), which can be considered as a control group. In the secondary trial, no specific control group is mentioned for Intervention 1 (Exemestane Alone), but it's assumed that participants received the standard care for that trial. Intervention 2 (Combination) in the secondary trial includes a separate comparison group, but that's not the focus of the expert statement. Therefore, both trials have control groups as required by the statement, and there is no contradiction with the provided CTRs."
    },
    "93a8e018-ac25-48b2-81d2-fd5b01be8f37": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01463007",
        "Secondary_id": "NCT00965523",
        "Statement": "A higher number of patients in the secondary trial suffured from infection compared to those in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"A higher number of patients in the secondary trial suffered from infection compared to those in the primary trial\" is entailed by the provided Clinical Trial Reports. In the primary trial, there was 1 infection in 41 participants (2.44%). In the secondary trial, there were 2 infections in 81 participants (2.47%). Thus, there is a higher number of infections in the secondary trial."
    },
    "d72c45e5-6654-4afe-91a0-1f47b0c13dc0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00464646",
        "Statement": "Anna is a 57 year old female with an ECOG of 0, diagnosed with a HER2-positive invasive adenocarcinoma of the breast, with ipsilateral nodes pN2. She is eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR, as Anna's diagnostic information (HER2-positive invasive adenocarcinoma of the breast, pN2 nodes) aligns with the eligibility criteria (HER2-positive breast cancer, pN2 nodes) outlined in the CTR. The additional information provided about Anna's age, ECOG performance status, and lack of metastatic disease further aligns with the overall patient eligibility criteria in the CTR."
    },
    "e68b5690-11fd-4567-8dcc-dec91d1e4bb8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01033032",
        "Statement": "The only adverse event recorded in the primary trial was one single case of spinal fracture.",
        "Label": "Contradiction",
        "explain": "Contradiction. The CTR for the primary trial reports \"PLEURAL EFFUSION\" as an adverse event, occurring in 1/3 (33.33%) of participants. This is in clear contradiction to the statement that only one adverse event was recorded in the primary trial."
    },
    "e1417a26-2f40-4dd6-b598-e66e57312595": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01931163",
        "Secondary_id": "NCT00274469",
        "Statement": "Less than 5% of cohort 1 of the primary trial had LACRIMAL DISORDER, 0% of the secondary trial patients were recorded as having LACRIMAL DISORDER.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided CTRs. \n\nJustification:\n\nThe statement claims that less than 5% of cohort 1 in the primary trial had LACRIMAL DISORDER, while no cases were reported in the secondary trial. However, the CTRs indicate that no cases of LACRIMAL DISORDER were reported in either the primary (section Adverse Events 1) or secondary (section Adverse Events 1 and Adverse Events 2) trials. This contradicts the statement, as it suggests that there should have been at least one case in either the primary or secondary trial, given the stated percentage for the primary trial."
    },
    "6ee89773-958b-4eb9-bc67-18fa98a70c2d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00365365",
        "Statement": "the primary trial only recorded one type of acute adverse event.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nJustification: \n\nThe statement that \"the primary trial only recorded one type of acute adverse event\" contradicts the provided CTR data, as the primary trial reported several types of acute adverse events such as Febrile neutropenia, Neutropenia, Thrombocytopenia, Acute coronary syndrome, Cardiac failure congestive, Myocardial infarction, Abdominal pain, Diarrhoea, and Upper gastrointestinal haemorrhage."
    },
    "4d776c28-8ed1-4f3f-9837-0821029d3775": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00063570",
        "Statement": "None of the patients in cohort 1 of the primary trial had a platlet deficiency, and none of the patients in cohort 2 were constipated. ",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the provided CTRs. In the primary trial's Adverse Events 1 section for cohort 1, no Thrombocytopenia (platelet deficiency) was reported, and in the secondary trial's Adverse Events section for cohort 2, no Constipation was reported. The statement aligns with the data presented in the CTRs."
    },
    "50e54a67-9cfb-4259-b810-2e9bc0b09b4c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00611624",
        "Secondary_id": "NCT00600340",
        "Statement": "the primary trial and the secondary trial require patients to undergo a minimum of two weeks of Mammosite Therapy.",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nThe primary trial states that Intervention 1 is five days of Mammosite Therapy with no additional specification given. Therefore, it does not entail a minimum of two weeks of Mammosite Therapy. In contrast, neither of the secondary trials involves Mammosite Therapy, as they both include different interventions: Bevacizumab plus Paclitaxel and Bevacizumab plus Capecitabine. Thus, the statement contradicts the information presented in the CTRs."
    },
    "9f23f617-b8ec-4665-ad0b-9a9bc8b19691": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00688740",
        "Secondary_id": "NCT00191815",
        "Statement": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts.",
        "Label": "Contradiction",
        "explain": "Contradicted. The statement asserts that the most common adverse event in both primary and secondary trials is Neutropenia with a total of 3 cases across all cohorts. However, the primary trial reported a total of 2 adverse events (0.27%) out of 744 participants, whereas the secondary trial reported only 1 adverse event (1.49%) out of 67 participants for Neutropenia. Hence, the stated total of 3 cases is not substantiated by the data provided in the CTRs."
    },
    "b76c9c21-64f7-487b-bf08-e232a9da0174": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01490892",
        "Secondary_id": "NCT02364388",
        "Statement": "The intervention in the primary trial requires an injection and two different imaging modalities, whereas the secondary trial firstly requires a consultation followed by an intensive radiotherapy treatment.",
        "Label": "Contradiction",
        "explain": "Contradicted. The statement contradicts the information in the primary CTR, which describes an intervention that includes perflutren injections and imaging modalities, whereas the secondary CTR describes MAESTRO intervention with a consultation and intensive radiotherapy treatment. No part of these descriptions match, making the statement contradictory to the provided CTRs."
    },
    "66aaca41-f5f9-4ed4-b165-9510b7c64456": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03136367",
        "Secondary_id": "NCT00129935",
        "Statement": "Only patients who identify as female are eligible for the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed based on the provided CTRs. In both trials, the inclusion criteria specify that participants must be assigned female at birth. Therefore, the statement is in accordance with the clinical trial data and avoids contradiction with the given descriptions."
    },
    "611317e3-83f9-4e8d-9a9d-3dcda62fb6cb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00206427",
        "Statement": "A patient in the primary trial had a fungal infection of the mouth.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the primary CTR under the \"Adverse Events\" section, specifically the event \"Infection-oral thrush\" which occurred in 1/49 (2.04%) of the patients."
    },
    "d6b09c0f-979c-4151-87f9-830b964e275d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Statement": "Urosepsis was the most common adverse event in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Urosepsis was the most common adverse event in the primary trial\" is contradicted by the CTR data. According to the Adverse Events section of the primary trial, the total number of adverse events was 3, and Urosepsis occurred in 2 (16.67%) out of 12 participants. However, other adverse events like Brain hemorrhage complicating CNS metastasis and Rash also occurred, with frequencies of 8.33% and 0.00%, respectively. Since no adverse event had a higher occurrence than Urosepsis, the statement is a contradiction to the provided information."
    },
    "92da8d30-a7e9-4fb4-95e4-484b53279ad7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01570036",
        "Secondary_id": "NCT00021255",
        "Statement": "the primary trial and the secondary trial monitor the DFS of their patient cohorts, however the secondary trial reports the % of patients with DFS >= 5 years whereas the primary trial reports % of participants with DFS >= 2 years.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTRs. While the primary trial reports the percentage of participants with DFS at 24 months, the secondary trial reports the percentage of participants with DFS for up to 5 years. However, both trials use the same outcome measurement (Disease-free Survival) and monitor patients' survival status until a specific time point (2 years for the primary trial and up to 5 years for the secondary trial). Therefore, the statement correctly reflects the differences in time frames for reporting DFS between the trials."
    },
    "762c3b23-547a-40cb-86c9-767294f4a142": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165605",
        "Statement": "A 56 year old patient with a masectomy would not be eligible for the primary trial, due to her age.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nJustification: \n\nThe primary trial's inclusion criteria state \"Female, age 18 or older,\" thus a 56 year old patient would meet the age requirement. However, she would not be eligible due to having undergone a mastectomy, which is not specified in the primary trial's inclusion criteria."
    },
    "95a509d6-2990-49ac-b36c-aedf842f17ee": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01111825",
        "Statement": "There were no observed cases of Constipation, Diarrhoea, oedemas or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the Primary Trial's Adverse Events sections for Patients 1 and 2, as neither group reported any occurrences of Constipation, Diarrhoea, oedemas, or Febrile neutropenia. (Reference: Primary Trial - Adverse Events sections for Patients 1 and 2)."
    },
    "9bdc9efc-89eb-4b6b-961c-ceb5d686ebe6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Statement": "One patient in the primary trial experienced a grade 4 adverse event.",
        "Label": "Entailment",
        "explain": "The statement \"One patient in the primary trial experienced a grade 4 adverse event\" is contradicted by the data provided in the primary trial's Adverse Events section. According to the data, no participant in the primary trial experienced a grade 4 adverse event. The data indicates that the maximum grade for adverse events was 3 for several types of adverse events. (Refer to Adverse Events 1 section in the primary CTR.)"
    },
    "19c2c2d7-4c33-4842-9ed4-02cfae663ce2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00066573",
        "Secondary_id": "NCT01091454",
        "Statement": "There was 1 case of night blindness in the primary trial, and 0 in the secondary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nThe statement asserts that there was 1 case of night blindness (nyctalopia) in the primary trial but none in the secondary trial. However, according to the provided CTRs, there was only 1 case of night blindness reported in the primary trial (Adverse Events 1 section, under Ocular - Other) and none reported in the secondary trial (Adverse Events 1 section, under Nyctalopia). The statement matches the information for the primary trial but contradicts the secondary trial's data, which states no cases of night blindness."
    },
    "1fdaafdc-766b-488e-9cc4-cbcad74ade97": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01818063",
        "Secondary_id": "NCT00559507",
        "Statement": "In the primary trial and the secondary trial the only drugs administered orally are Doxorubicin and Veliparib.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs as follows:\n\nIn the primary trial, Arm 2 of Intervention 2 includes Veliparib given PO.\nIn the secondary trial, Intervention 1 includes Saracatinib given PO (but it is not mentioned in the primary CTR). However, the statement only makes reference to drugs administered in both trials, which are Doxorubicin and Veliparab, both of which are given orally, as stated in the CTRs. Therefore, the statement is entailed by the information provided."
    },
    "2e591059-5a3b-4a69-84c5-59d9604394a8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02040857",
        "Statement": "All genders are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the following part of the primary CTR: \"Men and both pre- and postmenopausal women are eligible.\" However, the secondary trial's statement \"All genders are eligible for the primary trial\" seems to be inclusive, but it overlooks the gender specification in the primary CTR."
    },
    "94a54cdf-4c1c-4994-929a-ced7a33f2b43": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00866905",
        "Statement": "Less than 1% of patients in the primary trial became depressed.",
        "Label": "Entailment",
        "explain": "The expert's statement, \"Less than 1% of patients in the primary trial became depressed,\" is contradicted by the CTR data provided. The CTR reports that 1/168 (0.60%) of patients in the primary trial experienced depression. Hence, the expert's statement, suggesting a lower percentage, does not harmonize with the clinical trial data."
    },
    "b217583e-2dbb-4951-8f73-cac08e365a7a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00562718",
        "Statement": "Patients with pacemakers or stents may be allowed to participate in the primary trial at their physician's discretion.",
        "Label": "Entailment",
        "explain": "The statement \"Patients with pacemakers or stents may be allowed to participate in the primary trial at their physician's discretion\" is not explicitly stated in the CTR for the primary trial. Therefore, it cannot be entailed or directly contradicted based on the provided information alone. However, the CTR does mention that patients with no \"clinically significant cardiac disease\" or \"uncompensated coagulopathy\" are eligible for the trial. It does not explicitly state that patients with pacemakers or stents are ineligible, but further clarification from the trial's investigators or protocol would be necessary to determine if they can participate at their discretion."
    },
    "42086f11-1fb1-4041-8d1e-e150d4cc09ea": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00304096",
        "Statement": "A minimum bodyweight of 50kg is required to participate in the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nJustification: \n\nThe primary trial's patient characteristics section clearly states that the bodyweight requirement is over 110 lbs (without clothes), which is equivalent to approximately 50 kg with clothing. However, this statement specifies a minimum bodyweight of 50 kg without specifying whether or not the requirement is with or without clothing. As a result, the statement contradicts the information in the CTR."
    },
    "0d75c493-58ce-4a45-8823-a9a1126751b3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00916578",
        "Statement": "the primary trial is testing a combination of chemotherapy and radiotherapy.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary trial description specifies a single arm study with open label Phase II design, meaning it is testing capecitabine monotherapy along with radiotherapy, not a combination of two distinct chemotherapies."
    },
    "d0d4e184-0764-4c28-9af7-4535c7ed1aad": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00303108",
        "Statement": "Cohort 2 of the primary trial produced marginally better results than cohort 1.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the provided data. Both cohorts had similar percentage ranges for the ORR, but cohort 2 had a slightly higher percentage of 31.0 (17.6 to 47.1) compared to cohort 1 with 30.8 (17.0 to 47.6). Therefore, cohort 2's marginally better results are evident from the ORR data in the CTRs."
    },
    "e45886af-1edd-4987-a280-2609a86fd3dd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02413320",
        "Statement": "Females over the age of 20 that have recieved chemotherapy in the last 4 weeks , are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial states that females with leukocytes less than 3,000/uL and absolute neutrophil count less than 1500/uL are not eligible for the trial. The statement by the expert includes females that have received chemotherapy in the last 4 weeks, who might have lower counts, making the statement contradictory to the eligibility criteria in the primary trial."
    },
    "c207ff16-b7d0-49e4-9177-0597044f3008": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03374995",
        "Statement": "Some the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks, others participants may have it administered by ubcutaneous injection.",
        "Label": "Contradiction",
        "explain": "Contradiction. According to the primary trial CTR, Group I patients receive topical keratin application at least BID (twice daily) until the end of radiation therapy (approximately 3-6 weeks). However, the expert statement suggests that some patients may receive it via subcutaneous injection, which is not mentioned in the CTR for the topical keratin administration in the primary trial."
    },
    "35234f08-cf01-478f-b739-600b5a6ea3d9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00550771",
        "Statement": "16/179  patients in the primary trial Experienced Cardiac Events, with the majority of those coming from cohort 2.",
        "Label": "Entailment",
        "explain": "The statement \"16/179 patients in the primary trial Experienced Cardiac Events, with the majority of those coming from cohort 2\" can be entailed by the information provided in the CTRs. \n\nJustification: \n\nAccording to the CTR, the number of participants who experienced cardiac events in cohort 1 (PLD Based Regimen) was 5, and in cohort 2 (Doxorubicin Based Regimen), the number was 11. Thus, the total number of participants who experienced cardiac events across both cohorts is 16. Since the statement mentions that 16 of the 179 participants experienced cardiac events, the statement is consistent with the CTR data. \n\nFurthermore, the statement mentions that \"the majority of those\" came from cohort 2. This is also consistent with the CTR data, as the number of participants who experienced cardiac events in cohort 2 was higher than in cohort 1. \n\nTherefore, the statement is entailed by the information in the CTRs."
    },
    "87adb323-6f56-4e1a-a04d-8437ac571eab": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01805089",
        "Statement": "Patients with Lactiferous duct carcinomas are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the primary trial's Inclusion Criteria, which explicitly lists ductal carcinoma in situ but not specifically lactiferous duct carcinoma as an eligible cancer diagnosis."
    },
    "94410f2c-9c1c-4130-b479-738e343ba9f7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT04080297",
        "Statement": "There is a least one route of administration shared by the interventions used in the primary trial and the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed. Both the primary and secondary trials involve interventions where some medications are given orally (caplets), specifically filgrastim and the Q-122 intervention."
    },
    "b811e872-90ef-4649-9c8d-f5488f316ccc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00671918",
        "Secondary_id": "NCT00571987",
        "Statement": "Patients with pure ductal carcinoma in situ (DCIS) are eligible for both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "explain": "Justification for entailment:\n\nThe primary trial includes patients with DCIS as a subtype of breast cancer under the inclusion criteria. Moreover, it specifies that these patients are eligible if lymph node biopsy is part of their surgical plan. The secondary trial includes patients with DCIS as a specific diagnosis under the inclusion criteria. Therefore, the statement that patients with pure ductal carcinoma in situ (DCIS) are eligible for both trials is entailed by the information in the given CTRs, as both trials allow participation of patients with DCIS.\n\nJustification for contradiction:\n\nThere is no contradiction between the statement and the provided CTRs, as the statement is entailed by the information in the CTRs. The statement neither asserts anything contradictory to the CTRs nor contradicts any specific parts of them."
    },
    "f66f4c30-2d39-4e29-876a-487bca9a8ccf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02835625",
        "Secondary_id": "NCT00486525",
        "Statement": "the primary trial and the secondary trial do not use any chemotherapy or radiotherapy in their interventions ",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the information provided in both the primary and secondary trial Intervention sections. There is no mention of chemotherapy or radiotherapy being used in either of the interventions described in either trial.\n\nPrimary Trial Intervention 1: Digital Breast Tomosynthesis, Digital Breast Tomosynthesis + Synthetic Mammography\nNo use of chemotherapy or radiotherapy is explicitly stated in the text. However, since the interventions only involve breast imaging techniques, it can be inferred that no chemotherapy or radiotherapy is used.\n\nPrimary Trial Intervention 2: Digital Mammography\nSimilar to the first intervention, no mention or indication of chemotherapy or radiotherapy use is present.\n\nSecondary Trial Intervention 1: Arm I: Yoga Therapy\nNo chemotherapy or radiotherapy is used in the yoga therapy intervention as it is a non-pharmacological intervention.\n\nSecondary Trial Intervention 2: Arm II: Wait-List\nThe wait-list group does not receive any intervention involving chemotherapy or radiotherapy, as stated in the provided description."
    },
    "34f50f3f-d6a7-4e22-84cb-6a41f0b8c1f6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00452673",
        "Statement": "7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities.",
        "Label": "Contradiction",
        "explain": "The statement \"7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities\" is entailed by the information in the CTRs. In Results 1, it is stated that the first cohort (DL 1) consisted of 6 participants and had 1 DLT. The next cohort (DL 2) had 3 additional participants and had 0 DLTs. So, in total, 7 participants in cohort 1 (the first 3 from DL 1 and the 4 from DL 2) experienced dose-limiting toxicities. Additionally, the statement in the CTR about the definition of DLT aligns with the description in the expert's statement."
    },
    "011991a5-724d-4b95-b9ab-9e1371d77368": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00086957",
        "Statement": "All of the patients in cohort 1 of the primary trial experienced Leukopenia and Febrile neutropenia.",
        "Label": "Contradiction",
        "explain": "The given statement \"All of the patients in cohort 1 of the primary trial experienced Leukopenia and Febrile neutropenia\" cannot be entailed based on the provided Clinical Trial Reports (CTRs) information. \n\nExplanation: \n\nThe statement suggests that all patients in cohort 1 of the primary trial had both Leukopenia (low white blood cell count) and Febrile neutropenia (low white blood cell count with fever). \n\nHowever, the CTRs only indicate that:\n\nPrimary Trial: \n- Cohort 1: 2 patients (100.00%).\n- Adverse Events for Cohort 1: \n  - Total: 2/2 (100.00%)\n  - Leukopenia: 1/2 (50.00%)\n  - Febrile neutropenia: 2/2 (100.00%)\n\nFrom the provided CTR data, only two patients in the cohort had both Leukopenia and Febrile neutropenia, but not all patients had both conditions. Therefore, the statement is contradicted by the data in the CTRs."
    },
    "8421197a-3a35-4738-b1c8-83cce0ac4115": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02896855",
        "Secondary_id": "NCT00171314",
        "Statement": "the secondary trial recorded more total occurences of cardiac adverse events than the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the data in the provided CTRs. The primary trial recorded 4 instances of cardiac adverse events (out of a total of 120 participants), whereas the secondary trial recorded only 1 instance (out of a total of 254 participants). Therefore, the primary trial had a higher number of cardiac adverse events than the secondary trial."
    },
    "d09091f1-3fc5-498b-8c59-4678590c8464": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Secondary_id": "NCT01498458",
        "Statement": "Although there is a much higher percentage of patients with Enterocolitis in the secondary trial than in cohort 1 of the primary trial, no robust comparisons can be made due to the significant differences in cohort sizes.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the information in the CTRs as the statement mentions \"Enterocolitis\" which is not mentioned anywhere in either the primary or the secondary trial's adverse events sections. Therefore, no comparison can be made based on the provided data."
    },
    "203a2e22-cae9-4bfe-b82d-6dc665a66ce6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00821886",
        "Statement": "Patients prescribed with bisoprolol or labetalol to treat atrial fibrillation are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the primary trial's exclusion criteria, which specify that patients with uncontrolled arrhythmias are excluded from participation (Section: Exclusion Criteria). However, the statement only mentions atrial fibrillation (AF), which is a type of arrhythmia. Bisoprolol and labetalol are beta-blockers that are commonly used to manage AF symptoms and reduce the risk of cardiovascular events. The primary trial does exclude patients with a history of significant cardiac disease, but it does not specifically mention beta-blockers as a reason for exclusion, making the statement contradictory to the provided CTR."
    },
    "f4909215-5b14-42d9-bda4-4d112cf2a108": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02574455",
        "Statement": "More than 1/3 patients in cohort 1 of the primary trial experienced an adverse event.",
        "Label": "Contradiction",
        "explain": "The statement \"More than 1/3 patients in cohort 1 of the primary trial experienced an adverse event\" is entailed by the information in the CTR as the total number of adverse events in cohort 1 of the primary trial was 69/258 (26.74%), which is more than 1/3 of the total number of participants in that cohort."
    },
    "9c27202c-7090-4be5-840e-351992aeb81c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093808",
        "Secondary_id": "NCT00394082",
        "Statement": "the primary trial and the secondary trial reported the same number of dehydrated patients during the studies.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nThe primary trial reported 1 dehydrated patient out of 46 participants (2.17%), while the secondary trial reported 2 dehydrated patients out of 50 participants (4.00%). Therefore, the statement that \"the primary trial and the secondary trial reported the same number of dehydrated patients during the studies\" is not entailed by the information presented in the CTRs."
    },
    "fc7d8ffd-9896-4806-a095-d435cde83c88": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00528567",
        "Secondary_id": "NCT01196052",
        "Statement": "The total number of patients affected by adverse events in cohort 2 the primary trial, is larger than the cohort size of the secondary trial.",
        "Label": "Entailment",
        "explain": "Contradiction.\n\nExplanation:\n\nThe statement asserts that \"The total number of patients affected by adverse events in cohort 2 of the primary trial, is larger than the cohort size of the secondary trial.\" However, this is contradicted by the data in the CTRs since the total number of patients in cohort 2 of the primary trial is smaller (1288) than the cohort size of the secondary trial (148). Therefore, it is not entailed by the information provided."
    },
    "23116aca-0064-4426-b147-7af688a82443": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Secondary_id": "NCT02287675",
        "Statement": "Men suffering from Ulcerative colitis are excluded from the primary trial, but eligible for the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary CTR as men are explicitly excluded from the inclusion criteria. There is no information related to ulcerative colitis in either the primary or secondary CTRs."
    },
    "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005879",
        "Secondary_id": "NCT01217385",
        "Statement": "The only criterias for entry to the primary trial and the secondary trial is that patients must be female, over the age of 21 and british.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted, according to the provided Clinical Trial Reports (CTRs), as there are numerous eligibility requirements beyond just being female, over the age of 21, and British for both trials.\n\nFor the primary trial, patients must have specific conditions related to breast disease, hormone receptor status, hematologic, hepatic, renal, cardiovascular, ovarian, prior concurrent therapy, and other factors. (CTR sections: DISEASE CHARACTERISTICS, PATIENT CHARACTERISTICS, HORMONE REPLACEMENT THERAPY, PRIOR CONCURRENT THERAPY)\n\nFor the secondary trial, patients must have a pathologically confirmed diagnosis of invasive breast cancer, tumor size greater than 2cm, no contraindications for primary chemotherapy, planned definitive breast surgery following completion of neoadjuvant therapy, normal organ and marrow function, and other specified conditions. (CTR section: INCLUSION CRITERIA)\n\nTherefore, the stated criterion of just being female, over the age of 21, and British does not harmonize with the comprehensive descriptions outlined in the CTRs, making it a contradiction."
    },
    "98850daf-738c-4005-b476-8c5479ad3b79": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00033514",
        "Statement": "Mark has HER2 positive breast cancer, he is eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed in the CTR for the primary trial. According to the inclusion criteria, women with HER2 positive breast cancer are eligible to participate. Mark's condition of having HER2 positive breast cancer fulfills this requirement, making him eligible for the trial."
    },
    "fd8ddc92-4625-4392-b7ef-0ea218e2eb1c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00916578",
        "Statement": "the primary trial is testing a combination of capecitabine once daily with radiotherapy.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted based on the CTR descriptions provided. In the primary trial, patients received capecitabine 825 mg/m2 bid, and one of the doses was taken 2 hours before radiotherapy. In the secondary trial, there's no mention of capecitabine being given once daily, and the statement implies that it is taken in combination with radiotherapy every day. The discrepancy lies in the dosing frequency of capecitabine and, thus, the statement contradicts the information provided in the CTRs."
    },
    "a4ed4cc0-9444-4a5d-863c-578fd42b8794": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00425854",
        "Statement": "Intervention of Cohort B is described as Afatinib 50 mg, taken orally, bi-weekly.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted. In the primary CTR, the intervention for Cohort B specifies that patients receive an oral dose of Afatinib 50 mg once daily (qd), not bi-weekly as stated in the expert's claim."
    },
    "a4dcb9b6-7b6f-4467-a159-d6e770f6762f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01313039",
        "Secondary_id": "NCT01031446",
        "Statement": "Nursing patients are not eligible for the primary trial or the secondary trial, due to potential harm to the nursing infant from the study interventions.",
        "Label": "Entailment",
        "explain": "The statement is entailed in the primary and secondary CTRs.\n\nJustifications: \n\nIn the primary CTR, under exclusion criteria, it is mentioned that \"patients who are pregnant or breast-feeding are excluded from the study.\" This directly implies nursing patients are also excluded.\n\nIn the secondary CTR, under patient characteristics, it is mentioned that \"Fertile patients must use effective barrier contraception during and for 3 months after completion of study treatment.\" This further indicates that nursing patients should not participate in the study as they are not using effective contraception to prevent nursing.\n\nTherefore, since the statement aligns with the CTRs and is not contradictory, it is entailed."
    },
    "be1c82e6-200d-4bef-b723-c78655fa40e5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00291694",
        "Statement": "the primary trial does not specificy the route of administration of its intervention.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the provided CTRs.\n\nExplanation:\n\nThe CTRs do not include information about the route of administration for the interventions specified (celecoxib and placebo) in the primary and secondary trials. Consequently, the statement that \"the primary trial does not specify the route of administration of its intervention\" aligns with the information provided in the CTRs."
    },
    "790047b1-43e3-486e-b41c-eaa89026eae7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02447328",
        "Statement": "In the primary trial 11.1% of patients had serious adverse events, no patients had serious  Adverse Drug Reactions, and over half of patients had Unexpected adverse events.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary CTR reports 11.1% for serious adverse events (AEs), but it also reports 0% for serious Adverse Drug Reactions (ADRs). Therefore, the statement's claim that \"no patients had serious Adverse Drug Reactions\" contradicts the CTR. The remaining claim about over half of patients having unexpected adverse events (71.6%) aligns with the data in the CTR (24.7%-35.5% for unexpected ADRs)."
    },
    "fc8ed290-e2b3-4eea-a837-d369dcd9b5da": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00875979",
        "Statement": "None of the 3 patients in cohort 1 of the primary trial experienced any adverse events.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR data in Adverse Events 1, as the number of adverse events for each type, including the total, is reported as zero for all patients in cohort 1 of the primary trial."
    },
    "207b0895-91de-4238-8d50-e2b8b7420fb0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00559845",
        "Secondary_id": "NCT00426556",
        "Statement": "In total there were more adverse events in the secondary trial than in the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nJustification:\n\nThe statement \"In total there were more adverse events in the secondary trial than in the primary trial\" is contradicted by the provided CTRs. The data shows that there were fewer adverse events in the secondary trial compared to the primary trial. Specifically, in the primary trial, there were a total of 8 adverse events out of 54 participants, whereas in the secondary trial, there were a total of 3 adverse events out of 17 participants."
    },
    "1340769c-b55c-480c-a4c4-130034e128ce": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00317720",
        "Statement": "Patients must have at least 1 prior treatment with trastuzumab to be eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Patients must have at least 1 prior treatment with trastuzumab to be eligible for the primary trial\" is entailed by the CTR as it states \"History of trastuzumab resistance, defined as the development of progressive disease after trastuzumab-based therapy for metastatic breast cancer. Patients may not have received more than 2 prior trastuzumab-based regimens and one lapatinib-based regimen (either as single agent or in combination with chemotherapy) for metastatic breast cancer.\" This implies that patients must have undergone at least one prior trastuzumab treatment before participating in the trial."
    },
    "a4d6e27f-737b-4597-86e1-79b3f064cbee": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02694029",
        "Statement": "Candidates for the primary trial are expected to be capable of holding their breath underwater for 30 seconds.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial's inclusion criteria state that patients must be able to maintain a 30 second breath hold. However, the expert's statement suggests that candidates for the primary trial are expected to be capable of holding their breath underwater for 30 seconds, which is an entirely different context. The CTR does not indicate that patients are required to hold their breath underwater during the trial."
    },
    "3edf0cf2-62ea-4ac6-82aa-2bb1566c6c43": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00887575",
        "Secondary_id": "NCT01610284",
        "Statement": "Cohort 1 of the secondary trial had more than 3x the cohort size of cohort 1 of the primary trial.",
        "Label": "Entailment",
        "explain": "The statement does not contradict the provided CTRs, as the information about adverse events does not influence the statement regarding the cohort sizes in either trial."
    },
    "030eded8-6513-4028-b1fe-fefd6dd388ad": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02429427",
        "Statement": "Patients with a platelet count of 50,0000 x 109/l are not eligible for the primary trial",
        "Label": "Contradiction",
        "explain": "Contradicted. The Primary Trial's inclusion criteria specify that Platelets must be greater or equal to 100 x 109/l."
    },
    "412d3ee2-bbfb-4e24-b159-684ae144e742": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00054275",
        "Statement": "A patient with minimal symptoms but a severe obstruction of the left main coronary artery would be unable to participate in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary CTR as it specifies no cardiac arrhythmia or unstable angina pectoris, which implies that patients with stable coronary artery obstructions, including minimal symptoms with severe obstructions of the left main coronary artery, may be eligible to participate."
    },
    "d1d77877-9c85-41c8-9eca-6fd75b254a15": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00768222",
        "Statement": "Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan, she cannot take part in the primary trial due to her age.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the information in the primary trial's Inclusion and Exclusion Criteria sections. The statement mentions Rachel being 19 years old with skin ulcerations and allergic reactions to triclosan as reasons for her inability to participate in the primary trial. However, the Inclusion Criteria state that the participants must be 18 years of age or older, and the Exclusion Criteria mention having skin ulceration and known allergy or intolerance to triclosan as reasons for exclusion. These criteria contradict the statement, as Rachel does not meet the age requirement and possesses the specified exclusion criteria."
    },
    "c32d1b74-07ab-4afb-9db6-878e20727661": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02279108",
        "Statement": "Adult Patients with Histologically proven Unifocal HER2- infiltrating breast cancer that have not had Previous lumpectomy or same side mammary reduction and have no Contra-indication to surgery are excluded from the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary trial's inclusion and exclusion criteria. The statement specifies that the adult patients must have unifocal HER2-infiltrating breast cancer and no previous lumpectomy or same side mammary reduction, which aligns with the inclusion criteria. Moreover, the statement excludes patients with contra-indication to surgery, which is consistent with the exclusion criteria in the primary trial."
    },
    "ba0c0dc6-826b-426f-8738-eec23e47f6b0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03045653",
        "Statement": "Sharone had a hip replacement 2 months prior, she is not elgible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Sharone had a hip replacement 2 months prior, she is not eligible for the primary trial\" is contradicted by the inclusion criteria of the primary trial, specifically the exclusion of \"major surgery (excluding placement of vascular access) within 4 weeks before study treatment.\" However, in this case, the surgery was performed more than 4 weeks before the study treatment and should not disqualify Sharone from participation."
    },
    "77982c81-d147-48d9-909c-18b9a98224e9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT02129556",
        "Statement": "Only 1 type of infection recorded across the duration of both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement can be contradicted by the provided CTRs.\n\nJustification:\n\nIn the Primary Trial, there are two types of infections recorded - Upper respiratory tract infection and Infection.\n\nIn the Secondary Trial, there is only one type of infection recorded - Gastroenteritis.\n\nTherefore, the statement that \"Only 1 type of infection recorded across the duration of both the secondary trial and the primary trial\" is incorrect according to the given CTRs."
    },
    "7f1af51d-e22b-4285-aea4-3dc80c3ab2ec": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00687440",
        "Secondary_id": "NCT01307891",
        "Statement": "Results from the primary trial and the secondary trial indicate Abraxane + Tigatuzumab produce better ORR than Caelyx, Docetaxe and Trastuzumab.",
        "Label": "Contradiction",
        "explain": "The statement can be entailed based on the following information in the CTRs:\n\n1. From the primary trial, the objective response rate (ORR) for the Arm/Group Title: Caelyx, Docetaxel, Trastuzumab was 45.0% (11 out of 26 participants) and for the secondary trial Arm/Group Title: Abraxane + Tigatuzumab, it was 45.0% (17 out of 39 participants) according to Result 1. Although their ORRs seem identical, it's important to note that the patient populations, treatment protocols, and measurement time frames can differ between trials (e.g., different baseline demographics, different assessment methods, or varying time points for response evaluation). Therefore, further analysis, such as statistical tests, would be needed to definitively determine if these ORRs represent significantly different treatment outcomes.\n\n2. Result 2 from the secondary trial shows an ORR of 61.1% (13 out of 21 participants) for the Arm/Group Title: Abraxane Alone. Comparing this ORR with those of the primary trial arms, Abraxane + Tigatuzumab and Caelyx, Docetaxel, Trastuzumab, it is evident that Abraxane + Tigatuzumab seems to have a higher ORR than Caelyx, Docetaxel, and Trastuzumab based on the given data.\n\nTherefore, according to the provided CTR data, the statement \"Results from the primary trial and the secondary trial indicate Abraxane + Tigatuzumab produce better ORR than Caelyx, Docetaxel, and Trastuzumab\" can be considered entailed. However, it's essential to note that further analyses and comparisons would be necessary to confirm these findings and account for potential differences in patient populations and treatment regimens."
    },
    "2e03f6f1-0d4f-4ebf-8781-20918d70d78f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165605",
        "Statement": "A 56 year old patient with a masectomy would not be eligible for the primary trial",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the primary trial's inclusion criteria, which state that \"Intact breast (not surgically absent)\" is a requirement for participation. The patient described in the statement underwent a mastectomy, which is a surgical removal of the breast, and therefore would not meet this inclusion criterion."
    },
    "57e74ef2-f170-47bd-a908-2a7b3cec150d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00482391",
        "Statement": "Patients with No QT prolongation are excluded from the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the Primary Trial's ELIGIBILITY CRITERIA, where it is specified that \"No QT prolongation (> 500 ms)\" is an exclusion criterion."
    },
    "b5957a75-140f-445b-99dc-199b8182b8ed": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01805089",
        "Statement": "pre-menopausal patients with Lactiferous duct carcinomas are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradiction. \n\nJustification: \n\nThe primary trial inclusion criteria state that patients must be postmenopausal (CTR, Inclusion Criteria), whereas the expert statement asserts that pre-menopausal patients are eligible. Therefore, the expert statement contradicts the primary trial inclusion criteria."
    },
    "142cc983-b0cc-4f9f-b3ef-4eb57e2a317b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00486525",
        "Statement": "The difference between the two cohorts of the primary trial is that cohort 1 received higher doses of IMGN853, whereas cohort 2 received lower doses more frequently.",
        "Label": "Contradiction",
        "explain": "Contradicted. The CTRs describe different interventions for each cohort: one receiving yoga therapy and the other being wait-listed. The statement makes no reference to the interventions and instead focuses on the dosing of a drug (IMGN853), which is not mentioned in the provided CTRs."
    },
    "f57350c2-ac90-47ea-92b4-d903509bf07a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03252431",
        "Statement": "patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time. There was no recorded difference whatsoever. ",
        "Label": "Contradiction",
        "explain": "To assess the entailment of the expert's statement, we need to examine if the CTR data supports the claim of \"no recorded difference in time spent with Grade 4 Neutropenia between the F-627 and Neulasta arms.\" \n\nFirst, let's compare the mean duration of Grade 4 Neutropenia for each arm:\n\nF-627 arm: Mean (SD) = 0.2 (0.51) days\nNeulasta arm: Mean (SD) = 0.2 (0.45) days\n\nAlthough the standard deviation differs slightly, the means are almost identical, suggesting minimal difference between the groups. The expert's statement appears to be entailed by the data in both the F-627 and Neulasta Results sections.\n\nJustification for the entailment: The expert's statement aligns with the data in the CTR, stating no difference in the duration of Grade 4 Neutropenia between the two treatment arms."
    },
    "77c61307-567d-4ac2-a7f7-85feffd30473": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00167414",
        "Statement": "Patients do not need to have a known hormone receptor status to participate in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the Primary Trial's Inclusion Criteria which states \"No more than 5 metastatic sites involving one or more different organs (liver, lung or bone).\" This condition implies that patients must have known metastatic sites, and therefore, a hormone receptor status is likely to be determined during the diagnostic workup for metastases. Thus, the statement \"Patients do not need to have a known hormone receptor status to participate in the primary trial\" contradicts the provided CTR."
    },
    "35dd977f-53d8-4400-b5cb-34caaa938e78": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00764322",
        "Statement": "The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 mg/m2 over 4 months.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted. The CTR does not provide the average increase in endoxifen concentration for the Ultra-rapid Metabolizers group over 4 months. It only provides the mean (standard deviation) endoxifen concentrations at baseline and after 4 months for this group. No calculation of average increase is given in the CTR."
    },
    "54554da5-e67f-4da5-819b-a85b7bc5d52c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00444535",
        "Statement": "Less than 1/3 participants in the primary trial achieved Progression-free Survival Rate After 12 Weeks of Study Treatment.",
        "Label": "Entailment",
        "explain": "Contradiction\n\nJustification:\n\nThe statement, \"Less than 1/3 participants in the primary trial achieved Progression-free Survival Rate After 12 Weeks of Study Treatment,\" contradicts the CTR data in Results 1. In this CTR, 69.2% (36 of 52) of participants in the Lapatinib + Bevacizumab arm did not show disease progression or death by Week 12. This is more than 1/3 of the participants, as the statement suggests. The CTR data directly contradicts the expert's statement."
    },
    "592edd64-7841-4c19-ba75-583066308137": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00343863",
        "Statement": "On days 1-7 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV, oral cyclophosphamide, dexamethasone IV or orally and ondansetron IV.",
        "Label": "Contradiction",
        "explain": "The statement is entailed, as the CTR for both Intervention 1 and Intervention 2 specify that all patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7. Additionally, patients receive dexamethasone IV or orally on day 1 and ondansetron IV or palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride). This means that Cohort 1 in the primary trial receives all the mentioned treatments over the 7-day period."
    },
    "a1d207c8-2d57-4c49-89fa-60ceacf65829": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00228943",
        "Statement": "Clinically depressed patients are not able to participate in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Clinically depressed patients are not able to participate in the primary trial\" is contradicted by the information in the Primary Trial's Inclusion Criteria section, specifically, there is no exclusion criterion related to depression in the provided CTR."
    },
    "4a8f0562-355b-4a68-8790-c283d93ce766": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093808",
        "Secondary_id": "NCT00394082",
        "Statement": "the primary trial and the secondary trial reported the same percentage of dehydrated patients during the studies.",
        "Label": "Contradiction",
        "explain": "Both trials reported 1/46 dehydration cases in the primary trial and 1/50 dehydration cases in the secondary trial. Therefore, the percentage of dehydrated patients in the primary trial (2.17%) is equal to the percentage in the secondary trial (2.00%). The statement is entailed by the provided data."
    },
    "04a9b8af-d01f-4090-97e2-0c0fcf8f7fe4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02491892",
        "Secondary_id": "NCT00887575",
        "Statement": "Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial\" is entailed by the information in the CTRs. \n\nJustification: \nThe CTRs provide the number of adverse events for both cohorts, including the number of cases for diarrhea and dyspepsia in each trial. Cohort 1 of the secondary trial had 2 cases of diarrhea and 1 case of dyspepsia, whereas in the primary trial, there was 0 case of diarrhea and 0 case of dyspepsia in cohort 1. This means that cohort 1 in the secondary trial experienced more instances of both diarrhea and dyspepsia than the cohort in the primary trial."
    },
    "3cd353ed-af0d-4356-8f45-efc1e91a2a0d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02878057",
        "Statement": "Patients that are ambulatory and capable of all selfcare but unable to carry out any work activities, are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "Contradiction. The primary trial's inclusion criterion specifies that patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 are eligible. According to the Performance Status Scale used by ECOG, a performance status of 0 or 1 indicates that the patient is fully ambulatory and capable of all self-care but confined to bed or chair more than 50% of waking hours in a day (Performance Status: A Guide for Clinicians. National Cancer Institute. <https://www.cancer.gov/about-nci/organization/ccg/research/education/pdq/comp/ps>). However, the statement in question specifically excludes patients who are ambulatory but unable to carry out any work activities. This definition does not align with the ECOG performance status criteria used in the primary trial and thus contradicts the information presented in the CTR."
    },
    "b8473ae8-11c9-4578-aab8-ee96e6287715": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00580333",
        "Secondary_id": "NCT00934856",
        "Statement": "Candidates must have a life expectancy exceeding 3 months to particpate in the primary trial, there is no mimimum life expectancy define for the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement should be contradicted. The primary trial's inclusion criteria specify a life expectancy of at least 12 weeks (not exceeding 3 months is exclusion), whereas the secondary trial does not have a minimum life expectancy stated in the provided inclusion criteria."
    },
    "4243dc45-5a64-486d-ae2a-11448db00dcf": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00246090",
        "Secondary_id": "NCT00266799",
        "Statement": "Cohort 1 of the primary trial 15% less total adverse events than cohort 2 of the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Cohort 1 of the primary trial has 15% less total adverse events than cohort 2 of the secondary trial\" can be entailed based on the provided CTR data. \n\nExplanation:\n\nTo calculate the difference in total adverse events between cohort 1 of the primary trial and cohort 2 of the secondary trial, we need to find the percentage difference in their respective total adverse event counts. \n\nIn the primary trial, the total number of adverse events in cohort 1 is 88. In the secondary trial, the total number of adverse events in cohort 2 is 46. \n\nTo find the difference, we can subtract the number of adverse events in cohort 2 from the number in cohort 1 and then divide it by the number of adverse events in cohort 1, and finally multiply the result by 100 to get the percentage difference.\n\nPercentage difference = (Number of adverse events in cohort 1 - Number of adverse events in cohort 2) / Number of adverse events in cohort 1 * 100%\n\nPercentage difference = (88 - 46) / 88 * 100% = 46.61%\n\nSince the percentage difference is negative (-46.61%), we need to take its absolute value to get the actual difference.\n\nAbsolute difference = |Percentage difference| = |-46.61%| = 46.61%\n\nThe absolute difference of 46.61% is greater than 15%. Therefore, the statement that cohort 1 of the primary trial has 15% less total adverse events than cohort 2 of the secondary trial is contradicted by the data provided in the CTRs.\n\nHowever, if the statement was \"Cohort 1 of the primary trial has 15% fewer total adverse events than cohort 2 of the secondary trial\", the statement would be entailed based on the CTR data as the number of adverse events in cohort 1 is indeed fewer than in cohort 2, and the difference is around 15%.\n\nThus, the given statement \"Cohort 1 of the primary trial has 15% less total adverse events than cohort 2 of the secondary trial\" is contradicted by the data provided in the CTRs, and the statement \"Cohort 1 of the primary trial has 15% fewer total adverse events than cohort 2 of the secondary trial\" is entailed.\n\nTherefore, the statement \"Cohort 1 of the primary trial has 15% fewer total adverse events than cohort 2 of the secondary trial\" is the correct interpretation of the expert's statement based on the given CTR data."
    },
    "fb5fc14d-2bd9-4a02-9f6a-635c0055a8d5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00073528",
        "Secondary_id": "NCT00191152",
        "Statement": "cohort 1 of the secondary trial had a much longer median PFS than cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "explain": "To assess the entailment of the statement, we need to compare the median PFS between cohort 1 of the primary trial (Placebo + Letrozole 2.5 mg) and cohort 1 of the secondary trial (Gemcitabine Plus Docetaxel). However, the provided CTR data only includes the number of participants with PFS and the median PFS for each arm in the secondary trial. Therefore, we cannot directly compare the PFS between the two trials based on the provided information.\n\nThus, the statement is contradicted, as there is insufficient information to establish whether it is entailed by the given CTR data.\n\nIf the expert's statement was about the median TTDP (Time to Disease Progression) instead, the comparison could be made based on the provided data, and a definitive answer could be given. But since the statement pertains to PFS, it contradicts the available data."
    },
    "f616e3d8-6c1a-4b99-ac79-ea87895e37b7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00902330",
        "Secondary_id": "NCT00952731",
        "Statement": "Cohort 2 of the primary trial is the control group and cohort 1 is the control group in the secondary trial.",
        "Label": "Entailment",
        "explain": "Contradicted \n\nExplanation: \n\nIn the primary trial, cohort 1 (Arm I) receives active treatment with CES and cohort 2 (Arm II) receives a sham intervention. In the secondary trial, cohort 1 (Treatment Gel + Oral Placebo) receives active treatment with afimoxifene gel and oral placebo, while cohort 2 (Placebo Gel + Oral Treatment) receives placebo gel and active treatment with tamoxifen. The statement asserts that both cohorts are controls in each trial, which is contradicted by the information provided in the CTRs."
    },
    "2f700407-8baf-4e5f-8fc0-378a294512f5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01313039",
        "Secondary_id": "NCT01031446",
        "Statement": "Nursing patients are not eligible for the primary trial or the secondary trial, due to potential harm to the father from the study interventions.",
        "Label": "Contradiction",
        "explain": "The statement \"Nursing patients are not eligible for the primary trial or the secondary trial, due to potential harm to the father from the study interventions\" is contradicted by both CTRs.\n\nThe primary CTR explicitly states that \"Patients must have the ability to understand and willingness to sign an English or a Spanish language written informed consent document.\" (ELIGIBILITY CRITERIA section) and does not mention any exclusion for nursing patients. The secondary CTR similarly states that \"Patients must be able to swallow and retain oral medication.\" and \"Fertile patients must use effective barrier contraception during and for 3 months after completion of study treatment.\" (PATIENT CHARACTERISTICS section) and does not mention any exclusion for nursing mothers either. Therefore, there is no justification for the statement based on the given CTRs."
    },
    "cebee448-235d-49ff-8e87-56639399548b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02287675",
        "Statement": "Informed consent is optional for entry in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary CTR. The CTR explicitly states that the subject must provide written informed consent before participating in the study and obtaining HIPAA authorization. Therefore, the statement \"Informed consent is optional for entry in the primary trial\" is in contradiction to the provided information."
    },
    "d3f0dd2f-a5b9-4ff4-8a6b-65c9947cb710": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01073865",
        "Statement": "Females over the age of 18, whose last period was 2 years prior to randomisation are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradiction. \n\nJustification: \n\nThe primary trial's inclusion criteria state that females must have their last menstruation within 1 year of randomization. The expert's statement suggests a 2-year window, which exceeds the primary trial's criteria, making it in contradiction to the information provided in the CTR."
    },
    "7a981da3-dc7f-4e1f-ae5b-26e5399ba2a5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187744",
        "Statement": "sepsis, due to the presence of an implanted device was a common adverse event in the primary trial",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the data in the CTRs. Although both trials report an instance of device related sepsis, the frequency of this adverse event is relatively low in both trials, and it is not the most common adverse event reported in either trial. In the primary trial, the total adverse event rate was 6.19%, and only one case of device related sepsis occurred. In the secondary trial, the total adverse event rate was 5.36%, and again, one case of device related sepsis was reported. These frequencies do not support the expert's claim that sepsis due to an implanted device was a common adverse event in the primary trial."
    },
    "af677d94-a376-42ea-93fe-91963a071199": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00676793",
        "Secondary_id": "NCT01931163",
        "Statement": "Patients with dysphagia cannot participate in the secondary trial, but may be eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Patients with dysphagia cannot participate in the secondary trial, but may be eligible for the primary trial\" can be entailed by the given CTRs if we assume that \"dysphagia\" refers to a swallowing disorder that does not interfere with the ability to undergo breast biopsies as required by the study protocol in the primary trial. However, if dysphagia poses a risk for administering oral medication (as in the secondary trial), then it would contravene the eligibility criteria for both trials. Specifically, for the primary trial, under the \"Participant Must Be Able to Swallow and Retain Oral Medication\" inclusion criteria; for the secondary trial, under the \"Able to swallow and retain oral medication\" inclusion criteria."
    },
    "6579e25e-8dcf-44b5-a50d-7c84672cba89": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981305",
        "Statement": "Only people who have previously been diagnosed with cancer and are currently receiving ongoing treatment for their primary tumor are eliglbe for the primary trial, as long as they are over the age of 20.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTR of the primary trial. The statement's condition that participants have been diagnosed with cancer and are currently receiving ongoing treatment aligns with the CTR's inclusion criteria that participants are breast cancer survivors and have undergone operation and chemotherapy. The statement's age requirement (being over 20 years old) also matches the CTR's inclusion criteria.\n\nTherefore, the statement is entailed by the CTR of the primary trial."
    },
    "1ac9c526-91e6-4e0d-8570-0a78e3ec78db": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00451555",
        "Statement": "Cohort 1 and 2 of the primary trial recorded exactly the same percentage of each type of adverse events.",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nExplanation:\n\nThe provided CTRs report different rates of adverse events for each cohort in the primary trial. For example, the percentage of patients experiencing myocardial infarction is 1.06% in cohort 1 and 2.56% in cohort 2. Therefore, the statement that \"Cohort 1 and 2 of the primary trial recorded exactly the same percentage of each type of adverse events\" is contradicted by the data in the CTRs."
    },
    "79c07f36-daf9-4844-ad8a-f362fbbaaf81": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00767520",
        "Statement": "Both cohorts of the primary trial reported the same precentage of patients vomiting during the trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed based on the given CTR information. The primary trial reported 2/79 (2.53%) cases of vomiting, and the secondary trial reported 2/76 (2.63%) cases of vomiting. The percentage difference is insignificant (within rounding error), and both trials report a similar percentage of patients experiencing vomiting."
    },
    "bced9c90-5ce0-416c-a168-f9e74359b332": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01381874",
        "Statement": "The Exemestane group in the primary trial had a better median Tumor Response than the Abiraterone Acetate + Prednisone group, however the patient with the maximum TR was in the Abiraterone Acetate + Prednisone group.",
        "Label": "Contradiction",
        "explain": "The given statement is not directly entailed by the provided CTR information, as it goes beyond the data presented. The CTRs provide median PFS data for each group but do not mention tumor response or the individual participant with the maximum tumor response. The statement's comparison of median Tumor Response and the maximum TR between groups is not directly supported by the data given. However, the statement does not contradict the CTR information, as both trials' results are within the same time frame and neither treatment resulted in a complete lack of disease progression for all patients."
    },
    "ce88c763-0062-48dc-b5e1-f81af32f2628": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00593827",
        "Secondary_id": "NCT00478257",
        "Statement": "Patients with HER2 negative BC are eligible for both the primary trial and the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed. \n\nJustification: \nBoth primary and secondary trials include patients with HER2 negative breast cancer as an inclusion criteria. \n\nPrimary Trial: Inclusion Criteria: Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer.\n\nSecondary Trial: Inclusion Criteria: stage I-III breast cancer, adjuvant or neoadjuvant anthracycline-based chemotherapy. The term \"breast cancer\" in the secondary trial includes HER2 negative breast cancer as it is a subtype of breast cancer.\n\nTherefore, patients meeting the HER2 negative breast cancer criterion in both trials are eligible for participation in both trials."
    },
    "982469a3-2fc1-40b4-92a9-d531b6c0ab5d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00296036",
        "Statement": "the primary trial administers the Urea/Lactic Acid Cream topically, twice daily, and the placebo is administered orally once a day.",
        "Label": "Contradiction",
        "explain": "The statement is contradictory to the provided CTRs. In the primary trial, patients receive Urea/Lactic Acid Cream applied to the palms and soles twice daily, while in the secondary trial, no information about the administration route or frequency of the placebo in the secondary trial is mentioned. However, the statement asserts that the primary trial uses oral administration for the placebo, and the secondary trial uses topical application for the Urea/Lactic Acid Cream, which contradicts the given information in the CTRs."
    },
    "71d16ba8-2cc9-4cb0-aa14-6b6adf0dd625": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334802",
        "Secondary_id": "NCT00167414",
        "Statement": "There is no age limit for either the secondary trial or the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs since there is no age limitation mentioned in both the primary and secondary trials' inclusion criteria."
    },
    "e6901a45-4c97-4618-bfcb-6f6dd046ef0c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00143390",
        "Statement": "In the primary trial There was less than 3 months difference between the maximum and minimum recorded TTP of the Exemestane group.",
        "Label": "Contradiction",
        "explain": "The statement \"In the primary trial, there was less than 3 months difference between the maximum and minimum recorded TTP of the Exemestane group\" is entailed by the provided CTR information. \n\nJustification: \nThe CTR reports that the median TTP for the Exemestane group was 13.8 months (95% CI: 10.8-16.5) with a time frame of up to 2008 days. The maximum TTP within this group would be close to, but not exceed, the median. Since the median is the midpoint of the data distribution, there will always be some participants with shorter and longer TTP values around this point. The difference between the maximum and minimum TTP values within the Exemestane group can be calculated as follows: Maximum TTP - Minimum TTP = (13.8 months + 16.5 months) / 2 - 10.8 months = 1.9 months. This falls under the 3 months difference mentioned in the statement."
    },
    "e94ea1b1-1816-4bac-b1ca-f6d66b95702a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00004888",
        "Statement": "Most the primary trial participants suffered Grade 3 or above Cardiotoxicity Events After Cycle 8 of the study.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the information in the CTRs. According to Results 1 and Results 2, no participant in either arm suffered a Grade 3 Cardiotoxicity Event after Cycle 8, and the total number of participants with Grade 3 Cardiotoxicity Events is zero in both trials. The statement's claim that \"most\" participants suffered Grade 3 or above events contradicts the actual data presented in the CTRs."
    },
    "0e3c62f7-a152-4370-9d09-b69a715c0a21": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01216319",
        "Secondary_id": "NCT03346161",
        "Statement": "the secondary trial and the primary trial are evaluating surgical interventions for breast reconstruction for patients that have had mastectomies.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. Both trials in the description focus on breast reconstruction interventions for patients who have had mastectomies. In the Primary Trial, the intervention is a specific surgical method using the Biodesign Nipple Reconstruction Cylinder. In the Secondary Trial, the interventions are using a decision tool (BREASTChoice) or a surgical care booklet (American Society of Plastic Surgeons booklet) which are considered as enhanced usual care for surgical interventions. Thus, both trials evaluate surgical interventions for breast reconstruction for patients that have had mastectomies."
    },
    "7191b5e9-4f29-4261-8a64-51653ee151fe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00410813",
        "Statement": "In the primary trial, Dasatinib, 70 mg, Twice Daily results in a better median PFS than Dasatinib, 100 mg, Daily.",
        "Label": "Entailment",
        "explain": "The expert's statement \"In the primary trial, Dasatinib, 70 mg, Twice Daily results in a better median PFS than Dasatinib, 100 mg, Daily\" is entailed by the CTR data. The median PFS for the Dasatinib, 70 mg, Twice Daily arm is 15.3 (8.7 to 20.1) weeks, while for the Dasatinib, 100 mg, Daily arm it is 10.3 (8.4 to 16.7) weeks. Therefore, a longer median PFS is observed in the Dasatinib, 70 mg, Twice Daily arm."
    },
    "639ccada-370d-4709-bdd7-1b29bbcc8769": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01597193",
        "Statement": "ECOG > 1 and a life expectancy over 12 weeks are necessary to participate in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the Primary Trial's Inclusion Criteria, as it specifies that an Eastern Cooperative Oncology Group (ECOG) status of 0 or 1 and an estimated life expectancy of at least 3 months are required for participation in the trial."
    },
    "8c6e6c06-c409-4c42-b195-e9d2a1065b97": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02069093",
        "Statement": "All of the patients in the primary trial had minimal Stomatitis symptoms and a normal diet.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the information in the Primary Trial's Outcome Measurement section. In this section, it is reported that the incidence of grade 2 stomatitis (symptomatic, but able to swallow a modified diet) was 2 out of 86 participants. This information contradicts the statement that \"all of the patients in the primary trial had minimal Stomatitis symptoms and a normal diet.\""
    },
    "b5183c1c-adb5-4877-b061-50a16d6a5b52": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Secondary_id": "NCT01301729",
        "Statement": "None of the patients in the primary trial committed suicide, however there was one such case in the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the CTRs. \n\nJustification: \n\nIn the primary CTR, there is no mention of any patient experiencing suicide (completed suicide in the secondary statement). \n\nIn the secondary CTR, there is a mention of one patient experiencing completed suicide in the adverse events section. \n\nTherefore, the statement contradicts the information provided in the primary CTR."
    },
    "69f57cdb-22e9-4a3a-8f19-6095c66c6497": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01855828",
        "Secondary_id": "NCT00696072",
        "Statement": "the secondary trial uses Clinical Benefit (CBR) as outcome measurement, which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement should not be directly contradicted based on the provided information in the CTRs. However, it is important to note that the primary trial measures pCR rate, which is not the same as CBR used in the secondary trial. The two outcome measurements assess different aspects of treatment efficacy. The primary trial evaluates the presence or absence of invasive cancer cells in surgical specimens (pCR), whereas the secondary trial focuses on the clinical benefit of treatments, which includes complete response, partial response, and stable disease for a specific duration. Therefore, the statements should not be directly contradicted, but they address different aspects of treatment evaluation in distinct clinical trials."
    },
    "ea505463-c509-416e-ad88-11576764b734": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01771666",
        "Secondary_id": "NCT01256567",
        "Statement": "Japanese participants with an ECOG <=1 are eligible for the secondary trial and the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary and secondary CTRs. \n\nJustifications:\n\nThe primary CTR inclusion criterion states: \"Women with an Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Status of 0,1,2.\"\nThe secondary CTR inclusion criterion states: \"The participant is Japanese\" and \"The participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\"\n\nSince both trials allow Japanese participants with ECOG \u2264 1, the statement \"Japanese participants with an ECOG <=1 are eligible for the secondary trial and the primary trial\" is entailed by the provided information in the CTRs."
    },
    "81669281-db01-4493-a797-0d60f448f706": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00930930",
        "Statement": "The overall most frequent adverse event in the primary trial was Dehydration.",
        "Label": "Entailment",
        "explain": "The statement \"The overall most frequent adverse event in the primary trial was Dehydration\" is entailed by the CTR data provided in the Adverse Events 1 section of the primary trial. The total number of adverse events in the primary trial was 22, and Dehydration occurred 5 times, which is 22.73% of the total number of adverse events. Although this percentage is slightly higher than 22.92% mentioned in the CTR, the difference is negligible, and the statement accurately conveys that Dehydration was the most frequent adverse event in terms of the number of occurrences."
    },
    "40dbf023-ead5-45fc-bdce-bf40e1955578": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00382785",
        "Secondary_id": "NCT00784849",
        "Statement": "Neither the primary trial or the secondary trial use Low Dose Magnesium Oxide, High Dose Magnesium Oxide or Mometasone in their intervention.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTR sections. None of the described interventions in neither the primary nor the secondary trial involve the use of Low Dose Magnesium Oxide, High Dose Magnesium Oxide, or Mometasone."
    },
    "b64ae9c9-956a-421e-a41f-1886408fec2a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00003782",
        "Statement": "One of the cohorts in the primary trial had more than 5% of patients experiencing side effects.",
        "Label": "Contradiction",
        "explain": "The given statement contradicts the Adverse Events sections of both the primary and secondary trials, as none of the cohorts had more than 5% of patients experiencing side effects (based on the reported numbers). According to the provided CTRs, the total percentage of adverse events for the primary trial was 3.78%, and for the secondary trial it was 2.46%. Neither of these figures exceeds 5%."
    },
    "e0980234-0611-44de-9165-54bdd086663d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01539317",
        "Secondary_id": "NCT01323530",
        "Statement": "the primary trial uses a topical intervention and the secondary trial uses a combination of oral and intravenous treatments.",
        "Label": "Entailment",
        "explain": "The statement is not entailed by the provided CTRs as both trials involve human subjects and report interventions, but they differ in the type of intervention used - topical in the primary trial and oral and intravenous in the secondary trial. However, there is no information in the CTRs that directly contradicts the statement."
    },
    "3366c10a-3d41-48ae-bfa8-26b9e655761e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005908",
        "Statement": "There were 8 cases of pharyngitis in cohort 2 of the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradiction. \n\nThe CTR for the primary trial does not report any instance of pharyngitis in the adverse events section of cohort 1, let alone in cohort 2. Therefore, the statement that there were 8 cases of pharyngitis in cohort 2 contradicts the provided CTR information."
    },
    "be29030a-98e8-40ad-9138-90076fdb50d3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01572727",
        "Statement": "Cohort 1 of the primary trial recorded more white blood cell related adversse events than cohort 2.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the given CTR data. The primary trial reported 3.48% more white blood cell related adverse events (FEBLE NEUTROPENIA, LEUKOPENIA, and NEUTROPENIA combined) in cohort 1 compared to cohort 2 in the secondary trial (2.99% and 0.49% respectively). While the absolute numbers vary, the percentage differences in the occurrence of white blood cell related adverse events between the two cohorts support the expert's statement. The specific parts of the CTRs that justify this conclusion are: Adverse Events 1 for the primary trial and Adverse Events 2 for the secondary trial."
    },
    "a31298d5-20ae-4a3d-a57b-e97288fff6c0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01097460",
        "Statement": "Every patient in the primary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years.",
        "Label": "Entailment",
        "explain": "The statement \"Every patient in the primary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years\" can be entailed based on the information provided in the CTR for the \"Results 1\" section of the primary trial. The CTR indicates that the time frame for measuring the incidence of treatment-emergent AEs is 2 years, and all participants were analyzed, which means every participant experienced at least one treatment-emergent AE during the study. Therefore, the statement is entailed given the data presented in the CTR."
    },
    "54e93334-0f21-4ea2-b0f2-34473385da53": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00003830",
        "Statement": "The most common adverse event in both cohorts of the primary trial was Anaphylaxis, which affected less than 1% of patients.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the provided data in both CTRs as the percentage of Anaphylaxis cases in each cohort is less than 1% (0.18% and 0.18%) and the total number of patients in each trial is similar (2788 and 2800)."
    },
    "fbedd8fc-05e8-4438-b780-d7483aed3b45": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00404066",
        "Statement": "Abnormal LVEF, Pregnancy or lactating automatically eliminates patients from participating in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the CTR, specifically the EXCLUSION CRITERIA sections of both trials. For the primary trial, patients with an abnormal left ventricular ejection fraction (LVEF) are excluded, but they are still eligible if the abnormality is within the institutional range of normal. For the secondary trial, pregnancy and lactating women are excluded, but this is already covered in the INCLUSION CRITERIA of the primary trial under the condition \"Women of child-bearing potential must have negative pregnancy test and must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation.\" Therefore, neither abnormal LVEF nor pregnancy or lactating automatically eliminates patients from participating in the primary trial."
    },
    "4bd9f061-6420-443d-8f84-b703733644ac": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01202591",
        "Statement": "100% of patients in the primary trial suffered life threatening adverse events.",
        "Label": "Contradiction",
        "explain": "Contradiction. \n\nThe statement is not entailed by the provided data in the CTRs as there is no evidence that all participants in either arm (AZD4547 40mg bd Cont + Ex 25mg or AZD4547 80mg bd Cont + Ex 25mg) experienced life-threatening adverse events. The CTRs only report the number of participants in each arm."
    },
    "e6d3354b-b36a-42b9-b406-61a9af594686": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00046891",
        "Statement": "cohort 1 of the primary trial recieves 120 mg of Ginkgo Biloba twice daily.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. The primary trial's Intervention 1 section clearly specifies that patients will receive 120 mg of Ginkgo Biloba twice daily."
    },
    "62b3d09e-6b2a-4827-8ceb-96ccafca18d4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00896649",
        "Statement": "prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement that \"prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in the primary trial\" is contradicted by the information in the CTRs provided. In the primary CTR, there is no specification regarding prior hormonal treatment. However, the secondary CTR is silent on this criterion. Thus, it is not possible to entail the statement based on the given data. Instead, the statement contradicts the lack of explicit information about prior hormonal treatment in the primary CTR, which implies that it could be either included or excluded."
    },
    "065a6cfe-3991-4dd5-8a55-22b9b31d1fc3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00317603",
        "Statement": "Participants of the primary trial must be older than 18, have histologically confirmed stage 3 or above breast cancer, ECOG<2 and a life expectancy exceeding 6 months.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary CTR inclusion criteria as it specifies that participants must be \"18 years of age or older\" with \"Histologically confirmed Stage III or above breast cancer,\" have an \"ECOG performance status 0 or 1,\" and have an \"estimated life expectancy of greater than or equal to 6 months.\""
    },
    "85c315e5-7ae4-4764-8b02-87d36f67a159": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00278109",
        "Secondary_id": "NCT01881230",
        "Statement": "Gemcitabine is not used in the primary trial, and used in only one of the arms of the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed. \n\nThe primary trial does not include the use of gemcitabine as part of the interventions. \n\nIn the secondary trial, arm A uses gemcitabine in combination with nab-Paclitaxel, and arm B does not use gemcitabine. Therefore, based on the information provided in the CTRs, the statement that \"Gemcitabine is not used in the primary trial, and used in only one of the arms of the secondary trial\" is accurate."
    },
    "497188e0-9d88-406f-b163-c154516cb12c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01560416",
        "Statement": "There was over 10% more cases of adverse events in cohort 2 than in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "explain": "The statement can be contradicted by the provided CTR. In the Primary Trial Adverse Events section 1, there were 2/15 (13.33%) adverse events in Cohort 1, and in the Secondary Trial Adverse Events section 2, there were 11/35 (31.43%) adverse events in Cohort 2. However, the absolute difference between them is not 10%. Therefore, the expert's statement contradicts the information in the CTRs."
    },
    "abc437e1-9e38-4d68-ab9f-fdbaf37d20f3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Secondary_id": "NCT00662025",
        "Statement": "Patients with BUN < 20 mg/dL,  Platelet count: <90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 may be eligible for both the primary trial and the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Patients with BUN < 20 mg/dL, Platelet count: <90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 may be eligible for both the primary trial and the secondary trial\" can be contradicted based on the inclusion and exclusion criteria provided in the CTRs.\n\nIn the primary trial, the inclusion criteria state that Creatinine must be within a normal upper value in the institution, but the statement includes the condition BUN (Blood Urea Nitrogen) being less than 20 mg/dL, which is below the normal upper value for Creatinine and BUN in most institutions. Thus, the statement is contradictory to the primary trial inclusion criteria.\n\nFurthermore, the primary trial exclusion criteria state that patients should not be treated with other pyrimidine fluoride antineoplastic agents. The secondary trial also includes this exclusion criterion, but the statement does not mention anything regarding the use of pyrimidine fluoride antineoplastic agents. Therefore, it is impossible to determine whether patients meeting the conditions mentioned in the statement are eligible for the secondary trial based on the information given in the statement alone.\n\nTherefore, the statement is contradictory to the primary trial inclusion criteria and does not fully provide sufficient information to determine eligibility for the secondary trial."
    },
    "f26fb90b-a9a5-4614-9680-2e9f6f0ba649": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01828021",
        "Secondary_id": "NCT01326481",
        "Statement": "Patients in the primary trial and the secondary trial did not have any of the same adverse events, except Supraventricular extrasystoles which was the most common event in both trials.",
        "Label": "Contradiction",
        "explain": "The statement is entailed based on the information in the CTRs. In the primary trial, Supraventricular extrasystoles occurred in 1/25 (4.00%) of patients, and in the secondary trial, it occurred in 1/19 (5.26%) of patients. Both trials reported this adverse event, and it was the only one that occurred in both trials. All other adverse events listed were unique to each trial."
    },
    "90dd042b-c16c-4ea7-b360-625bd5e64590": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00388726",
        "Statement": "A 75 year old female patient, with an ECOG of 1 and an estimated life expectancy of more than a year would be eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the Primary Trial's Inclusion Criteria, specifically the ECOG Performance Status of 0 to 2 and the Life expectancy of >= 3 months. Additionally, the patient being a female, having a confirmed breast carcinoma, and meeting all other eligibility criteria listed are requirements for the Primary Trial. No contradictions are apparent."
    },
    "9b03c9e7-ca64-4e9f-9c10-f8c2d64ff0b7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01271725",
        "Statement": "In the primary trial The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 13% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group.",
        "Label": "Entailment",
        "explain": "The statement can be entailed based on the information presented in the CTRs. Specifically, the Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 10% (as opposed to 13% in the statement for clarity) and it was 23% for the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group. The difference between the two percentages (13% - 10% = 3%) is less than the difference claimed in the statement (13% lower), but the general trend of a higher OR percentage in the combination therapy group holds true. Therefore, the statement is substantiated by the data in the CTRs.\n\nCTR Primary: Results 1 (OR for Afatinib Monotherapy: 10%, exact 95% CI: 10-18%) and Results 2 (OR for Afatinib and Paclitaxel or Vinorelbine Combination Therapy: 23%, exact 95% CI: 16-30%)."
    },
    "20cc98f8-a71a-466d-a39c-735899791613": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00915603",
        "Secondary_id": "NCT02511730",
        "Statement": "INR equal to or above 1.5 is mandatory for participation in the primary trial, it is not necessary for the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement \"INR equal to or above 1.5 is mandatory for participation in the primary trial, it is not necessary for the secondary trial\" can be contradicted based on the provided CTRs.\n\nThe primary trial inclusion criteria state that \"International normalized ratio (INR) <=1.5 or prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits (WNL) of the institution (if patient is not on anti-coagulation therapy)\" (CTR, Primary Trial: Inclusion Criteria: Adequate coagulation). However, it also allows patients receiving anti-coagulation treatment to be eligible if the INR is stable and within the therapeutic range.\n\nThe secondary trial, on the other hand, does not mention any specific INR requirement in either its inclusion or exclusion criteria.\n\nTherefore, the statement contradicts the provided CTRs by implying that the INR requirement is the same for both trials when, in fact, it differs between them."
    },
    "fa1c6f63-ae37-4c18-918b-7b9ba445fd81": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00391092",
        "Statement": "In total there were 32 cases of Febrile neutropenia in the primary trial.",
        "Label": "Entailment",
        "explain": "Contradiction.\n\nThe CTR for the primary trial reports a total of 14 cases of febrile neutropenia out of 206 participants (6.80%). This information contradicts the statement that there were 32 cases of febrile neutropenia."
    },
    "6d0b2acc-11f4-479f-9a86-004e2f5f7599": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT04080297",
        "Statement": "IV is used as route of administration by the interventions in the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed.\n\nJustification:\n\nThe primary trial's intervention includes several treatments given via IV (doxorubicin hydrochloride, methotrexate, trastuzumab, and tamoxifen citrate). The secondary trial's intervention 1 also involves a treatment given via IV (100 mg Q-122, no specific route mentioned but assumed to be IV as per the expert's statement and common administration practices of Q-122).\n\nTherefore, both primary and secondary trials include interventions administered via IV, which satisfies the statement's condition."
    },
    "7e9c3980-9f12-40c7-920e-76594db26fd1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02352779",
        "Secondary_id": "NCT00263588",
        "Statement": "The differences between cohorts in the primary trial is once cohort recieves a placebo and the other Low-dose Omega-3 Fatty Acid, in contrast the difference in the secondary trial is patient characteristics.",
        "Label": "Entailment",
        "explain": "The statement should be entailed by the provided CTRs since:\n\n1. In the primary trial, the differences between the two intervention arms lie in the administration of low-dose omega-3 fatty acid versus placebo in arms I and II, respectively.\n2. In the secondary trial, the differences between the two cohorts (A and B) are in the patient characteristics, with cohort A having ECOG performance status 0-1 and 1-2 prior trastuzumab-containing regimens and cohort B having ECOG performance status 2 or more and more than 2 prior trastuzumab-containing regimens.\n\nThere is no contradiction to the statement with the provided information in the CTRs."
    },
    "c83e003d-d12d-4f72-ab1f-c39f3a13326b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00499083",
        "Secondary_id": "NCT03045653",
        "Statement": "In order to be eligible for both the secondary trial and the primary trial, patients must be female, over the age of 18, ECOG <2 and have Histologically confirmed HER2 negative breast cancer.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary and secondary trial CTRs. \n\nJustification:\n\nThe statement requires female gender, age over 18 years old, and histologically confirmed HER2 negative breast cancer as common inclusion criteria for both trials. The primary trial specifies female gender and the inclusion of HER2 negative breast cancer in its disease characteristics (ELIGIBILITY CRITERIA), while the secondary trial explicitly states this requirement in its inclusion criteria."
    },
    "cae58656-76e7-447a-940e-dfcc78159173": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00244933",
        "Statement": "the primary trial monitors the occurrence of anemia in its adverse events.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTR data. The term \"anemia\" is not explicitly mentioned in the primary trial's adverse events section. However, the mention of \"Hemoglobin (Hgb)\" and the occurrence of one event (1/19) in the primary trial indicates anemia, as a hemoglobin level below normal (Hgb < 13.5 g/dl for men and <12 g/dl for women) is a common diagnostic criterion for anemia. In addition, the term \"anemia\" is mentioned in the secondary trial's context, which strengthens the entailment."
    },
    "94c4c3fc-7bcb-407b-86b5-6699305d3dbd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02481050",
        "Statement": "There are no adverse events in the primary trial that occurred more than once.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the Primary Trial data. The section on Adverse Events lists multiple occurrences of certain adverse events, such as Sepsis (occurred twice), Chest pain, Asthenia, Upper gastrointestinal haemorrhage, and Pain (all occurred once each), which contradicts the expert's statement that no adverse events in the primary trial occurred more than once."
    },
    "103fbaa8-1852-402a-9368-36bbf6c747b2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00022516",
        "Statement": "At most 3 patients in the primary trial suffered from Neutropenia.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed based on the CTR data in the Adverse Events section of the primary trial. The total number of patients with Neutropenia in the primary trial was reported as 5 out of 473. Therefore, the statement \"At most 3 patients in the primary trial suffered from Neutropenia\" is valid as the given data implies that the number of patients with Neutropenia is less than or equal to 3."
    },
    "731dc36f-983d-4d4c-97ac-6e3eeee23a40": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00581256",
        "Statement": "Patients with left-sided breast cancer and an ECOG of 3 are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The inclusion criteria for the primary trial state that patients with a performance status of 0-2 by ECOG criteria are eligible, but the statement excludes patients with a performance status of 3."
    },
    "b2883781-f4e9-405e-9231-7a07e46c35b0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429299",
        "Statement": "Only one cohort in the primary trial is administered trastuzumab at 4 milligrams per kilogram.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nBoth the CTRs for primary trial Intervention 1 and Intervention 2 describe the administered trastuzumab dosage for all participants. Intervention 1 specifies a first dose of 4 mg/kg and subsequent weekly doses of 2 mg/kg, while Intervention 2 administers 1500 mg/day, which translates to approximately 4.35 mg/kg per week based on a patient weight of 70 kg. Therefore, both cohorts receive trastuzumab at dosages different from the one stated in the expert's claim."
    },
    "932c2135-381a-4675-a782-e683eca8d935": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT00606931",
        "Statement": "the primary trial and the secondary trial both use vaccine based interventions, however this is done in different intervals and for a different duration of time.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the information in the CTRs. \n\nJustification: \nBoth trials involve vaccine-based interventions (HER2/neu peptide vaccine in the primary trial and PET guided biopsy with an implied vaccine component in the secondary trial, although not explicitly stated). The primary trial specifies the vaccine is given intradermally on certain days, and the patients receive ex vivo-expanded HER2-specific T cells intravenously along with cyclophosphamide and sargramostim. The secondary trial describes a PET guided biopsy, but no information about timing or duration of the vaccine intervention is provided. However, the statement acknowledges the difference in vaccine administration intervals and durations between the trials. The primary trial's intradermal and intravenous vaccine administrations, as well as the specified duration, are distinct from the secondary trial's implied vaccine use in a PET guided biopsy. Therefore, even though the details are not identical, the statement accurately reflects the differences in the vaccine-based interventions between the trials."
    },
    "6461007d-fc18-43e2-a797-11cb0a4512ce": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01648322",
        "Secondary_id": "NCT00436566",
        "Statement": "the primary trial has a shorter time frame than the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the time frames specified in the provided Clinical Trial Reports. In the primary trial, the outcome measurement is the duration of moderate neutropenia after the first cycle of chemotherapy, and the time frame is \"The first of 4, 21 Day Chemotherapy Cycles.\" In contrast, the secondary trial's outcome measurement is the number of patients with congestive heart failure (CHF) while on active treatment, and the time frame is \"6 months.\" The duration of the primary trial is less than the secondary trial as indicated by the specified time frames."
    },
    "819e85b0-2d4e-4535-b920-4e18868da883": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00630032",
        "Secondary_id": "NCT00428922",
        "Statement": "Patients with radiologically confirmed metatases in the CNS are excluded from both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by both CTRs since neither trial includes patients with CNS metastases in their inclusion criteria (Primary Trial: Exclusion criteria; Secondary Trial: Exclusion criteria)."
    },
    "cc0d6fe8-69c4-49d3-b321-00e47c155db6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03098550",
        "Statement": "There results from cohort 3 of the primary trial were inconclusive.",
        "Label": "Contradiction",
        "explain": "The statement \"There results from cohort 3 of the primary trial were inconclusive\" cannot be definitively entailed or contradicted based on the provided CTR information.\n\nExplanation:\n\nThe CTRs do not provide any details about cohort 3 of the primary trial, such as the specific disease type, treatment regimen, or number of participants. Consequently, it is not possible to determine if the statement is entailed or contradicted based on the information given."
    },
    "0fbb4fb4-620b-4ee9-aaa8-956992026cef": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Statement": "Less than half of patients in cohorts 1 and 2 in the primary trial experienced adverse events.",
        "Label": "Entailment",
        "explain": "The statement \"Less than half of patients in cohorts 1 and 2 in the primary trial experienced adverse events\" is entailed by the provided data in the CTRs. \n\nJustifications: \n\n1. The total number of adverse events in both cohorts 1 and 2 of the primary trial combined is 42/22 (19.05%). This number is less than 50% of the total number of patients in both cohorts which is 22.\n\n2. The statement applies to both cohorts 1 and 2, while the CTR provides the data for each cohort separately. Therefore, the statement can be verified by combining the data from both cohorts in the CTR."
    },
    "69b12ff4-6bb4-4207-b400-67795709c3c8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02679755",
        "Statement": "Every patient in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events.",
        "Label": "Entailment",
        "explain": "The statement \"Every patient in the Palbocicliclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events.\" is entailed by the given CTR data, as all participants in the Australia Cohort (152 participants) had adverse events (152 participants with adverse events). However, it's important to note that not all adverse events may be related to the study treatment, but the statement does not specify that, and the CTR does not differentiate between treatment-related and unrelated adverse events.\n\nThe following parts of the CTRs were used to derive the answer:\nResults 1: Participants with adverse events: 92 in the Palbociclib+Letrozole India Cohort, and Results 2: Participants with adverse events: 152 in the Palbociclib+Letrozole Australia Cohort."
    },
    "9c0b258d-1e66-4eaa-b4e7-a9098eaed1d7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00829166",
        "Statement": "Female patients with Peripheral neuropathy grade 3 or 4 are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR as it explicitly includes Peripheral neuropathy of Grade >/= 3 as an exclusion criterion. (Primary Trial: Exclusion Criteria)"
    },
    "9872cf9f-6f43-44d3-97ce-e205e0e5fc6c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00464646",
        "Statement": "Anna is a 57 year old female with an ECOG of 0, diagnosed with an invasive adenocarcinoma of the breast, IHC results were 1+. She is eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "Anna's eligibility for the primary trial is entailed according to the following criteria in the CTR:\n\n1. She is female.\n2. She is 57 years old and has an ECOG performance status of 0.\n3. She has been diagnosed with an invasive adenocarcinoma of the breast.\n4. The IHC results indicate that her tumor has a 1+ staining score for HER2.\n5. She has not undergone axillary staging surgery prior to study entry.\n6. Her blood counts and liver function tests meet the requirements.\n7. Her serum creatinine is less than ULN and UPC ratio is less than 1.0.\n8. Her LVEF has been assessed within 3 months prior to study entry.\n\nTherefore, the statement that \"Anna is a 57 year old female with an ECOG of 0, diagnosed with an invasive adenocarcinoma of the breast, IHC results were 1+. She is eligible for the primary trial.\" is justified and entailed by the information provided in the CTR."
    },
    "efc15257-5e19-4b7e-8b51-da94840784d8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623233",
        "Secondary_id": "NCT01525589",
        "Statement": "the primary trial recorded 1 patient with a deficiency of platelets in the blood, whereas a total of 6 patients with a platelet deficiency where found in the secondary trial.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nJustification: \n\nThe statement asserts that in the secondary trial, there were 6 patients with a platelet deficiency, whereas the primary trial recorded only 1 such patient. However, the CTRs provided do not support this statement. In the primary CTR, there is indeed a report of 1 patient with Thrombocytopenia (platelet deficiency), but in the secondary CTR, there are only 6 cases of Thrombocytopenia, which is different from the statement's assertion of \"6 patients with a platelet deficiency\" in total across all adverse events (which would include anemia, febrile neutropenia, neutropenia, and thrombocytopenia). Therefore, the statement is contradicted by the data present in the CTRs."
    },
    "0d4ea69b-5e78-48c2-ba3e-d51dc5336ee1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01310231",
        "Secondary_id": "NCT00093808",
        "Statement": "19.57% of patients in the secondary trial developed an eating disorder, there were no cases of this happening in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted. The secondary trial Adverse Events section reports one case of anorexia (eating disorder), but this is different from the statement which claims \"there were no cases of this happening in the primary trial.\" The primary trial Adverse Events section does not mention anorexia at all."
    },
    "7990b9bf-ac76-4f21-b9a1-5e0b4d91b9a9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02129556",
        "Statement": "Cohort 1 of the primary trial had a much higher number of deaths than cohort 2.",
        "Label": "Contradiction",
        "explain": "The statement \"Cohort 1 of the primary trial had a much higher number of deaths than cohort 2\" is contradicted by the provided data in the CTRs. The percentage of deaths in Cohort 1 was 33.33% compared to 17.31% in Cohort 2 from the primary trial, but this difference does not qualify as \"much higher\" based on the given data. Additionally, the data from the secondary trial is not relevant to this comparison. Therefore, the statement contradicts the provided information in the CTRs."
    },
    "e4961c1a-83e2-40ed-93ac-64d5cef1f84a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01819233",
        "Statement": "All the primary trial participants must reduce the number of calories in their diets by a quarter throughout the duration of the study.",
        "Label": "Entailment",
        "explain": "The statement is entailed. The primary trial's intervention specifies that patients receive guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet, and they follow the caloric restricted diet for 10 weeks. The expert's statement mirrors this information, mandating a 25% caloric reduction throughout the study duration, which aligns with the CTR description."
    },
    "9cb1c975-0d49-4437-af56-1a4f97e30aef": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01663727",
        "Secondary_id": "NCT00072293",
        "Statement": "There is no maximum or minimum age defined for participation in the primary trial or the secondary trial.",
        "Label": "Entailment",
        "explain": "Contradiction\n\nJustification:\nThe primary CTR specifies \"For patients, any age,\" but later in the Exclusion Criteria it lists \"Life expectancy of < 12 weeks.\" This contradicts the statement as it implies a minimum age requirement for participation.\n\nSimilarly, the secondary CTR states \"Age: Any age,\" but it doesn't mention any maximum age restriction. However, the primary trial has a minimum life expectancy requirement of 12 weeks which is not present in the secondary trial, thus creating an age implication that contradicts the statement.\n\nHence, the statement \"There is no maximum or minimum age defined for participation in the primary trial or the secondary trial\" is incorrect according to the provided CTRs."
    },
    "51699ae8-d297-4635-95c1-4ed38c8706c3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02732119",
        "Statement": "Mark suffered Refractory ventricular fibrillation twice in the last month he is therefore excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary trial exclusion criteria do not mention any cardiac events or history of ventricular fibrillation as exclusion factors."
    },
    "c2c73b99-f89c-4dd3-8362-295f9a7965f3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02756364",
        "Statement": "In order to meet the inclusion criteria for the primary trial patients must have had ineffective aromatase inhibitor (AI) therapy before study entry, ",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the inclusion criteria of the primary trial stating \"Progressive Disease (PD) during prior aromatase inhibitor (AI) therapy.\" The expert's statement implies that patients have not responded positively to AI therapy, which aligns with the definition of progressive disease in the trial's inclusion criteria. Therefore, this statement is justified and in agreement with the CTR."
    },
    "180d7b66-9ee9-40fb-b4c7-a6060e6f67b7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02129556",
        "Statement": "Cohort 1 of the primary trial had a much higher mortality rate than cohort 2.",
        "Label": "Entailment",
        "explain": "The statement \"Cohort 1 of the primary trial had a much higher mortality rate than cohort 2\" is entailed by the provided data in the CTRs. In the primary trial Adverse Events 1 section, there were 2 deaths in cohort 1 out of 6 participants (33.33%), whereas in Adverse Events 2 section of the secondary trial, there were 9 deaths out of 52 participants (17.31%). Therefore, the mortality rate in cohort 1 was higher than cohort 2."
    },
    "949ac54b-a871-4134-a507-c98a4de55720": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394082",
        "Secondary_id": "NCT01033032",
        "Statement": "the primary trial recorded cases of Anaphylaxis and Spinal compression fracture, neither of these were observed in the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTRs. In the primary CTR, there was one reported case of anaphylactic reaction (1/50) and one case of spinal compression fracture (1/50) among the participants. In contrast, the secondary CTR reported no cases of anaphylactic reaction or spinal compression fracture. Therefore, the statement accurately reflects the differences in adverse events between the two trials."
    },
    "02407f87-235d-4240-98fe-498b352cce75": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00167414",
        "Statement": "Patients must have Human epidermal growth factor receptor 2 (HER2) overexpressive tumors to participate in the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The CTR for the primary trial does not specify HER2 overexpression as a requirement for inclusion."
    },
    "61a524d4-1697-4a10-b36a-a0c6cda79526": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00030823",
        "Statement": "Patients with stage I, II, III or IV triple negative breast cancer are not eliglbe for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement contradicts the primary trial, specifically the ELIGIBILITY CRITERIA section, as it excludes patients with stage I, II, III, or IV triple negative breast cancer from participating in the trial. However, the primary trial includes such patients under certain conditions (e.g., Stage I, II, or III previously treated with adjuvant chemotherapy and clinically free of identifiable disease, but have rising CA 15-3 or CEA levels)."
    },
    "304977b6-9742-4c3b-84fd-e5ef1737a143": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01597193",
        "Statement": "ECOG < 2 and a life expectancy over 12 weeks are necessary to participate in the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary trial's inclusion criteria state that ECOG status should be 0 or 1 and the estimated life expectancy should be at least 3 months. The expert's statement specifies ECOG < 2 and a life expectancy over 12 weeks, which is stricter than the stated inclusion criteria."
    },
    "87c65217-85d9-4f05-87aa-f4dfacd9f25a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01790932",
        "Statement": "patients with Phosphoinositide 3-kinase inhibitor based treatments are ineligible for the primary trial",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR's Exclusion Criteria. The criteria explicitly state that \"Have received previous treatment with PI3K inhibitors\" is a disqualification for the trial."
    },
    "19e89ebc-a417-47a8-bfa7-1778baead178": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01385137",
        "Secondary_id": "NCT00593346",
        "Statement": "Placebo treatment is used in the secondary trial, but there is only a test group in the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. In the primary trial, there is both an intervention (Omegas-3-fatty acid) and a control group (Placebo). Hence, it is incorrect to assert that there is only a test group in the primary trial."
    },
    "561a0631-1eb3-48d1-baa2-81eb3fa79b98": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00950300",
        "Secondary_id": "NCT00615901",
        "Statement": "the primary trial recorded a patient with chest pain, whereas the secondary trial observed a patient with abdominal pain.",
        "Label": "Entailment",
        "explain": "The statement can be considered neither entailed nor contradicted based on the provided information in the CTRs. While there is no contradiction regarding adverse events with respect to chest pain or abdominal pain mentioned in the statement and the CTRs, the statement does not entail any information directly from the CTRs as it only describes different types of pain observed in the two trials."
    },
    "bc617e84-a0c1-400b-9ad5-88b56d1805e8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01671319",
        "Statement": "1/42 patients in cohort 1 of the primary trial fainted.",
        "Label": "Entailment",
        "explain": "The statement \"1/42 patients in cohort 1 of the primary trial fainted\" is entailed by the CTR under ADVERSE EVENTS section of the primary trial, where it is mentioned that \"Syncope (fainting) 1/42 (2.38%)\" occurred."
    },
    "8a8b7b19-9328-4cb3-b01c-8f4c358f4ac5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01097642",
        "Statement": "Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T3 N1 M0) are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary trial inclusion criteria as it specifies adult patients with invasive bilateral breast carcinoma (T3 N1 M0) as eligible, which is explicitly included in the given inclusion criteria: \"Patients with histologic confirmation of invasive breast carcinoma. Patients with T1N1-3M0 or T2-4 N0-3M0.\""
    },
    "bb4f69b0-0e2e-44e6-a3b6-049f4a8505fe": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00354640",
        "Statement": "Patients taking Intervention 1 of the primary trial receive higher doses of anastrozole than of simvastatin.",
        "Label": "Contradiction",
        "explain": "Contradicted. The CTR for the primary trial specifies that patients receive 1 milligram of anastrozole and 40 milligrams of simvastatin daily. This contradicts the statement suggesting that patients receive higher doses of anastrozole than simvastatin."
    },
    "b059e44b-9830-4c45-858e-ebd007fbaf69": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00148668",
        "Statement": "Cohort 1 and 2 of the primary trial recorded the same number of patients with Febrile Neutropenia.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted. According to the provided CTRs, Cohort 1 of the primary trial had no cases of Febrile Neutropenia, while Cohort 2 of the secondary trial had 1 case. Therefore, the statement does not follow from the data presented. (Adverse Events 1 and 2)"
    },
    "fec065ca-fbde-476d-ab0d-7e7054e29858": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00436917",
        "Statement": "Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine, or with a prior surgery at the lumbosacral spine are excluded from the primary trial, as these would interfere with the necessary CT and MRI scans for the study.",
        "Label": "Contradiction",
        "explain": "Contradicted. The expert's statement is not entailed by the CTR information provided for the primary trial. According to the CTR, the exclusion criteria for the primary trial state that patients with a Cobb angle > 15 degrees at the lumbar spine and those with disease of the spine that would preclude the proper acquisition of a lumbar spine DXA are excluded. However, the expert's statement mentions a Cobb angle exceeding 20 degrees, which is more restrictive than the stated exclusion criterion in the CTR. Additionally, the expert's statement mentions patients with a prior surgery at the lumbosacral spine as excluded, but this condition is also not explicitly stated as an exclusion criterion in the CTR for the primary trial."
    },
    "ea3bd229-001c-487f-9cda-edf2e699dbb2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01153672",
        "Secondary_id": "NCT01432145",
        "Statement": "Patients in the primary trial receive vorinostat at the same frequency, dosage and through the same route of administration as the secondary trial receive 6-Mercaptopurine.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the CTRs. In the primary trial, patients receive vorinostat PO QD for 2 weeks, followed by AI therapy PO QD for 6 weeks, while in the secondary trial, 6-Mercaptopurine is given PO once a day and Methotrexate PO once a week. Vorinostat and 6-Mercaptopurine are not administered at the same frequency, dosage, or route of administration."
    },
    "576e519a-1ef3-43e5-a13c-6058ad71f388": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00297596",
        "Secondary_id": "NCT00580333",
        "Statement": "Patients have received prior radiation treatment, to treat the current breast cancer, in the last two 2 weeks before study entry are eligible for the primary trial but excluded from the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed in the primary CTR but contradicted in the secondary CTR.\n\nJustification:\n\nIn the primary CTR, the exclusion criterion for prior radiation therapy is that \"it should not be to the only site of evaluable disease.\" However, in the inclusion criteria, it is mentioned that patients with prior radiation therapy are eligible, provided it was not to the only site of evaluable disease and all prior chemotherapy, trastuzumab, and radiation therapy were completed > 2 weeks before enrollment.\n\nIn the secondary CTR, the exclusion criterion for prior radiation therapy is \"any prior radiation therapy for the current breast cancer.\"\n\nThus, in the primary CTR, patients who have undergone radiation therapy in the last 2 weeks before study entry for a non-evaluable site would be eligible, but in the secondary CTR, such patients would be excluded. This statement accurately reflects the information in the CTRs.\n\nHowever, it's important to note that the statement does not specify which trial it refers to, so the context is critical for understanding its meaning and the entailment relationship with the CTRs."
    },
    "699d0cb5-1ebb-441d-aa7e-041a48923b00": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03374995",
        "Statement": "the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks.",
        "Label": "Entailment",
        "explain": "The statement is entailed as it aligns with the information in the Intervention 1 section of the primary trial, where patients receive topical keratin twice daily (BID) until the end of radiation therapy, which is approximately 3-6 weeks."
    },
    "6ec27be7-aa61-4ba8-b92a-98dcaee1eb0b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01127373",
        "Statement": "Patients with T1N1M0, T2N1M0, T3N1M0 and TxN1M0 tumors are eliglbe for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary trial inclusion criteria. The N1 stage indicates the presence of metastatic disease in at least one regional lymph node, which is allowed according to the primary trial eligibility criteria as long as the M stage is 0 (no distant metastases). The T stage can be any T stage (T1, T2, T3, or Tx), as the M0 and N1 criteria are the focus of this statement and are satisfied. Therefore, patients with T1N1M0, T2N1M0, T3N1M0, and TxN1M0 tumors are eligible for the primary trial, in accordance with the provided CTR."
    },
    "6e882de6-e55f-40a4-95a1-bdb176e68a18": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266799",
        "Statement": "None of the patients in cohort 1 of the primary trial had ACUTE VESTIBULAR or acute coronary syndrome.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nJustification: \n\nThe CTR for the primary trial does not provide information regarding coronary syndrome, but it does report one case of acute vestibular syndrome in cohort 1."
    },
    "525ed182-07e9-4548-87b3-c831e0b7389e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00834678",
        "Statement": "Patients with lymphopenia can participate in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Patients with lymphopenia can participate in the primary trial\" is contradicted by the CTR, specifically under PATIENT CHARACTERSISTICS, where it states \"WBC > 1,500/mm\u00b3\". Lymphopenia is a condition characterized by a decrease in the number of lymphocytes in the blood, and a WBC count less than 1,500/mm\u00b3 implies the presence of lymphopenia. Therefore, the statement contradicts the CTR as it suggests that patients with lymphopenia can still be included, while the CTR explicitly states that patients must have a WBC count greater than 1,500/mm\u00b3 to participate."
    },
    "233d2ec1-1383-4088-90af-c5a948847631": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00110084",
        "Secondary_id": "NCT01961544",
        "Statement": "the primary trial and the secondary trial both reported cases of Pseudomonal sepsis in their patients.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. The primary and secondary trials both report cases of Pseudomonal sepsis (1/50 in the primary trial and 1/101 in the secondary trial)."
    },
    "8e3fe244-d47d-48ce-ab29-4a5226024aad": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00426556",
        "Statement": "There were an equal number of cases of Febrile neutropenia, Leukopenia and Neutropenia across cohorts in the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The CTRs provide data for adverse events in two different trials. In the primary trial, there were no cases of Febrile neutropenia, Leukopenia, or Neutropenia recorded. Consequently, no equal number of cases existed across cohorts for these adverse events. (Primary Trial: Adverse Events 1 and 2)"
    },
    "670443b0-89bf-4af4-a9ab-4cdff26d09a8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005957",
        "Statement": "T4 N3 M0 adenocarcinoma of the breast are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. According to the primary CTR, patients with T4, N2-3, or M1 disease prior to surgery are not eligible for the trial. Therefore, a T4 N3 M0 patient would be ineligible based on the provided disease characteristics alone."
    },
    "455748bf-8e12-4834-8126-ab77cab16200": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00332709",
        "Secondary_id": "NCT00659373",
        "Statement": "All the primary trial participants receive the same dose of Letrozole, only certain patients in the secondary trial are administered Exemestane.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTRs. In the primary trial, all participants receive Letrozole 2.5 mg/day. In the secondary trial, some participants receive Exemestaine 25mg orally daily instead of Letrozole, but they also receive ovarian function suppression (OFS). However, the statement only mentions that Letrozole is given to all participants in the primary trial and that Exemestaine is given to some participants in the secondary trial, but it does not specify that all participants in the secondary trial receive a different dose of Letrozole or that they do not receive any Letrozole at all. Therefore, the statement that \"All the primary trial participants receive the same dose of Letrozole, only certain patients in the secondary trial are administered Exemestane\" is consistent with the information provided in both CTRs."
    },
    "d29bd9dd-b52e-4b18-82ea-e2914dfb9579": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "the primary trial Patients receiving Neratinib Plus Capecitabine had a Mean (95% Confidence Interval)  Progression Free Survival more than 2 months longer than patients administered with Lapatinib Plus Capecitabine.",
        "Label": "Entailment",
        "explain": "The statement is entailed. \n\nJustifications: \n\nAccording to the primary trial CTR, the Mean (95% Confidence Interval) of PFS for patients receiving Neratinib Plus Capecitabine is 8.8 (7.8 to 9.8) months, while for patients receiving Lapatinib Plus Capecitabine it is 6.6 (5.9 to 7.4) months. The difference between these means is approximately 2.2 months (8.8 - 6.6). This difference falls outside the 95% confidence interval of Lapatinib Plus Capecitabine, indicating that it is unlikely that the PFS of patients receiving Lapatinib Plus Capecitabine is as long or longer than those receiving Neratinib Plus Capecitabine. Therefore, the statement that the PFS is more than 2 months longer for patients receiving Neratinib Plus Capecitabine is consistent with the data provided in the CTRs."
    },
    "2649c857-f98d-4529-9a4a-4f8b17813cb8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00337103",
        "Statement": "The Median Overall Survival for cohort 1 patients was 44 days longer than for patients in cohort 2 of the primary trial.",
        "Label": "Entailment",
        "explain": "To determine if the expert's statement is entailed or contradicted, we need to calculate the difference in Median Overall Survival (MOS) between the two cohorts.\n\nFrom CTR1: MOS for cohort 1 (Eribulin Mesylate 1.4 mg/m^2): 484 days (95% CI: 462-536)\nFrom CTR1: MOS for cohort 2 (Capecitabine 2.5 g/m^2/day): 440 days (95% CI: 400-487)\n\nCalculation: \nDifference in MOS = MOS cohort 1 - MOS cohort 2\n= 484 days - 440 days\n= 44 days\n\nSince the expert's statement matches the calculated difference, the statement is entailed. No contradiction is present."
    },
    "0a6e8720-ea47-4520-bd02-e0eb8fcd880f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00399802",
        "Statement": "The Single IV Infusion of ZA 4 mg group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group",
        "Label": "Entailment",
        "explain": "Justified (Entailed) \n\nReasoning: \nThe statement \"The Single IV Infusion of ZA 4 mg group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group\" is entailed by the provided CTR data. \n\nResults 1 and 2 show that:\n- The Mean Percentage Change from Baseline in Urinary N-telopeptide of Type I Collagen for the Single IV Infusion of ZA 4 mg group was -73% (95% CI: -80% to -62%)\n- The Mean Percentage Change from Baseline in Urinary N-telopeptide of Type I Collagen for the Odanacatib 5 mg group was -77% (95% CI: -82% to -71%)\n\nGiven that a smaller value indicates a smaller percentage change, it can be deduced that the Single IV Infusion of ZA 4 mg group exhibited a smaller percentage change in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group."
    },
    "ce6630d3-d3b7-4870-a486-9b6284a454f0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02679755",
        "Statement": "More patients in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events compared to patients in the Palbociclib+Letrozole India Cohort.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the data in the CTRs. The Palbociclib+Letrozole Australia Cohort had a higher percentage of participants with treatment-emergent adverse events (100.0%) compared to the Palbociclib+Letrozole India Cohort (92.0%)."
    },
    "27e31574-5a73-4a68-997d-daa84797a65a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02162719",
        "Statement": "Both the primary trial and the secondary trial at least partly administer their interventions intravenously.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs. \n\nJustification:\nIn the primary trial, suramin is given intravenously, and paclitaxel is given intravenously as well. In the secondary trial, ipatasertib is given orally, but paclitaxel is still given intravenously in both the intervention and control groups. Therefore, both trials involve intravenous administration of paclitaxel, which is a common component of their interventions."
    },
    "e21171de-ad49-4fc5-9c5d-aa362ca61c8a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00014222",
        "Statement": "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events, whereas cohort two recorded 41.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided CTR data. According to the data, cohort one reported one instance of keratitis (an eye-related adverse event) out of 680 patients (0.15%). Cohort two reported no instances of eye-related adverse events out of 688 patients. Therefore, the expert's statement of 2/680 patients in cohort one and 41 patients in cohort two experiencing eye-related adverse events contradicts the reported data."
    },
    "5dcdeac8-1c4a-4c24-9074-bbe93fcf4d32": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02518191",
        "Statement": "Cohort 2 of the primary trial is the control group, as the Eligible patients with breast cancer treated with GnRHa every 28 days.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. In the primary trial's Intervention 1 section, it is stated that patients in this group received GnRHa every 28 days while undergoing chemotherapy. According to the statement, Cohort 2 refers to the group of patients who did not receive GnRHa. Since Intervention 2 in the primary trial does not involve GnRHa administration, it can be inferred that Cohort 2 is indeed the control group, as stated in the clinical trial expert's claim."
    },
    "38f47a03-f71d-4072-a005-b954fb6069da": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00684983",
        "Statement": "The Median length of time that a patient in Arm A of the primary trial lived with the disease without it getting worse was half a year.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information provided in the CTR. In Results 1, it is mentioned that the median survival time for Arm A is 6.0 months, which is equivalent to living with the disease for half a year."
    },
    "e41917b8-d921-4797-b845-0121a75104a4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129376",
        "Statement": "More than 2% of patients in the primary trial experienced a clinically significant inflammation of the back of the throat.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nThe statement is not entailed by the provided CTR data for the primary trial. The CTR reports one case of Acute Pharyngitis, but it does not specify the percentage of patients who had clinically significant inflammation of the back of the throat. Moreover, the CTR does not mention any inflammation cases or statistics related to the secondary trial."
    },
    "bcb2d4a9-f2da-4a51-861b-3d5a9fbb6541": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02513472",
        "Statement": "Cohort 1 patients in the primary trial surivied almost twice as long as those in cohort 2.",
        "Label": "Contradiction",
        "explain": "Contradiction \n\nJustification: \n\nThe CTRs do not provide sufficient information to establish the statement \"Cohort 1 patients in the primary trial survived almost twice as long as those in cohort 2\" as entailed. The given CTRs only present the Objective Response Rate (ORR) and do not include data regarding the survival length or time-to-event analyses for participants in each cohort."
    },
    "3e56c28c-6d5c-49c4-aaf7-b4e2cb3ca2d7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02491892",
        "Secondary_id": "NCT00887575",
        "Statement": "Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial, this is due to the significant difference in cohort size.",
        "Label": "Contradiction",
        "explain": "The statement can be entailed based on the provided information. The statement mentions that cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial. This is due to the significant difference in cohort size. According to the CTRs, the total number of participants in cohort 1 of the primary trial was 41, and there were 1 case of diarrhea and 1 case of dyspepsia. In cohort 1 of the secondary trial, the total number of participants was 37, and there were 2 cases of diarrhea and 1 case of dyspepsia. The difference in the number of cases can be attributed to the difference in cohort size."
    },
    "27397dfc-b6cf-41a3-862c-a99ccd2ddd5d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01881230",
        "Statement": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group",
        "Label": "Contradiction",
        "explain": "The statement \"The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group\" is contradictory to the data presented in the CTRs.\n\nJustification: \n\nIn the primary trial, the median PFS for the Arm A (Nab-Paclitaxel + Gemcitabine) group was 5.5 months (4.1 to 7.0) and for Arm B (Nab-Paclitaxel + Carboplatin) group was 8.3 months (5.7 to 10.6). A 83% difference in PFS between the two arms translates to a difference of approximately 4 months. However, the difference in PFS between the two groups is only 2.8 months. Therefore, the statement that the Gemcitabine group had a median PFS more than 83% less than the Carboplatin group contradicts the data provided in the CTRs."
    },
    "6214280f-f665-48d3-b33f-9d798deff71f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01855828",
        "Secondary_id": "NCT00696072",
        "Statement": "the secondary trial uses Overall Survival (OS) as outcome measurement, which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted. The primary trial measures the Proportion of Participants With a Pathologic Complete Response Rate, whereas the secondary trial measures the Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years. These outcome measurements are not equivalent. Specifically, the primary trial focuses on the pathologic complete response rate at the time of surgery, whereas the secondary trial assesses the clinical benefit and disease-free interval over the course of several years."
    },
    "108b54a9-b5cc-4f31-956f-e4e2e653d756": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00089999",
        "Statement": "In total more participants in the primary trial had no tumor Response, than partial response, and 0 participants had a complete response.",
        "Label": "Entailment",
        "explain": "Contradiction. \n\nJustification: \n\nThe statement asserts that more participants in the primary trial had no tumor response than partial response, and no participants had a complete response. However, the CTR clearly states that there were 15 participants with PR in the Lapatinib 1500 mg QD arm, and 18 participants with PR in the Lapatinib 500 mg BID arm, making a total of 33 participants with PR. There were 0 participants with CR in both arms. The statement is incorrect as it contradicts the provided data."
    },
    "662f4992-0155-4a82-926f-b1821539aab7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00723125",
        "Secondary_id": "NCT00617942",
        "Statement": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery, compared to 60% in cohort 1 of the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement can be contradicted based on the provided CTRs. In the primary trial, the Pathological Complete Response Rates at Surgery were reported for Cohort 1, which had 16 out of 28 participants achieving this response. Therefore, the percentage of participants with Pathological Complete Response Rates at Surgery in Cohort 1 was calculated as (16/28) x 100% = 57.14%.\n\nHowever, the statement mentions that 57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery, which is the same percentage given in the statement. However, it also states that 60% of participants in cohort 1 of the secondary trial had this response. The secondary trial does not provide enough information to calculate this percentage directly, but it can be inferred that it is different from the one in the primary trial since it is not equal to 57%.\n\nHence, the statement contradicts the data presented in the CTRs."
    },
    "398f744b-97cf-4f95-b162-99ec6652d327": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01091454",
        "Secondary_id": "NCT00054275",
        "Statement": "There were more cases of Anemia and Leukopenia in the primary trial than the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"There were more cases of Anemia and Leukopenia in the primary trial than the secondary trial\" is contradicted by the given Clinical Trial Reports. In the Primary Trial, there were 4 cases of Anemia and 0 cases of Leukopenia. In contrast, in the Secondary Trial, there were 1 case of Anemia and 4 cases of Leukopenia. Therefore, the number of cases of Anemia was fewer in the primary trial, and the number of cases of Leukopenia was greater in the secondary trial. Hence, the statement is contradicted by the data presented in the CTRs."
    },
    "43421f19-878e-46f7-b456-8031835af649": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00632489",
        "Statement": "the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib, whereas the dose of Capecitabine changes with Body surface area.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nJustification: \n\nThe CTR does not indicate a set dosage of 1000 mg PO daily for Lapatinib in the primary trial. However, the dosage of Capecitabine does change based on Body Surface Area (BSA) in the secondary trial as stated by the expert. \n\nHowever, the primary trial's CTR specifies that Capecitabine's dose ranges from 825 mg/m2 to 1250 mg/m2, which is based on Body Surface Area (BSA), not a set dosage as stated in the expert's statement for Lapatinib. \n\nTherefore, the statement contradicts the provided information in the CTRs."
    },
    "13fa44e7-38be-48fb-a0eb-6b212549f526": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02260531",
        "Statement": "the percentage of participants achieving complete response (CR) or partial response (PR) was much lower in the HER2-positive group in the primary trial,than in the ER+ and/or PR+ group.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the data presented in the CTRs. In Results 1 for the HER2-positive group (Cohort 1), the percentage of participants achieving CR or PR is given as 5 (0.2-24). In contrast, in Results 2 for the ER+ and/or PR+ group (Cohort 2), the percentage is given as 14 (0.4-58). Thus, the percentage for the ER+ and/or PR+ group is higher than for the HER2-positive group, supporting the statement."
    },
    "12ae2315-cc50-43ac-a595-762c85c1ec58": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02308020",
        "Statement": "There were no participants in cohort 1 of the primary trial with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the primary trial's outcome measurement description, as it specifies that the OIRR is reported for the primary trial, but no participants in cohort 1 (Part A) achieved a CR or PR based on RANO-BM response criteria according to the statement. However, the CTR provides data on the number of participants with CR or PR for cohort 1, implying that such data should be available in the trial results. Therefore, the statement contradicts the information provided in the CTR."
    },
    "11403f92-661b-4334-8dfb-098586610ec6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02536339",
        "Secondary_id": "NCT00371345",
        "Statement": "Respiratory illnesses were observed in most of the patients in the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nThe statement \"Respiratory illnesses were observed in most of the patients in the primary trial and the secondary trial\" is contradicted by the information provided in the CTRs. According to the Primary Trial Adverse Events section, only one patient in the primary trial experienced Pneumonia, which is a type of respiratory illness. Meanwhile, none of the respiratory illnesses listed in the Secondary Trial Adverse Events section, such as Sinusitis, Pneumonia, and Lobar Pneumonia, were mentioned in the primary trial. Therefore, respiratory illnesses were not observed in most of the patients in both trials as stated in the expert's claim.\n\nAdditionally, it's worth mentioning that the overall occurrence rates of adverse events are different between the two trials (17.95% in the primary trial and 28.57% in the secondary trial), and no respiratory illnesses appeared in the majority of the participants in either trial."
    },
    "2823adfc-b3a4-4626-9690-0c292aa8da04": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01422408",
        "Statement": "the primary trial is a phase II trial in which all participants will recieve topical fluocinonide 0.05% face cream twice daily for two weeks.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the CTR for the primary trial, as it specifies the use of topical fluocinonide 0.05% cream for the vaginal area, whereas the statement mentions the application to the face."
    },
    "1cda051f-27d0-4027-94cf-7b5340173ca2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02504424",
        "Secondary_id": "NCT03708393",
        "Statement": "the primary trial and the secondary trial do not have the same number of study groups.",
        "Label": "Entailment",
        "explain": "The statement is entailed. \n\nJustification: The primary trial involves one intervention group using the AeroForm Tissue Expander, whereas the secondary trial comprises two intervention groups: one using an Intrauterine System (IUS) alone and the other using IUS plus Orally Active Agent (IUS+OA). Therefore, the primary trial and the secondary trial do have different numbers of study groups."
    },
    "2ca24749-7c1d-4697-a1aa-8bf5d13fb8c3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00435409",
        "Secondary_id": "NCT00319254",
        "Statement": "The patient with the shortest PFS was in the secondary trial, at only 5 days, and the longest recorded PFS was in the primary trial at 78 months.",
        "Label": "Contradiction",
        "explain": "The given statement cannot be directly entailed or contradicted based on the provided CTRs information alone.\n\nTo entail the statement, there should be evidence of a specific patient in each trial with the shortest (5 days) and longest (78 months) PFS. However, the CTRs only provide median PFS and the corresponding 95% Confidence Intervals for each arm, not individual patient data.\n\nTherefore, we cannot make a definitive judgment based on the available information."
    },
    "1e91c023-96e8-459b-9070-02df13339617": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Statement": "In the primary trial the FEC-75 Then Paclitaxel/Trastuzumab group produced better Pathological complete response (pCR) rates than the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group.",
        "Label": "Entailment",
        "explain": "The statement is entailed. In the primary CTR, the pCR rate for the FEC-75 Then Paclitaxel/Trastuzumab group was 56.5% (47.8-64.9) compared to 54.2% (45.7-62.6) for the Paclitazomib/Trastuzumab Then Trastuzumab/FEC-75 group. The difference in pCR rates can be computed, and a statistical test (Chi-square test at the two-sided 0.05 level) and a confidence interval (95%) can be calculated to determine whether this difference is statistically significant and meaningful, respectively. If the difference is found to be statistically significant with a confidence interval that does not include zero, it would support the statement that the FEC-75 Then Paclitaxel/Trastuzumab group produced better pCR rates. Additionally, both trial arms underwent surgery, laboratory biomarker analysis, and correlative studies, ensuring comparable assessment standards."
    },
    "a15b4c0c-232b-4209-bf60-35d160e41d2c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03012477",
        "Statement": "One patient in the primary trial experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Anemia.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTR data, as both the statement and the CTR mention that one patient in the primary trial experienced a thromboembolic event, and the statement also correctly identifies the most common adverse event as Anemia, which occurred in 3/34 (8.82%) of the patients. The CTR also provides the number of patients experiencing each adverse event, which supports the statement's assertion."
    },
    "795d634a-9f9c-49a2-a4e7-ec99bd3600f2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02667626",
        "Statement": "the primary trial is testing a web-based educational tool and the secondary trial is testing a medical device on Post-menopausal Women.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial is testing a web-based educational tool (SCPR) in young breast cancer participants, while the secondary trial is not mentioned to involve a medical device or be limited to post-menopausal women. There is no information provided in the CTRs regarding the nature of the second trial or the population being studied."
    },
    "e2d4c56c-a68f-4751-907d-9c2355c9528b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01463007",
        "Secondary_id": "NCT00965523",
        "Statement": "A significantly higher proportion of patients in the secondary trial suffured from infection compared to the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"A significantly higher proportion of patients in the secondary trial suffered from infection compared to the primary trial\" is entailed by the provided information in the Adverse Events sections of the CTRs. In the primary trial, one patient had an infection, accounting for 2.44% of the total participants. In contrast, the secondary trial reported two infection cases, representing 2.47% of the total number of patients. Although both trials have similar proportions of infections, the higher number of infections in the secondary trial justifies a significantly higher proportion for that trial."
    },
    "50f1c6c5-abe6-4178-93cf-32b5a8a3e9e9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00193050",
        "Secondary_id": "NCT00232479",
        "Statement": "Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by both CTRs since the inclusion criteria for both trials specify that patients must be over the age of 18 with a life expectancy over 6 months. (Primary CTR: Eligibility Criteria; Secondary CTR: Inclusion Criteria). However, it is important to note that the primary CTR includes additional inclusion and exclusion criteria beyond age and life expectancy that must also be met for participation."
    },
    "9ad3444c-143d-4c28-a08a-e0c9cda44900": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00243503",
        "Secondary_id": "NCT00448279",
        "Statement": "the primary trial and the secondary trial did not observe any of the same adverse events in their patients.",
        "Label": "Contradiction",
        "explain": "Contradicted. In the primary trial, there is a reported case of febrile neutropenia in both trials, which contradicts the expert's statement that no same adverse events were observed in both trials."
    },
    "43061a8b-c1b2-4b5e-b935-73733d674fb4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01401959",
        "Secondary_id": "NCT00852930",
        "Statement": "the primary trial designates specific interventions to its patients depending on their tumour response, patients with complete response go to cohort A and all other in cohort B, in contrast the secondary trial assigns interventions randomly.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the CTRs provided. The primary trial assigns interventions based on patients' tumor response, not randomly, as stated in the secondary trial. This discrepancy is evident in the following parts of the CTRs:\n\nPrimary Trial:\nINTERVENTION: specific interventions to its patients depending on their tumour response\nPatients with triple-negative breast cancer who do not have a pathological complete response following neoadjuvant therapy and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days for 6 cycles via the intravenous (IV) route (Cohort A).\nPatients with hormone receptor positive (ER and/or PR positive), HER negative breast cancer breast cancer who do not have a pathological complete response following neoadjuvant therapy and surgery will receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days for 6 cycles via the intravenous (IV) route (Cohort B).\n\nSecondary Trial:\nINTERVENTION: the secondary trial assigns interventions randomly.\nHowever, there is no mention of randomization in the secondary trial's CTRs. The statement is an assertion not grounded in the provided information.\n\nTherefore, the statement is contradicted by the information provided in the CTRs."
    },
    "fc7369dc-0fc5-4823-a8eb-5ac85188fd60": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00416572",
        "Statement": "Patients suffering from ovarian or lung cancer are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted. The primary trial's inclusion criteria only specify breast cancer as the permitted diagnosis, while the statement excludes patients with ovarian or lung cancer."
    },
    "25ec56f0-e472-4423-92ae-8d4840b067b5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03475992",
        "Secondary_id": "NCT03106077",
        "Statement": "Participants in the primary trial receive different interventions depending on their pre-diagnosis, whereas all patients in the secondary trial took the same intervention.",
        "Label": "Entailment",
        "explain": "The statement is entailed. In the primary trial, patients received different interventions (microwave breast imaging with or without prior biopsy) based on their pre-diagnosis (palpable breast lump or breast cyst). In contrast, in the secondary trial, all patients received the same intervention (IMGN853 with a dose of 6 mg/kg given every 3 weeks). This difference in intervention type and administration between the two trials aligns with the statement."
    },
    "2c9e9407-e990-41bd-a87b-9d294c78f727": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02286843",
        "Statement": "the primary trial is testing a novel radiotracer called PET/CT to evaluate its use for visualization of HER2+ lesions.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary CTR section, specifically the statement \"PET/CT imaging with these novel radiotracers will allow evaluation of all identifiable malignant lesions.\" This aligns with the expert's claim of evaluating HER2+ lesions using a novel radiotracer called PET/CT."
    },
    "f3cebdf7-be0c-45ad-85bd-bde827524e20": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00693719",
        "Statement": "the primary trial recorded less than 5 different Adverse Events .",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nJustification: \n\nThe statement asserts that the primary trial recorded less than 5 different adverse events. However, the provided CTR data for the primary trial clearly lists 5 distinct adverse events: bleeding, pain, dehydration, dyspnea, and a total number of occurrences. The statement contradicts the given CTR data."
    },
    "b5c7bfd2-d491-400c-8444-8bc424cd5dbf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01705691",
        "Statement": "A patient in the primary trial suffered from Kidney stones.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nJustification:\n\nThe CTRs provided do not mention any patient in either trial suffering from Kidney stones or Nephrolithiasis."
    },
    "53c62057-d6ea-4639-adaf-98cb1544a394": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00425672",
        "Statement": "Patients receiving intervention 1 of the primary trial undergo a 21 day treatment cycle, up to a total of 6 times, but will stop earlier if they suffer disease progression or unacceptable toxicity occurs.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the INTERVENTION 1 section of the primary CTR. The CTR states that patients receive ONTAK over 1 hour on days 1-5 and the treatment repeats every 21 days for up to 6 courses. The statement made by the expert reflects the same information, but in a different way, stating that patients undergo a 21 day treatment cycle up to a total of  six times. The expert's statement does not contradict any information in the CTR."
    },
    "599b37cd-f380-48ac-864d-e766a7af963e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01570036",
        "Secondary_id": "NCT00021255",
        "Statement": "the primary trial and the secondary trial monitor the %  of their patient cohorts with DFS < 6years.",
        "Label": "Contradiction",
        "explain": "The statement can be entailed by the CTRs. \n\nJustification: \nIn both trials, the primary outcome measurement is disease-free survival (DFS). In the primary trial, DFS is reported at 24 months, while in the secondary trial, DFS is reported until relapse or death or up to 5 years. The statement does not specify a particular duration for DFS, and therefore, it encompasses the DFS data from both trials. Moreover, the statement refers to the percentage of their patient cohorts with DFS less than 6 years, which is not explicitly stated in the CTRs. However, the percentage of participants who survived can be inferred from the CTRs and used to calculate the percentage with DFS less than 6 years by subtracting the percentage with DFS greater than or equal to 6 years. For instance, in the primary trial, the percentage of participants with DFS at 24 months is 89.8%, so the percentage with DFS less than 6 years would be the complement of 89.8%, i.e., 10.2%.\n\nTherefore, the statement is entailed by the CTRs as both trials monitor the percentage of their patient cohorts with DFS, although the statement is more general in its language."
    },
    "c428ec76-4d22-4d2d-8c06-1675bd431d41": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02222337",
        "Statement": "Participants for the primary trial must be in pairs, a breast cancer survivor and a caregiver, both must be ethnically Hispanic.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the Primary Trial's Inclusion Criteria, as both the breast cancer survivor and the caregiver being ethnically Hispanic is a requirement for participation. No contradiction exists with the CTR information."
    },
    "6cbc1567-2b51-45c0-ab1b-cac0b5fc7c38": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03283553",
        "Statement": "the primary trial has two cohorts.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nExplanation: \n\nThe primary trial only describes two interventions, not two cohorts. Therefore, the statement \"the primary trial has two cohorts\" is contradicted based on the information provided in the CTRs."
    },
    "a9d5c664-896f-4bb1-95e7-1deaa88848ef": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00089479",
        "Secondary_id": "NCT02964234",
        "Statement": "Agatha had her 53rd birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. Agatha is of white british origin. she is eligible for the primary trial but not the secondary trial, due to her age.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary CTR since Agatha matches the inclusion criteria for the primary trial (female patient, age 18-70 years, adenocarcinoma of the breast, no evidence of metastatic disease). However, the statement is contradicted by the secondary trial criteria since Agatha is of white British origin and does not meet the age requirement for the secondary trial (52-75 years old)."
    },
    "62b5fe62-470d-46e3-82a6-d57cd6cab452": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00471276",
        "Secondary_id": "NCT00951665",
        "Statement": "Gastrointestinal haemorrhage was more common in patients from cohort 1 of the primary trial than cohort 1 of the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Gastrointestinal haemorrhage was more common in patients from cohort 1 of the primary trial than cohort 1 of the secondary trial\" is contradicted by the information in the CTRs. According to the provided data, the number of cases of gastrointestinal haemorrhage is equal in both trials for cohort 1, with one occurrence in each. Hence, the statement is not entailed by the information in the CTRs."
    },
    "de349a2d-80ee-4c34-ab9f-38eb467c77d7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01106040",
        "Secondary_id": "NCT01441596",
        "Statement": "the primary trial and the secondary trial are not studying patient PFS, ORR or DLTs.",
        "Label": "Entailment",
        "explain": "Contradicted\n\nJustifications: \n\nThe primary trial does report on outcomes related to Lymphoseek and blue dye detection of lymph nodes, but it does not directly mention Patient Progression-Free Survival (PFS), Objective Response Rate (ORR), or Dose-Limiting Toxicities (DLTs). However, the secondary trials do report on patient outcomes, specifically the percentage of participants with patient benefit at week 12 according to predefined criteria for both Afatinib monotherapy and Afatinib in combination with Vinorelbine arms. These trials could be considered indirectly related to PFS and ORR, as improvement in neurological signs and symptoms and no tumour-related worsening could be considered indicative of disease stabilization or response. Thus, the statement is contradicted by the information presented in the CTRs."
    },
    "0d37bf26-bc74-4a01-9bc9-61e2fa3051da": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00446030",
        "Secondary_id": "NCT00975676",
        "Statement": "the primary trial and the secondary trial have no overlap in the drugs they use for their interventions.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the information provided in the CTRs.\n\nJustification:\nIn the primary trial, HER2 negative participants were given chemotherapy with docetaxel, doxorubicin, and cyclosphosphamide (TAC) + bevacizumab, and HER2 positive participants were given chemotherapy with docetaxel, carboplatin, and trastuzumab (TCH) + bevacizumab. Bevacizumab is the only drug that is used in common between the two trials, but it is used in different combinations with different chemotherapy drugs. Triptorelin is the drug used in the secondary trial, along with either tamoxifen or exemestane. Thus, there is no overlap in the drugs being used for the interventions between the primary and secondary trials as stated in the expert's claim."
    },
    "69f7a93d-7134-40ec-aff3-50acd7119d2c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02425891",
        "Secondary_id": "NCT00593827",
        "Statement": "the secondary trial and the primary trial both measure PFS of their patient cohorts.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided information in the CTRs. In both trials, the outcome measure is Progression-Free Survival (PFS) of the patient cohorts. Therefore, the statement correctly reflects the similarity in the measurements across the trials."
    },
    "8de31b0f-7127-4c8b-b5e0-060e7a83fae5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01299038",
        "Statement": "Joe has a known history of Hepatitis. However as he is over the age of 18 is still eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Joe has a known history of Hepatitis. However, as he is over the age of 18, he is still eligible for the primary trial\" is contradicted by the CTR. The exclusion criteria of the primary trial state that \"Known history of hepatitis C or active hepatitis B infection (baseline testing not required)\" is a reason for ineligibility. Therefore, the statement is not entailed by the CTR as stated."
    },
    "207a1d82-a61b-4b5f-bebf-0706def6729d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008150",
        "Secondary_id": "NCT00375427",
        "Statement": "In total the secondary trial recorded only 1 more case of Mucosal inflammation than the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The statement asserts that there is a difference in the number of reported cases of mucosal inflammation between the two trials. However, the CTRs provided do not mention the number of cases of mucosal inflammation in the primary trial. Therefore, the statement contradicts the available information.\n\nCTR-based justification: \n- The primary trial Adverse Events 1 and 2 sections do not mention any case of mucosal inflammation.\n- The secondary trial Adverse Events 1 section reports 0 cases, while Adverse Events 2 reports 1 case. However, no such information is available for the primary trial."
    },
    "968aeaf1-44b9-4454-8c99-e3c207037485": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01491737",
        "Statement": "There were 4 cases of Febrile neutropenia and heart failure in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nThe CTR for the primary trial indicates that there were a total of 46 adverse events in the entire cohort, out of which only one case each was reported for heart failure (section: Adverse Events 1) and febrile neutropenia (section: Adverse Events 1). No cohort information is provided in the CTR for the secondary trial, so it cannot be assumed that there were 4 cases of both febrile neutropenia and heart failure in cohort 1 of the primary trial."
    },
    "2b79f9cc-4262-4353-ad28-91cda07a9b9a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02988986",
        "Statement": "Patients must have AST, ALP and ALT < 1.5 ULN to participate in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Patients must have AST, ALP and ALT < 1.5 ULN to participate in the primary trial\" should be entailed by the CTR as the inclusion criteria specify \"Renal status: Creatinine clearance 50 mL/min based on Cockcroft-Gault estimate or based on urine collection (12 or 24 hour); Hepatic status: Serum total bilirubin 1 x ULN (in the case of known Gilbert's syndrome, a higher serum total bilirubin [< 1.5 x ULN] is allowed), aspartate aminotransferase and alanine aminotransferase 1.5 x ULN, and alkaline phosphatase 1.5 x ULN.\" While AST, ALT, and ALP are mentioned separately in the statement and the CTR, they are all liver function tests, and having values below the upper limit of normal for these tests is a requirement for participation in the trial based on the CTR."
    },
    "d56ffd81-4007-477b-b3c3-0fdb89806931": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00723398",
        "Statement": "Patients with diabetes insipidusare not suitable for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Patients with diabetes insipidus are not suitable for the primary trial\" is contradicted by the CTRs provided. Diabetes insipidus is not listed among the exclusion criteria for either trial. Therefore, the statement contradicts the information in the CTRs."
    },
    "f62e6c20-862b-4ce3-9121-0d93ff050839": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01373671",
        "Secondary_id": "NCT00686127",
        "Statement": "Lidoderm products are used in a intervention arm 1 of the secondary trial, and an FFDM product is used in arm 1 of the primary trial",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided CTRs. \n\nJustification: \n\nIn the primary trial, FFDM is used in intervention arm 1. FFDM is not a Lidoderm product, but it is mentioned in the primary CTR. \n\nIn the secondary trial, Lidocaine patch (a Lidoderm product) is used in intervention arm 1, and a placebo patch is used in intervention arm 2.\n\nThe statement asserts that a Lidoderm product is used in the secondary trial's intervention arm 1 and an FFDM product is used in the primary trial's intervention arm 1. This statement is consistent with the information in the CTRs because an FFDM product is mentioned in the primary trial, and a Lidocaine patch (a Lidoderm product) is mentioned in the secondary trial. There is no contradiction between the statement and the CTRs."
    },
    "833eeb4b-4921-468a-947d-bacfc7816ae6": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02162719",
        "Secondary_id": "NCT02131064",
        "Statement": "the primary trial and the secondary trial investigate the effects of their intervention on patient tpCR.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the provided information. In the primary trial, the outcome measurement is not directly related to tpCR. However, the trials are investigating the effects of interventions (Ipatasertib and Paclitaxel vs Placebo and Paclitaxel) on patient outcomes. In the secondary trial, the outcome measurement is tpCR, which aligns with the general focus of the expert's statement about the trials investigating the effects of interventions on this particular patient outcome. Therefore, the statement is an accurate summary of the trials' objectives."
    },
    "6dea5ffa-066d-45bf-b7e5-df3ae5bca0b6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00006110",
        "Secondary_id": "NCT00464646",
        "Statement": "the secondary trial records several gastrointestinal adverse events, whereas the primary trial doesn\u201a\u00c4\u00f6\u221a\u00d1\u221a\u00a5t record any GI adverse events.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the provided information. In the primary trial, there are no reported gastrointestinal adverse events according to Adverse Events 1 and Adverse Events 2. In contrast, the secondary trial reports several gastrointestinal adverse events, specifically hemorrhage, GI - stomach, and perforation, GI - colon, in Adverse Events 1 and ulcer, GI - stomach, in Adverse Events 2."
    },
    "c317750d-6ef7-494d-8040-2c7fa3d777fb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "the secondary trial and the primary trial both used MRI for their interventions.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the Clinical Trial Reports (CTRs). Both the primary and secondary trials involve the use of Magnetic Resonance Imaging (MRI) as a part of their interventions. Therefore, the statement accurately reflects the information provided in each CTR."
    },
    "87eca8d2-72fe-4285-9884-6d2ec7bae6df": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00567190",
        "Statement": "There was exactly the same proportion of anemic patinets in both cohorts of the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nThe statement is contradicted by the data presented in the CTRs. The primary trial had 3 anemic patients out of 396 participants (0.76%), while the secondary trial had 3 anemic patients out of 408 participants (0.74%). However, the statement asserts that the proportion of anemic patients was exactly the same in both cohorts, which is not the case based on the provided data."
    },
    "7a87c605-fc41-4d0a-9291-85e88f6eb510": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01000662",
        "Secondary_id": "NCT02413008",
        "Statement": "the secondary trial is testing a Gel which is applied inside the vagina, and the primary trial is testing an intervention which requires daily radiation of the breast(s).",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTRs as both trials involve interventions that require administration through specific routes. In the secondary trial, the intervention is a vaginal gel, and in the primary trial, the interventions are radiation therapies applied to the breast. Although the routes of administration and types of interventions differ between the trials, the statement's assertion that one trial tests a vaginal gel and the other tests a breast radiation is in line with the information in the CTRs."
    },
    "fbb853c9-bed4-4cde-a283-2d91b23d35bf": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01964924",
        "Secondary_id": "NCT00524303",
        "Statement": "the primary trial and the secondary trial both report results on pathologic evidence of invasive disease withing their patient cohorts after their interventions, using different outcome measurements.",
        "Label": "Entailment",
        "explain": "The statement is entailed, as both trials report the presence of pathologic evidence of invasive disease within their patient cohorts after interventions, although they use different outcome measurements. In the primary trial, the outcome measurement is Objective Response Rate (ORR), which includes Complete Response (CR) and Partial Response (PR) within the first 6 months after initiation of therapy with trametinib. In the secondary trial, the outcome measurement is Percentage of Participants With Overall Pathological Complete Response (pCR) after 26 weeks of therapy, which refers to the complete absence of invasive disease after treatment. However, the primary trial reports the absence of invasive disease through the CR and PR categories, while the secondary trial reports this through the pCR measure. Therefore, although the outcome measurements are different, they both relate to the presence or absence of invasive disease in the patient cohorts post-intervention."
    },
    "c3cc3621-a8ce-4f0d-a150-7e627f36e7c5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00482391",
        "Statement": "Patients with a QT interval longer than half a second are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary CTR does not mention any specific exclusion related to a QT interval longer than half a second."
    },
    "84aa97cf-efce-484e-825e-5af509e5988f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01441596",
        "Statement": "Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib monotherapy, up to 160% of the starting dose.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the information in Intervention 1 of the primary trial, as the text states that if a patient is well tolerated on Afatinib monotherapy, the dose may be escalated to 50 mg per day, which is 125% of the starting dose. Therefore, it follows that a patient could potentially receive a dose up to 160% of the starting dose (i.e., 1.6 * 50 mg = 80 mg per day) according to the given information."
    },
    "a40e172a-8839-499d-896d-be71a7ca4905": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03076190",
        "Secondary_id": "NCT03196635",
        "Statement": "Molecular Breast Imaging is not applied in either the primary trial or the secondary trial interventions, however all participants taking part in these studies will need to receive stem cell transplants.",
        "Label": "Contradiction",
        "explain": "Contradicted\n\nJustification:\nThe provided CTR sections describe the interventions used in the primary and secondary trials. The primary trial mentions two intervention groups: Intervention 1 (Health Education Active Control Group) and Intervention 2 (My Surgical Success Treatment Group). The secondary trial also mentions two intervention groups: Intervention 1 (All Study Participants, PA Compression Image Sets) and Intervention 2 (All Study Participants, TC Compression Image Sets). Nowhere in these sections does it state or imply that participants received stem cell transplants. Therefore, the statement that \"all participants taking part in these studies will need to receive stem cell transplants\" contradicts the information given in the CTRs."
    },
    "9e972e33-9ecd-4a8b-8337-7bee209f790b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02202252",
        "Statement": "The difference between cohort 1 and 2 of the primary trial is assesment by ultrasonography and the insertion of an additional negative pressure drain for patients in cohort 2.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the information in the CTRs. In both the single drain and double drain groups of the primary trial, ultrasonography is performed one day after the removal of the drains to examine seroma under the flaps and in the axilla (ELIGIBILITY CRITERIA and RESULTS sections are not relevant for this comparison, as no contradictory information is provided there). However, the main difference between the two cohorts lies in the number of drains inserted: one negative pressure drain below the lower flap and directing to the axilla in the single drain group, and two negative pressure drains, one in the axilla and one below the lower flap, in the double drain group (INTERVENTION sections). The expert's statement correctly reflects this difference."
    },
    "f29768ba-5d79-4528-839f-933ab13faaa1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01943916",
        "Secondary_id": "NCT01653964",
        "Statement": "All subjects in the primary trial and the secondary trial will be adminstered 4 mCi Tc-99m sestamibi and undergo Molecular breast imaging.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. In the primary trial, it is stated that \"Each subject served as her own control, with imaging of each mass by both the test and control modalities\" (implying that each subject undergoes two imaging sessions), and no information is given about the amount of Tc-99m sestamibi used for molecular breast imaging in this trial. In the secondary trial, it is explicitly stated that \"Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi\". However, the statement only refers to the administration of 4 mCi Tc-99m sestamibi and molecular breast imaging, which is a subset of the information in both trials. Therefore, the statement is a valid entailment given the provided CTRs."
    },
    "343e0a32-aebe-4bbb-97c0-b2c597c36802": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00392392",
        "Secondary_id": "NCT00503906",
        "Statement": "the primary trial records two different types of pain in its adverse events, in the abdomen and chest area, the secondary trial does not record any types of pain in its participants. ",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nExplanation: \n\nThe statement asserts that the secondary trial does not record any types of pain in its participants while the primary trial records two types, abdominal and chest pain. However, the provided CTRs for both trials show that they both report adverse events related to pain. In the secondary trial, there is a record of \"Seizure/Syncope\" [1] which could potentially be classified as a pain-related adverse event, but for the sake of argument, let's assume it is not. Nevertheless, there is a record of \"Pain - Chest\" in the primary trial, which is not present in the secondary trial. Therefore, the statement contradicts the information given in the provided Clinical Trial Reports."
    },
    "4d51608c-b0d8-4019-9b9a-34cf1c3d5087": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00558103",
        "Statement": "All participants in the primary trial are administered with Lapatinib 1500 mg PO QD and Pazopanib 800 mg.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed by the CTR information, specifically the Intervention sections for Cohort 1 in the Primary Trial for both Intervention 1 and Intervention 2. The participants in these interventions receive 1500 mg of lapatinib PO QD and either placebo (in Intervention 1) or 800 mg of pazopanib PO QD (in Intervention 2). Thus, when combined, they all receive the stated dosages mentioned in the expert's claim."
    },
    "7bb88699-1536-4fdc-9cb2-c5ef350d559b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00331552",
        "Secondary_id": "NCT01306942",
        "Statement": " trastuzumab was used for the interventions in the primary trial and the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed, as both the primary and secondary trial interventions involve the use of trastuzumab. Specifically, in the primary trial, trastuzumab is administered intravenously as part of combination therapy with cyclophosphamide and pegylated doxorubicin hydrochloride. In the secondary trial, trastuzumab is administered intravenously as part of combination therapy with dasatinib and paclitaxel. In both trials, trastuzumab forms a constituent part of the treatment interventions."
    },
    "c86ef61b-7565-465a-82ba-25e7ac050ccc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02139358",
        "Secondary_id": "NCT02574455",
        "Statement": "There was one case of hemorrhaging in the primary trial, and no recorded cases in the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the CTRs. In the primary trial, there were two instances of hemorrhaging reported (Duodenal hemorrhage and Neutrophil count decreased). However, none were reported in the secondary trial."
    },
    "58dec898-e0af-41c1-96f9-7163d3e3e855": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02019277",
        "Secondary_id": "NCT00863655",
        "Statement": "the primary trial and the secondary trial recorded three of the same types of adverse events",
        "Label": "Entailment",
        "explain": "The statement \"the primary trial and the secondary trial recorded three of the same types of adverse events\" is entailed by the provided data in the CTRs.\n\nJustifications: \n\nThe statement is harmonious with clinical trial data as both trials report occurrences of anaemia, febrile neutropenia, and mucosal inflammation.\n\nAnaemia: \n- Primary trial reports 3/50 occurrences in total (1.00%).\n- Secondary trial reports 49 occurrences in total (10.11%).\n  - Trial 1 reports 1 occurrence (2.00%).\n  - Trial 2 reports 48 occurrences (10.00%).\n\nFebrile neutropenia: \n- Primary trial reports 4 occurrences in total (8.00%).\n- Secondary trial reports 42 occurrences in total (0.09%).\n  - Trial 1 records 4 occurrences (8.00%).\n  - Trial 2 records 38 occurrences (8.26%).\n\nMucosal inflammation: \n- Primary trial reports only 1 occurrence in total (2.00%).\n- Secondary trial does not explicitly report mucosal inflaction, but there are mentions of oesophagitis and gastritis which might be related, and there are 7 occurrences in total, but it's not clear if they are the same events reported in the primary trial.\n\nThe statement does not contradict the descriptions as it only claims that three adverse events are shared between trials without specifying the exact number of occurrences, which is consistent with the data in the CTRs."
    },
    "5cf74526-9f91-498d-a13a-6393dcd45b7b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02291913",
        "Statement": "One patient in the primary trial suffered from an inflammation of the liver.",
        "Label": "Contradiction",
        "explain": "Contradicted. There is no mention of any patient in the primary trial suffering from an inflammation of the liver. The reported adverse events for the primary trial only include Anemia, Cardiac failure congestive, Constipation, Esophagitis, Gastrointestinal hemorrhage, Non-Cardiac chest pain, Pain, Cholecystitis, Diverticulitis, Cellulitis, and Gastroenteritis. (Primary Trial: Adverse Events 1)"
    },
    "154caa20-3be1-4cee-a838-2d90b44566c4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00191269",
        "Statement": "the primary trial did not use PFS to evaluate the performance of its interventions.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary trial did use Progressive Disease (PD) as an outcome measure in its Results section. However, Progression-Free Survival (PFS) was not explicitly mentioned in the given statement of the eligibility criteria or intervention sections. Nonetheless, the occurrence of PD in the Results section of the primary trial indicates some evaluation of disease progression, which is a key component of PFS assessment, albeit not explicitly reported as such."
    },
    "c40d8532-4e66-4eef-9644-91f20a02066d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02001974",
        "Statement": "No cases of Oesophageal adenocarcinoma were recorded in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the primary trial data, specifically the ELIGIBILITY CRITERIA and ADVERSE EVENTS sections. In the ELIGIBILITY CRITERIA of the primary trial, there is no mention of oesophageal adenocarcinoma as an exclusion criterion. Therefore, it is plausible that patients with this condition were included in the trial. In contrast, the ADVERSE EVENTS section for the primary trial reports one instance of oesophageal adenocarcinoma. Hence, the statement is contradicted by the provided data."
    },
    "3d450be5-4587-48e5-ae2e-745623606631": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01289353",
        "Secondary_id": "NCT00429182",
        "Statement": "the primary trial and the secondary trial both administer bi-weekly oral Carboplatin to their test groups.",
        "Label": "Contradiction",
        "explain": "The statement should be contradicted. The primary trial administers weekly IV Carboplatin for 6 weeks, not bi-weekly oral Carboplatin. Similarly, the secondary trial administers Carboplatin IV on specific days prior to high-dose chemotherapy and stem cell transplant, not bi-weekly. Therefore, neither trial administers bi-weekly oral Carboplatin as stated."
    },
    "fa28753a-aa3b-4642-9fd4-a2414fd8a472": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00943670",
        "Statement": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle, post T-DM1 intravenous (IV) infusion.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR data. The mean change from baseline in QTcF interval for the T-DM1 arm/group is indeed highest at Cycle 3 Day 1, 15 minutes post-dose [4.7 (9.6)] compared to other timepoints in the primary trial."
    },
    "5e700303-cd26-4024-a260-62f6a1c297ed": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01000662",
        "Secondary_id": "NCT02413008",
        "Statement": "the secondary trial is testing a Gel which is applied to the breast, whereas the primary trial is testing an intervention which requires daily radiation of the breast.",
        "Label": "Contradiction",
        "explain": "Contradicted. The secondary trial involves a vaginal gel intervention, whereas the primary trial involves radiation therapy to the breast. There is no mention of the breast in the secondary trial CTR. Specific sections: Primary CTR (INTERVENTION 1 and 2), Secondary CTR (INTERVENTION 1 and 2)."
    },
    "4c4c191c-de68-44c8-a23c-2455acc43d46": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00371345",
        "Secondary_id": "NCT00475670",
        "Statement": "There is no overlap between adverse events obeserved in the primary trial and the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the CTR data. In the primary trial, there were reports of OEDEMA PERIPHERAL (1/70, 1.43%) and GENERAL PHYSICAL HEALTH DETERIORATION (3/70, 4.29%), which are not listed in the secondary trial. Conversely, the secondary trial reported cases of NEUTROPENIA (1/41, 2.44%) and FEBRILE NEUTROPENIA (1/41, 2.44%), which were not observed in the primary trial. Therefore, there is an overlap in adverse events between the trials, contrary to the expert's statement."
    },
    "e5a4cb11-2a00-4144-93ba-f5462d7efbf0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01818063",
        "Secondary_id": "NCT00559507",
        "Statement": "In the primary trial and the secondary trial the only drugs administered orally are saracatinib and Veliparib.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the following evidence from the provided CTRs:\n\n1. INTERVENTION 1 (Primary Trial): The only drugs given orally in Arm 1 are not mentioned, but in Arm 2, Veliparib is given PO BID. However, the statement focuses on both arms in the primary trial, so it is still entailed that only oral drugs mentioned are saracatinib and Veliparib.\n2. INTERVENTION 2 (Primary Trial): The statement is explicitly stated that only oral drugs administered are saracatinib and Veliparib.\n3. INTERVENTION 1 (Secondary Trial): Saracatinib is given PO on days 1-28.\n\nThus, the statement is an accurate reflection of the data provided in the given sections of the two CTRs."
    },
    "03d72e5f-b921-4aeb-802c-4dc4ee1a7e4c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01720602",
        "Secondary_id": "NCT00082810",
        "Statement": "the primary trial participants receive more anastrozole, letrozole and exemestane than patients in the secondary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nThe primary trial participants receive AI therapy with anastrozole, letrozole, or exemestane. Each patient takes one of these treatments daily for 4 weeks during each 6-week treatment course. In contrast, the secondary trial employs fulvestrant 250 mg intramuscularly and tipifarnib 300 mg orally, given daily for a total of 15 days per 28-day course. The number of doses for the individual treatments in the primary trial is higher due to the different dosing frequency and longer treatment course length. However, the total daily dose for anastrozole, letrozole, or exemestane is less than the combined daily doses for fulvestrant and tipifarnib. Therefore, despite the higher number of doses administered, the total amount of medication received per day and, consequently, per patient is less in each primary trial arm than in the secondary trial."
    },
    "27a4d1a8-185b-4483-85ce-0fbb3d323b99": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01945775",
        "Statement": "The shortest PFS in the Talazoparib group of the primary trial was over a month longer than the study duration.",
        "Label": "Contradiction",
        "explain": "Contradiction. The shortest PFS in the Talazoparib group was 5.4 months (less than the trial duration of up to 36.9 months) as stated in the CTR (Results 1, Median PFS: 5.4 months, 95% CI: 4.2 to 6.8 months)."
    },
    "ff797dd4-0b4d-42fc-808d-27c439563ce2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01743560",
        "Statement": "By week 48 of the primary trial none of the patients had Complete Response, 7 had partial response and 15 had progressive disease.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs. \n\nJustification: \n\nIn the primary CTR, it is stated that at week 48, none of the patients in the Everolimus and Exemestane arm had a best overall response of complete response (CR). Furthermore, 7 patients had a best overall response of partial response (PR), and 15 patients had a best overall response of progressive disease (PD). This information directly matches the statement made by the clinical trials expert."
    },
    "9f666667-0fde-4d79-b53c-33c0ffbbed90": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00494481",
        "Statement": "Paula recently had fell down a flight of stairs and fractured her hip, she is excluded from the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Paula, who recently fractured her hip after falling down a flight of stairs, is excluded from the primary trial\" is entailed by the CTRs provided.\n\nExplanation: \n\nPaula's exclusion from the primary trial is due to her history of a significant cardiac event (fracturing her hip after a fall), which is listed in the exclusion criteria."
    },
    "47084742-d031-4e59-865c-d8687282c782": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00494481",
        "Statement": "Paula recently had a heart attack, she is excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Paula, who recently had a heart attack, is excluded from the primary trial\" is entailed by the CTRs provided. The Primary Trial's Eligibility Criteria section excludes subjects with significant cardiac events. A heart attack is considered a significant cardiac event; thus, Paula's exclusion follows the trial's criteria."
    },
    "ae583ea3-36a5-472c-acda-825cd7d513b6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454805",
        "Statement": "In the primary trial there were no cases of subendocardial myocardial infarction in cohort 1 or 2.",
        "Label": "Entailment",
        "explain": "The statement \"In the primary trial there were no cases of subendocardial myocardial infarction in cohort 1 or 2\" is not directly entailed by the provided CTR data for both trials, as the CTRs do not report any instances of subendocardial myocardial infarction. Therefore, the statement is neutral, neither entailed nor contradicted, with respect to the given data."
    },
    "a18c447b-de08-48ef-8e65-0ecaa775c2b0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00206427",
        "Statement": "A patient in the primary trial had a vaginal fungal infection.",
        "Label": "Contradiction",
        "explain": "The provided statement is not entailed by the given CTR data, as there is no mention of a vaginal fungal infection in either the primary or secondary trial Adverse Events sections."
    },
    "18b900fb-b071-43df-b37d-c68a89ef78c0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00050167",
        "Statement": " Patients with metastasis in four or more axillary lymph nodes are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Patients with metastasis in four or more axillary lymph nodes are eligible for the primary trial\" is contradicted by the CTR. According to the Eligibility Criteria section of the primary trial, patients with pN2a (metastasis in four to nine axillary lymph nodes) are eligible for adjuvant therapy, but they are NOT eligible for the neoadjuvant portion of the protocol. Therefore, the statement does not hold true for the entire trial, and it contradicts the provided information in the CTR."
    },
    "ebdf2841-b5e0-431a-8dc7-e100c5d27ccf": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00932373",
        "Statement": "Patients with Grade III peripheral neuropathy or above are eliminated from participation in the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The primary trial's inclusion criteria state that patients with a Grade 2 peripheral neuropathy are allowed to participate. Therefore, the statement that patients with Grade III peripheral neuropathy or above are eliminated from participation contradicts the CTR."
    },
    "d56745c3-ba0b-4b42-b3cf-ac060f658d83": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00670982",
        "Statement": "Acute coronary syndrome was the most prevalent adverse event in the primary trial, other than Thrombocytopenia .",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided data in the Primary Trial's Adverse Events section. The most prevalent adverse event, aside from Thrombocytopenia, was Neutropenia, which occurred in 17.24% of patients, while acute coronary syndrome is absent in the reported adverse events."
    },
    "0ef77b5d-684a-4a87-bf61-8d4bc9975b7f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01446159",
        "Statement": "the primary trial only had a total of 6 patients in across both its cohorts.",
        "Label": "Entailment",
        "explain": "The statement \"the primary trial only had a total of 6 patients in across both its cohorts\" is contradicted by the CTR as it states that there were a total of 3 patients in each trial, making for a total of 6 patients across both trials. There is no mention in the CTR of only 2 or fewer patients in total. Therefore, the expert's statement contradicts the provided data."
    },
    "03c7f31f-788c-4edb-a885-b6cb0fca05da": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00375505",
        "Statement": "In the primary trial patients in control group had a Z-score of 0.037, higher than the test group score. ",
        "Label": "Contradiction",
        "explain": "The expert's statement contradicts the CTR data. \n\nJustification: \n\nIn the primary CTR, the mean Z-score for the Placebo group is -0.075 (0.041), which is less than the mean Z-score for the Zometa group (0.037, 0.042). This indicates that the patients in the Placebo group had a lower bone mineral density change compared to the patients in the Zometa group, not a higher one as stated by the expert."
    },
    "e43c01e9-20a2-4435-a32b-224d5f460d7c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "The minimum Progression Free Survival for patients in cohort 1 the primary trial was 1.6 months.",
        "Label": "Entailment",
        "explain": "Contradicted. The statement is contradicted by the information provided in the Primary Trial's \"Outcome Measurement\" section, which states that the median PFS for patients in the Capecitabine arm was 2.8 months (1.6 to 3.2). This median value is higher than the 1.6 months claimed in the expert statement."
    },
    "c55f34ab-b883-465e-89dc-75bbeb8afa77": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00369655",
        "Secondary_id": "NCT00091832",
        "Statement": "One patient in the primary trial had a Confirmed tumor partial response, No patients in the secondary trial were evaluated for tumor response.",
        "Label": "Entailment",
        "explain": "Contradicted\n\nJustification: \n\nThe statement contradicts the information provided in the CTRs. The statement asserts that no patients in the secondary trial were evaluated for tumor response, while the primary trial reports the outcome measure as tumor response using RECIST criteria. Therefore, the trials address different outcomes and cannot be compared directly. Additionally, the statement does not provide any justification for why no patients in the secondary trial were evaluated for tumor response, which raises concerns about the validity of the statement."
    },
    "0ee36ceb-5790-440e-b6ad-10a0b7a23f43": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01925170",
        "Secondary_id": "NCT00324259",
        "Statement": "Participant in cohort 1 of the primary trial undergo a Mammography, whereas patients in cohort 1 of the secondary trial receive 6 mg Estradiol, and no Mammography.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nJustification: \n\nThe statement contradicts the information provided in the CTRs. In the primary trial, patients in cohort 1 underwent Mammography only, whereas in the secondary trial, patients in cohort 1 were given 6 mg Estradiol but no Mammography was mentioned. Therefore, the two groups are not equivalent, and the statement is not entailed by the CTRs."
    },
    "2535da13-e0f7-44df-aa02-89765d8d51cb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02419807",
        "Secondary_id": "NCT00777101",
        "Statement": "Patients with HER2 + breast cancer stage 1-4  are eligible for both the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided CTRs.\n\nJustification:\n\nThe primary trial includes patients with clinical stage 1 or 2 breast cancer, while the secondary trial is designed for patients with stage IIIB, IIIC, or IV erbB2 (HER2) positive breast cancer. These populations are not equivalent, as the primary trial excludes patients with advanced stage breast cancer, and the secondary trial specifically includes such patients. Furthermore, the primary and secondary trials have distinct eligibility criteria for prior treatments, surgical procedures, and organ functions. Therefore, patients with HER2+ breast cancer stage 1-4 cannot be eligible for both trials as described in the statement."
    },
    "94fc6e05-8a73-43d9-a48c-531d36dfbbcd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00548184",
        "Statement": "The majority of breast cancer patients in the primary trial treated with Lapatinib + Trastuzumab experienced at least Near Complete Pathologic Response, or better, after 12 weeks.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the data provided in the Primary Trial's Results 1 section. According to the data, 18 participants (29.7%) experienced a Complete Pathologic Response, while 16 participants (25%) had a Near Complete Pathologic Response. In total, 34 participants (53.1%) had either a Complete or Near Complete Pathologic Response. The statement claims that \"the majority of breast cancer patients in the primary trial treated with Lapatinib + Trastuzumab experienced at least Near Complete Pathologic Response,\" which aligns with the data, as over half of the participants had this response or better."
    },
    "0057172f-d019-401b-a516-993a7b46a67b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01306942",
        "Statement": "Participants of cohort 1 in the primary trial received more Dasatinib than those in cohort 2.",
        "Label": "Entailment",
        "explain": "The statement is entailed. In the primary trial, patients in cohort 1 received Dasatinib 100mg (daily) and patients in cohort 2 received Dasatinib 140mg (daily). Hence, cohort 1 received less dosage (100mg) per day compared to cohort 2 (140mg), but over the course of each cycle, cohort 1 received more total Dasatinib due to the longer cycle length in phase I (38 days vs 28 days)."
    },
    "bb23e8b8-c7d6-4e58-80a2-0555db5645e9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03096847",
        "Secondary_id": "NCT01840163",
        "Statement": "Female Patients recently prescribed Rapamycin are not eligible for the primary trial, but may be eligible for the secondary trial as long as they have a stage 1 to 2 Ductal carcinoma in situ and can speak english.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the primary trial's inclusion criteria. The primary trial states that patients who have received any mTOR inhibitor are excluded. Rapamycin is a mTOR inhibitor, making patients currently prescribed Rapamycin ineligible for the primary trial despite meeting any other requirements. However, according to the secondary trial's inclusion criteria, female patients with a Stage 1-2 Ductal carcinoma in situ who can speak English are eligible, regardless of any prior mTOR inhibitor use."
    },
    "c4588d2c-b0d4-428d-a958-29787b9d4ec5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00545077",
        "Statement": "Only cohort 2 of the primary trial receive Bevacizumab, but both cohorts undergo Endocrine Therapy .",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs. \n\nJustification: \n\nBoth arms (A and B) in the primary trial involve endocrine therapy (ET). In Arm A, patients may receive either letrozole or fulvestrant as endocrine therapy, while in Arm B, patients receive endocrine therapy along with bevacizumab. The statement correctly specifies that both cohorts undergo endocrine therapy but only cohort 2 receives bevacizumab."
    },
    "ee1f81d1-7e99-44dc-bb6a-ed002a78c9f6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00364611",
        "Statement": "Patients with clinically significant grade 3 PVD are eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradiction. The Primary Trial's EXCLUSION CRITERIA state, \"Presence of any non-healing wound, fracture, or ulcer, or the presence of clinically significant (>/= Grade 2) peripheral vascular disease.\" The statement \"Patients with clinically significant grade 3 PVD are eligible for the primary trial\" is contradictory to the information in the CTR because grade 3 PVD falls under the category of clinically significant peripheral vascular disease, making patients with this condition ineligible for the trial according to the provided criteria."
    },
    "00466f98-52b8-41f3-9bf1-2edaad950be9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02504424",
        "Secondary_id": "NCT03708393",
        "Statement": "the primary trial and the secondary trial both require the patients to activate the interventions by remote control.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. In the primary trial, it is stated that \"AeroForm Tissue Expander: The AeroForm Tissue Expander is activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.\" In the secondary trial, although the specific type of implant is different (an intrauterine system or IUS), the activation method is the same, as mentioned under both INTERVENTION 1 and INTERVENTION 2: \"IUS Alone imaging\" and \"IUS+OA imaging\" do not provide information about the activation method for the IUS. Therefore, the assumption that both trials require patients to activate the interventions by remote control is valid based on the provided information."
    },
    "50a524ae-2135-45f7-ae9b-515fd4e2e404": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02445586",
        "Secondary_id": "NCT02115984",
        "Statement": "More than half of patients in the primary trial experienced adverse events, and 100% of patients in the secondary trial did not experience an adverse event.",
        "Label": "Contradiction",
        "explain": "Contradicted. The statement is contradicted by the Adverse Events sections of both CTRs. In the primary trial, 59.62% of patients experienced adverse events, and in the secondary trial, 100.00% of patients experienced adverse events (specifically, nausea after the CT before day 7)."
    },
    "b2062e01-0ea6-4ee8-94a1-b59dc40901d3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01688609",
        "Statement": " Patients must have histologically or cytologically confirmed ERBB2+ invasive breast cancer, with Primary tumor > 2 cm in diameter to participate in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed as both trials require patients with histologically or cytologically confirmed invasive breast cancer and have a primary tumor larger than 2 cm in diameter (T2) as measured by caliper or ultrasound (CTR Primary: Inclusion Criteria). The difference lies in the additional requirement of ERBB2+ status for the secondary trial (CTR Secondary: N/A), which does not contradict the given information in the primary trial as the CTR does not mention any restrictions related to ERBB2 status for the primary trial."
    },
    "4dbce51b-1cfc-4d5f-82bb-ce9319ace3af": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00826267",
        "Statement": "Cohort 1 and 2 of the primary trial receive different quantities of different drugs.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the CTRs as both Cohort 1 and Cohort 2 receive different quantities (50 mg for Afatinib and 1500 mg for Lapatinib) of different drugs (Afatinib and Lapatinib) according to the Intervention sections in the primary trial."
    },
    "43a9cc96-4020-459c-8fa4-4bbde7173f7a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02447328",
        "Statement": "In the primary trial 11 patients had serious adverse events, no patients had serious  Adverse Drug Reactions, and over half of patients passed away from Unexpected adverse events.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nIn the primary CTR, there were 11 patients with serious adverse events (AEs), but there were no patients with serious Adverse Drug Reactions (ADRs). However, the expert's statement asserts that no patients had serious ADRs, which contradicts the CTR. Furthermore, the expert's statement claims that over half of patients passed away from Unexpected adverse events, while the CTR reports that 71.6% of patients had Unexpected AEs and 24.7% of these were fatal. The expert's statement seems to imply that all Unexpected AEs led to deaths, but the CTR does not make this claim."
    },
    "ff319fa6-89b6-4f1a-871d-456edb91b69b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03045653",
        "Statement": "Sharone had a hip replacement 3 weeks prior, she is not elgible for the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Sharone had a hip replacement 3 weeks prior, she is not eligible for the primary trial\" is contradicted by the CTR inclusion criteria as Sharone's hip replacement surgery within 4 weeks before study treatment is listed in the exclusion criteria for the primary trial. (Exclusion Criteria: \"Evidence of major surgery (excluding placement of vascular access) within 4 weeks before study treatment.\") Therefore, the statement contradicts the information in the CTR."
    },
    "a321acf0-2296-4588-bf96-85b22bf1420f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00274456",
        "Statement": "There are a total of 14 cases of neutropenia related adverse events in the primary trial across both cohorts.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTRs, as the total number of neutropenia adverse events in the primary trial, across both cohorts, is indeed 14, as reported in Adverse Events 1 and Adverse Events 2 sections, with 10 and 4 events respectively."
    },
    "b841dfd8-4676-4d3c-a57d-6ba1055b8597": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02027376",
        "Statement": "A patient was treated with Pertuzumab for 6 months, and this treatment was discontinued 2 months prior to study entry and the patient has fully recovered from the entailing side effects, hence this patient is eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "The patient's previous treatment history of Pertuzumab does not explicitly contradict the eligibility criteria of the primary trial, but the statement needs to be examined more closely to ensure entailment.\n\nJustification:\n\n1. The patient's capability to understand and comply with the protocol and signed informed consent document is not mentioned in the expert's statement, so it should be assumed the patient meets this criterion.\n2. The statement implies the patient is a female with advanced breast cancer, which aligns with the primary trial's inclusion criteria.\n3. The statement does not provide any information about the patient's hormonal receptor status, HER2 status, or TN status, which are essential elements of the primary trial's inclusion criteria. If these requirements have been met, then the patient is eligible based on the available information.\n4. The statement mentions the patient's disease status as \"measurable or non-measurable,\" but it does not explicitly state it's according to RECIST 1.1 criteria, which is a minor issue, as it's assumed the standard for measuring disease status in clinical trials.\n5. The patient's age, WHO Performance Status, and life expectancy also align with the primary trial's inclusion criteria.\n6. The statement does not mention any lab values, but the primary trial's exclusion criteria don't explicitly state lab values are required at the time of study entry. However, it is important to note, that if any lab values were outside the normal range during the treatment with Pertuzumab, they could potentially be a concern and need to be assessed for eligibility.\n7. The statement mentions the patient's recovery from side effects after discontinuing Pertuzumab for 2 months, which aligns with the primary trial's exclusion criteria related to receiving treatment with other investigational agents or receiving wide field radiotherapy within a certain period. However, it's essential to consider the specific side effects experienced and their impact on the patient's health to determine eligibility.\n8. The statement does not mention any conditions related to the exclusion criteria, such as liver or renal disease, pancreatitis, second primary malignancies, GI disease, peripheral vascular disease, cardiac function, ECG abnormalities, or family history of prolonged QT-interval syndrome, which is a positive sign for eligibility.\n\nBased on the provided statement, assuming that the patient's hormonal receptor status, HER2 status, and TN status align with the primary trial's inclusion criteria, the patient appears eligible for the primary trial as they meet all the essential inclusion criteria and do not meet any of the exclusion criteria mentioned in the provided CTR."
    },
    "1dd4acd1-657c-40c0-b5ab-9c7adbe4ebf4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042535",
        "Statement": "The Maximum Tolerated Dose (MTD) of of 1-Pemetrexed-d-tryptophan (indoximod) observed in the primary trial was 800 mg.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed by the primary CTR as per the given information, which reports the MTD of indoximod to be 800 mg PO BID with up to 6 fixed doses Ad.p53 DC vaccinations q2wks (as per the trial design, 3+3, 7 DLs, 6 treated patients, and 0 or 1 patient experiencing DLT at this dose level). Therefore, the statement made by the clinical trial expert falls within the established MTD reported in the primary CTR."
    },
    "48d40c7e-3514-43c3-a31a-7b391727f012": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01209195",
        "Statement": "Lower doses of MM-121 are utilised in cohort1 of the primary trial than in cohort 2, Paclitaxel doses are the same for both cohorts.",
        "Label": "Entailment",
        "explain": "The expert's statement is entailed by the CTR data. In the Primary Trial's Intervention 1 section for Cohort 1, the MM-121 dose is given as 20 mg/kg for the loading dose and 12 mg/kg weekly thereafter. In Intervention 2 for Cohort 2, the MM-121 dose is increased to 40 mg/kg for the loading dose and maintained at the same 12 mg/kg weekly dosage. Therefore, the lower doses of MM-121 in Cohort 1 are evident from the CTR. The Paclitaxel dosage remains constant at 80 mg/m2 weekly for both Cohorts 1 and 2, as stated in the Primary Trial's Intervention sections for both cohorts."
    },
    "dd98fca1-27a7-41c2-ba0c-3ff90aceab54": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01305941",
        "Statement": "Patients must present IHC 3+ or FISH amplified results to participate in the primary trial, meaning their cancer is Histologically-confirmed as being HER2-positive.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR. The primary trial inclusion criteria state that patients must have histologically-confirmed HER2-positive breast cancer as evidenced by IHC 3+ or FISH amplified results (Section 1: Eligibility Criteria). Therefore, the expert's statement aligns with the clinical trial requirements."
    },
    "b975dc12-757e-4ef5-af33-83dfce12e6cc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01989676",
        "Statement": "the primary trial only records GI adverse events.",
        "Label": "Contradiction",
        "explain": "Contradicted\n\nExplanation: \n\nThe provided CTRs report various types of adverse events for each trial. The statement that \"the primary trial only records GI adverse events\" contradicts the data presented, as the CTR for the primary trial lists numerous types of adverse events beyond GI events."
    },
    "2c4254c9-9c40-492f-aa45-2a9ab47579b3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02658734",
        "Secondary_id": "NCT02073487",
        "Statement": "Female Patients with LVEF > 50%,  who have previously undergone treatment with trastuzumab emtansine or lapatinib are still eligible for the secondary trial but are excluded from the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nJustification:\nThe statement is contradictory to the primary CTR inclusion criteria as it allows females with a history of treatment with trastuzumab emtansine or lapatinib to participate in the secondary trial, while the primary trial explicitly excludes such individuals."
    },
    "e140b055-b7fc-4802-a79b-9dfe7d136876": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01575522",
        "Secondary_id": "NCT00181363",
        "Statement": "the primary trial and the secondary trial are testing completely different modalities of interventions.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the information provided in the CTRs. In the primary trial, patients receive Tivantinib as an oral intervention, whereas the secondary trial does not involve any drug intervention but rather tests different positions (Prone vs Supine). These interventions are distinct from each other and therefore, the statement is entailed."
    },
    "0a6418c8-63a6-4900-bfc9-1659acbe1ad7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02581839",
        "Statement": "At least 8 participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) >= 3 months.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR data. \n\nJustification: \n\nThe CTR specifies that the Kaplan-Meier curve of CNS PFS and the estimation of PFS and its 95% CI will be provided at 12 weeks (Results 1). However, the minimum reported PFS for a participant is 3 months (the statement). The fact that at least 8 participants have achieved PFS >= 3 months does not contradict the CTR, as the CTR does not state that all participants have been analyzed after 3 months. The statement's assertion falls within the reported range of the PFS data (88.9% to 99.7%), and there is no contradictory information presented in the CTR that would challenge the statement's validity."
    },
    "2db9e0c7-d94b-47d2-a61f-55a0896d714e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00789581",
        "Secondary_id": "NCT02445586",
        "Statement": "the secondary trial reported more cases of Haematemesis, but the primary trial had more cases of Sinus tachycardia.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided CTR data. While the secondary trial reported a higher number of cases of Haematemesis (2/52 or 3.85% versus 1/305 or 0.33% in the primary trial), the primary trial reported a higher number of cases of Sinus tachycardia (1/305 or 0.33% versus 1/52 or 1.92% in the secondary trial)."
    },
    "3129e58d-0c16-42a5-90b4-f26e048dfe58": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01644890",
        "Statement": "Throughout the primary trial, one patient in cohort 1 developed issues with their vision.",
        "Label": "Contradiction",
        "explain": "The statement \"Throughout the primary trial, one patient in cohort 1 developed issues with their vision\" can be entailed by the CTR if Macular fibrosis (1/214) or Cataract (0/214 for Primary trial but 1/213 for Secondary trial) is present in cohort 1 and is not explicitly stated to be unrelated to the treatment. However, the statement would be contradicted by the CTR if there are no mentions of vision issues (such as macular fibrosis or cataract) in cohort 1 in either trial."
    },
    "7be7cecb-d265-4098-9969-a40555702573": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00679211",
        "Statement": "1 patient in the primary trial was diangosed with Influenza.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTR as there is a recorded instance of Influenza in Adverse Events 1 section of the Primary Trial (1/110 or 0.91%). Therefore, the statement matches the data in the CTR without contradiction."
    },
    "5b0d3709-7879-4dea-96c3-29178cd9f162": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00767520",
        "Statement": "Both cohorts of the primary trial reported the same number of patients vomiting during the trial.",
        "Label": "Entailment",
        "explain": "The statement should be contradicted based on the given CTRs. In the Primary Trial, there were 2 vomiting cases out of 79 participants (2.53%). In contrast, the Secondary Trial reported only 1 vomiting case out of 76 participants (1.32%). Therefore, the total number of patients vomiting in each trial is not the same."
    },
    "af70a3a9-d2d0-4d65-81fe-15a1becb5e95": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01420146",
        "Secondary_id": "NCT00077376",
        "Statement": "the primary trial and the secondary trial both have a control arm, and several test arms.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nExplanation:\n\nThe primary trial involves a single arm study with Zr89-trastuzumab (INTERVENTION 1) as the intervention, and no control arm is mentioned. The secondary trial describes a treatment regimen involving Ixabepilone, carboplatin, and trastuzumab (INTERVENTION 1) as the test arms, but no control arm is specified in the given text. The statement asserts that both trials have control arms and several test arms, which contradicts the actual information in the CTRs."
    },
    "a378f448-eef0-465a-abc0-8b4dd1156bb5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00372424",
        "Secondary_id": "NCT00041067",
        "Statement": "Patients with HER2 positive breast tumors are eligible for the primary trial and the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by both CTRs.\n\nJustification:\n\n1. In the Primary Trial CTR, the inclusion criteria specify patients with \"HER2-positive breast cancer.\"\n2. In the Secondary Trial CTR, the disease characteristics section specifies patients with \"HER2-positive breast cancer by FISH or immunohistochemistry 3+ staining confirmed in the adjuvant or metastatic setting.\"\n\nTherefore, the expert's statement that \"Patients with HER2 positive breast tumors are eligible for the primary trial and the secondary trial\" aligns with the information in the given CTRs. This statement is entailed by the provided information in both the Primary and Secondary CTRs."
    },
    "f30182a1-b82a-497c-885c-9bd2e805db62": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01487954",
        "Statement": "All patients in the primary trial had to drink 237 ml of water, either Alkaline Water or Distilled, depending on which cohort they are in.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided information in the CTRs. The patients in the primary trial are instructed to drink 8 ounces (236.59 ml) of alkaline or distilled water within 30 minutes prior to and after undergoing radiation therapy every day for 6 weeks. Hence, the total volume of water each patient consumes during the trial is 8 ounces * 5 days/week * 6 weeks = 237 ml. The statement correctly captures this information."
    },
    "ae87e5a3-fdd8-4003-ae80-4b370cade158": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "2% of the primary trial patients had Recurrence-free Survival < 3 years.",
        "Label": "Entailment",
        "explain": "The statement \"2% of the primary trial patients had Recurrence-free Survival < 3 years\" is entailed by the information provided in the CTRs. \n\nJustification: \n\nFrom the Primary Trial's Results section (Results 1), we know the following: the overall number of participants analyzed was 100, and the percentage of subjects with Recurrence-free Survival of 98 (92.2 to 99.5)%. This implies that 2% of the subjects had Recurrence-free Survival less than 3 years (since 3 years is not mentioned in the statement, but the statement's range of less than 3 years is included in the definition of Recurrence-free Survival as a time frame of up to 3 years in the Primary Trial CTR).\n\nTherefore, the statement is entailed by the data in the CTRs."
    },
    "9f3062db-16fb-41b8-ac10-f205f66070c8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00696072",
        "Statement": "Most patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years.",
        "Label": "Contradiction",
        "explain": "The statement \"Most patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years\" is entailed by the CTR information, as indicated by the following details:\n\n1. In the primary trial, 20 out of 56 participants (35.7%) in the Dasatinib + Letrozole arm had a DFI greater than 2 years.\n2. No explicit information is given in the CTR that contradicts the statement for the Dasatinib + Letrozole arm.\n\nHowever, it is important to note that the CTR does not provide enough information to definitively conclude that \"Most patients\" in the Letrozole arm had a DFI greater than 2 years. Although the number of participants with DFI greater than 2 years in the Letrozole arm is also 20 out of 61, it is not explicitly stated that most of them had this outcome. Therefore, while the statement is entailed for the Dasatinib + Letrozole arm, it is not entailed for the Letrozole arm based on the information given in the CTRs."
    },
    "a1c5685a-8e6e-4733-aa8b-7040bac1a397": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00022672",
        "Statement": "There were no patients in either cohort of the primary trial with a PFS exceeding 6 months.",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nJustification:\nIn the primary trial, the median PFS for the Trastuzumab + Anastrozole group was 4.8 months (3.7 to 7) and for the Anastrozole group was 2.4 months (2 to 4.6) in the 24-month time frame. The Kaplan Meier estimates of PFS at the end of the study for the Trastuzumab + Anastrozole group were 5.8 months (4.6 to 8.3) and for the Anastrozole group were 2.9 months (2.1 to 4.5). Both median and Kaplan Meier estimates for the Trastuzumab + Anastrozole group exceed 6 months."
    },
    "d58683e2-d276-4184-a8e9-c9df6ffd8047": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00559507",
        "Statement": "the primary trial participants are given saracatinib PO for a maximum of 28 days.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. In the primary trial, patients receive saracatinib PO for 28 days and the treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity, which implies that patients are given saracatinib for a maximum of 28 days at a time."
    },
    "28d8f88a-e8cb-40c0-a12b-ef555f83ff59": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01904903",
        "Secondary_id": "NCT01663727",
        "Statement": "Patients must have LVEF < 50% to be eligible for the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "The given statement should be contradicted based on the information in the provided CTRs.\n\nJustification:\n\nFor the primary trial, patients with LVEF less than 50% are eligible. However, for the secondary trial, patients with LVEF less than 50% are excluded.\n\nPrimary Trial, Inclusion Criteria: LVEF < 50%\nSecondary Trial, Exclusion Criteria: LVEF < 50%\n\nTherefore, the statement \"Patients must have LVEF < 50% to be eligible for the primary trial and the secondary trial\" is incorrect.\n\nAdditionally, the primary trial has different inclusion criteria for breast cancer type and HER2 status compared to the secondary trial, further supporting the conclusion that the statement is contradictory."
    },
    "0ee4c935-18bd-4807-a2af-041a3d84e125": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02721147",
        "Statement": "Stephanie has been living with her boyfriend for 2 months, she is eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary trial's inclusion criteria, as it states that Stephanie is female, her age is unspecified but > 21 years, she has a diagnosis of non-recurrent stage I-III breast cancer, and she has completed active treatment 6 months-5 years ago with current endocrine therapy use being acceptable. There is no explicit statement about the length of time Stephanie has lived with her boyfriend in the inclusion criteria, but it is mentioned as a requirement in the primary trial. Thus, even with the shorter duration of living with her boyfriend, she still meets the other necessary criteria and is eligible for the trial."
    },
    "355fb813-cbe0-44f5-b04a-87813e060d54": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00371254",
        "Statement": "Patients must have eceptorsestrogen receptor (ER) -, progesterone receptor (PR) - and human epidermal growth factor receptor 2 (HER2) - breast cancer, aswell as not having Dysphagia.",
        "Label": "Entailment",
        "explain": "Contradiction. The primary CTR inclusion criteria state that patients must have locally advanced or metastatic breast cancer, but it does not specify that they must be ER+, PR+, or HER2- for eligibility. The secondary trial's statement adds a new requirement, which is not mentioned or entailed in the primary CTR."
    },
    "274d9d2b-9227-4496-a525-d5477b0003ce": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00796978",
        "Secondary_id": "NCT01276041",
        "Statement": "More patients in cohort 1 of the secondary trial suffered from oedema in their limbs, compared to patients in cohort 2 of the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"More patients in cohort 1 of the secondary trial suffered from edema in their limbs, compared to patients in cohort 2 of the primary trial\" cannot be determined to be entailed or contradicted based on the provided information.\n\nExplanation:\n\nThe statement does not directly entail or contradict the information in the CTRs as it does not mention the number of patients who suffered from edema specifically in either of the trials. The CTRs do list edema as an adverse event in the secondary trial, but they do not provide the number of cases or the percentage of patients who experienced this symptom in either cohort 1 or 2. Therefore, without this information, it is impossible to establish entailment or contradiction."
    },
    "3ab9c66c-06fc-4bc5-b504-d9193efa8701": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290745",
        "Statement": "in the primary trial participants from different ethnicities receive different interventions.",
        "Label": "Contradiction",
        "explain": "Contradiction. \n\nThe CTR for the primary trial does not indicate that participants from different ethnicities receive different interventions. Both tamoxifen and letrozole are given to participants with ductal carcinoma in situ, regardless of ethnicity. (INTERVENTION 1 section in both primary and secondary trials)"
    },
    "d39078d9-9bc3-4b91-a012-e95f14813c9a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01252277",
        "Statement": "Fiona's step sister, who is 34 years old was diagnosed with a ductal carcinoma, therefore fiona may be eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Fiona's step sister, who is 34 years old was diagnosed with a ductal carcinoma, therefore fiona may be eligible for the primary trial\" is contradicted by the CTR. According to the CTR, women who have had invasive breast cancer diagnosed or treated within the past five years are excluded from the primary trial. Therefore, Fiona would not be eligible for the study based on this information, despite her step sister's diagnosis."
    },
    "02538194-97ac-4749-9301-83f108927478": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00041067",
        "Secondary_id": "NCT01273896",
        "Statement": "Patients with ER positive, PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by both CTRs as they both allow patients with ER and PR positive, and HER2 positive tumors to participate in the trials. The specific information can be found in the ELIGIBILITY CRITERIA sections of both CTRs. For the primary trial, the information is given as \"No hormone receptor status specified,\" which can be inferred to include ER and PR positivity. In the secondary trial, the inclusion criteria explicitly state \"HER2+ disease must have received prior treatment with Trastuzumab, and Patients with ER and/or PR+ disease must have received prior treatment with hormonal therapy.\" This implies that ER and PR positive patients are included in the trial."
    },
    "6d9113b4-9d18-4a1b-bc78-cc3ac1150876": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572038",
        "Secondary_id": "NCT00826267",
        "Statement": "Each patient in the primary trial receives 3 different drugs, whereas in the secondary trial patients receive 1 of 2 possible drugs.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information provided in the CTRs. In the primary trial, participants received pertuzumab, trastuzumab, and taxane (which can be docetaxel, paclitaxel, or nab-paclitaxel), making a total of 3 distinct drugs. In contrast, the secondary trial had patients receiving either Afatinib or Lapatinib, constituting 2 different drugs for each participant. Therefore, the number of unique drugs administered in each trial matches the given statement."
    },
    "99599b71-85d7-4c15-8d23-4294732f87cf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00558103",
        "Statement": "All participants in the primary trial are administered with Lapatinib 1500 mg PO QD.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the CTR as follows:\n\n1. In Intervention 1 for Cohort 1 of the primary trial, participants received lapatinib 1500 mg PO QD.\n2. In Intervention 2 for Cohort 1 of the primary trial, participants received lapatinib 1500 mg PO QD.\n\nTherefore, all participants in the primary trial are indeed administered with Lapatinib 1500 mg PO QD, as stated."
    },
    "adbc193f-ffd6-49ce-9acd-7b1675adf0c0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00768222",
        "Statement": "Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan, she cannot take part in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the CTR. Rachel's exclusion from the primary trial is due to having skin ulcerations (exclusion criterion) and having a known allergy or intolerance to triclosan (exclusion criterion). Therefore, the statement's claim that Rachel cannot participate in the trial contradicts the information in the CTR."
    },
    "c476f92a-a450-4e5c-9688-6557ff3d822b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01617668",
        "Statement": "Patients must have healthy kidneys, liver and ovaries to participate in the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. The primary trial's inclusion criteria state \"Adequate renal function,\" \"Adequate liver function,\" and no specific exclusion for ovaries. However, the secondary statement mentions only kidneys, liver, and ovaries without specifying any conditions, so the more inclusive statement from the CTR applies."
    },
    "39d685a4-b179-4687-a273-2a44e675f2c6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00900627",
        "Statement": "The two groups in the primary trial receive the same drug treatment, but group 2 gets double the dose.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the information provided in the CTRs. Both groups in the primary trial are indeed receiving the same drug treatment (AZD8931) but the dose intensity is different, with group 1 receiving 160 mg twice daily (bd) and group 2 receiving double the dose, which is 120 mg twice daily (bd). This aligns with the statement made by the clinical trial expert."
    },
    "c66963b9-19e0-4c0f-bb65-2fec15e60b8f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00965523",
        "Statement": "The most common adverse events in the primary trial where Infection and Stomatitis, affecting a total of 14 patients.",
        "Label": "Contradiction",
        "explain": "The statement is entailed based on the information provided in the Adverse Events sections of both the primary and secondary trials. The statement correctly identifies Infection and Stomatitis as the most common adverse events, affecting a total of 14 patients in the primary trial. The total number of patients with these adverse events (2 + 12 = 14) is consistent with the data given in the CTR."
    },
    "f541ce25-c43e-496b-98e6-8470fe23f840": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00559845",
        "Secondary_id": "NCT00426556",
        "Statement": "In total there were more adverse events in cohort 1 of the secondary trial than in cohort 2 of the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The total number of adverse events in cohort 1 of the secondary trial (3/6 or 50.00%) is less than that of cohort 1 in the primary trial (8/54 or 14.81%). This contradicts the statement."
    },
    "dafe9dce-420e-46dc-a8ed-ac2f4c84b49b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01224678",
        "Statement": "Intervention 2 of the primary trial resulted in a lower percentage in Mammographic Density than intervention 1.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the data presented in the CTRs. From Results 1 and 2, the mean percentage change in mammographic density for the Placebo group is -3.4 (7.1), and for the Vitamin D group is -1.4 (11.9). The negative values indicate a decrease in mammographic density, and the absolute value of the mean percentage change is smaller in the Vitamin D group (-1.4) than in the Placebo group (-3.4). This difference aligns with the expert's statement that Intervention 2 (Vitamin D) resulted in a lower percentage in Mammographic Density than Intervention 1 (Placebo)."
    },
    "24d81b18-ce9c-4927-9386-9ebef969a159": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00291135",
        "Secondary_id": "NCT00291694",
        "Statement": "The duration of treatment in the primary trial is half as long as in the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed. In the primary trial, letrozole is given for a total duration of 6 months (2.5 mg daily), while in the secondary trial, both celecoxib and placebo groups receive treatment for a total duration of 12 months. Thus, the duration of treatment in the primary trial is indeed half as long as in the secondary trial. (Refer to the INTERVENTION sections of the primary and secondary trial CTRs)"
    },
    "0046e113-8ac5-4725-a285-e78b8c26f825": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02756364",
        "Statement": "In order to meet the inclusion criteria for the primary trial patients must have had aromatase inhibitor (AI) therapy before study entry, resulting in complete tumor response.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTR as per the inclusion criteria for the primary trial stating \"Progressive Disease (PD) during prior aromatase inhibitor (AI) therapy.\" This indicates that patients had previous AI therapy but did not respond completely, which aligns with the expert's statement."
    },
    "e90f7748-f4b4-4822-8768-586c3f2f9980": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00499083",
        "Secondary_id": "NCT03045653",
        "Statement": "In order to be eligible for both the secondary trial and the primary trial, patients must be female, over the age of 18, ECOG <2 and have Histologically confirmed HER2 + breast cancer.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nThe primary trial's eligibility criteria specify HER2/neu-negative tumors, and further testing is required for tumors in the indeterminate range. Contrastingly, the secondary trial's inclusion criteria necessitate HER2/neu-negative breast cancer. Therefore, patients who meet the requirements for the secondary trial cannot fulfill the conditions for the primary trial."
    },
    "fb8f09d6-c393-4943-bc67-fa0f0a6bdd86": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429572",
        "Secondary_id": "NCT02455453",
        "Statement": "post-menopausal patients are excluded from the secondary trial, but eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted. According to the CTRs, post-menopausal patients meet the inclusion criteria for the secondary trial and are excluded from the primary trial due to different eligibility criteria."
    },
    "3c3fb5e3-1994-455a-bae4-6d267c5c89d7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00932373",
        "Statement": "Patients with Grade I peripheral neuropathy or above are eliminated from participation in the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary CTR includes \"Grade 2 peripheral neuropathy\" in the exclusion criteria, but it does not mention \"Grade I peripheral neuropathy\" as an exclusion."
    },
    "2ecd62df-f5ea-417d-8783-2174a6d77087": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03573804",
        "Secondary_id": "NCT02781051",
        "Statement": "Participants of the primary trial must undergo at least one MRI during the intervention and a strict chemotherapy regiment, whereas in the secondary trial patients must use a fitbit.",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nJustification:\nThe statement contradicts the information in the primary CTR as it mentions \"a strict chemotherapy regiment,\" which is not mentioned in the provided Intervention section of the CTR. The secondary trial does not involve chemotherapy as stated. The only interventions mentioned in the primary CTR are MRI evaluations by two different radiologists. In contrast, the secondary trial involves a physical activity intervention with no mention of chemotherapy. Therefore, the statement's claim about \"a strict chemotherapy regiment\" is contradictory to the information provided in the CTRs. The comparison between the trials should focus on the specified interventions rather than unmentioned elements."
    },
    "b43c02bf-c4b0-495f-b7ba-879f409cb685": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01781299",
        "Statement": "all subjects in the primary trial must commit to a regular exercise schedule.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nThere is no mention of a regular exercise schedule for participants in the provided sections of the primary or secondary CTRs. The CTRs exclusively discuss the implantation of different acellular dermal matrices (AlloDerm RTU and SurgiMend PRS) at the time of tissue expander placement for each trial arm."
    },
    "fdff0cf1-a0a2-4516-bdf7-109ac7adb266": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03136367",
        "Secondary_id": "NCT00129935",
        "Statement": "Only patients which have been assigned as female at birth are eligible for the secondary trial and the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary and secondary trial CTRs since both trials specify that only females are eligible for participation. (Primary Trial: Inclusion Criteria: Assigned female at birth; Secondary Trial: No mention of males as eligible participants)."
    },
    "6babfc60-5043-4f2b-9605-3e44744265e9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00398567",
        "Statement": "80% of patients in the primary trial did not suffer any adverse events.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the Adverse Events section of the Primary Trial since only one participant (1/4) reported an adverse event, and there were no reports of adverse events for three-quarters (3/4) of the participants (80%)."
    },
    "5ca02204-6120-4b02-bf3b-fba94d6fac4f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00274469",
        "Statement": "No more than 1% of either cohorts of the primary trial felt nauseous.",
        "Label": "Entailment",
        "explain": "The statement \"No more than 1% of either cohorts of the primary trial felt nauseous\" is contradicted by the data in the CTRs. In the Adverse Events section of the Primary Trial, one participant experienced nausea out of 101 (1.00%). In the Adverse Events section of the Secondary Trial, none of the participants experienced nausea out of 103. Therefore, the statement is false and contradicts the data in the CTRs."
    },
    "625c2690-ec9e-4ecc-85c0-9b5ca8467848": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00836186",
        "Statement": "Patients cannot be excluded from the primary trial on the basis of gender or ethnicity.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary CTR as it explicitly states \"Women of all races and ethnic groups are eligible for this trial.\" (INCLUSION CRITERIA) Therefore, gender is not a reason for exclusion, and the statement is consistent with the CTR."
    },
    "c28ad685-4c91-492a-85ab-180f37d9cef5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00290758",
        "Statement": "There was one GU and three GI adverse events recorded in the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. \n\nJustification: \n\nThe statement \"There was one GU and three GI adverse events recorded in the primary trial\" is contradicted by the provided CTR data in both the primary and secondary trials. \n\nIn the primary trial, there is one recorded adverse event for \"Obstruction, GU: Uterus\" under the renal - Other category, which does not fit the definition of GU (Genitourinary) or GI (Gastrointestinal) adverse events as per the statement. Moreover, there are no recorded adverse events under the categories of \"GI\" in the primary trial. \n\nIn the secondary trial, there are no adverse events mentioned under the categories of \"GU\" or \"GI\" either. Thus, neither trial reports the occurrence of one GU and three GI adverse events as stated by the clinical trial expert."
    },
    "52e8d676-1744-4fdb-bab4-a553874329bd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00829166",
        "Statement": "Female patients with Peripheral neuropathy >0 are excluded from the primary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted. The primary trial's exclusion criteria state that peripheral neuropathy of Grade >/= 3 is a disqualifying condition. However, the expert's statement refers to female patients with any peripheral neuropathy, which is not specified to be of a certain grade. This discrepancy contradicts the information in the CTR."
    },
    "beff8878-9405-412d-af3a-0f2720275bf3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00068601",
        "Secondary_id": "NCT01684215",
        "Statement": "the primary trial and the secondary trial both use subcutaneous injections as the route of administration for their interventions.",
        "Label": "Contradiction",
        "explain": "Contradicted\n\nExplanation:\n\nThe statement asserts that both trials use subcutaneous injections as the route of administration for their interventions. However, the primary trial specifies that cyclophosphamide (which is part of the interventions in both trials) is given as part of the chemotherapy regimen via an unspecified route, whereas goserelin (only in the primary trial) is given subcutaneously. The secondary trial, on the other hand, describes PD-0332991 as being given orally. Thus, there is a contradiction between the statement and the provided CTRs."
    },
    "96f41881-6ba5-4688-8471-9462fc727919": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00089661",
        "Statement": "On average cohort 1 participants in the primary trial had an increased Lumbar Spine Bone Mineral Density, whereas those in cohort 2 lost mineral density.",
        "Label": "Entailment",
        "explain": "The statement \"On average cohort 1 participants in the primary trial had an increased Lumbar Spine Bone Mineral Density, whereas those in cohort 2 lost mineral density\" is entailed by the provided CTR information.\n\nJustification:\n\nThe statement's claim about the average percentage change in Lumbar Spine Bone Mineral Density aligns with the data presented in the CTR. Specifically, the statement refers to an increase in cohort 1 and a decrease in cohort 2, which corresponds to the 4.8 (4.3 to 5.4) percent change for Arm/Group Title: Denosumab 60 mg Q6M and the -0.7 (-1.3 to -0.1) percent change for Arm/Group Title: Placebo.\n\nTherefore, there is no contradiction between the statement and the CTR data."
    },
    "9dbf55d5-6af3-4250-b5cb-97799cdf778a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "There were no cases of Intracranial hemorrhage in the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. \n\nExplanation: \n\nThe statement asserts that there were no cases of intracranial hemorrhage in the primary trial. However, the given CTR does not mention any occurrence of intracranial hemorrhage in either the adverse events section of the primary trial (Section 3) or in the description of the secondary trial."
    },
    "e8ce8686-8d5f-4d31-b442-0cb52b7b2bec": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00338728",
        "Statement": "Participants of the primary trial higher doses of Imatinib mesylate than Letrozole, but are administered Letrozole twice as often.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the primary trial's INTERVENTION 1 description. In this trial, Letrozole is administered once a day daily for 28 days, whereas Imatinib mesylate is given twice a day daily for 28 days. The number of Letrozole doses (28) is the same as that of Imatinib mesylate doses in a cycle, but the frequency of Letrozole administration is twice as often as Imatinib mesylate. Therefore, the statement that \"Participants of the primary trial higher doses of Imatinib mesylate than Letrozole\" is false according to the given CTR."
    },
    "d72709fd-e94e-4c27-bf56-3f028c0bbd3f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01118624",
        "Statement": "The majority of the primary trial participants achieved CR or PR.",
        "Label": "Contradiction",
        "explain": "The statement \"The majority of the primary trial participants achieved CR or PR\" is entailed by the information in CTR Results 1 if the proportion of patients in the Pralatrexate arm achieving CR or PR is a majority of the total number of participants analyzed in that trial (22). The CTR does not specify the exact number of patients achieving CR or PR, but it does indicate that the overall response is considered in the ORR, which includes both CR and PR. Therefore, based on the available information, it is possible that a majority of the participants achieved a CR or PR, and this is consistent with the data given in the CTR. However, it is important to note that further analysis would be required to definitively confirm this, as the exact numbers are not provided in the CTR."
    },
    "bdf078ad-37b0-4f8f-80a3-35fa8e59fd2b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00463788",
        "Statement": "Best Overall Response (BOR) was less than 10% higher in cohort 1 of the primary trial than in cohort 2.",
        "Label": "Entailment",
        "explain": "To evaluate the entailment or contradiction of the statement, we need to compare the percentage of participants with BOR in cohort 1 and cohort 2 of the primary trial. The statement asserts that the difference in BOR between the two cohorts is less than 10 percentage points.\n\nFrom the provided information, we can determine the percentage of participants with BOR for each cohort as follows:\n- Cohort 1 (Cisplatin and Cetuximab): 20.0% (13.1-28.5)\n- Cohort 2 (Cisplatin only): 10.3% (3.9-21.2)\n\nTo check the entailment, we need to find if the difference between these percentages is less than 10 percentage points. In this case, the difference is 9.7 percentage points which is greater than 10 percentage points. \n\nTherefore, the statement is contradicted by the data presented in the CTRs.\n\nNote: In order for the statement to be entailed, the difference between the percentages should be less than 10 percentage points as stated. In this instance, the difference is higher, which indicates that the statement is contradicted by the information provided in the CTRs."
    },
    "49f44497-2382-4658-b716-38e66c5c52b7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00425854",
        "Statement": "Intervention of Cohort B is described as Afatinib 50 mg, taken orally, for every day of the study.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the Primary Trial INTERVENTION 1 section, where it is explicitly stated that patients in Cohort B received an oral dose of Afatinib with a dosage of 50 mg qd (once daily)."
    },
    "4a6dc84a-3afd-4060-b8c5-981895f31099": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00312208",
        "Statement": "Cases of Cardiomyopathy and Coagulation disorders were only observed in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "explain": "The statement should be contradicted. According to the CTRs provided, there is one case of Cardiomyopathy in the primary trial (in cohort 1) and zero cases in the secondary trial. However, both trials list coagulation disorders in both cohorts with different frequency. Therefore, the statement only being applicable to cohort 1 regarding cardiomyopathy is incorrect, based on the information provided. Additionally, there is one case of coagulation disorders in cohort 2 of the primary trial, and no cases reported in the secondary trial."
    },
    "11e84dc4-6573-4ad7-b2d9-cfc66b626e1c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02574455",
        "Statement": "More than a quarter of patients in cohort 1 of the primary trial experienced an adverse event.",
        "Label": "Entailment",
        "explain": "The statement is entailed based on the information in both CTRs. The total number of adverse events for cohort 1 in the primary trial is 69/258, which is more than a quarter (26.74%). Similarly, cohort 1 in the secondary trial had 64 adverse events out of 224 participants (28.57%), also exceeding a quarter of the cohort."
    },
    "f1f2e066-a016-422f-8627-d0e477933352": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193063",
        "Statement": "In the primary trial patient cohort, 3 different types of infections are observed. ",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR data in the Adverse Events section of the Primary Trial. Specifically, the statement identifies three types of infections observed in the trial cohort, while the CTR data lists a total of 9 instances of infection-related adverse events (pneumonia, port site, and urinary tract). Therefore, the three types of infections stated by the expert are present in the CTR data."
    },
    "efbd87d7-f8ac-42c6-ac9a-e3a35d354885": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00295867",
        "Statement": "Patients with a Karnofsky status of 94% are eligible for the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The Karnofsky Performance status of 94% is not mentioned in the inclusion criteria for the primary trial. The lowest acceptable value is 90%. (Primary Trial: Eligibility Criteria)"
    },
    "a604244f-789f-4c12-8c5a-96c86d1b976e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the AZD0530 175 mg group, with a -75.9 % change from baseline.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR as it correctly identifies the biggest change in percentage change from baseline in betaCTX at Week 4 observed in the primary trial as being in the AZD0530 175 mg group, with a -75.9% change (as given in Results 1: \"Geometric Mean (95% Confidence Interval): Unit of Measure: Percentage change in betaCTX -75.9 (-75.9 to -65.4)\")."
    },
    "2b543cc7-e295-4dc6-ad04-a2e43e9b3d97": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565083",
        "Statement": "Two different types of tachycardia occurred to patients in cohort 2 of the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the data in the CTR. In Adverse Events 2 of Primary Trial, one patient experienced supraventricular tachycardia (1/107 or 0.93%) and one patient experienced tachycardia (1/107 or 0.93%). Therefore, two different types of tachycardia indeed occurred in cohort 2 of the primary trial."
    },
    "987b1da5-0276-417d-a659-8e298529ccac": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01684215",
        "Statement": "In the primary trial there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991.",
        "Label": "Entailment",
        "explain": "The statement should be entailed based on the information provided in the CTRs. Both the PD-0332991 100 mg and 125 mg cohorts had an identical percentage (16.7%) of participants experiencing DLTs, as indicated by the results (Results 1 and 2) in the respective CTR sections. Therefore, the statement that \"there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991\" is an accurate reflection of the trial data and should be entailed."
    },
    "b9e8a0b3-574f-4079-9191-214af99e97a8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01176916",
        "Secondary_id": "NCT00186121",
        "Statement": "postmenopausal women with T1-4N1-3M1 Early invasive breast cancer are eligible for the primary trial, and Premenopausal women with T4-4N1-3M1 Early invasive breast cancerare eligible for the secondary trial.",
        "Label": "Contradiction",
        "explain": "The given statement contradicts both primary and secondary trial inclusion criteria. For the primary trial, the statement includes postmenopausal women with T1-4N1-3M1 Early invasive breast cancer, which is a subset of the specified inclusion criteria (ER positive, postmenopausal women with T1-4N1-3M0 breast cancer who have received adjuvant Tamoxifen therapy). However, the secondary trial inclusion criteria explicitly states that premenopausal women with T4-4N1-3M1 Early invasive breast cancer are eligible, which is different from the statement's claim. The primary trial does not allow women who have received aromatase inhibitors, while the secondary trial allows those with positive estrogen and/or progesterone receptor determination. Therefore, the statement contradicts information present in both CTRs."
    },
    "0151d1fa-05c8-45a0-b21e-f08478ea5110": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01697345",
        "Secondary_id": "NCT00513292",
        "Statement": "Fluorouracil, testosterone, and cyclophosphamide (FEC) are used in both cohorts of the secondary trial, but not in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. The primary trial does not involve the use of FEC (Fluorouracil, epirubicin, and cyclophosphamide) in cohort 1, as stated in the provided description. In contrast, the secondary trial includes FEC in both interventions but not in the first phase (12 weeks) of cohort 1. This aligns with the statement."
    },
    "b4b3ebdf-0e46-48fd-a57d-7d2a6c8a48de": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01075100",
        "Secondary_id": "NCT00290758",
        "Statement": "several different mental health issues were observed in the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"several different mental health issues were observed in the primary trial and the secondary trial\" is entailed by the provided CTRs. In the primary trial, the adverse event \"Mood Alteration: Depression\" was observed in 1 participant out of 48, whereas in the secondary trial, a participant out of 64 reported a sexual issue, which could be considered a mental health issue. This indicates that at least one mental health issue was observed in each trial. However, it is important to note that the primary trial also reported adverse events related to various other body systems, but the statement specifically mentions mental health issues. Therefore, the statement is a valid inference from the given data."
    },
    "b838a265-99e4-42f0-bd72-b4f72d7eb16e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02027376",
        "Statement": "A patient was treated with Pertuzumab for 6 months, and this treatment was discontinued less than 1 month prior to study entry and the patient has not fully recovered from the entailing side effects, hence this patient is eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The given statement can be contradicted with the primary trial's exclusion criteria. Specifically, the patient having received a small molecule therapeutic within 4 weeks prior to study drug initiation makes the patient ineligible according to the CTR. The statement mentions a patient who had received treatment with Pertuzumab, which is considered a monoclonal antibody therapy, and the side effects of which have not yet fully resolved. Since Pertuzumab falls into the category of a biological therapy (as mentioned in the secondary trial statement), it can be inferred that it is also a small molecule therapeutic based on the information provided in the primary trial exclusion criteria (patients who have received any other investigational agents 5 t1/2 or 4 weeks (whichever is shorter) prior to study drug initiation or who have not recovered from the side effects of such therapy). Therefore, based on the CTR, this patient would be ineligible for participation in the trial."
    },
    "240e9cb0-3e40-4478-9d2c-fb4ff22e1e21": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00676793",
        "Secondary_id": "NCT01931163",
        "Statement": "Patients suffering from vomiting are still eligible for both  the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement can be contradicted based on the following exclusion criteria in both primary and secondary trials:\n\nPrimary Trial: No mention of vomiting as an exclusion criterion.\nSecondary Trial: No mention of vomiting as an exclusion criterion.\n\nHowever, the eligibility criteria in the secondary trial state that patients must have adequate gastrointestinal function, but it does not specify vomiting as a disqualifier. Therefore, the statement does not have to be entailed, but it does not contradict the information in the CTRs either."
    },
    "a1644573-fba8-4598-8353-a40d3ef1968c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00428922",
        "Secondary_id": "NCT00499083",
        "Statement": "Patients with prior chemotherapy for the treatment of stage 4 cancer are not eligible for either the primary trial or the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed as both primary and secondary trials explicitly exclude patients with prior chemotherapy in the metastatic setting. (Primary Trial: Exclusion Criteria, Secondary Trial: Prior Concurrent Therapy)."
    },
    "ba533122-db9d-49e1-a2d1-936c8fdfdd00": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01298193",
        "Statement": "More than 15 patients in cohort 1 of the primary trial experienced adverse events.",
        "Label": "Entailment",
        "explain": "Contradiction. \n\nThe statement asserts that more than 15 patients in cohort 1 of the primary trial experienced adverse events. However, the provided CTR data states that a total of 31 adverse events were reported out of 185 participants, which amounts to 16.76%. Cohort-specific adverse event data for cohort 1 is not provided; however, it is clear that the overall total includes all participants from both cohorts. Therefore, the statement contradicts the provided data as it suggests that more than 15 patients from cohort 1 experienced adverse events, whereas the actual data indicates that fewer than half of the participants in total experienced adverse events."
    },
    "f20cd859-7159-457a-a1cb-56bdb01d521b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00274456",
        "Statement": "There are a total of 7 cases of Gastritis in the primary trial across both cohorts.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the provided data in the CTRs. In the Primary Trial Adverse Events section, there is no report of any case of Gastritis (0/76) for either cohort. Similarly, in the Secondary Trial Adverse Events section, there is no mention of Gastritis cases (0/number_of_participants)."
    },
    "d33df923-6c12-4135-b339-5cefdd240985": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00003782",
        "Statement": "Neither of the cohorts in the primary trial had more than 5% of patients experiencing side effects.",
        "Label": "Entailment",
        "explain": "The statement should be entailed. \n\nExplanation:\n\nBoth Adverse Events 1 and Adverse Events 2 in the Primary Trial have a total of 109 events out of 1748 patients, resulting in a combined rate of 6.24% (109/1748). However, neither of the rates exceeds 5% for a single cohort. Specifically, Adverse Events 1 had a rate of 3.78% (66/1748) and Adverse Events 2 had a rate of 2.46% (43/1748). Therefore, the expert's claim that neither cohort had more than 5% of patients experiencing side effects is consistent with the provided CTRs."
    },
    "0f49a1ec-ed73-465b-be20-b70fe990b1f0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00333775",
        "Secondary_id": "NCT00201864",
        "Statement": "There are several coagulative adverse events recorded in the primary trial, but not a single one in the secondary trial.",
        "Label": "Contradiction",
        "explain": "Contradicted\n\nExplanation:\n\nThe statement asserts that there are coagulative adverse events recorded in the primary trial but none in the secondary trial. However, the CTRs provided do not mention any coagulative adverse events such as thrombosis, thromboembolism, or bleeding in the primary trial. The only adverse events mentioned are febrile neutropenia, neutropenia, leukopenia, anaemia, thrombocytopenia, atrial fibrillation, arrhythmia, arteriospasm coronary, atrioventricular block first degree, and cardiac failure.\n\nIn contrast, the secondary trial reports thromboembolism as an adverse event occurring in 2/40 participants (5.00%). Therefore, the statement contradicts the information in the CTRs."
    },
    "7370c10d-f6e7-4153-9649-9d2598ce1ed7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03196635",
        "Secondary_id": "NCT01943916",
        "Statement": "the primary trial and the secondary trial are both evaluating imaging techniques.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR information provided. Both the primary and secondary trials involve evaluations related to imaging techniques in their interventions. In the primary trial, image sets were evaluated for acceptability of overall clinical image quality for both study groups (PA and TC compression image sets). In the secondary trial, imaging of masses was conducted using both test and control modalities for each subject, and specificity difference was measured for the overall population. The commonality between both trials lies in their focus on imaging techniques, making the expert's statement entailed."
    },
    "3f89537a-479e-4314-b9de-4caf845850fc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the Zoledronic Acid 4 mg group, with a -73.0 % change from baseline.",
        "Label": "Contradiction",
        "explain": "The statement should be entailed. The expert's statement is consistent with the result presented in the CTR for the Zoledronic Acid 4 mg group, which has a geometric mean percentage change from baseline of -73.0 (-73.0 to -63.2). The statement correctly identifies the largest change from baseline in betaCTX observed in the primary trial, which is also reflected in the CTR."
    },
    "8e9f417a-dc0f-4c20-9cf7-5f8586c23df2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01985971",
        "Secondary_id": "NCT03273426",
        "Statement": "Patients will have to undergo an MRI scan of the spine for before entry for both the secondary trial and the primary trial, for the primary trial patients will also need to have a brain MR and PET imaging, after study entry.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the primary CTR since it requires MRI scans of the spine for both trials, which is consistent with the primary CTR's inclusion criteria specifying the need for brain MR and PET imaging. However, it may not be directly entailed by the secondary CTR as it does not explicitly mention the requirement for an MRI scan of the spine before entry for that trial."
    },
    "8ba451be-606a-4a57-a85e-82b5e5b286fc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03366428",
        "Statement": "3/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of over 30 ms.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR information. \n\nJustification: \nAccording to the primary trial, there were 3 participants (6.1%) out of 49 with a maximum change from baseline in QTcF > 30 ms. Therefore, 3 out of 49 is equal to 3/49, which is consistent with the expert's statement."
    },
    "46906361-5133-4db9-b9e5-b9b7f80a8666": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00721630",
        "Secondary_id": "NCT00364611",
        "Statement": "the primary trial and the secondary trial recorded the same proportion of patients experiencing nausea.",
        "Label": "Contradiction",
        "explain": "Contradiction. The primary trial recorded a higher proportion of patients experiencing nausea (1/23 or 4.35%) compared to the secondary trial, which had no reported cases of nausea among the 20 patients (0.00%). The statement does not harmonize with the clinical trial data."
    },
    "ab17f223-3f70-4b63-bfc5-1fca5d6ec05d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "In order to be eligible for the primary trial, patients must not have prior radiation, anthracycline or systemic anticancer therapy , and must have T1-3, N0 and M0 breast cancer.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the information in the Primary Trial's Inclusion Criteria section, specifically the Exclusion Criteria subsection that includes \"Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy, chemotherapy).\", \"Prior anthracycline therapy or taxoids (paclitaxel, docetaxel) for any malignancy.\", and \"Prior radiation therapy for breast cancer.\" The statement also aligns with the Inclusion Criteria that specifies T1-3, N0, and M0 breast cancer. The expert's statement only omits mentioning negative axillary lymph nodes (N0) from the breast cancer stage, but this does not contradict the CTR's inclusion criteria."
    },
    "3320983d-55cb-49f9-9265-ca4e77acf62a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01094184",
        "Statement": "A patient who had a Joint injection in the last month would not be eligible for the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the Primary Trial's Eligibility Criteria section, specifically, there is no exclusion mentioned regarding joint injections for patients to not be eligible for the trial."
    },
    "6c57e451-a706-4b32-ae71-254e9d0e04de": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01250379",
        "Statement": "None of the patients in the primary trial had Thrombocytopenia, congestive Cardiac failure, Pancytopenia, Acute coronary syndrome or Atrial fibrillation.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the data in the primary and secondary trial Adverse Events sections. In the primary trial, there were 5 cases of Thrombocytopenia, 0 cases of congestive Cardiac failure, 0 cases of Pancytopenia, 0 cases of Acute coronary syndrome, and 1 case of Atrial fibrillation. In the secondary trial, there were 5 cases of Thrombocytopenia, 2 cases of congestive Cardiac failure, 1 case of Pancytopenia, 1 case of Acute coronary syndrome, and 1 case of Atrial fibrillation. Therefore, the statement is contradicted by the data in the CTRs."
    },
    "73a5f715-6d4c-43f3-ace4-9f1217d3d0c4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00383500",
        "Statement": "the primary trial is not testing a drug based intervention, it is testing a Medical device called the Flexitouch.",
        "Label": "Entailment",
        "explain": "The statement \"the primary trial is not testing a drug based intervention, it is testing a Medical device called the Flexitouch\" is entailed by the CTR information provided, as both Intervention 1 and Intervention 2 described in the Primary Trial involve the use of a medical device - the Flexitouch for Intervention 1, and no mention of drugs for either intervention."
    },
    "83883edd-ea16-4b20-8a97-2a545f957add": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00006110",
        "Secondary_id": "NCT00464646",
        "Statement": "the secondary trial records only gastrointestinal adverse events, whereas the primary trial doesn\u201a\u00c4\u00f6\u221a\u00d1\u221a\u00a5t record any GI adverse events.",
        "Label": "Contradiction",
        "explain": "Contradicted.\n\nExplanation:\n\nThe provided statement asserts that the secondary trial records only gastrointestinal adverse events whereas the primary trial doesn't have any. However, the Adverse Events sections in both primary and secondary CTRs list various types of adverse events, including gastrointestinal events. Therefore, the statement contradicts the information given in the CTRs.\n\nAdditionally, for the primary trial, the Adverse Events section mentions 'Nervous system disorders - Other, specify' with one occurrence (13.46% of the total adverse events). The statement doesn't take this into account and only considers gastrointestinal adverse events.\n\nHence, the statement contradicts the information provided in both trials."
    },
    "ad0628ef-be51-4d54-a5c6-7608df258629": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00895414",
        "Statement": "Orange juice is banned for patients undertaking the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement \"Orange juice is banned for patients undertaking the primary trial\" is contradicted by the provided CTR as grapefruit juice, not orange juice, is explicitly prohibited for patients in the primary trial."
    },
    "619d88fd-cef5-4f1a-83dc-3cc710c1c93d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00203502",
        "Statement": "Less than 30% of patients in the primary trial experienced at least 1 adverse event.",
        "Label": "Contradiction",
        "explain": "The statement is contradicted by the data in the primary trial's Adverse Events section, where 100.00% of patients experienced at least one adverse event."
    },
    "42d6a15e-fa43-4ebc-b627-70f4dd0233f8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00322374",
        "Statement": "Cohort 2 of the primary trial receive a higher dose of Ixabepilone than cohort 1, but the same dose of Epirubicin.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the provided CTR information. In the primary trial, the dosage of Ixabepilone is different between the two cohorts, with cohort 2 receiving a higher dose (30 mg/m^2) compared to cohort 1 (25 mg/m^2). Both cohorts received the same dose of Epirubicin (75 mg/m^2).\n\nCTR references:\nPrimary Trial: INTERVENTION 1 and INTERVENTION 2."
    },
    "fc60c272-ceeb-47b5-b25b-dca832a2a57e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02203565",
        "Secondary_id": "NCT00194779",
        "Statement": "laboratory biomarker analysis and questionnaires are used in the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed.\n\nJustifications:\n- In the primary CTR, laboratory biomarker analysis is mentioned as an optional correlative study (INTEROVENTION 1, CTR1).\n- In the secondary CTR, laboratory biomarker analysis is listed as a correlative study twice (INTEROVENTION 1, CTR2).\n- Questionnaires are mentioned as ancillary studies in the primary CTR (INTERVENTION 1, CTR1).\n- Questionnaires are not explicitly mentioned in the secondary CTR, but they can still be used in the trial as ancillary studies since they were not excluded.\n\nTherefore, the statement that \"laboratory biomarker analysis and questionnaires are used in the secondary trial and the primary trial\" is an entailed conclusion based on the provided CTR information."
    },
    "dfe1236f-ac29-4c1c-a287-6f46abb7703d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00810797",
        "Secondary_id": "NCT00828074",
        "Statement": "Skin infections were more common in patients in cohort 2 of the secondary trial, than in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the CTRs. In the primary trial, there was one case (1/36) of skin infection in cohort 1, and in the secondary trial, there were two cases (2/41) of skin infection in cohort 2. Therefore, the frequency of skin infections is higher in cohort 2 of the secondary trial than in cohort 1 of the primary trial (2.44% vs. 2.78%). However, it's important to consider that the total number of patients in each cohort is also different, and the absolute number of cases might not be the most relevant measure when comparing the incidence of an adverse event between trials. Nevertheless, based on the provided information, the statement is semantically entailed."
    },
    "b1060434-0f7c-4c4a-bcff-53c3124bb51e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02513472",
        "Statement": "Cohort 1 of the primary trial produced better Objective Response Rate results than cohort 2.",
        "Label": "Entailment",
        "explain": "The statement \"Cohort 1 of the primary trial produced better Objective Response Rate results than cohort 2\" is entailed by the given CTR information as follows:\n\n1. According to the CTR, the primary trial had two cohorts: Stratum 1 and Stratum 2. Stratum 1 consisted of participants who were never treated with systemic anticancer therapy in the metastatic setting, while Stratum 2 consisted of participants who were previously treated with 1 to 2 lines of systemic anticancer therapy in the metastatic setting.\n2. The Objective Response Rate (ORR) was calculated based on independent imaging review using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The ORR for each cohort is reported as a percentage in the Results section.\n3. The ORR for Stratum 1 was 25.8% (15.8-38.0), and the ORR for Stratum 2 was 21.8% (14.2-31.1).\n\nThus, the statement \"Cohort 1 of the primary trial produced better Objective Response Rate results than cohort 2\" is entailed by the given CTR information because Stratum 1 had a higher ORR percentage than Stratum 2."
    },
    "e2862bbf-562f-4c96-abf1-fc9f07655b46": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00627978",
        "Statement": "Women with leptomeningeal metastases are unfortunately excluded from the primary trial, as this would complicate the evaluation of neurologic and other adverse events.",
        "Label": "Entailment",
        "explain": "Contradicted.\n\nExplanation: \n\nThe statement \"Women with leptomeningeal metastases are unfortunately excluded from the primary trial\" contradicts the CTR's exclusion criteria, which explicitly states, \"Patients with known and active brain and/or leptomeningeal metastases should be excluded from this clinical trial.\" (Primary CTR: Eligibility Criteria)"
    },
    "aed75656-1594-4d99-be42-7097f7926c18": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00240071",
        "Statement": "At least one participant of the primary trial died in under a 100 days.",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nThe CTR does not provide any information indicating that at least one participant in the Avastin (Bevacizumab) Plus Hormone arm died within 100 days. The median PFS in this arm was 125.5 days (90 to 256 days), which implies that the majority of participants survived beyond 100 days."
    },
    "6ce5a9d7-5793-43b0-92ed-980cca3be02b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01961544",
        "Statement": "the primary trial reported a combined total of 3 cases of Pericardial effusion, Asthenia and Gastritis in cohort 1.",
        "Label": "Contradiction",
        "explain": "Contradiction.\n\nThe primary CTR reports a total of 20 adverse events in cohort 1, out of which 3 are Pericardial effusion, Asthenia, and Gastritis. However, the statement asserts that there are only 3 cases in total, which contradicts the reported number of adverse events in the CTR."
    },
    "b2a4f905-c6b5-4977-95de-5aa6424a5bb6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00217399",
        "Statement": "To be included in the primary trial, patients must have at least 1 unidimensionally measurable lesion, there are no size boundaries for eligibility.",
        "Label": "Contradiction",
        "explain": "Contradiction. The primary trial's inclusion criteria explicitly state that patients must have at least one unidimensionally measurable lesion with specific size boundaries for eligibility. For instance, a lesion must be >= 10 mm on CT scan or >= 20 mm on CT scan or MRI, or >= 10 mm on physical exam for eligibility. Therefore, the statement that there are no size boundaries for eligibility contradicts the information provided in the CTR."
    },
    "a611e8dd-cafc-46dd-b8ed-3fa7c5f5a7b4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00591851",
        "Statement": "There were 4 different Gastrointestinal adverse events recorded in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR data in Adverse Events section of cohort 1 in the primary trial. The statement claims there were 4 different gastrointestinal adverse events recorded, which is consistent with the CTR reporting Diarrhea, Abdominal Pain, Lower gastrointestinal hemorrhage, and Nausea as separate adverse events. All of these events fall under the category of gastrointestinal adverse events."
    },
    "4db02d9b-d96e-4ced-947c-71cebcccc933": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00847171",
        "Secondary_id": "NCT01764022",
        "Statement": "Sufferers of Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is contradicted by the Primary CTR, as individuals with systemic lupus erythematosis are explicitly listed as having prior or currently active autoimmune diseases requiring management with systemic immunosuppression, and are not allowed to participate in the Primary trial (section \"PRIOR CONCURRENT THERAPY: No prior or currently active autoimmune disease* requiring management with systemic immunosuppression\"). However, the statement suggests that such individuals might be eligible for the Secondary trial, which contradicts the exclusion in the Primary trial."
    },
    "cfb07772-e485-491c-8ae3-9009e3d04415": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00201864",
        "Statement": "One patient in the primary trial had a WBC count far below normal.",
        "Label": "Contradiction",
        "explain": "The statement \"One patient in the primary trial had a WBC count far below normal\" is not explicitly stated in the provided CTRs, and there is no entailment or contradiction with the information provided. The CTRs only report adverse events such as nausea, vomiting, chest pain, hypercalcemia, and thromboembolism for the primary trial, but they do not mention WBC count for any patient. Therefore, it is neither entailed nor contradicted based on the available information."
    },
    "a283b69c-0f36-4773-a711-9e6088a8ee63": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01712009",
        "Secondary_id": "NCT00343382",
        "Statement": "Cohort 2 patients in the primary trial receive naproxen at the same frequency as cohort 2 patients in the secondary trial receive Pilocarpine.",
        "Label": "Entailment",
        "explain": "The statement \"Cohort 2 patients in the primary trial receive naproxen at the same frequency as cohort 2 patients in the secondary trial receive Pilocarpine\" can be entailed based on the given information. \n\nJustification: \n\nThe frequency of naproxen administration in the primary trial for cohort 2 is 5 days in each of the 4 cycles, beginning on the day of pegfilgrastim administration, which translates to approximately every 3 weeks. \n\nIn the secondary trial, the frequency of Pilocarpine administration is 2 times per day for 6 weeks. However, since 6 weeks equates to approximately 42 days (assuming 7 days per week), and patients receive Pilocarpine for the entire duration of 6 weeks, this frequency translates to about 2 times per day.\n\nTherefore, both cohorts receive medication twice a day for a comparable duration, satisfying the statement."
    },
    "8d90d538-3b56-48dd-bd58-007d266c923c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00915018",
        "Statement": "The only cases of cardiac problems in the primary trial occurred in cohort 1.",
        "Label": "Contradiction",
        "explain": "The statement \"The only cases of cardiac problems in the primary trial occurred in cohort 1\" is contradicted by the CTRs provided since cohort 2 of the secondary trial also reported cases of cardiac problems, specifically, one instance of cardiac failure congestive and one instance of left ventricular dysfunction. Therefore, the statement does not hold true for both trials. \n\nSpecifically, the CTR of the primary trial indicates that there were two cases of cardiac failure congestive and one case of cardiac tamponade in the entire trial population. However, the statement only mentions cohort 1, neglecting the existence of cardiac problems in cohort 2 from the secondary trial. \n\nTherefore, the statement \"The only cases of cardiac problems in the primary trial occurred in cohort 1\" contradicts the information in the CTRs provided."
    },
    "fa0fe1a0-2b89-4b78-8fdb-04dee84b4421": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Secondary_id": "NCT03592121",
        "Statement": "Patients are not required to be sexually active to receive the primary trial intervention, this is however a requirement for the secondary trial.",
        "Label": "Entailment",
        "explain": "The statement is not contradicted by the CTRs. However, it is entailed by the information given in the ELIGIBILITY CRITERIA section of the Primary Trial, as it does not state any requirement for sexual activity, while the Secondary Trial's ELIGIBILITY CRITERIA explicitly mentions it as a requirement. Therefore, the statement is valid for the Primary Trial but not for the Secondary Trial."
    },
    "8502cb9e-e382-41bc-b547-02d2d7beb381": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00620373",
        "Statement": "the primary trial tests two different breast imaging modalities, namely X-ray and gamma imaging.",
        "Label": "Entailment",
        "explain": "The statement \"the primary trial tests two different breast imaging modalities, namely X-ray and gamma imaging\" is contradicted by the CTRs provided. The primary trial indeed involves two different reporting arms, but both arms utilize only one specific imaging modality each - mammography for Intervention 1 and gamma imaging for Intervention 2. The statement suggests testing of both X-ray and gamma imaging within the same trial, which is not supported by the information presented in the CTRs."
    },
    "f6c64bb3-1836-4685-8541-8856f003524b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01105312",
        "Statement": "Patients with non-measurable diseases are only eligible for phase I of the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the Primary Trial's ELIGIBILITY CRITERIA as it specifies that \"Measurable or non-measurable disease for phase I study (The Phase I portion of this study closed and the Phase II portion of the study opened as per NCCTG Addendum 6, effective January 23, 2012.)\" and \"Measurable disease only for phase II study.\""
    },
    "79272218-91b9-4331-ba44-6a3709a13f62": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00073528",
        "Secondary_id": "NCT00191152",
        "Statement": "the secondary trial and the primary trial study the Progression Free Survival (PFS) of their participants, however they use different Units of Measure.",
        "Label": "Entailment",
        "explain": "The statement should be entailed. In the primary trial, the outcome measurement defines PFS as the time from randomization until the earliest date of disease progression or death due to any cause, if sooner. Although the units of measure for the primary and secondary trial results differ, both trials assess PFS. Therefore, the difference in units of measure does not contradict the statement."
    },
    "97e3b0d7-3320-4eb5-bc42-5031db87692e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01964924",
        "Secondary_id": "NCT00524303",
        "Statement": "the primary trial and the secondary trial both report Objective Response Rate (ORR) of their patients.",
        "Label": "Contradiction",
        "explain": "The statement is entailed. Both primary and secondary trials report Objective Response Rates (ORR) for their patients. The primary trial uses RECIST 1.1 criteria and defines ORR as the proportion of patients with a PR or CR within the first 6 months of therapy with Trametinib. The secondary trial defines pCR as the absence of invasive breast cancer and axillary lymph nodes cancer after 26 weeks of therapy, and ORR is the sum of pCR in the breast and axillary lymph nodes. Although the definitions and time frames differ, they both report the proportion of patients with a response to the treatment."
    },
    "83251670-803e-4fec-a5cf-50f052932752": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708214",
        "Statement": "All Participants with disease progression (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group.",
        "Label": "Contradiction",
        "explain": "The statement \"All Participants with disease progression (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group\" is entailed by the information in the CTRs. \n\nJustification:\nThe statement asserts that all participants who experienced disease progression in the primary trial were in the Afatinib 50 mg With Letrozole group. This can be confirmed by examining the Results 1 and Results 2 sections of the primary trial CTR. Specifically, we can see that:\n\n- In Results 1, we find that the percentage of participants with disease progression in the Afatinib 50 mg With Letrozole group was 70.96% (3.67-100%), indicating that all participants in this group experienced disease progression.\n- In Results 2, we find that no participants in the Afatinib 40 mg With Letrozole group experienced disease progression, as the percentage was 0.00 (0.00-24.71).\n\nTherefore, according to the data provided in the CTRs, the statement that \"All Participants with disease progression (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group\" is an entailed statement."
    },
    "efd950a8-ae79-4d4a-9ce7-3f1d0a37e6de": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01610284",
        "Statement": "1 patient in the primary trial had an abrupt loss of heart function.",
        "Label": "Entailment",
        "explain": "The statement \"1 patient in the primary trial had an abrupt loss of heart function\" is entailed by the information in the CTR under the heading \"Cardiac arrest\" in Adverse Events 1, where it is mentioned that 1 patient experienced a cardiac arrest."
    },
    "e00b0ccc-e53b-44ba-9555-b6f8d6d5e55a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT01926886",
        "Statement": "The most common adverse event in the primary trial was Febrile neutropenia (42.86%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%).",
        "Label": "Entailment",
        "explain": "The statement is entailed. The expert's statement accurately reflects the adverse event data presented in each CTR, specifically mentioning the most common adverse event in each trial. In the primary trial, the most common event was Febrile neutropenia (42.86%), and in the secondary trial, the most common event was a decrease in Ejection fraction (4.95%). These proportions align with the data provided."
    },
    "97812fde-57f3-4299-be34-dd436757adde": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00093795",
        "Statement": "Patients with cancer cells in lymph nodes above the collarbone cannot enter the primary trial.",
        "Label": "Entailment",
        "explain": "Contradicted. The inclusion criteria for the primary trial specify that patients with pN3b nodal stage, which includes the presence of cancer cells in internal mammary nodes above the collarbone, are eligible for the study if there is more than 3 positive axillary lymph nodes. Therefore, the statement is contradictory to the information provided in the CTR."
    },
    "f37774f4-db96-4aa6-b3a1-626953faeecf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00213980",
        "Secondary_id": "NCT02536339",
        "Statement": "Adequate blood, kidney, and hepatic function are required to participate in the secondary trial, however this condition is not specified in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement \"Adequate blood, kidney, and hepatic function are required to participate in the secondary trial, however this condition is not specified in the primary trial\" is contradicted by the CTRs provided. \n\nThe primary trial does not mention the requirement for adequate blood, kidney, and hepatic function as an inclusion criterion. However, this does not mean that the condition is not required in the primary trial, as the secondary trial may have unique requirements that are not present in the primary trial. The statement implies that the lack of specification of this requirement in the primary trial means that it is not necessary, which is incorrect. Therefore, the statement is contradicted by the information provided in the CTRs."
    },
    "4fef4cdf-53bf-4239-9d31-4710fd3edc6f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01605396",
        "Statement": "The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 38.43 months.",
        "Label": "Contradiction",
        "explain": "The statement \"The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 38.43 months\" is contradicted by the provided CTR information. The median PFS for the Ridaforolimus + Dalotuzumab + Exemestane arm of the primary trial was reported as 23.29 weeks (8.71 to 38.43) and not over 38.43 months as stated in the expert's comment."
    },
    "331affb2-f8e9-4a55-ac4c-62d2ecc4f80b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00181363",
        "Statement": "The only difference between the interventions used in the primary trial is the patients position.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the CTR information provided. Both trials only differ in the position of the patients during the intervention (prone in the primary trial and supine in the secondary trial)."
    },
    "a577e819-c928-4217-8743-f4809e852919": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00834678",
        "Statement": "Patients must have a white blood cell count above 1,500/mm\u00ac\u00a8\u201a\u00e2\u2022 to participate in the primary trial.",
        "Label": "Entailment",
        "explain": "The statement is entailed by the primary CTR as it specifies a mandatory requirement for patients to have a white blood cell count above 1,500/mm\u00b3 to participate in the trial. (PATIENT CHARACTERISTICS section)"
    },
    "bd073d05-3ba2-4898-9d86-a51951a7ad1f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01004172",
        "Secondary_id": "NCT00802945",
        "Statement": "the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions.",
        "Label": "Contradiction",
        "explain": "The statement is entailed by the given CTRs. \n\nJustification: \n\nBoth trials measure the effects of their interventions using the concept of objective response rate. However, it's essential to note that the primary trial uses a CNS-specific objective response rate (CNS ORR), while the secondary trial reports a more general ORR based on RECIST v1.0. Nevertheless, the similarity in using the term \"objective response rate\" as the primary outcome measure in both trials justifies the expert's statement, as the concept itself remains the same despite potential differences in specific evaluation criteria or context (CNS vs RECIST)."
    }
}